Clinical Medicine Lecture Notes provides a comprehensive, accessible introduction to the management and treatment of medical conditions. A short manual of techniques on communication and physical examination in Part 1 is supported by the core knowledge required on diseases specific to each body system in Part 2.

Combining readability with high quality illustrations, this seventh edition has been thoroughly revised to reflect up-to-date practice in examination and clinical investigation, and advances in the evidence base supporting modern day clinical practice. Numerous figures and tables help distil the information for revision purposes, and there are new chapters on the medical interview and assessment.

Whether you need to develop your knowledge for clinical practice, or refresh that knowledge in the run up to examinations, Clinical Medicine Lecture Notes will help foster a systematic approach to the clinical situation for all medical students and hospital doctors.

For information on all the titles in the Lecture Notes series, please visit: www.lecturenoteseries.com

Titles of related interest
Medicine at a Glance, Third Edition
Patrick Davey 2010
9781405186162

Medicine at a Glance: Core Cases
Patrick Davey 2010
9781444335118

The Hands-on Guide for Junior Doctors, Fourth Edition
Anna Donald, Mike Stein and Ciaran Hill 2011
9781444334661

For more information on the complete range of Wiley-Blackwell medical student and junior doctor publishing, please visit: www.wileymedicaleducation.com

To receive automatic updates on Wiley-Blackwell books and journals, join our email list. Sign up today at www.wiley.com/email

All content reviewed by students for students

Wiley-Blackwell Medical Education books are designed exactly for their intended audience. All of our books are developed in collaboration with students. This means that our books are always published with you, the student, in mind.

If you would like to be one of our student reviewers, go to www.reviewmedicalbooks.com to find out more.
Contents

Preface to the Seventh Edition iv
Preface to the First Edition v

Part 1 Clinical Examination
1 The medical interview 1
2 General examination 7
3 Cardiovascular system 10
4 Respiratory system 19
5 The abdomen 28
6 Neurological system 39
7 Endocrinology and metabolism 57
8 Musculoskeletal system 62
9 Assessment 66

Part 2 Clinical Medicine
10 Cardiovascular disease 73
11 Respiratory disease 110
12 Gastroenterology 128
13 Liver disease 144
14 Renal disease 153
15 Neurology 171
16 Endocrine disorders 208
17 Metabolic disorders 229
18 Rheumatology 269
19 Dermatology 297
20 Haematology 321
21 Infectious diseases 336
22 Toxicology 351

SI Units conversion table 361

Index 362

The plate section can be found facing page 314
Preface to the Seventh Edition

History-taking and examination remain the essential tools of clinical medicine. However, the environment in which medicine is practised has changed since the first edition of Lecture Notes in Clinical Medicine in 1975. The seventh edition follows the format of previous editions of this book with two sections: Clinical Examination and Clinical Medicine. Each section has been updated to reflect the increased evidence upon which clinical practice is based and the more objective methods of assessment that are now used.

It is rewarding to discover how many readers have found the text useful for study, for revision and for the practice of clinical medicine. Please continue to let us have your views.

John Bradley
Mark Gurnell
Diana Wood

Acknowledgements

We would like to thank Dr Ellie Gurnell, Dr Mark Lillicrap and Dr Narayanan Kandasamy for their contributions, help and advice during the preparation of the manuscript.
Preface to the First Edition

This book is intended primarily for the junior hospital doctor in the period between qualification and the examination for Membership of the Royal Colleges of Physicians. We think that it will also be helpful to final-year medical students and to clinicians reading for higher specialist qualifications in surgery and anaesthetics.

The hospital doctor must not only acquire a large amount of factual information but also use it effectively in the clinical situation. The experienced physician has acquired some clinical perspective through practice: we hope that this book imparts some of this to the relatively inexperienced. The format and contents are designed for the examination candidate but the same approach to problems should help the hospital doctor in his everyday work.

The book as a whole is not suitable as a first reader for the undergraduate because it assumes much basic knowledge and considerable detailed information has had to be omitted. It is not intended to be a complete textbook of medicine and the information it contains must be supplemented by further reading. The contents are intended only as lecture notes and the margins of the pages are intentionally large so that the reader may easily add additional material of his own.

The book is divided into two parts: the clinical approach and essential background information. In the first part we have considered the situation which a candidate meets in the clinical part of an examination or a physician in the clinic. This part of the book thus resembles a manual on techniques of physical examination, though it is more specifically intended to help the candidate carry out an examiner's request to perform a specific examination. It has been our experience in listening to candidates' performances in examinations and hearing the examiner's subsequent assessment that it is the failure of a candidate to examine cases systematically and his failure to behave as if he were used to doing this every day of his clinical life that leads to adverse comments.

In the second part of the book a summary of basic clinical facts is given in the conventional way. We have included most common diseases but not all, and we have tried to emphasise points which are under-stressed in many textbooks. Accounts are given of many conditions which are relatively rare. It is necessary for the clinician to know about these and to be on the lookout for them both in the clinic and in examinations. Supplementary reading is essential to understand their basic pathology, but the information we give is probably all that need be remembered by the non-specialist reader and will provide adequate working knowledge in a clinical situation. It should not be forgotten that some rare diseases are of great importance in practice because they are treatable or preventable, e.g. infective endocarditis, hepatolenticular degeneration, attacks of acute porphyria. Some conditions are important to examination candidates because patients are ambulant and appear commonly in examinations, e.g. neurosyphilis, syringomyelia, atrial and ventricular septal defects.

We have not attempted to cover the whole of medicine, but by cross-referencing between the two sections of the book and giving information in summary form we have completely omitted few subjects. Some highly specialised fields such as the treatment of leukaemia were thought unsuitable for inclusion.

A short account of psychiatry is given in the section on neurology since many patients with mental illness attend general clinics and it is hoped that readers may be warned of gaps in their knowledge of this important field. The section on dermatology is incomplete but should serve for quick revision of common skin disorders.

Wherever possible we have tried to indicate the relative frequency with which various conditions are likely to be seen in hospital practice in this country and have selected those clinical features which in our view are most commonly seen and where possible have listed them in order of importance. The frequency with which a disease is encountered by any individual physician will depend upon its prevalence in the district from which his cases are drawn and also on his known special interests. Nevertheless, rare conditions are rarely seen; at least in the clinic. Examinations, however, are a 'special case'.

We have used many generally accepted abbreviations, e.g. ECG, ESR, and have included them in the index instead of supplying a glossary.

Despite our best efforts, some errors of fact may have been included. As with every book and authority, question and check everything – and please write to us if you wish.

We should like to thank all those who helped us with producing this book and, in particular, Sir Edward Wayne and Sir Graham Bull who have kindly allowed us to benefit from their extensive experience both in medicine and in examining for the Colleges of Physicians.

David Rubenstein
David Wayne
November 1975
Good communication between doctor and patient forms the basis for excellent patient care and the clinical consultation lies at the heart of medical practice. Good communication skills encompass more than the personality traits of individual doctors – they form an essential core competence for medical practitioners. In essence, good communication skills produce more effective consultations and, together with medical knowledge and physical examination skills, lead to better diagnostic reasoning and therapeutic intervention. The term ‘communication skills’, when applied to medical practice, describes a set of specific skills that can be taught, learned and assessed. A large evidence-base shows that health outcomes for patients and both patient and doctor satisfaction within the therapeutic relationship are enhanced by good communication skills.

In this chapter the medical interview as a whole will be considered and then the way in which communication skills should be approached in different types of assessment encountered by students and trainees reviewed.

There are a number of different models for learning communication skills in use throughout the world. They are generally similar and all emphasise the importance of patient-centred interview methods. This chapter is based on the Calgary–Cambridge model (Fig. 1.1) which has been widely adopted in Europe and the USA and with which the authors are familiar as a means of teaching and learning and as a framework for assessment (Silverman et al. 2005). Like all clinical skills, communication skills can only be acquired by experiential learning. This may take the form of small group learning with role play, the use of actors in simulated learning environments or, for more experienced learners, in recorded real consultations with subsequent feedback.

Effective consultation

Effective consultations are patient-centred and efficient, taking place within the time and other practical constraints that exist in everyday medical practice. The use of specific communication skills together with a structured approach to the medical interview can enhance this process. Important communication skills can be considered in three categories: content, process and perceptual skills (see Table 1.1); these mirror the essential knowledge, skills and attitudes required for good medical practice. These skills are closely interrelated so that, for example, effective use of process skills can improve the accuracy of information gathered from the patient, thus enhancing the content skills used subsequently in the consultation.

Structure

Providing structure to the consultation is one of the most important features of effective consultation. Process skills should be used to develop a structure that is responsive to the patient and flexible for different consultations. Six groups of skills can be identified and each will be considered below.

Sequential in the consultation:

- initiating the session
- gathering information (including from physical examination)
- explanation and planning
- closing the session

Throughout the consultation:

- organisation
- relationship building
Initiating the session

The initial part of a consultation is essential to form the basis for relationship building and to set objectives for the rest of the interview. Before meeting a patient, the doctor should prepare by focusing him- or herself, trying to avoid distractions and reviewing any available information such as previous notes or referral letters.

Initiating the session

Providing structure

- Make organisation overt
- Attending to flow

Building the relationship

- Using appropriate non-verbal behaviour
- Developing rapport
- Involving the patient

Initiating the session

- Preparation
- Establishing initial rapport
- Identifying the reasons for the consultation

Gathering information

- Exploration of the patient’s problems to discover the:
  - Biomedical perspective
  - Patient’s perspective
  - Background information – context

Physical examination

- Providing the correct type and amount of information
- Aiding accurate recall and understanding
- Achieving a shared understanding: incorporating the patient’s illness framework
- Planning: shared decision-making

Closing the session

- Ensuring appropriate point of closure
- Forward planning


Table 1.1 Categories of communication skills

<table>
<thead>
<tr>
<th>Skill</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Content skills</td>
<td>Knowledge-based: appropriate questions and responses; accurate information gathering and explanation to patient; clear discussion of investigation and treatments based on knowledge</td>
</tr>
<tr>
<td>What the doctor communicates</td>
<td></td>
</tr>
<tr>
<td>Process skills</td>
<td>Skills-based: verbal and non-verbal communication skills; relationship building; organising and structuring the interview</td>
</tr>
<tr>
<td>How the doctor communicates</td>
<td></td>
</tr>
<tr>
<td>Perceptual skills</td>
<td>Attitude-based: clinical reasoning and problem-solving skills; attitudes towards the patient; feelings and thoughts about the patient; awareness of internal biases</td>
</tr>
<tr>
<td>What the doctor is thinking</td>
<td></td>
</tr>
</tbody>
</table>
Gathering information

An accurate clinical history provides about 80% of the information required to make a diagnosis. Traditionally, history-taking focused on questions related to the biomedical aspects of the patient’s problems. Recent evidence suggests that better outcomes are obtained by including the patient’s perspective of their illness and by taking this into account in subsequent parts of the consultation. The objectives for gathering information should therefore include exploring the history from both the biomedical and patient perspectives, checking that the information gathered is complete and ensuring that the patient feels that the doctor is listening to them.

Further information is gathered from the physical examination. Establishment of a good rapport during the first part of the consultation will facilitate communication during the examination. An appropriate chaperone should be present during the physical examination.

Explanation and planning

Explanation and planning is crucially important to the effective consultation. Establishment of a management plan jointly between the doctor and the patient has important positive effects on patient recall, understanding of their condition, adherence to treatment and overall satisfaction. Patient expectations have changed and many wish to be more involved in decision-making about investigation and treatment options. The goals of this part of the consultation are

Avoid jargon: use clear concise language; explain any medical terminology.
Find out what the patient knows: establish prior knowledge; find out how much they wish to know at this stage.
‘Chunk and check’: provide information in small amounts and check understanding; use this to assess how to proceed.
Organise explanation: develop a logical sequence; categorise information; repeat and summarise; signpost what is coming next; use diagrams or charts, written information or instructions.
Relate the information to the patient’s perspective.
Respond to patient’s cues: verbal and non-verbal; allow patient to ask questions or clarify information.
Involving the patient: share thoughts; reveal rationale for opinions; offer your opinion of what is going on and name it where possible; explore management options; take the patient’s lifestyle and cultural background into account in the discussion.
Negotiate a mutually agreeable action plan: check that this meets the patient’s expectations and addresses their concerns.
thus to gauge the amount and type of information required by each individual patient, to provide information in a way that the patient can remember and understand and which takes their perspectives into account, to arrive at a shared understanding of the problem and to engage the patient in planning the next moves.

**Closing the session**

Closing the interview allows the doctor to summarise and clarify the plans that have been made and what the next steps will be. It is also important to ensure that contingency plans are in place in case of unexpected events and that the patient is clear about follow-up arrangements. Continuing to foster the doctor–patient relationship in this way has positive effects on adherence to treatment and health outcomes.

**Two essential parts of effective consultation skills run throughout the interview – organisation and relationship building. The way in which these two are used is shown in Table 1.2.**

- **Organisation** allows a flexible but ordered and logical process to occur within an appropriate time-frame. It encourages patient participation and collaboration and facilitates accurate information gathering.
- **Building a relationship** with the patient involves a number of communication skills that enable the doctor to establish rapport and trust between themselves and the patient. It maximises the chances of accurate information gathering, explanation and planning and can form part of the development of a continuing relationship over time. It is vital to patient and doctor satisfaction with the consultation process.

---

**Special circumstances**

Certain circumstances demand a special approach to communication skills, such as breaking bad news, dealing with cultural diversity, using an interpreter, and consultation with the elderly, with mentally ill patients or the parents of a sick child. In essence, the core communication skills described here form the basis for any of the more difficult communication

---

### Table 1.2 Skills for organising the consultation and building the relationship

<table>
<thead>
<tr>
<th>Organising the consultation</th>
<th>Building the relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summarising</strong></td>
<td><strong>Non-verbal communication</strong></td>
</tr>
<tr>
<td>Summarise the end of a specific line of enquiry; confirm your understanding; allow patient to correct; order information; reflect on what to do next.</td>
<td>Includes eye contact, facial expression, posture, proximity, body movement, touch; use of time, your appearance, manner; the environment.</td>
</tr>
<tr>
<td><strong>Signposting</strong></td>
<td><strong>Rapport</strong></td>
</tr>
<tr>
<td>Structure the interview overtly; draw attention to what you are about to say; introduce summaries; help patient to understand where the interview is going; ask permission to move on through the interview.</td>
<td>Accept patient’s views; empathise to show understanding of patient’s views and feelings; support by expressing concern, willingness to help, acknowledge efforts to cope; be sensitive towards embarrassing or difficult issues.</td>
</tr>
<tr>
<td><strong>Sequencing</strong></td>
<td><strong>Involve the patient</strong></td>
</tr>
<tr>
<td>Maintain a logical sequence to the interview; use flexible but ordered organisation by signposting and summarising.</td>
<td>Share your thoughts to encourage patient interaction; explain your rationale for doing things; explain your actions during the physical examination.</td>
</tr>
<tr>
<td><strong>Timing</strong></td>
<td></td>
</tr>
<tr>
<td>Pace the interview; use other skills to achieve good timing.</td>
<td></td>
</tr>
</tbody>
</table>
Breaking bad news

**Prepare:** ensure you have all the clinical details and know the facts; set aside enough time; encourage the patient to bring a relative or friend.

**Start the session:** review what has happened so far; assess the patient’s state of mind; find out what they know and what they are thinking.

**Share the information:** warn the patient that the news is not good; give the information clearly and in small amounts; relate to the patient’s perspective; do not overwhelm with information in the first instance; check repeatedly that the patient understands.

**Be sensitive:** respond to the patient’s emotions – tears, anger, denial; allow time for silences and questions and respond to them honestly; gauge the patient’s wishes for information and respond accordingly; be empathic and concerned; check the patient’s understanding of what you have said and elicit their concerns and understanding of the situation; do not be afraid to show your own emotions.

**Make a plan:** explain what will happen next; give hope but be realistic; confirm your role as a partner in care.

**Closure:** summarise and check the patient’s understanding; respond to additional questions; check the patient’s support systems and offer to speak to family if requested; make an early follow-up appointment.

Approach to communication skills assessment

**Past papers:** the format of the examination should be available for review; look at the communication skills stations; familiarise yourself with the format; are the process and content components weighted and, if so, how?

**Be prepared:** obtain as much information as possible in advance of the assessment; how long are the stations? Is the station simply an observed communication scenario or is a structured viva involved? In some examinations the clinical scenario is available in advance of the examination to allow preparation of content – if so, read it carefully and be certain of the medical facts.

**Read the instructions:** in most summative assessments the scenario is presented at the station with a few minutes’ reading time. Read the scenario carefully. Think about the content as well as the process skills.

**Be clear about the task:** are you required to take a history, to give information, gain consent for a procedure, talk to a relative or colleague?

**Make a plan:** before you enter the station, have a clear plan as to how you will approach the consultation and what you wish to achieve.

**Think about what you might encounter:** communication skills assessments usually use simulated patients who may respond in a number of ways. For example, how will you deal with an emotional patient, a non-communicative patient or an angry response to breaking bad news?

**Listen to the examiner:** if you are asked to present and discuss the case, listen carefully to the examiner and present the salient features in a clear and logical manner.

Assessment of communication skills

Clinical competence is assessed at all levels of medical education. Communication skills are usually assessed in undergraduate examinations by stations in Objective Structured Clinical Examinations (OSCEs). More varied assessments take place for postgraduates, including stations in the Royal College of Physicians MRCP Part 3 examination (Practical Assessment of Clinical Examination Skills; PACES) and mini-CEX assessments as part of ongoing workplace-based assessments for trainees. Students and trainees attempting these assessments should have been through appropriate skills scenarios. Complex situations require the doctor to use basic skills to a higher level. Preparation and planning, listening to the patient, delivering information in small amounts with regular checking and allowing time for information to be assimilated and for questioning are paramount. Closure is also important, ensuring the patient knows what is happening and is clear about the next steps.
communication skills experiential learning programmes allowing them to develop skills in simulated environments and practise them in clinical settings (Fig. 1.2). Whatever the assessment format, a number of factors should be addressed.

**Reference**

General examination

Introduction

General examination can reveal abnormalities in a number of systems which may assist in making an accurate diagnosis.

Disorders of gait, speech and mood should be apparent on first meeting the patient and during the consultation process. Dyspnoea may be observed and abnormal movements, including tremor or paucity of facial expression, should be noted.

During the general examination, obvious features of systemic disease in one site should be correlated with signs elsewhere.

Hands

Note
- joint disorders – arthritis, gout, deformity
- neuromuscular changes – muscle wasting, loss of function
- skin temperature
  - warm, cyanosed hands with bounding pulse in CO₂ retention
  - cold pale hands with arterial disease
- fingers
  - Raynaud’s phenomenon, other signs of systemic sclerosis
  - nicotine staining
  - Osler’s nodes (endocarditis, vasculitis)
- nails
  - anaemia (pallor, koilonychia)
  - peripheral cyanosis
  - splinter haemorrhages
- clubbing – swelling of the ends of the fingers with increased curvature of the nails and loss of the angle at the nail beds
- palmar erythema

- Dupuytren’s contracture
- tremor
  - fine tremor may be exaggerated by placing a piece of paper over the patient’s outstretched hands
  - outstretched hands exaggerate the coarse tremor of CO₂ retention
  - flapping tremor in hepatic failure, uraemia – ask the patient to cock their wrists with the hands outstretched
  - resting tremor of Parkinson’s disease – hands flexed and showing coarse ‘pill-rolling’ tremor relieved by intention
  - intention tremor – benign or cerebellar

Face

Check for
- anaemia: examine the insides of the eyelids, look for glossitis (pernicious anaemia) and angular chelitis
- dental hygiene, tonsillar enlargement, buccal pigmentation inside the mouth

Cardiorespiratory system
- cyanosis: examine the underside of the tongue
- observe pursing of the lips on expiration in obstructive airways disease
- lupus pernio indicates sarcoidosis

Gastrointestinal system
- jaundice – examine the sclera
- spider naevi
- Peutz-Jeghers syndrome
- hereditary haemorrhagic telangiectasia

Neurological system
- Upper motor neuron (UMN) or lower motor neuron (LMN) facial palsy: differentiate stroke from Bell’s
palsy; examine the external auditory meatus for evidence of herpes zoster
• ptosis and oculomotor palsies
• Parkinsonism
• myopathy: cataract and frontal baldness suggest dystrophia myotonica
• ophthalmic herpes zoster including the conjunctiva

Endocrine system
Observe typical features of
• thyrotoxicosis: including thyroid eye disease in Grave’s disease
• hypothyroidism
• Cushing syndrome
• acromegaly
• Paget’s disease involving the skull

Auto-immune diseases
• systemic lupus erythematosus – photosensitive ‘butterfly rash’
• scleroderma – microstomia, tightening of the skin
• dermatomyositis – ‘heliotrope’ periorbital rash

Skin diseases
• acne vulgaris
• acne rosacea
• psoriasis: check behind the ears
• port wine stain

Rheumatological system
• gouty tophi – check the pinnae

Neck
Examine
• the jugular venous pressure (JVP)
• the thyroid gland
• cervical lymph nodes including the occipital group
Axillae

*With shoulders relaxed examine*
- anterior, posterior and lateral walls and apices of axillae for lymphadenopathy

Breasts (Fig. 2.1)

*Examine systematically in women and men where indicated*
- nipples
- four quadrants of each breast
- axillary tails of each breast
- axillae

Legs

*Cardiorespiratory system*
- pitting oedema – note the extent of peripheral oedema
- evidence of peripheral vascular disease – absent foot pulses, delayed capillary filling, ulceration, gangrene
- varicose veins – note and examine formally if present
- ulceration – note whether venous or arterial
- assess the temperature of the dorsum of each foot, noting asymmetry, interdigital infection and loss of hair
- palpate the dorsalis pedis and posterior tibial pulses
- palpate the popliteal and femoral pulses
- auscultate for bruits over femoral pulses

Rheumatological system
- obvious joint deformity consistent with specific arthritides including gout
- bone deformity – Paget’s disease in the tibiae

Neurological system
- Charcot joints
- peripheral neuropathy
- effects of chronic neurological lesions – UMN (stroke), multiple sclerosis, polio
- subacute combined degeneration of the cord; hereditary ataxias

Skin
- cellulitis
- varicose eczema with haemosiderosis
- psoriasis
- specific skin lesions – erythema nodosum

Endocrine system
- pretibial myxoedema
- pyoderma gangrenosum

Notes

*Lymphadenopathy*
A systematic approach to the detection of lymphadenopathy is required. Examine all the major lymph nodes in a logical order:
- cervical
- suprACLavicular
- axillary
- inguinal.

If lymphadenopathy is detected, examine the abdomen for hepatosplenomegaly.
Cardiovascular system

Introduction

Diagnostic accuracy when assessing patients with cardiovascular disease relies heavily on the medical history. Many patients with ischaemic heart disease have few or no physical signs and a characteristic history of peripheral vascular disease may be elicited. Key features in the cardiovascular history are shown in Box 3.1.

Systematic and thorough examination of the cardiovascular system is a core skill for physicians. Accurate assessment of peripheral cardiovascular signs aids the interpretation of auscultatory findings. Patients with ischaemic heart disease may have few physical signs and physicians should be aware of the likely sites and significance of scars from previous surgical or radiological intervention. Cardiac valvular disease and septal defects usually give rise to murmurs which may be diagnostic. In clinical practice arrival at the final cardiac diagnosis is aided by an electrocardiogram (ECG), chest X-ray (CXR) and echocardiogram (ECHO) and by more complex radiological intervention as appropriate including magnetic resonance imaging (MRI), computerised tomography (CT) and angiography.

Blood pressure

- measure the blood pressure lying and standing

Hands

Inspect for

- clubbing
- splinter haemorrhages
- palmar erythema
- nicotine staining

Arterial pulses

Palpate

- radial pulse to assess the rate and rhythm
- radial and brachial pulses in both arms, comparing right and left
- carotid pulses
- radial and femoral pulses simultaneously to assess radiofemoral delay

Rate

- count radial for at least 15 s if rhythm regular, at least 30–60 s if irregular
- check the jugular venous pressure (JVP) whilst counting

Rhythm

- regular (sinus rhythm)
- regularly irregular (extra or dropped beats)

General inspection

Note

- peripheral or central cyanosis: central cyanosis is accompanied by peripheral cyanosis by definition
- dyspnoea and orthopnoea
- malar flush
- xanthelasmata
Box 3.1 Important features in the cardiovascular history

<table>
<thead>
<tr>
<th>Chest pain</th>
<th>Breathlessness</th>
<th>Cough</th>
<th>Oedema</th>
<th>Syncope</th>
<th>Calf pain</th>
<th>Peripheral vascular disease (PVD)</th>
<th>Others</th>
<th>Visual disturbance</th>
<th>Risk factors</th>
<th>Past history</th>
<th>Medication</th>
<th>Family history</th>
</tr>
</thead>
<tbody>
<tr>
<td>onset</td>
<td>on exertion</td>
<td>with or without sputum</td>
<td>ankle swelling</td>
<td>on exertion</td>
<td>intermittent claudication</td>
<td>cold peripheries with colour/sensory changes</td>
<td>transient hemiparesis</td>
<td>transient (e.g. amaurosis fugax)</td>
<td>smoking</td>
<td>hypertension</td>
<td>antihypertensives</td>
<td>ischaemic heart disease</td>
</tr>
<tr>
<td>duration</td>
<td>orthopnoea</td>
<td></td>
<td>swelling of lower limbs and sacral area</td>
<td>postural</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>obesity</td>
<td>cerebrovascular disease</td>
<td>antianginal therapy</td>
<td>diabetes</td>
</tr>
<tr>
<td>nature</td>
<td>paroxysmal nocturnal dyspnoea</td>
<td></td>
<td></td>
<td>sudden</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hypertension</td>
<td>peripheral vascular disease</td>
<td>statins</td>
<td>hyperlipidaemia</td>
</tr>
<tr>
<td>precipitating factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>diabetes</td>
<td>congenital heart disease</td>
<td>oral contraceptives and estrogen replacement therapy (HRT)</td>
<td>hypertension</td>
</tr>
<tr>
<td>relieving factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hyperlipidaemia</td>
<td></td>
<td></td>
<td>hyperlipidaemia</td>
</tr>
<tr>
<td>distribution and radiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>oral contraceptives and estrogen replacement therapy (HRT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>previous episodes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>oral contraceptives and estrogen replacement therapy (HRT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>associated symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>oral contraceptives and estrogen replacement therapy (HRT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(nausea, vomiting, pallor)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>oral contraceptives and estrogen replacement therapy (HRT)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- irregularly irregular (atrial fibrillation; the pulse rate is different from the heart rate; listen and count at the apex whilst palpating the pulse)
- Volume and character (Table 3.1)
- collapsing pulse: raise the patient’s arm above the level of the heart whilst holding four fingers over the anterior forearm
- slow – rising, low volume, alternans, bisferiens and paradoxus by palpating the carotid pulse

Jugular venous pressure and pulse (Table 3.2; Fig. 3.1)

The patient should be lying at 45° with the neck relaxed. The JVP is seen welling up between the two heads of sternomastoid in the front of the neck on expiration.

Measure

- the vertical height of the top of the column of blood above the sternal angle.

The sternal angle is about 5 cm above the left atrium when the patient is lying at 45°. The normal central venous pressure (CVP) is 7 cm and therefore the jugular vein is normally just visible.

In the neck, the venous pulse differs from the arterial pulse:

- its height varies with posture, it is impalpable and low pressure means that it is easily abolished by light finger pressure
- it fills from above when light finger pressure is applied to the root of the neck
- the height varies with respiration (fall with inspiration and rise with expiration)
- there are two peaks with each pulsation, ‘a’ and ‘v’.

The JVP is a better guide to right atrial pressure than the superficial external venous pulse which may be tortuous or obstructed by soft tissues in the neck.

If neither is obvious:

- Suspect a low level: unless the liver is tender, press on the abdomen gently but firmly. The ‘hepatojugular reflux’ (not ‘reflex’) has no pathophysiological significance; the sole purpose of this manoeuvre is to demonstrate the vein and to show that it can be filled (i.e. that the pressure is not high).
- Suspect a high level: the top of the column may be above the mastoid. Check if the ear lobes move with the cardiac cycle and sit the patient vertically to get a greater length of visible jugular vein above the right atrium.

If the jugular venous pressure is raised (especially if > 10 cm):

- A large ‘a’ wave (corresponding with atrial systole) occurs when the right atrial pressure is raised, e.g.
tricuspid stenosis, pulmonary hypertension, pul-
mmonary stenosis and mitral stenosis.

- A cannon wave is a massive ‘a’ wave occurring in complete heart block when the right atrium contracts against a closed tricuspid valve.
- There is no ‘a’ wave in atrial fibrillation because there is no atrial systole.
- A large ‘v’ wave (corresponding with ventricular systole) indicates tricuspid incompetence (usually secondary to marked heart failure).

Heart

Observe
- scars of previous surgery
- visible apex beat
- visible parasternal heave

Palpate
- apex beat
- left parasternal area
- apex, base and aortic areas for thrills

The apex beat may be thrusting in left ventricular hypertrophy, displaced by cardiomegaly or left ventricular dilatation or tapping in nature, suggesting the accentuated first sound of mitral stenosis.

A parasternal heave is present when there is right ventricular hypertrophy.

Thrills are palpable murmurs felt over the relevant area in systole or diastole.

**Auscultate the precordium** (Fig. 3.2)
- Use the bell of the stethoscope to examine low-pitched noises, especially diastolic murmurs at the apex, and the diaphragm to examine high-pitched noises and the precordium generally.
- Palpate the right carotid artery when auscultating to identify the stages of the cardiac cycle.
- Ask the patient to roll onto their left side and listen over the apex to accentuate mitral murmurs and check their radiation.
- Ask the patient to sit up, lean forwards and hold their breath in expiration to listen for aortic diastolic murmurs.

### Table 3.1 Abnormalities of the arterial pulse

<table>
<thead>
<tr>
<th>Type</th>
<th>Character</th>
<th>Seen in</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slow-rising</td>
<td>Low amplitude, slow rise, slow fall</td>
<td>Aortic stenosis</td>
</tr>
<tr>
<td>Collapsing</td>
<td>Large amplitude, rapid rise, rapid fall</td>
<td>Aortic incompetence; severe anaemia, hyperthyroidism; arteriovenous shunt; heart block; patent ductus arteriosus</td>
</tr>
<tr>
<td>Low volume</td>
<td>Thready</td>
<td>Low cardiac output states; hypovolaemic shock; valvular stenosis; pulmonary hypertension</td>
</tr>
<tr>
<td>Alternans</td>
<td>Alternate large- and small-amplitude beats ...</td>
<td>Left ventricular failure</td>
</tr>
<tr>
<td>Bisferiens</td>
<td>Double-topped (‘notched’)</td>
<td>Aortic stenosis with aortic incompetence</td>
</tr>
<tr>
<td>Paradoxus</td>
<td>Pulse volume decreases excessively with ...</td>
<td>Cardiac tamponade, constrictive pericarditis, severe inspiratory airways obstruction</td>
</tr>
<tr>
<td>Absent radial</td>
<td></td>
<td>Congenital anomaly (check brachials and blood pressure)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tied off at surgery or catheterisation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Arterial embolism</td>
</tr>
</tbody>
</table>

### Table 3.2 Raised jugular venous pressure (JVP)

<table>
<thead>
<tr>
<th>Character</th>
<th>Compression of neck and abdomen</th>
<th>Conclusion</th>
</tr>
</thead>
</table>
| Non-pulsatile | No change in JVP               | Superior mediastinal obstruction  
|            |                                 | • carcinoma of bronchus  
|           |                                 | • large goitre  
| Pulsatile | Jugular vein fills and empties  | Right heart failure  
|           |                                 | Expiratory airways obstruction  
|           |                                 | Fluid overload  
|           |                                 | Cardiac tamponade  |
Check for radiation of aortic stenotic murmurs to the carotid area.

Identify
- first and second heart sounds
- additional heart sounds
- murmurs and their radiation
- pericardial friction rub

First heart sound (S1): occurs at the onset of systole when mitral and tricuspid valves close; loud in hyperdynamic circulation and mitral stenosis, soft in heart failure and mitral regurgitation.

Second heart sound (S2): occurs at the end of systole when aortic and pulmonary valves close; split on inspiration (A2 then P2); fixed splitting in atrial septal defect; variable splitting with bundle branch blocks.

Third heart sound (S3): occurs immediately after S2 in early diastole; normal in young people and pregnancy; presents as ‘gallop rhythm’ in left ventricular failure.

Fourth heart sound (S4): occurs at the end of diastole before S1; present in severe left ventricular hypertrophy and aortic stenosis.

Systolic clicks: occur in early or mid-systole; indicate aortic or pulmonary stenosis, mitral valve prolapse and prosthetic heart valves.

Opening snap (OS): occurs in early diastole; indicates mitral stenosis with mobile valve leaflets and prosthetic valves; absent in calcific mitral stenosis.

Cardiac murmurs: auscultatory features are shown in Table 3.3.

Pericardial friction rub: low-pitched and scratchy; heard over the lower sternum; varies with posture and breathing.

Complete the examination
- auscultate the carotids for bruits
- examine for ankle oedema
- sit the patient up and examine the lung bases for crackles and pleural effusions and check for sacral oedema
- examine the abdomen for hepatomegaly (which may be pulsatile) and abdominal aortic aneurysm
- dipstick the urine

Notes
Heart failure
A full cardiovascular history should be taken, focusing on evidence of chronic ischaemia or hypertension.

Left ventricular failure (LVF)
Signs
- dyspnoea on exertion or at rest
- tachycardia
- gallop rhythm
- fine bi-basal crackles of pulmonary oedema
- pleural effusions

Right ventricular failure (RVF)
Signs
Signs of LVF plus
- raised JVP
- ankle oedema
- sacral oedema
- hepatomegaly
- ascites

If RVF is secondary to chronic lung disease (cor pulmonale) there is clinical evidence to suggest chronic obstructive pulmonary disease, pulmonary embolism or other forms of chronic lung disease.
Hypertension

A full cardiovascular history should be taken. Specific features in the history of a patient with hypertension are shown in Box 3.2.

Mild or moderate hypertension usually produces no abnormalities on physical examination other than raised blood pressure. Physical signs suggest long-standing or severe hypertension.

Examine for
- left ventricular hypertrophy
- loud A2 second heart sound
- heart failure
- cerebrovascular disease
- hypertensive retinopathy
- renal failure

Consider secondary causes of hypertension.

Look for evidence of

- Renal artery stenosis: renal artery bruit in the epigastrium
- Polycystic kidney disease
- Other forms of chronic kidney disease
- Coarctation of the aorta: radial-femoral arterial pulse delay, weak femoral pulses, bruits of the coarctation and of the scapular anastomoses, visible pulsation of the anastomoses.
- Cushing syndrome
- acromegaly

Phaeochromocytoma and primary hyperaldosteronism (Conn syndrome) have no specific features on physical examination.

Figure 3.2 Suggested stethoscopic route (1–4) for listening to heart valves. 1, apex; 2, lower left sternal edge; 3, left second intercostal space; 4, right second intercostal space.
The ECG

A normal ECG is shown in Fig. 3.3.

Aide mémoire

- horizontally one little square is 0.04 s; one big square is 0.2 s
- vertically one little square is 0.1 mV
- normal PR interval is 0.12–0.2 s
- normal QRS duration is up to 0.12 s

The QT interval varies with rate. Upper limits of normal are approximately:
- rate 60/min QT 0.43 s
- rate 75/min QT 0.39 s
- rate 100/min QT 0.34 s.

Rate

- Count the large squares between two QRS complexes and divide into 300 (i.e. if two squares, the rate is 150/min).

Table 3.3 Characteristics of cardiac murmurs

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Murmur and position</th>
<th>Radiation and notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic stenosis</td>
<td>Harsh ejection systolic, maximal in second RICS; often loud with thrill. Possible ejection click</td>
<td>Radiates into neck</td>
</tr>
<tr>
<td>Aortic regurgitation</td>
<td>Blowing early diastolic decrescendo murmur maximal in third LICS, occasionally in second RICS. Best heard with patient sitting forwards in expiration</td>
<td>Radiates between right carotid and cardiac apex. Look for signs of coexistent connective tissue or other disorders</td>
</tr>
<tr>
<td>Mitral stenosis</td>
<td>Mid or late rumbling diastolic murmur at apex; presystolic accentuation if sinus rhythm. Loud mitral first sound. Opening snap if valve pliable</td>
<td>Turn patient on left side (and exercise) to accentuate murmur. Often atrial fibrillation</td>
</tr>
<tr>
<td>Mitral incompetence</td>
<td>Pansystolic at apex</td>
<td>Radiation to axilla; often heard parasternally</td>
</tr>
<tr>
<td>Mitral prolapse</td>
<td>Midsystolic at apex. High-pitched with click</td>
<td>Usually benign. Rarely associated connective tissue disease</td>
</tr>
<tr>
<td>Tricuspid incompetence</td>
<td>Pansystolic; maximal lower sternum</td>
<td>‘V’ wave in neck and pulsatile liver</td>
</tr>
<tr>
<td>Pulmonary stenosis</td>
<td>Midsystolic; maximal in second LICS. Click if stenosis is valvular</td>
<td>Increase on inspiration. Pulmonary component of second sound quiet and delayed</td>
</tr>
<tr>
<td>Pulmonary incompetence</td>
<td>Blowing early diastolic murmur, maximal in second and third LICS</td>
<td>Very rare</td>
</tr>
<tr>
<td>Ventricular septal defect</td>
<td>Loud, rough, pansystolic; maximal at third to fourth LICS parasternally</td>
<td>Small VSDs common</td>
</tr>
<tr>
<td>Atrial septal defect</td>
<td>Pulmonary systolic murmur with fixed split second sound</td>
<td>Possible tricuspid diastolic murmur if atrial septal defect flow is large</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td>Machinery murmur, maximal in late systole, extending into diastole.</td>
<td>Also audible posteriorly</td>
</tr>
<tr>
<td>Coarctation of the aorta</td>
<td>Loud rough systolic, maximum over apex of left lung both posteriorly and anteriorly</td>
<td>Murmurs of scapular and internal mammary shunt collaterals. Radial femoral delay. Hypertension in arms</td>
</tr>
</tbody>
</table>

RICS, right intercostal space; LICS, left intercostal space; VSD, ventricular septal defect.

The rate is: less than 60/min a bradycardia; greater than 100/min, a tachycardia.

Regularity

- Use the edge of a piece of paper to mark off a series of R waves, and then shift the paper along one or more complexes.
- The marks on the paper will still correspond with the R waves if the rhythm is regular. Total irregularity usually indicates atrial fibrillation

Estimate the mean frontal QRS axis (Fig. 3.4)

- To gain a rough idea of the axis, find the limb lead with the maximum net positive deflection (sum of the positive R wave and negative Q and S waves); the axis lies close to this.
Calculate the total deflection (R wave minus Q and S waves) in leads I and AVF which are perpendicular to each other (at 0 and 90° respectively).

Add these together as vectors (use the squares on the ECG paper); the net vector is the axis (see Fig. 3.4)

the normal range is 0–90°.

Check individual waves and intervals

for their presence, shape and duration.

P wave (atrial depolarisation)

is most easily seen in V1 and V2

is peaked in right atrial hypertrophy and bifid in left atrial hypertrophy (left atrial depolarisation occurs slightly later than right, giving a second peak)

may be ‘lost’ (in the QRS complex) in nodal rhythm.

PR interval

PR interval measured from the beginning of the P wave to the beginning of the QRS complex is usually 0.12–0.2 s.

If the PR interval is prolonged or a normal 1 : 1 ratio of PQRS complexes is lost heart block is present (p. 87).

A short PR interval occurs in atrioventricular re-entrant tachycardias.

QRS complex

The QRS complex is caused by the rapid depolarisation of the right and left ventricles.

If the QRS complex is longer than 0.12 s bundle branch block exists.

ST segment

The ventricles are depolarised during the ST segment, which is normally isoelectric.

T wave

The T wave is caused by repolarisation of the ventricles.

QT interval

The QT interval is measured from the beginning of the QRS complex to the end of the T wave. It varies with heart rate, and the corrected QT (QTc) is calculated by dividing the QT interval by the square root of the preceding R – R interval. QTc values between 0.35 and 0.45 s are considered normal. Prolongation is associated with ventricular arrhythmias.

U wave

occurs after the T wave and can be a normal finding.

Peripheral vascular system

Patients with peripheral vascular disease may complain of:

transient motor or sensory loss in transient ischaemic attacks (TIAs)

intermittent claudication

intermittent visual loss.

General examination

Compare and assess

temperature of the dorsum of each foot

haemosiderosis, lipodermatosclerosis

loss of hair over lower limbs and feet

arterial ulceration

venous ulceration

Check

capillary return in the great toe

Examine the arterial pulses

radial

brachial

carotid

femoral

popliteal

posterior tibial

dorsalis pedis

Pathological (broad, deep) Q waves are greater than 0.04 s (one small square wide) and greater than 0.2 mV. They may be normal in AVR or V1.
Figure 3.3 (a) Normal 12-lead electrocardiogram (ECG). (b) Waves of the normal ECG.
Palpate the abdomen for evidence of abdominal aortic aneurysm. Auscultate for bruits in the carotid arteries, epigastrum (renal artery stenosis), femoral arteries, and varicose veins where present.

Figure 3.4 (a) Position of the limb leads. (b) Calculation of the cardiac axis.

**Palpate**
- the abdomen for evidence of abdominal aortic aneurysm

**Auscultate for bruits**
- carotid arteries

**Examine**
- epigastrum (renal artery stenosis)
- femoral arteries
- varicose veins where present
Clinical assessment of the respiratory system is essential for accurate diagnosis, particularly in the context of acute respiratory disease where speedy clinical decision-making is of the essence. Whilst simple radiography, measurement of oxygen saturation and blood gas analysis are available in the majority of emergency clinical settings, the mainstay of diagnosis remains the clinical assessment. In chronic lung disease, the availability of sophisticated radiology and respiratory physiology can be used to confirm the diagnosis and monitor disease progress.

**History**

Key features of the history in a patient with respiratory disease are shown in Table 4.1.

**Examination**

Key abnormalities detected on examination of the chest are shown in Table 4.2.

**General observation: note**

- dyspnoea
- cyanosis
- evidence of loss of weight

**Examine the hands for**

- clubbing
- tobacco staining
- coarse tremor of outstretched hands
- bounding radial pulse

**Check**

- the pulse rate
- the height of the jugular venous pressure
- the tongue for cyanosis

**Observe**

- the shape of the chest and spine
- scars
- chest movements for symmetry and expansion
- the use of accessory muscles in the neck and shoulders
- visibly enlarged cervical lymph nodes

**Count**

- the respiratory rate

Examine the front and back of the chest in a logical manner, usually by palpating, percussing and auscultating the front of the chest first, followed by the rear. When examining the back of the chest, ask the patient to put their hands on their hips to facilitate examination of the lung bases laterally.

**Palpation**

The anterior surface markings of the lungs are shown in Fig. 4.1.

**Palpate for**

- chest expansion, comparing the movements of the two sides
- the trachea in the suprasternal notch to assess mediastinal shift with the patient’s head partially extended. (Local anatomical and pathological variants may produce tracheal deviation in the absence of lung disease, e.g. a goitre or spinal asymmetry. The position of the heart apex beat is of no help in assessing lung disease except if there is marked mediastinal shift.)
- cervical lymphadenopathy

**Percussion**

- examine the apices by percussing the clavicles
- move down the chest alternating right and left to compare both sides
### Table 4.1 Key features of the history in respiratory disease

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic details</td>
<td>Age, sex, current and previous occupations</td>
<td>Identify risk of occupational lung disease</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Dyspnoea, chest pain, wheeze, cough, sputum and haemoptysis</td>
<td>Establish pattern of symptoms and their likely causes</td>
</tr>
<tr>
<td>Past medical history</td>
<td>Previous episodes or other lung disease</td>
<td>Suggestive of chronic or relapsing symptoms, i.e. asthma, COPD</td>
</tr>
<tr>
<td>Allergies</td>
<td>Identify known allergies in patient or family</td>
<td>Potential for allergic lung diseases</td>
</tr>
<tr>
<td>Smoking</td>
<td>Establish accurate smoking history</td>
<td>Increased risk of chronic lung disease and cancer</td>
</tr>
</tbody>
</table>

#### Auscultation

*Listen for*

- bronchial breathing
- diminished breath sounds
- added sounds
  - wheezes
  - crackles
  - pleural rubs
- vocal resonance

#### Notes

**Haemoptysis**

**Aetiology: common**

- bronchial carcinoma
- tuberculosis
- pulmonary embolism with infarction
- infection (e.g. pneumococcal pneumonia, lung abscess and *Klebsiella pneumoniae*)

**Aetiology: uncommon**

- foreign body – history of general anaesthetic, visit to dentist or inhalation of food
- coagulation disorders
- bronchiectatic cavities
- mitral stenosis
- Wegener’s granulomatosis
- Goodpasture syndrome
- intrapulmonary vascular tumours

**Investigation of haemoptysis**

The usual clinical problem is to exclude carcinoma and tuberculosis. A full history and clinical examination will usually identify pulmonary infarction, foreign body, bronchiectasis, mitral stenosis and pulmonary oedema.

**Perform**

- sputum microscopy and culture, including for acid-fast bacilli
- sputum cytology for malignant cells
- chest X-ray
- CT or MRI scan to define the site and nature of the lesions seen on chest X-ray
- bronchoscopy with biopsy for cytology and culture
- CT guided biopsy of mass lesions
- isotope (V/Q) lung scan +/– spiral CT if pulmonary embolism is suspected

About 40% of patients with haemoptysis have no demonstrable cause. Patients who have had a single small haemoptysis, no other symptoms and a normal chest X-ray (postero-anterior and lateral) should have a follow-up chest X-ray after 1–2 months. Patients who have more than one small haemoptysis should be referred for bronchoscopy.

#### Clubbing

Finger clubbing is associated with a range of respiratory diseases, but also with disease in the cardiovascular and gastrointestinal systems. Rarely, clubbing may be familial and innocent.

**Respiratory causes**

- carcinoma of bronchus
- chronic suppurative lung disease: empyema, lung abscess, bronchiectasis, cystic fibrosis
- fibrosing alveolitis
- asbestosis
- mesothelioma

**Cardiac causes**

- cyanotic congenital heart disease
- subacute bacterial endocarditis
<table>
<thead>
<tr>
<th>Pathology</th>
<th>Reduced chest wall movement</th>
<th>Mediastinal shift</th>
<th>Percussion note</th>
<th>Breath sounds</th>
<th>Vocal resonance</th>
<th>Added sounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pleural effusion</td>
<td>Affected side</td>
<td>Away from lesion (if large effusion)</td>
<td>Stony dull</td>
<td>Reduced or absent</td>
<td>Reduced or absent</td>
<td>Possibility of crackles above the effusion None</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>Affected side</td>
<td>Away from lesion (if tension)</td>
<td>Normal or hyper-resonant</td>
<td>Reduced or absent</td>
<td>Reduced or absent</td>
<td>Crackles Fine, end-inspiratory crackles Coarse crackles</td>
</tr>
<tr>
<td>Consolidation</td>
<td>Affected side</td>
<td>None</td>
<td>Dull</td>
<td>Bronchial breathing</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Generalised fibrosis</td>
<td>Both sides</td>
<td>None</td>
<td>Normal</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Localised fibrosis</td>
<td>Affected side</td>
<td>Towards lesion</td>
<td>Dull</td>
<td>Bronchial breathing</td>
<td>Increased</td>
<td>Increased</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>None or both sides</td>
<td>None</td>
<td>Normal</td>
<td>Vesicular with prolonged expiration</td>
<td>Normal</td>
<td>Coarse crackles, expiratory wheezes</td>
</tr>
<tr>
<td>Asthma</td>
<td>Both sides</td>
<td>None</td>
<td>Normal</td>
<td>Vesicular with prolonged expiration</td>
<td>Normal</td>
<td>Expiratory wheezes</td>
</tr>
</tbody>
</table>
**Gastrointestinal causes**

- Crohn’s disease
- ulcerative colitis
- hepatic cirrhosis

**Cyanosis**

Cyanosis is a clinical description which refers to the blue-ish colour of a patient’s lips and tongue (central) or fingers (peripheral). Central cyanosis is always accompanied by peripheral cyanosis.

Cyanosis is an unreliable guide to the degree of hypoxaemia. Central cyanosis is usually caused by the presence of an excess of reduced haemoglobin in the capillaries. Thus, in anaemia, severe hypoxaemia may be present without cyanosis.

**Examine**

- the underside of the patient’s tongue and their finger nail beds (compare nail beds with your own)

If the tongue is cyanosed, the cyanosis is central in origin and secondary to:
- chronic bronchitis and emphysema, often with cor pulmonale
- congenital heart disease (cyanosis may be present only after exercise)
- polycythaemia
- massive pulmonary embolism.

If the tongue is not cyanosed but the finger nail beds are, the cyanosis is peripheral and secondary to:
- physiological causes (cold)
- pathology in peripheral vascular disease (the cyanosed parts feel cold).

Left ventricular failure may produce cyanosis that is partly central (pulmonary) and partly peripheral (poor peripheral circulation).

A rare cause of cyanosis, not caused by increased circulating reduced haemoglobin, is the presence of methaemoglobin (and/or sulphaemoglobin). The patient is relatively well and not necessarily dyspnoeic. Methaemoglobinemia is usually drug-induced, e.g. sulphonamides, primaquine or nitrates.

**Investigation of the respiratory system**

**Chest radiology**

Normal chest X-rays are shown in Fig. 4.2 (postero-anterior) and Fig. 4.3 (lateral). Fig. 4.4 is a radiological chest diagram of lobar collapse. CT chest scans are shown in Fig. 4.5.

*CT scanning* is more sensitive than plain CXR and may be useful in detecting interstitial lung disease, cavitation and empyema.

**Blood gases**

*The normal arterial values are:*

- $PaO_2$ 10–13 kPa (values fall with age)
- $PaCO_2$ 4.7–6.0 kPa
- pH 7.35–7.45
- Standard $HCO_3^-$ 23–27 mmol/l

The pH indicates acidosis or alkalosis.
\( \text{PaCO}_2 \) reflects alveolar ventilation. 
\( \text{PaO}_2 \) reflects ventilation/perfusion imbalance, gas transfer or venous-to-arterial shunts.

\( \text{PaCO}_2 \)
- raised may account for an acidosis of respiratory origin, e.g. respiratory failure
- reduced may account for an alkalosis as a result of hyperventilation

\( \text{PaO}_2 \)
- raised suggests the patient is on added oxygen
- reduced indicates lung disease (the \( \text{PaCO}_2 \) is usually high) or a right-to-left shunt

\( \text{HCO}_3^- \)
- raised standard \( \text{HCO}_3^- \) accounts for a metabolic alkalosis
- reduced accounts for a metabolic acidosis (usually renal or diabetic ketoacidosis)

**Interpretation of blood gases**

**Arterial gas patterns**
- High \( \text{PaCO}_2 \), low \( \text{PaO}_2 \): respiratory failure resulting from chronic obstructive pulmonary disease, asthma or chest wall disease (e.g. ankylosing spondylitis, neuromuscular disorders).
- Normal or low \( \text{PaCO}_2 \), low \( \text{PaO}_2 \): hypoxia as a result of parenchymal lung disease with normal airways. Hyperventilation due to hypoxia lowers the \( \text{PaCO}_2 \) (e.g. pulmonary embolism, fibrosing alveolitis).
Also seen with venous admixture from right-to-left shunts
• Low PaCO₂, normal PaO₂: usually hyperventilation.

Causes of hypoxaemia
• Hypoventilation: sedative drugs, central nervous system disease, neuromuscular disease, chest trauma, obstructive sleep apnoea. The arterial PaCO₂ is characteristically high.
• Ventilation/perfusion imbalance: hyperventilation of some alveoli cannot compensate for the hypoxaemia resulting from the hypoventilation of other alveoli. Transfer factor is reduced.
• Physiological shunt (venous admixture): deoxygenated blood passes straight to the left heart without perfusing ventilated alveoli. This occurs in cyanotic congenital heart disease. The arterial PaO₂ is not significantly improved by the administration of oxygen.
• Low inspired oxygen concentration because of altitude or faulty apparatus.

Type 1 respiratory failure (low PaO₂, normal/low PaCO₂)
Patients with lung disease causing hypoxaemia with hyperventilation, e.g. pulmonary oedema, pneumonia,
asthma, pulmonary fibrosis and pulmonary thromboembolism.

**Type 2 respiratory failure (low \( \text{PaO}_2 \), high \( \text{PaCO}_2 \))**

Patients with hypoxaemia and a high \( \text{PaCO}_2 \) due to defective ventilation caused by airways obstruction, reduced chest wall compliance or central nervous system disease.

---

**Pulmonary function tests**

**Spirometry (Fig. 4.6)**

Subject exhales as fast and as long as possible from full inspiration into a spirometer, before and after bronchodilatation.

**Interpretation**

- Volume expired in the first second is the forced expiratory volume in 1 s (FEV1).
- Total expired is the forced vital capacity (FVC). Relaxed (slow) vital capacity may provide a better measure of trapped gas volume in chronic airways obstruction.
- Constriction of the major airways reduces the FEV1 more than the FVC.
- Restriction of the lungs reduces the FVC and, to a lesser degree, the FEV1.
- \( \text{FEV1} : \text{FVC} (\text{FEV}%) \) ratio is low in obstructive airways disease (e.g. chronic bronchitis and asthma) and normal or high in fibrosing alveolitis and other interstitial lung diseases.
- Peak expiratory flow rate (PEFR) measures the rate of flow of exhaled air at the start of a forced expiration.

Normal values for all these tests vary with age, sex and size and appropriate nomograms should be consulted.

**Transfer factor**

- measures the transfer of a small concentration of carbon monoxide in the inspired air on to haemoglobin
- vital capacity must be over 1 litre and subject able to hold the breath for 15 s
- reduced in diseases that reduce ventilation or perfusion or alter the balance between them
- increased in pulmonary haemorrhage

Correction must be made for haemoglobin concentration, because transfer factor varies directly with haemoglobin. Its chief value is for monitoring progression in interstitial disease and in confirming a diagnosis of pulmonary haemorrhage.

---

**Figure 4.4** Diagrammatic representation of radiological appearance of lobar collapse.

(a) Normal. (b) Right upper lobe: trachea deviated to right, right diaphragm and hilum elevated. (c) Left upper lobe: trachea deviated to left, left hilum and diaphragm elevated. (d) Right middle lobe: right heart border lost. (e) Left lower lobe: trachea may deviate to left, shadow behind heart. (f) Right lower lobe: trachea may deviate to right, outline of right diaphragm lost.
Figure 4.5  (a) CT of chest at the level of T4 vertebra. (b) Diagrammatic representation. (c) The same CT in which a different window setting has been used to visualise the lung markings (the window settings determine the range of densities displayed).
Figure 4.6 Spirometric patterns. (a) Normal (elderly man) forced expiratory volume/forced vital capacity (FEV/FVC) = \(3.0/4.0 = 75\%\). (b) Restrictive, FEV/FVC = \(1.8/2.0 = 90\%\). (c) Obstructive, FEV/FVC = \(1.4/3.5 = 40\%\).
Examination of the abdomen may reveal abnormalities in a number of different systems including gastrointestinal, renal, haematological and cardiovascular disorders. Metabolic abnormalities including acute diabetic ketoacidosis and chronic hypercalcaemia may present with abdominal pain. In a patient with an acute abdomen, careful history-taking and examination forms a vital part of the initial management. In individuals with chronic disease, the history should dictate appropriate further investigations.

Key features in the history relating to gastrointestinal disease are shown in Table 5.1.

---

**Examination of the abdomen**

*General observation: note*
- is the patient in pain?
- evidence of weight loss

*Inspect*
- tongue, mouth, teeth and throat
- limbs for evidence of IV drug use

*Examine the hands for*
- clubbing
- leukonychia, koilonychia
- palmar erythema
- spider naevi
- Dupuytren’s contracture

*Inspect the eyes and conjunctivae for*
- anaemia
- jaundice
- xanthelasmata

*Palpate for lymphadenopathy*
- neck
- supraclavicular fossae
- axillae
- groins

A scheme for examination of the abdomen is shown in Fig. 5.1. Lie the patient flat (one pillow) with arms by the sides. Look before palpation, have warm hands and palpate gently so as to gain the patient’s confidence and to avoid hurting them. Ask the patient to let you know if you are hurting them. Check this by looking at the patient’s face periodically during palpation, especially if you elicit guarding or rebound tenderness.

*Observe the abdomen for*
- general swelling with eversion of the umbilicus in ascites
- visible enlargement of internal organs: liver, spleen, kidneys, gall bladder, stomach, urinary bladder and pelvic organs
- abnormally distended veins: usually in cirrhosis with the direction of flow away from the umbilicus (portal hypertension). The flow is upwards from the groin in inferior vena cava obstruction (Fig. 5.2)
- scars of previous operations, striae, skin rashes and purpura
- pigmentation
- visible peristalsis

*Palpate and percuss*
- For internal organs and masses: start palpation in the right iliac fossa and work upwards towards the hepatic and splenic areas, first superficially and then deeper.
- Percuss the liver and spleen areas to avoid missing the lower border of a very large liver or spleen.

**Liver**

- The upper border is in the fourth to fifth intercostal space on percussion.
- The liver moves down on inspiration.
Percussion over the liver is dull. If enlarged, the liver edge may be tender, regular or irregular, hard, firm or soft. Pulsatility suggests tricuspid incompetence. The liver may be of normal size but low because of hyperinflated lungs in chronic obstructive airway disease.

**Spleen**
- Smooth rounded swelling in left subcostal region, usually with a distinct lower edge.
- The spleen enlarges diagonally downward and across the abdomen in line with the ninth rib.
- The examining hand cannot get above the swelling.
- Percussion over the spleen is dull.
- There is a notch on the lower border of the spleen.
- The spleen may be more easily palpated with the patient lying on the right side with the left leg flexed and abducted.

**Kidneys**
- Palpated in the loins bimanually, i.e. most easily felt by pushing the kidney forwards from behind on to the anterior palpating hand.
- They move slightly downwards on inspiration.
- The examining hand can easily get between the swelling and the costal margin.
- Percussion is resonant over the kidneys.
- The lower pole of the right kidney can often be felt in thin normal persons.

**Abnormal masses**
- Palpate for abnormal masses particularly in the epigastrium (gastric carcinoma) and suprapubic region (bladder distension, ovarian and uterine masses). Describe in terms of their size and margins.
- Note colonic masses. The descending colon is commonly palpable in the left iliac fossa.
- The abdominal aorta is pulsatile, bifurcates at the level of the umbilicus and is easily palpable in thin and lordotic patients. Abdominal aortic aneurysms are expansile.
- Check for ascites: examine for shifting dullness by noting a change in percussion note with the patient supine and lying on their left side. A fluid thrill may be demonstrable in large, tense effusions.

### Table 5.1 Key features of the history in gastrointestinal disease

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic details</strong></td>
<td>Age, sex, occupation</td>
<td>Identify age-related and occupational risks</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td>Dysphagia, dyspepsia, vomiting, haematemesis, abdominal pain, weight loss, diarrhoea, constipation, lower GI bleeding, symptoms of malabsorption including steatorrhoea, jaundice, pale stools, dark urine</td>
<td>Establish pattern of symptoms and their likely causes. Length of history important in aetiology of diarrhoea and jaundice</td>
</tr>
<tr>
<td><strong>Past medical history</strong></td>
<td>Previous episodes or other GI disease; blood transfusions; recent anaesthesia</td>
<td>May suggest recurrent or chronic GI disease; hepatitis</td>
</tr>
<tr>
<td><strong>Social history</strong></td>
<td>Contacts with jaundiced patients; recent travel; residence abroad</td>
<td>Risk of infectious hepatitis; infectious diarrhoea</td>
</tr>
<tr>
<td><strong>Family history</strong></td>
<td>Family history of jaundice</td>
<td>Consider Gilbert syndrome</td>
</tr>
<tr>
<td><strong>Alcohol, smoking, drug abuse</strong></td>
<td>Establish alcohol and smoking history; enquire after IV drug abuse</td>
<td>Important in aetiology of a number of GI and hepatic diseases</td>
</tr>
<tr>
<td><strong>Medication</strong></td>
<td>Careful history, in particular aspirin and NSAIDs, steroids; phenothiazines, oral contraception, antibiotics</td>
<td>Many drugs with GI/hepatic side effects</td>
</tr>
</tbody>
</table>

NSAIDs, Non-steroidal anti-inflammatory drugs.
Auscultate for
- bowel sounds
- renal and femoral bruits

Notes

Splenomegaly
The major causes of splenomegaly are haematological and infectious (Table 5.2.)

Hepatomegaly
The causes of hepatomegaly are shown in Table 5.3.

Hepatosplenomegaly
The causes are similar to those for splenomegaly alone:

- chronic leukaemias
- cirrhosis with portal hypertension
- lymphoproliferative disorders
- myelofibrosis

Palpable kidneys
The left kidney is nearly always impalpable, but the lower pole of a normal right kidney may be felt in thin people.

Unilateral enlargement
- renal cell carcinoma
- hydronephrosis
- cysts
- hypertrophy of a single functioning kidney

Bilateral enlargement
- polycystic kidney disease
bilateral hydronephrosis
amyloidosis

Following renal transplantation a kidney may be palpable in one iliac fossa and the patient may appear cushingoid as a result of steroid therapy. Look for scars of previous surgery and forearm arteriovenous shunts.

Mass in right subcostal region

Consider
- liver (including Riedel’s lobe)
- colon
- kidney
- gall bladder (rarely)

Investigations
- ultrasound: identifies solid or cystic masses
- abdominal CT scan
- liver function tests
- urine for haematuria and proteinuria
- stool for occult bleeding

As appropriate
- sigmoidoscopy, barium enema and colonoscopy
- MRI scan

Suprapubic mass

Consider
- bladder distension
- pregnancy
- uterine masses (usually benign fibroid tumours, rarely malignancy)
- ovarian tumours

Ascites

Clinical features
- abdominal distension
- dullness to percussion in the flanks
- shifting dullness
- fluid thrill

Causes
- intra-abdominal neoplasia including gynaecological pathology
- hepatic cirrhosis with portal hypertension
- congestive cardiac failure
- constrictive pericarditis
- nephrotic syndrome
- low albumin states
- tuberculous peritonitis

Diagnostic paracentesis should be performed and examined for:
- protein content (>30 g/l suggests an exudate, <30 g/l suggests a transudate)
- microscopy and bacterial culture (including acid-fast bacilli)
- cytology.

Paracentesis may occasionally be required for the relief of severe symptoms; repeated paracentesis leads to excessive protein loss and should be avoided if possible.

Dysphagia

Dysphagia includes both difficulty with swallowing and pain on swallowing. The former symptom is more prominent in obstruction and the latter with inflammatory lesions.
Figure 5.3 (a) CT and (b) diagrammatic representation at the level of T11 vertebra. (c) CT and (d) diagrammatic representation at the level of L1 vertebra.
Causes

Common
- carcinoma of the oesophagus
- carcinoma of the gastric fundus
- peptic oesophagitis (with pain) proceeds to stricture with difficulty in swallowing

Rare
- achalasia of the cardia
- external pressure: carcinoma of the bronchus, retrosternal goitre
- dysmotility syndrome
- neurological disease: myasthenia gravis, bulbar palsies
- Plummer–Vinson syndrome – iron deficiency anaemia, koilonychia and glossitis with a post-cricoid oesophageal web

Investigations
- haemoglobin, serum iron and ferritin
- barium swallow (Fig. 5.4)
- upper GI endoscopy with biopsy to differentiate between benign peptic stricture and carcinoma

Table 5.2 Causes of splenomegaly

| Massive splenomegaly          | Chronic myeloid leukaemia |
| athletes: Infectious          | Bacterial                 |
| Haematological               | Brucellosis               |
| Inflammatory/                | Salmonella                |
| granulomatous disease        | Septicaemia               |
| Congestive                   | Bacterial endocarditis    |
| Storage diseases             | TB                        |
| Others                       | Megaloblastic anaemia     |
|                              | Idiopathic thrombocytopenia |
|                              | Congenital spherocytosis  |
|                              | Autoimmune haemolytic anaemias |
|                              | Polycythaemia rubra vera  |
|                              | Hodgkin’s disease         |
|                              | Lymphomas                 |
|                              | Chronic lymphatic leukaemia |
|                              | Sarcoïdosis               |
|                              | Felty syndrome            |
|                              | SLE                       |
|                              | Hepatic cirrhosis         |
|                              | Extrahepatic portal hypertension |
|                              | Niemann–Pick              |
|                              | Gaucher’s                 |
|                              | Amyloidosis               |

Table 5.3 Causes of hepatomegaly

| Common                          | Congestive cardiac failure |
| Other causes: Infectious        | Secondary carcinomatous deposits |
| Haematological                 | Cirrhosis (usually alcoholic) |
| Malignant                      | Glandular fever             |
| Granulomatous disease          | Viral hepatitis              |
| Storage diseases               | HIV/AIDS                     |
| Others                         | Amoebic cysts               |
|                                | Hydatid cysts               |
|                                | Leukaemia                    |
|                                | Reticuloendothelial disorders |
|                                | Hepatoma                     |
|                                | Sarcoidosis                  |
|                                | Gaucher’s                   |
|                                | Primary biliary cirrhosis    |
|                                | Haemochromatosis             |
|                                | Amyloidosis                  |

Diarrhoea

Acute gastroenteritis with diarrhoea and vomiting is the second most common group of disorders affecting the whole community (second to acute respiratory infections).

Specific features on examination in a patient with diarrhoea include
- evidence of weight loss, anaemia and clubbing
- abnormal abdominal masses
• signs of bowel obstruction
• hepatomegaly
• findings from digital rectal examination and sigmoidoscopy.

Infectious diarrhoea

Non-specific
• generally acute and viral in origin
• infant diarrhoea is usually caused by a rotavirus
• treatment of infectious diarrhoea is generally symptomatic

Food poisoning
• *Salmonella typhimurium* uncommon in Western countries
• *Salmonella enteritidis* infection from eggs and poultry
• *E. coli* serotypes generally from processed meat
• staphylococcal food poisoning, produced by the bacterial toxin, from precooked meats and dairy foods

Campylobacter infection
• common cause of bacterial gastroenteritis
• carried and communicated by cattle (milk), also common in poultry
• incubation takes up to a week, followed by fever, myalgia and cramping diarrhoea, occasionally bloody

Clostridium difficile infection (*pseudomembranous colitis*)
• follows antibiotic therapy; generally in hospital inpatients

Dysentery
• bacillary dysentery caused by *Shigella* organisms
• consider amoebic dysentry and giardiasis in individuals recently returned from endemic areas

Enteric fevers
• consider typhoid and paratyphoid in individuals recently returned from endemic areas

Cryptosporidium
• causes severe and sometimes intractable diarrhoea in HIV/AIDS

**Non-infectious diarrhoea**

Consider
• drugs
• diverticular disease
• colon cancer: alternating with constipation
• irritable bowel syndrome
• inflammatory bowel disease: ulcerative colitis and Crohn’s disease
• malabsorption syndromes
• thyrotoxicosis

Investigation

Acute diarrhoea
• full blood count for anaemia, liver and renal function tests
• blood cultures for *E. coli*, *Salmonella typhi*, *S. para-
typhi* and *S. enteritidis* where indicated in the history
• stool examination for cysts, ova and parasites
• stool culture
• sigmoidoscopy: biopsy and histology may be diagnostic

Chronic diarrhoea
• full blood count for anaemia, liver and renal function tests
• sigmoidoscopy with biopsy
• barium enema
• endoscopic duodenal biopsy if the history suggests malabsorption
• small-bowel barium studies if Crohn’s disease suspected

Bloody diarrhoea
• colon cancer
• diverticular disease
• ulcerative colitis
• dysentery
• ischaemic colitis
• *Campylobacter enteritis*

Rectal bleeding
• commonly caused by haemorrhoids and fissures
• other causes require investigation with sigmoidoscopy, barium enema and colonoscopy

Dysentery (bacillary and amoebic), typhoid, paratyphoid and cholera are notifiable to the public health authorities in the UK.

Jaundice

General

• Yellow colouration of the skin and sclerae is usually only apparent when the serum bilirubin is over 35 mmol/l.
• Hepatic jaundice causes deep yellow jaundice progressing to a greenish tinge.
• Haemolytic jaundice causes lemon-yellow skin colouration.
• The sclerae are not coloured in those with yellow skin caused by hypercarotinaemia.

Specific features on examination of the abdomen in a jaundiced patient include

• recent operation scars suggesting cholecystectomy or surgery for intra-abdominal carcinoma
• hepatomegaly: irregular when infiltrated with carcinoma or in early cirrhosis, tender in infectious and acute alcoholic hepatitis and occasionally in congestive heart failure
• splenomegaly in portal hypertension, spherocytosis and infectious mononucleosis
• palpable enlarged gall bladder suggesting bile duct obstruction caused by carcinoma of the pancreas (rather than gallstones)
• ascites.

Causes

Common

• viral hepatitis
• biliary obstruction from gallstones or carcinoma of the head of the pancreas
• drugs
• metastases
• intrahepatic cholestasis (including ascending cholangitis and primary biliary cirrhosis)
• infectious mononucleosis
• Gilbert syndrome

Uncommon

• haemolytic anaemia
• congenital hyperbilirubinaemia
• stenosis or carcinoma of the major bile ducts or ampulla

Investigation aims to

• discover the site of any biliary outflow obstruction
• determine the degree of impairment of liver cell function and its cause
• eliminate rare causes such as haemolysis
• establish potential for treatment.

Haematology

Check

• full blood count, reticulocyte count and Coombs’ test

A normal reticulocyte count virtually excludes haemolytic jaundice. Leukocytosis may suggest infection or carcinoma. Abnormal mononuclear cells suggest infectious mononucleosis or viral hepatitis.

Liver function tests

• Measure the ability of the liver to perform normal functions (e.g. serum albumin is a measure of protein synthesis; prothrombin time is a measure of synthetic function; bilirubin is a measure of bile salt conjugation and excretion).
• Liver enzymes (alkaline phosphatase, transaminases) are indicators of ductal or liver cell damage.
• In obstructive jaundice the alkaline phosphatase is greatly elevated compared with transaminases; in hepatocellular disease transaminases are predominantly raised.

Bilirubin

• Bilirubin derived from red cell breakdown is transported to the liver where it is conjugated to glucuronic acid. Conjugated bilirubin is secreted in the bile and degraded in the gut by bacteria to form urobilinogen. Urobilinogen is either excreted in the stool or reabsorbed from the gut and excreted by the kidneys.
• Serum bilirubin is predominantly unconjugated in haemolytic jaundice and the other liver function tests are usually normal. It is mainly conjugated in obstructive jaundice.

Causes of increased bilirubin

• hepatocellular failure
• biliary obstruction
• haemolysis
• Gilbert syndrome

Alkaline phosphatase

Alkaline phosphatase is found in high levels in biliary canaliculi, osteoblasts, intestinal mucosa and placenta.
Elevated in
- obstructive jaundice
- hepatocellular jaundice
- growth in adolescence
- pregnancy

Normal in
- Gilbert syndrome (p. 37)
- myeloma

A raised level in the absence of other signs of liver disease or abnormal liver function tests suggests the presence of malignant secondary deposits in the bone or Paget’s disease. Consider measuring isoenzymes if there is doubt.

Causes of increased hepatic alkaline phosphatase
- extra-hepatic cholestasis
- obstructive jaundice
- intra-hepatic cholestasis (e.g. cirrhosis, drugs, cholangitis, primary biliary cirrhosis)
- obstructive phase of hepatitis

Causes of increased bone alkaline phosphatase (osteoblastic activity)
- Paget’s disease
- bone metastases
- osteomalacia
- hyperparathyroidism
- normal growth in puberty
- fractures

Transaminases
Elevated serum transaminases (alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase) indicate hepatocellular damage. Slight elevation is consistent with obstructive jaundice.

Causes of elevated alanine aminotransferase
- active liver cell damage, including drugs, hepatitis and metastatic infiltration
- acute myocardial infarction (peaks at 24–48 h, may fall to normal by 72 h). The degree of elevation reflects the amount of muscle damage
- acute pancreatitis
- haemolysis

Elevated aspartate aminotransferase levels parallel the alanine aminotransferase

Urinalysis
- conjugated bilirubin renders the urine dark yellow
- urobilinogen is colourless but on standing the urine turns brown as urobilinogen is converted to urobilin by oxidation.
- Haemolytic jaundice is acholic (no bilirubin in the urine) but the urine contains excess urobilinogen because excess bilirubin reaches the intestine and is re-excreted as urobilinogen.
- Obstructive jaundice produces dark brown urine with excess bilirubin but a reduction of urinary urobilinogen (little or no bilirubin reaches the gut because of the obstruction and therefore cannot be reabsorbed and re-excreted).

In the early stages of acute viral hepatitis, excess urobilinogen may sometimes be present before clinical jaundice becomes apparent. This is a result of failure of the liver to take up the excess urobilinogen absorbed from the gut. With increasing severity, biliary obstruction develops and as conjugated bilirubin appears in the urine it disappears from the gut and urobilinogen disappears from the urine. The reciprocal effect also occurs during recovery.

Serology
Check
- viral hepatitis serology – hepatitis A–E, cytomegalovirus (CMV) and Epstein–Barr virus (EBV)
- antimitochondrial antibodies (primary biliary cirrhosis)
- antinuclear factor and smooth-muscle antibodies (chronic active hepatitis)

Abdominal radiology in jaundice
- Plain X-ray and ultrasound may show gallstones.
- Ultrasound, CT (Fig. 5.3) and MRI may show primary or secondary tumours, pancreatic carcinoma, stones in the gall bladder and dilated biliary ducts in obstruction.
- Isotope liver scans may demonstrate secondary deposits.

Needle liver biopsy
Biliary obstruction is a relative contraindication because of the potential danger of biliary peritonitis. Ultrasound and CT-guided biopsy may provide the histological diagnosis in focal lesions. Check the prothrombin time and platelet counts are normal. Fresh frozen plasma will quickly reverse the prothrombin time for the duration of the procedure.
Other investigations

- Endoscopic retrograde cholangiopancreatography (ERCP) is valuable to define obstruction of the pancreaticoduodenal tree, for sphincterotomy, to release stones and to relieve obstruction by insertion of a stent.
- \( \alpha \)-fetoprotein is raised in hepatocellular carcinoma.

Congenital non-haemolytic hyperbilirubinaemias

These may explain persistent jaundice in the young after viral hepatitis or slight jaundice in the healthy.

Gilbert syndrome (autosomal dominant)

- Common congenital hyperbilirubinaemia (1–2% of the population). There is impaired glucuronidation of bilirubin (reduced uridine diphosphate glucuronyl transferase (UDPGT)) resulting in raised unconjugated plasma bilirubin and acholuria. About 40% of cases have a reduced red cell survival with a consequent increase in bilirubin production.
- The plasma bilirubin is usually <35 mmol/l.
- Diagnosis is by exclusion: there is no haemolysis and the other liver function tests are normal.
- Fasting and intercurrent illness produce a rise in plasma bilirubin.
- The liver is histologically normal.
- The prognosis is excellent and treatment unnecessary.

Dubin–Johnson syndrome (autosomal recessive)

- rare benign disorder of failure to excrete conjugated bilirubin
- plasma bilirubin is conjugated
- histologically the liver is stained black by centrilobular melanin

Renal disease

Key features in the history of a patient with renal disease are shown in Table 5.4.

Specific features on examination in a patient with renal disease include:

- uraemic pallor (pale, brownish-yellow appearance of skin)

<table>
<thead>
<tr>
<th>Table 5.4 Key features of the history in renal disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renal failure</td>
</tr>
<tr>
<td>Urinary tract infection</td>
</tr>
<tr>
<td>Medication</td>
</tr>
<tr>
<td>Past history</td>
</tr>
<tr>
<td>Family history</td>
</tr>
</tbody>
</table>

- bruising
- hypertension and its consequences
- postural hypotension
- signs of dehydration
- hyperventilation from acidosis
- palpable bladder in outflow obstruction
- palpable kidneys: polycystic disease and hydronephrosis
- ankle or sacral oedema suggesting nephrotic syndrome or fluid overload
- renal artery bruits
- signs of dialysis: arteriovenous fistula, continuous ambulatory peritoneal dialysis (CAPD) catheter
- transplanted kidney
- peripheral neuropathy
- pericarditis
- muscular twitching, hiccups, fall in blood pressure and uraemic frost in severe untreated renal failure
- digital rectal examination (DRE) will reveal prostatic hypertrophy or carcinoma.

Basic investigations

- bloods: urea, creatinine, potassium and bicarbonate. Calculate estimated glomerular filtration rate (eGFR) using recognised equations (e.g. MDRD formula http://www.renal.org/eGFRcalc/GFR.pl)
- urinalysis: microscopy, protein and glucose
• ultrasonography: renal outflow obstruction and renal size

**Urea and creatinine**

Production rate of urea varies, making it a less useful measure of renal function than creatinine, which is produced at a roughly constant rate proportional to skeletal muscle mass.

**Increased serum urea**

- decreased excretion: renal failure especially dehydration and pre-renal failure
- increased protein catabolism: steroids, surgery, cytotoxic therapy, trauma, infection
- increased protein intake: dietary, gastrointestinal haemorrhage

**Decreased serum urea**

- decreased synthesis: extensive liver disease, low protein intake (malnutrition or malabsorption)
- increased excretion: increased GFR in pregnancy
- dilution: syndrome of inappropriate ADH secretion (SIADH), excess intravenous fluids

**Increased serum creatinine**

Impaired renal function: creatinine rises above the normal range when there is ~50% loss of renal function

**Creatinine clearance**

- patient performs a 24-h collection of urine and a single measurement of plasma creatinine is made during this time. Creatinine clearance (millilitres per minute) is measured as:

\[
\text{urine creatinine concentration (\(\mu\text{mol/l}\)) \times vol (ml) \div \text{plasma creatinine (\(\mu\text{mol/l}\)) \times time (min)}}
\]

Small quantities of creatinine are excreted by the renal tubules. The creatinine clearance therefore slightly overestimates the GFR. Chromium-51 ethylenediamine tetra-acetic acid (\(^{51}\text{Cr EDTA}\)) clearance more accurately reflects the GFR. It is calculated from the rate of disappearance of a bolus injection of \(^{51}\text{Cr EDTA}\) from the blood.

**Decreased serum creatinine**

- loss of muscle mass
Neurological system

Disorders of the neurological system present with a wide range of symptoms and signs, reflecting the complexity of the system as a whole and numerous pathological mechanisms. For the non-specialist student, trainee or physician, it is important to develop a logical and systematic approach to the clinical history and examination based on knowledge of the underlying anatomy and physiology. Neurological diagnosis has been transformed by advances in radiology and other imaging techniques, including developments in functional imaging. Appropriate use and interpretation of modern investigative techniques rely upon accurate clinical assessment.

History
Key features of the history in a patient with neurological disease are shown in Table 6.1.

Examination of the nervous system
It is important to develop a technique for examination of the nervous system which is rapid and accurate. Analysis of clinical signs is facilitated by knowledge of underlying neuroanatomy shown in the simplified diagrams in this chapter. Examination of the nervous system also requires clear communication with the patient to promote understanding of the sometimes unfamiliar instructions to be given.

Mental state and higher cerebral function

General observation: note
• general appearance and behaviour

• speech
• mood
• abnormal beliefs and/or perceptions

Cognitive function
Loss of memory for recent events more than for distant events is a feature of organic cerebral disease and an early feature of dementia.
• Use the Mini-Mental State Examination (MME).
• MME consists of 12 questions. Maximum score is 30 and a normal score is 26–30. A score of less than 24 indicates cognitive impairment: 21–25 suggests dementia (likelihood ratio = 5), and 20 or less is highly suggestive of cognitive impairment (likelihood ratio = 8).

Other tests of cognitive function
Concentration: serial sevens
Ask the patient:
• to subtract 7 from 100, then seven from the answer and so on
• to remember a series of numbers forward and backward: most people can remember five or more forward and four or more backward
• to repeat a complex sentence, e.g. ‘The one thing a nation requires to be rich and famous is a large, secure supply of wood.’

Orientation
Ask the patient, for example:
• their name, date of birth, address
• the date and the place of the interview
• to name the monarch, prime minister, members of favourite sports teams, famous places and capitals.
Table 6.1 Features of the history in neurological disease

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic details</td>
<td>Age, sex, handedness, current and previous occupations</td>
<td>CNS orientation; identify risk of occupational disease</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Headaches; facial pain; disordered consciousness ('fits, faints and funny turns'); vertigo; sensory symptoms including numbness, paraesthesias and pain; motor symptoms including weakness, incoordination, involuntary movements and gait disorders; acute confusional states; memory disorders and symptoms of dementia; speech and language problems; visual disturbances; perceptual problems; sphincter disturbance</td>
<td>Establish pattern of symptoms and their likely causes including relapsing and remitting pattern or progressive problems; establish details of symptoms particularly related to their location and nature, precipitating and relieving factors</td>
</tr>
<tr>
<td>Past medical history</td>
<td>Cardiovascular disease; diabetes; trauma; inflammatory/immunological disease; infections including HIV/AIDS</td>
<td>Potential causes of neurological disorders</td>
</tr>
<tr>
<td>Social and family history</td>
<td>Alcohol; smoking; recreational drug use; family history of similar neurological disorders</td>
<td>Potential causes of neurological disease or vascular impairment; potential genetic syndromes</td>
</tr>
<tr>
<td>Medication</td>
<td>Review all medication</td>
<td>Neurological side effects for many medications</td>
</tr>
<tr>
<td>Mental state</td>
<td>Assess mental state</td>
<td>Depression is a common feature of chronic neurological syndromes including chronic pain, movement disorders and early dementia</td>
</tr>
</tbody>
</table>

Mood

Observe:

- facial expression, posture, movement.

Ask the patient:

‘Do you feel sad or depressed, are you anxious or worried, does your mood change rapidly and, if so, what happens?’

Expressive (motor) dysphasia and aphasia

Observe:

- patient’s understanding is intact
- word finding is difficult
- speech is absent in aphasia.

Nominal dysphasia describes a specific expressive dysphasia in which the patient knows what an object is but cannot name it.

Hold up an object, e.g. a pen.

Ask the patient:

- ‘What is this?’
- Pause
- ‘Is it a watch?’ ‘No’
- ‘Is it a key?’ ‘No’
- ‘Is it a pen?’ ‘Yes’

Check for associated spatial problems:

- dressing apraxia: observe the patient
- constructional apraxia: ask the patient to copy your drawing of a house or simple shape.

Speech disorders

Dysarthria

Observe:

- slow or slurred speech in conversation
- local lesions in the mouth
- features of pseudobulbar palsy
- generalised motor or myopathic disorders.

Test articulation; ask the patient to repeat: ‘Baby hippopotamus’ and ‘West Register Street’
Receptive (sensory) dysphasia

Observe:
- failure to understand the meaning of words
- fluency: no problem with motor speech but meaningless responses to questions.

Tactile agnosia

This indicates damage to the contralateral sensory lobe. Ask the patient:
- to recognise and distinguish objects placed in the hand (failure known as astereognosis)
- to recognise figures drawn on the palm with the eyes closed (failure known as dysgraphaesthesia).

Cranial nerves

Remember diagrams of cross-sections of the brainstem and of the floor of the fourth ventricle (Figs. 6.2, 6.3) because these may greatly improve the analysis of a cranial nerve lesion. The following paragraphs outline a system for examination of the cranial nerves that recognises the need to examine parts of the head and neck in a logical order rather than by following the order of the cranial nerves directly.

Sense of smell

Ask the patient:
'Has there been any recent change in your sense of smell?'
If yes:
- assess informally with easily available substances (coffee granules, oranges)
- test formally with fresh ‘smell bottles’

Eyes

Observe and examine:
- visual acuity, either quickly with available literature, formally with Snellen charts or by counting fingers if vision is very poor
- visual fields to confrontation
  - compare the patient’s visual fields with your own
  - the patient’s head should be level with yours and at arm’s length away
  - when testing the right eye, ask the patient to look straight into your left eye and vice versa for the patient’s left eye.

Ask the patient to:
‘Keep looking at my eye and tell me when you first see my finger out of the corner of your eye.’
- preferably using a red-headed hatpin, or your finger, bring the target towards the centre of the field of vision from the four diagonals (upper right, upper left, lower right, lower left)
- the nasal and superior fields are limited by the nose and eyebrow, respectively
- move the pin across the centre of each eye to examine for a central scotoma
- test for visual inattention (extinction and hemineglect) by asking the patient to identify which fingers you are moving with your hands held at the outer edges of the patient’s visual fields.

Ptosis

- third nerve lesion (complete ptosis)
- sympathetic lesion (partial ptosis) or as part of Horner syndrome
- generalised muscle weakness (myasthenia gravis, dystrophia myotonica, facio-scapulohumeral dystrophy, congenital lesions)

Dorsal columns

Spinocerebellar tracts

Spinothalamic tracts

Sensory Motor

Lateral corticospinal tract

Figure 6.1 Cross-section through the spinal cord.
Pupillary reflexes and accommodation

- examine the pupillary reflexes in subdued light
- inspect the pupil for irregularity
- flash a pen-torch twice at each eye, once for direct and once for consensual responses; move the torch in from the side so as to avoid an accommodation-convergence reflex
• ask the patient to focus on your finger held at arm’s length and then move your finger to the patient’s focal point, observing convergence and pupillary constriction

**External ocular movements (3rd, 4th and 6th nerve)**

Ask the patient:
*’Do you have any double vision?’*
If the patient has not noticed diplopia:
• test the eye movements formally by asking the patient to follow your finger with their eyes, moving your finger slowly through the gaze regions
• examine upwards and downwards gaze for each eye in full abduction and adduction
• note any nystagmus.

Diplopia is maximal when looking in the direction of action of the paralysed muscle. The image further from the midline arises from the paralysed eye.
If the patient has noticed diplopia:
• ask in which direction it is worst
• move your forefinger in that direction and then ask if the two fingers that the patient sees are parallel to each other (lateral rectus palsy: 6th nerve) or at an angle (superior oblique palsy: 4th nerve)
• cover up each eye in turn and ask which image has disappeared.

**Nystagmus**

Ask the patient:
*’Look at my finger’*
• hold the patient’s gaze in full abduction in each direction for a few seconds
• examine for nystagmus
• repeat with the eyes in upgaze.

**Perform fundoscopy**

Ask the patient to:
*’Focus on a point at a distance ahead and slightly upwards’*

Using the ophthalmoscope:
• check the red reflex
• focus through the lens and vitreous
• assess the optic disc, noting colour, cupping, margins and vessels
• examine the retina in all four quadrants
• observe the macula and major vessels.

**Face**

**Facial expression (7th nerve, motor)**

Ask the patient to:
*’Screw up your eyes very tightly’*
• compare how deeply the eyelashes are buried on the two sides
*’Raise your eyebrows’*
• compare right and left sides
*’Show your teeth’*
• compare the nasolabial grooves.

**Facial sensation (5th nerve, sensory)**

Test the three divisions on both sides:
• light touch with cotton wool
• corneal reflexes.

**Mouth**

Ask the patient to:
*’Clench your teeth’* (masseters, 5th nerve, motor)
• palpate the masseters
• test the jaw jerk: place one finger horizontally across the front of the jaw and tap the finger with a tendon hammer with the jaw relaxed and the mouth just open
*’Open your mouth and keep it open’* (pterygoids, 5th nerve, motor)
• attempt to force it closed
• in a unilateral lesion, the jaw deviates towards the weaker side
*’Say aaah’* (9th and 10th nerves: both mixed)
• observe the movement of the uvula and soft palate: normally they move upwards and remain central and the posterior pharyngeal wall moves little
• in a unilateral lesion the soft palate is pulled away from the weaker side
• test the gag reflex (9th nerve sensory, 10th nerve motor)
*’Put your tongue out’* (12th nerve)

Look for:
• wasting
• fasciculation
• in a unilateral lesion protrusion towards the weaker side.

**Neck (11th nerve)**

Observe:
• muscle wasting
Ask the patient to:
‘Lift your head off the pillows’
‘Put your chin on your right (or left) shoulder’
- resist the movement
- observe and palpate the sternomastoids
‘Shrug your shoulders’
- attempt to push them down
- observe and palpate the bulk of trapezius.

Hearing and vestibular function (8th nerve)

Test hearing:
- whisper a number in each ear in turn, obstructing the contralateral ear
- perform Weber and Rinne tests (see below)
- inspect eardrums with an auriscope if indicated.

Test vestibular function if indicated:
- perform the Hallpike manoeuvre
- request caloric tests.

The limbs

Figs. 6.4 and 6.5 give an overview of the motor and sensory systems.

Arms: motor system

Observe:
- obvious muscle wasting
- fasciculation or tremor
- wasting of the small muscles of the hand, noting whether ulnar or thenar.

Test muscle tone:
- holding the arm, ask the patient to relax and move the arm gently at the elbow and wrist using an...
irregular rhythm to discourage resistance. Ask the patient to relax and, holding the thigh, shake the leg gently
- note cogwheel rigidity, which may be more obvious at the wrist.

Test muscle power in groups. Explain what you are doing to the patient:
*I am going to test the strength of some of your muscles*

Shoulder (C5):
*‘Hold both arms out in front of you and close your eyes’*
Observe drifting of one arm indicating:
- weakness of the muscles at the shoulder
- loss of position sense with no evidence of weakness
- lesions of the cerebral cortex (when the patient will not be aware of the drift, sometimes even with open eyes).

Box 6.1 A simple aide-mémoire for reflexes

A simple aide-mémoire for reflexes and controlling muscle groups is 12345678
Ankle jerk S1, 2
Knee jerk L3, 4
Biceps jerk C5, 6
Triceps jerk C7, 8
Shoulder abduction: ‘Bend your elbows and lift your arms up to the side; don’t let me push them down’

• resist the action

Shoulder adduction: ‘Now pull them in towards your chest; don’t let me stop you’

• resist the action

Observe:
• winging of the scapula (nerve to serratus anterior, C5, 6, 7).

Elbow:
Flexion: C5, 6, 7 (biceps):
‘Bend your elbow, bring your hand to your shoulder; don’t let me straighten it’

Extension: C7: (triceps):
‘Now straighten your elbows and push me away’

Wrist:
Extension: C7:
‘Hold your arms out straight, cock up your wrists; don’t let me straighten them’

Hand grip: C8, T1:
‘Squeeze my fingers hard and stop me pulling them out of your grip’

Finger abduction: ulnar nerve:
‘Spread your fingers apart; don’t let me push them together’

• push against 1st and 5th fingers

Finger adduction: ulnar nerve:
Place a piece of paper between straight fingers
‘Don’t let me pull it out’

• attempt to pull the paper from between the patient’s fingers

Abduction of thumb: median nerve:
‘Place your hand down flat with the palm upward and the thumb overlying the forefinger. Lift the thumb vertically and don’t let me push it down’

Opposition of thumb: median nerve:
‘Put your thumb and little finger together and stop me pulling them apart with your forefinger’

Reflexes (Box 6.1)

Tendon reflexes:
• when testing reflexes, it is essential that the muscle involved is completely relaxed
• watch the muscle for contraction

Biceps:
• ask the patient to rest their arm across their abdomen with the elbows partially flexed
• place a finger over the flexor tendon and tap your finger

Triceps:
• rest the patient’s forearm on yours and tap the triceps tendon directly

Supinator:
• ask the patient to rest their arm across their abdomen with the elbows partially flexed
• hold the patient’s hand loosely
• tap the supinator tendon directly above the wrist

If a reflex is difficult to elicit or absent, demonstrate reinforcement:
• ask the patient to concentrate on contracting muscles at a distant site when instructed (e.g. ‘Grip your hands together’ or ‘Clench your teeth’).

Coordination

Finger–nose test:
Hold your forefinger at arm’s length from the patient: ‘Touch my finger, then your nose, then my finger, going backwards and forwards as quickly and accurately as you can’

• intention tremor is more marked when the patient has to stretch to reach your finger
• the tremor is not altered by closing the eyes

keep your finger still and then ask the patient to repeat the test to establish past-pointing – deviation of the patient’s finger consistently to one side of your own indicates the side of a cerebellar lesion

Dysdiadochokinesia:
Demonstrate to the patient: ‘Tap rapidly on the back of your hand like this.….and now alternate the front and back of your hand like this’

• rapid repetitive alternating movements of the wrists are irregular in both force and rate in cerebellar disease

Muscular weakness alone may make the patient unsteady in all these tests, and this may resemble an intention tremor.

Sensation

The sensory dermatomes are shown in Fig. 6.6.

When testing sensation:
• Ensure that the patient understands what sensations you are testing and what is an appropriate response.
• Demonstrate the normal response in an area not thought to be affected (usually over the sternum).
In all modalities use a single touch; moving a stimulus induces two-point discrimination.

Always check from side to side, comparing right with left and work systematically.

Joint position sense (proprioception), vibration sense and accurate sensation (pin-prick, two-point discrimination) are relayed in the dorsal spinal tracts. Poorly localised diffuse touch, pain and temperature sensation are carried in the lateral spinothalamic tracts.

**Diffuse touch (cotton wool) and accurate touch (pin-prick):**

- Establish the normal response by touching cotton wool or neurotips pin onto the sternum and checking the patient’s recognition of the sensation.

‘Close your eyes and say “Now” every time you feel the touch’

- Examine the arms systematically along the distribution of the dermatomes.

**Vibration sensation:**

- Ensure during testing that the tuning fork is vibrating but not making a loud noise.
- Establish the normal response by placing the tuning fork onto the sternum and checking the patient’s recognition of the vibration sensation. Stop the vibration to allow the patient to recognise the difference.

‘With your eyes closed say “Yes” if you can feel the vibration and tell me when it stops’

- Work distally to proximally, checking over bony prominences in the fingers, wrists and elbows.

**Joint position sense (proprioception):**

- Establish the normal response: with the patient looking, hold a finger by its sides (holding the top and bottom introduces diffuse touch sensations). Move the finger up and down, explaining what you are doing.
‘Now with your eyes closed tell me whether I move your finger up or down’

Temperature sensation:
- use readily available stimuli such as a warm finger and cold tuning fork handle

‘Now with your eyes closed tell me whether this is cold or warm’
- work distally to proximally

**Legs: motor system**

Observe:
- obvious muscle wasting
- fasciculation or tremor

Test muscle tone:
- lift the knee off the bed briskly while the patient is relaxed and see if the heel is lifted. Let it drop; observe how stiffly it falls
- roll the leg to and fro, and see if the foot is rigid at the ankle or normally loose
- bend the knee to and fro using an irregular rhythm to discourage resistance

Test muscle power in groups.

Explain what you are doing to the patient:
‘I am going to test the strength of some of your muscles in your legs’

Hip flexion (L1, L2):
- ‘Lift your leg up straight and don’t let me push it down’
- push down on the patient’s knee

Hip extension (L5, S1):
- ‘Lift your leg up straight: push my hand down to the bed’
- place your hand under the ankle and resist the movement

Knee flexion (L5, S1, S2):
- ‘Bend your knee and bring your heel up to your bottom: don’t let me straighten it’
- put your hand behind the ankle and resist the movement

Knee extension (L3, L4):
- ‘Now straighten your leg’
- put your hand on the patient’s shin and resist the movement

Ankle plantar flexion (S1):
- ‘Push your foot down: don’t let me push it up’
- place your hand under the patient’s foot and resist the movement

Ankle dorsiflexion (L4, L5):
- ‘Bend your foot upwards and don’t let me pull it down’
- place your hand on the dorsum of the foot and resist the movement

**Reflexes (Box 6.1)**

When testing reflexes it is essential that the muscle involved is completely relaxed and watch the muscle for contraction.

**Patellar reflexes:**
- ensure the knee joint is relaxed and held in flexion
- right knee – place your arm under the knee and rest your hand on the patient’s left knee
- left knee – rest your arm over the right knee and support the underside of the left knee
- tap the patellar tendon with reinforcement if necessary

**Ankle reflexes:**
- externally rotate the patient’s ipsilateral hip and partially flex the knee
- place your hand under the foot and gently flex the ankle; do not hold the ankle in extreme flexion
- tap the Achilles’ tendon with reinforcement if necessary

**Clonus:**
If the reflexes are brisk examine for ankle clonus:
- with the leg held in the position for examination of the ankle reflexes flex the ankle and sustain the flexion to observe rhythmic contraction of the muscles

**Plantar reflexes:**
- gently but firmly draw an orange stick up the outer border of the sole and across the heads of the metatarsals
- observe the flexion (normal) or extension (UMN lesion) of the big toe

**Coordination**

Heel–shin test: this is primarily a test for intention tremor.
Instruct the patient, demonstrating what you mean:
‘Put your heel on your knee and slide it down your shin. Move it up and down as quickly and accurately as you can’

**Sensation**

The sensory dermatomes are shown in Fig. 6.6.

Note the caveats given above for examination of the arms.
Diffuse touch (cotton wool) and accurate touch (pin-prick):

- Establish the normal response by touching cotton wool or neurotips pin onto the sternum and checking the patient’s recognition of the sensation.

‘Close your eyes and say “Now” every time you feel the touch’

- Examine the legs systematically along the distribution of the dermatomes.

Vibration sensation:

- Ensure during testing that the tuning fork is vibrating but not making a loud noise.
- Establish the normal response by placing the tuning fork onto the sternum and checking the patient’s recognition of the vibration sensation. Stop the vibration to allow the patient to recognise the difference.

‘With your eyes closed say “Yes” if you can feel the vibration, and tell me when it stops’

- Work distally to proximally, checking over bony prominences in the toes, ankles and knees.

Joint position sense (proprioception):

- Establish the normal response: with the patient looking, hold the big toe by its sides (holding the top and bottom introduces diffuse touch sensations). Move the toe up and down, explaining what you are doing.

‘Now with your eyes closed tell me whether I move your toe up or down’

- If abnormal joint position sense is detected, move proximally and test in larger joints (ankle, knee).

Temperature sensation:

- use readily available stimuli such as a warm finger and cold tuning fork handle

‘Now with your eyes closed, tell me whether this is cold or warm’

- work distally to proximally.

If there is evidence of a symmetrical peripheral neuropathy establish the upper border by testing sensation from the foot towards the knee.

Gait

Ask the patient to walk a few steps:

- observe obvious patterns of gait disturbance (see below).

Perform Romberg’s test

Ask the patient to stand with feet close together. Stand close and be prepared to support them if you suspect a sensory abnormality.

‘Close your eyes’

- observe if the patient is more unsteady with the eyes closed (positive test)
- a positive Romberg’s test indicates loss of joint position sense (posterior column lesion)

Truncal ataxia

Ask the patient to stand with feet together:

- sway suggests truncal ataxia in a cerebellar lesion.

Notes

Visual field defects

Field defects (Fig. 6.7) are described by the side of the visual field which is lost; thus ‘temporal field loss’ indicates loss of the temporal field of vision and denotes damage to the nasal retina or its connections to the visual cortex. Formal perimetry will accurately define defects.

- Temporal hemianopia in one eye alone or in both eyes (bitemporal hemianopia) suggests a chiasmal compression, usually from a pituitary tumour.
- Homonymous hemianopia (loss of nasal field in one eye and temporal field in the other) may occur with any postchiasmal lesion, most commonly following a vascular lesion affecting the occipital cortex (usually with macular sparing, because of the dual blood supply to the occipital cortex from the posterior and middle cerebral arteries). The side of the field loss is opposite to the side of the damaged cortex (i.e. a right-sided cerebral lesion produces a left homonymous hemianopia).

- Upper quadrant field loss suggests a temporal lesion of the opposite cortex or optic radiation or, if bilateral, early chiasmal compression due to pituitary expansion. A lower quadrant field loss suggests a parietal lesion.

- Central scotoma. Loss of vision in the centre of the visual field occurs in acute retrobulbar neuritis, most commonly caused by multiple sclerosis.

- Hemi-inattention suggests a contralateral posterior parietal lesion.

Pupillary reflexes

Pupil size is controlled by the balance between parasympathetic (constrictor) and sympathetic (dilator) tone.
Constriction of the pupil in response to light: this is relayed via the optic nerve, optic tract, lateral geniculate nuclei, the Edinger–Westphal nucleus of the 3rd nerve and the ciliary ganglion. The cortex is not involved.

Constriction of the pupil with accommodation: convergence originates within the cortex and is relayed to the pupil via the 3rd nerve nuclei. The optic nerve and tract and the lateral geniculate nucleus are not involved. Therefore:

If the direct light reflex is absent and the convergence reflex is present, a local lesion in the brainstem or ciliary ganglion is implied, possibly as a result of degeneration in the ciliary ganglia, e.g. the Argyll Robertson pupil.

If the convergence reflex is absent and the light reflex is present, a lesion of the cerebral cortex is implied, e.g. cortical blindness.

If the pupil is constricted consider:

- Horner syndrome (see below)
- opiates, pilocarpine
- pontine haemorrhage

- Argyll Robertson pupil (irregular, no light reflex)
- normal old age.

If the pupil is dilated consider:

- mydriatics (e.g. homatropine, tropicamide or cyclopentolate)
- 3rd-nerve lesion
- Holmes–Adie syndrome (pupils constrict sluggishly to light, associated with absent tendon reflexes)
- congenital defect.

In the unconscious patient a fixed dilated pupil (3rd-nerve lesion) may indicate temporal lobe herniation on the same side caused by raised intracranial pressure, intracranial bleeding, tumour or abscess.

Horner syndrome

Horner syndrome comprises unilateral:

- partial ptosis (sympathetic)
- miosis (constricted pupil) with normal reactions
- anhidrosis (decreased sweating over face)
- enophthalmos (indrawing of orbital contents).

The syndrome results from lesions of the sympathetic nerves to the eye, anywhere from the
hypothalamus downwards through the sympathetic nucleus of the brainstem and during their passage through the cervical and upper thoracic cord, the anterior spinal first thoracic root, the sympathetic chain, stellate ganglion and carotid sympathetic plexus.

Look for evidence of a T1 lesion and scars of previous cervical sympathectomy, palpate the neck and supraclavicular fossae for lymphadenopathy and examine for signs of cardiovascular disease and syringomyelia where indicated.

Eye movements
These are controlled by the 3rd, 4th and 6th nerves. Conjugate movement is integrated by the medial longitudinal bundle, which connects the above nerve nuclei together and to the cerebellum and vestibular nuclei.

Squint (strabismus)
Congenital concomitant squints are present from childhood and are caused by a defect of one eye. The angle between the longitudinal axes of the eyes remains constant on testing extraocular movements, and there is no diplopia.

Paralytic squint is acquired and results from paralysis of one or more of the muscles that move the eye, or paralysis from proptosis.

Lateral rectus palsy (6th nerve)
- produces failure of lateral movement with convergent strabismus
- diplopia is maximal on looking to the affected side
- images are parallel and separated horizontally
- the outermost image comes from the affected eye and disappears when that eye is covered
- 6th nerve palsy may be a false localising sign in raised intracranial pressure

Superior oblique palsy (4th nerve)
- diplopia is maximal on downward gaze
- images are at an angle to each other when the palsied eye is abducted and one above the other when the eye is adducted
- diplopia is noticed most on reading or descending stairs

Third nerve palsy
- may not present with diplopia in the presence of complete ptosis
- when the lid is lifted the eye is seen to be ‘down and out’ (divergent strabismus)
- there is severe (angulated) diplopia

• the pupil may be dilated
• it may be painful if caused by aneurysm of the posterior communicating artery

Myopathic conditions may cause diplopia in myasthenia gravis, thyroid eye disease and dystrophia myotonica.

Nystagmus
Nystagmus is the repetitive to and fro movement required when the fixed gaze drifts off target (‘drift-correction-drift’). Usually the correction is faster than the drift and the direction of the fast phase is the direction of the nystagmus; it is usually more pronounced when the patient looks in the direction of the fast phase. Nystagmus is usually horizontal and conjugate but may be vertical or rotational.

Horizontal nystagmus
- Vestibular nystagmus occurs following damage to the inner ear, the 8th nerve or its brainstem connections and is present only in the first few weeks after the damage because central compensation occurs. It is greater on looking away from the side of a destructive lesion.
- Cerebellar nystagmus occurs usually with lateral lobe lesions; central (vermis) lesions causing severe truncal ataxia may cause no ophthalmic nystagmus. As cerebellar disease is frequently bilateral, nystagmus may occur to both sides. If it is unilateral it is greater towards the side of the destructive lesion.

Vertical nystagmus
The direction of jerks is vertical and vertical gaze usually makes it more pronounced.

Rotatory nystagmus
The phases of the nystagmus are equal in duration. It is secondary to an inability to fix objects and focus with one or both eyes because of partial blindness.

Facial palsy
In unilateral UMN lesions, e.g. following a cerebrovascular accident (CVA), movements of the upper face are retained because it is represented on both sides of the cerebral cortex.

Absence of forehead grooves and a sagging lower eyelid are seen in complete LMN lesions (e.g. Bell’s palsy).

Taste sensation over the anterior two-thirds of the tongue is supplied by the sensory component of the 7th nerve (chorda tympani) which divides from the motor nerve in the middle ear. Absent taste
sensation in this distribution indicates that a facial nerve paresis must be caused by a lesion above this level. Thus this may be observed in herpes zoster of the geniculate ganglion (Ramsay Hunt syndrome) but not in facial palsies associated with tumour of the parotid gland.

**Hearing**

The anatomy of the ear is shown in Fig. 6.8.

Air conduction is normally better than bone conduction.

**Rinne test**

Place a vibrating tuning fork behind the ear on the mastoid process and then rapidly move its prongs in line with the external meatus. Ask the patient: ‘Is it louder behind (with the tuning fork on the mastoid) or in front (with the tuning fork in line with the external meatus)?’

Normally it is louder in front – this is termed Rinne-positive. Negative is abnormal and implies conductive (air) deafness in that ear.

**Weber test**

Place a vibrating tuning fork on the middle of the patient’s forehead. Ask the patient: ‘In which ear is the noise loudest?’

In the absence of nerve deafness, the sound is louder in the ear where air conduction is impaired.

**Dizziness and giddiness**

Dizziness and giddiness are common neurological presenting features. True vertigo suggests a disorder of the brainstem (vascular disease or demyelination), labyrinthitis or Ménière’s disease. Dizziness or unsteadiness without vertigo, particularly if intermittent, suggests postural hypotension, a cardiovascular disorder such as transient cardiac arrhythmias, aortic stenosis or carotid emboli. Transient dizziness is rarely associated with temporal lobe epilepsy. Often no organic cause is found.

**Vertigo**

Vertigo refers to unsteadiness with a subjective sensation of rotation of the environment around the

![Figure 6.8 Anatomy of the ear.](image-url)
Vertigo results from disease of the inner ear, 8th nerve or its connections in the brainstem.

**Dysarthria**

In dysarthria there is an inability to articulate properly because of local lesions in the mouth or disorders of the muscles of speech. There is no abnormality of the content of speech. Certain neurological disorders produce typical dysarthric features such as the scanning speech of cerebellar dysfunction or the monotonous high-pitched tones observed in pseudobulbar palsy.

**Dysphasia and aphasia**

These are disorders of the symbolic aspects of language, both written and spoken. In right-handed people and 50% of left-handed people, the left hemisphere is dominant for speech. Dysphasia and aphasia are common following stroke.

Pure expressive (motor) dysphasia results from lesions in the postero-inferior part of the frontal lobe (Broca’s area). Word finding is difficult in expressive dysphasia and speech absent in aphasia. In nominal dysphasia there is a specific defect in recognition and naming of objects which may be associated with spatial problems such as dressing and constructional apraxias.

Receptive (sensory) dysphasia results from lesions of the dominant temporo-parietal lobe (Wernicke’s area). There is failure to understand the meaning of words although the motor aspects of speech are preserved. This can produce ‘fluent dysphasia’ when the patient responds to questions with meaningless responses.

**Bulbar and pseudobulbar palsies**

The symptoms of dysarthria, dysphagia and nasal regurgitation result from paralysis of the 9th, 10th and 12th cranial nerves.

Pseudobulbar palsy (UMN) is the more common disorder and is caused by bilateral lesions of the internal capsule, usually following sequential, bilateral CVAs but also seen in multiple sclerosis. Bulbar (LMN) palsy is rare and usually caused by motor neuron disease or Guillain–Barré syndrome.

Acquired dyslexia (difficulty in reading), dysgraphia (difficulty in writing) and dyscalculia (difficulty in calculating) are features of lesions in the posterior parietal lobe. Agnosia denotes damage to the contralateral sensory cortex and is the inability to understand or recognise objects and forms in the presence of normal peripheral sensation. Tactile agnosia is most common. Visual agnosia describes the inability to recognise objects when viewed and denotes a lesion of the occipital cortex.

Apraxia is the inability to perform complex and sequential actions to command in the presence of normal coordination, sensation and motor power. It occurs with lesions of the parietal cortices connected by the corpus callosum.

**Patterns of motor loss in the limbs**

**Lower motor neuron lesions**

There is reduced or absent power with marked muscle wasting. The muscles are flaccid and the reflexes absent. The lesion affects the motor distribution of the spinal root or peripheral nerve.

**Upper motor neuron lesion**

There is reduced or absent power, with wasting in long-established lesions. The muscle tone and reflexes are increased and clonus may be present. The plantar response is upgoing.

There is a characteristic distribution of weakness:
- in the arms, weakness is more marked in elbow extension than flexion and wrist dorsiflexion than palmar flexion
- in the legs, weakness is more marked in hip flexion, knee flexion and ankle dorsiflexion than in their antagonist movements.

Consequently a hemiplegic person tends to walk with a stiff extended affected lower limb and stiff flexed affected upper limb.

**Proximal myopathy**

Proximal muscle wasting and weakness seen in myopathic disorders causes a typical rolling gait with difficulty standing from the sitting position, climbing stairs or lifting the arms to comb hair or reach to high shelves.

**Patterns of sensory loss in the limbs**

**Peripheral neuropathy**

Reduction or absence of vibration and position senses not only suggest dorsal column loss but also may be part of a mixed sensorimotor peripheral neuropathy. All modalities are reduced, with a ‘glove and stocking’ distribution of loss being characteristic.
Dorsal column loss without spinothalamic loss

This occurs in both legs in vitamin B12 deficiency and in the ipsilateral leg in hemisection of the cord (Brown–Séquard syndrome).

Spinothalamic loss without dorsal column loss (dissociated anaesthesia)

This occurs in syringomyelia, usually in the arms.

Spinal cord lesions

Dissociated sensory loss is a feature of spinal cord lesions.

Cerebral cortical lesions

Astereognosis and dysgraphaesthesia occur with parietal sensory loss.

Isolated peripheral nerve lesions

Median nerve lesion (carpal tunnel syndrome)

Patients with carpal tunnel syndrome complain of tingling and numbness of the fingers and/or weakness of the thumb, which are at their worst on waking and relieved by hanging the arm downwards. It is usually unilateral at the time of presentation and remains so if idiopathic. Pain at the flexor aspect of the wrist may occasionally radiate up to the elbow and exceptionally, as far as the shoulder. Examination demonstrates:

- **motor loss**: thenar wasting and weakness of thumb abduction and opposition
- **sensory loss**: palmar surface only, on the thumb and two-and-a-half fingers (i.e. index, middle and half of the ring finger)
- **positive Tinel’s sign**: percussion over the flexor retinaculum elicits tingling in the same sensory area.

Ulnar nerve lesion

The ulnar nerve supplies all the small muscles of the hand except three of the four muscles of the thenar eminence. It may be compressed in the ulnar tunnel at the wrist or in the ulnar groove at the elbow. Patients may complain of tingling or deadness and/or weakness of the ring and little fingers. Examination demonstrates:

- **motor loss**: with flattening of the contours of the hand caused by muscle wasting. The ring and little fingers are held slightly flexed, and there is loss of power in abduction and adduction of the fingers (claw hand)
- **sensory loss**: back and front, over the one-and-a-half ulnar fingers (i.e. little finger and half the ring finger)
- ‘filling in’ of the ulnar groove at the elbow and limitation of movement at the elbow.

In 2–3% of people, the ulnar nerve supplies all the hand muscles.

Radial nerve lesion

This is rare and usually results from prolonged local pressure to the nerve (e.g. an arm over the back of a chair). It causes wrist-drop. Sensory loss may be very limited because the median and ulnar nerve territories overlap the radial territory.

Lateral cutaneous nerve of the thigh

Compression causes meralgia paraesthetica, a syndrome characterised by hyperalgesia, burning pain and numbness in the lateral aspect of the thigh.

Lateral popliteal lesion

The lateral popliteal (common peroneal) nerve supplies the peroneal muscles which dorsiflex and evert the foot. The nerve may be damaged as it passes over the head of the fibula, resulting in foot-drop. There may be sensory loss over the outer aspect of the leg and foot.

Abnormalities of coordination

Incoordination is usually caused by one of two abnormalities – cerebellar or proprioceptive dysfunction. Cerebellar dysfunction reflects a failure in controlling accurate limb movements whereas proprioceptive dysfunction is characterised by ignorance of limb position when visual and cutaneous clues are excluded.

Cerebellar incoordination

Cerebellar incoordination is characterised by ipsilateral intention tremor, past-pointing and failure of rapid repetitive coordinated movements (dysdiadochokinesia). It is associated with truncal ataxia, ‘scanning’ speech and characteristic wide-based gait.

Proprioceptive incoordination (dorsal column loss)

When there is loss of proprioception the patient can still place the limbs accurately by looking at them;
tests are performed with the eyes open and the eyes closed. When the patient’s coordination is worse with the eyes closed than with them open they are said to have loss of position sense. If there is dorsal column loss but no spinothalamic loss there is said to be a dissociated sensory loss. Dissociated sensory loss is evidence of spinal cord disease. Finger–nose and heel–shin tests are normal when the patient can see but incoordinate when they cannot. Romberg’s test is positive. The gait is ataxic and the patient walks on a wide base with high steps. Muscle tone and the tendon reflexes may be diminished.

**Combined lower and upper motor neuron lesions**

Rarely, combined upper and lower motor neuron lesions are observed. Classically this is seen in subacute combined degeneration of the cord (severe vitamin B12 deficiency) and hereditary ataxias such as the hereditary spinomuscular ataxias (including Friedrich’s ataxia). Increased muscle tone and spasticity is associated with absent reflexes, peripheral dorsal column neuropathy and cerebellar signs in the case of the hereditary syndromes. Examination of the feet reveals *pes cavus* due to the combined motor neuron effects.

**Abnormal gait**

**Hemiplegia**

The affected leg is rigid and describes a semicircle with the toe scraping the floor (circumduction).

**Paraplegia**

‘Scissors’ gait – both paralysed legs are held stiffly in extension and describe a semicircle in turn.

**Festinant gait: Parkinson’s disease**

The footsteps are small in amplitude and tend to accelerate as the patient moves forward towards an obstruction (‘marche au petit pas’). There is difficulty stopping and turning. The arms tend to be held flexed and characteristically do not swing.

**Cerebellar gait**

The patient walks on a wide base with the arms held wide with ataxia and veering and staggering towards the side of the disease.

**Sensory (dorsal column) ataxia**

A high stepping gait. The patient walks on a wide base and looks at the ground.

**Steppage (drop-foot) gait**

There is no dorsiflexion of the foot as it leaves the ground and the affected leg (or legs) are lifted high to avoid scraping the toe.

**'Rolling' gait**

The pelvis drops on each side as the leg leaves the ground due to myopathic changes in the pelvic muscles.

**Tremors**

A tremor is a rhythmic oscillating movement of a limb or part of a limb and may be seen at rest or in action.

**Physiological tremor**

This is best seen with the arms outstretched and is reproduced by laying a piece of paper across the outstretched hands. It is seen in:

- normal people
- anxiety
- fatigue.

**Exaggerated physiological tremor**

This is seen in:

- thyrotoxicosis
- hypoglycaemia
- illicit drug ingestion
- excess caffeine intake
- and with prescribed drugs, including:
  - β-agonists
  - theophylline
  - tricyclic antidepressants
  - phenothiazines
  - amphetamines.

**Essential tremor**

This is similar to physiological tremor but of slower oscillation. It:

- is familial
- increases with age
- is exaggerated by β-agonists, caffeine, anxiety
- is relieved by alcohol, β-blockers.
Resting tremor
This is characteristic of Parkinson’s disease. Resting tremor is:
• maximal at rest and with emotion
• inhibited by movement
• demonstrated by passive, slow flexion-extension movements at the wrist
• mainly distal and asymmetrical
• when combined with cogwheel rigidity and flexion comprises the typical ‘pill-rolling’ tremor of Parkinson’s disease.

Intention tremor
This is the oscillation exaggerated at the end of a movement. It is:
• characteristic of cerebellar disease
• reduced or absent at rest
• associated with past-pointing, nystagmus, dysarthria and ataxia, including truncal ataxia.

Asterixis
This is the flapping tremor associated with metabolic disorders. It occurs in:
• end-stage renal failure
• hepatic failure
• hypercapnia
• drug toxicity.

Chorea, athetosis and ballismus
These are rare, non-rhythmic combinations of purposeful movements and abnormal postures caused by disorders of the basal ganglia and their connections. Choreiform movements:
• are non-repetitive, involuntary, abrupt, jerky movements of the face, tongue and limbs
• may be localised or generalised
• occur in lesions of the extrapyramidal system and with phenothiazine toxicity
• are seen in Huntington’s disease.

Dramatic jerking (ballistic) movements occur following lesions in the subthalamic structures and slower writhing movements are called athetosis.
Dystonia refers to slow sinuous writhing movements of the face and limbs, especially the distal parts.
In torsion spasm (dystonia) the movements are similar but slower and affect the proximal parts of the limbs. The movements are purposeless.
Patients with endocrine and metabolic disorders present with a wide range of symptoms and signs, or with none, the diagnosis being discovered by routine biochemical testing. Diabetes mellitus, thyroid disease and polycystic ovary syndrome are common, most other endocrinopathies are rare and present with classical endocrine syndromes. If the possibility of endocrine disease is raised, then a careful history and examination will establish the likely causes. The diagnosis must be confirmed by appropriate biochemistry, including dynamic testing, and by relevant imaging techniques.

**History**

Key features of the history in a patient with endocrine and metabolic disease are shown in Table 7.1.

**Examination**

*General observation: note*

- height and weight – calculate body mass index (BMI – weight/height^2)
- evidence of weight loss
- obesity and pattern of fat distribution
- loss of secondary sexual characteristics
- evidence of virilisation in women – male pattern hair distribution, altered muscle bulk and body habitus, deep voice and cliteromegaly

Where indicated, e.g. by delayed growth or lack of consonance of pubertal development, make a formal assessment of pubertal status.

**Observe**

**Obvious features of classical endocrine and metabolic syndromes**

- Graves’ disease
- hypothyroidism
- hyperlipidaemias
- polycystic ovary syndrome
- Cushing syndrome
- acromegaly
- altered mood

**Speech and voice disorders**

- hoarseness
- virilised – deep voice in women
- slow slurred speech in hypothyroidism
- pressure of speech in thyrotoxicosis

The emphasis of the examination of the endocrine system should be dictated by the particular organ system that appears to be involved.

**Hands**

*Observe*

- palmar erythema
- temperature and sweating
- fine tremor of outstretched hands
- thyroid acropachy
- onycholysis
- orange-yellow discolouration (carotenaemia)
- small muscle wasting
- extensor tendon xanthomas
- increased pigmentation of palmar creases
- soft tissue enlargement and arthropathy
Table 7.1 Key features of the history in a patient with endocrine and metabolic disease

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic details</td>
<td>Age, sex, height, weight, reproductive status</td>
<td>Establish body mass index; consider growth and development disorders; subfertility</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Weight changes; thirst and polyuria; heat intolerance; palpitations; tremor; pruritus; insomnia and irritability; lethargy; depression; diarrhoea or constipation; dry hair; hoarseness; swelling of the neck; dysphagia; periorbital swelling; change in nail beds; menstrual dysfunction; hirsutism; headaches; visual disturbance; muscle weakness; arthralgia; galactorrhoea; loss of libido; loss of secondary sexual characteristics; changes in facial appearance; xanthelasma; renal colic; tetany; skin changes – dry skin, acne, vitiligo, rashes, striae, foot ulcers; symptoms of specific lesions – acanthosis nigricans, pretibial myxoedema, necrobiosis lipoidica</td>
<td></td>
</tr>
<tr>
<td>Past medical history</td>
<td>Previous episodes of similar symptoms; other endocrine disorders; autoimmune disease; ischaemic heart disease; hypertension; bone fractures</td>
<td>Consider associated endocrine disorders or autoimmunity; effects of endocrine disease on cardiac dysfunction; hyperlipidaemia; secondary hypertension; endocrine manifestations of malignancy</td>
</tr>
<tr>
<td>Social and family history</td>
<td>Alcohol; smoking; diet; number of children and/or desire for pregnancy; family history of autoimmune endocrine disease or genetic cancers</td>
<td>Potential causes of endocrine disease; potential genetic syndromes or cancers</td>
</tr>
<tr>
<td>Medication</td>
<td>Review all medication including complementary therapies</td>
<td>Endocrine/metabolic side effects especially with corticosteroids, amiodarone, thiazides</td>
</tr>
</tbody>
</table>

Examine for

- Dupuytren’s contracture
- carpal tunnel syndrome: thenar wasting; appropriate sensory changes; perform Tinel’s test
- poor joint mobility: the ‘prayer sign’ will demonstrate impaired metacarpophalangeal (MCP) or interphalangeal (IP) joint extension

Arterial pulse

- bradycardia
- sinus tachycardia
- atrial fibrillation

Blood pressure

- lying and standing blood pressure: note postural hypotension

Trousseau’s sign – maintaining the cuff at above systolic pressure for 3 min induces carpal spasm of the hand and wrist in the presence of hypocalcaemia

Skin

Observe

- hirsutism
- loss of body hair
- greasy skin and acne
- dry skin
- vitiligo
- bruising
- abdominal striae
- folliculitis
- eruptive xanthomatosis

Examine for

- lipodystrophy at insulin injection sites
- acanthosis nigricans
Face

Observe

- cranial nerve palsies
- xanthelasmata
- hypothyroid facies
  - dry, thickened skin
  - hoarse voice
  - periorbital puffiness
  - macroglossia, pallor and ‘lemon-yellow’ tinge when severe, causing anaemia and carotenaemia
- features of acromegaly
  - increased supraorbital ridges
  - protrusion of lower jaw (prognathism with malocclusion)
  - soft tissue overgrowth
  - macroglossia
  - increased spacing of the teeth
  - deafness
- features of Cushing syndrome
  - moon face
  - acne
  - plethora
  - hirsutism with thinning of scalp hair
- hirsutism
- acne
- frontal alopecia
- mucocutaneous candidiasis

Perform

- Chvostek’s sign – tapping over the facial nerve anterior to the ear induces ipsilateral twitching of the facial muscles in the presence of hypocalcaemia

Eyes

Note

- cataracts
- thyroid eye disease
  - signs of hyperthyroidism
    - lid retraction
    - lid lag
  - signs of Graves’ disease
    - exophthalmos
    - proptosis
    - lid retraction
    - lid lag
    - periorbital oedema
    - chemosis
    - conjunctival injection
    - conjunctival ulceration
    - diplopia on upgaze
    - external ophthalmoplegia

Perform

- visual fields
- fundoscopy
  - diabetic retinopathy, laser scarring
  - papilloedema

Neck

Examine

- carotid pulses
- carotid bruits
- thyroid gland
- cervical lymphadenopathy

Breasts

Note

- galactorrhoea; spontaneous or expressible
- gynaecomastia

External genitalia

Confirm

- pubertal stage where appropriate

Examine for

- testicular volume, penile length in men
- cliteromegaly in women
- evidence of intersex disorders

Legs

Examine for

- peripheral vascular disease
- proximal myopathy
- peripheral neuropathy
- ischaemic signs in feet
- foot ulceration
- Charcot joints
- necrobiosis lipoidica
- Achilles’ tendon xanthomata
- pretibial myxoedema

Notes

The diabetic foot

Examination of the feet in patients with diabetes is essential and should be performed on a regular basis,
at least at the annual review and more frequently where there are problems.

**Observe**
- colour and temperature
  - pale and cool in ischaemia
  - blueish-pink and warm in neuropathy
- callus formation over weight-bearing areas or dorsum of toes
- fungal infection of the toes and toenails
- ulceration
  - establish whether arterial or neuropathic
  - make accurate notes of size, depth, margins, infection
- loss of the plantar arch
- clawing of the toes
- Charcot joints

**Palpate**
- peripheral pulses

**Test**
- capillary refill
- sensation formally
  - establish stocking sensory neuropathy if appropriate
- reflexes

### Assessment of thyroid status

Assessment of thyroid status involves examination of the thyroid gland and clinical evaluation to establish whether the patient is euthyroid, hyperthyroid or hypothyroid.

### Examination of the thyroid gland (Fig. 7.1)

In normal men the thyroid gland is impalpable. A small soft symmetrical enlargement may be present in normal women.

Patients with multinodular goitres are usually euthyroid but commonly develop subclinical or frank hyperthyroidism after many years. Often the clinical problem relates to their size, which may produce compression of the trachea, oesophagus or laryngeal nerve and sometimes causes distress from the cosmetic appearance.

Single nodules, particularly if the patient is euthyroid, should be regarded as malignant and immediate investigation including ultrasound, fine needle aspiration cytology (+/- radionuclide uptake scanning) should be performed. Rapid expansion in size and the presence of pain suggest malignancy.

During examination of the thyroid gland the patient’s chin should be slightly flexed to relax the tissues. The thyroid gland moves upwards on swallowing. To demonstrate this, the patient should be given a sip of water to hold in the mouth and then swallow when asked.

**Inspect**
- the neck from the front and sides

**Observe**
- size of the thyroid gland
- obvious asymmetry
- upward movement on swallowing
- scars from previous thyroid surgery

**Palpate**
- the thyroid from behind both at rest and during swallowing

**Assess**
- character
  - diffuse, symmetrical enlargement
  - multinodular, usually asymmetrical
  - unilateral solitary nodules
- mobility
- tenderness
- retrosternal extension: feel in the suprasternal notch and percuss over the upper sternum for dullness
- tracheal displacement
- cervical lymphadenopathy

**Auscultate**
- over a diffusely enlarged gland for a systolic bruit which occurs in thyrotoxicosis
Assessment of thyroid status

Thyrotoxicosis has a number of causes and examination aims to distinguish Graves’ disease from non-autoimmune causes of hyperthyroidism.

Signs of hyperthyroidism

General

- evidence of weight loss

Hands

- palmar erythema
- warm, sweaty palms
- fine tremor of outstretched hands – place a piece of paper over the outstretched hands to demonstrate
- onycholysis

Arterial pulse

- sinus tachycardia
- atrial fibrillation

Blood pressure

- systolic hypertension, increased pulse pressure

Hair

- generalised alopecia

Eyes

- lid retraction
- lid lag – ask the patient to fix their gaze on your finger held slightly in front and above their head and to follow your finger with their eyes as you move it slowly downwards in a forwards arc

Neck

- goitre – examine as above

Cardiovascular system

- signs of heart failure

Neuromuscular

- hyper-reflexia
- clonus
- proximal myopathy

Signs of Graves' disease (hyperthyroidism plus)

Eyes

- exophthalmos
- proptosis
- periorbital oedema

- chemosis
- conjunctival injection
- conjunctival ulceration
- diplopia on upgaze
- external ophthalmoplegia

Other signs (rarely)

- pretibial myxoedema
- thyroid acropachy
- vitiligo

Signs of hypothyroidism

General

- evidence of weight gain
- hoarse voice
- vitiligo

Hands

- cool hands, dry skin
- myxoedema – examine dorsum of hands
- carotenaemia – orange-yellow discolouration of palms

Arterial pulse

- sinus bradycardia

Blood pressure

- hypertension

Hair

- dry coarse hair
- generalised alopecia
- thinning of eyebrows (rarely outer third)

Eyes

- anaemia
- periorbital myxoedema

Neck

- goitre – examine as above
- commonly impalpable thyroid in primary autoimmune hypothyroidism

Cardiovascular system

- pericardial effusion

Respiratory system

- bilateral pleural effusions

Neuromuscular

- delayed relaxation phase of reflexes
- cerebellar signs
Disorders of the musculoskeletal system are common, accounting for around 25% of consultations in general practice in the UK and forming the major causes of physical disability in the elderly population. There are a wide range of underlying pathologies, but non-inflammatory conditions far outweigh inflammatory disorders. The major symptoms of musculoskeletal disorders are pain, stiffness, swelling and immobility; systematic examination is generally regional and attempts should be made to establish the source of pain which may lie in muscles, tendons and periarticular structures. Diagnosis should be confirmed by appropriate imaging including plain X-rays, CT/MRI scans and radionuclide scans if indicated, together with blood tests for inflammatory markers, haematology and immunology.

History
Key features of the history in a patient with musculoskeletal disease are shown in Table 8.1.

Examination
Before examining the musculoskeletal system it is essential to enquire about painful joints and to examine with care so as not to exacerbate pre-existing pain. Position the relevant joints or region carefully, observe the patient’s face during the examination and keep checking for pain.

A rapid, general assessment of the musculoskeletal system is shown in Table 8.2 – the GALS screen. The GALS screen aims to establish:

- if there are any abnormal joints
- the nature of the joint abnormality
- the distribution of joint abnormalities
- whether or not there are associated diagnostic features.

If the GALS screen is normal then further examination is not required during a general medical assessment. Any abnormalities identified should lead to detailed examination of the musculoskeletal system.

Detailed examination of the musculoskeletal system should be performed regionally, involving observation, palpation and manipulation (‘Look, Feel and Move’). Always make a quick survey of the patient and their surroundings prior to starting a regional examination routine. Look for obvious clues including evidence of joint replacements, mobility aids and hand warmers.

For each region or affected joint(s):

**Observe at rest**
- skin changes
- swelling
- muscle wasting
- deformity

**Palpate for**
- tenderness
  - joint line, periarticular
- warmth
- swelling
  - fluid, soft tissue, bony
- crepitus
  - loud and palpable with joint damage
- joint stability

**During movement observe**
- restriction
- hypermobility
- pain on usage
Notes

Examination of the hands

Careful examination of the hands will reveal musculoskeletal disorders and accompanying general medical or neurological deficits.

Preparation and positioning
With the patient seated, ask them to

• expose their upper limbs to above the elbows
• bend elbows
  o observe extensor surface for rheumatoid nodules, psoriatic plaques, scars, gouty tophi, deformity
• rest their hands, palms downwards on a pillow.

Observe

Dorsum of hand

Skin

• rash
  o psoriasis, Gottron’s patches in dermatomyositis (p. 283), vasculitis
• atrophy ± purpura
  o rheumatoid arthritis, steroid usage
• rheumatoid nodules
• gouty tophi
• evidence of Raynaud’s phenomenon
• sclerodactyly

Nails

• psoriatic pitting
• onycholysis
  o psoriasis
  o thyrotoxicosis
• splinter haemorrhages
  o vasculitis
  o bacterial endocarditis
• clubbing: consider general medical causes of clubbing, especially those associated with rheumatological disease, e.g. pulmonary fibrosis

Muscles

• wasting dorsal interossei
  o disuse atrophy
  o T1 lesion

Joints

Rheumatoid arthritis

• wrist: subluxation of carpus/distal radio-ulnar joint
• metacarpophalangeal (MCP) joints: swelling ± subluxation; ulnar deviation
• interphalangeal (IP) joints: swelling of proximal interphalangeal (PIP) joints
• Swan neck, Boutonniere deformities of fingers
• Z deformity of thumb

Osteoarthritis

• Heberden’s nodes
• Bouchard’s nodes

<table>
<thead>
<tr>
<th>Feature</th>
<th>Details</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic details</td>
<td>Age, sex, height, weight</td>
<td>Establish body mass index; musculoskeletal disorders more common in the elderly and in women</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Pain – may be worse on usage (mechanical), after rest (inflammatory) or at night</td>
<td>Identify significant symptom patterns including site, duration and aggravating/relieving factors</td>
</tr>
<tr>
<td></td>
<td>Stiffness – early morning or disuse stiffness (inflammation); may be associated weakness and deformity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Swelling, deformity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Symptoms of systemic illness – weight loss, fatigue</td>
<td></td>
</tr>
<tr>
<td>Past medical history</td>
<td>Previous episodes of similar symptoms; autoimmune disease; dermatological disease</td>
<td>Consider associated autoimmunity</td>
</tr>
<tr>
<td>Social and family history</td>
<td>Occupation; hobbies – sport, gardening; household environment; activities of daily living</td>
<td>Potential causes of injury; inability to cope at home</td>
</tr>
<tr>
<td>Medication</td>
<td>Review all medication including complementary therapies</td>
<td>Side effects – NSAIDs, corticosteroids</td>
</tr>
</tbody>
</table>

Table 8.1 Key features of the history in a patient with musculoskeletal disease
Psoriasis
- dactylitis
- PIP and/or distal interphalangeal (DIP) joint swelling

Gout
- asymmetrical PIP and/or DIP joint swelling

Palmar surface of hand

Skin
- palmar erythema: rheumatoid arthritis
- anaemia
- calcinosis: localised systemic sclerosis
- vasculitis

Muscles
- wasting of all intrinsic muscles
  - disuse atrophy in painful arthritis
  - spinal cord T1 lesion
- disproportionate wasting of thenar eminence
  - carpal tunnel syndrome
- disproportionate wasting of hypothenar eminence
  - ulnar nerve lesion

Palpate (working from proximal to distal) Joints: establish
- the nature of the swelling
  - synovitis: boggy
  - fluid: fluctuant
  - bone: hard
- whether there is active synovitis
  - warmth over swollen wrist or MCP joints
  - tenderness
  - palpate over dorsal wrist joint line
  - depress distal ulna
  - perform
    - metacarpal squeeze
    - bimanual palpation of IP joints

Table 8.2 The GALS screen

<table>
<thead>
<tr>
<th>Preliminary questions</th>
<th>Gait</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gait</td>
<td>Symmetry and smoothness of movement</td>
</tr>
<tr>
<td></td>
<td>Normal stride length</td>
</tr>
<tr>
<td></td>
<td>Ability to turn normally</td>
</tr>
<tr>
<td>Arms (sitting)</td>
<td>Inspect for wrist/finger swelling/deformity</td>
</tr>
<tr>
<td>Hands</td>
<td>Squeeze across 2nd-5th metacarpals (tenderness indicates synovitis of MCP joints)</td>
</tr>
<tr>
<td>Grip strength</td>
<td>Turn hands over (inspect for muscle wasting, normal forearm supination/pronation)</td>
</tr>
<tr>
<td>Elbows</td>
<td>Power grip (’Make a tight fist’)</td>
</tr>
<tr>
<td>Shoulders</td>
<td>Precision grip (’Touch your thumb to individual fingers in turn’)</td>
</tr>
<tr>
<td></td>
<td>Full extension (’Put your arms out straight’)</td>
</tr>
<tr>
<td></td>
<td>Abduction and external rotation (’Put your hands behind your head’)</td>
</tr>
<tr>
<td>Legs (lying)</td>
<td>Inspect for swelling/deformity/quadriceps bulk</td>
</tr>
<tr>
<td>Knees</td>
<td>Check for knee effusion</td>
</tr>
<tr>
<td>Hips</td>
<td>Check for knee crepitus whilst passively flexing the knee</td>
</tr>
<tr>
<td>Feet</td>
<td>Check internal rotation of hips</td>
</tr>
<tr>
<td>Spine (standing)</td>
<td>Squeeze across metatarsals (tenderness indicates synovitis of MTP joints)</td>
</tr>
<tr>
<td>Inspection from behind</td>
<td>Inspect for callosities on soles of feet</td>
</tr>
<tr>
<td>Trigger points</td>
<td>Pressure over mid-supraspinatus</td>
</tr>
<tr>
<td>Inspection from in side</td>
<td>Kyphosis</td>
</tr>
<tr>
<td>Inspection from in front</td>
<td>Normal flexion (’Lean down and touch your toes’)</td>
</tr>
<tr>
<td></td>
<td>Lateral cervical flexion (’Touch your ear on your shoulder’)</td>
</tr>
</tbody>
</table>

Skin

- nodules – consistency
- sclerodactyly

Movement

Ask the patient to:

- make a fist and ’bury fingers’ (forearm supinated)
  - function of MCP and IP joints
- turn clenched fists over (pronate forearm)
  - function of radio-ulnar joints
- extend little finger alone (rest of fist clenched)
  - integrity of extensor digiti minimi
- extend all fingers
  - integrity of extensor communis
- place palms together
  - flexion contractures of digits
- with palms together, bend wrists back
  - integrity of extensor digiti minimi
- with hands back-to-back, bend wrists forward
  - integrity of extensor communis

Patients with wrist synovitis are at risk of extensor tendon rupture. The first tendon to rupture is usually the extensor digiti minimi. Although rarely important functionally, it provides a warning that other extensor tendons are endangered.

Function

Impaired joint movement does not invariably correlate with poor hand function and vice versa.

Test

- power grip
- precision grip
- if relevant, ask the patient to demonstrate doing up buttons or writing

To complete the examination of the hands, an assessment of peripheral neurological function and vascular status should be made.

Sensory examination

*Assess sensation in the following areas:*

- radial border of index finger
  - median nerve or C6
- ulnar border of little finger
  - ulnar nerve or C8
- over 1st dorsal interosseus muscle
  - radial nerve
- distal middle finger
  - C7
- qualitative change in sensation
  - glove distribution neuropathy moving from distal to proximal.

Motor examination

*Test*

- abduction or adduction of fingers
  - ulnar nerve or T1
- abduction of thumb – the plane of movement is at 90° to the palm
  - median nerve or T1
- extension of fingers or wrist
  - radial nerve or C6/7
- hook grip
  - C8

Perform

- Tinel’s test (p. 54) in suspected carpal tunnel syndrome

Vascular examination

*Observe*

- colour and temperature of hand/individual digits

*Palpate*

- radial and ulnar pulses
- for capillary return in finger pulps
Medical students and postgraduate trainees should be aware of some of the basic principles of assessment. An understanding of the way in which examinations are designed, implemented and scored ensures better preparation for the range of assessment formats that may be encountered during medical education and training programmes. In this chapter some important characteristics of assessment will be described briefly followed by a focus on the assessment of clinical competence.

**Summative assessments** measure the achievement of learning goals at the end of a course or programme of study. Summative assessments are formal and used to determine progression to the next stage of a course, to signify the need for remediation, for graduation purposes or registration with a national professional body. Little feedback is provided to learners. ‘High-stakes assessments’ are summative assessments with implications for professional progression such as Finals examinations in medical school, membership of Royal Colleges or Specialty Board Examinations in North America.

**Formative assessments** are designed specifically to provide feedback to learners about their progress. Formative assessments should be ongoing, frequent, non-judgemental and carried out in informal settings. They allow learners to engage with the educational process, offering them the opportunity to identify strengths and weaknesses and take appropriate action. Feedback is central to formative assessment and should encourage learners towards deep learning and understanding. Formative assessments may be in a number of different formats, including Objective Structured Clinical Examinations (OSCEs), mini-Clinical Examinations (mini-CEX), Direct Observation of Procedural Skills (DOPS), Cased-Based Discussions (CBD) or written work.

### Key features of assessment tools

**Reliability:** reflects the reproducibility of the assessment tool and the accuracy with which a score is being measured. It is higher in written assessments such as multiple choice and extended matching question formats, and lower in clinical competency-based assessments where there are more uncontrolled variables. Reliability is quantitative and reflected by the statistic known as Cronbach’s alpha. Evaluation using generalisability theory can be performed to account for complex variables.

**Validity:** reflects the accuracy with which a test measures what it is purported to measure. It is a qualitative factor that evaluates the authenticity of an assessment and its fitness for purpose. A number of categories of validity are described; for example, the **content validity** reflects the way in which the test items relate to the curriculum content being assessed, **face validity** refers to the ‘real life’ nature of the assessment and high **construct validity** suggests that the test discriminates well between the abilities of candidates.

**Educational impact:** assessment is an important driver of learning; appropriate assessment tools encourage learners to acquire the desired knowledge, skills and attitudes.

**Cost-effectiveness:** reflects the practical aspects of assessment and helps determine the choice of assessment tool.

**Acceptability:** successful assessment formats must be acceptable to the teaching faculty and the learners.

**Blueprinting:** ensures the assessment tool samples content across the full range of learning objectives for the curriculum.
Standard setting

Numerous methods to determine pass-marks for different assessment formats are available.

**Norm-referencing:** in norm-referenced assessments the pass mark is determined by examiners using comparison within the cohort of examinees and thus the pass-mark varies at each sitting. A percentage of candidates will pass the assessment on each occasion (Fixed Percentage Method). Norm-referencing does not take account of the content of the assessment or the competence of the candidates.

**Criterion-referencing:** in criterion-referenced assessments the pass-mark is set in advance by a team of experienced examiners using their judgement about the degree of difficulty of the assessment and the minimum score expected of a candidate who just reaches the acceptable standard. A number of criterion-referenced standard setting methods are described including the Angoff and Ebel procedures.

Good practice for summative assessments in medical education demands that a minimum competence (safety) level should be set – the assessment should identify the Pass/Fail border and all candidates who reach the required standard should pass the examination. Assessments should thus be criterion-referenced by experienced examiners who recognise the standard required of the candidates at whatever level of undergraduate or postgraduate experience. Norm-referencing is not acceptable for high-stakes professional examinations.

**Borderline group methods:** these methods have been developed specifically for use in OSCE and similar formats where an experienced, trained clinician examiner is present at every station to score each candidate. In essence, each examiner scores the candidate using the station checklist – this constitutes the candidate’s score for that station. In addition, the examiner awards the candidate a global score, based on an overall judgement of performance. Global rating scales include a spread of judgements such as ‘fail – borderline fail – borderline pass – clear pass – outstanding’. The mean score of all candidates marked borderline becomes the pass-mark for that station and the mean of all the stations’ borderline scores becomes the pass-mark for the assessment. These methods have gained credibility as they allow experienced clinicians to make judgements about professional competence and they are currently the gold-standard methods for assessments of clinical competence.

Assessments in medical education fall into three main categories – those that measure knowledge, competence and performance. ‘Miller’s Triangle’ (Fig. 9.1) illustrates the relationship between these categories.

**Knowledge:** this underpins all forms of assessment. Basic and applied knowledge can be tested in a variety of ways, commonly by written, oral or computer-based assessment formats such as multiple choice (MCQ), extended matching (EMQ) and structured essay (SEQ) questions, structured vivas and case-based discussions (CBD).

**Competence:** tests of competence assess a learner’s ability to demonstrate applied knowledge in

**Performance**

- Multi-rater (360°), patient reports

**Knowledge**

- Written, oral, computer-based assessment

**Competence**

- OSCE, mini-CEX, DOPS

**Performance**

- DOES

---

a controlled environment in which they know they are being assessed. Typically these take the form of skills-based assessments such as OSCEs and variants of the OSCE format, or workplace-based assessments such as mini-clinical examinations (mini-CEX) or direct observations of clinical practice (DOPS).

**Performance**: performance-based assessments aim to assess the application of knowledge and

<table>
<thead>
<tr>
<th>Clinical Exam</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centre: Centre 1</td>
</tr>
<tr>
<td>Session: Session 1</td>
</tr>
</tbody>
</table>

### Neurological (PNS) Examination

Key to marking: G = good, A = adequate, I = Inadequate or not done

This station assesses the candidate's ability to examine the peripheral nervous system in upper and lower limb and make a diagnosis.

**THIS IS A 15 MINUTE STATION**

1. Introduction and orientation (name and role and confirms patient's agreement)
2. Rapport (shows interest, respect and concern, appropriate body language)
3. Appropriately exposes the upper and lower limbs
4. Inspects the limb for wasting, involuntary movements and fasciculations as well as scars including the neck and lumbar spine for arm and leg respectively
5. Assesses the muscle tone, including clonus in lower limbs
6. Checks the power of movements at all joints starting proximally – using MRC grading scale and any weakness – including shoulder abduction, elbow flexion/extension, wrist extension, finger extension and abduction and thumb abduction
7. Checks coordination (finger–nose in arm, heel–shin in leg)
8. Checks reflexes +/- with reinforcement biceps, triceps, supinator in upper limb and knee and ankle in lower limb
9. Checks plantar responses in lower limb examination (if upper limb case)
10. Checks sensation starting distally with joint position sense, then light touch, pin prick
11. Checks for walking in lower limb examination and pronotr drift in upper limb examination
12. Communicates with patient appropriately during examination (explains what he/she is doing, gains patient's co-operation)
13. Examines patient in a professional manner (gentle, watches for pain, maintains dignity and privacy)
14. Closure (thanks patient, leaves patient comfortable)

**Examiner to ask:**

*"Please summarise your key findings"*

15. Candidate presents key findings
16. Candidate presents summary in a fluent, logical manner

*"What do you think is the most likely diagnosis?"
17. Candidate makes a reasonable attempt at a diagnosis

---

**Figure 9.2** Example of a score sheet for an OSCE station testing the candidate’s ability to examine the neurological system. From University of Cambridge School of Clinical Medicine 2005.
**RCP MINI CLINICAL EVALUATION EXERCISE**

<table>
<thead>
<tr>
<th>Patient problem/Diagnosis:</th>
</tr>
</thead>
</table>

### Case Setting
- Out-patient
- In-patient
- A&E

Is the patient:
- New
- Follow-up

### Case Complexity
- Low
- Moderate
- High

### Focus of mini-CEX
- (more than one may be selected)
- Data Gathering
- Diagnosis
- Management
- Counselling

### What type of consultation was this?
- Good news
- Bad news
- Neither

---

**Date (DD/MM/YY):**

**Year of SpR training:**

---

**Patient problem/Diagnosis:**

### Case Setting
- Out-patient
- In-patient
- A&E

Is the patient:
- New
- Follow-up

**Case Complexity:**
- Low
- Moderate
- High

**Focus of mini-CEX**

**What type of consultation was this?**

---

**Assessor’s comments on trainee’s performance on this occasion (BLOCK CAPITALS PLEASE):**

**Trainee’s comments on their performance on this occasion (BLOCK CAPITALS PLEASE):**

---

**Trainee’s signature**

**Assessor’s signature**

---

**Figure 9.3** Example of mini-CEX assessment: mini-CEX evaluation form. Reproduced by kind permission of the Joint Royal Colleges of Physicians Training Board.
### Direct Observation of Procedural Skills (DOPS) – Anaesthesia

Please complete the questions using a cross (x). Please use black ink and CAPITAL LETTERS.

**Trainee’s surname:**

**Trainee’s forename(s):**

**GMC number:**

*GMC NUMBER MUST BE COMPLETED*

**Clinical setting:**

- Theatre
- ICU
- A&E
- Delivery suite
- Pain clinic
- Other

**Procedure:**

**Case category:**

- Elective
- Scheduled
- Urgent
- Emergency
- Other

**ASA Class:**

- 1
- 2
- 3
- 4
- 5

**Assessor’s position:**

- Consultant
- SASG
- SpR
- Nurse
- Other

<table>
<thead>
<tr>
<th>Number of times previous DOPS observed by assessor with any trainee:</th>
<th>0</th>
<th>1–4</th>
<th>5–9</th>
<th>&gt;10</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Number of times procedure performed by trainee:</th>
<th>0</th>
<th>1–4</th>
<th>5–9</th>
<th>&gt;10</th>
</tr>
</thead>
</table>

**Please grade the following areas using the scale below:**

<table>
<thead>
<tr>
<th>Below expectations</th>
<th>Borderline</th>
<th>Meets expectations</th>
<th>Above expectations</th>
<th>U/C*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

1. Demonstrates understanding of indications, relevant anatomy, technique of procedure
2. Obtains informed consent
3. Demonstrates appropriate pre-procedure preparation
4. Demonstrates situation awareness
5. Aseptic technique
6. Technical ability
7. Seeks help where appropriate
8. Post procedure management
9. Communication skills
10. Consideration for patient
11. Overall performance

*U/C Please mark this if you have not observed the behaviour and therefore feel unable to comment.

Please use this space to record areas of strength or any suggestions for development.

---

**Trainee satisfaction with DOPS:**

**Assessor satisfaction with DOPS:**

<table>
<thead>
<tr>
<th>Not at all</th>
<th>Highly</th>
</tr>
</thead>
</table>

**What training have you had in the use of this assessment tool?**

- Face-to-face
- Have read guidelines
- Web/CDROM

**Assessor’s signature:**

**Date:**

**Time taken for observation (in minutes):**

**Time taken for feedback (in minutes):**

**Assessor’s GMC number:**

**Acknowledgement:** Adapted with permission from the American Board of Internal Medicine.

PLEASE NOTE: failure to return all completed forms to your administrator is a probity issue.

---

**Figure 9.4** Example of DOPS assessment: DOPS evaluation form. With permission from the Royal College of Anaesthetists.
Assessment of clinical competence

Objective structured clinical examinations (OSCEs)

Summative assessment of clinical competence generally involves an OSCE or similar format such as the Royal College of Physicians MRCP Part 3 Practical Assessment of Clinical Examination Skills (PACES) examination. In these types of assessment, candidates rotate through a series of stations which may address clinical, communication or practical skills in a series of tasks. Each station is designed individually and marked by an assessor who may be a doctor, another clinician, a non-clinical medical teacher or a simulated patient. Marking schemes are designed in advance and piloted to ensure practicality and efficacy. The time for each station varies according to the task, so that simple practical skills may be allowed five minutes whereas more complex communication scenarios will have a longer time allocation. A wide range of skills may be assessed in this way, including simulated practical skills scenarios using manikins or models, communication skills stations with simulated patients and clinical examination of real patients. The range of OSCE stations has increased with improved simulation technology, so that candidates may be faced, for example, with emergency scenarios combining practical skills with simulated patients trained to provide appropriate responses to the ongoing scenario.

OSCEs are more ‘fair’ than traditional clinical examinations in which candidates were taken to see a varying (often small) number of short cases by one or two examiners and each asked a different set of questions. In an OSCE all candidates experience the same number of stations and perform the same tasks. Reliability is increased as each candidate is scored by a greater number of trained assessors using predetermined criteria, reducing the chance of examiner bias, increasing consistency and resulting in a clearer view of the candidate’s overall abilities. The greater the number of stations, the more reliable the assessment and generalisable the results. Reliability is balanced against validity, cost-effectiveness and acceptability – thus examiners may choose to sacrifice a degree of reliability (obtained with simulation) for validity and acceptability (increasing the number of real patients).

Approach to the OSCE: prepare, practise and perform

Prepare: study information about the examination available in advance; be clear about what is being examined; familiarise yourself with the format; study sample station checklists and any other information provided. Is there a minimum number of stations you must pass to be successful? What skills are covered in the OSCE? Does it include practical, communication and clinical skills stations or just one of these? How long are the stations? Does the examination use real or simulated patients? Is a structured viva involved at any or all of the stations? Are there data interpretation stations such as radiology or clinical pathology? Think about the stations you are likely to encounter and prepare for each one.

Practise: practise for the exam specifically; attend a course with practice OSCE circuits (usually for postgraduates); see as many patients as possible and practise physical examination skills with a colleague for feedback. Can you examine each of the major systems accurately and efficiently within the allotted time? Practise ‘set piece’ examinations (for example ‘this patient has some difficulty walking – please examine his legs’; ‘this lady has some pain in her joints – please examine her hands’). Consider likely communication skills scenarios and practise your approach. Are you able to perform all the required practical skills? If not, arrange additional training in a skills centre. Practise for the data interpretation stations.

Perform: OSCEs test your clinical competence in a simulated environment – you need to perform! Carefully read the scenario and instructions at each station; be clear about the task. Are you required to take a history, to give information, gain consent for a procedure or talk to a relative or colleague? In a clinical station are you expected to examine a whole system, part of a system or to comment more widely? Plan how you will approach the station before entering it. Listen to the examiner – do they wish you to talk as you examine or present your findings at the end? Watch the clock – ensure that you will finish the station in the allotted time. Answer questions clearly and concisely; do not make up physical signs! If you didn’t find anything, say so. Allow the examiner to understand your clinical reasoning and why you would choose a particular course of management.

Finally move on: try to forget any mistakes you think you have made – the OSCE format means that an atypical poor performance in one station will be compensated by good performance elsewhere.
OSCE stations are generally marked using a checklist such as the one shown in Fig. 9.2.

Checklists are designed in advance and take into account the learning objectives for the curriculum and the level at which the examination is set. For example, a clinical examination station for a junior medical student might focus on correct physical examination process skills whereas a similar station for postgraduates may include an evaluation of the candidate’s overall approach to the patient and their ability to elicit and interpret physical signs correctly.

**Mini-clinical examinations (mini-CEX)**

The mini-CEX allows a clinical tutor to observe a trainee’s interaction with a patient in a clinical setting. Developed for use in postgraduate settings, mini-CEX assessments are increasingly used in the assessment of senior medical students.

The mini-CEX format involves observation of a clinical activity such as taking a focused history, examining a system or giving information. The learner presents the salient features and offers a diagnosis and management plan. The tutor completes a pre-designed checklist and records areas of good practice and new training needs (Fig. 9.3).

The clinical encounter should last about 15 min and feedback is provided at the end. Generally during an educational programme several mini-CEX assessments are required, allowing trainee and tutor to monitor progress. Records of mini-CEX assessments form part of a portfolio of clinical training and ensure that the trainee’s development of clinical skills has been evaluated and recorded. Although not designed for high-stakes assessment, adequate completion of the required number of mini-CEX assessments may be necessary to ensure progression through a training programme.

**Direct observation of procedural skills (DOPS)**

The DOPS assessment is a variant of the mini-CEX designed to evaluate a student or trainee’s ability to perform practical clinical skills. Trainees choose a skill from the approved list for their stage of training and generally should perform several DOPS at each stage of their educational programmes. The encounters are short and feedback is provided at the end (see Fig. 9.4).
Cardiovascular disease

Ischaemic heart disease
This typically presents as the tight or crushing central chest pain of angina or myocardial infarction. Less commonly, it presents as an arrhythmia or conduction defect, or heart failure.

Myocardial ischaemia is normally caused by atherosclerosis, but cardiac pain is also produced by:
- aortic dissection
- paroxysmal tachycardias
- severe anaemia, cardiomyopathy, coronary artery embolism and vasculitis – all rare causes.

Coronary artery disease
Examination of atherosclerotic plaques indicates an interaction between blood constituents and cellular elements of the arterial wall. Alteration of normal endothelial cell function may allow accumulation of macrophages, which form foam cells and provoke proliferation of smooth-muscle cells and connective tissue. Cholesterol crystals and other lipids accumulate at the base of plaques, which are covered by a fibrous cap. Plaque rupture leads to thrombosis.

Factors associated with coronary artery disease include:
- Sex: it is more common in men than women, particularly before the menopause.
- Age: there is a steady increase with age.
- Smoking: is a powerful risk factor for coronary heart disease (CHD). Cessation is associated with significant reduction in risk, which decreases by half after 1 year and approaches that of never-smokers after several years.
- Hypertension: the risk of coronary heart disease rises progressively with increasing blood pressure. Although most antihypertensive trials have shown a lower than expected reduction in risk, this may reflect the short duration of the trials.
- Obesity: central adiposity is a better marker for CHD risk than the overall level of obesity.
- Hyperlipidaemia: CHD is associated with raised total cholesterol and high ratio of total cholesterol: high-density lipoprotein (HDL) cholesterol. Hypertriglyceridaemia appears to be associated more with risk of myocardial infarction than coronary atherosclerosis, possibly because it affects coagulation.
- Diabetes mellitus: hyperlipidaemia in diabetics is a powerful risk factor. Men with diabetes have 2–3 times and women 4–5 times the background population risk of CHD.
- Alcohol: the association between CHD and alcohol is J-shaped – the lowest risk is associated with moderate alcohol intake.

Angina pectoris
Diagnosis
The diagnosis of angina is clinical, based on the characteristic history:
- site: central chest
- character: usually tight, heavy, crushing
- radiation: to arms, epigastrium, jaw or back
- precipitation: by effort or emotion, particularly after meals or in the cold
- relief: within minutes by rest or sublingual or buccal glyceryl trinitrate.

There are no specific physical signs. A non-cardiac cause is favoured by continuation for several days, precipitation by changes in posture or deep breathing, the ability to continue normal activities, and lack of relief by rest. The more common alternatives in the differential diagnosis are oesophageal pain and musculoskeletal pain.
Unstable angina refers to:
- angina of effort of recent onset with no previous history
- increased frequency and/or severity of pre-existing angina
- angina at rest.

Investigation

Electrocardiogram

The electrocardiogram (ECG) is usually normal between attacks, but may show evidence of old myocardial infarction, T-wave flattening or inversion, bundle branch block or signs of left ventricular hypertrophy. ST segment depression is usually seen during attacks and may be provoked by exercise testing. A negative exercise test, in which there is no chest pain, no ST depression, no arrhythmia and no sustained fall in blood pressure, indicates a good prognosis. Radionuclide studies can be performed if the patient is physically unable to exercise. Images at rest are compared with images obtained after pharmacological stimulation of coronary flow to evaluate the presence of local ischaemia or infarction.

In unstable angina there is ST depression or T-wave change during typical anginal pain but without diagnostic elevation in cardiac enzymes. Nitrates can reverse ST segment elevation.

Coronary arteriography may provide unequivocal evidence of arterial narrowing and define its site to guide revascularisation procedures.

Management of stable and unstable angina

Risk factors should be identified and advice given about stopping smoking, losing weight and taking regular exercise. Treat hypertension and hyperlipidaemia. Anaemia should be investigated and treated.

Sublingual glyceryl trinitrate remains the mainstay of symptomatic treatment. The major side effect is headache. It should be taken for pain, and prophylactically before known precipitating events. Long-acting nitrates such as isosorbide-5 mononitrate in a 60-mg sustained release formulation given once daily in the morning can give therapeutic plasma nitrate concentrations during the day, and allow a gradual fall during the night to prevent nitrate tolerance without a pre-dose rebound in angina. β-blockers reduce morbidity as well as control symptoms in stable angina. If necessary a dihydropyridine calcium-channel blocker such as amlodipine (not verapamil or diltiazem) can be added. If a β-blocker is contraindicated or not tolerated, diltiazem or verapamil can be used. Nicorandil, a potassium-channel activator, can also be beneficial. ACE inhibitors should be used in patients who also have left ventricular dysfunction or diabetes, unless there are contraindications. Low-dose aspirin (75 mg/day) reduces the risk of acute coronary events and myocardial infarction in patients with stable angina. Clopidogrel, an adenosine diphosphatase (ADP) receptor antagonist, may confer additional benefits but increases the risk of bleeding (see Trials Box 10.1). Diet and statins should be used to reduce LDL cholesterol with a target of < 2.0 mmol/l.

TRIALS BOX 10.1 Anti-platelet and anti-coagulant agents in ischaemic heart disease and myocardial infarction

The CHARISMA investigators randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg/day) plus low-dose aspirin (75–162 mg/day) or placebo plus low-dose aspirin and followed them for a median of 28 months. Overall, clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing the rate of myocardial infarction, stroke or death from cardiovascular causes. There was a suggestion of benefit with clopidogrel treatment in patients with symptomatic atherothrombosis and a suggestion of harm in patients with multiple risk factors. (New England Journal of Medicine 2006; 354:1706–1717.)

The thrombolysis in myocardial infarction (TIMI) IIB trial randomised 3,910 patients with angina/non-Q-wave myocardial infarction to intravenous unfractionated heparin for ≥ 3 days followed by subcutaneous placebo injections or uninterrupted antithrombin therapy with enoxaparin during both the acute phase and outpatient phase. Enoxaparin was superior to unfractionated heparin for reducing a composite of death and serious cardiac ischaemic events without causing a significant increase in the rate of major haemorrhage. No further relative decrease in events occurred with outpatient enoxaparin treatment, but there was an increase in the rate of major haemorrhage. (Circulation 1999; 100: 1593–1601.)
Patients with unstable angina (evidence of ongoing myocardial ischaemia without evidence of infarction) should be admitted to hospital and precipitating factors (e.g. anaemia, arrhythmia) identified and treated. Non-ST segment elevation myocardial infarction (NSTEMI) is a closely related condition in which there is sufficient myocardial damage to release a marker of cardiac injury such as troponin or the MB isoenzyme of creatine phosphokinase (creatine phosphokinase has two subunits, which are either B (brain) or M (muscle) types; CK-MB containing B and M subunits is found in cardiac muscle - page 77). Treatment involves bed rest with ECG monitoring whilst pain is ongoing, and escalation of anti-ischaemic therapy. This should include low-dose aspirin, intravenous unfractionated or subcutaneous low-molecular-weight heparin (see Trials Box 10.1) and sublingual nitroglycerin, followed by intravenous nitrates. β-blockade can be added if there is ongoing pain and no contraindication. If β-blockers are contraindicated a non-dihydropyridine calcium antagonist (e.g. verapamil or diltiazem) can be used in the absence of severe left ventricular dysfunction or other contraindications. An ACE inhibitor can be added if hypertension persists despite the above measures. Pain should be controlled with morphine if not relieved, and supplemental oxygen administered if needed to maintain SaO₂ > 90%.

**Coronary angiography and revascularisation**

Indications for coronary angiography differ between units, but angiography with a view to percutaneous coronary intervention or cardiopulmonary bypass surgery should be considered in all patients with evidence of recurrent ischaemia (angina or ST-segment changes at rest or with minimal activity) or a strongly positive stress test despite medical therapy.

Coronary revascularisation can be achieved by coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) using catheter-borne devices (usually a balloon or laser) to open stenotic areas within coronary arteries (see Trials Box 10.2). CABG tends to be recommended in patients with three vessel disease, significant left main coronary artery disease or two vessel disease with significant proximal left anterior descending coronary artery disease and abnormal left ventricular function. PCI was initially only used for more proximal one vessel disease. Improved techniques, the advent of drug eluting stents and improved pharmacological therapies following PCI have reduced the risk of restenosis or occlusion, and PCI is now used in more complex situations. Patients should receive dual antiplatelet treatment with aspirin and clopidogrel following PCI with stent placement. The recommended duration of clopidogrel therapy depends on the type of stent.

---

**Myocardial infarction**

The European Society of Cardiology, the American College of Cardiology Foundation, the American Heart Association and the World Heart Federation published a universal definition of myocardial infarction in 2007 (Thygesen et al. 2007).

The criteria for diagnosis of acute myocardial infarction are met if there is a rise in biomarkers of cardiac injury (preferably troponin) together with one of the following:

- symptoms of myocardial ischaemia
- ECG changes indicative of new ischaemia – new ST segment or T-wave changes, or new LBBB (p. 79)
- development of pathological Q waves (p. 77)
- evidence of new loss of viable myocardium or new regional wall motion abnormality on imaging.
Aetiology

The most common cause is thrombosis in association with an atheromatous plaque that has cracked or ruptured. Necrosis of muscle supplied by the vessel is followed by scarring.

Rare causes (consider in young patients without risk factors) are:

- coronary artery embolism: from thrombus in left atrium or ventricle, or mitral or aortic valve lesions
- congenital abnormalities, such as anomalous origin of coronary artery from pulmonary artery
- coronary artery vasculitis: consider Kawasaki disease in children (p. 287)
- dissecting aneurysm with coronary artery occlusion.

The size and location of the infarct depend on which artery is involved (Fig. 10.1) and the presence of any collateral supply. Occlusion of:

- left anterior descending affects the anterior wall of the left ventricle, and sometimes the septum
- right coronary artery involves the inferior part of the left ventricle, as well as part of the septum and right ventricle
- left circumflex involves the lateral or posterior walls of the left ventricle.

The infarct may extend from endocardium to epicardium (transmural) or involve only the subendocardial region.

There may be a

- past history of hypertension, stroke, intermittent claudication, diabetes mellitus, hyperlipidaemia, smoking
- family history of cardiovascular disease, hyperlipidaemia.

Symptoms

- Pain: onset, duration (usually over 20 min), character (often tight or compressing), site and radiation (usually chest going to arms or neck). Associated sweating, breathlessness, nausea and vomiting are common. There may be a previous history of angina or myocardial infarction.

NB: Intensity is no guide to the extent of the infarct, especially in the elderly and in diabetics where pain may be absent. If there is interscapular pain associated with a ‘myocardial infarction’ syndrome, consider dissection of the thoracic aorta.

Examination

Once any distress has been alleviated by pain control there may be no signs. Examine:

- for associated diseases:
  - xanthelasmata and xanthomata of hyperlipidaemia
  - evidence of diabetes, thyroid disease, diabetes mellitus, gout, cigarette smoking (smell and finger staining)
- pulse for small volume (low cardiac output), arrhythmia
- blood pressure (hypotension usually indicates low cardiac output; hypertension may not be long-standing)
- jugular venous pressure (JVP) is usually normal – elevation suggests heart failure

Figure 10.1 Anatomy of the coronary arteries. Note that the right coronary artery supplies both the SA and AV nodes.
listen to heart for:
- fourth heart sound (common); third heart sound if there is heart failure
- pericardial friction rub
- mitral regurgitation (papillary muscle dysfunction or ventricular dilatation)
- ventricular septal defect (VSD) caused by a ruptured septum (rare)
- listen to lungs for basal crackles of heart failure.

Investigations

**ECG (see p. 78 and Box 10.1)**

Serial ECGs typically show ST segment elevation and T-wave inversion, with the development of Q waves indicating full-thickness myocardial necrosis. Changes occur in the anterior chest (V) leads in anterior myocardial infarction (Fig. 10.2) and in leads II, III and augmented voltage foot (AVF) in inferior myocardial infarction (Fig. 10.3).

Sub-endocardial myocardial infarction leads to ST segment and T-wave changes, but not Q waves. A normal ECG does not exclude myocardial infarction. Posterior infarction is rare and does not produce Q waves, but gives a tall R wave in V1.

Right ventricular infarction is usually associated with inferior infarction, and produces ST elevation which can be detected if right ventricular leads (V3R and V4R) are recorded by placing chest electrodes on the right side of the chest in positions equivalent to V3 and V4.

**Cardiac biomarkers**

Troponin T, from cardiac muscle breakdown, is cardiac specific and the marker of choice.

Creatine kinase (CK) is formed by dimerisation of two polypeptide chains, B and M, giving rise to three different isoenzymes. The predominant isoenzyme in skeletal muscle is MM, whereas in brain it is BB. Cardiac muscle contains both MM and MB, and the
**Box 10.1 ECG patterns in common clinical conditions**

Myocardial infarction

A characteristic pattern of ECG changes typically evolves:

- First few minutes – peaked T waves.
- First few hours – ST segment elevation, inversion of T waves, development of Q waves.
- After a few days the ST segment returns to normal (persistent elevation raises the possibility of left ventricular aneurysm).
- The T waves may eventually become upright, but in full thickness untreated myocardial infarction Q waves persist indefinitely.
- Rhythm abnormalities are common.
- Left bundle branch block (Fig. 10.8, p. 79) may occur at any stage, making further interpretation of the site, timing or extent of an infarct impossible.

Pulmonary embolism (Fig. 10.4)

- Tachycardia and transient arrhythmias (particularly AF).
- Right axis deviation.
- Right ventricular strain pattern – dominant R wave and inverted T waves in V1–4.
- RBBB.
- Occasionally S1, Q3, T3 pattern (S wave in lead I, Q and inverted T in III).

Ventricular hypertrophy

Large R waves occur over the appropriate ventricle in the chest leads (V1–2 for right ventricular hypertrophy and V5–6 for left ventricular hypertrophy). There tend to be large negative S waves in reciprocal leads (e.g. large S in V1 in left ventricular hypertrophy). A number of voltage criteria for left ventricular hypertrophy have been identified; for example, with normal QRS complexes if the sum of the S in V1 plus the R in V5 is greater than 35 mm, left ventricular hypertrophy is present on voltage criteria.

---

**Figure 10.4** Acute pulmonary embolism with S1, Q3, T3 pattern, a mean frontal QRS axis towards the right (±90°) and right ventricular (RV) strain pattern in leads V1–3.
Digoxin
Sagging (reverse tick) ST segments, T-wave inversion.

Metabolic abnormalities

Hyperkalaemia (Fig. 10.5). Flattened P wave, broad QRS complex, peaked T wave.

Hypokalaemia (Fig. 10.6). Prolonged PR, depressed ST, flattened T wave and prominent U wave.

Hypocalcaemia (Fig. 10.7). Prolonged QT interval.

Bundle branch block

- The QRS complex is greater than 0.12 s.
- In left bundle branch block (LBBB) the complex is negative (V- or W-shaped) in V1 (Fig. 10.8). Causes include ischaemic heart disease, myocardial infarction, cardiomyopathy, hypertension and aortic stenosis.
MB isoenzyme is used in diagnosis of myocardial infarction, although it is also elevated in skeletal muscle disease and by muscle trauma.

Management

Early mortality (within 4 weeks) is chiefly within the first 2 h and usually from ventricular fibrillation. Any patient suspected of having a myocardial infarction requires:

- pain relief – usually in the form of opiates plus antiemetics
- oxygen
- aspirin 300 mg to chew immediately
- nitrates should be administered for relief of ongoing ischaemic pain and can be used to control blood pressure and treat heart failure
- transfer to specialist facilities for reperfusion therapy.

Reperfusion therapies

Shortening the time between recognition of symptoms and seeking medical help, and initiation of reperfusion treatment with thrombolysis or primary percutaneous coronary intervention is a key element of management (see Trials Box 10.3).

Several studies in the late 1980s showed that intravenous streptokinase reduced mortality in patients reaching hospital with myocardial infarction from just over 10% to around 8%. ISIS-2 (Second International Study of Infarct Survival) showed that aspirin gives additional benefit, and subsequent trials showed that alteplase had similar effects.

Streptokinase 1,500,000 units is given by intravenous infusion over 1 h. It is cheaper than alternatives but can cause allergic reactions. Its potential for repeated use is limited by antibody formation. Alteplase (recombinant tissue plasminogen activator, rtPA) is

---

**Figure 10.9** Right bundle branch block. RSR in the right ventricular leads V1–2 and slurred S waves in the left ventricular leads I, AVL and V4–6.

- In right bundle branch block (RBBB) the complex is positive (M-shaped) in V1 (Fig. 10.9). In addition to occurring in conditions associated with LBBB, RBBB occurs in conditions that put a strain on the right ventricle (e.g. COPD, pulmonary embolism). RBBB can occur in an otherwise normal heart.

**Fascicular block**

There are three fascicles to the bundle of His: right, left anterior and left posterior. Block of one of the left bundles (unifascicular block) produces the following patterns with QRS complexes of normal width:

- In left anterior hemiblock there is left axis deviation.
- In left posterior hemiblock there is right axis deviation.

**Sinoatrial disease (sick sinus syndrome)**

This is a chronic disorder often associated with ischaemic heart disease in which sinus bradycardia and/or episodic sinus arrest can alternate with episodes of rapid supraventricular arrhythmia. Symptoms include dizziness, syncope, palpitations and dyspnoea. Permanent pacing may be necessary. Diagnosis is most easily made using 24-h ambulatory ECG monitoring.
not antigenic but is expensive. It is critically important to start thrombolysis within 12 h of myocardial infarction; additional benefit is obtained if started within 6 h.

Contraindications to thrombolysis are recent bleeding, severe hypertension (blood pressure > 200/120 mmHg), active peptic ulceration, recent stroke (within the last 2 months), proliferative diabetic retinopathy, severe liver or renal disease, pregnancy/lactation, bacterial endocarditis and acute pancreatitis.

Primary percutaneous coronary intervention (PCI) is the preferred treatment if it is rapidly available (Box 10.3). The European Society of Cardiology and the American College of Cardiology/American Heart Association Task Forces all recommend a target for the time from arrival in the emergency department to angioplasty (door-to-balloon time) of 90 min.

**β-Blockade**

ISIS-1 (First International Study of Infarct Survival) showed that intravenous β-blockade in the early stages of myocardial infarction may confer benefit, but is contraindicated if there is bradycardia, hypotension, heart failure, asthma, sick-sinus syndrome or heart block (second- or third-degree or bifascicular). Long-term β-blockade post-infarction is routine in the absence of contraindications.

**Angiotensin-converting enzyme inhibitors**

Angiotensin-converting enzyme (ACE) inhibitors are beneficial, particularly in patients with anterior myocardial infarction, but their use may be limited by hypotension.
**Anticoagulant and antiplatelet therapy**

NICE Technology Appraisal 230 recommends the thrombin inhibitor bivalirudin in combination with aspirin and clopidogrel for the treatment of adults with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

**Complications**

- **Heart failure** (p. 88).
- **Shock**: the patient is hypotensive, pale, cold, sweaty and cyanosed. Arrhythmias are common. Treatment is with:
  - oxygen
  - diuretics if pulmonary oedema
  - vasodilators – ACE inhibitors (arterial and venous) or nitrates (venous) if blood pressure allows
  - inotropes – dopamine and dobutamine increase cardiac contractility by stimulating β-receptors in cardiac muscle. Low doses of dopamine (< 5 mcg/kg/min) induce vasodilatation and increase renal perfusion, whereas higher doses cause vasodilatation and may exacerbate heart failure.
- **Arrhythmias** (see p. 84 and Table 10.1).
- **Sinus tachycardia**: usually requires no treatment.
- **Supraventricular extrasystoles**: common, but rarely requires treatment.
- **Supraventricular tachycardia**: arise from the atria or atrioventricular junction. Management depends on the nature of the tachycardia.
- **Sinus or nodal bradycardia**: may be caused by sedation, particularly with opiates. If the rate is < 50 beats/min and the patient is hypotensive, give atropine 0.6 mg intravenously and repeat twice if necessary. If unsuccessful, consider cardiac pacing.
- **Heart block**: all degrees of heart block are more serious if they complicate anterior rather than inferior infarcts.
  - first-degree: requires no therapy
  - second-degree: monitor and consider atropine. Many physicians would consider cardiac pacing for Mobitz type II with anterior infarcts (p. 88)
  - third-degree (complete heart block): atropine and isoprenaline may be helpful while awaiting cardiac pacing.

NB: Complete heart block is more common in inferior myocardial infarctions because the atrioventricular nodal artery is a branch of the right coronary artery; complete heart block complicating anterior infarction is ominous because it implies a large muscle infarction.

- **Ventricular tachycardia**: this can respond to intravenous amiodarone, but proceed to direct current (DC) cardioversion without delay if no success or there is haemodynamic collapse.
- **Ventricular fibrillation**: this is frequently within 6 h of myocardial infarction (see Cardiorespiratory arrest, p. 88).

**Electromechanical dissociation** (complexes on ECG with no pulse – see Cardiorespiratory arrest, p. 88).

**Late complications**

**Ventricular aneurysm** can cause heart failure, angina, arrhythmias and emboli from thrombi within the aneurysm. There may be cardiac enlargement and abnormal cardiac pulsation (e.g. an impulse at the left sternal border). Its presence is suggested by ST-segment elevation persisting in convalescence. The aneurysm may be demonstrated by echocardiography, radionuclide studies or left ventriculography. Surgical removal is indicated for heart failure or arrhythmias. Anticoagulants reduce the risk of emboli.

**Papillary muscle dysfunction** or rupture may cause heart failure. There is a pansystolic or late systolic mitral regurgitant murmur. Echocardiography confirms the diagnosis. Surgery may be indicated.

**Ruptured ventricular septum** is rare. Urgent surgical repair may be required for severe heart failure.

**Myocardial rupture** leads to death from tamponade (unless immediate surgery is available). Dressler (post-myocardial infarction) syndrome occurs weeks or months after myocardial infarction or cardiac surgery. It is characterised by fever, pleurisy and pericarditis, and the presence of antibodies to heart muscle.

**Invasive and non-invasive assessment post myocardial infarction**

Patients with ongoing angina (or other evidence of ischaemia) at rest or on minimal exertion or left ventricular dysfunction should undergo coronary angiography to evaluate the need for coronary revascularisation. Patients in whom angiography is not planned should undergo exercise testing towards the end of the hospital admission or early after discharge to assess functional capacity and look for evidence of inducible ischaemia. Echocardiography should be performed to assess left ventricular function. Dipyridamole or adenosine stress myocardial perfusion imaging can be used in patients unable to exercise or if baseline abnormalities compromise ECG interpretation during exercise testing.

**Rehabilitation**

Cardiac rehabilitation programmes reinforce the importance of secondary prevention and promote adoption of a healthy lifestyle. Dietary education is given to achieve normal BMI and reduce dietary cholesterol and saturated fat. Active involvement in self-rehabilitation should be encouraged. The importance of stopping smoking must be stressed and strategies to help smokers used.

Patients should be encouraged to increase activity gradually over 1–2 months, when return to work can
## Table 10.1 Cardiac arrhythmias

<table>
<thead>
<tr>
<th>Rhythm</th>
<th>Rate</th>
<th>Diagnosis</th>
<th>Underlying diseases</th>
<th>Therapy (pp. 84–88)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrial</td>
<td>Regular</td>
<td>100–100</td>
<td>Sinus tachycardia</td>
<td>Anxiety, cardiac failure, thyrotoxicosis, fever, anaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100–200</td>
<td>Supraventricular tachycardia</td>
<td>None (60%), thyrotoxicosis, digoxin, tobacco, caffeine, Wolff–Parkinson–White syndrome</td>
</tr>
<tr>
<td></td>
<td>300</td>
<td>70–200</td>
<td>Atrial flutter with block</td>
<td>Ischaemic heart disease, thyrotoxicosis, digoxin</td>
</tr>
<tr>
<td></td>
<td>60–15–50</td>
<td>15–50</td>
<td>Complete heart block with cannon 'a' waves in jugular vein pulse, variable intensity first sound, wide pulse pressure</td>
<td>Postinfarction, idiopathic, digoxin, cardiomyopathy</td>
</tr>
<tr>
<td></td>
<td>40–60</td>
<td>40–60</td>
<td>Sinus bradycardia</td>
<td>Athletes, myocardial infarction, myxoedema, hypothermia, sinoatrial disease</td>
</tr>
<tr>
<td></td>
<td>Irregular</td>
<td>Multiple ectopics (including coupled beats), ECG basically regular</td>
<td>Ischaemia, digoxin, thyrotoxicosis, cardiomyopathy</td>
<td>As heart block if following myocardial infarction</td>
</tr>
<tr>
<td></td>
<td>60–100</td>
<td>Atrial flutter with varying block</td>
<td>Ischaemia, rheumatic heart disease</td>
<td>Rate control – β-blocker, calcium antagonist, digoxin</td>
</tr>
<tr>
<td></td>
<td>&lt; 100 treated</td>
<td>Atrial fibrillation (apex rate is only guide to true heart rate. ECG essential)</td>
<td>Ischaemic and rheumatic heart disease, thyrotoxicosis, pulmonary embolism, constructive pericarditis, cardiomyopathy or bronchial carcinoma</td>
<td>Rate control – β-blocker, calcium antagonist, digoxin</td>
</tr>
<tr>
<td></td>
<td>100+ untreated</td>
<td></td>
<td></td>
<td>Rate control DC cardioversion, amiodarone, sotalol</td>
</tr>
<tr>
<td></td>
<td>Cardiac arrest</td>
<td>120–200</td>
<td>Ventricular tachycardia</td>
<td>Myocardial infarction and ischaemia</td>
</tr>
<tr>
<td></td>
<td>120–200 No peripheral pulse</td>
<td>Ventricular fibrillation and sometimes ventricular tachycardia. Ventricular asystole</td>
<td></td>
<td>See p. 88</td>
</tr>
</tbody>
</table>

DC, direct current; ECG, electrocardiogram
be considered. Patients should be advised about driving restrictions (p. 88).

**Long-term pharmacological treatments**

Unless contraindicated, aspirin, β-blockade, angiotensin blockade and statins (Trials Box 10.4) should be started in all patients and continued indefinitely. Target LDL cholesterol should be less than 2.0 mmol/l.

**Arrhythmias**

(See Table 10.1.)

**Supraventricular tachycardias**

Supraventricular tachycardias arise from the atria or atrioventricular junction. QRS complex is normal unless there is also bundle branch block.

**Sinus tachycardia**

In sinus tachycardia the rate is >100 beats/min. An underlying cause (anxiety, exercise, fever, anaemia, heart failure, thyrotoxicosis) can usually be identified.

**Atrial fibrillation**

Atrial fibrillation (AF) is predominantly a disease of the elderly, occurring in 0.2% of men aged 47–56 and 3% of those aged 77–86 (Framingham study, 1949). Rheumatic AF occurs in association with rheumatic valve disease, whereas in non-rheumatic AF there is an underlying metabolic disorder or other form of cardiac disease. Lone AF occurs in the absence of valvular, myocardial or other identifiable disease. The common causes are:

- ischaemic heart disease
- thyrotoxicosis
- mitral valve disease
- cardiomyopathy.

---

**TRIALS BOX 10.4 Statins**

The Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL) study enrolled 8,888 patients aged 80 years or younger with a history of acute MI: 4,439 patients were randomly assigned to receive a high dose of atorvastatin (80 mg/day) and 4,449 patients were randomised to usual-dose simvastatin (20 mg/day). During treatment, mean LDL cholesterol levels were 104 mg/dl in the simvastatin group and 81 mg/dl in the atorvastatin group. More intensive lowering of LDL cholesterol did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary endpoints and non-fatal acute MI. There were no differences in cardiovascular or all-cause mortality. (JAMA 2005; 294(19): 2437–2445.)

In the Treating to New Targets (TNT) study, 10,001 patients with coronary heart disease and LDL cholesterol levels of less than 3.4 mmol/l were randomly assigned to receive either 10 mg or 80 mg of atorvastatin per day. The mean LDL cholesterol levels were 2.0 mmol/l during treatment with 80 mg of atorvastatin, and 2.6 mmol/l during treatment with 10 mg of atorvastatin. There was an absolute reduction in the rate of major cardiovascular events of 2.2% and a 22% relative reduction in risk in patients receiving more intensive lipid-lowering therapy.

This occurred with a greater incidence of elevated aminotransferase levels. (New England Journal of Medicine 2005; 352: 1425–1435.)

The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction-22 (PROVE IT TIMI-22) study enrolled 4,162 patients who had been hospitalised for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The intensive lipid-lowering statin regimen provided greater protection against death or major cardiovascular events than the standard regimen. (New England Journal of Medicine 2004; 350: 1495–1504.)

The prospective studies collaboration performed a meta-analysis of 61 prospective observational studies consisting of almost 900,000 adults without previous disease and with baseline measurements of total cholesterol and blood pressure. During nearly 12 million person years at risk between the ages of 40 and 89 years, there were more than 55,000 vascular deaths (34,000 ischaemic heart disease, 12,000 stroke, 10,000 other); 1 mmol/l lower total cholesterol was associated with about a half, a third and a sixth lower ischaemic heart disease mortality in both sexes at ages 40–49, 50–69 and 70–89 years, respectively, with no apparent threshold. (Lancet 2007; 370: 1829–1839.)
Management

Check serum potassium, echocardiogram and thyroid function. The aims are to restore sinus rhythm or control the ventricular rate and minimise the risk of embolisation.

Direct current (DC) cardioversion can establish sinus rhythm in 90% of patients, but relapse is common. Long-term amiodarone reduces the frequency of relapse, although side effects can limit its use. Anticoagulant treatment is recommended for 3 weeks before and at least 4 weeks after successful cardioversion (see Box 10.2).

NB Side effects of amiodarone are reversible corneal microdeposits, photosensitivity, skin discolouration, hypothyroidism, hyperthyroidism, diffuse pulmonary alveolitis and fibrosis, peripheral neuropathy and myopathy.

Medical therapy

Quinine, flecainide and amiodarone have all been used to restore and maintain sinus rhythm. Digoxin does not restore sinus rhythm, but is effective in controlling the ventricular rate, either alone or in combination with β-blockers.

The incidence of ischaemic stroke (embolic or thrombotic) is increased in patients with AF, and anti-thrombotic treatment is recommended (Box 10.2 and Table 10.2).

Atrial flutter

The atria discharge at around 300/min, giving the characteristic ‘saw-tooth’ baseline on ECG (see Fig. 10.10). There is usually atrioventricular block, leading to a ventricular rate of 150/min (2:1) or 100/min (3:1). The rate is basically regular but is affected by 2:1, 3:1 and variable block. The causes are similar to AF, although atrial flutter is less common.

Management

Drugs such as sotalol, amiodarone, propafenone and flecainide can be effective in restoring sinus rhythm. DC cardioversion can also be used to terminate atrial flutter.

### Box 10.2 Anti-thrombotic therapy in patients with atrial fibrillation, including paroxysmal atrial fibrillation, and atrial flutter

The American College of Chest Physicians Evidence-Based Clinical Practice Guidelines on antithrombotic therapy in atrial fibrillation (CHEST 2008; 133 (Suppl 6): 546S–592S) recommend long-term anticoagulation with warfarin (or other vitamin K antagonist) with an INR target of 2.5 (range 2.0–3.0) in patients with AF, including those with paroxysmal AF, who have had a prior ischaemic stroke, transient ischaemic attack (TIA) or systemic embolism, and in patients who have two or more of the following risk factors: age > 75 years, history of hypertension, diabetes mellitus, moderately or severely impaired left ventricular systolic function and/or heart failure. In patients with only one of these risk factors long-term antithrombotic therapy with either warfarin or aspirin at a dose of 75–325 mg/day is recommended, and in patients with none of these risk factors long-term aspirin therapy at a dose of 75–325 mg/day is recommended. Recommendations for patients with atrial flutter are similar, although the evidence base is less strong. Long-term anticoagulation with warfarin is also recommended for patients with AF and mitral stenosis, and with AF and prosthetic heart valves.

### Table 10.2 Summary of recommendations for antithrombotic therapy in atrial fibrillation

<table>
<thead>
<tr>
<th>Associated conditions</th>
<th>Recommended antithrombotic treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior ischaemic stroke, TIA or systemic embolisation</td>
<td>Warfarin² – INR target 2.5 (range 2.0–3.0)</td>
</tr>
<tr>
<td>Two or more risk factors¹</td>
<td>Warfarin² – INR target 2.5 (range 2.0–3.0) or aspirin 75–325 mg/day</td>
</tr>
<tr>
<td>One or more risk factor¹</td>
<td>Warfarin² – INR target 2.5 (range 2.0–3.0)</td>
</tr>
<tr>
<td>Mitral stenosis</td>
<td>Warfarin² – INR target 2.5 (range 2.0–3.0)</td>
</tr>
<tr>
<td>Prosthetic valve</td>
<td>Warfarin² – INR appropriate for the specific type of prosthesis</td>
</tr>
</tbody>
</table>

¹Risk factors: age > 75 years, history of hypertension, diabetes mellitus, moderately or severely impaired left ventricular systolic function and/or heart failure.
²Or other oral vitamin K antagonist.
For patients with AF of $\geq 48$ h or of unknown duration for whom pharmacologic or electrical cardioversion is planned, anticoagulation with warfarin for 3 weeks before elective cardioversion and for at least 4 weeks after sinus rhythm has been maintained is recommended.

**Atrial tachycardia**

The atrial rate is slower than in atrial flutter, being between 120 and 200/min. The ECG shows abnormally shaped P waves (see Fig. 10.11). There is often a degree of atrioventricular (AV) block.

**Management**

**Terminating an episode of atrial tachycardia**

- First try unilateral carotid sinus massage or Valsalva manoeuvre.
- Adenosine (3 mg by rapid injection into central or large peripheral vein) usually causes rapid reversion to sinus rhythm. Its short half-life (10 s) means that side effects (facial flushing, bronchospasm, bradycardia) are usually short-lived.
- Verapamil may be preferable in asthmatics but should be avoided if hypotension or heart failure are present. Verapamil is contraindicated in patients taking β-blockers.
- Disopyramide and amiodarone may be useful in resistant supraventricular tachycardia.
- Cardioversion under short-acting general anaesthesia is used when rapid results are required and other procedures have failed.

**Preventing atrial tachycardia**

If they fail, sodium channel blockers (propafenone or flecainide) may be indicated. In tachycardias involving accessory connections, agents that affect fast channel dependent tissue (propafenone, flecainide, cibenzoline, disopyramide or hydroquinidine) are effective. Potassium current blockers, such as sotalol or amiodarone, represent an alternative therapy.

**Pre-excitation syndromes**

In addition to the AV node, an additional connection (accessory pathway) between the atria and ventricles allows atrial impulse to be transmitted more quickly to the ventricles – hence the term pre-excitation syndrome. The main types are Wolff–Parkinson–White and Lown–Ganong–Levine syndromes.

**Wolff–Parkinson–White syndrome** is caused by an accessory pathway (bundle of Kent) that bypasses the AV junction. It is characterised by a short PR interval and a widened QRS complex because of the presence of a δ wave (see Fig. 10.12). In type A, the ventricular complex is positive in lead V1; in type B, it is negative. Two main arrhythmias occur:

- In **re-entrant tachycardia** the normal (AV node) conduction pathway and the accessory pathway form a circuit through which impulses repeatedly circulate. The δ wave is lost. Drugs that block the AV node (e.g. adenosine, verapamil) usually restore sinus rhythm.
- In **atrial fibrillation** most ventricular complexes are broad because of the presence of δ waves on the upstroke. AV nodal blocking drugs may increase...
the ventricular rate and should be avoided. DC cardioversion usually terminates AF. Amiodarone may be used to slow conduction in the accessory pathway.

Lown–Ganong–Levine is also characterised by a short PR interval but has a normal QRS, i.e. without a δ wave. It is also complicated by paroxysmal tachycardia.

**Ventricular tachycardia**

The ventricular rate is usually 120–200/min. It usually reflects serious underlying myocardial disease. It is often self-limiting, but if sustained may cause hypotension and shock. The ECG shows a broad-complex tachycardia, and P waves dissociated from the ventricular activity may be seen (see Fig. 10.13). The axis is often bizarre.

**Management**

Amiodarone can be used, but DC cardioversion should be performed if there is shock.

In *torsade de pointes* the QRS axis progressively changes so that the complexes appear to twist continuously. There is QT prolongation in sinus rhythm. Underlying causes should be identified and treated (antiarrhythmic drugs, hypokalaemia, hypomagnesaemia, tricyclic anti-depressants). Antiarrhythmic agents may aggravate the condition. DC cardioversion or pacing is often effective in terminating attacks, which if left untreated may degenerate into ventricular fibrillation. Intravenous infusion of magnesium sulphate is also often effective.

**Ventricular fibrillation**

See Cardiorespiratory arrest, p. 88.

**Heart block (see Fig. 10.14)**

In *first-degree block* the PR interval is prolonged. In *second-degree block* the normal 1:1 ratio of P:QRS complexes is lost but a relationship between P waves and QRS complexes still exists. The relationship may
be either progressive lengthening of the PR interval until one QRS complex is dropped (Mobitz type I or Wenckebach) or dropped QRS complexes without a change in the PR interval (Mobitz type II).

If there is complete dissociation between P waves and QRS complexes third-degree heart block exists. The QRS complex rate (and hence ventricular rate) is usually slow (15–50/min) and regular. Cardiac pacing is often required.

Cardiorespiratory arrest
Clinical features
- sudden loss of consciousness
- absent carotid and femoral pulses
- respiratory arrest follows shortly after

Aetiology
- almost invariably cardiac arrhythmia (ventricular fibrillation (VF), ventricular tachycardia (VT) or asystole)
- rarely, the primary event is respiratory arrest (e.g. severe asthmatic attack)

Management
The Resuscitation Council UK Guidelines (http://www.resus.org.uk/pages/guide.htm) contain information about basic and advanced life support, including algorithms for in-hospital resuscitation (Fig. 10.15) and advanced life support (Fig. 10.16).

Cardiovascular disorders and driving
Full details of the DVLA’s current medical standards of fitness to drive can be found at http://www.dft.gov.uk/dvla/medical/ataglance.aspx.

Group 1 entitlement
- Angina: driving must cease when symptoms occur at rest, with emotion or at the wheel.
- Acute coronary syndromes: if successfully treated by coronary angioplasty, driving may recommence after 1 week provided no other disqualifying condition.
- Pacemaker insertion: driving must cease for at least 1 week.
- Arrhythmia: driving must cease if the arrhythmia has caused or is likely to cause incapacity.
- Thoracic and abdominal aortic aneurysm: DVLA should be notified of any aneurysm 6 cm or more in diameter. An aortic diameter of 6.5 cm or more disqualifies the patient from driving.

Heart failure
Heart failure has a prevalence in the UK, Scandinavia and the USA of about 1% overall and 10% in the elderly.

New York Heart Association classification
Class I. Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnoea or anginal pain.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnoea or anginal pain.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnoea or anginal pain.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

Pathophysiology
- Cardiac size increases as a result of dilatation or muscle fibre hypertrophy. In response to increased volume load, ventricular volume increases (the heart dilates). This is initially beneficial as the strength of contraction increases as the cardiac muscle is stretched (Starling’s law). However, contraction declines as stretch becomes extreme.
- Cardiac output is diminished by definition, resulting in reduced perfusion to vital organs.
- Sympathetic nervous activity and plasma noradrenaline (norepinephrine) levels increase, leading to increased heart rate, myocardial contractility and arterial and venous tone.
Renal blood flow is reduced, leading to activation of the renin–angiotensin system (p. 92). Angiotensin II causes vasoconstriction and, by stimulating aldosterone, sodium and water retention. These mechanisms increase both pre- and afterload. 

Preload is the extent to which cardiac muscle is stretched prior to contraction; it is reflected by the ventricular volume at the end of diastole – the end-diastolic volume.

Afterload is the load the ventricle contracts against during systole, which is produced by the aortic valve and the arterial tree.

Heart failure is therefore associated with vasoconstriction through angiotensin II and sympathetic nervous activity, and salt and water retention. These mechanisms initially increase cardiac output (Starling’s law) and blood pressure, but do so at the expense of reduced peripheral blood flow and circulatory congestion.

Aetiology

It is important to identify the underlying cause:

- ischaemic heart disease with left ventricular dysfunction (the most common cause)
- hypertension
- cardiomyopathy
- valvular heart disease

Figure 10.15 In-hospital resuscitation algorithm. Reproduced with the kind permission of the Resuscitation Council (UK). ABCDE – Airway Breathing Circulation Disability Exposure.
Unresponsive?
not breathing or
only occasional gasps

Call resuscitation team

CPR 30 : 2
Attach defibrillator/monitor
Minimise interruptions

Assess
rhythm

Shockable
(VF/pulseless VT)

Non-shockable
(PEA/asystole)

1 Shock

Return of
spontaneous circulation

Immediately resume
CPR for 2 min
Minimise interruptions

Immediate post cardiac
arrest treatment
• Use ABCDE approach
• Controlled oxygenation
  and ventilation
• 12-lead ECG
• Treat precipitating cause
• Treatment control/
  therapeutic hypothermia

Immediately resume
CPR for 2 min
Minimise interruptions

During CPR
• Ensure high-quality CPR rate, depth, recoil
• Plan actions before interrupting CPR
• Give oxygen
• Consider advanced airway and capnography
• Continuous chest compressions when advanced
  airway in place
• Vascular access (intravenous, intraosseous)
• Give adrenaline every 3–5 min
• Correct reversible causes

Reversible causes
• Hypoxia
• Hypovolaemia
• Hypo-/hyperkalaemia/metabolic
• Hypothermia
• Thrombosis – coronary or pulmonary
• Tamponade – cardiac
• Toxins
• Tension pneumothorax

Figure 10.16 Advanced Life Support Algorithm. Reproduced with the kind permission of the Resuscitation Council (UK). PEA – pulseless electrical activity
congenital heart disease (ASD, VSD)
pericardial disease
in high-output heart failure excessive cardiac workload may result from anaemia, Paget’s disease and thyrotoxicosis.

There may also be precipitating factors:
- anaemia
- fluid retention (NSAIDs, renal disease)
- infection (especially of the lungs with reduced PaO₂; endocarditis)
- drugs with negative inotropism (most anti-arrhythmic drugs except digoxin).

Clinical features

In left heart failure left ventricular end-diastolic pressure (LVEDP) is increased. Pulmonary congestion causes dyspnoea, orthopnoea and paroxysmal nocturnal dyspnoea, and leads to acute pulmonary oedema. Fatigue results from reduced muscle blood flow. Signs are tachycardia, third heart sound, crackles at the lung bases and pulmonary effusions.

Right heart failure is usually caused by pulmonary congestion of left heart failure. It also complicates lung disease (cor pulmonale), pulmonary hypertension, right ventricular infarction, and pulmonary and tricuspid valve disease. Signs are raised JVP, hepatomegaly (cardiac cirrhosis may occur if chronic), oedema and ascites.

Investigation

All patients with newly diagnosed heart failure require the following:
- full blood count to exclude anaemia
- creatinine and electrolytes to look for evidence of impaired renal function as a cause of fluid retention or a consequence of reduced renal perfusion
- chest X-ray for evidence of cardiomegaly, venous hypertension or pulmonary oedema
- ECG for evidence of myocardial ischaemia or infarction, left ventricular hypertrophy, arrhythmia
- echocardiography to exclude valvular or pericardial disease and assess left ventricular function.

Further investigations, including cardiac radionuclide studies, exercise testing and coronary angiography, may be indicated.

Echocardiography

Thickening of stenotic valves, often with calcification, gives rise to intense echoes with limited movement of the valve leaflets. Doppler can be used to assess pressure gradients across stenosed valves and is extremely sensitive in detecting valve regurgitation.

In dilated cardiomyopathy both end-diastolic and end-systolic dimensions are increased, and shortening fraction reduced.

Hypertrophic cardiomyopathy is suggested by thickening of the left and/or right ventricle or interventricular septum in the absence of aortic stenosis or hypertension. There is typically anterior motion of the mitral valve during systole, and mid-systolic closure of the aortic valve. Doppler can be used to detect a pressure gradient across the left ventricular outflow tract.

Pericardial effusion appears as an echo-free space around the heart. If tamponade develops ventricular wall movement is reduced.

Radionuclide studies

Ejection fraction is reduced and there may be dilatation of the heart. A fall in ejection fraction on exercise is a poor prognostic sign. Regional abnormalities of the ventricular muscle usually indicate myocardial ischaemia or infarction. Regional paradoxical movement suggests an aneurysm.

Coronary angiography

Coronary revascularisation is recommended in patients with hypoperfused but viable myocardium.

Treatment

- **Diuretics** are used to control sodium and water retention. Furosemide 40 mg/day or bumetanide 1 mg/day are usually effective. Higher doses may be required and synergism between thiazide and loop diuretics can be exploited. Careful monitoring of fluid status and renal function is required.
- **ACE inhibitors** have beneficial effects on all classes of heart failure. They should be considered in all patients, even if asymptomatic, because they reduce afterload and may enable remodelling of the left ventricle muscle. Use may be limited by side effects, which include hypotension, renal impairment, hyperkalaemia and cough (when angiotensin II antagonists can be substituted).
- **β-Blockade** with carvedilol, bisoprolol or metoprolol, titrated from very small doses, inhibits the adverse effects of sympathetic activity, outweighing their negative inotropic effects.
- **Low dose aldosterone antagonists** (e.g. spironolactone or eplerenone) should be considered, but carry the risk of hyperkalaemia.

A combination of hydralazine and a nitrate should be considered in patients who are symptomatic despite angiotensin and β-blockade or who are unable to tolerate these treatments.
**Digoxin** is useful for control of concomitant atrial fibrillation. Recent studies have also shown a benefit in patients with heart failure in sinus rhythm.

Atrial-synchronised biventricular pacemakers (cardiac resynchronisation therapy) eliminate the delay in activation of the left ventricle seen in many patients with left ventricular systolic dysfunction, which can increase left ventricular filling time, reduce mitral regurgitation and reduce septal dyskinesis (see Trials Box 10.5).

**Ventricular arrhythmias and sudden death**

Patients with previous cardiac arrest or ventricular arrhythmias are at highest risk of sudden death and should be considered for placement of an implantable cardioverter-defibrillator.

**Hypertension**

**Aetiology**

In over 90% of cases no specific cause is found and the hypertension is known as essential. The aetiology is probably multifactorial. Predisposing factors include:

- increasing age
- obesity
- excessive alcohol intake.

Hypertension may be secondary to:

- renal disease
- endocrine disease – Cushing syndrome, Conn syndrome, phaeochromocytoma, acromegaly
- oral contraceptive pill
- eclampsia
- coarctation of the aorta.

**Genetic factors**

Blood pressure levels show a strong familial aggregation that cannot be accounted for by shared environment alone. However, the genetic and environmental factors contributing to hypertension are likely to be extremely diverse, confounding the search for responsible genes. Attention has principally been directed towards the identification of candidate genes. These include genes involved in the renin–angiotensin system, together with a number of important vasoconstrictor and vasodilator substances which have recently been identified.

**Renin–angiotensin–aldosterone system**

A number of factors, including hypotension, hypovolaemia and hyponatraemia, stimulate renin release from the juxtaglomerular apparatus. Renin converts angiotensinogen to angiotensin I, which is then converted by ACE to angiotensin II. Angiotensin II causes arteriolar vasoconstriction, activation of the sympathetic nervous system, and antidiuretic hormone (ADH) and aldosterone secretion. In the kidney angiotensin II causes a relatively greater increase in efferent (postglomerular) compared to afferent (pre-glomerular) arteriolar constriction, thereby maintaining glomerular filtration in the face of reduced renal perfusion.

**Endothelins, prostacyclins and nitric oxide**

These are derived from the vascular endothelium. They regulate vascular contraction and relaxation, particularly in the coronary circulation. Endothelins are a family of structurally related 21-amino-acid peptides and the most potent vasoconstrictors. At least three different isoforms exist. Endothelin-1 (ET-1) is the predominant peptide generated by vascular endothelial cells. It is generated from proendothelin-1 by the action of endothelin-converting enzyme, a metalloprotease. Two distinct endothelin receptors have been identified. ET-1 has been implicated in the pathophysiology of a number of conditions involving vasoconstriction, including heart failure, pulmonary hypertension, subarachnoid haemorrhage, Raynaud’s phenomenon and Prinzmetal angina.

### Trials Box 10.5 Cardiac resynchronisation therapy (CRT)

A systematic review found that cardiac resynchronisation reduces morbidity and mortality in patients with left ventricular systolic dysfunction, prolonged QRS duration and NYHA class 3 or 4 symptoms when combined with optimal pharmacotherapy. (JAMA. 2007; 297(22): 2502–2514.)

A meta-analysis on the effects of cardiac resynchronisation therapy in heart failure patients with narrow QRS complex found that in patients with baseline mechanical asynchrony, who underwent CRT after optimal medical management, there was a significant reduction in NYHA class, improvement in LVEF and increase in 6-min walk distance during follow-up. (Cardiology Journal 2008; 15(3): 230–236.)
Prostacyclin is produced by endothelial cells, platelets and monocytes via a phospholipase A2 (PLA2)-dependent pathway, and causes smooth-muscle cell relaxation and also inhibition of platelet aggregation, via intracellular increases in cyclic 3',5'-adenosine monophosphate (cAMP). Prostacyclin is synthesised in response to the same inflammatory mediators that raise cytoplasmic-free calcium as nitric oxide. Interleukin-1 (IL-1) and tumour necrosis factor increase the activity of the enzymes mediating prostacyclin generation.

Nitric oxide (NO, originally named endothelial-derived relaxing factor) is produced by oxidation of the guanidine-nitrogen terminal of L-arginine, forming NO and citrulline. Production of NO is regulated via activity of NO synthase, a predominantly cytosolic calcium-calmodulin-requiring enzyme which is similar in structure to cytochrome P450 enzymes. Two distinct types of the enzyme have been identified, designated constitutive and inducible.

Constitutive NO synthase is a calcium-calmodulin-requiring enzyme that is responsible for the transient release of small (picomolar) quantities of NO from vascular endothelium, platelets, mast cells, adrenal medulla and some neurons. Enzyme activity is increased by:

- inflammatory mediators, such as thrombin, histamine, bradykinin, serotonin and leukotriene C4, which raise intracellular calcium
- mechanical forces, such as shear stress
- acetylcholine.

Inducible NO synthase is not dependent on calcium-calmodulin and causes a sustained release of larger (nanomolar) amounts of NO from activated macrophages, neutrophils, vascular endothelium and microglial cells. It is induced by bacterial endotoxin, IL-1, tumour necrosis factor and interferon-γ.

Pharmacology of nitric oxide
NO mediates the action of some commonly used vasodilators. Glycerol trinitrate and organic nitrate esters react with thiols such as cysteine and glutathione to yield unstable intermediates which release NO. Sodium nitroprusside spontaneously releases NO.

Pathophysiology
In its early stages hypertension is thought to be characterised by increased cardiac output with normal peripheral resistance. As hypertension progresses peripheral resistance increases and cardiac output returns to normal.

Left ventricular hypertrophy (LVH) may be present even in mild hypertension and is associated with increased risk of cardiac dysfunction, atherosclerosis, arrhythmias and sudden death.

Diagnosis of LVH
- ECG: S wave in V1 and R wave in V5 or V6 ≥ 35 mm. May be associated with ST-segment depression or T-wave inversion (‘strain pattern’).
- Echo: much more sensitive than ECG. The left ventricular mass index (LVMI) is calculated from left ventricular wall thickness and left ventricular internal diameters in systole and diastole, and body surface area.
- Severe LVH present if LVMI > 110 g/m² in women or > 131 g/m² in men.

There is good evidence that treatment of hypertension results in regression of LVH.

Symptoms
There are usually no symptoms of hypertension. Headaches or visual disturbance occur in severe or accelerated hypertension.

Examination
The blood pressure is measured at rest. If high (systolic > 140 mmHg, diastolic > 90 mmHg), check in both arms, and unless very severe recheck on at least three separate occasions before considering treatment. A large cuff should be used in the 10% of the population with arm circumference over 33 cm. Phase V diastolic (disappearance) should be recorded together with the patient’s posture and the arm used.

Mild or moderate hypertension usually gives no other abnormalities on examination. In long-standing or severe hypertension look for evidence of LVH with an aortic ejection murmur and loud aortic second sound. The optic fundi may show evidence of retinopathy with arterial narrowing and arteriovenous nipping (indicating atherosclerosis), haemorrhages and exudates. Papilloedema indicates the presence of malignant hypertension.

Ten percent of cases have an underlying definable cause: it is essential to think of these less common causes.

- Observe the face for evidence of Cushing syndrome – usually caused by corticosteroid administration.
- Examine for aortic coarctation – feel both radials and measure blood pressure in both arms. Look for radial–femoral delay, weak femoral pulses, bruises of the coarctation and scapular anastomoses which may produce visible pulsations.
- Listen for an epigastric or paraumbilical bruit of renal artery stenosis.
Subjects according to risk of cardiovascular disease and local guidelines. Glycaemic control should also be optimised in diabetic subjects.

**Thiazide diuretics** inhibit distal tubular sodium reabsorption. Low doses (e.g. bendroflumethiazide 2.5 mg/day or chlorothalidone 25 mg/day) have maximal antihypertensive effect. Higher doses confer little additional antihypertensive effect, but cause more marked adverse metabolic effects, including hypokalaemia, hyponatraemia, hypochloroemic alkalosis, hyperuricaemia, hyperglycaemia and hyperlipidaemia.

**Calcium-channel blockers** inhibit inward movement of calcium ions through slow channels in cell membranes. They influence the function of cardiac myocytes, the specialised conducting cells of the heart, and vascular smooth-muscle cells. Three classes, which differ in their relative effects on the heart and blood vessels, are available:

- The phenylalkylamine, verapamil, slows conduction in the sinoatrial and atrioventricular nodes and depresses myocardial contraction, but is less potent as a vasodilator.
- The benzothiazepine, diltiazem, slows conduction in the sinoatrial and atrioventricular nodes, but causes less myocardial depression and vasodilatation.
- The dihydropyridines (e.g. nifedipine, nicardipine, amlodipine, felodipine, isradipine, lacidipine) have little effect on cardiac contraction or conduction, but are more potent arterial vasodilators. Dihydropyridines vary in their effects on different vascular beds. Nimodipine acts preferentially on cerebral arteries and is used to prevent vascular spasm following subarachnoidal haemorrhage.

**ACE inhibitors** (e.g. captopril, lisinopril, ramipril) inhibit conversion of angiotensin I to II, which is a vasoconstrictor and stimulates aldosterone production. They should be considered for treatment of hypertension when β-blockers or thiazides are contraindicated or ineffective. They may cause excessive hypotension, particularly in the presence of sodium depletion. In heart failure, first doses are usually given at bedtime, and where possible diuretic therapy should be stopped for a few days before initiating treatment. Side effects include hyperkalaemia (particularly in the presence of renal disease), persistent dry cough, blood dyscrasias, rashes and angioedema. ACE inhibitors should be used with caution in renal disease (see below).

**Angiotensin-II receptor antagonists** (e.g. losartan, valsartan) are similar in effect to the ACE inhibitors but, because they do not inhibit the breakdown of bradykinin and other kinins, avoid the dry cough that can prohibit the use of an ACE inhibitor.

**β-Blockers** reduce blood pressure and cardiac output, block peripheral adrenoceptors and alter baroreceptor reflex sensitivity. β-Blockers with intrinsic...
sympathomimetic activity (e.g. acebutalol, pindolol) stimulate as well as block adrenergic receptors, and may cause less bradycardia and coldness of the extremities. Water-soluble β-blockers (e.g. atenolol, nadolol) are less likely to cross the blood–brain barrier and cause sleep disturbance. Some β-blockers have less effect on β2-(bronchial) receptors (e.g. atenolol, bisoprolol, metoprolol). They are therefore relatively cardioselective, and less likely to provoke bronchospasm. However, all β-blockers should be avoided in patients with asthma or chronic obstructive airways disease.

β-Blockers are no longer recommended as first line therapy because of evidence that they perform less
well than other drugs, particularly in the elderly, and increasing evidence that they carry an unacceptable risk of provoking type 2 diabetes.

Moxonidine, methyldopa and clonidine are centrally acting antihypertensive drugs. Aliskiren inhibits the action of renin.

Severe hypertension

Very severe hypertension (diastolic > 140 mmHg) or malignant hypertension (with papilloedema) should be treated in hospital. BP should be reduced gradually with a calcium-channel blocker. Rapid falls in BP can precipitate myocardial ischaemia and reduce cerebral and renal perfusion, leading to stroke and deteriorating renal function. Intravenous vasodilators, e.g. hydralazine and sodium nitroprusside, are rarely required.

Hypertension in relation to other conditions

Diabetes

Hypertension is more common in patients with diabetes mellitus. Possible reasons include:

- obesity
- increased sympathetic nervous stimulation and catecholamine production
- diabetic nephropathy
- insulin resistance and the associated hyperinsulinaemia.

Treatment

ACE inhibitors or angiotensin receptor blockers with or without a thiazide diuretic (which may provoke hyperglycaemia) are usually the preferred initial therapy. Calcium-channel blockers, α-blockers and β-blockers are also useful. BP control should be combined with aggressive management of dyslipidaemia and hyperglycaemia.

Renal disease

Hypertension is an important cause and consequence of renal disease.

Hypertension as a cause of renal disease

Estimates of the prevalence of chronic kidney disease because of hypertension vary widely. Renal failure caused by hypertension is more common in black than white people, and there appears to be familial clustering of hypertensive renal disease within the black population, raising the possibility of a genetic susceptibility to hypertensive renal damage.

Renal failure is an invariable feature of accelerated hypertension in which acute, severe hypertension is associated with gross intimal hyperplasia leading to occlusion of the lumen of small arteries and arterioles within the kidney. Renal failure is a rapid consequence if the BP is not gradually reduced.

Renal disease as a cause of hypertension

Hypertension may occur in renal disease as a result of:

- activation of the renin-angiotensin-aldosterone system
- retention of salt and water
- altered production or excretion of vasoactive substances (e.g. endothelin)
- alterations in the structure and function of resistance vessels.

Renovascular hypertension

The presence of an abdominal bruit, atherosclerosis elsewhere, hypokalaemia or deteriorating renal function following treatment with ACE inhibitors are all suggestive of renovascular hypertension.

Atherosclerotic renal disease accounts for most cases, is bilateral in 25% of cases, is most common in the elderly and often results from a plaque in the first part of the renal artery. Fibromuscular renal artery disease occurs predominantly in young women, is frequently bilateral and often involves the distal portion of the artery, giving rise to a beaded appearance on arteriography.

Diagnosis

Renal arteriography remains the principal method, although duplex ultrasonography and differential isotope renography before and after captopril may also provide useful information. Contrast-enhanced magnetic resonance angiography provides accurate imaging, but its use is limited because in patients with renal dysfunction exposure to gadolinium contrast agents is associated with nephrogenic systemic fibrosis, a systemic fibrosing disorder that principally affects the skin.

Treatment

Medical treatment is aimed at reducing cardiovascular risk with aspirin, statins and antihypertensive agents (ACE inhibitors should be used with caution
as renal perfusion in the presence of renal artery stenosis is dependent on angiotensin II). The benefits of revascularisation are unclear (see Trials Box 10.7).

Pregnancy

Stroke volume and heart rate increase during pregnancy, leading to increased cardiac output. BP usually falls during early pregnancy as a result of reduced peripheral resistance, but rises towards non-pregnant values by term.

**Gestational hypertension** occurs in women who develop hypertension without proteinuria after 20 weeks of gestation. Hypertension before 20 weeks suggests chronic hypertension, which is confirmed if hypertension persists after delivery.

**Pre-eclampsia** is defined by pregnancy-induced hypertension (systolic blood pressure of 140 mm Hg or more or a diastolic blood pressure of 90 mm Hg or more on two occasions at least 6 h apart) and proteinuria greater than 300 mg/24 h or urinary protein : creatinine ratio $> 30$ mg/mmol. Serum uric acid is usually raised. It may lead, often rapidly, to haemolysis, epileptic seizures, abnormal liver function tests and low platelet count (HELP syndrome). Pre-eclampsia affects about 5% of primiparae, but is less common in subsequent pregnancies by the same father.

**Treatment**

Mild pre-eclampsia is treated with bed rest and close maternal and fetal monitoring. NICE guidance (www.nice.org.uk/CG107) recommends treatment for moderate hypertension (150/100–159/109 mmHg) or severe hypertension (≥160/110 mmHg) with labetalol as first line. Calcium-channel blockers do not appear to be teratogenic but can inhibit labour. ACE inhibitors are associated with fetal abnormalities and are contraindicated. Diuretics interfere with physiological plasma volume expansion. Parenteral hydralazine or α-blockers can be used for control of severe hypertension. Seizures (eclampsia) are managed with intravenous magnesium sulphate. Delivery cures both eclampsia and pre-eclampsia. Low-dose aspirin (75–81 mg/day) is effective at preventing pre-eclampsia in women at increased risk.

---

**TRIALS BOX 10.7 Revascularisation in renovascular disease**

In the ASTRAL (Angioplasty and STent for Renal Artery Lesions) trial 806 patients with atherosclerotic renovascular disease were randomised either to undergo revascularisation in addition to receiving medical therapy or to receive medical therapy alone. The investigators found substantial risks but no evidence of a worthwhile clinical benefit from revascularisation in patients with atherosclerotic renovascular disease. (*New England Journal of Medicine* 2009; 361(20): 1953–1962.) The STAR (the benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery) study compared stent placement and medical treatment consisting of antihypertensives, a statin and aspirin with medical treatment only in a randomised controlled trial involving 140 patients with creatinine clearance less than 80 ml/min per 1.73 m² and atherosclerotic renal artery stenosis of 50% or greater. Stent placement with medical treatment had no clear effect on progression of impaired renal function but led to a small number of significant procedure-related complications.

---

**Valvular heart disease**

See Chapter 3, Fig. 3.2.

**Aortic stenosis**

**Aetiology**

**Valvular stenosis**

Valvular stenosis is caused by calcification of a congenital bicuspid valve or rheumatic valve disease. Over the age of 60 years, degenerative calcification of an otherwise normal valve is more common.

**Congenital aortic stenosis (very rare)**

Congenital aortic stenosis can be due to subvalvular stenosis (with fibromuscular hypertrophy or hypertrophic obstructive cardiomyopathy) or supravalvular stenosis (with elfin facies and infantile hypercalcaemia; Williams syndrome).

**Symptoms**

There may be no symptoms initially. Later angina, dyspnoea and syncope (which may be a result of the low cardiac output) occur. Left ventricular failure and sudden death are relatively common and probably caused by ventricular arrhythmia.
Signs

- Regular slow-rising, slow-falling (plateau) pulse.
- Small pulse pressure (e.g. BP 105/90 mmHg).
- Left ventricular hypertrophy (sustained and heaving apex).
- There may be an aortic thrill in systole.
  - Auscultation: an aortic systolic ejection murmur occurs, maximal in the right second intercostal space radiating to the neck, with a quiet delayed or absent second sound. An ejection click indicates valvular stenosis. The murmur becomes less marked when the stenosis is very tight because the flow falls as the heart pump fails.

NB Neither supravalvular nor subvalvular stenosis has an ejection click. Post-stenotic dilatation is uncommon in subvalvular stenosis (see below).

Investigations

- ECG shows LVH and usually left atrial hypertrophy. Severe stenosis in adults is unlikely if LVH is not present.
- Chest X-ray: left ventricular enlargement may not be present, even in the presence of a prominent apex beat. The aorta is small and may be dilated distal to the valve (post-stenotic dilatation). The aortic valve may be calcified (best seen on lateral chest X-ray).
- Echocardiography defines the size of the orifice and degree of thickening and calcification of the valve, which may be bicuspid. Doppler can be used to assess the gradient across the valve.
- LVH and function can also be assessed.
- Cardiac catheterisation: the pressure gradient across the valve can be measured during angiography by withdrawing the catheter across the valve. In addition, coronary arteriography should be performed, because 25% of patients over 50 will also have significant coronary artery disease.

Complications

- left ventricular failure
- infective endocarditis
- syncpe
- sudden death

Management

Valve replacement is indicated for asymptomatic severe stenosis (gradient > 50 mmHg), or for symptomatic deterioration including syncope. Catheter studies are performed to confirm the site of the obstruction and gradient and assess the state of the coronary arteries.

Aortic regurgitation

Aetiology

Congenital bicuspid valve and infective endocarditis are the most common identifiable causes. Rheumatic valve disease is now a rare cause. Less common associations include seronegative arthritis (ankylosing spondylitis, Reiter syndrome, colitic and psoriatic arthropathy), congenital lesions (coarctation of the aorta, Marfan syndrome), traumatic rupture and syphilis.

Symptoms

There are usually none until dyspnoea from pulmonary oedema occurs. Angina is not common.

Signs

The pulse has a sharp rise and fall (‘water-hammer’ or ‘collapsing’) and there is a wide pulse pressure. There may be marked carotid pulsation in the neck (Corrigan’s sign). The left ventricle is enlarged and the apex displaced laterally.

There is an early blowing diastolic murmur at the left sternal edge maximal in the left third and fourth intercostal spaces, heard best with the patient leaning forward and with the breath held in expiration. The second sound is quiet. There is usually a systolic flow murmur, which does not necessarily indicate aortic stenosis. There may be a diastolic murmur at the apex, which sounds like mitral stenosis, as the regurgitant aortic jet strikes the mitral valve (Austin Flint murmur).

Investigations

- ECG shows left ventricular hypertrophy.
- Chest X-ray shows cardiac enlargement.
- Echocardiography will demonstrate dilatation of the aortic root and the separation of the cusps. Left ventricular function and dimension can be assessed. The mitral valve can be affected with fluttering of the anterior leaflet and premature closure if the regurgitation is severe.

Management

- Surgical. Valve replacement should be considered for symptomatic deterioration if the heart size increases rapidly or if the left ventricular internal diameter is > 55 mm on echocardiography in a young patient, even if asymptomatic.

Dominance of the lesion in combined rheumatic aortic stenosis/aortic regurgitation

Aortic regurgitation is dominant if the pulse volume is high, the pulse pressure collapsing and the left
ventricle enlarged and displaced. Aortic stenosis is dominant if the pulse is of small volume (‘plateau pulse’) and the pulse pressure low. The ventricular apex of a hypertrophied ventricle is not necessarily displaced.

**Mitral stenosis**

**Aetiology**

This is almost invariably a late consequence of rheumatic fever. Mitral stenosis is the most common rheumatic valve lesion and is four times more common in women than in men. Thirty percent of patients give no history of the illness because it was either very mild or has been forgotten.

**Symptoms**

- Dyspnoea occurs at night and on exertion and is caused by pulmonary oedema.
- Palpitation is caused by atrial fibrillation. There is a risk of embolism.
- Haemoptysis is caused by pulmonary hypertension, pulmonary oedema or pulmonary embolism.
- Fatigue and cold extremities are caused by a low cardiac output. Angina may rarely occur.

**Signs**

- Mitral facies. This is a dusky purple flush of the cheeks with dilated capillaries (malar flush).
- Arterial pulse is of small volume caused by obstruction to flow at the mitral valve. It may be irregular because of atrial fibrillation.
- The apex beat is tapping. This represents a palpable first sound.
- If pulmonary hypertension has developed, there is a left parasternal heave of right ventricular hypertrophy. A diastolic thrill can be present in severe disease.

**Auscultation**

The mitral first sound is loud because the mitral valve is held wide open by high atrial pressure until ventricular systole slams it shut.

The length of the murmur is proportional to the degree of stenosis. The murmur starts when blood starts to flow through the mitral valve, i.e. when atrial pressure exceeds ventricular pressure. The tighter the stenosis, the higher atrial pressure and therefore the longer the murmur. The murmur can be difficult to hear in mild cases, but it can be made easier to hear by exercise tachycardia and with the patient lying on the left side. The presence of an opening snap and a loud first sound suggest a pliable valve. If the valve is rigid these cannot occur. Presystolic accentuation is caused by the increased flow through the valve produced by atrial systole and it is therefore absent in atrial fibrillation.

NB Some of the signs of mitral stenosis can be given by the Austin Flint murmur of aortic regurgitation (the regurgitant aortic jet strikes the normal mitral valve) and very rarely by a left atrial myxoma.

**Assessment**

- The degree of stenosis can be assessed from the severity of dyspnoea, the duration of the murmur and evidence of the degree of left atrial enlargement on ECG and chest X-ray. The tighter the stenosis, the longer the murmur and the closer the opening snap to the second sound.
- The mobility of the valve is denoted by the presence of an opening snap and a loud mitral first sound (and absence of valve calcification on the chest X-ray).
- **Pulmonary hypertension:** fatigue and symptoms of right heart failure indicate raised pulmonary vascular resistance. The development of pulmonary hypertension is indicated by a dominant ‘a’ wave in the jugular venous pulse (unless in atrial fibrillation), a loud pulmonary second sound, right ventricular hypertrophy, rarely pulmonary incompetence and low-volume peripheral arterial pulse (mnemonic: April).
- Presence of other lesions: mitral regurgitation and other valve lesions must be noted and assessed, particularly if symptoms indicate surgical intervention. Atrial fibrillation may suggest a greater degree of myocardial disease, which is always present to some extent.
- ECG: in early disease, the P mitrale of left atrial hypertrophy develops. This disappears with the later onset of atrial fibrillation. Right ventricular hypertrophy may be present.
- Chest X-ray: characteristically, there is left atrial enlargement plus upper lobe venous congestion with septal lines (Kerley B) just above the costophrenic angles and enlargement of the pulmonary arteries. The mitral valve may be calcified. Haemosiderosis in the lung fields is rare.
- Echocardiogram allows measurement of the reduced diastolic closure rate of the mitral valve. It also demonstrates valve thickening and calcification (a mitral valve area of < 1.5 cm² indicates critical stenosis) and gives an assessment of ventricular function.

**Complications**

- pulmonary oedema
- right heart failure
- atrial fibrillation
systemic embolisation
infective endocarditis

Management

Anticoagulation is indicated when atrial fibrillation develops or there is left atrial enlargement. Control the rate of untreated atrial fibrillation (p. 84).

Valvotomy (trans-septal balloon or open valvotomy) is indicated in patients who are symptomatic or have pulmonary hypertension. Valve replacement is indicated if the valve morphology is not suitable for valvotomy or there is left atrial thrombus despite anticoagulation or concomitant moderate to severe regurgitation.

Mitral regurgitation

Aetiology

- floppy (prolapsing) mitral valve leaflets
- ischaemic papillary muscle dysfunction, particularly after inferior myocardial infarction
- severe left ventricular failure with dilatation of the mitral ring
- rheumatic fever
- rarely, cardiomyopathy, congenital malformation (Marfan syndrome), infective endocarditis and rupture of the chordae tendinae

Symptoms

Progressive dyspnoea develops as a result of pulmonary congestion and this is followed by right heart failure. Angina and haemoptysis are more common than in mitral stenosis. Fatigue and palpitation are common.

Signs

- Palpation: LVH and a systolic thrill are characteristic. A left parasternal heave may be present and is caused by systolic expansion of the left atrium rather than by right ventricular hypotrophy.
- Auscultation: there is an apical pansystolic murmur radiating to the left axilla. The mitral sound is soft. There may be a third sound caused by rapid ventricular filling. A short mid-diastolic murmur in severe mitral regurgitation does not necessarily indicate valve stenosis.
- Mitral valve prolapse produces a late systolic click and murmur. It is late because the posterior leaflet of the valve only starts to leak when the ventricular pressure is at its highest. It occurs in two clinical situations. In the middle-aged and elderly it is associated with a wear and tear disorder of the leaflet, chordae or papillary muscles (particularly after myocardial infarction). A floppy valve can be detected in up to 5% of young people by echocardiography. The prognosis is usually excellent, although it has been associated with arrhythmias, syncope, atypical chest pain and bacterial endocarditis.

Investigations

- ECG may show LVH and the P mitrale of left atrial hypertrophy. Atrial fibrillation is less common than in mitral stenosis.
- Chest X-ray: the left atrium and ventricle are enlarged, the former sometimes being enormous.
- Echocardiography helps to distinguish between the various causes and to assess left ventricular function.
- Assessment of the dominance of the lesions in combined mitral stenosis/mitral regurgitation: mitral stenosis is more likely to be the dominant lesion if the pulse volume is small (in the absence of failure) and if there is no LVH.

Complications

These are similar to those in mitral stenosis except that infective endocarditis is more common and embolism less common.

Management

Valve repair or replacement is indicated if the symptoms are severe and uncontrolled by medical therapy, or if pulmonary hypertension develops. Indications for anticoagulation are atrial fibrillation, systemic embolism and prosthetic valves.

Other valve disease

Tricuspid regurgitation

Tricuspid regurgitation may be caused by dilatation of the tricuspid valve ring in right ventricular failure from any cause, rheumatic fever (where it is invariably associated with disease of mitral and/or aortic valves), endocarditis in drug addicts, or carcinoid heart disease. The signs include:

- giant ‘v’ waves in the jugular venous pulse and systolic pulsation of an enlarged liver (both caused by the transmission of ventricular filling through the open tricuspid valve)
- right ventricular enlargement causing marked pulsation at the lower left sternal edge and a pansystolic murmur, loudest in inspiration, heard at the lower end of the sternum.

There is often ankle and sacral oedema, ascites and jaundice from hepatic congestion.
**Pulmonary stenosis**

Pulmonary stenosis is usually congenital but may follow maternal rubella. Rarely, it is associated with Noonan syndrome (Turner’s phenotype affecting males and females with normal chromosome number). Rheumatic fever and carcinoid are extremely rare causes. Fatigue and syncope occur if the stenosis is severe. Patients may show peripheral cyanosis, a low-volume pulse and a large ‘a’ wave in the jugular venous pulse wave. Right ventricular hypertrophy causes a parasternal heave. There is a systolic thrill and murmur in the pulmonary area (second left intercostal space) and an ejection click. The pulmonary component of the second sound is quiet and late.

**Atrial myxoma**

Atrial myxoma may mimic valve disease. It is very rare. It usually occurs in the left atrium and presents with features of mitral stenosis, systemic emboli and constitutional upset with fever. It can mimic bacterial endocarditis. It is best diagnosed by echocardiography where the tumour produces characteristic echoes as it moves between the mitral valve leaflets in ventricular diastole and in the atrium in systole. It is fatal unless removed surgically. Rarely it is a manifestation of the autosomal dominant Carney Complex.

**Congenital heart disease**

Congenital heart disease may present as an isolated cardiac abnormality or as part of a systemic syndrome.

**Maternal rubella**

Maternal rubella infection is dangerous in the first 3 months of pregnancy (particularly the first month when 50% of fetuses are affected). The cardiac lesions are in three groups:

- patent ductus arteriosus
- septal defects: atrial septal defect, ventricular septal defect, Fallot’s tetralogy
- right-sided outflow obstruction: pulmonary valve, artery or branch stenoses.

The systemic syndrome includes cataract, nerve deafness and mental retardation. All children are offered rubella vaccine at the age of 12 years. Boys are included to reduce transmission. Fertile women given vaccine must not become pregnant in the immediate future.

If a pregnant woman is in contact with rubella, serum should be taken for antibody levels to rubella if these are not known. If raised, this is evidence of previous infection and there is little or no risk to the fetus. If the titre is not raised, a repeat sample is measured 3–4 weeks later (or if symptoms appear in the mother) and if the titre has risen significantly, this is evidence of recent infection. The earlier that this occurs in the pregnancy, the greater the risk to the fetus.

**Down syndrome (usually 21-trisomy)**

This is associated with septal defects, particularly ventricular.

**Turner syndrome (XO)**

This is associated with coarctation of the aorta. Affected females are short and the neck may appear webbed. Ovaries fail to develop properly, leading to primary amenorrhoea. Hearing loss, renal anomalies and hypothyroidism are recognised associations.

**Marfan syndrome (arachnodactyly)**

This is an autosomal dominant connective tissue disorder which affects the aortic media, eyes and limb skeleton. The prevalence is approximately 1 in 5,000.

It is characterised by disproportionate length of the long bones, which results in span exceeding height and long fingers and toes. Joints tend to be hyper-extensible. There is frequently a high arched palate, pectus excavatum, scoliosis, little subcutaneous fat and lens dislocation with myopia. The aortic media is weak with a tendency to dilatation of the ascending aorta and aortic valve ring, resulting in aortic valve regurgitation and dissection of the aorta. Mitral regurgitation may develop.

**Working classification**

An asterisk denotes the most frequent.

**Stenosis**

- semilunar valves: aortic stenosis (supra- and sub-valvular and valve stenoses), pulmonary stenosis
- atrioventricular valves: mitral stenosis, tricuspid stenosis
- major arteries: coarctation of aorta*, pulmonary artery stenosis

**Regurgitation**

- semilunar valves: aortic regurgitation, pulmonary regurgitation (very rare)
- atrioventricular valves: mitral regurgitation, tricuspid regurgitation, Ebstein’s anomaly
Shunts

- **left-to-right**: ASD⁺, VSD⁺, patent ductus arteriosus (PDA)⁺, aortopulmonary window
- **right-to-left** (cyanotic): transposition of the great vessels, Fallot’s tetralogy⁺, Eisenmenger syndrome

Atrial septal defect (ASD)

This accounts for 10% of all cases of congenital heart disease. It occasionally occurs in Marfan syndrome.

- **Ostium secundum** (70% of ASDs) is usually uncomplicated. Compared with other congenital heart defects, there is a high (and late) incidence of atrial fibrillation (20%) and an extremely low incidence of endocarditis.
- **Ostium primum** (30% of ASDs) is often complicated because it tends to involve the atrioventricular valves to produce mitral and tricuspid regurgitation and may even have an associated VSD. In most respects (embryology, cardiodynamics, complications and prognosis) it is quite different from ostium secundum ASD.

Symptoms

In simple lesions there are usually no symptoms, although dyspnoea occurs in 10% of cases. Symptoms usually occur for the first time in middle age. It is usually detected at routine chest X-ray.

Signs

Characteristically, there is fixed, wide splitting of the second sound. Flow through the defect does not itself produce a murmur, but increased right heart output gives a pulmonary flow murmur and large shunts may produce a tricuspid diastolic flow murmur. In ostium primum there may be signs of the associated lesions and mitral (plus occasional tricuspid) regurgitation. The precordium may be deformed and the pulse volume small. A left parasternal lift of right ventricular hypertrophy may be present.

Assessment

**ECG**

- **Ostium secundum**: there is partial right bundle branch block with right axis deviation and right ventricular hypertrophy. Atrial fibrillation may occur.
- **Ostium primum**: usually, there is left axis deviation with evidence of right ventricular hypertrophy. Conduction defects and junctional dysrhythmias occur.

**Chest X-ray**

This shows enlargement of the right atrium and ventricle with enlarged pulmonary arteries and plethoric lung fields (evidence of increased right-sided flow). The aorta appears small (evidence of decreased left-sided blood flow).

**Cardiac catheterisation**

This reveals a step up in oxygen saturation in the right atrium.

Complications

- Eisenmenger syndrome. If the left-to-right shunt through the defect results in pulmonary hypertension with pressure above systemic level, a reversed shunt develops.
- Atrial fibrillation.
- Tricuspid regurgitation (from right ventricular enlargement).
- Infective endocarditis occurs in ostium primum, but rarely in ostium secundum defects.

Management

Surgical repair has been largely replaced by percutaneous closure.

Patent ductus arteriosus

This represents 15% of all cases of congenital heart disease. It is associated with the rubella syndrome. It is more common in females.

Symptoms

Usually there are none. Bronchitis and dyspnoea on exertion occur later and with severe lesions.

Signs

The pulse may be collapsing (water hammer) and the left ventricle hypertrophied. There is a continuous (machinery) murmur with systolic accentuation, maximal in the second left intercostal space and posteriorly. This continuous murmur must be distinguished from the other causes, i.e. jugular venous hum, mitral regurgitation plus aortic regurgitation, VSD plus aortic regurgitation, pulmonary arteriovenous fistulae.

Assessment

- The **ECG** is normal or there may be left ventricular hypertrophy.
• chest x-ray: the aorta and left ventricle may be enlarged. the pulmonary artery is enlarged and there is pulmonary plethora.
• echocardiography shows a dilated left atrium and left ventricle.

complications
• endarteritis (of the ductus)
• heart failure (eisenmenger syndrome, p. 104, as a result of pulmonary hypertension and shunt reversal)

management
indometacin is given within 1–3 weeks of birth to close the duct, possibly by blocking prostaglandin e production in the duct muscle. if this is unsuccessful, surgical ligation (1–5 years) is required or possibly an umbrella occlusion device. cyanosis contraindicates surgery.

Ventricular septal defect
This accounts for 25% of congenital heart disease cases.
• small defect: this is also called maladie de Roger. there is a loud murmur with a normal-sized heart, chest x-ray and ECG.
• large defect: the clinical importance of this depends on the pulmonary vascular resistance, which determines how much shunting is present and its direction of flow.

symptoms
there are none unless the VSD is large, when there may be dyspnoea and bronchitis.

signs
there may be a small-volume pulse and LVH may be present (and right ventricular hypertrophy too, if there is pulmonary hypertension). A pansystolic murmur (and thrill) is present in the fourth left intercostal space. A mitral diastolic flow murmur implies a large shunt.

assessment
• ECG shows LVH.
• chest x-ray: enlargement of the left atrium and ventricle may be present. the pulmonary arteries are enlarged if there is pulmonary hypertension.

Complications
• endocarditis can occur, with emboli into the pulmonary circulation
• eisenmenger syndrome (p. 104)

management
• a small VSD may close spontaneously. surgery is not indicated for the endocarditis risk alone.
• a large VSD needs closure in most cases to prevent the development of irreversible pulmonary vascular damage.

Fallot's tetralogy
This accounts for 10% of cases of congenital heart disease and 50% of cyanotic congenital heart disease. The four features (tetralogy) are:
1. VSD in which the shunt is from right to left because of;
2. pulmonary stenosis, infundibular or valvular;
3. right ventricular hypertrophy caused by the consequent load on the right ventricle;
4. associated dextroposition of the aorta so that it sits over the defect in the septum.

Symptoms
• syncope
• squatting (this may help decrease the right-to-left shunt by increasing systemic resistance and reducing venous return)
• dyspnoea
• retardation of growth

Signs
• cyanosis and finger clubbing
• the typical murmur is of pulmonary stenosis with a quiet or inaudible pulmonary second sound. There is no VSD murmur.

assessment
• the ECG usually shows moderate right atrial and ventricular hypertrophy.
• chest x-ray shows a normal-sized but boot-shaped heart and a large aorta with a small pulmonary artery and pulmonary oligaemia. it is boot-shaped because of the small left pulmonary artery.
• polycythaemia is common.

complications
• cyanotic and syncopal attacks (sometimes fatal)
• cerebral abscesses
• endocarditis
• paradoxical emboli
• strokes (thrombotic–polycythaemia)
• epilepsy is more common than in the general population

Management
Surgical correction.

Coarctation of the aorta
These represent 5% of congenital heart disease cases. It is associated with berry aneurysms, Marfan and Turner syndromes. Ninety-eight percent are distal to the origin of the left subclavian artery.

Signs
• Classically, there is radial–femoral arterial pulse delay, with a smaller volume femoral pulse than radial. The blood pressure may be raised in the arms (especially on exercise), different between the two sides and low in the legs. Asymmetry of radial pulses may be present.
• Visible and/or palpable scapular collateral arteries.
• Left ventricular hypertrophy.
• The murmurs are:
  o a systolic murmur at front and back of the left upper thorax
  o collateral murmurs over the scapulae
  o an aortic systolic murmur (of an associated bicuspid valve in 70% of cases) that is usually obscured by the coarctation murmur.

Assessment
• ECG for LVH.
• Chest X-ray: a double aortic knuckle results from stenosis and post-stenotic dilatation. There is rib notching (and notching at the scapular margin) and normal or large cardiac shadow.

Associations
Bicuspid aortic valve, cerebral artery aneurysms (berry aneurysms) and patent ductus arteriosus.

Management
Percutaneous intervention (angioplasty with or without stenting or surgical correction).

Infective endocarditis

Acute
Heart valves are infected as part of an acute septicaemia. Healthy valves are often affected. It follows infection with staphylococcus, often in association with indwelling intravenous catheters or primary infection of the lungs or skin. *Streptococcus pneumoniae*, *Haemophilus influenzae*, gonococcus and meningococcus may also be responsible.

Subacute
This is usually bacterial – subacute bacterial endocarditis (SBE).

Predisposing abnormalities
• Congenital: VSD, PDA, coarctation of the aorta and bicuspid aortic valves.
• Acquired: rheumatic valve disease now accounts for less than one-quarter of all UK cases. Mitral valve prolapse, calcified aortic stenosis and syphilitic aortitis (rare) predispose to endocarditis. It occurs on prosthetic valves. The normal tricuspid valve is at special risk in drug addicts.

Organisms
The origin of infection varies with the infecting organism and includes teeth and tonsils (Streptococcus viridans), urinary tract and bowel (S. faecalis), central venous catheterisation (Staphylococcus) and the skin (Staphylococcus). Rarer causes include Coxiella burnetii (Q fever) and fungi.

Diagnosis
The diagnosis of infective endocarditis should be considered in any patient with a predisposing cardiac lesion who develops any illness. The most efficient way to establish the diagnosis is by:
• repeated examination, particularly for changing murmurs
• blood cultures (at least three sets)
• urinalysis for microscopic haematuria
• echocardiography for vegetations, including transoesophageal echocardiography (TOE) if not detected by transthoracic echocardiogram.

Clinical features

The symptoms and signs may be considered in three groups.

1 Signs of general infection: lethargy, malaise, anemia and low-grade fever are frequent but not invariable. Clubbing of the fingers and splenomegaly are fairly late signs (6–8 weeks). There may be transient myalgia or arthralgia. The white cell count may be low, normal or high.

2 Signs of underlying cardiac lesions must be sought. New lesions and changing murmurs are highly suggestive and the patient must be examined for these daily.

3 Embolic phenomena: large emboli may travel to the brain and viscera or cause occlusion of peripheral arteries. Emboli from left-to-right shunts (VSD and PDA) and on right-sided heart valves go to the lungs, giving pleurisy and lung abscesses.

Vasculitic phenomena cause splinter haemorrhages in the nail bed and microscopic haematuria. Osler’s nodes in the finger pulp are pathognomonic but rare. Roth spots in the eye also occur rarely.

The renal lesions in SBE are of two kinds:

- a diffuse, proliferative glomerulonephritis (not specifically diagnostic of SBE)
- a focal, embolic glomerulonephritis.

Immune complexes are present in serum and complement levels reduced.

Management

Prophylaxis

Patients with acquired valvular heart disease, valve replacement, structural congenital heart disease, hypertrophic cardiomyopathy and previous infective endocarditis are at increased risk of endocarditis. NICE has reviewed the need for antibiotic prophylaxis in these patients and recommends that antibiotic prophylaxis against infective endocarditis should not be offered to people undergoing dental procedures or procedures involving the upper and lower gastrointestinal tract, genitourinary tract or upper and lower respiratory tract. Episodes of infection in people at risk of infective endocarditis should be investigated and treated promptly.

Chemotherapy

It is essential to obtain blood culture before starting chemotherapy. Antibiotic therapy is guided by identification of the causative organism, but it should not be delayed in the presence of good clinical evidence even if cultures are negative. Eighty percent of cases are due to streptococcal and staphylococcal organisms. *Staphylococcus aureus* is the most frequent organism when the source of infection has been an intravenous catheter and in intravenous drug abusers who commonly infect tricuspid valves. It also frequently causes endocarditis in patients with insulin-dependent diabetes mellitus. A wide spectrum of organisms can infect prosthetic valves. Gram-positive and Gram-negative bacilli are relatively uncommon causative organisms. Fungal endocarditis, particularly *Candida*, usually occurs in patients with prosthetic valves, compromised immune systems and intravenous drug abuse.

Therapy should be continued for at least 4 weeks (intravenously for at least the first 2 weeks), if effective blood concentrations can be achieved. The patient should be carefully followed for recurrence. Emboli may occur for up to 1–2 months after cure.

Indications for surgery

Surgery must be considered early for valve rupture, intractable heart failure, resistant infection particularly of a valve prosthesis, and if the organisms are drug-resistant.

Culture-negative endocarditis

This diagnosis is considered after six successive negative cultures when culture technique is known to be good. The following should be considered:

- unsuspected organisms, e.g. *Coxiella burnetii* (Q fever), especially if the aortic valve is diseased. The diagnosis depends on finding a rise in antibody titre. *Bacteroides*: anaerobic culture is required (and kept for up to 3 weeks). Fungi: *Candida, Aspergillus, Histoplasma*.
- partly treated bacterial causes
- right-sided endocarditis
- systemic vasculitis, systemic lupus erythematosus (SLE), atrial myxoma or the antiphospholipid syndrome (p. 280)
- non-bacterial thrombotic endocarditis associated with carcinoma.

Constrictive pericarditis

Aetiology

This is now rare. It may be caused by tuberculosis following spread from the pleura or mediastinal lymph glands. It may follow acute viral or pyogenic pericarditis, but the cause is often unclear. Haemopericardium, irradiation and carcinoma account for a few cases. It may be simulated by restrictive cardiomyopathy (p. 107).
Clinical features

Symptoms result from cardiac constriction with decreased filling and low cardiac output. Right heart failure predominates over left. Fatigue and ascites with little or no ankle swelling are characteristic, but dyspnoea and ankle swelling may occur later. Pulmonary oedema and paroxysmal nocturnal dyspnoea are rare.

Examination

The pulse is rapid and volume small and there may be arterial paradox (pulsus paradoxus), as with acute pericarditis. Atrial fibrillation is present in 30% of cases. Ascites may be the presenting feature and the elevated JVP may be missed because it is so high. The classical JVP signs of diastolic collapse (steep ‘y’ descent) and a further rise on inspiration (Kussmaul’s sign) are often not observed. The liver, and sometimes the spleen, is enlarged. Ventricular contraction may cause localised indrawing of the chest wall at the apex. The heart sounds may be normal, although quiet. A third sound, brought about by an abrupt end to ventricular filling, may be present. There is no rub.

Investigation

- **ECG:** there may be widespread ST changes with low-voltage complexes, and atrial fibrillation.
- **Chest X-ray:** there may be calcification of the pericardium (often seen only in the lateral film). Cardiomegaly, if present, is less than one would expect from the degree of right (and possibly left) heart failure.
- **Echocardiography** shows the rigid, thickened pericardium, particularly if calcified, large atria with normal (or small) ventricles, and ventricular filling predominantly in early diastole.
- **CT scan** demonstrates the thickened pericardium in almost all cases.

Management

No action is needed if the patient is symptom-free and the assessment confirms mild disease. Close follow-up is essential. Pericardiectomy is performed if severe constriction is present.

Acute pericarditis

Aetiology

Pericarditis is common within the first week of acute myocardial infarction. Dressler syndrome is uncommon and occurs between 2 weeks and 2 months after myocardial infarction or cardiac surgery. It is characterised by fever, pleurisy, and pericarditis.

Infective pericarditis is usually a complication of chest infection. Acute benign pericarditis often follows a respiratory infection and is probably viral. A rising antibody titre to Coxsackie B virus is sometimes found. Suppurative pericarditis is rare. It results from infection with staphylococcus or, occasionally, haemolytic streptococcus. Tuberculous pericarditis is very rare and non-suppurative.

Pericarditis occurs as part of systemic syndromes, including rheumatic fever, SLE, severe uremia, local extension of carcinoma of the bronchus and following trauma.

Clinical features

There is central, poorly localised tightness in the chest that varies with movement, posture and respiration. There may be pain referred to the left shoulder if the diaphragm is affected. The pericardial rub varies with time, position and respiration.

The signs of pericardial effusion without tamponade are an absent apex beat, a silent heart and disappearance of the rub. Tamponade, which is rare, produces the following:

- **Pulsus paradoxus:** the pulse volume decreases in the normal person on inspiration. This is more marked with tamponade and is then known as pulsus paradoxus. The paradox that Kussmaul noted was that the heart continued to beat strongly while the peripheral arterial pulse virtually disappeared during inspiration.
- **A rise in the JVP on inspiration (Kussmaul’s sign).**

Both pulsus paradoxus and Kussmaul’s sign result from decreased cardiac filling on inspiration because of the descending diaphragm stretching the pericardium and increasing the intrapericardial pressure.

Assessment

- **ECG:** there is raised concave elevation of the ST segment in most leads (especially II and V3–4) and T-wave inversion. The voltage is low in the presence of effusion.
- **Chest X-ray:** it is unchanged in the absence of effusion. Effusion classically produces an enlarged pear-shaped cardiac shadow with loss of normal contours.
- **Echocardiography** is the most sensitive way of detecting pericardial fluid with free space between the heart and pericardium.

Management

Aspirate for tamponade (if the systolic arterial blood pressure falls below 90–100 mmHg). Treat the underlying condition. Recurrent effusion with tamponade is treated by insertion of a drain or creation of a pericardial window.
Syphilitic aortitis and carditis

Late syphilis is rare in the UK. Acquired syphilis affects the aorta, the aortic ring to produce dilatation or aneurysm, and aortic regurgitation and the coronary artery orifices to cause angina.

Cardiomyopathy

This word means disorder of the heart muscle. It is usually restricted to cardiomyopathies of unknown cause or association. They are classified into three major groups depending upon the clinical effects of the abnormality on the left ventricle, which may be: hypertrophied, dilated or restricted.

Hypertrophic cardiomyopathy

Also known as HCM, it is usually familial. It results in asymmetrical LVH associated with:

- loss of left ventricular distensibility which leads to symptoms of dyspnoea, pulmonary oedema and syncope – some patients develop angina
- hypertrophy, particularly of the left ventricle and septum with mitral regurgitation – in some patients this disappears with progression of the disease as the heart muscle fails.

Signs

There is a steep-riseing, jerky pulse (unlike the slow-rising, plateau pulse of aortic valve stenosis), cardiac hypertrophy, a palpable atrial beat followed by a late systolic aortic ejection murmur, usually heard best in the left third and fourth intercostal spaces. There may be associated signs of mitral regurgitation. Complications include arrhythmias, systemic embolism, congestive heart failure and sudden death.

Investigation

Echocardiography shows asymmetrical septal hypertrophy, systolic anterior movement of the mitral valve and a narrow left ventricular cavity with hypertrophied trabeculae and papillary muscles. A 24-h ECG record may identify those most at risk from sudden death from dysrhythmias.

Management

β-blockade is given to increase left ventricular compliance and reduce the incidence of dysrhythmias and angina. Other anti-arrhythmic therapies or implantable cardioverter-defibrillator should be considered. Patients who develop atrial fibrillation should be anticoagulated and digoxin can be added. Patients are at risk from endocarditis. Treat for cardiac failure and if medical therapy fails, consider transplantation. Patients should receive genetic counselling and screening of their families should be offered.

Dilated (congestive) cardiomyopathy

This is very rarely familial. The label ‘congestive cardiomyopathy’ covers a large group of aetologically unrelated disorders which tend to present as low-output congestive heart failure. By convention, the more common and more easily diagnosed myocardial disorders are excluded, i.e. ischaemic, hypertensive and rheumatic heart diseases. Angina, systemic and pulmonary infarcts, conduction defects and arrhythmias occur.

Aetiology

- Alcoholism and thiamine deficiency (beriberi).
- Infections: viruses, e.g. influenza A2, Coxsackie B, Toxoplasma, diphtheria.
- Infiltrations: sarcoidosis, amyloidosis (primary and secondary to myeloma), haemochromatosis.
- Muscular dystrophies and Friedreich’s ataxia (p. 205).
- Endocrine: hyper- and hypothyroidism.
- Postpartum.

Management

Heart failure should be treated (p. 88). Anticoagulants are given because of the risks of embolism. Any underlying pathology (e.g. thyroid disease, autoimmune disease) should be treated appropriately.

Restrictive cardiomyopathy

The efficiency of the ventricles as pumps is restricted by endocardial fibrosis or by granulation tissue – respectively endomyocardial fibrosis (EMF) of equatorial Africa or Löffler eosinophilic endomyocardial disease. In the UK, amyloidosis is the most common cause of this rare condition.
Peripheral arterial disease

There are four common clinical syndromes: intermittent claudication, acute obstruction, ischaemic foot and Raynaud’s phenomenon.

Intermittent claudication

Most cases are found in males over 50 years of age. The disorder is associated with smoking, diabetes mellitus and hyperlipidaemia, and occasionally precipitated by anaemia. Obstruction is most commonly femoropopliteal, and less often aortoiliac or distal.

Diagnosis

The history is of pain in the calf on effort with rapid relief by rest. The Leriche syndrome is buttock claudication with impotence. The major peripheral arterial pulses are reduced or absent. There may be arterial bruits over the aorta, iliac or femoral arteries. The tissues of the leg atrophy with reduced muscle bulk and hair loss is common. There may be cyanosis, pallor or redness, oedema, ulcers or gangrene.

Doppler ultrasound is useful. Arteriography is required if surgery is contemplated.

Prognosis

Claudication usually indicates generalised vascular disease and most patients die from cardiovascular or cerebrovascular disease. Diabetes mellitus and persistent smoking are associated with a worse prognosis.

Management

- Stop smoking.
- Manage hyperlipidaemia and take aspirin.
- Exercise within the effort tolerance to help develop collateral vessels. Treat obesity and hypertension.
- Check for and treat diabetes, polycythaemia and anaemia.
- Attend carefully to foot hygiene.
- Dilatation of narrowed arteries using balloon catheter angioplasty may be successful.

Endarterectomy is indicated if there is a high block with good distal blood flow on angiography. Bypass (prosthetic or vein graft) surgery may be indicated if angiography shows the vessels to be satisfactory distal to the block.

Acute obstruction

This may be caused by thrombosis or due to embolism (usually blood clot in atrial fibrillation). Ninety percent of cases are in the legs.

Diagnosis

Pain (usually severe) is associated with numbness, paraesthesia and paresis. There is pallor and coldness of the limb below the obstruction followed by cyanosis. The limb becomes anaesthetic and the arterial pulses weak or absent.

Management

Treatment should involve vascular surgeons and radiologists, and approaches include anticoagulation and antiplatelet agents, thrombolytic agents and embolectomy, angioplasty and arterial bypass surgery.

Ischaemic foot

This is usually caused by chronic arterial obstruction distal to the knees. It is most commonly seen in diabetes and is associated with neuropathy and local infection.

Symptoms

- Areas of necrosis and ulceration.
- Pain in the foot (often not present in diabetics because of associated peripheral neuropathy).
- Intermittent claudication.

Signs

If the large arteries are narrowed there is pallor and/or cyanosis, empty veins in the feet with trophic changes in nails and absence of hair. The feet are cold and pulses diminished or are absent.

In diabetes, it is often chiefly the small vessels that are affected. The foot pulses can be present despite ischaemia of the toes.

Management

Foot hygiene is important, especially in diabetes. Pain may be severe and require morphine. Angioplasty, stenting or vascular bypass surgery are often not technically feasible. If amputation is required it is frequently above the knee.
Raynaud's phenomenon

Definition
Intermittent, cold-precipitated, symmetrical attacks of pallor and/or cyanosis of the digits without evidence of arterial obstructive disease. The digits become white (arterial spasm), then blue (cyanosis) and finally red (reactive arterial dilatation).

Aetiology
- Idiopathic and familial, usually in young women (Raynaud’s disease).
- Auto-immune disease, especially SLE and scleroderma.
- Arterial obstruction, e.g. cervical rib.
- Trauma, usually in occupations involving vibrating tools (vibration white finger).
- Drugs, including β-blockers, the contraceptive pill and ergot derivatives.

Management
Treatment is disappointing. The hands and feet should be kept warm and free from infection. The patient is reassured about the long-term prognosis (usually good) and advised to stop smoking. Electrically heated gloves can be very helpful. Calcium antagonists (e.g. nifedipine) or patches of glyceryl trinitrate can be tried. Sympathectomy is sometimes successful as a last resort, particularly in the presence of recurring skin sepsis. Intravenous prostacyclin (epoprostenol) has been used in severe cases.

REFERENCE
11

Respiratory disease

The most common respiratory diseases are infections of the upper respiratory tract, e.g. the common cold. The most common diseases of the lower respiratory tract are pneumonia, asthma and carcinoma of the bronchus.

Chronic obstructive pulmonary disease (COPD)

Definitions

The WHO-sponsored ‘Global initiative for chronic obstructive lung disease’ (http://www.goldcopd.com) defines COPD as ‘a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gases.’

It covers many previously used labels, including:

- **Emphysema** – enlargement of the air spaces distal to the terminal (smallest) bronchioles with destructive changes in the alveolar wall. In centrilobular emphysema, damage is limited to the central part of the lobule around the respiratory bronchiole, whereas in panacinar emphysema, there is destruction and distension of the whole lobule. If the air spaces are > 1 cm in diameter they are called bullae.
- **Chronic obstructive airways disease**.
- **Chronic airflow limitation**.

Poorly reversible airflow limitation may also occur in bronchiectasis, cystic fibrosis, tuberculosis and some cases of chronic asthma.

- **Chronic bronchitis** is daily cough with sputum for at least 3 months a year for at least 2 consecutive years.

Pathogenesis

There is typically chronic inflammation throughout the airways and pulmonary vasculature. In the trachea, and bronchi and bronchioles that are >2–4 mm in internal diameter, inflammatory cells infiltrate the surface epithelium and there is hypersecretion from enlarged mucus-secreting glands and increased numbers of goblet cells. In small bronchi and bronchioles that have an internal diameter <2 mm, chronic inflammation is associated with remodelling of the airway wall, with fibrosis, narrowing the lumen and producing fixed airways obstruction.

Destruction of the lung parenchyma typically occurs as centrilobular emphysema. In mild cases lesions usually involve upper lung regions, but in advanced disease they may appear diffusely throughout the entire lung. Vascular changes occur early. Intimal thickening of the vessel wall is followed by smooth-muscle proliferation and an inflammatory cell infiltrate. These pathological changes lead to characteristic physiological changes. Mucus hypersecretion and ciliary dysfunction cause a chronic productive cough. Airflow limitation, hyperinflation and gas exchange abnormalities cause breathlessness. Pulmonary hypertension and cor pulmonale are late features.

Aetiology

- **tobacco smoking**
- **atmospheric pollution**
- **α1-antitrypsin deficiency** is a recessive disorder accounting for about 5% of patients with emphysema (and about 20% of neonatal cholestasis). Five percent of homozygotes tend to develop emphysema by the age of 40 years and heterozygotes are at risk. The emphysema is predominantly of the lower zones and is much worse in smokers.

Most die from one of three diseases: CHD; COPD; lung cancer (the risk of many cancers is increased by smoking).
Clinical presentation

Often the patient has a productive morning cough and an increased frequency of lower respiratory tract infections producing purulent sputum. The organisms responsible are usually Haemophilus influenzae, Streptococcus pneumoniae and the respiratory viruses. Over years there is slowly progressive dyspnoea with wheezing, exacerbated in the acute infective episodes. There is clinical emphysema with hyper-inflation of the lungs. Respiratory failure (p. 113) and chronic right heart failure (cor pulmonale) are long-term complications.

Investigation

Ventilatory function tests

The diagnosis of COPD is established by spirometry, which shows a post bronchodilator FEV₁ : forced vital capacity (FVC) ratio < 70%. The peak expiratory flow rate (PEFR) is reduced. The airways obstruction is only partially reversible by bronchodilator (or other) therapy.

Chest X-ray

This may be normal. Abnormalities correlate with the presence of emphysema and are caused by:
- overinflation with a low, flat, poorly moving diaphragm and a large retrosternal window on lateral X-ray
- vascular changes with loss of peripheral vascular markings but enlarged hilar vessels – the heart is narrow until cor pulmonale develops
- bullae if present.

The chest X-ray is an important investigation because it excludes other disease (carcinoma, tuberculosis, pneumonia, pneumothorax).

Arterial blood gas estimations

These may be normal. In later stages the PaO₂ falls and the PaCO₂ rises, particularly with exacerbations.

Electrocardiogram (ECG)

This records the presence and progression of cor pulmonale (right atrial and ventricular hypertrophy).

Sputum for bacterial culture and sensitivity

This is useful in acute infective episodes when infections other than Haemophilus influenzae or Streptococcus pneumoniae may be present.

Haemoglobin

This may show secondary polycythaemia.

Box 11.1 Management of COPD

A systematic review to evaluate the effectiveness of COPD management strategies concluded that long-acting inhaled therapies, supplemental oxygen and pulmonary rehabilitation are beneficial in adults who have bothersome respiratory symptoms, especially dyspnoea, and FEV₁ less than 60% predicted. (Annals of Internal Medicine 2007; 147(9): 639–653.)

Management (Box 11.1)

Management should include assessment and reduction of risk factors in addition to the management of stable COPD and exacerbations. There should be a stepwise increase in treatment according to disease severity.

Patients benefit from rehabilitation and exercise programmes. Education can help patients to cope and achieve goals, including stopping smoking.

Bronchodilators are used to prevent or reduce symptoms: the β₂-agonists, e.g. salbutamol (Ventolin), terbutaline (Bricanyl), the anticholinergic ipratropium (Atrovent) or a combination of these drugs are given by metered aerosol or nebuliser on an as-required or regular basis. Theophylline may also help.

Regular treatment with inhaled steroids can benefit patients with a documented spirometric response to steroids, or who have repeated exacerbations requiring treatment with antibiotics or oral steroids. Chronic treatment with systemic steroids should be avoided. Long-term home oxygen (> 15 h/day) increases survival in patients with chronic respiratory failure. Patients should receive annual influenza vaccination.

Exacerbations are treated with inhaled bronchodilators; theophylline and systemic steroids are effective treatments. Although a cause is often not identified, infection is a common trigger and patients with signs of infection are given antibiotics – amoxicillin or a macrolide (erythromycin or clarithromycin). Bacterial sensitivities are useful if clinical improvement has not occurred.

Non-invasive intermittent positive pressure ventilation (NIPPV) can decrease the need for intubation and mechanical ventilation.

Asthma

Asthma affects 5–7% of the population of Europe and North America. It is characterised by recurrent shortness of breath, wheeze or cough caused by reversible
narrowing of the airway lumen. The principal cause of increased airways resistance is contraction of smooth-muscle cells as a result of hypersensitivity to many different stimuli such as cold air, smoke, exercise and emotion, as well as antigens. Thickening of the airways by oedema and cellular infiltrates, as well as blockage of airways by mucus and secretions, also contribute. Wheeze is not an essential feature.

Asthma is sometimes classified into extrinsic and intrinsic, although treatment is the same.

Clinical features

Acute attacks

These may be fairly abrupt in onset and brief in duration (hours), or longer (a week or two). Longer severe attacks are called ‘status asthmaticus’ (p. 113). In an attack the patient feels tightness in the chest and both inspiratory and expiratory effort are difficult. There may be a cough that is initially dry but later becomes productive, particularly if there is infection. The patient usually sits up with an overinflated chest, an audible expiratory wheeze, using the accessory muscles of respiration. The respiratory rate may be little altered but the pulse is invariably rapid. Acute attacks are precipitated by specific allergens (e.g. pollens or house dust mite), exertion, cold air, sensitisation is of value in only a small number

Recurrent asthma

Mild asthmatics (particularly with extrinsic asthma) usually have normal respiratory function between attacks, but those with long-standing severe asthma tend to develop some degree of dyspnoea and persistent airways obstruction between acute attacks.

Investigation

Investigation includes chest X-ray (for regional collapse, pneumonia, pneumothorax) and measurement of ventilatory function (FEV₁ or PEFR, preferably at several times a day on several days at home) and the response to bronchodilators. Variability through the day, especially with a ‘morning dip’ in PEFR, is characteristic. Skin hypersensitivity tests performed by pricking standard allergens into the skin can help the patient recognise and avoid environmental precipitants. Bronchial reactivity may be more precise but should be tested only in carefully controlled conditions. Adrenaline (0.5 ml of 1 : 1000) must be available in case of acute anaphylactic reactions (p. 115).

Management of chronic asthma

The patient should be asked about precipitating factors, including upper respiratory tract infection, season (grass pollen and fungal spores), cold, exercise, food, house dust (contains the mite *Dermatophagoiides*), smoke, emotion and drugs (e.g. aspirin, NSAIDs, β-blockers). Patients should be trained to use a peak flow meter reliably and to document values at home. Increasing morning dips provide an early warning of deterioration.

Most patients respond to simple therapy and may be controlled by:
- removing known allergies, e.g. feather pillows, cats
- inhaled short-acting β₂-agonists, e.g. salbutamol, as required – the response is a guide to severity
- inhaled corticosteroids in a regular regimen
- inhaled sodium cromoglicate (Intal)
- inhaled antimuscarinic preparations, e.g. ipratropium (Atrovent)
- theophylline preparations, given as a slow-release preparation at night to control overnight symptoms
- leukotriene receptor antagonists, e.g. montelukast, are used as add-on therapies in the prophylaxis of moderate asthma not controlled by the above therapies
- oral steroids may be required for exacerbations
- hyposensitisation is of value in only a small number of patients who demonstrate specific allergies.

The British Thoracic Society (http://www.brit-thoracic.org.uk/) has established guidelines for a stepwise approach to the management of asthma. A cumulative drug regimen is prescribed for each step, stepping up if necessary to achieve control, and stepping down when control is good.

**Step 1.** Inhaled short-acting β₂-agonist as required.

**Step 2.** Add inhaled steroid 200–800 mcg/day.

**Step 3.** Add inhaled long-acting β₂-agonist, and assess response. Good response – continue inhaled long-acting β₂-agonist; benefit but control still inadequate – increase inhaled steroid up to 800 mcg/day; no response – stop inhaled long-acting β₂-agonist and increase inhaled steroid up to 800 mcg/day.

**Step 4.** Consider trial of increased dose of inhaled steroid up to 2000 mcg/day; addition of fourth drug, e.g. leukotriene receptor antagonist, SR theophylline, β₂-agonist tablet.

**Step 5.** Addition of a daily steroid tablet in lowest dose providing adequate control; maintain high dose inhaled steroid; consider other treatments to minimise use of oral steroids; refer for specialist care.

NB When metered aerosols are used, always check inhaler technique. A number of simple inhalers are available: spacers, discs, rotahalers, breath-actuated aerosols.

Acute severe asthma

Acute severe asthma is a life-threatening condition. It typically occurs in poorly controlled individuals.
whose condition has been deteriorating over days or weeks, but death can be sudden and sometimes unexpected, as the patient may not appear severely ill. It is this lack of recognition of severity plus inadequate early treatment that is so dangerous. Most patients have some degree of respiratory failure at presentation. The term status asthmaticus is sometimes used to describe severe asthma attacks that have not responded to conventional therapy.

Features of severe life-threatening asthma are as follows.

Clinical
- severe breathlessness (unable to complete sentence in one breath)
- exhaustion, confusion
- tachycardia, bradycardia or other arrhythmia
- hypotension
- cyanosis
- respiratory rate > 25 breaths/min
- poor respiratory effort
- silent chest

Laboratory
- $PaO_2 < 8$ kPa
- oxygen saturation < 92%

Clinical presentation
Inability to speak or difficulty in maintaining speech is one criterion of severity. It also implies inability to drink and dehydration. Hypoxaemia is usually then present.

Very severe, life-threatening airways obstruction is indicated by absence of wheeze (because of poor ventilation), PEFR < 33% of best (PEFRs can usually not be obtained), bradycardia or hypotension, and confusion, drowsiness and exhaustion. Cyanosis is also ominous and tends to occur at a lower $PaO_2$ than in the chronic bronchitic (because the bronchitic tends to have polycythaemia).

NB Signs of drowsiness, cyanosis, bradycardia or hypotension signify a very severe attack and vigorous treatment is essential before they are apparent.

Investigation
Arterial blood gases provide the most useful guide to the severity of the attack and to the success of treatment. The following values indicate a very severe attack: $SaO_2 < 92\%$, $PaO_2 < 8$ kPa, $PaCO_2 > 5.0$ kPa. A chest X-ray is useful if pneumothorax, pneumomediastinum or consolidation are suspected. It should also be performed if there is a failure to respond to treatment and if asthma is life threatening.

Management
Sedation may depress respiration further and is contraindicated.
- **Continuous high-flow oxygen.**
- **Bronchodilators:** $\beta_2$-agonists (e.g. salbutamol, terbutaline) plus ipratropium by oxygen-driven nebuliser or intravenous infusion if inhaled therapy cannot be used reliably.
- **Corticosteroids.** Give oral prednisolone, or intravenous hydrocortisone if unable to swallow. Continue oral prednisolone 40–50 mg daily for at least five days or until recovery.
- **Intravenous fluids** are required to make up the initial dehydration and for as long as oral fluids are not taken. Monitor urine output.
- **Bacterial infection** is a rare trigger but antibiotics are given if it is present or strongly suspected. The usual organisms are *Streptococcus pneumoniae* or *Haemophilus influenzae*.
- **Mechanical ventilation** may be necessary. Persistent or increasing elevation of arterial $PaCO_2$, or worsening hypoxia especially with accompanying exhaustion, indicates the need for artificial ventilation.

Discharge from hospital after PEFR returns to > 75% of best, with day variability < 25%, with early clinic follow-up.

Respiratory failure
Respiratory failure can be defined as a reduction in arterial $PaO_2$ below 8 kPa with a normal arterial $PaCO_2$ (hypoxaemic respiratory failure), or with an increase in arterial $PaCO_2$ above 6.6 kPa (hypercapnic respiratory failure).

NB The normal range for $PaO_2$ is about 10–13 kPa. Values of $PaO_2$ are lower in the elderly.

The $PaO_2$ may fall while the $PaCO_2$ remains normal. This may occur with alveolar parenchymal lung disease: infiltrations, fibrosing alveolitis and ‘pure’ emphysema. Much more commonly, both arterial gas levels are abnormal. This occurs with ventilatory failure.

Acute
- patients with normal lungs, with upper airways obstruction (e.g. croup and acute anaphylaxis) or mechanical failure (e.g. flail chest) or central nervous system depression of respiratory drive (e.g. sleep apnoea, drug overdosage, stroke)
- patients with abnormal lungs (e.g. asthma, chronic bronchitis)
**Chronic**

Usually in patients with abnormal lungs, especially COPD. These patients are particularly likely to develop acute failure if infection occurs.

In restrictive disorders, lung expansion is limited by:

- lung disease, such as fibrosis collapse, oedema, consolidation
- pleural disease, such as fibrosis, effusion or mesothelioma
- chest-wall disease, such as costospinal rigidity and deformity, or abdominal splinting by obesity, ascites or pregnancy
- neuromuscular disease, such as muscular dystrophy, myasthenia or phrenic nerve paralysis.

**Acute on chronic respiratory failure**

This usually occurs on a background of COPD.

**Clinical presentation**

- peripheral vasodilatation with headache, engorged veins in the fundi, warm hands and a bounding pulse, all caused by carbon dioxide retention
- varying degrees of agitation, confusion, drowsiness and coma
- increasing cyanosis
- signs of right heart failure
- flapping tremor of the outstretched hands and papilloedema are late signs

**Management**

This consists of the measures used for COPD as given above, with the addition of controlled oxygen therapy. The danger to life in this situation is hypoxia, but, paradoxically, relief of hypoxia may make the situation worse by causing hypercapnia. Give oxygen at 24 or 28% by Ventimask (or other controlled technique) if the arterial $\text{Pa}_2\text{O}_2$ or oxygen saturation is low, targeting oxygen saturation at 94–98% unless the patient is at risk of hypercapnia, when the target should be lower at 88–92%. Oxygen is given continuously until the acute situation (including infection and heart failure) has recovered. $\text{PaCO}_2$ is monitored. For chronic respiratory failure controlled oxygen can be given continuously at home with improvement in symptoms and an increase in life expectancy (Trials Box 11.1).

**Indications for respiratory support and mechanical ventilation**

If the $\text{PaCO}_2$ falls, conservative therapy should be continued and reassessed periodically. If the $\text{PaCO}_2$ rises, this indicates that the patient’s ventilation is inadequate and is the prime indication for non-invasive positive pressure ventilation using a full facial or nasal mask that delivers ventilatory support from a flow generator (Trials Box 11.2), or if this fails mechanical positive-pressure ventilation. Patients should be

**Trials Box 11.1 Home oxygen therapy in COPD**

A systematic review of the effect of domiciliary oxygen therapy in patients with COPD found that long-term home oxygen therapy improved survival in a selected group of COPD patients with severe hypoxaemia (arterial $\text{Pa}_2\text{O}_2$ less than 8.0 kPa). Home oxygen therapy did not appear to improve survival in patients with mild to moderate hypoxaemia or in those with only arterial desaturation at night. (Cochrane Database Systematic Review 2005; (4): CD001744.)

**Trials Box 11.2 Non-invasive positive pressure ventilation in acute respiratory failure**

A systematic review of non-invasive positive pressure ventilation (NPPV) in patients admitted to hospital with acute respiratory failure secondary to an exacerbation of COPD showed the benefit of NPPV as first-line intervention as an adjunct therapy to usual medical care in all suitable patients. The review concluded that NPPV should be considered early in the course of respiratory failure and before severe acidosis ensues, as a means of reducing the likelihood of endotracheal intubation, treatment failure and mortality. (Cochrane Database Systematic Review 2004; (3): CD004104.)
ventilated before they become exhausted. The final decision to ventilate a patient is determined mainly on the basis of respiratory function before the acute illness: if very poor, it may not be possible to wean the patient off the ventilator.

**Acute anaphylaxis**

This rare condition occurs following exposure to allergens such as certain foods, e.g. peanuts; drug therapy, e.g. penicillin; and insect stings. Clinical features range from mild with flushing of the face, pruritus and blotchy wheals, to severe with asthma, respiratory obstruction from oedema of the larynx (angioedema) and circulatory collapse.

Immediate treatment is with adrenaline (epinephrine) 0.5 ml of 1 : 1000 (1 mg/ml) solution, i.e. 500 μg given intramuscularly and repeated after 5 min if no improvement is observed. Oxygen, if available, is important early on. An intravenous fluid challenge is given if there is hypotension. Hydrocortisone takes several hours to act. It is given (after the first injection of adrenaline (epinephrine)) in a dose of 200 mg slowly intravenously or intramuscularly, with chlorphenamine 10 mg slowly intravenously or intramuscularly.

In patients with a history of anaphylaxis allergens should be identified and avoided. Most patients will wish to carry self-administration preassembled pens containing adrenaline (epinephrine) for intramuscular injection.

Hereditary angioedema is a rare condition caused by C1 esterase deficiency (autosomal dominant). It gives rise to erythema, patchy oedema and colicky abdominal pain. It responds to danazol prophylaxis and fresh frozen plasma (or if available plasma derived C1 inhibitor) to correct the deficiency during attacks.

**Pneumonia**

*Community-acquired pneumonia* affects approximately 5–10/1000 adults per year. One in 1000 requires hospitalisation, and mortality in these patients is around 10%.

**Clinical presentation**

Symptoms of cough, sputum, pleurisy and dyspnoea are less common in the elderly.

Clinical findings include fever, tachypnoea, crackles and signs of consolidation. The likely causative agent cannot be predicted from clinical findings.

The most common organism in UK studies of hospitalised patients is *Streptococcus pneumoniae* (approximately one-third of cases in which an organism is identified), followed by *Chlamydia pneumoniae* and *Mycoplasma pneumoniae*. *Haemophilus influenzae*, *Legionella* species, *Chlamydia psittaci* and *Staphylococcus aureus* account for most of the remainder. Gram-negative bacilli, *Coxiella burnetii* and anaerobes are rare. Viruses (including influenza) account for 10–15% of cases.

**Investigations**

Investigations are performed to establish the diagnosis and assess severity.

- **Chest X-ray** shows infiltrates. Computed tomographic (CT) scanning is more sensitive and may be useful in detecting interstitial disease, cavitation and empyema.
- **Blood gases** to assess severity and guide oxygen treatment.
- **Blood count** – white cell count >15 × 10⁹/l suggests bacterial infection; white cell count >20 × 10⁹/l or <4 × 10⁹/l indicates poor prognosis. Haemoglobin for haemolysis.
- **Creatinine and liver function tests** for underlying or associated renal or hepatic disease.
- **Gram staining and culture of sputum** – but cough is unproductive in one-third of patients, and negative results are common, particularly if antibiotics have been given.
- **Blood culture**.
- **Pleural fluid**, if present, should be aspirated for culture.

**Management**

- **Oxygen** – to maintain PaO₂ above 8 kPa and oxygen saturation >92%.
- **Antibiotics** – the organism is usually unknown initially. Treatment is started immediately and should cover *Streptococcus pneumoniae*. In uncomplicated pneumonia, treatment is usually started with oral amoxicillin or a macrolide (erythromycin or clarithromycin). In severe pneumonia intravenous therapy is given, often using a combination of a macrolide (erythromycin) and a second- or third-generation cephalosporin (cefuroxime or cefotaxime). The choice of antibiotics should take account of local guidelines, which will take account of other factors, including the incidence of *Clostridium difficile* enteritis.
- **Intravenous fluids** may be required.
- **Analgesia** for pleuritic pain.

*Pneumococcal pneumonia* is the most common bacterial pneumonia. *S. pneumoniae* is a Gram-positive
diplacoccus. It affects all ages, but is more common in the elderly, after splenectomy, in the immunosuppressed, alcoholics, patients with chronic heart failure and those with pre-existing lung disease. It typically presents acutely with fever, pleuritic pain and rust-coloured sputum. It causes both lobar and broncho-pneumonia. Treatment is with penicillin, or erythromycin in the penicillin-sensitive. A polysaccharide pneumococcal vaccine is available for those at high risk. It should be given at least 2 weeks before splenectomy and before chemotherapy.

*Staphylococcal pneumonia* produces widespread infection with abscess formation. It may complicate influenzal pneumonia, and this makes it relatively common during epidemics of influenza. It also occurs in patients with underlying disease, which prevents a normal response to infection, e.g. chronic leukaemia, lymphoma, cystic fibrosis. Fluoroquinolone is the drug of choice, although increasingly *Staphylococcus aureus* is methicillin resistant (MRSA) and requires treatment with vancomycin. Lung abscess, empyema and subsequent bronchiectasis are relatively common complications.

*Legionnaire's disease* was first described in a group of American army veterans (legionnaires). The causative Gram-negative bacillus flourishes in the cooling waters of air-conditioners and may colonise hot-water tanks kept at below 60°C. It begins as an influenza-like illness with fever, malaise and myalgia, and proceeds with cough (little sputum), dyspnoea and sometimes severe anorexia, marked confusion and coma. Diarrhoea and vomiting are common and renal failure may develop. Examination shows consolidation that usually affects both lung bases. X-ray changes may persist for more than 2 months after the acute illness. Erythromycin or ciprofloxacin are the antibiotics of choice, but the mortality remains high.

NB Legionnaire’s disease (and *Mycoplasma pneumoniae* or psittacosis) should be suspected in all patients who develop pneumonia that does not respond to standard antibiotics.

*Mycoplasma pneumoniae* is caused by *M. pneumoniae*, the only mycoplasma definitely pathogenic to humans. The clinical picture resembles bacterial pneumonia, although cough and sputum are absent in one-third of cases.

Respiratory symptoms and signs and X-ray changes (patchy consolidation with small effusions) are usually preceded by several days of influenza-like symptoms. Polyarthritis occurs and may persist for months. Malaise and fatigue may persist long after the acute illness is over. The diagnosis is confirmed by a rise in serum titres of the respiratory syncytial virus (RSV), so called as it is a respiratory virus which produces syncytium formation when grown in culture. Infection may be indistinguishable from acute bacterial bronchitis or bronchiolitis in children and infants. The presence of a skin rash supports the likelihood of RSV infection.

Acute viral pneumonia in adults is less common but occurs during epidemics of influenza. Fever, headache and myalgia are followed after a few days by dry cough and chest pain. Treatment is largely symptomatic (paracetamol, rest, fluids). Influenza vaccines are available for those at high risk. The most common cause of pneumonia during influenza epidemics results from secondary bacterial infection, the most serious being staphylococcal pneumonia. The viruses of measles, chickenpox and herpes zoster may directly affect the lung. The diagnosis is confirmed by a rise in specific antibody titre.

*Aspiration pneumonia* comes in two main varieties, differentiated from each other by the type of fluid aspirated and the circumstances in which it occurs. Aspiration of gastric contents may produce a severe chemical pneumonitis with considerable pulmonary oedema and bronchospasm (Mendelson syndrome). The acute respiratory distress and shock can be very rapidly fatal and very difficult to treat. It tends to occur in states of reduced consciousness such as general anaesthesia, drunks and when gastric lavage (for drug overdose) has been performed inexpertly.

Aspiration of bacteria from the oropharynx may follow dental anaesthesia and can occur in bulbar palies. The bacteria, apart from *Bacteroides*, are nearly all penicillin-sensitive and amoxicillin (or ampicillin) with metronidazole are the antibiotics of choice until sensitivities of isolated organisms are known. Recurrent episodes occur in some oesophageal disorders, including hiatus hernia, stricture, achalasia of the cardia, and in patients with diverticula or pharyngeal pouch.

*Recurrent bacterial pneumonia* in the absence of chronic bronchitis arouses suspicion of:
- bronchial carcinoma preventing drainage of infected areas of lung
- bronchiectasis
- cystic fibrosis
- achalasia of the cardia, 25% of which present as chest disease, pharyngeal pouch and neuromuscular disease of the oesophagus, e.g. bulbar palsy, all producing aspiration
- hypogammaglobulinaemia and myeloma.
Opportunistic infection of the lungs occurs in patients immunosuppressed as a result of treatment, e.g. for myeloproliferative disorders or acquired immunodeficiency syndrome (AIDS, p. 343).

Lung abscess
Aetiology
- aspiration (see above)
- bronchial obstruction, usually by carcinoma or a foreign body (especially peanuts and teeth)
- pneumonia partially resolved or treated, particularly when caused by the *Staphylococcus*, *Klebsiella* or *Pneumococcus* organisms

Clinical features
There is a swinging fever and the patient is very ill. The sputum is foul and purulent and there is a high polymorph cell count. Clubbing may develop.

Investigation
Sputum is sent for Gram stain and culture, and blood for culture. Chest X-ray shows round lesions which usually have a fluid level, and serial X-rays monitor progress. It may be necessary to proceed to bronchoscopy to exclude obstruction and to obtain a biopsy and sputum trap specimen.

Treatment
Antibiotic therapy is given according to sensitivities and continued until healing is complete. Repeated postural drainage is started. In resistant cases, repeated aspiration, antibiotic instillation and even surgical excision may be required.

Bronchiectasis
Bronchiectasis means dilatation of the airways. It only becomes of clinical significance when infection and/or haemoptysis occurs within these dilated airways. Severe forms are now rare, especially in the young.

Aetiology
- following acute childhood respiratory infection, particularly measles, whooping cough or pneumonia
- cystic fibrosis
- bronchial obstruction predisposes to bronchiectasis (e.g. peanuts)

- tuberculosis has become less common as a cause
- congenital (rare): primary ciliary dyskinesia, e.g. Kartagener syndrome (bronchiectasis, sinusitis, situs inversus)

Clinical features
- chronic cough, often postural
- sputum, often copious, especially with acute infections
- halitosis
- febrile episodes
- haemoptysis: may be the only symptom (‘dry bronchiectasis’) and is occasionally severe
- dyspnoea, coarse basal crepitations and wheeze
- cyanosis and clubbing
- loss of weight and cor pulmonale in advanced cases

Management
Stop smoking. The object is to get rid of chronic sepsis. Twice-daily postural drainage will help empty dilated airways and decrease the frequency of further infections. Bronchodilators will often help improve clearance of sputum. Antibiotics, as for chronic bronchitis, are given for acute infections and exacerbations. Treatment is unnecessary in the absence of symptoms. Surgery is rarely indicated unless there is uncontrolled bleeding because the disease is seldom limited to one or two lung segments. Patients with severe disease may develop respiratory failure.

Pneumothorax
Aetiology
Spontaneous pneumothorax
This is the most common type and usually occurs in normal, tall, thin, young, male smokers following rupture of a small subpleural bulla. There is history of sudden onset of one-sided pleuritic pain and/or dyspnoea. Dyspnoea rapidly increases in tension pneumothorax and the patient becomes cyanosed. The classical signs are diminishment of movement on the affected side with deviation of the trachea to the other side. There is hyperresonance to percussion and reduced pulmonary sounds (breath sounds, tactile fremitus and vocal resonance). Pneumothoraces are best diagnosed by seeing a lung edge on X-ray; it is clearest on an expiratory film (Fig. 11.1). It recurs in 25% of cases within 5 years, usually in the first year. Conditions predisposing to pneumothorax include:

- emphysematous bullae
- tuberculosis – often with a small effusion
- bronchial asthma.
Other rare causes include staphylococcal pneumonia, carcinoma, occupational lung disease and connective tissue disorders, e.g. Marfan and Ehlers–Danlos syndromes. Familial spontaneous pneumothorax is associated with mutations in the folliculin gene.

**Management (of spontaneous pneumothorax)**

Often no therapy is required if the pneumothorax is small and symptoms minor. Spontaneous recovery occurs in 3–4 weeks. Indications for aspiration of air are:

- tension pneumothorax (an acute emergency)
- breathlessness
- moderate or complete collapse of the lung (> 50% of the total lung field on chest X-ray).

Aspirate using a 16-gauge cannula and three-way tap. If this fails, insert an intercostal catheter with a valve or water seal. When the lung is re-expanded, X-ray the chest. If the lung remains expanded for 24 h the tube may be removed and, if not, suction should be applied to the tube.

Rarely, a continuing air leak persists from the lung into the pleural space (bronchopleural fistula). Pleurodesis with talc, abrasion or tetracycline may be required.

**Cystic fibrosis**

This is an autosomal recessive disorder affecting 1 in 3000 live births that occurs equally in males and females and usually presents in early childhood. It is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7. CFTR functions as a cyclic adenosine monophosphate (cAMP)-regulated chloride channel on the apical surface of airway and other epithelial cells. Abnormally thick secretions are produced by glandular tissue. It predominantly affects the pancreas and respiratory tract, leading to pancreatic insufficiency and lung damage from recurrent chest infections. Secondary bronchiectasis or lung abscess may result. Recurrent small haemoptyses and finger clubbing are common, and pneumothorax occurs. Persistent productive cough is associated initially with *Staphylococcus aureus, Haemophilus influenzae* and Gram-negative bacilli. Later, *Pseudomonas aeruginosa* predominates and is associated with a poor prognosis.

Other manifestations are meconium ileus in newborns, diabetes mellitus, biliary obstruction and azoospermia (over 90% of males).

With improved survival cystic fibrosis is a disease of both adults and children. Most males are sterile and women subfertile. A high sodium concentration in the sweat (above 70 mmol/l) is characteristic.

**Management**

- pancreatic enzymes and fat-soluble vitamins
- clearance of pulmonary secretions and treatment of infections
- chest physiotherapy with postural drainage
- bronchodilators
- inhaled recombinant human deoxyribonuclease 1 (rhDNase) reduces the viscoelasticity of sputum by digesting viscous extracellular DNA in mucus (it is expensive)
antibiotics – exacerbations are usually treated with two parenteral antibiotics (to reduce antibiotic resistance). Choice is guided by sensitivity of isolated organisms but often includes an aminoglycoside with an antipseudomonal penicillin (e.g. ticarcillin), cephalosporin or quinolone. The benefits of maintenance antibiotic therapy have to be weighed against the risks of antibiotic resistance. Inhaled aminoglycosides may allow delivery of high concentrations to the lungs with less risk of toxicity. Although macrolide antibiotics are not directly active against *Pseudomonas aeruginosa*, several studies have shown a benefit from maintenance treatment with azithromycin (three times a week) with a small improvement in lung function, improved nutritional status and less frequent pulmonary infections.

Lung transplantation should be considered for respiratory failure.

The social and emotional problems can be enormous and, for this reason, as well as the complexity of clinical management, the condition should be supervised from specialist centres.

Lung cancer

In incidence

This causes about 40,000 deaths per year in the UK, half of them under 65 years of age. About 80% are non-small cell lung cancer and 20% small cell. They are two to three times more common in men than women. Most non-small cell cancers are squamous cell, but about 5% are undifferentiated large cell tumours and about 10% are adenocarcinoma. Alveolar cell carcinoma, an adenocarcinoma, is very rare.

Aetiology

Cigarette smoking. The increased mortality risk of carcinoma of the bronchus (squamous and small cell) has an approximately straight-line relationship with numbers of cigarettes smoked per day (increased risk of death = cigarettes smoked per day, numerically). Stopping smoking decreases the risk by one-half in 5 years, and to only twice that of life-long non-smokers in 15 years.

Other atmospheric pollution (coal smoke and diesel fumes) may prove to be aetiologically relevant, but quantitatively small compared with cigarettes. Exposure to chromium, arsenic, radioactive materials or asbestos (which in addition produces interstitial fibrosis and mesothelioma) is associated with a higher incidence of lung cancer.

Clinical presentation

The patient is usually a cigarette smoker, sometimes with tobacco-stained fingertips. Cough or the accentuation of an existing cough is the most common early symptom, and haemoptysis the next. Dyspnæa, central chest ache and pleuritic pain, and slowly resolving chest infection are common early manifestations. Occasionally, patients are identified following a routine chest X-ray. The patient may also present with inoperable disease.

- Metastatic deposits involving brain, bone, liver, skin, kidney, adrenal glands or other site.
- Symptoms from local extension, e.g. superior vena cava obstruction (puffy, dusky head, neck and arms, a raised pulseless jugular venous pulse, headache, dilated veins over the chest wall), cervical lymph glands, dysphagia from oesophageal involvement, cardiac arrhythmia and pleural effusion. The Pancoast syndrome consists of symptoms from local extension at the apex of the lung. There may be pain in the shoulder, upper back or arm, weakness and atrophy of the hand muscles from brachial plexus involvement, hoarseness from involvement of the recurrent superior laryngeal nerve, or a Horner syndrome (p. 50).

The presence of systemic and non-specific symptoms (anorexia, weight loss and fatigue) usually, but not always, implies late and possibly inoperable disease.

Blood and marrow

Anaemia (often normochromic or normocytic). Polycythaemia is uncommon. Marrow infiltration is common in small cell carcinoma.

Neuromuscular

Dementia or focal neurological deficit (caused by cerebral secondaries or rarely cortical atrophy), cerebellar syndrome, mixed sensorimotor peripheral neuropathy, proximal myopathy, polymyositis (p. 283) and the myasthenic (Eaton–Lambert) syndrome (p. 196).

Skin, connective tissue, bone

Clubbing, hypertrophic pulmonary osteoarthropathy, dermatomyositis and acanthosis nigricans.

Endocrine

Syndromes caused by ectopic hormone production, the pituitary-like ones (adrenocorticotrophic hormone (ACTH), antidiuretic hormone (ADH), prolactin) usually from oat cell tumours, and parathyroid hormone from squamous cell tumours. Hypercalcaemia is usually caused by bone secondaries.
Cardiovascular
Atrial fibrillation (local extension) and migratory thrombophlebitis. Pericarditis.

Diagnosis
Chest X-ray may show:
- the tumour, often visible as a unilaterally enlarged hilum or peripheral circular opacity, occasionally cavitated
- collapse/consolidation caused by bronchial obstruction by the tumour
- effusion, raised hemidiaphragm of phrenic paralysis and bone erosion suggest local extension.

Magnetic resonance imaging (MRI) or CT scan show the tumour position better and demonstrate bronchial narrowing and mediastinal involvement. Positron emission tomography (PET) scan can be used for detecting metastatic spread. Exfoliative cytology may be diagnostic.

Fibreoptic bronchoscopy with biopsy is performed if possible to establish histological diagnosis and assess operability. The site of the tumour is a guide to operability (not less than 2 cm from the carina). CT-guided percutaneous needle biopsy is used for peripheral lesions.

Treatment
Patients are staged using a TNM (tumour, node, metastasis) classification. Overall survival rates are poor: in the UK around 20% survive 1 year and just over 5% survive 5 years. Surgery offers the only ‘cure’. Surgery is contraindicated by metastasis (present in 60% of cases at the time of presentation – chiefly in bone and liver), local spread and inadequate respiratory function. Radical radiotherapy or continuous hyperfractionated accelerated radiotherapy (CHART) can be offered to patients who are inoperable, or in whom resection is incomplete. Chemotherapy with a third generation drug (docetaxel, gemcitabine, paclitaxel or vinorelbine) plus a platinum drug (cisplatin or carboplatin if tolerated) should be offered to patients with more advanced disease.

Small cell carcinoma may be palliated with chemotherapy, using a platinum based multi-drug regime. Radiotherapy may have a role if the disease is limited or responds to chemotherapy.

Sarcoidosis
Sarcoidosis is characterised by a systemic non-caseating granulomatous infiltration that may involve any tissue. It most commonly affects the lungs, mediastinal lymph nodes and skin. The aetiology is not known.

Clinical presentation
See Fig. 11.2.

Pulmonary sarcoid
In the UK, the annual incidence of clinical disease is 3–4/100,000. It typically occurs in young people of 20–40 years and in females more commonly than males. It usually presents as a subacute syndrome with fever, malaise and lassitude, erythema nodosum, mediastinal hilar lymphadenopathy. Dyspnoea is not usually a feature of this acute form, which is self-limiting (2 months to 2 years).

Less commonly and more seriously, it presents as a chronic insidious disease with respiratory symptoms of cough and progressive dyspnoea with malaise and fever leading to progressive pulmonary fibrosis.

Non-pulmonary sarcoid
Apart from erythema nodosum, this is relatively uncommon.
- skin – erythema nodosum (not sarcoid tissue) in the acute syndrome; infiltration of scars: lupus pernio
- hypercalcaemia occurs in about 10% of patients with sarcoidosis, and hypercalciuria is even more common. It may be the presenting abnormality and responds to steroids. It is due to the uncontrolled synthesis of 1,25-dihydroxyvitamin D3 by macrophages
- eyes – uveitis and keratoconjunctivitis sicca
- parotitis
- hepatosplenomegaly
- generalised lymphadenopathy
- bone and joints, producing cystic lesions most commonly in the phalanges
- nervous system, causing isolated cranial nerve lesions and peripheral neuropathy

Bronchial adenoma
This rare tumour is usually benign but locally invasive. Ninety percent of cases are histologically ‘carcinoid’ tumours, but only a few patients present with the carcinoid syndrome. They usually present with cough and haemoptysis. The tumour may occur either anywhere within the thoracic cavity and appear as a well-circumscribed peripheral mass on chest X-ray or, more often, in the major bronchi and appear as a pedunculated intrabronchial mass seen bronchoscopically. The tumours are removed in view of the risk of neoplastic change.
• heart – conduction defects and arrhythmias
• endocrine, producing diabetes insipidus from pituitary involvement (very rare)
• renal damage from hypercalcaemia or an associated interstitial nephritis or glomerulonephritis

**Investigation**

The chest X-ray shows symmetrical lobulated bilateral hilar and paratracheal gland enlargement (interbronchial rather than tracheobronchial) or, less commonly, parenchymal mottling or diffuse fibrosis. CT scan will help distinguish gland enlargement from prominent pulmonary artery shadows.

Angiotensin converting enzyme (ACE) is produced by epithelioid cells of sarcoid granulomata. Elevated serum ACE can be useful in diagnosis and monitoring disease activity, although it can also be elevated in other granulomatous diseases.

‘Blind’ transbronchial lung biopsy at bronchoscopy often shows non-caseating epithelioid granulomas. Liver biopsy may reveal granulomas. The Mantoux test is usually negative; a positive test is not uncommon but a strongly positive test is very unusual. Polyclonal increase in \( \gamma \)-globulins is non-specific but common.

**Management**

The differential diagnosis of bilateral hilar lymph node enlargement is from Hodgkin’s disease (and other reticuloses), and any deviation of the patient’s syndrome from the usual pattern makes a definite diagnosis by biopsy imperative. Treatment, other than simple analgesics and NSAIDs, is usually unnecessary.

Indications for corticosteroids in sarcoidosis (e.g. prednisolone 20 mg/day, reducing after 1 month to the minimum dosage necessary to suppress activity for 1 year) include the following:

• Progressive lung disease, to try to prevent fibrosis. The indication is progressive pulmonary shadowing or increasing breathlessness. The effect of therapy is monitored by symptoms, chest X-rays and lung function tests, including Transfer Factor of the Lung for Carbon Monoxide, \( Tlco \).
• Hypercalcaemia.
When vital organs are threatened, e.g. eyes, nervous system, kidneys and heart.

Steroid-sparing drugs, including methotrexate and azathioprine, are often used when long-term treatment is needed. Tumour necrosis factor blockade has been effective in refractory cases.

**Prognosis (of pulmonary sarcoid)**

Complete clinical resolution in 3–4 months, and radiological resolution in 1–2 years, occurs in 70–80% of cases. The chest X-ray remains abnormal in about half of all cases (Table 11.1). Clinical disability brought about by the disease is much less common and is related to:

- age – the younger, the better
- presence of erythema nodosum, where over 95% recover by 1 year
- extent of extrapulmonary involvement – bone or chronic skin lesions indicate chronicity, and the more widespread it is, the worse the prognosis
- extent of intrathoracic involvement.

**Tuberculosis**

Infection with the acid-alcohol-fast bacillus (AAFB) of *Mycobacterium tuberculosis* affects predominantly the lungs, lymph nodes and gut (Fig. 11.3). Some features of the disease vary with the patient’s sensitivity to tuberculin. NICE has published guidelines on the diagnosis and treatment of tuberculosis (http://www.nice.org.uk/CG033).

**Primary tuberculosis**

This is the syndrome produced by infection with *M. tuberculosis* in non-sensitive patients, i.e. in those who have not previously been infected. There is a mild inflammatory response at the site of infection (subpleural in the mid-zones of the lungs, in the pharynx or in the terminal ileum), followed by spread to the regional lymph nodes (hilar, cervical and mesenteric respectively). The combination of a focus with regional lymph node involvement is called the *primary complex*. One to two weeks following infection, with the onset of tuberculin sensitivity, the tissue reaction changes at both the focus and in the nodes, to the characteristic caseating granuloma. Patients are usually symptomless. The complex heals with fibrosis and, frequently, calcifies without therapy. The enlarged lymph node may be obvious in the neck or cause obstruction to a bronchus with consequent collapse. Blood dissemination of the organisms occurs rarely from the primary complex to cause widespread miliary disease, especially in infants.

**Post-primary tuberculosis**

This is the syndrome produced by infection with *M. tuberculosis* in the previously infected and therefore tuberculin-sensitive patient. Reactivation (or reinfection) is followed by an immediate brisk granulomatous response that tends to localise the disease, and regional lymph node involvement is uncommon. As with primary tuberculosis, the lesion may:

- heal with fibrosis (and calcification)
- rupture into a bronchus, giving tuberculous bronchopneumonia
- spread via the blood to produce miliary tuberculosis of liver, spleen, lungs, choroid, bone and/or meninges.

**Presenting features**

Symptoms occur relatively late and therefore in established disease. The earliest are non-specific, such as malaise, fatigue, anorexia and weight loss. Of more specific symptoms, the most common is cough, often with mucoid sputum. Other symptoms include repeated small haemoptysis, pleural pain, slight fever or, occasionally, exertional dyspnoea. Frequently, the diagnosis is made presymptomatically on routine chest radiography. Signs also occur late in the disease and are not very specific, e.g. crepitations (usually apical) and, later, signs of consolidation, pleural effusion or cavitation.

---

**Table 11.1** Prognosis of pulmonary sarcoid

<table>
<thead>
<tr>
<th>Stage</th>
<th>X-ray appearance</th>
<th>Spontaneous remission (% of cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Bilateral hilar lymphadenomegaly without pulmonary infiltrates</td>
<td>60–90</td>
</tr>
<tr>
<td>II</td>
<td>Bilateral hilar lymphadenomegaly plus pulmonary infiltrates</td>
<td>40–70</td>
</tr>
<tr>
<td>III</td>
<td>Parenchymal infiltrates without bilateral hilar lymphadenomegaly</td>
<td>10–20</td>
</tr>
<tr>
<td>IV</td>
<td>Extensive fibrosis with distortion or bullae</td>
<td>0</td>
</tr>
</tbody>
</table>
Diagnosis

Clinical suspicion should be particularly high in high-risk groups:
- the hostel-dwelling ‘down-and-out’, and the alcoholic
- Pakistani and Indian immigrants (lymph node tuberculosis is common in Indian and Pakistani patients)
- diabetics
- patients with AIDS
- patients on immunosuppressive therapy (steroids or cytotoxic drugs).

Ideally, the diagnosis is made by repeated examination for AAFB in sputum and bronchial washing on direct smear or culture. At least three sputum samples, including one early morning sample, should be sent for culture and microscopy. Sometimes the diagnosis can only be made radiologically, where activity is suggested by:
- changing ‘soft’ shadows
- progression of apical lesions
- cavitation
- with a strongly positive Mantoux test.

It may be necessary to treat on clinical grounds alone and response to specific therapy is taken as proof of diagnosis.

Tuberculosis is notifiable in the UK.

NB AAFB on microscopy may not be pathogenic mycobacteria, particularly in urine specimens.

Management

Admit patients who are sputum smear positive to a single room, with negative pressure if multidrug-resistant tuberculosis is suspected. Risk factors for drug resistance include:
- prior treatment for tuberculosis or prior treatment failure
- contact with drug-resistant tuberculosis
- birth in a foreign country
- HIV infection
- age between 25 and 44
- male gender.

Close contacts should be screened with chest X-ray, Mantoux test and/or interferon-gamma assay depending on their age and bacille Calmette–Guérin (BCG)
status (Box 11.2). People identified by screening as having latent tuberculosis are usually treated with 3 months of rifampicin or isoniazid, or 6 months of isoniazid.

For tuberculous meningitis see p. 199.

Common antituberculosis drug doses and complications

The first four drugs are considered ‘first-line’.

- Rifampicin 450–600 mg/day: abnormal liver function tests. Colours the urine pink.
- Isoniazid (INAH) 300 mg/day (with pyridoxine 10 mg): peripheral neuropathy and encephalopathy – these are extremely rare, occur in slow acetylators and respond to pyridoxine, often given prophylactically.
- Pyrazinamide 1.5–2.0 g/day: hepatotoxic (rare but severe).
- Ethambutol 15 mg/kg/day: optic neuritis with colour vision and acuity reduced.
- Streptomycin 1 g/day by intramuscular injection: vertigo and nerve deafness. In the elderly and in the presence of raised blood urea, the dosage is reduced to 0.75 or 0.5 g/day to maintain blood levels of 1–2 mg/ml.

Dust diseases

These include the pneumoconioses, asthma and allergic alveolitis. Pneumoconioses are caused by the inhalation and retention in the lung of dust, and include:

- coal pneumoconiosis
- silicosis in rock drilling and crushing – also occurs in coal miners
- asbestosis in insulation workers; this can produce fibrosis, carcinoma and pleural mesothelioma.

These are radiographic diagnoses made in the light of the patient’s known occupational hazards; the shadows are caused by the metals themselves, e.g. siderosis (iron) and stannosis (tin). All are rare.

In the UK, workers who have developed pneumoconiosis or silicosis can receive compensation from the Industrial Injuries Scheme, administered by the Department for Work and Pensions. In 2010 there were 345 new assessed cases of coal worker’s pneumoconiosis and 60 cases of silicosis.

Clinical features

In the early stages there are no symptoms but X-ray changes occur; later there is dyspnoea on exertion, cough, sputum and attacks of bronchitis. In coal miners, progressive massive fibrosis may occur and in Caplan syndrome pulmonary nodules occur in association with rheumatoid arthritis. The patients may eventually develop cor pulmonale.

Asthma

Occupational asthma can occur in response to precipitants of animal, vegetable, bacteriological or chemical origin. Some of the more common occupations are: animal laboratory workers (urinary proteins), grain and flour workers (mites and flour), sawmill operatives and carpenters (hardwoods), those who manufacture biological detergents (inhalation of Bacillus subtilis proteolytic enzymes), in the electronics industry (colophony in solder flux), paint sprayers and polyurethane workers (isocyanates), workers with epoxy resins or platinum salts, and those in the pharmaceutical industry. All these are recognised for compensation under industrial injuries legislation in the UK.

Extrinsic allergic alveolitis

Inhalation of organic dusts may give a diffuse allergic (type III precipitin-mediated) reaction in the alveoli and bronchioles.
Aetiology

Exposure to mouldy hay (*Micropolyspora faeni*) causes farmer’s lung, to mouldy sugar cane causes bagassosis, to mushroom dust causes mushroom picker’s lung, to bird droppings (containing avian serum proteins) causes bird fancier’s lung, to contaminated malting barley (*Aspergillus clavatus*) causes malt worker’s lung. Precipitating antibodies against the offending antigen can often be found in the patient’s blood.

Clinical features

Acute (i.e. 4–6 h after exposure)

Dyspnoea, dry cough, malaise, fever and limb pains occur, and examination shows fine inspiratory crepitations with little wheeze. The symptoms subside in 2–3 days.

Chronic

After repeated acute attacks fibrosis occurs with persistent inspiratory crepitations, respiratory failure and cor pulmonale.

Investigation

Chest X-ray shows a diffuse haze initially and later micronodular shadowing develops, progressing to honeycombing. Ventilatory function tests initially show a reversible restrictive defect with low TLCO during the acute attacks. This becomes permanent as the chronic disorder develops. There is little or no obstruction. The $P_{a}O_2$ falls and $P_{a}CO_2$ is normal or reduced by the hyperventilation. There is no eosinophilia.

Treatment

Separate the patient and the allergen. Ventilation and personal protective equipment may reduce dust exposure. High-dose steroids are tried in serious cases and should be continued only if there has been a measured response in lung function.

Obstructive sleep apnoea

The sleep apnoea syndrome has been defined as absence of airflow in periods of at least 10 s occurring at least 5 times per hour during sleep, with daytime drowsiness.

There are repeated episodes of upper airways obstruction during sleep with hypoxaemia and sudden arousal. This results in poor sleep, snoring, excessive daytime sleepiness and observed apnoeas in sleep. It is associated with male gender, obesity and evening alcohol consumption. It is a risk factor for the development of hypertension and has been associated with type 2 diabetes, ischaemic heart disease and stroke. Diagnosis requires overnight sleep studies (observation in a sleep laboratory) where arterial oxygen saturation can be monitored. Management involves slimming and alcohol reduction, followed by continuous positive airways pressure (CPAP) if these fail. Surgery may be of value if there is evidence of anatomical obstruction.

Pulmonary embolism

Emboli usually arise in the veins of the pelvis or legs and, rarely, from the right atrium.

They occur more frequently:

- following surgery (classically, although not always, about 10 days)
- following myocardial infarction
- following a stroke
- in disseminated malignancy
- in prolonged bed rest associated with illness
- during air flights over 3 h or 3000 miles, not necessarily economy class
- following trauma, especially to the pelvis and legs (including caesarean section)
- in antiphospholipid syndrome (p. 280)

The risk may increase if other factors are present:

- advancing age
- obesity
- pregnancy and postpartum
- treatment with oestrogens (oral contraceptive pill or hormone replacement therapy)
- previous venous thrombosis or family history of it.

Patients who die from pulmonary embolism have often had premonitory signs and symptoms of small emboli (unexplained breathless attacks) or venous thrombosis in the previous weeks. A deep vein thrombosis should be regarded as potential pulmonary embolus and must be suspected, diagnosed and treated as an emergency.

Clinical features

The clinical features of deep venous thrombosis include:

- erythema and warmth of the affected leg
- swelling and tenderness.
Thromboses that extend above the knee are more likely to produce clinically recognisable and life-threatening pulmonary emboli.

NB Diagnosis is confirmed by ultrasound with vein compression or venography. Swelling of the calf also occurs in rupture of a Baker’s cyst behind the knee. An effusion of the knee makes this more likely. The cyst can often be shown on ultrasound.

Clinical presentation (of pulmonary embolus)

This depends upon the size of the embolus. Multiple small acute emboli may remain undetected until up to 50% of the vascular bed is involved and present with effort dyspnoea.

- **Small.** Transient faints and dyspnoea, with slight pyrexia.
- **Medium.** Usually results in infarction and produces, in addition, haemoptysis, pleurisy and, occasionally, a pleural effusion.
- **Large.** Acute cor pulmonale with sudden dyspnoea and shock. There is a small-volume rapid pulse, with hypotension, cyanosis, peripheral vasoconstriction and a raised jugular venous pressure. There may be a gallop rhythm.

Investigation

Chest X-ray

This may demonstrate:

- pulmonary oligaemia of the affected segment (usually present but difficult to diagnose except in retrospect)
- the corresponding pulmonary artery is sometimes dilatated at the hilum
- small areas of horizontal linear collapse, usually at the bases, with a raised diaphragm
- a small pleural effusion.

With larger emboli, the heart enlarges acutely and the superior vena cava distends.

ECG

Electrocardiogram changes usually occur only with larger emboli but are then common. The characteristic changes are as follows (see also p. 78):

- tachycardia
- right ventricular ‘strain’ pattern (inverted T waves in leads V1–4)
- acute, often transient, right bundle branch block pattern
- S1, Q3, T3 pattern
- transient arrhythmias, e.g. atrial fibrillation.

Arterial blood gases

With larger emboli, a fall in $\text{Pa}_2$ and $\text{Pa}_C0_2$ is common.

Lung perfusion scan

This may show underperfusion of one or more parts of the lung that are radiologically normal (and ventilated normally on ventilation scan).

Combined ventilation and perfusion scans

These may be helpful in pre-existent lung disease in which ventilation and perfusion defects are usually matched. A normal scan virtually excludes pulmonary embolism.

Pulmonary angiography

This is the most precise method of investigation for cases presenting difficulty in diagnosis. High resolution CT pulmonary angiogram has a high accuracy rate for the evaluation of pulmonary embolism.

D-DIMER

D-DIMER is a fibrin degradation product formed by the enzymatic activity of plasmin on cross-linked fibrin polymers. Plasma levels can be measured and are raised in patients with pulmonary embolism or deep vein thrombosis. Negative test results rule out the likelihood of these diseases.

Treatment

Prophylaxis is given pre- and postoperatively, especially in lower abdomen and lower limb surgery, and in patients confined to bed or with predisposing disorders (e.g. cardiac failure). Aspirin with graduated-compression stockings are given to at-risk long-distance air travellers. Low-molecular-weight heparins are prepared by depolymerisation of standard (unfractionated) heparin. They have a longer duration of action than standard heparin and, given as a once-daily subcutaneous dose, produce a more predictable anticoagulant response. They are safe and effective as low-dose prophylaxis, and can be used in weight-adjusted dosage for treatment of deep vein thrombosis without laboratory monitoring.

For established deep vein thrombosis or pulmonary embolism, patients are usually treated with low molecular weight heparin initially, followed by warfarin for a minimum of 3 months.

In massive pulmonary embolism, cardiac massage and correction of acidosis with urgent intravenous heparin may improve survival. With large emboli, oxygen in high concentration and thrombolytic therapy with urokinase or streptokinase may be valuable. The operative removal of large emboli with bypass surgery may be life-saving.
Placement of a vena caval filter should be considered when anticoagulation is hazardous or in patients who develop emboli despite adequate anticoagulation.

**Hyperventilation syndrome**

Breathlessness in the absence of abnormal clinical signs and increased by emotion (e.g. clinical examinations and ward rounds) should never be described as psychogenic until the following diagnoses have been excluded:

- early pulmonary congestion of left ventricular failure
- silent multiple pulmonary emboli (lung scan may be diagnostic)
- lymphangitis carcinomatosa
- interstitial fibrotic pulmonary infiltrations
- metabolic acidosis (e.g. uraemia, diabetic ketosis)
- respiratory muscle weakness.

The chest X-ray may appear normal in all of these at the time of presentation.

Hyperventilation syndrome may be the presenting symptom of psychiatric disease and the patient should be asked about symptoms of anxiety and depression and enquiries made about personality previously. The breathlessness is usually episodic and not directly related to degree of exertion (often even occurring at rest). It is frequently described as an inability to take a deep breath or shortage of oxygen. There are associated symptoms of hypocapnia (tingling in the fingers, dizziness, headache, heaviness in the chest, cramp). Tetany may occur with carpopedal spasm. Spirometry usually gives a disorganised trace, but the \( FEV_1 \) and \( FVC \) are normal when obtained.

**Fibrosing alveolitis**

**Clinical features**

The disease begins in middle age and presents with progressive dyspnoea and dry cough, usually without wheeze or sputum. The typical signs are clubbing, cyanosis and crepitations in the mid and lower lung fields. Polyarthritis is common. There is an association with autoimmune diseases, particularly rheumatoid arthritis.

**Investigation**

The arterial \( PaO_2 \) is reduced and hyperventilation may cause a reduction in \( PaCO_2 \). Spirometry (p. 25) demonstrates a restrictive pattern, i.e. a grossly reduced \( FVC \) with rapid initial exhalation of this small volume, thus giving a normal or high \( FEV_1 : FVC \). The transfer factor is reduced.

Chest X-ray shows diffuse bilateral basal nodular-reticular shadowing that extends upwards as the disease progresses. The differential diagnosis of the chest X-ray includes other causes of diffuse pulmonary fibrosis and infiltration: occupational dust lung diseases, sarcoidosis, scleroderma, lymphangitis carcinomatosa, collagen diseases, miliary tuberculosis, radiation pneumonitis, drugs (busulphan and other cytotoxic drugs, nitrofurantoin, paraquat), histoplasmosis, coccidioidomycosis and histiocyotosis X. Clinically, the problem is less difficult. Lung biopsy, either open by thoracotomy or transbronchial via a bronchoscope, may be diagnostic. There is alveolitis with lymphocytic and plasma cell infiltration and diffuse pulmonary fibrosis.

**Management**

The disease is progressive and, although steroids are usually given, sometimes in combination with azathioprine or cyclophosphamide, response is variable. The patient eventually dies with severe hypoxia. Lung transplantation should be considered, although about 15% of cases develop carcinoma of the lung.

**Adult respiratory distress syndrome**

Adult respiratory distress syndrome (ARDS) refers to acute progressive respiratory failure starting hours to days after a number of pulmonary or systemic insults. These include sepsis, trauma (lung contusion or non-thoracic), aspiration (gastric contents, toxins, smoke), shock from any cause, disseminated intravascular coagulation, and air and fat emboli. It can occur in association with pneumonia, and may be drug-induced (heroin, barbiturates). The pulmonary oedema is caused by capillary leakage rather than the elevated left atrial pressure of heart failure.

It is characterised by:

- arterial hypoxia
- reduced thoracic compliance
- normal pulmonary capillary wedge pressure
- diffuse infiltrates on chest X-ray.

**Treatment**

This should be aimed at the underlying condition, although in many cases the lung injury has already occurred. Ventilation with positive end-expiratory pressure is usually necessary. Neither steroids nor surfactant have been shown to be of benefit in sepsis-associated ARDS. Mortality is high (50–70%) and associated with sepsis, organ failure and age.
Symptoms arising in the gastrointestinal tract are extremely common. In clinics most are a result of disturbances in motility and over one-third of cases may have irritable bowel syndrome. Peptic ulcer, hiatus hernia, appendicitis, diverticulitis, haemorrhoids, ulcerative colitis and carcinoma of the colon are common. Carcinoma of the stomach and carcinoma of the oesophagus are less common.

**Gastric and duodenal ulceration**

**Aetiology**

Infection with *Helicobacter pylori* and the use of anti-inflammatory drugs, both steroidal and non-steroidal (including aspirin), are the most common precipitating factors. Smoking increases the rate of ulcer recurrence and slows ulcer healing. Very rarely, ulceration is associated with Zollinger–Ellison syndrome (p. 134), multiple endocrine neoplasia (MEN) Type 1 syndrome (p. 226), hyperparathyroidism (p. 264) and stress (e.g. extensive burns – Curling’s ulcer).

*Helicobacter pylori* colonises the mucus layer overlying the gastric epithelium. Infection is often asymptomatic, although a chronic superficial gastritis invariably affects the underlying mucosa. *H. pylori* infection is associated with peptic ulceration and an increased incidence of gastric cancer. Production of urease and cytotoxins and disruption of the gastric mucosal barrier are thought to contribute to disease production.

There is an association between *H. pylori* infection and the development of B-cell gastric lymphomas of mucosa-associated lymphoid tissue (MALT). Early stage MALT lymphomas may respond to eradication of *H. pylori*.

**Clinical presentation**

It is usually impossible, on the basis of history and examination alone, to differentiate between non-ulcer dyspepsia, duodenal ulceration, benign ulceration of the stomach and carcinoma of the stomach, but carcinoma is much less common.

Pain may be retrosternal or epigastric or occur anywhere in the anterior upper abdomen. Anorexia, vomiting and weight loss are more frequent and severe in carcinomatous ulcers of the stomach than in benign peptic ulceration.

**Examination**

The patient characteristically puts the hand over the upper abdomen when asked where the pain is, and there may be epigastric tenderness. The presence of an epigastric mass suggests a carcinoma. A gastric splash (or succussion) indicates the rare pyloric obstruction caused by benign duodenal stricture or due to carcinoma of the pyloric antrum.

**Complications**

- bleeding (p. 135)
- perforation (usually duodenal ulceration)
- pyloric stenosis

**Investigation**

Endoscopy with gastric biopsy is important in establishing the diagnosis and allows identification of *H. pylori* infection (see Box 12.1). Duodenal ulcers are virtually always benign. Gastric carcinomas are more common on the greater curve and in the antrum, but lesser curve ulcers may, nevertheless, be malignant. The size of the ulcer is no guide to whether a carcinoma is present. Carcinomas may have a rolled edge. Biopsy can give histological
confirmation. Repeat endoscopy after 4 weeks of treatment should show healing of a gastric ulcer. If this has not occurred the presence of a carcinoma becomes more likely.

Barium meal should be performed if dysphagia is present.

Management

Antacids and diet often ameliorate symptoms but do not hasten healing. The patient should stop smoking.

Patients with proven *H. pylori* infection are given eradication therapy, usually with a 7-day course of triple therapy comprising two antibiotics (chosen from clarithromycin, metronidazole and amoxicillin) in combination with a proton-pump inhibitor such as omeprazole. Approximately 10% of patients fail treatment due to either poor compliance or antibiotic resistance to metronidazole or to a lesser extent clarithromycin.

H₂-receptor antagonists reduce gastric acid output. Maintenance treatment prevents ulcer relapse. In patients with a history of bleeding duodenal ulcer, long-term treatment with H₂-antagonists appears safe and effective in preventing recurrent haemorrhage.

H⁺/K⁺-ATPase (proton-pump) inhibitors cause a profound reduction in gastric acidity.

Misoprostol, a synthetic prostaglandin analogue, is effective in reducing gastrointestinal damage induced by non-steroidal anti-inflammatory drugs (NSAIDs).

Indications for surgery

Duodenal ulcer

Acute indications include:

- perforation
- pyloric obstruction
- persistent haemorrhage.

Failed medical management

- a common indication in the past, this is now rare.

Gastric ulcer

- acute indication:
  - persistent haemorrhage
- non-acute indications:
  - carcinoma
  - failed medical treatment, either if there is a possibility of carcinoma or for persistent symptoms.

Gastric carcinoma

Gastric carcinoma is a leading cause of cancer mortality worldwide. It is associated with *H. pylori* infection. It affects mainly the pylorus and antrum. Symptoms are those of a gastric ulcer in the early stages, but dysphagia may occur. Occasionally the patient complains of no more than weight loss.

The prognosis is poor. Resection with removal of the primary tumour and regional lymph nodes is the most effective treatment.

Hiatus hernia and gastro-oesophageal reflux

Aetiology

Weakness of the diaphragmatic sphincter allows the lower oesophagus and cardia of the stomach to rise into the thorax. Gastro-oesophageal reflux may occur in the presence or absence of a hiatus hernia and is aggravated by smoking and alcohol.

Symptoms

Retrosternal burning pain, usually episodic, with acid regurgitation into the throat and flatulence that may give relief; worse on lying flat or bending. It is relieved by milk and antacids. Bleeding may give positive occult blood tests and anaemia. Oesophagitis may lead to ulceration and/or stricture.

Investigations

If persistent and symptoms are severe or if associated with dysphagia (to exclude benign or malignant stricture) or weight loss (to exclude oesophageal or gastric carcinoma), barium swallow or endoscopy will reveal the hernia and the presence of gastric acid reflux.
Management

- Weight reduction and stop smoking. Avoid clothes that constrict and increase intra-abdominal pressure, and avoid foods that induce symptoms if recognised. Sleep propped up (raise head of the bed).
- Antacids for symptoms. Metoclopramide increases oesophageal sphincter contraction and increases gastric emptying. It is a dopamine antagonist and may induce acute dystonic reactions which respond to procyclidine. A course of an H2-receptor antagonist or a proton-pump inhibitor usually relieves symptoms if severe.
- Surgery for hiatus hernia is very rarely indicated in the absence of stricture formation as it is a major procedure and the results are uncertain. In Barrett’s oesophagus, reflux is associated with columnar metaplasia of the normal stratified squamous epithelium of the lower oesophagus. It can progress to low-grade dysplasia, high-grade dysplasia and carcinoma. Surveillance allows earlier treatment by endoscopic resection or ablation, or oesophagectomy.

Inflammatory bowel disease (ulcerative colitis and Crohn’s disease)

Aetiology

In ulcerative colitis and Crohn’s disease environmental factors are thought to trigger inflammation of the bowel in genetically prone individuals.

Ulcerative colitis

Ulcerative colitis is a distal non-transmural inflammatory disease of the rectum (proctitis) with a variable extension proximally up the large bowel. Although it is restricted to the large bowel, ileal inflammation (backwash ileitis) can occur. Genome-wide association studies have suggested links with multiple loci, including variants in the immunosuppressive cytokine IL-10.

Clinical features (Table 12.1)

Ulcerative colitis may occur at any age, but usually presents in the 20- to 40-year age group with bloody diarrhoea, passage of mucus or pus and abdominal pain. In severe colitis, fever, tachycardia, marked abdominal tenderness, anaemia and weight loss are usually present, and marked dilatation of the colon (toxic megacolon) may lead to perforation. The disease follows a chronic relapsing–remitting course, with variation in the activity and extent of the disease changing in individual patients over the years. At any one time about 50% of patients are in remission.

Diagnosis

This is suggested by the clinical picture and may be confirmed, except in the very ill, by sigmoidoscopy with biopsy. The extent of disease is confirmed by colonoscopy or imaging studies. Infectious causes should be excluded.

Sigmoidoscopy

The rectal mucosa is always abnormal in ulcerative colitis. Abnormal appearances, in order of severity, are:

- granular mucosa with loss of normal vascular pattern
- presence of pus and blood
- visible ulceration with contact bleeding at the rim of the sigmoidoscope.

Histology

Histology shows superficial inflammation with chronic inflammatory cells infiltrating the lamina propria with crypt abscesses, with little involvement of the muscularis mucosa and with reduction of goblet cells.
Imaging
Imaging by barium enema, CT or MR shows loss of normal haustral pattern with shortening of the large intestine (Fig. 12.1). The bowel takes on the appearance of a smooth tube (hosepipe appearance). Undermined ulcers and pseudopolyi may be seen. Stricture formation or carcinoma produces fixed areas of narrowing.

Plain abdominal film will show acute dilatation when present, and bowel gas may outline mucosal ulceration. Barium enema examination in such circumstances may produce perforation.

Differential diagnosis
- Carcinoma of the colon, which may present with bloody diarrhoea.
- Infective enteritis. The acute case may resemble Campylobacter enteritis or bacillary dysentery, and the chronic case amoebic colitis (these should be excluded by stool examination).
- Antibiotic-associated pseudomembranous colitis (PMC) follows within 3 weeks of taking antibiotics. It is caused by toxins of Clostridium difficile when it colonises the colon following antibiotic-induced suppression of the normal bacterial flora of the gut. On sigmoidoscopy, characteristically there are patchy yellowish areas of necrotic mucosa. Histology shows mucosal destruction with characteristic exudation of fibrin and inflammatory cells in the cross-sectional shape of a mushroom. C. difficile and its toxin may be found in the stool. The condition responds to oral metronidazole or vancomycin.

Treatment
Oral 5-aminosalicylic acid compounds are used to induce remission in mild to moderate colitis. Sulfasalazine is a combination of 5-aminosalicylic acid (5-ASA) and sulphapyridine, which acts as a carrier to deliver 5-ASA to its site of action in the colon. Mesalazine is 5-ASA by itself, and olsalazine is two linked molecules of 5-ASA that separate in the lower bowel. These newer aminosalicylates lack sulphonamide-related side effects, although their benefit over sulfasalazine in ulcerative colitis is unclear. 5-ASA compounds can be delivered by suppositor in proctitis. In moderate colitis that does not respond to 5-ASA or severe colitis, oral steroids should be started, and azathioprine can be added for its steroid-sparing effect. Rectal steroids can be used in proctitis. In patients refractory to 5-ASA and steroids, the anti-TNF (tumour necrosis factor) agent infliximab can induce remission and reduce the need for colectomy in the short term.

Treatment can usually be tapered once remission is achieved, but all of the above agents have been used to maintain remission.

Patients with severe colitis should be admitted to hospital for intravenous steroids and fluids and managed jointly by the gastroenterologist and surgeon. Patients who do not respond to intravenous steroids may respond to ciclosporin, tacrolimus or infliximab, but the need for colectomy should be continuously reviewed.
**Surgery**

Surgery (proctocolectomy, or total colectomy with ileal J pouch–anal anastomosis) is indicated if there is:

- severe haemorrhage
- perforation
- acute toxaemia with dilatation of the colon which fails to respond within 24–48 h to high-dose steroids.

Elective surgery is indicated if regular colonoscopy shows high-grade dysplasia or cancer, or in patients who are intolerant of or refractory to long-term medical treatments.

**Crohn’s disease**

Crohn’s disease is a relapsing inflammatory disease that can affect any site in the alimentary tract from mouth to anus.

**Aetiology**

Current evidence suggests that genetic and environmental factors contribute to an abnormal mucosal immune response that is facilitated by the gut microbiota and epithelial cell abnormalities. Nucleotide-binding oligomerisation domain 2/caspase recruitment domain-containing protein (NOD2/CARD15) was identified as the first susceptibility gene in Crohn’s disease in 2001. NOD2 contains an intracellular receptor for components of microbial pathogens, and influences inflammatory responses by regulating activation of the transcription factor NFκB. Genome-wide association studies have since implicated many other genes including the interleukin-23 receptor (IL23R) and autophagy-related 16-like 1 (ATG16L1) genes.

**Clinical features (Table 12.1)**

Peak incidence is between ages 10 and 40. The terminal ileum is most frequently diseased, followed by the colon and less commonly the upper gastrointestinal tract. It usually presents as intermittent abdominal pain with diarrhoea, sometimes with passage of blood or mucus. Less commonly it presents as an ‘acute abdomen’ with signs of acute appendicitis with or without a palpable mass or obstruction. A mass in the right iliac fossa from terminal ileitis must be differentiated from a caecal carcinoma and an appendix abscess. Amoebic abscess and ileocaecal tuberculosis are less common causes.

The granulomatous inflammatory process affects short lengths of the intestine, leaving normal bowel between skip lesions. The wall is thickened and the lumen narrowed. Mucosal ulceration and regional lymphadenopathy are present. The characteristic microscopic features are of submucosal inflammation, less marked than in ulcerative colitis. There are numerous fissures down to the submucosa with or without chronic granulation tissue, consisting of non-caseating granulomas not unlike those found in sarcoid.

**Imaging (Fig. 12.2)**

**Barium enema**

The terminal ileum is most commonly involved and may produce incompetence of the ileocaecal valve. Mucosal ulceration may be deep and ‘spikes’ of barium may enter deep into the bowel wall (rose thorn). Lesions may be multiple with normal bowel between (skip lesions). Coarse cobblestone appearance of the
mucosa appears early. Later in the disease, fibrosis produces narrowing of the intestine (string sign) with some proximal dilatation.

**Small-bowel enema**

There may be mucosal ulceration, luminal narrowing or pooling of barium in irregular clumps at the site of an inflammatory mass.

Cross-sectional imaging with multi-slice CT, MR with oral contrast and MR enteroclysis, in which contrast is inserted through a naso-duodenal tube, provide alternative approaches.

Indium-labelled white cell scanning is helpful in localising active inflammatory bowel disease.

**Histology**

In Crohn’s disease the characteristic microscopic features are of submucosal inflammation, less marked than in ulcerative colitis. There are numerous fissures down to the submucosa with or without chronic granulation tissue consisting of non-caseating granulomas not unlike those found in sarcoid.

**Complications**

Fever, anaemia and weight loss. Hypoalbuminaemia results from loss of protein and in small-bowel disease malabsorption. Fistulae, perianal fissures and sepsis and intestinal sepsis may all complicate Crohn’s disease.

**Treatment**

Aminosalicylates and corticosteroids have been used to induce remission. The newer aminosalicylates may be of more benefit in treating Crohn’s disease. Mesalazine suppositories can be useful for localised rectal disease. Budesonide that is formulated to be released in the terminal ileum and colon can be effective with fewer side effects than conventional steroids. It is a steroid that is rapidly metabolised in the liver after absorption. Enteral nutrition has been used to induce remission but is less effective that steroids. Anti-TNF treatment with infliximab, adalimumab or certolizumab pegol are usually reserved for patients who do not enter remission with mesalazine or steroids. Methotrexate or ciclosporin may be of value in patients refractory to these treatments. Attention to nutritional deficiencies (p. 253) and electrolyte imbalance is essential.

Azathioprine, anti-TNF therapies and enteral nutrition have been shown to be effective in maintaining remission (see Trials Box 12.1). Smoking cessation is important in maintainence of remission.

Antibiotics (ciprofloxacin and metronidazole) are widely used for the treatment of fistulas in Crohn’s disease. Azathioprine may be effective, but anti-TNF treatments with infliximab and adalimumab are increasingly used to heal fistulas.

**Surgery**

In Crohn’s disease surgery is used for relief of acute emergencies (obstruction), abscesses and fistulae.

---

**TRIALS Box 12.1 Maintenance of remission in Crohn’s disease**

Cochrane reviews found that azathioprine is effective in maintaining remission. (*Cochrane Database of Systemic Reviews* 2000; (2): CD000067.) Infliximab 5 mg/kg or 10 mg/kg, given every 8 weeks, is effective for the maintenance of remission and maintenance of fistula healing in patients who have responded to infliximab induction therapy. Adalimumab 40 mg weekly or every other week is effective for the maintenance of remission in patients who have responded to adalimumab induction therapy. Certolizumab pegol 400 mg every 4 weeks is effective for the maintenance of remission in patients who have responded to certolizumab induction therapy. (*Cochrane Database of Systemic Reviews* 2008; (1): CD006893.) The available evidence also suggests that supplementary enteral nutrition may be effective for maintenance of remission in Crohn’s disease. (*Cochrane Database of Systemic Reviews* 2007; (3): CD005984.)

Other reviews concluded that use of conventional systemic corticosteroids in patients with clinically quiescent Crohn’s disease does not appear to reduce the risk of relapse over a 24-month period of follow-up (*Cochrane Database of Systemic Reviews* 2003; (4): CD000301), and found no evidence to suggest that 5-ASA preparations are superior to placebo for the maintenance of medically induced remission in patients with Crohn’s disease. (*Cochrane Database of Systemic Reviews* 2005; (1): CD003715.)

NB Smoking aggravates Crohn’s disease but can improve the clinical course of ulcerative colitis. Nicotine may be of value in maintaining remission in ulcerative colitis.
Surgery eventually becomes necessary in about 30% of cases. Resection of diseased intestine and bypass operations may become necessary for severe, chronic ill health, but unlike in ulcerative colitis these are not curative. Fistula formation may result and recurrence is the rule. Intestinal obstruction is best managed conservatively in the first instance with gastric aspiration and intravenous feeding to allow time for the acute inflammation to resolve.

The benefit of colonoscopy surveillance for colorectal carcinoma in ulcerative colitis and Crohn’s disease remains unclear. The risk is greater if the entire colon is involved, if the history is prolonged (10% after 10 years), if the first attack was severe and if the first attack occurred at a young age. Medical treatment appears to lessen the risk of carcinoma.

**Extraintestinal manifestations of inflammatory bowel disease**

Extraintestinal complications usually respond to treatment of the inflammatory bowel disease. Clubbing is fairly common. Occasionally, uveitis, arthritis and skin rashes (erythema nodosum and pyoderma gangrenosum) occur. Renal stones are more common, and primary sclerosing cholangitis is often associated with inflammatory bowel disease.

**Intestinal cancer in inflammatory bowel disease**

Patients with ulcerative colitis are at increased risk of colorectal cancer. In Crohn’s disease there is an increased risk of both colorectal and small-bowel cancer. The risk of cancer depends on the duration and extent of the disease, and may be reduced by medical treatment to reduce disease activity and surveillance colonoscopy.

**Endocrine tumours of the gut**

All are very rare.

**Apudomas**

Amine precursor uptake and decarboxylation (APUD) cells are the hormone-secreting cells found chiefly along the length of the gastrointestinal tract. They have molecular and functional similarities with each other and may form various kinds of functioning tumour. They secrete a number of hormones including gastrin, cholecystokinin, secretin, glucagon and vasoactive intestinal peptide (VIP).

**Zollinger–Ellison syndrome**

This rare disorder is characterised by multiple recurrent duodenal and jejunal ulceration associated with a very high plasma gastrin level (> 300 mg/l with the patient off H₂-receptor blockade), gross gastric acid hypersecretion and the presence of a gastrin-secreting adenoma (which may be malignant), usually in the pancreas but sometimes in the stomach wall.

Diarhoea sometimes with steatorrhoea may be a feature (lipase is inactivated by the low pH). The volume of gastric secretion is enormous (7–10 l/24 h) and acid secretion persistently raised (and raised little further by pentagastrin). Normal fasting gastrin is < 100 pg/ml. In Zollinger–Ellison syndrome there is a rise in serum gastrin level > 200 pg/ml after infusion of secretin 2 units/kg.

The presence of an adenoma may be associated with adenomas of other endocrine glands, i.e. adrenals, parathyroids and anterior pituitary (p. 226).

Treatment is by removal of the tumour, which is usually benign. If it cannot be found, give either long-term proton-pump inhibitor or H₂-blockade.

**Vipoma**

Vipoma is a variant of the Zollinger–Ellison syndrome with severe watery diarrhoea, hypokalaemia with or without achlorhydria caused by a pancreatic tumour producing a VIP. Abdominal pain and flushing are typical features. Vipomectomy may be curative.

- Benign tumours account for 40% of cases.
- Malignant tumours account for 60% of cases. Two-thirds have metastasised at diagnosis.

**Endocrine tumours of the pancreas**

These are very rare indeed but are sometimes discussed in examinations.

**Insulinoma**

Insulinoma is a tumour of the pancreatic islet β cells which produces episodic hypoglycaemic attacks which may present as epilepsy or abnormal behaviour. Fasting produces prolonged hypoglycaemia with high insulin
levels in the serum. In all, 10% are malignant and 5% are multiple.

**Glucagonoma**

Glucagonoma is a tumour of the α cells which produces a syndrome of mild diabetes with diarrhoea, weight loss, anaemia, glossitis and a migratory necrolytic rash.

**Gastrointestinal haemorrhage**

**Upper gut**

**Aetiology**

**Acute**

Peptic ulcer accounts for 50–70% of non-variceal bleeding (see p. 150 for variceal bleeding). Other causes include gastric erosions, Mallory–Weiss (mucosal oesophageal tears caused by retching) and oesophagitis. Half the patients are over 60 years old. The concurrent use of NSAIDs or aspirin with selective serotonin reuptake inhibitors (SSRIs) greatly increases the risk of upper gastrointestinal bleeding.

Oesophagitis, oesophageal ulcer, gastric ulcer and malignancy are more common in elderly people. Mallory–Weiss syndrome, gastritis and duodenal ulcer are more common in young people. Oesophageal varices, oesophageal ulcer and gastrointestinal malignancy are associated with increased risk of death. Poor prognostic factors include older age, comorbid illness, presentation with syncope, evidence of continued bleeding or rebleeding, low initial haemoglobin and elevated urea, creatinine or serum aminotransferase.

**Clinical presentation**

Haematemesis is a reliable indication of bleeding above the duodenojejunal flexure as is bright-red rectal bleeding of the lower colon or rectum. The colour of altered blood passed per rectum is related to transit time more than to the site of bleeding.

Faintness, weakness, sweating, palpitation and nausea often precede the evidence of bleeding. The patient is pale and sweating and has tachycardia and hypotension.

**Chronic**

Bleeding from hiatus hernia and gastric carcinoma is usually insidious (but not always).

**Management**

Admit to hospital (trivial bleeding can quickly progress to exsanguination), where management should follow local protocol.

Patients should be evaluated immediately and resuscitated if there is evidence of intravascular volume loss:

- Establish venous access. Take blood for grouping and cross-matching, creatinine, urea and electrolytes, liver function tests including the prothrombin time and full blood count with platelets.
- Treat shock if present with transfusion of blood (or colloid if blood is not yet available) and monitor by frequent pulse and blood pressure. If the patient has cardiac disease or is elderly, or if the bleeding is continuous and severe, a central venous pressure monitor can help to guide further transfusion and rebleeding. A central venous pressure of 5–10 cm of saline should be maintained. Oxygen should be given. The urine output should be monitored in shocked patients.

**Variceal bleeding**

**Investigation (for site and cause of bleeding)**

Within 24 h, as soon as the patient’s condition allows, upper gastrointestinal endoscopy should be performed; this shows the site of bleeding in up to 90% of cases. Local diathermy or injection of a sclerosant may arrest bleeding. Selective angiography may show the site of active bleeding if not previously determined, particularly when angiodysplasia must be excluded. If bleeding is sufficiently fast (2 ml/min) a labelled red blood cell isotope scan or selective angiography may help to locate bleeding, e.g. from a Meckel’s diverticulum.

If bleeding continues or recurs, surgery may be necessary (see below). Rebleeding is more likely if the endoscopy shows adherent clot or a visible non-bleeding vessel in an ulcer.

Proton-pump inhibitors reduce mortality, rebleeding and the need for surgical intervention (see Trials Box 12.2). Intravenous bolus followed by continuous infusion of proton-pump inhibitor should be considered in high-risk patients. Patients should be advised not to smoke.

**Indications for surgery (in haemorrhage from peptic ulcer)**

Surgery should be considered in patients who bleed after endoscopic treatment. However, such patients are often elderly and high risk. Surgery is associated
with a mortality of 10–20%, and further attempts at endoscopic treatment should be considered if bleeding recurs. See Trials Box 12.3.

Lower gut
Acute loss may occur from haemorrhoids, fissures, ulcerative colitis and Crohn’s disease, ischaemic colitis, rectal, colonic and caecal carcinoma and diverticular disease. Patients with chronic and occult bleeding usually present with lethargy and iron-deficiency anaemia and diagnosis is confirmed by positive faecal occult blood tests. Any of the causes of upper or lower gut bleeding given above may be responsible. Other very rare causes include polyps and vascular abnormalities, such as arteriovenous malformations, angiodysplasia of the ascending colon, Peutz–Jeghers syndrome (small intestinal polyposis and blotchy pigmentation around the mouth) and Rendu–Osler–Weber (hereditary (autosomal dominant) haemorrhagic telangiectasia in which thin-walled dilatated blood vessels rupture causing gastrointestinal bleeding, epistaxis, haemoptysis or haematuria) syndromes. Meckel’s diverticulum, polyps and endometriosis may also present with bleeding.

Steatorrhoea and malabsorption
Malabsorption signifies impaired ability to absorb one or more of the normally absorbed dietary constituents, including protein, carbohydrates, fats, minerals and vitamins.

Steatorrhoea signifies malabsorption of fat, and is defined as a faecal fat excretion of more than 18 mmol/day (6 g/day) on a normal fat intake (50–100 g). Apart from the occasions when the cause of steatorrhoea is obvious (such as obstructive jaundice), the diagnostic problem revolves around the differentiation between enteropathy (commonly gluten-induced) and other causes of steatorrhoea.

Diarhoea is not necessarily a presenting symptom and malabsorption may present with one or more of the following: weight loss, failure to thrive in infancy, steatorrhoea, wasting and muscle weakness.

TRIALS Box 12.3 Endoscopic retreatment versus surgery
Lau et al. studied 1,169 of 3,473 adults who were admitted to hospital with bleeding peptic ulcers and underwent endoscopy to re-establish haemostasis. Of the 92 patients who suffered recurrent bleeding, 48 were randomly assigned to undergo immediate endoscopic retreatment and 44 were assigned to undergo surgery. In patients with peptic ulcers and recurrent bleeding after initial endoscopic control of bleeding, endoscopic retreatment reduced the need for surgery without increasing the risk of death and was associated with fewer complications than surgery. (New England Journal of Medicine 1999; 341: 455–456.)
Gluten-sensitive enteropathy (coeliac disease)

Aetiology

There is mucosal sensitivity to wheat gluten (in particular gliadin, a polypeptide in gluten) and to barley and rye, and occasionally oats (although not rice or maize). It is associated with human leucocyte antigen (HLA) DQ2 (95% of patients) and DQ8. There is an increased incidence in near-relatives, and an association with variants in the interleukin 18 receptor accessory protein gene on chromosome 2q12.1 has been reported. Anti-tissue transglutaminase and anti-endomysial antibodies have largely replaced anti-gliadin and anti-retiuclin antibodies in diagnosis. The prevalence of coeliac disease is around 1%.

NB Virtually all patients with dermatitis herpetiformis have gluten-sensitive enteropathy.

Clinical presentation

There is usually a history of intermittent or chronic increased bowel frequency, classically with pale, bulky, offensive, frothy, greasy stools that flush only with difficulty. There may be a history of intermittent abdominal colic, flatus and abdominal distension. Depending on the severity and duration of the disease, there may be weakness and weight loss. If the malabsorption started in childhood, the patient may be short compared with unaffected siblings or parents. Children may present with irritability, failure to gain weight or failure to thrive. Occasionally patients do not have gastrointestinal symptoms, but present with anaemia, osteoporosis, abnormal liver function tests or rarely neurological manifestations (ataxia or peripheral neuropathy).

The malabsorption involves not only fat and the fat-soluble vitamins but also minerals and water-soluble vitamins (Table 12.2).

Examination

In addition to the features mentioned above there may be evidence of weight loss or clubbing. Signs of subacute combined degeneration of the cord are very rare.

NB The anaemia has many causes including anorexia, blood loss, mucosal damage, folate deficiency and bacterial overgrowth.

Diagnosis

Diagnosis depends on demonstrating villous atrophy on duodenal biopsy, and can be confirmed by repeat biopsy showing a return to normal after several months of a gluten-free diet.

Table 12.2 Vitamin and mineral deficiency following malabsorption

<table>
<thead>
<tr>
<th>Vitamin/mineral</th>
<th>Deficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin B₁₂</td>
<td>Produces megaloblastic anaemia (p. 324)</td>
</tr>
<tr>
<td>Iron</td>
<td>Produces iron-deficiency anaemia (p. 323)</td>
</tr>
<tr>
<td>Vitamin D and calcium</td>
<td>Results in osteomalacia with bone tenderness and muscle weakness. Tetany may occur Children may develop rickets</td>
</tr>
<tr>
<td>Vitamin B group</td>
<td>Glossitis and angular stomatitis</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>Deficient prothrombin formation produces bruising and epistaxis Associated impairment of amino-acid absorption</td>
</tr>
<tr>
<td></td>
<td>May produce hypoproteinaemia and oedema</td>
</tr>
<tr>
<td>Potassium</td>
<td>May produce muscle pain and weakness</td>
</tr>
<tr>
<td></td>
<td>Abnormalities of cardiac rhythm</td>
</tr>
</tbody>
</table>

NB There may be a predisposition to malignancy – small intestinal lymphomas and oesophageal and small and large intestinal carcinoma – in gluten-induced enteropathy and there is some evidence that gluten-free diets reduce the incidence of these.

Treatment

Lifelong adherence to a gluten-free diet is essential. Treat vitamin and mineral deficiencies. Assess bone mineral density and initiate treatment to prevent osteoporosis if indicated (p. 258).

Other causes of malabsorption

Bile salt deficiency

Patients present with obstructive jaundice usually secondary to carcinoma of the head of the pancreas or to gallstones or, rarely, in primary biliary cirrhosis or bile duct stricture.

Pancreatic enzyme deficiency

This is usually caused by chronic pancreatitis or carcinoma affecting the pancreatic ducts (also, rarely, cystic fibrosis, pancreatic calculi and benign pancreatic cystadenoma). It may be very difficult to differentiate between chronic pancreatitis and carcinoma at presentation.

Tests for malabsorption, glucose tolerance, serum bilirubin and barium meal are of little help.
Imaging

- Straight abdominal X-ray can demonstrate the presence of calcification of the pancreas or of gallstones, which favour chronic pancreatitis.
- Ultrasound, which can be difficult to interpret, shows changes in pancreatic size and shape, and calcification. The biliary tract, neighbouring structures and fluid collections can be shown. Endoscopic ultrasound allows more detailed study.
- CT scan, unlike standard ultrasound, is not affected by bowel gas. It may show gallstones and dilated ducts from partial obstruction at the sphincter of Oddi.
- Magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP) can give information about the biliary tract and help define tumours and cystic lesions.

Investigation

Tests of exocrine pancreatic function

These are rarely used clinically because they are difficult to perform.

Stimulation tests

The duodenum is intubated and duodenal contents aspirated before and after a stimulus (e.g. secretin, cholecystokinin). The fluid is analysed for pancreatic enzymes and bicarbonate.

Bentiromide test

Bentiromide is a synthetic peptide that releases para-aminobenzoic acid (PABA) when cleaved by pancreatic chymotrypsin. PABA is absorbed and excreted in urine. The patient is given bentiromide and urinary PABA measured in a 6-h urine sample. A reduction in PABA excretion indicates pancreatic dysfunction.

Symptoms of pancreatic malabsorption are improved by a low-fat diet (40 g/day), replacing minerals and vitamins, and giving pancreatic supplements (e.g. Nutrizym, Creon, Pancrex V Forte), preferably with H2-blockade. Avoid alcohol.

Other intestinal disease

Post-surgical

Incomplete food mixing may follow gastrectomy or gastroenterostomy and there may be a diminished area for absorption following small bowel resection.

Abnormal intestinal organisms

Bacterial overgrowth can be distinguished from ileal disease using the early (40 min) peak in breath hydrogen after lactulose (10 g) or glucose (50 g).

The normal bacterial count in jejunal juice is $< 10^1$–$10^5$ organisms/ml. The organisms (Escherichia coli and Bacteroides) break down dietary tryptophan to produce indoxylsulphate (indican) which is excreted in the urine. Overgrowth can be detected by urinary indican excretion of more than 80 mg/24 h.

An aetiological role of the cultured organisms in malabsorption is difficult to prove, but the steatorrhoea may respond to antibiotic therapy (e.g. tetracycline or erythromycin). There may be a close association between bacterial overgrowth and stasis from blind loops, diverticula and strictures. It may occur after gastrectomy as a result of reduced acid and pepsin, and in diabetic autonomic nephropathy.

In the radioactive bile acid breath test, 14C glycine-labelled bile salt is given orally, and anaerobic bacteria in the intestine deconjugate the bile acid. The released 14C amino acid is transported to the liver and metabolised to 14CO2 which can be detected in the breath.

Crohn’s disease

See p. 132.

Rare causes

The following are very uncommon but well recognised.

- Disaccharidase deficiency. Malabsorption of lactose, maltose and sucrose may occur in isolation caused by primary enzyme deficiency, or as part of a general malabsorption picture in any disease that damages the intestinal brush border. The most important is isolated lactase deficiency which presents, usually in children, with milk intolerance and malabsorption. Patients have abdominal pain, diarrhoea, distension and borborygmi (i.e. symptoms of bacterial fermentation of unabsorbed sugars) after 50 g lactose by mouth and the blood glucose rises by $< 1.1$ mmol/l over the following 2 h. The diagnosis is confirmed by absence of lactase activity in the jejunal mucosa on biopsy. Management consists of withdrawal of milk and milk products from the diet.

- Other intrinsic disease of the intestinal wall caused by tuberculosis, Hodgkin’s disease, lymphosarcoma, diffuse systemic sclerosis, amyloidosis and Whipple’s disease (intestinal lipodystrophy), associated with the organism Tropheryma whippelli.

- Tropical sprue is a disorder that produces steatorrhoea and occurs almost exclusively in Europeans in or from the tropics, especially in India and the Far East. The aetiology is unknown. The most common associated deficiency is folic acid. The disease frequently remits spontaneously on return from the tropics. In some cases that do not remit, a course of parenteral folic acid, metronidazole or oral tetracycline may be curative.

- Very rarely, malabsorption is associated with diabetes, cardiac failure and giardiasis.
Investigation of malabsorption

In a patient with a characteristic history, the investigation with the greatest likelihood of achieving a diagnosis is jejunal biopsy. However, tests of absorption may quantitate the degree of malabsorption and help with the differential diagnosis between pancreatic and intestinal disease.

Using the hydrogen breath test, after an oral dose of lactose (2 g/kg up to 50 g, in 250 ml water), normal subjects show no rise in breath hydrogen over the following 3 h because they absorb the disaccharide completely. If, because it is not absorbed higher up the gut, the disaccharide reaches the colon, the anaerobic bacteria there ferment it so that hydrogen can be detected in the breath at about 90 min. The hydrogen breath test can also be used to assess small-bowel transit time using lactulose.

NB Intestinal malabsorption tends to give a total malabsorption. Pancreatic malabsorption (p. 137) is much less common and tends to affect the absorption only of fat and proteins and to leave the absorption of sugars, minerals and water-soluble vitamins relatively unaffected.

Blood tests
- Anaemia is common and may be iron-deficient, megaloblastic or both (dimorphic).
- Serum and red cell folate, iron and transferrin may be low.
- Serum albumin may be reduced and the prothrombin time prolonged.
- Serum calcium, phosphate and magnesium may be low and the serum alkaline phosphatase increased (osteomalacia pattern).

Tests of absorption

Faecal fat excretion
The diagnosis of steatorrhoea is made formally by measuring faecal fat excretion over 3–5 days on a normal diet of 50–100 g of fat in 24 h (upper limit of normal 6 g/24 h to 18 mmol/24 h). This is now rarely required and has been replaced by the radioactive triolein breath test. Triolein is a triglyceride that is hydrolysed by pancreatic lipase and absorbed in the small intestine. It releases CO₂ upon metabolism. ¹⁴C-triolein is given to the patient and the amount of exhaled ¹⁴C (as ¹⁴CO₂) is measured. Values less than 3.5% suggest fat malabsorption.

Radiology
A small intestinal barium meal with a flocculable contrast medium may show flocculation and segmentation of barium as evidence of excess mucus secretion. Of more significance are widening of the small intestinal calibre and increased distance between adjacent loops of the bowel, indicating thickening of the intestinal wall. All these changes are non-specific and the main purpose of the barium meal is to detect diverticula, fistulae or Crohn’s disease. MR enteroclysis (p. 133) is an alternative to barium studies.

The bones may show evidence of osteomalacia and/or osteoporosis, and even of hyperparathyroidism (secondary or tertiary) if very severe and prolonged.

Diverticular disease

Diverticula occur anywhere in the alimentary tract but occur chiefly in the colon causing diverticulosis. They are caused by a weakening of the colonic wall and increased intracolonic pressure. They affect chiefly the descending and sigmoid colon. It is a disorder of middle and old age, more common in women than men, and is usually discovered incidentally during barium enema performed to exclude colonic carcinoma.

Clinical features
Inflamed diverticula produce diverticulitis with:
- pain, discomfort and tenderness in the left iliac fossa (there may be a mass from pericolic abscess) – ‘appendicitis of the left side’
- change in bowel habit with constipation and/or diarrhoea sometimes alternating (NB exclude carcinoma)
- rectal bleeding, which may be acute and sometimes massive and the first symptom
- subacute obstruction
- frequency of micturition and cystitis, resulting from vesicocolic fistula
- perforation with peritonitis or fistulae.

Management
Acute diverticulitis may be extremely painful and require rest in bed, analgesia and antibiotics (e.g., ciprofloxacin and metronidazole). Occasionally surgery is required, particularly resection with defunctioning colostomy for obstruction or perforation.

Dietary fibre
Diverticulosis is rare in communities that take a fibre-rich diet, where there is also far less carcinoma of the colon and appendicitis. A diet high in dietary fibre results in bulkier stools and rapid intestinal transit times. Fibre-rich diets also decrease serum cholesterol and increase faecal excretion of bile salts.
Irritable bowel syndrome

Clinical presentation

Irritable bowel syndrome is one of the most common bowel disorders, affecting about 20% of adults in the industrialised world, more often female than male. It is associated with abnormal gut motility. Patients present with different combinations of various characteristic symptoms, e.g., colicky abdominal pain, eased by bowel movement which is often loose with pencil-like stools at the onset of pain, alternating constipation/diarrhoea, bloating and a sense of incomplete evacuation. Examination is usually normal, although there may be tenderness in the left iliac fossa. Patients often have symptoms of anxiety and/or depression.

The cause of the disturbed gastrointestinal function is unknown, but increased sensitivity to distension of the bowel and abnormalities of motility are found in some patients.

Investigation

Diagnosis is usually made from the pattern of symptoms and signs on history and examination, but investigation to exclude more serious disease is often necessary, particularly in patients over 45 years old (where weight loss, rectal bleeding and altered bowel habit may point to carcinoma of the colon).

Treatment (Trials Box 12.4)

A number of therapies may be beneficial, although there is no uniformly successful treatment. Antispasmodics may be tried, e.g., hyoscine (Buscopan) 10–20 mg t.d.s. before meals. If a cause of anxiety (e.g., cancer) can be identified and treated, symptoms may be markedly reduced and psychological therapy may help. 5-HT₃ antagonists (e.g., ondansetron) or antidepressants (tricyclics and SSRIs) can help with abdominal pain and discomfort, urgency and stool frequency in patients with diarrhoea-predominant symptoms (but not those with constipation/bloating). Occasionally, specific foods (cereal, dairy, fructose) may produce symptoms of irritable bowel syndrome, and these should be excluded from the diet. Fibre may help, but makes symptoms worse in some patients.

Ischaemic colitis

Clinical features

This is a disorder of middle and old age that often presents as an acute abdomen with the sudden onset of pain followed by bloody diarrhoea, sometimes copious.

Diagnosis

If subacute, it must be distinguished from the bleeding of diverticular disease and of ulcerative colitis. Any part of the colon can be affected, although, because it has the most precarious blood supply, the splenic flexure is usually involved. If the colon looks normal on sigmoidoscopy, ulcerative colitis is virtually excluded, although large-bowel Crohn’s disease or diverticular disease is not. Imaging shows mucosal oedema with characteristic ‘thumb-printing’, as if a thumb had been pressed along the outside of the affected colon.

Prognosis

In mild cases there may be complete recovery but colonic strictures can develop later. In colonic gangrene, surgical resection is necessary. The differential diagnosis includes Campylobacter enteritis, and diverticular disease, in which bleeding can be considerable. Pseudomembranous colitis does not usually cause bloody diarrhoea.

TRIALS Box 12.4 Treatment of irritable bowel syndrome

Systematic reviews and meta-analyses have shown that fibre, antispasmodics and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome (British Medical Journal 2008; 337: a2313). In addition, antidepressants are effective in treatment. There is less high-quality evidence for routine use of psychological therapies in irritable bowel syndrome, but available data suggest these may be of comparable efficacy (Gut 2009; 58(3): 367–378). Tegaserod (a 5-HT₄ partial agonist) appears to improve the overall symptomatology of irritable bowel syndrome and frequency of bowel movements in those with chronic constipation. (Cochrane Database of Systemic Reviews 2007; (4):CD003960.)
Pancreas

Carcinoma

Most pancreatic cancers are adenocarcinoma. Less common are mucinous cystadenocarcinoma and endocrine, adenosquamous, anaplastic, intraductal papillary mucinous and acinar cell carcinoma.

Clinical presentation

Patients present with one or more of the following features:

- anorexia and weight loss
- indigestion or epigastric pain often indistinguishable from duodenal or gastric ulceration. Back pain suggests pancreatic disease (and posterior ulcers)
- obstructive jaundice. Intermittent jaundice suggests a gallstone in the bile duct (rarely carcinoma of the ampulla of Vater)
- about 20% of patients have diabetes, usually of short duration, and some present with it.

Investigation

Ultrasound or CT scan may show the tumour. ERCP may confirm the diagnosis and allows palliative stenting of the obstructed common bile duct to relieve pruritus and jaundice.

Management

Resection is the only curative treatment, but less than 10% of patients are suitable for surgery. Adjuvant chemotherapy may be of benefit. Five-year survival is 25% in patients undergoing pancreatectomy and less than 5% overall.

Islet cell tumours

See Zollinger–Ellison syndrome and insulinoma (p. 134).

Acute pancreatitis

Aetiology

About 80% of cases are associated with gall bladder disease (especially gallstones) or alcoholism.

Clinical presentation

There may be a previous history of cholecystitis or biliary colic associated with gallstones. Pancreatitis occurs occasionally in association with mumps, drugs (e.g. thiazides) and severe hypertriglyceridaemia.

Abdominal pain, often very severe, occurs suddenly, usually in the epigastrium or across the upper abdomen with radiation to the back or shoulder. It spreads to involve the entire abdomen, which is tender with guarding and rebound tenderness. Hypotension with sweating and cyanosis occurs in severe attacks. There may be bruising around the umbilicus or in the flanks.

Differential diagnosis

It presents initially as an ‘acute abdomen’ and resembles:

- cholecystitis
- acute myocardial infarction
- dissecting aortic aneurysm
- mesenteric vascular occlusion
- intestinal perforation, particularly duodenal ulcer (although shock is not often a feature of a perforated duodenal ulcer).

Investigation

The serum amylase is usually very high (>1,000 units/ml) within 24 h of onset. The level falls rapidly. Posterior duodenal ulcers can also cause very high amylase levels but not usually above 1,000 units. Peritoneal fluid also has high amylase levels.

Straight abdominal X-ray may show gallstones, pancreatic calcification (indicating previous inflammation) and a distended loop of jejunum or transverse colon if they are close to the inflamed pancreas. Serum calcium may fall. There is usually a leucocytosis.

CT is useful in establishing the diagnosis and excluding other pathology.

Management

- If the diagnosis is definite, conservative management is preferred by most clinicians.
- Relieve pain.
- Give intravenous fluids to correct electrolyte imbalance and maintain the circulating volume, while monitoring the central venous pressure.
- Give nutritional support with enteral or parenteral nutrition (see Trials Box 12.5).
- Monitor the blood glucose.
- Renal support with haemodialysis or haemofiltration may be required.
- Monitor oxygen saturation and give oxygen.
- Patients with severe pancreatitis or organ dysfunction should be managed in a high dependency or critical care unit.
- Patients with extensive (>30%) or infected necrosis of the pancreas require surgical or laparoscopic drainage.
Other measures are of less certain value:

- therapeutic ERCP with sphincterotomy in patients with gallstones
- prophylactic antibiotics.

**Prognosis**

Overall mortality is less than 10%. Gallstones should be removed early after recovery. Alcohol should be avoided if it is a possible cause. Pancreatic pseudocysts may resolve spontaneously but can require drainage if they cause symptoms or become infected.

**Chronic pancreatitis**

**Aetiology**

Alcoholism and gallstones are the commonest causes; also pancreatic malformations, hyperparathyroidism, cystic fibrosis and haemachromatosis. Mutations in the PRSS1 gene, encoding cationic trypsinogen, have also been associated with chronic pancreatitis.

**Clinical presentation**

- recurrent, although mild, attacks that resemble acute pancreatitis
- malabsorption and steatorrhoea from pancreatic insufficiency
- anorexia and weight loss
- diabetes mellitus when the islet cells are involved
- obstructive jaundice, which may be intermittent
- in association with cystic fibrosis and haemachromatosis

**Investigation**

The serum amylase is unhelpful in chronic pancreatitis although it is sometimes raised. Imaging (CT or MR) can be helpful but may be normal in early disease and it can be difficult to distinguish between inflammatory and malignant mass at a later stage.

Investigate for malabsorption and exocrine pancreatic function (p. 138), diabetes mellitus (p. 229) and obstructive jaundice (p. 35), if relevant.

**Treatment**

- There is no specific therapy for chronic pancreatitis.
- Treat pancreatic malabsorption with a low-fat diet (45 g/day), fat-soluble vitamins, calcium and pancreatic enzymes (e.g. Pancrex V, Creon).
- Treat diabetes mellitus (p. 229).
- Remove gallstones if present.
- Consider sphincterotomy or pancreatectomy if recurrent attacks.
- Alcohol is forbidden.
- Chronic severe pain is common and may lead to opiate addiction.

---

**Gall bladder**

**Acute cholecystitis**

**Clinical features**

The history is of fever, occasionally with rigors, and abdominal pain, usually right subcostal with acute pain on palpation over the gall bladder region. The disease is more common in obese females over 40, but may occur in young adults. Gallstones are present in over 90% of cases. Occasionally, acute cholecystitis may be difficult to distinguish from a high appendicitis and right basal pneumonia and even perforated peptic ulcer, pancreatitis and myocardial infarction.

**Management**

The acute inflammation usually settles with bed rest, analgesia (pethidine) and antibiotics according to local protocol. The gall bladder is removed and early laparoscopic cholecystectomy is the preferred option in many units.

Rarely, an empyema develops or the gall bladder perforates.

**Chronic cholecystitis**

**Clinical presentation**

Recurrent episodes of cholecystitis are usually associated with gallstones. The attacks are often less severe than classical acute cholecystitis, and may resemble...
peptic ulceration and peptic oesophagitis. Myocardial ischaemia may be confused if the site of the pain is high.

Gallstones

Cholelithiasis is twice as common in women as men. There is an increased incidence in women taking oral contraceptives, 10–15% of the Western population develop gallstones, and the incidence increases with age. Classically gallstones occur in the fat, fertile female over 40 years. They are usually cholesterol or mixed. Rarely, they are pigment stones associated with haemolytic anaemia.

Clinical features

Most stones produce no symptoms, but they may cause:

- flatulence upwards
- biliary colic
- acute cholecystitis
- chronic cholecystitis
- obstructive jaundice, which may be intermittent, giving attacks of fever, jaundice and upper abdominal pain – Charcot’s triad. Gall bladder empyema from bile duct obstruction is uncommon.

Gallstones are associated with acute and chronic pancreatitis and their presence indicates a higher risk of gall bladder carcinoma, although this is still extremely rare.

Investigation

Ultrasonography will reveal most stones. CT or MR provide alternative imaging modalities. Cholecystogram will confirm and reveal the gallstones, but contrast medium will not concentrate in the gall bladder if the bilirubin is above 35 mmol/l and intravenous cholangiography then becomes necessary, although it only shows stones in the biliary tree.

Although surgeons may explore the bile duct at surgery, stones are sometimes missed and may later produce symptoms. Operative cholangiography and/or fibreoptic examination of the bile duct make this less likely.

Management

If causing symptoms, the gall bladder and stones should be removed. It is at this stage that pigment stones are detected and indicate investigation for haemolysis. In elderly patients or if surgery is contraindicated, sphincterotomy via ERCP may release the stones if they are in the common bile duct. Ursodeoxycholic acid may prevent formation of stones and dissolve radiolucent stones if the stones are <2 cm in diameter and if the gall bladder is functioning. The stones may recur after treatment. Asymptomatic stones found incidentally are sometimes removed to prevent complications, particularly in younger patients.
The most common liver diseases are acute viral hepatitis, drug jaundice, gallstones, biliary tract obstruction and carcinomatous secondary deposits.

**Acute hepatitis**

This refers to inflammation of the liver with little or no fibrosis and little or no nodular regeneration. There may be minor distortion of lobular architecture. If there is extensive fibrosis with nodular regeneration (and hence distortion of architecture) the condition is called cirrhosis. These diagnoses are made histologically and there may or may not be clinical evidence of previous hepatic disease.

Inflammation with necrosis of liver cells results from:

- **Infection**, most commonly acute infectious hepatitis A, but also with the viruses of hepatitis B, C and E, infectious mononucleosis, cytomegalovirus (CMV) and yellow fever, and associated with septicaemia and leptospirosis. Amoebic hepatitis is common on a worldwide basis and usually presents as a hepatic abscess or amoeboma.

- **Chemical poisons** and **drugs** are less frequent causes of acute hepatitis. Toxic chemicals include carbon tetrachloride, vinyl chloride, and ethylene glycol and similar solvents (glue sniffing). Toxic drugs include alcohol (ethanol and methanol), halothane (after repeated exposures), isoniazid and rifampicin, paracetamol, methotrexate, chlorpromazine and the monoamine oxidase inhibitors.

- **Pregnancy** (rare).

If the patient recovers this is usually complete, but, rarely, progressive necrosis may affect almost the entire liver (fulminant hepatic failure or acute massive necrosis) causing hepatic coma (p. 149) and death.

**Viral hepatitis**

The clinical features of acute hepatitis A, B, C and E are similar, although they differ in severity, time course and progression to chronic liver disease.

**Hepatitis A**

Hepatitis A (infectious hepatitis) is a single-stranded RNA picornavirus of the enterovirus family which is excreted in the stool towards the end of the incubation period and disappears as the illness develops. Anti-hepatitis A virus immunoglobulin M (IgM) appears at the onset of the illness and indicates recent infection. The disease is endemic but small epidemics may occur in schools or institutions. Spread is usually via the faecal-oral route by food products such as shellfish.

**Clinical presentation**

After an incubation period of 2–6 weeks there is gradual onset of influenza-like illness with fever, malaise, anorexia, nausea, vomiting and upper abdominal discomfort associated with tender enlargement of the liver and, less commonly, the spleen. In smokers, there may be a distaste for cigarettes. After 3–4 days the urine becomes characteristically dark and the stools pale – evidence of cholestasis. Symptoms usually become less severe as jaundice appears, although pruritus may develop. Jaundice and symptoms tend to improve after 1–2 weeks and recovery is usually complete, although mild symptoms continue for 3–4 months in a few patients. Recurrent hepatitis A is extremely rare and immunity probably lifelong.
**Diagnosis**

Diagnosis depends on detecting anti-hepatitis A virus IgM in serum.

**Differential diagnosis**

- Obstructive jaundice, either in the early cholestatic phase or in the rare case where cholestatic jaundice persists after other clinical and biochemical evidence of liver cell damage has settled. It is dangerous to diagnose infective hepatitis in patients over 40 years old – a safeguard against misdiagnosing major bile duct obstruction.
- Drug jaundice (p. 152).
- Glandular fever.
- Yellow fever (travellers).
- Acute alcoholic hepatitis may present with enlargement and tenderness of the liver and, sometimes, obstructive jaundice. There are usually other signs of alcoholism.
- Wilson’s disease must not be overlooked (pp. 152 and 205).

**Management**

If hospitalised, the patient should be isolated. Virus is present in stools for 1–2 weeks before the onset of jaundice and for 1 week after. Symptomatic treatment only is required in the active disease state. No dietary restriction, other than alcohol, is necessary. Liver function tests usually return completely to normal in 1–3 months.

Recovery is the rule in virtually every case. Occasionally jaundice may be prolonged by intrahepatic cholestasis, and corticosteroids can be used to reduce the jaundice rapidly, particularly if associated with pruritus.

Fulminant hepatic failure is rare but has a mortality of about 50%. Management should be in a specialised centre where liver transplantation can be considered.

**Prophylaxis**

Active immunisation with inactivated virus is recommended for travellers to endemic areas.

Passive immunisation with pooled human immunoglobulin gives partial, short-lived immunity, but is effective immediately after the injection.

**Hepatitis B (Fig. 13.1)**

Hepatitis B is a double-stranded DNA hepadnavirus. It is spread by infected blood and serum and also occurs in saliva, semen and vaginal secretions. It is most frequently transmitted by sexual activity, shared needles used by drug addicts, and from mother to child. Health workers and other at-risk groups are now screened and offered vaccination.

![Figure 13.1 The hepatitis B virion.](image-url)
Hepatitis B virus causes acute liver disease that ranges from subclinical to fulminant hepatitis, and chronic diseases including chronic hepatitis, cirrhosis and hepatocellular carcinoma.

Clinical features
After a long incubation period of 6 weeks to 6 months, there is typically a gradual onset of lethargy, anorexia, abdominal discomfort, jaundice and hepatomegaly. It is often asymptomatic in infants. Occasionally immune-mediated extrahepatic manifestations occur with polyarthritis, skin rashes and glomerulonephritis. Cholestatic hepatitis is rare. Mutated viral strains may be associated with fulminant hepatic failure.

Diagnosis
Hepatitis B virus has three different antigens: a surface antigen (HepBsAg), a core antigen (HepBcAg) and an internal component (HepBeAg). HepBsAg appears in the blood about 6 weeks after acute infection and has usually gone by 3 months. HepBeAg occurs at a similar time and denotes high infectivity. HepBcAg is usually found only in the liver. The development of antibodies to HepBsAg usually follows acute infection and indicates immunity. In about 5% of cases antibodies do not appear and HepBsAg persists in the blood (carrier state).

Hepatitis D virus (Delta virus) is an incomplete RNA virus that depends on the hepatitis B virus to replicate. It can cause an aggressive chronic hepatitis in HepBsAg-positive patients. Chronic infection is usually associated with progressive liver disease.

Management
Isolate if hospitalised. In the majority of cases spontaneous recovery occurs and treatment is supportive, as for hepatitis A. Of the estimated 50 million new cases of hepatitis B diagnosed worldwide 75% occur in Asia, and 5–10% of adults and up to 90% of children become chronically infected. Prevalence in the UK is < 2%. The carrier state is usually asymptomatic but is associated with chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma. Antiviral agents include interferon-α2b, pegylated interferon-α2a, the nucleoside analogue lamivudine and telbivudine, and the nucleotide analogues adefovir and entecavir. Hepatitis B viral DNA becomes undetectable in up to 75% of patients treated for 1 year with nucleoside analogues, but recurrence of viral DNA after treatment withdrawal is common and viral resistance occurs with prolonged use. Pegylated interferon-α2a is more expensive but 1-year seroconversion rates of 30% have been reported.

Immunisation
Immunisation using recombinant HepBsAg is advised for occupational high-risk groups, including health workers, patients with chronic renal failure, intravenous drug abusers, individuals who change sexual partners frequently, patients who receive regular blood products, and family contacts of a case or carrier. Immunisation takes up to 6 months to confer immunity, and booster is recommended after 5 years.

Hepatitis C
Hepatitis C is a single-stranded RNA flavivirus. It predominantly affects intravenous drug abusers and patients who have received multiple blood transfusions. It accounts for 20% of acute hepatitis, 70% of chronic hepatitis, nearly half the cases of end-stage cirrhosis, 60% of primary liver cancer and 30% of liver transplants in the UK.

Clinical features
Frequently asymptomatic – fewer than 10% of adults become jaundiced. Acute hepatitis following blood transfusion has been virtually eradicated by the introduction of testing of blood products for hepatitis B and C. The incubation period varies from 2 to 26 weeks. Sixty to eighty percent of those acutely infected develop chronic infection, which leads to cirrhosis in around 25% of patients over a 20- to 30-year period. Hepatocellular carcinoma has an annual incidence of around 3% in those with cirrhosis.

Diagnosis
Diagnosis is usually by antibody detection. First-generation enzyme-linked immunosorbent assay (ELISA) using recombinant antigen C100 is relatively non-specific. Newer assays using putative core antigens are more specific, although false positives still occur. The mean time from infection to antibody detection is 12 weeks. Hepatitis C virus RNA determination by PCR (polymerase chain reaction) is used to monitor hepatitis C infection.

Management
Progression to chronic active hepatitis and cirrhosis is much more common in hepatitis C than hepatitis B infection. Combination therapy with pegylated interferon-α and the nucleotide analogue ribavirin achieves a sustained virological response in 40–50% of individuals infected with hepatitis C genotype 1, which is prevalent in Western countries.

Hepatitis E
Hepatitis E virus is an RNA hepevirus that is endemic in the developing world. Transmission is faecal–oral.
Clinical features

Infection is usually self-limiting, and it does not have a carrier state, but can cause fulminant hepatic failure in pregnant women, with mortality rates of around 20%.

Hepatitis G

Hepatitis G is a positive-stranded RNA flavivirus. There is no evidence at present that it causes acute or chronic liver disease.

Autoimmune hepatitis

Autoimmune hepatitis is characterised by hepatocellular inflammation and necrosis, which tends to progress to cirrhosis. It may be triggered by acute viral hepatitis and can coexist with chronic viral hepatitis. It has been classified into two types based on the presence of autoantibodies:

Type I autoimmune hepatitis is the commonest type, with a female: male ratio of 8:1. It is characterised by the presence of anti-nuclear antibody (50–70%) or anti-smooth muscle cell antibody (50–80%). Anti-mitochondrial antibodies are present in 20% of cases. IgG concentrations and serum aminotransferases are elevated. Liver histology reveals plasma cell infiltrates, liver cell rosettes and piecemeal necrosis. It is associated with HLA B8, DR3 and DR4.

Type II autoimmune hepatitis typically affects girls aged 2–14 years, although 20–30% of cases occur in adults. Onset is often acute, with rapid progression to liver failure. It is characterised by the presence of anti-liver kidney microsome antibodies or anti-liver cytosol type 1 antibodies in the absence of antinuclear or antismooth muscle cell antibodies. It is associated with HLA B14, DR3 and the complement allele C4AQO.

Management

Immunosuppressive therapy improves survival in the majority of cases. Eighty percent of patients respond to steroids, alone or in combination with azathioprine. In patients who fail to respond, orthotopic liver transplantation is the treatment of choice.

Alcoholic hepatitis

Moderate alcohol consumption is associated with a reduction in mortality compared with either abstinence or heavy drinking (Trials Box 13.1). Drinking in excess of 3 units of alcohol daily may increase mortality, but sensitivity to alcohol varies between individuals (8 g = 1 unit of ethanol = present in a single (25-ml) measure of spirits; a small (125-ml) glass of 12% wine contains 1.5 units). The clinical features of alcoholic liver disease vary from no clinical evidence at all, through nausea, episodes of right abdominal pain associated with tender hepatomegaly, fever and polymorphic leukocytosis, to cirrhosis with portal hypertension and fulminant hepatic failure. Marked jaundice is not always present.

The pathological spectrum includes fatty liver, alcoholic hepatitis, cirrhosis and hepatocellular

---

**TRIALS BOX 13.1 Alcohol consumption and mortality**

Doll et al. studied mortality prospectively in 12,321 male doctors with various drinking patterns. Moderate alcohol consumption (1 or 2 units/day) was associated with lower all-cause mortality than consumption of no or substantial amounts. Alcohol consumption reduced ischaemic heart disease, irrespective of amount. (British Medical Journal 1994; 309: 911–918.)

Fuchs et al. followed 85,709 women aged 34–59 prospectively over a 12-year period. Light-to-moderate alcohol consumption (1.5–3.0 g/day) was associated with a reduced mortality rate, principally because of a decreased risk of death from cardiovascular disease. Heavier drinking was associated with an increased risk of death from other causes, particularly breast cancer and cirrhosis. (New England Journal of Medicine 1995; 332: 1245–1250.)

Grønbæk et al. examined the relationship between intake of different types of alcohol and death using pooled cohort studies of 13,064 men and 11,459 women aged 20–98. J-shaped relations were found between total alcohol intake and mortality at various levels of wine intake. They found that wine intake may have a beneficial effect on all-cause mortality that is additive to that of alcohol. This effect may be attributable to a reduction in death from both coronary heart disease and cancer. (Annals of Internal Medicine 2000; 133: 411–419.)
carcinoma. Alcoholic hepatitis is characterised by liver cell damage, inflammatory cell infiltration and fibrosis. Injured hepatocytes are swollen, with pale granular cytoplasm (‘ballooning degeneration’). In some cells Mallory’s bodies are seen by haematoxylin and eosin stain as purple-red aggregates of material, predominantly around the nucleus. The γ-glutamyltransferase, which reflects levels of microsomal enzyme induction, and the mean corpuscular volume may be the best indices of persistent ethanol ingestion.

The only effective treatment is total abstinence from alcohol, if necessary with the help of support services. Nutritional deficiencies are common. Vitamin B preparations and dietary supplementation are usually given.

### Chronic liver disease

Chronic hepatitis and cirrhosis are pathological diagnoses and therefore imply liver biopsy in suspected cases.

### Chronic hepatitis

Classification is usually based on a description of the aetiology (commonly viral hepatitis B or C; drug-induced (e.g. isoniazid, methyldopa); α1-antitrypsin deficiency; Wilson’s disease, haemachromatosis, chronic severe heart failure), the grade of necrosis and inflammation in portal or periportal and lobular regions, and the stage of fibrosis or cirrhosis.

### Cirrhosis

Cirrhosis is characterised by widespread fibrosis with nodular regeneration. Its presence implies previous or continuing hepatic cell damage. Liver function tests are normal in inactive disease (p. 35). Cirrhosis can be classified as compensated or decompensated, depending on the absence or presence of ascites, variceal haemorrhage, encephalopathy or jaundice.

### Classification of cirrhosis

Micronodular (portal cirrhosis) is characterised by regular thick fibrotic bands joining the portal tracts to hepatic veins and by small regenerative nodules. The liver is initially large with a smooth edge but subsequently shrinks with progressive fibrosis. It is often alcoholic in origin.

Macronodular (post-necrotic cirrhosis) is less common and characterised by coarse, irregular bands of fibrosis and loss of normal architecture and large regenerative nodules. It is believed usually to follow viral hepatitis with widespread necrosis. The liver is enlarged and very irregular as a result of large nodules.

Biliary cirrhosis is less common and is characterised by fibrosis around distended intrahepatic ducts. It may follow chronic cholangitis and biliary obstruction, or be idiopathic (primary).

### Primary biliary cirrhosis

There is progressive damage to intrahepatic bile ducts. Anti-mitochondrial antibodies are present in 95% of patients and this helps with the differential diagnosis from drug cholestasis, sclerosing cholangitis, carcinoma of the bile duct and biliary cirrhosis from chronic obstruction. It chiefly (90%) affects women between 40 and 60 years of age and presents with features of cholestasis, namely pruritus, jaundice with pale stools, dark urine and steatorrhoea, pigmentation and xanthelasma.

Osteodystrophy results from a combination of osteomalacia secondary to impaired vitamin D absorption and osteoporosis. The liver and spleen are usually palpable.

### Histology

Histology shows progression from granulomatous changes around the bile ducts through bile duct proliferation to fibrosis and finally cirrhosis.

### Management

The anion exchange resin cholestyramine which binds bile acids in the gut relieves pruritus. Supplementary fat-soluble vitamins are given. Osteoporosis is common, and bisphosphonates prevent bone loss, although their effect on fracture rate is unclear. The bile acid ursodeoxycholic acid slows disease progression, leading to an improvement in both liver biochemistry and long-term survival. Immunosuppressive agents are of no proven benefit. In patients with decompensated liver disease, liver transplantation should be considered. Five-year survival rates of 80% post liver transplant have been reported.

### Primary sclerosing cholangitis

There is progressive inflammation and fibrosis of intra- and extrahepatic ducts. The condition is diagnosed by endoscopic retrograde cholangiography or MRI. Inflammatory bowel disease coexists in 70% of cases. The radiological picture may be mimicked by bacterial and parasitic cholangitis, polycystic liver...
disease and cholangiocarcinoma, which is a recognised complication.

**Management**

Immunosuppression increases the risk of secondary bacterial cholangitis, although this may be required for coexistent inflammatory bowel disease. Endoscopic stenting of strictures carries the same risk. Liver transplantation is the only therapeutic option for advanced disease.

**Other causes of cirrhosis**

Other rare causes of cirrhosis include autoimmune hepatitis, haemochromatosis and Wilson’s disease. Cardiac cirrhosis may occur in chronic cardiac failure. Centrilobular congestion leads to necrosis and fibrosis, but nodular regeneration is not marked.

NB Schistosomiasis causes periportal fibrosis and is not a form of cirrhosis. Liver involvement is more common in *Schistosoma mansoni* (bowel) infections than in *S. haematobium* (bladder) as a result of the portal rather than the systemic drainage of the primary infected area in the former. The schistosomes cause a granulomatous fibrosis in the portal tracts and enlargement of the liver. In severe cases the liver shrinks and extensive fibrosis develops, leading to portal hypertension. There is little or no hepatocellular failure because the disease is presinusoidal. Late spread may occur to the lungs (cor pulmonale) and to the spinal cord (paraplegia).

**Clinical features**

Clinical features of chronic liver disease relate mostly to the development of hepatocellular failure and complications of portal hypertension.

**Hepatocellular failure**

Marked jaundice is uncommon. The oestrogen effects of gynaecomastia, spider naevi, liver palms and testicular atrophy may be present. In alcoholics, other features of alcoholism may be present (wasting, polyneuropathy, Korsakoff’s psychosis, dementia, delirium tremens and Wernicke’s encephalopathy, p. 186). Pigmentation, fetor hepaticus, clubbing, white nails, cyanosis and peripheral oedema may occur.

Encephalopathy (hepatic coma or precoma) may be absent or may completely dominate the picture. Precoma is characterised by irritability, confusion, drowsiness, flapping tremor, fetor and other signs of hepatocellular failure. Exaggerated reflexes and upgoing plantar responses may be present. Constructional apraxia may be demonstrated in inability to draw or copy a star.

**Acute liver failure**

There are two main clinical situations in which hepatocellular failure may be precipitated and in which there are different management objectives:

1. A previously healthy person with a serious hepatitic illness, such as paracetamol overdose or viral (C, B, A in that order) hepatitis. This can also occur with other drugs and with chemical poisoning. This is less common. The history is usually less than 8 weeks and there is no evidence of chronic liver disease. The object is to support the patient to give time for the liver to recover.

2. A person with previously ‘compensated’ chronic liver disease, often alcoholic, with an acute precipitating cause:
   - excess protein in the bowel, e.g. after gastrointestinal haemorrhage
   - acute alcoholic intoxication
   - intercurrent infection, particularly Gram-negative septicaemia
   - drugs, especially sedatives, and morphine or other alkaloids
   - trauma, including minor or major surgical procedures and paracentesis
   - electrolyte imbalance (potassium and/or sodium depletion), usually from the diuretics used to treat oedema and ascites.

The underlying damage to the liver is not treatable. Fulminant hepatic failure refers to hepatic encephalopathy occurring within weeks of the onset of other symptoms of acute liver failure. Profound hypotension and multiple organ failure are common. Cerebral oedema and sepsis are the most common causes of death.

**Management**

Preferably, this should be in a specialist unit.

- **Assess the conscious level.** Grade as follows (this is also a guide to prognosis):
  
  - **Grade 1** – drowsy, poor concentration
  - **Grade 2** – confused and disorientated
  - **Grade 3** – very drowsy, responding only to forceful, simple command, often aggressive and incoherent
  - **Grade 4** – unrousable, responding either only to painful stimuli (4a) or to none (4b).

  NB In alcoholic liver disease, conscious level may also be affected by delirium tremens, thiamine (and other B vitamins) deficiency, epilepsy and acute alcohol intoxication. Monitor intracranial
pressure and consider hourly mannitol (100 ml of 20%) until there is a diuresis.

- **Establish venous access** and consider nasogastric tube and central line.
- **Identify any site of bleeding** by fibroscopy and treat as appropriate: gastric or duodenal ulceration (p. 135); variceal bleeding (see below).
- **Correct and maintain fluid and electrolyte balance**. Sodium restriction may be required despite hyponatraemia, which may be dilutional. Hypokalaemia is treated with standard oral potassium preparations. Diuretics (spironolactone followed, if necessary, by loop diuretics) are given for ascites (p. 151). The blood glucose may be very low and should be maintained with dextrose infusions (up to 300 g/day).
- **Infection is common** so use prophylactic broad-spectrum antibiotics and antifungal treatment. Take blood cultures and send ascitic fluid for bacteriological examination, including tuberculosis. In patients with septicaemia, half have Gram-negative infection and half staphylococcal. Treat the infection immediately and then modify the antibiotic therapy as indicated by microbiological results, remembering that altered liver function may influence drug choice and dosage.
- **Minimise the protein load**. Identify any site of bleeding (see above). In those not bleeding, reduce the risk of gastrointestinal bleeding with H₂-blockers. Lactulose 50 ml t.d.s. produces osmotic diarrhoea to remove protein and blood (if present) from the bowel and prevents proliferation of ammonia-producing organisms. Selective intestinal decontamination by the administration of non-absorbable antibiotics (e.g. rifaximin) may eliminate ammonia-producing colonic bacteria. MgSO₄ enema, 80 ml of 50%, 12-hourly may be added.
- **Correction of coagulation defects** is not usually needed in the absence of clinically significant bleeding. Use fresh frozen plasma or blood and platelet infusion if the platelet count is low. Add vitamin K, 10 mg intravenously, in case there is any cholestatic element.
- **Inotropic support** may be indicated.
- **Support respiration**. Early elective ventilation may be needed to maintain PaO₂₂.
- **Renal failure** may require dialysis or haemofiltration.
- **Give B vitamins** parenterally. Thiamine deficiency is common in alcoholics.
- **Assess for liver transplantation**.

**NB** A reduced level of consciousness in hepatocellular failure may be caused by septicaemia, hypoglycaemia, raised intracranial pressure from cerebral oedema, subdural haematoma or epilepsy. Administration of N-acetylcysteine may be of benefit in acute liver failure caused by paracetamol overdose (p. 359) and other causes.

**Portal hypertension**

Portal hypertension is usually associated with cirrhosis. Other post-sinusoidal causes (which have poor hepatic function) are exceedingly rare and result from cardiac failure, constrictive pericarditis and hepatic vein thrombosis (Budd–Chiari syndrome, p. 151). Pre-sinusoidal obstruction causes portal hypertension with normal hepatic function in schistosomiasis (granulomatous portal tract fibrosis) and in obstruction to the portal vein by tumours or following venous thrombosis with umbilical sepsis.

Collateral circulation may be evident in the oesophagus (varices), anus (anorectal varices rather than haemorrhoids) and at the umbilicus where a venous hum may be heard. Tests of liver cell function are usually slightly abnormal, though not always so, and there may be hypersplenism.

Haematemesis is the commonest presenting symptom and may be precipitated by NSAIDs, including aspirin. Bleeding is often from peptic ulceration or erosions in the alcoholic, and H₂-blockade or proton-pump inhibitors are then useful.

Non-selective β-blockers are not effective in preventing the development of varices in patients with cirrhosis and portal hypertension and are associated with increased side effects.

**Management of bleeding varices**

The initial aim is to replace blood and correct coagulation defects. Short-term antibiotics to reduce bacterial infection reduces variceal rebleeding and death. Specific treatment with a combination of pharmacological and endoscopic therapy is better than either treatment alone.

- Endoscopic variceal ligation is safer and more effective than sclerotherapy.
- Vasopressin, octreotide, somatostatin and terlipressin reduce splanchnic blood flow and can be started prior to more definitive treatment.
- Non-selective β-blockers reduce portal pressure and are effective in preventing first bleed from varices, and as secondary prophylaxis after variceal bleeding.
- Surgical oesophageal transection or transjugular portosystemic shunting can be considered in patients with recurrent or intractable variceal bleeding.

**Management of ascites**

Ascites can be due to a combination of factors, including portal hypertension, hypoalbuminaemia and secondary hyperaldosteronism. Management involves:
sodium restriction
- diuretics – aldosterone antagonists (e.g. spironolactone), alone or in combination with loop diuretics in patients with marked sodium retention
- paracentesis is safe and effective, although expansion of plasma volume with albumin may be required if large quantities of ascitic fluid are removed
- peritoneo-venous shunting or ultrafiltration and reinfusion of ascitic fluid are rarely employed in the setting of refractory ascites.

Spontaneous infection of ascites is common in cirrhotic patients. Most episodes respond to intravenous cephalosporins or oral quinolones (e.g. ciprofloxacin), but the overall prognosis is poor.

Budd–Chiari syndrome
This results from obstruction of the hepatic veins. Causes are:
- hepatic venous thrombosis, usually in association with a hypercoagulable state such as the anti-phospholipid syndrome
- occlusion of the hepatic veins by tumour, abscess or cyst
- webs of the suprahepatic segment of the inferior vena cava (IVC).

Patients present acutely with tender hepatomegaly (without hepatojugular reflux), resistant ascites and hepatic failure. Chronic onset is associated with weight loss, upper gut bleeding and spider naevi. All patients have abnormal liver function tests, but the pattern is variable and similar to other chronic liver diseases. Only half have the diagnostic liver scintiscan finding of maximum uptake in the caudate lobe (which drains directly into the IVC) with decreased uptake in the rest of the liver. Liver biopsy shows congestion around the hepatic venules. Laparotomy may produce abrupt deterioration. Treatment is surgical by side-to-side portocaval shunting or orthotopic liver transplantation. If there is a web, surgical correction may be attempted by transatrial membranectomy.

Rare cirrhoses
Idiopathic haemochromatosis
(bronzed diabetes)
Idiopathic haemochromatosis is an autosomal recessive disorder of iron metabolism characterised by increased iron absorption and deposition, chiefly in the liver, pancreas, heart, synovial membranes and pituitary. HFE, the gene for hereditary haemochromatosis, has been mapped to chromosome 6 (6p21.3). The HFE protein is expressed in crypt enterocytes of the duodenum where it is thought to modulate the uptake of transferrin-bound iron from plasma.

First-degree relatives should be screened with serum iron and transferrin saturation. Females may present post-menopausally because continuous menstruation until then reduces the iron load.

Clinical presentation
It usually occurs in men over the age of 30 years who present with:
- diabetes mellitus
- skin pigmentation (caused by melanin rather than iron)
- hepatomegaly (large, regular, firm); portal hypertension and hepatocellular failure are not common
- progressive pyrophosphate polyarthropathy and chondrocalcinosis
- arrhythmias and cardiac failure
- testicular atrophy, loss of body hair and loss of libido
- osteoarthritis of the first and second metacarpophalangeal joints.

Diagnosis
The serum iron is raised so that the serum iron-binding capacity is nearly saturated. The serum ferritin is also raised. The patient is not anaemic or polycythaemic. The glucose tolerance test is usually abnormal.

Biopsy of most tissues (skin, marrow, testes) shows excess iron deposits, but diagnosis is often made on liver biopsy, which shows iron staining of the liver with perilobular fibrosis.

Treatment
Deplete the body of the excess iron (up to 50 g) by weekly venesection of 500 ml (which contains 250 mg of iron). This is continued until a normal serum iron is established and/or the patient becomes anaemic (in about 2 years). Maintenance venesection will be required (about 500 ml every 3 months, depending on the serum iron).

Treat appropriately the diabetes, hypogonadism, heart failure and arrhythmias, hepatic cell failure and portal hypertension. High alcohol intake must be stopped. The arthropathy and testicular function do not improve but other features do.

NB Primary hepatic carcinoma occurs in up to 20% of cases, whether treated or not. Alphafoetoprotein is a suitable screen.
Overload of the tissues with iron can follow either repeated blood transfusions (about 100 units), as for instance in thalassaemia, or, rarely, after excessive iron ingestion. If the iron is in the reticuloendothelial cells only, the patients tend not to develop serious sequelae and the condition is called haemosiderosis.

**Hepatolenticular degeneration**  
*(Wilson's disease, p. 205)*

Wilson’s disease is an autosomal recessive disorder of copper transport, resulting in copper accumulation and toxicity to the liver and brain, caused by mutations in a putative adenosine triphosphatase (ATPase) gene, with six putative metal binding regions similar to those found in prokaryotic heavy metal transporters. Neurological manifestations (p. 205) and signs of cirrhosis appear during adolescence or early adult life. Low ceruloplasmin is found in the serum. The Kayser–Fleischer ring is a deep copper-coloured ring at the periphery of the cornea, which is thought to represent copper deposits. Hypercalciuria and nephrocalcinosis are not uncommon in patients with Wilson’s disease.

**Drug jaundice**

Drugs are responsible for up to 10% of all patients admitted with jaundice.

**Hypersensitivity reactions**

These are the most common cause of drug jaundice. They are dose-independent.

**Cholestasis**

Clinically and biochemically this is an obstructive jaundice. Histologically, there are bile plugs in the canaliculi and there may be an inflammatory infiltrate of eosinophils in the portal tracts.

The classical example is chlorpromazine jaundice, which occurs 3–6 weeks after starting the drug. The prognosis is excellent if the drug is discontinued (and never given again).

Other drugs producing cholestasis are other phenothiazines, carbimazole, erythromycin estolate (but not the stearate), sulphonylureas, sulphonamides, rifampicin and nitrofurantoin. Occasionally there may be a more generalised reaction with fever, rash, lymphadenopathy and eosinophilia.

**Acute hepatitis**

Drugs occasionally cause acute necrosis. This is much less common but much more serious (mortality up to 20%). It occurs 2–3 weeks after starting the drug and can be caused by halothane (after multiple exposure), monoamine oxidase inhibitors, methyldopa (which more commonly gives haemolytic jaundice) and the antituberculous drugs ethionamide and pyrazinamide (p. 349).

**Direct hepatotoxicity**

In some cases hepatotoxicity is dose-dependent, although individual susceptibility is extremely variable. The mechanisms are:

- cholestasis (without inflammatory infiltrate or necrosis). Chiefly as a result of C17-substituted testosterone derivatives, i.e. anabolic and androgenic steroids, including methyltestosterone and most contraceptive pills
- necrosis resulting from organic solvents, e.g. methotrexate, 6-mercaptopurine, azathioprine.

**Haemolytic jaundice**

This is a rare complication of therapy. It may occur with methyldopa (which more commonly gives a positive Coombs’ reaction without jaundice) and the 8-aminoquinolines (e.g. primaquine) in patients with glucose-6-phosphate dehydrogenase deficiency.
Renal disease

Disease of the renal tract presents in only a few ways. Urinary tract infection is the most common, especially in females. In males it is prostatic hypertrophy and its consequences. Proteinuria, haematuria and disorders of excretory function often cause no symptoms if mild, being picked up during routine screening (e.g. insurance medical).

**Urinary tract infection**

There are two main clinical syndromes:

1. **Cystitis**, characterised by suprapubic tenderness, dysuria and frequency. NB These symptoms can occur without urinary infection. Other causes include non-specific urethritis, gonococcus, interstitial cystitis, drug-induced cystitis (e.g. cyclophosphamide), bladder stones and tumours, and vaginitis (infections or senile).

2. **Acute pyelonephritis** presents with dysuria, frequency, loin tenderness and fever, often with rigors and vomiting. Fever may be the only feature in children, in whom recurrent infection may be associated with vesicoureteric reflux that tends to diminish with age.

Bacteriuria is confirmed by finding a urinary excretion of more than 100,000 organisms/ml urine (counts of <10,000/ml are usually caused by contamination). Infection may be symptom-free. *Escherichia coli* is the most frequent organism (70–80% of cases). Other organisms (*Proteus, Staphylococcus, Streptococcus, Klebsiella and Pseudomonas*) are usually associated with structural abnormality or catheterisation, and reinfection. Tuberculosis classically causes a sterile pyuria. Pyuria can almost always be detected by careful microscopic examination of fresh unspun urine. Microscopic haematuria is common.

**Management**

Uncomplicated cases are treated with oral antibiotics such as trimethoprim and ampicillin (3-day course for cystitis, at least 7 days for pyelonephritis) after obtaining urine for culture and antibiotic sensitivity. Resistant organisms may be sensitive to co-amoxiclav (Augmentin) or ciprofloxacin. Patients with acute pyelonephritis who are vomiting or have evidence of septicaemia (blood cultures are positive in 20% of cases) require intravenous antibiotics.

There may be an obvious predisposing cause, e.g. pregnancy, urinary obstruction or catheterisation. Diabetes mellitus must be excluded. Acute pyelonephritis or more than two episodes of cystitis in a woman, or any infection in a man, suggest a structural abnormality. Ultrasound of the renal tract is performed to look for perinephric abscess, renal scarring, stone, tumours or obstruction. CT scanning or intravenous urography (IVU) and possibly cystoscopy may be necessary (frequent infections, persistent haematuria, dysuria or loin pain) to exclude small stones/tumours or bladder diverticula.

Women prone to recurrent infections should be given advice about complete emptying of the bladder (double micturition) and voiding soon after intercourse. Low-dose antibiotic prophylaxis (e.g. trimethoprim or cephalaxin) reduces the incidence of infection and can be used safely for long periods.

Children require investigation as infection in the presence of vesicoureteric reflux can lead to permanent kidney damage.

**Imaging the kidneys**

A plain abdominal film usually shows the renal outlines and identifies any calcification in the renal tract. Renal ultrasound is useful in determining renal size and contour, and defining the size, location and consistency (solid or cystic) of any renal mass, and looking for pelvicalyceal dilatation of obstruction.
IVU has the advantage of demonstrating the whole urinary tract, but its usefulness has been replaced in many cases by ultrasound, computed tomographic (CT) scanning and radionuclide scanning. Ultrasound and CT are particularly useful for anatomical studies, and radionuclide scanning for providing functional information. IVU should not be performed if there is a history of sensitivity to contrast media. Dehydration prior to the examination should be avoided in renal failure, diabetes or myeloma.

Isotope scanning (most commonly $^{99m}$Tc-diethylene triaminepentaacetic acid (DTPA) or $^{99m}$Tc-dimercaptosuccinate (DMSA)) can be used to assess renal blood flow, renal function and transit time of filtrate across the parenchyma into the collecting system. It can be useful in the diagnosis of renal artery stenosis and obstruction. In addition, the renal parenchyma can be visualised for evidence of scarring.

### Stones

Eighty percent of urinary tract stones contain calcium, usually as calcium oxalate. Less common constituents are uric acid (10%) or cystine. Staghorn calculi contain struvite, made up of calcium, ammonium and phosphate. Classical features are severe loin pain, with microscopic or macroscopic haematuria.

#### Clinical features

The most common presentation is with severe loin pain radiating to the groin (renal colic), with microscopic or macroscopic haematuria. About 1 in 1000 men and 1 in 3000 women present with their first kidney stone in a single year. Fifteen percent of patients develop recurrent stones within a year of first presentation, 30% by 5 years.

Recurrent stones should be investigated for a metabolic cause:

- hypercalciuria – 50% of stone-formers have increased urinary calcium excretion
- elevated serum calcium – usually caused by hyperparathyroidism in stone-formers
- hyperuricaemia
- cystinuria.

#### Management

The diagnosis is confirmed by imaging. Abdominal X-ray may detect calcium-containing stones. Ultrasound usually identifies stones and will detect dilatation of the renal pelvis or ureter, indicating obstruction. IVU or CT scanning provide the most sensitive methods of detecting stones. Most small stones (< 4 mm) will pass spontaneously, but those > 6 mm are rarely passed. In such cases stones are cleared by extracorporeal shock wave lithotripsy, endoscopic removal, either percutaneously or through cystoscopy with retrograde urethroscopy, or open surgical procedure.

### Measures to prevent stone formation

- Increased fluid intake – at least 2 l/day.
- Diet – increased risk of stone formation is associated with low rather than high calcium diet, and with diets high in sodium and protein.
- Thiazide diuretics reduce urinary calcium in hypercalciuria.
- Allopurinol reduces urinary uric acid excretion.
- Penicillamine and captopril form a complex with cystine, which renders it more soluble, and can be used to prevent or dissolve stones.
- Alkalisation of urine increases solubility of uric acid and cystine and may be of value in preventing uric acid or cystine stone formation by increasing solubility of these compounds.

### Chronic interstitial nephritis

The term chronic *pyelonephritis*, which implies infection, has been replaced by *chronic interstitial nephritis*, which is characterised by a chronic tubulo-interstitial inflammatory infiltrate. Interstitial involvement is usually secondary to papillary or tubular damage by infection, ischaemia, radiation, toxins or metabolic disease. The most common cause is reflux nephropathy (see below). Other causes include obstructive uropathy, drugs (cyclosporin, lithium, chronic analgesic ingestion), renovascular disease, sickle-cell disease, long-standing hypokalaemia, hypercalcaemia or hyperuricaemia, tuberculosis, sarcoid, heavy metal poisoning (lead, cadmium), radiation nephritis, Sjögren syndrome and hereditary nephritides (e.g. Alport syndrome).

#### Clinical features

There is usually altered tubular function (glycosuria, aminoaciduria, renal tubular acidosis and tubular proteinuria) with a variable degree of renal failure. Ultrasound and radionuclide scans may show obstruction, and the kidneys are often small and scarred.

#### Management

Treat any underlying cause. Give antibiotics (prophylactic if necessary) for infection. Patients are commonly unable to concentrate their urine, and need a high fluid intake.
Reflux nephropathy

Reflux of urine through a congenitally abnormal vesicoureteric junction occurs in about 1% of infants. Reflux of sterile urine into the kidney may cause renal damage through hydrostatic injury, but there is clear evidence that reflux of infected urine leads to renal scarring. Reflux is present in 50% of infants who develop urinary infection during their first year, and one-third of children who have infection before the age of 12 years. Reflux can also present with enuresis, hypertension and proteinuria. There is a familial incidence.

Management

Children with urinary infections (and possibly those with affected siblings or parents) should be screened with an ultrasound of the renal tract followed if necessary by a direct or indirect radionuclide micturating cystogram. Ureteric reimplantation and conservative treatment with antibiotics to prevent infection are equally effective in preventing scarring. Without surgery reflux generally resolves as the child grows older.

Proteinuria

Small amounts of low-molecular-weight proteins are normally filtered by the glomerulus, and reabsorbed or catabolised by proximal tubular cells. The kidneys normally excrete 50–80 mg protein daily, of which 30–50 mg is Tamm–Horsfall protein, a mucoprotein secreted by tubular cells. Proteinuria > 150 mg/day is abnormal, but proteinuria is more commonly quantified as urinary albumin creatinine ratio (ACR) or protein creatinine ratio (PCR), which are more easily obtained on a spot urine sample and tend to be more reproducible than 24 h collections. ACR > 2.5 mg/mmol in men and 3.5 mg/mmol in women or PCR > 15 mg/mmol are abnormal. A PCR of 100 mg/mmol or ACR of 70 mmol/l is approximately equal to 1 g of protein per 24 h. The conversion is non-linear for levels below this. Dipsticks primarily detect albumin and are relatively insensitive at detecting immunoglobulins or Bence Jones protein (immunoglobulin light chains). Microalbuminuria (urinary albumin excretion of 30–300 mg/day) is an early sign of diabetic nephropathy (p. 242).

Causes

- glomerular disease: glomerulonephritis, glomerulosclerosis (diabetic and hypertensive), glomerular amyloid deposition
- tubular disease (because of impaired reabsorption of filtered proteins): chronic interstitial nephritis, polyuric phase of acute tubular necrosis, Fanconi syndrome, tubular toxins (aminoglycosides, lead, cadmium)
- non-renal disease: fever, heavy exercise, heart failure. Orthostatic proteinuria, a benign condition in which proteinuria is present when upright but not when recumbent
- urinary tract disease: infection, tumours, calculi
- increased production of filterable proteins: immunoglobulin light chains (Bence Jones protein) in myeloma, myoglobulinuria, haemoglobinuria

Clinical presentation

Often asymptomatic (routine screening). Nephrotic syndrome if severe. There may be evidence of underlying cause (e.g. urinary infection, diabetes, hypertension).

Assessment

The history should include enquiries about recent infections, renal disease (including any family history), drugs and occupation. Examination may be normal, but there may be oedema, hypertension, heart failure or evidence of renal failure.

Investigation

- Serum creatinine and electrolytes and ACR or PCR.
- Serum complement (may be low in glomerulonephritis, p. 163), antinuclear antibodies (systemic lupus erythematosus, SLE), antineutrophil cytoplasmic antibodies (systemic vasculitis), cryoglobulin levels.
- Plain abdominal X-ray and ultrasound of renal tract for stones, structural abnormalities and renal size.

In the majority of cases these investigations fail to define the underlying cause, and renal biopsy may be necessary, particularly if nephrotic or there is impaired excretory function. This usually establishes the diagnosis and may identify a treatable cause (particularly some forms of glomerulonephritis).

In the absence of oedema, treatment should be directed towards any underlying cause or associated conditions (e.g. hypertension).

Nephrotic syndrome

The triad of:

- proteinuria
- hypoalbuminaemia
- oedema.
Aetiology

Any cause of severe proteinuria. Usually it is a consequence of glomerular disease – commonly glomerulonephritis (p. 163), diabetic glomerulosclerosis or renal amyloid. More than 75% of childhood and ~20% of adult nephrotic syndrome is as a result of minimal-change disease (p. 165). Tubular proteinuria is usually less than 2 g/day and does not cause nephrotic syndrome.

It is associated with thrombosis (loss of anticoagulant proteins such as antithrombin III, protein S, protein C), infection (loss of immunoglobulins) and hyperlipidaemia.

Management

Identify and treat any underlying cause. General management is aimed at the following:

- Reducing oedema with salt restriction and diuretics.
- Angiotensin-converting enzyme inhibitors reduce proteinuria, probably by lowering glomerular capillary pressure. NSAIDs also reduce proteinuria, but these agents reduce renal blood flow and glomerular filtration rate and cause salt retention.
- Treatment of hypertension: angiotensin-converting enzyme inhibitors and diuretics in the first instance, but additional agents may be required.
- Most physicians recommend a normal protein intake.
- Anticoagulate if immobile or thrombotic episode, or severe nephrotic syndrome. Look for and treat intercurrent infection.
- Hyperlipidaemia may be severe. Very-low-density lipoprotein cholesterol, low-density lipoprotein cholesterol and total plasma cholesterol are elevated, as are triglyceride levels. Although this pattern is associated with increased cardiovascular risk, the value of treatment with diet or lipid-lowering agents has not been fully assessed.

Haematuria

Isolated haematuria on dipstick testing of urine can occur in normal individuals. Microscopic haematuria is confirmed by finding more than three red cells per high-power-field of spun urine. Macroscopic haematuria is always abnormal.

Aetiology

Common

- renal tract infection
- renal tract stones (calcium oxalate 80%, triple phosphate 10%, urate 10%, cystine < 1%)
- tumours of the bladder, kidneys and prostate
- glomerulonephritis
- schistosomiasis is common worldwide

Uncommon

- hypertension
- renal trauma
- papillary necrosis
- renal infarction
- drugs – cyclophosphamide (haemorrhagic cystitis), anticoagulants
- medullary sponge kidney (usually benign developmental abnormality with medullary cysts which may be complicated by infection or calculi)

Familial causes

- polycystic kidneys (p. 159)
- Alport syndrome (p. 159)
- thin basement membrane disease (a generally benign condition in which haematuria is usually the only clinical feature)
- medullary cystic disease (tubulointerstitial nephritis with medullary cysts which usually progresses to renal failure)

The causes vary with age. Glomerular causes predominate in children and young adults, whereas tumours and calculi are common in the elderly.

Investigation

The likely source may be suspected from the history and examination. Microscopy of a fresh urine sample is performed in all patients to confirm the presence of red cells. The presence of red-cell casts or dysmorphic (abnormally shaped) red cells indicates glomerular bleeding (red cells are deformed by mechanical and osmotic stress as they pass through the tubules). Heavy proteinuria suggests a glomerular lesion, while white-cell casts indicate renal inflammation. Bacteria may be seen and culture should be performed. Urine should also be sent for cytology. Plasma creatinine to assess renal function. Plain abdominal film and ultrasound of the renal tract to assess renal size and look for structural lesions (calculi, tumours, cysts).

If glomerular bleeding is suspected (young age, hypertension, proteinuria, renal impairment, absence of structural lesion), consider renal biopsy to identify cause of proteinuria or renal dysfunction.

If a lesion of the renal tract is suspected (older age, no evidence of intrinsic renal disease) proceed to cystoscopy with CT if the upper renal tract has not been clearly identified by ultrasound.
NB Normal urine (centrifuged deposit) contains:

- Red cells 1 × 10^6 cells/24 h (3 per high-power-field).
- White cells 2 × 10^6 cells/24 h (6 per high-power-field).
- Hyaline casts are composed of uromucoid (Tamm–Horsfall protein which is excreted by normal tubular cells).
- Cellular casts result from adherence of either red cells (implying glomerular bleeding) or white cells (implying tubular inflammation) to the surface of hyaline casts.
- Epithelial cells may be found in normal urine as a result of contamination by cells from the vulva or prepuce.

Acute kidney injury

Characterised by a rapid rise in serum creatinine, usually with a decrease in urine output. The causes can be divided into prerenal, renal and postrenal.

Prerenal

Aetiology

- sepsis – the most common cause, usually complicating surgery or pneumonia
- hypovolaemia from any cause (e.g. haemorrhage, burns, severe diarrhoea or vomiting)
- cardiogenic shock
- drug-induced hypotension (e.g. following drug overdose)

NB Angiotensin-converting enzyme inhibitors may reduce glomerular perfusion sufficiently to cause renal failure if given in the presence of bilateral renal artery stenosis (p. 96). In accelerated (malignant) hypertension, acute, severe hypertension is associated with marked renal abnormalities. The most striking of these is gross intimal hyperplasia, leading to occlusion of the lumen in small arteries and arterioles. Renal failure is a rapid consequence of this condition if the blood pressure is not controlled.

Renal failure commonly complicates advanced liver disease. Plasma urea and creatinine may be normal because of reduced hepatic urea synthesis, low dietary protein intake and loss of muscle mass. There is often a precipitating cause (e.g. hypovolaemia following diuretic therapy, paracentesis or gastrointestinal bleeding, sepsis). Unexplained renal failure complicating liver disease is the hepatorenal syndrome. The prognosis is poor. Reinfusion of ascites into the internal jugular vein via a peritoneo-venous shunt can expand plasma volume and improve renal function, but does not improve survival.

Pathophysiology

Despite high blood flow (20% of cardiac output) the kidneys are particularly susceptible to ischaemia or toxin-induced renal cell injury.

The medulla receives less than 10% of renal blood flow and is at greatest risk of injury. The common response to severe injury (regardless of cause) is acute tubular necrosis (ATN). The necrosis of tubular epithelial cells is most prominent in the proximal tubules and thick ascending limb of the loop of Henle. The tubular lumen may be obstructed by cell debris and casts. Regeneration of tubular cells leading to recovery can take weeks. Severe prolonged ischaemia can cause acute cortical necrosis from which there is little chance of recovery.

The distinction between prerenal failure (in which concentrating powers are retained) and ATN (in which concentrating powers are lost) can be made on urinalysis. In prerenal failure urine osmolality is high (> 500 mosmol/kg), urine sodium is low (< 20 mmol/l) and the urine : plasma urea ratio is > 10 : 1. In ATN urine is isotonic with plasma (< 400 mosmol/kg), urine sodium is > 40 mmol/l and the urine : plasma urea ratio is < 10 : 1.

Renal Causes

- glomerulonephritis (p. 163)
- nephrotoxic drugs (e.g. aminoglycosides, cyclosporin A, amphotericin B)
- poisoning (e.g. heavy metals)
- myoglobinuria – following rhabdomyolysis myoglobin may cause tubular toxicity or form tubular casts. Creatine kinase is markedly elevated
- acute tubular (or cortical) necrosis complicating prerenal disease
- acute interstitial nephritis (usually a drug-induced hypersensitivity reaction which responds to withdrawal of the drug and a short course of corticosteroids. Eosinophils may be present within the predominantly mononuclear cell interstitial infiltrate)
- intrarenal obstruction (e.g. urate or oxalate crystals, calcium precipitation, tubular casts in myeloma)

NB Hypercalcaemia causes renal failure through renal vasoconstriction, direct tubular cell toxicity and distal tubular calcium phosphate precipitation.

Haemolytic–uraemic syndrome (HUS) is characterised by thrombocytopenia (platelet consumption), microangiopathic haemolytic anaemia (red cell fragments on film) and acute renal failure. It commonly follows a diarrhoeal illness in infants infected with a verotoxin-producing strain of Escherichia coli (serotype O157). In adults it may follow an upper respiratory tract infection or be associated with
cyclosporin A, the oral contraceptive pill or cytotoxic agents. Familial forms occur due to a mutation in complement factor H. Recovery usually occurs over a few weeks in children, but the prognosis for adults is poor.

Thrombotic thrombocytopenic purpura (TTP, p. 331) is closely related to HUS but is most common in women, and central nervous system involvement and fever are typical additional features. See Trials Box 14.1

Postrenal

Acute urinary tract obstruction from:

- prostatic hypertrophy
- renal and ureteric stones
- tumour of the renal pelvis, ureters or bladder
- blood clot
- sloughed papillae
- external compression from retroperitoneal fibrosis or tumours
- surgical mishap (e.g. ureteric involvement in hysterectomy).

NB Lesions above the bladder must involve both urinary tracts if there are two functioning kidneys.

Investigation

Where there is no obvious cause following careful history and examination, and preliminary biochemical and haematological assessment:

- Check that there is no obstruction. Rectal examination is obligatory to exclude prostatic disease in men, or a pelvic mass. The bladder is enlarged in urethral obstruction. Ultrasound to look for urinary tract dilatation is the simplest method of excluding obstruction, although dilatation may be absent, particularly if obstruction is acute. This will also give information about renal size (small kidneys indicate chronic renal disease; scarring usually indicates chronic interstitial nephritis or ischaemia).

- Proceed to renal biopsy if renal size is normal and there are no clues on investigations, including urinalysis (exclude infection; heavy proteinuria, granular or red cell casts indicate intrinsic renal disease), calcium, uric acid, protein electrophoresis (myeloma), antineutrophil cytoplasm antibodies (vasculitis), antiglomerular basement membrane antibodies (Goodpasture's disease), antinuclear antibodies (SLE), blood film, platelet, eosinophil count and coagulation (disseminated intravascular coagulation (DIC), TTP, HUS, drug-induced hypersensitivity).

Management

This should be undertaken in a specialised unit where facilities for renal replacement therapy are available.

- Identify and correct underlying causes – often multiple (e.g. hypotension, sepsis, DIC and aminoglycoside toxicity).

- Rapid correction of prerenal causes (intravenous fluids or blood for hypovolaemia, antibiotics for sepsis, inotropes, avoidance of nephrotoxic drugs) may prevent ATN and restore renal function. Loop diuretics (e.g. furosemide) are often given and may prevent tubular cell ischaemia through inhibition of active sodium chloride reabsorption, thereby reducing oxygen requirements.

- Relieve urinary tract obstruction from below (urethral catheterisation with or without ureteric stents) or above (nephrostomy). Prostatic obstruction in elderly men is the most common cause.

- Initiate treatment for any intrinsic renal disease (e.g. immunosuppression for certain forms of glomerulonephritis, p. 163).

- Continuing assessment of fluid status through input–output records, physical examination, daily weight, lying and standing blood pressure. Fluids should be restricted if there is oliguria or anuria, but patients are usually catabolic and nutrition should not be neglected. A protein intake of 0.6–0.8 g/kg/day with 30 kcal/kg/day should be maintained. In severely ill patients enteral or parenteral nutrition may be necessary.

TRIALS BOX 14.1 Management of HUS and TTP

A systematic review of interventions for haemolytic uraemic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) concluded that plasma exchange with fresh frozen plasma is the most effective treatment available for TTP. For patients with HUS, supportive therapy including dialysis appears to be the most effective treatment, but all studies in HUS have been conducted in the diarrhoeal form of the disease. (Cochrane Database Systematic Review 2009; (1): CD003595.)
Careful monitoring of electrolytes, urea, creatinine and acid–base status.

If renal failure persists, renal replacement therapy with haemodialysis or haemofiltration will be required. Absolute indications include hyperkalaemia (potassium above 6–7 mmol/l), markedly elevated plasma creatinine (> 1000 mmol/l, but absolute level must take clinical state into account), severe acidosis (bicarbonate below 10–15 mmol/l) and fluid overload with pulmonary oedema.

### Chronic kidney disease

#### Common causes

- Chronic glomerulonephritis (p. 163).
- Diabetic nephropathy (p. 242).
- Chronic interstitial nephritis (p. 154).
- Hypertension: estimates of the prevalence of chronic renal failure caused by hypertension vary widely, reflecting the fact that the diagnosis of renal disease caused by hypertension depends on the exclusion of other causes. Many cases may have undiagnosed renal disease. Renal failure because of hypertension is much more common in black people than white people, and within the black population there appears to be familial clustering of renal disease caused by hypertension, suggesting a genetic susceptibility to hypertensive renal damage.
- Renovascular disease (p. 96).
- Hereditary renal disease.
- Polycystic kidney disease: an autosomal dominant condition in which there is progressive cystic degeneration of the kidneys. Patients present with hypertension, abdominal pain, haematuria or chronic kidney disease. The diagnosis is confirmed by ultrasound, and family members should be offered screening. Progression to renal failure with hypertension is usual, although the age at which renal replacement therapy becomes necessary varies. Approximately 85% of cases are caused by a defect in PKD1, which maps to 16p13.3, and usually progress more slowly than those due to defects in the PKD2 gene, responsible for most non-16p-linked polycystic kidney disease, and localised to 4q13–q23.
- Alport syndrome: 85% of cases are due to mutations in the COLAAS gene on the X chromosome, which encodes the $\alpha_3$ chain of type IV collagen. Progressive chronic kidney disease associated with sensorineural deafness and eye lesions occurs in affected males, whereas females typically only have abnormalities on urinalysis. Autosomal forms have variable presentations and are due to mutations in the COLAAS or COLA44 genes on chromosome 2, encoding the $\alpha_3$ and $\alpha_4$ chains of type IV collagen. Alport syndrome is characterised by thinning and splitting of glomerular basement membrane (GBM). Thin basement membrane disease is a related condition in which thinning of the basement membrane is associated with microscopic haematuria, but renal function is usually preserved. Some patients with thin basement membrane disease have heterozygous mutations at the COLAAS/COLA44 locus.
- Long-standing urinary tract obstruction.

NB About 20% of patients with established renal failure present with bilaterally small kidneys and no diagnosis is reached. Under these circumstances renal biopsy is hazardous and unlikely to show reversible changes.

#### Clinical features

Screening for renal disease and the availability of dialysis mean that the classical manifestations of uraemia (literally urine in the blood) are now seen infrequently. Chronic kidney disease is typically slow to progress and usually presents with lethargy, general malaise, anorexia and nausea. Generalised pruritus is common. Impotence, menstrual irregularities and loss of fertility are common complaints in younger patients. In severe uraemia there is a characteristic fishy fetor, hiccups, vomiting, severe pruritus with skin excoriations, skin pigmentation, peripheral neuropathy and central nervous system derangements leading to lethargy, stupor and coma with fitting. Pericarditis may be associated with effusion and tamponade.

#### Investigations

##### Biochemical

Plasma creatinine provides a guide to the severity of renal failure and can be used to estimate glomerular filtration rate (eGFR). Creatinine is derived from metabolism of creatine in muscle. The rate of production correlates with muscle mass, and depends little on protein intake. Fifty percent loss of renal function is often needed before the serum creatinine rises above the normal range; it is therefore not a sensitive indicator of mild to moderate renal injury.

Urea $\text{H}_2\text{N}-\text{CO-NH}_2$ (molecular mass 60 Da) is toxic and is the most abundant nitrogenous compound to accumulate in renal failure. It is the end-product of protein metabolism and is synthesised primarily in the liver. It is freely filtered by the glomerulus, but approximately 50% is reabsorbed so urea clearance is less than glomerular filtration rate (GFR). Urea
Production increases with cellular catabolism (infection, trauma, steroid therapy) or following protein load (dietary or following gastrointestinal haemorrhage). It is reduced in liver failure.

Renal function is now most commonly reported as estimated GFR (eGFR), which is used to assess the severity of CKD (Table 14.1) and calculated as:

\[
eGFR = \frac{175 \times [(\text{plasma creatinine} \, \mu\text{mol/l})/88.4]^{-1.154}}{\text{age} \, \text{(years)}} - 0.203 \times 0.742 \text{ if female and } \times 1.21 \text{ if African American}
\]

This is usually calculated by using a web-based calculator (for example, see http://www.renal.org/eGFR-calc/GFR.pl).

- **Cr ethylene diaminetetra-acetic acid (EDTA) clearance** more accurately reflects the GFR. It is calculated from the rate of disappearance of a bolus injection of \(^{51}\text{Cr EDTA}\) from the blood. The normal GFR is \(~100 \,\text{ml/min per 1.73 m}^2\).
- **Hyperkalaemia** (p. 169) is common.
- A number of abnormalities of calcium and phosphate homeostasis occur. Phosphate retention is associated with:
  - reciprocal depression of serum calcium level
  - rise in the calcium × phosphate product.

The diseased kidneys fail to hydroxylate \(^{25}\text{-hydroxycholecalciferol}\) (25-HCC) to the more active form \(^{1-25}\text{-dihydroxycholecalciferol}\) (1–25-DHCC). This results in:
- reduced calcium absorption from the gut
- osteomalacia.

Thus, dihydroxycholecalciferol is reduced (because of reduced 1\(\alpha\)-hydroxylase activity in the kidney) with increased parathyroid hormone (PTH). The increased PTH may result from phosphate retention and a decrease in ionised calcium. The clinical consequences are:
- osteoporosis produced by hyperparathyroidism
- osteomalacia caused by lack of vitamin D
- ectopic calcification.

Hypocalcaemia rarely leads to tetany because acidosis and hypoproteinaemia reduce protein binding and increase ionised levels of calcium.

- Plasma uric acid is often raised (but clinical gout is rare).

### Haematology

Haematological investigations usually reveal a normocytic normochromic anaemia which responds to parenteral erythropoietin. Gastrointestinal blood loss, iron, vitamin B\(_{12}\) or folate deficiency, decreased red cell survival, hyperparathyroidism and aluminium toxicity may also contribute to anaemia and should be considered if there is a failed response to erythropoietin.

### Urinalysis

Urinalysis should be performed to quantify proteinuria, look for non-visible haematuria, exclude urinary infection and look for cellular casts indicating active renal inflammation.

### Ultrasound

Renal ultrasound identifies obstruction or renal scars and defines renal size (Table 14.2). Plain abdominal X-ray also defines the renal outline and excludes renal tract calcification. If renal size is normal and the cause
of renal disease unknown, renal biopsy should be considered.

Management

There are two main aims:

1 to slow the decline in renal function;
2 to prevent or treat complications (bone disease, cardiovascular disease, endocrine effects, anaemia, socioeconomic).

Risk factors for progression of renal disease are:

- persistent activity of underlying disease
- uncontrolled hypertension
- proteinuria
- infection
- nephrotoxins (drugs).

Pathophysiology

Possible mechanisms of progression of renal failure include:

- increased glomerular pressure (as a result of increased systemic blood pressure, or efferent arteriolar constriction as a consequence of increased angiotensin II levels)
- glomerular protein leakage
- lipid abnormalities.

Hypertension in chronic kidney disease

Progression of chronic kidney disease is attenuated by treatment of hypertension. Thiazide diuretics, β-blockers, angiotensin-converting enzyme inhibitors and calcium antagonists are all effective in patients with early renal damage. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium-channel blockers do not modify glucose or lipid metabolism, have a favourable effect on left ventricular hypertrophy and have a potentially nephroprotective effect by reducing increased renal vascular resistance. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists have the additional advantage of producing a fall in proteinuria in patients with both diabetic and non-diabetic renal disease. Renal function should be monitored as they can cause hyperkalaemia and reduce renal blood flow and precipitate acute renal failure, particularly in the presence of renal artery stenosis (p. 96). Serum creatinine and potassium should be checked before starting therapy, after 1–2 weeks, and after subsequent dose increases. If the creatinine rises > 30% or eGFR falls > 25%, the tests should be repeated, angiotensin blockade stopped and investigation for renal artery stenosis considered.

Dietary protein restriction

Protein is sometimes restricted, although there is little evidence that this retards progression of renal failure.

Complications

Bone disease

Hypocalcaemia from decreased renal 1,25-(OH)₂D₃ synthesis (Fig. 14.1), hyperphosphataemia and resistance to peripheral actions of PTH all contribute to renal bone disease. Parathyroid hormone secretion increases as a result of phosphate retention and reduced 1α-hydroxylation of vitamin D and its consequences. Treatment is by dietary phosphate restriction with or without phosphate binders (calcium carbonate or acetate, or non-calcium containing binders such as sevelamer or lanthanum carbonate if there are concerns over calcium load), and early use of low-dose 1α-hydroxylated vitamin D derivatives. The calcimimetic cinacalcet or parathyroidectomy may be indicated if there is tertiary hyperparathyroidism (p. 170).

Cardiovascular disease

Cardiovascular disease is the most common cause of mortality in patients with chronic kidney disease. It is
likely to reflect an increased incidence of hypertension, lipid abnormalities, glucose intolerance and haemodynamic abnormalities, including left ventricular hypertrophy, and possibly vascular calcification. Of these, hypertension is probably the most susceptible to treatment.

**Anaemia**

Circulating erythropoietin levels are inappropriately low. Parenteral recombinant erythropoietin increases haemoglobin, improves exercise tolerance and reduces the need for blood transfusion. In patients with

---

**Figure 14.1** Vitamin D metabolism and actions.
predialysis advanced renal failure, erythropoietin corrects anaemia and improves well-being, without affecting the rate of decline in renal function. Dose-dependent hypertension occurs in 35% of patients and can usually be controlled with hypotensive agents, although hypertensive encephalopathy can develop suddenly. Treating with erythropoietin to higher haemoglobin targets (within the normal range) is associated with increased cardiovascular risk (Trials Box 14.2).

Sexual dysfunction
Decreased libido and impotence are common. Hyperprolactinaemia is present in at least one-third of patients, resulting in an inhibitory effect on gonadotrophin secretion. Prolactin levels may be reduced by bromocriptine, although side effects are common (nausea, headache, drowsiness, postural hypotension).

Renal replacement therapy
Renal function can be replaced in end-stage renal disease by the following:

- **Haemodialysis.** Diffusion of solutes occurs between blood and dialysate which flow in opposite directions, separated by a semipermeable membrane. The most common problems are cardiovascular instability during dialysis, and difficulty establishing vascular access. This is achieved by:
  - arteriovenous fistula, typically at the wrist with arterialisation of the cephalic vein;
  - double-lumen jugular, subclavian or femoral line;
  - synthetic graft (usually Goretx) looping subcutaneously between an artery and vein in the forearm or leg.
- **Continuous ambulatory peritoneal dialysis.** Patients instil up to 21 of isotonic or hypertonic solutions into the peritoneal cavity via a permanent indwelling catheter. The fluid equilibrates, across the 2 m² of peritoneal membrane, with blood in peritoneal capillaries. After several hours the fluid containing toxic waste products is drained out. This procedure is repeated three or four times daily. Excess fluid is removed by hypertonic solutions. The major complication is peritonitis, usually caused by *Staphylococcus epidermidis* or *S. aureus*. Automated peritoneal dialysis involves using a machine to cycle the fluid during the night.

Renal transplantation
is the treatment of choice in most patients, but is limited by supply of donor organs.

**Assessment of dialysis adequacy**
Plasma urea and creatinine are poor predictors of outcome in dialysis patients – low predialysis urea, not high, has been found to be associated with increased mortality. This is because when protein intake is deficient or muscle mass is reduced, predialysis urea and creatinine may remain low even in the presence of inadequate dialysis. Assessment of dialysis adequacy is now achieved by the use of kinetic measurements – often referred to as *urea kinetic modelling*. Two parameters, *urea clearance* corrected for volume of distribution (Kt/V urea, where Kt = urea clearance and V = volume of distribution) and *protein catabolic rate*, have been found in several studies to be useful predictors of outcome.

**Glomerulonephritis**
This describes a number of disorders that affect one or more of the glomerular components in both kidneys (Fig. 14.2). Patients present with one or more features of renal disease – hypertension, haematuria, proteinuria, nephrotic syndrome and various degrees of renal failure.

The classification of glomerulonephritis is based on histology and immunofluorescence of renal tissue. Contraindications to renal biopsy include:

- one functioning kidney
- small kidneys
Confusion arises because renal biopsy findings do not necessarily correlate with clinical features, although they are sometimes useful in guiding management and predicting outcome.

Histological changes are described as:
- **focal** – affecting < 50% of glomeruli
- **diffuse** – affecting > 50% of glomeruli
- **segmental** – affecting part of the glomerulus
- **global** – affecting all of the glomerular tuft
- **proliferative** – an increase in glomerular cells (mesangial, epithelial and endothelial) with leucocytic infiltration
- **crescent** – a crescent-shaped proliferation of epithelial cells and mononuclear cells in Bowman’s capsule. It occurs in any severe form of glomerular injury
- **membranous** – thickening of the glomerular capillary wall
- **sclerosis** – capillary collapse with loss of the lumen.

**Clinical features**

Usually presents with haematuria (often provoked by infection).

**Aetiology**

Unknown. It is associated with liver disease (particularly alcoholic cirrhosis), coeliac disease, seronegative arthritis, neoplasia and infection.

**Prognosis**

It is probably the most common form of glomerulonephritis. Approximately 20% of cases progress to renal failure. Control of hypertension (ACE inhibitors are preferred) slows the decline of renal function. Steroids may be of benefit.

**Henoch-Schönlein purpura**

(See p. 289.)

**IgA-Nephropathy**

Granular mesangial deposition of immunoglobulin A (IgA, and usually C3) with variable segmental mesangial proliferation (measurement of serum immunoglobulins is usually unhelpful: 20–50% have raised IgA).

**Membranous nephropathy**

Diffuse uniform thickening of glomerular capillary wall, usually without cellular proliferation.
Classification

- Stage I: small subepithelial electron-dense deposits (diffuse granular IgG staining).
- Stage II: outgrowth of basement membrane between subepithelial deposits (seen as ‘spikes’ on silver stain).
- Stage III: deposits incorporated into basement membrane, which becomes less electron-dense.
- Stage IV: thickened vacuolated membrane, sclerosis.

Clinical manifestations
Proteinuria (often nephrotic), hypertension, haematuria, deteriorating renal function.

Aetiology
Idiopathic, drugs (penicillamine, gold), neoplasia, SLE, infections (hepatitis B, malaria), diabetes.

Prognosis
The course of idiopathic membranous nephropathy is highly variable. Approximately 25% of cases undergo complete spontaneous remission, 25% have a partial remission with stable impaired renal function, 25% have persistent nephrotic syndrome with stable renal function and 25% progress to end-stage renal disease. Poor prognosis is suggested by heavy proteinuria, hypertension, elevated creatinine at presentation, and stage IV lesion. Deterioration in renal function can be halted or reversed by immunosuppression, such as a regimen of alternating steroids and chlorambucil (Ponticelli regimen; New England Journal of Medicine 1992; 327: 599–603).

Membranoproliferative (mesangiocapillary) glomerulonephritis
Mesangial expansion (caused by increased matrix and mesangial cells) and thickened capillary loops (caused by extension of matrix and mesangial cells between GBM and endothelium, giving the characteristic double contour).

Classification

- Type I: subendothelial immune deposits (stain for C3 and Ig – most common type).
- Type II: linear dense deposits along GBM (linear C3, occasional Ig).

Aetiology
Secondary causes include:

- infection, whether bacterial (infective endocarditis, ‘shunt nephritis’, leprosy), viral (hepatitis B) or protozoal (schistosomiasis)
- neoplasia
- SLE
- cryoglobulinaemia.

Nephritic factor occurs in > 60% type I and 10–20% type II mesangiocapillary glomerulonephritis. It is an IgG autoantibody which binds to and stabilises C3 convertase (C3bBb), permanently activating the alternative pathway and depleting C3. It is associated with partial lipodystrophy.

Clinical features
Proteinuria and haematuria, with variable degree of renal failure.

Prognosis
There is no evidence to support the use of immunosuppressive therapy. Half of cases progress to established renal failure in 10 years.

Minimal-change nephropathy
Normal light microscopy, with negative immunofluorescence. There is podocyte foot process fusion on electron microscopy (a relatively non-specific consequence of proteinuria).

Clinical features
It accounts for over 75% of childhood and ~20% of adult cases of nephrotic syndrome.

Aetiology
It is associated with allergy and malignancy (e.g. Hodgkin’s disease).

Prognosis
The majority of cases respond to steroids. Cyclophosphamide is beneficial if relapsing. Cyclosporin may also be of benefit.
Focal glomerulosclerosis
Segmental sclerosis affecting some glomeruli (focal). Granular IgM and C3 may be present in areas of sclerosis.

Aetiology
Idiopathic – focal glomerulosclerosis accounts for 10–20% of adult and childhood nephrotic syndrome. It is also associated with reflux nephropathy, focal proliferative glomerulonephritis, drugs (heroin, analgesic abuse), diabetes mellitus, hyperfiltration in a remnant kidney, human immunodeficiency virus (HIV) infection, sickle-cell disease, malignancy and Alport syndrome.

Clinical features
Proteinuria, often with hypertension and renal impairment.

Prognosis
There is a poor response to treatment – a trial of immunosuppression is often given if there is progressive renal dysfunction. Steroids or cyclosporin are most commonly used.

Systemic vasculitis
There is necrotising inflammation of blood-vessel walls. Any organ system can be involved.

Renal involvement is usually seen in Wegener’s granulomatosis and microscopic polyangiitis. Typically, there is a focal proliferative glomerulonephritis, often with necrosis and crescent formation. Granulomatous inflammation of the upper and lower airway is usually present in Wegener’s granulomatosis.

Vasculitis has been classified according to clinical features, size of vessel and the presence of antibodies against neutrophil cytoplasm antigens (ANCA most commonly directed against neutrophil proteases, including proteinase-3 and myeloperoxidase) (Table 14.3).

Renal lesion
Focal proliferation with necrosis and epithelial cell crescent formation. Immunofluorescence usually negative or sparse granular Ig and C3. Presents with rapidly progressive glomerulonephritis.

Prognosis
Remission occurs in over 90% of patients using oral cyclophosphamide and prednisolone. Maintenance immunosuppression, usually with steroids and azathioprine or mycophenolate, is required. Relapse occurs in one-third of patients during the first year. Intravenous immunoglobulin, monoclonal anti-CD52 antibody therapy or rituximab may be effective in patients with vasculitis refractory to further increases in immunosuppression.

Antiglomerular basement membrane disease (Goodpasture's disease)

Proliferative glomerulonephritis – usually severe glomerular inflammation with crescents and necrosis. Immunofluorescence reveals linear IgG along GBM (may also occur in SLE and diabetes).

Aetiology
Anti-GBM antibodies recognise a restricted epitope on type IV collagen. They bind with high affinity to basement membrane in glomeruli, alveoli, the eye and ear.

NB Anti-GMB antibodies do not bind to Alport GBM in which type IV collagen is abnormal (p. 159),

<table>
<thead>
<tr>
<th>Table 14.3 Classification of vasculitis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANCA+</strong></td>
</tr>
<tr>
<td>Small vessel</td>
</tr>
<tr>
<td>Medium vessel</td>
</tr>
<tr>
<td>Large vessel</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

ANCA, antibodies against neutrophil cytoplasm antigens.
but may develop following transplantation of a normal kidney into a patient with Alport syndrome.

**Clinical features**

There is an acute renal failure caused by a rapidly progressive glomerulonephritis. Pulmonary haemorrhage (in smokers) causes breathlessness and hae-moptysis. Chest X-ray shows that pulmonary shadowing and transfer factor (TLCO) is increased by the presence of haemoglobin in alveoli. The combination is known as Goodpasture syndrome, and anti-GBM disease (Goodpasture’s disease) is a common cause. The other major cause is systemic vasculitis (see above).

**Prognosis**

The disease usually responds to plasma exchange (to remove the autoantibody) combined with steroids and cytotoxic therapy (usually cyclophosphamide). Recovery of renal function is rare once anuria or dialysis dependence has occurred.

---

**Systemic lupus erythematosus**

Renal involvement is common in SLE (p. 277) – over 90% of patients have abnormalities on renal biopsy. The World Health Organization (WHO) classification is shown in Table 14.4.

**Clinical features**

There can be almost any manifestation of renal disease, including hypertension, haematuria, proteinuria, nephrotic syndrome, acute renal failure and end-stage renal disease.

**Table 14.4 World Health Organization classification of renal disease in systemic lupus erythematosus (SLE)**

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Normal (extremely rare)</td>
</tr>
<tr>
<td>II</td>
<td>Mesangial changes</td>
</tr>
<tr>
<td>IIa</td>
<td>Deposits by immunofluorescence and electron microscopy</td>
</tr>
<tr>
<td>IIb</td>
<td>Hypercellularity as well</td>
</tr>
<tr>
<td>III</td>
<td>Proliferative glomerulonephritis (&lt; 50%)</td>
</tr>
<tr>
<td>IV</td>
<td>Proliferative glomerulonephritis (&gt; 50%)</td>
</tr>
<tr>
<td>V</td>
<td>Membranous glomerulonephritis</td>
</tr>
</tbody>
</table>

**Prognosis**

The prognosis differs according to WHO classification. It is good in class II, but poor in classes III and IV. The significance of membranous change (class V) is unclear. Steroids in combination with azathioprine or cyclophosphamide can slow progressive renal damage. Plasma exchange may provide additional benefits.

---

**Post-streptococcal glomerulonephritis**

Diffuse proliferative glomerulonephritis with granular deposits of C3 and IgG.

**Clinical features**

Oliguria, oedema, hypertension, haematuria and renal impairment follow 2–3 weeks after infection with a nephritogenic strain of group A β-haemolytic streptococci.

**Investigations**

Throat or skin cultures may show group A streptococci if penicillin has not been given. Antibodies against streptococcal antigens provide evidence of recent infection, e.g. antistreptolysin (ASO), antideoxyribonuclease-B (ADNase B). Hypocomplementaemia occurs with low C3 and CH50.

**Prognosis**

Spontaneous recovery is usual. The disease is now very rare.

---

**Fluid and electrolytes**

**Salt and Water**

Plasma sodium concentration and extracellular fluid volume vary independently of each other so alterations in plasma sodium reflect alterations in either sodium or water.

**Serum sodium decreased (hyponatraemia)**

This is when plasma sodium is < 130 mmol/l.

**Aetiology**

Too little sodium or too much water, or both.
Clinical features

In salt depletion there is thirst, dry tongue, reduced tissue turgor and postural hypotension. In severe depletion, mental confusion, hypotension and shock occur. None of these features is present if water excess because of inappropriate antidiuretic hormone (ADH) or psychogenic polydypsia is the cause.

Investigation

Check serum osmolality and urine sodium. If:
- Serum osmolality is decreased and urine sodium is increased:
  - excess renal sodium loss (renal failure, Addison’s disease, p. 224)
  - inappropriate ADH secretion. (NB Some drugs such as chlorpropamide and carbamazepine can have an ADH-like action on the kidney.)
- Serum osmolality is decreased and urine sodium is decreased:
  - extrarenal loss of sodium (e.g. gastrointestinal tract, burns)
  - fluid retention associated with cardiac failure, hepatic failure or nephrotic syndrome
  - psychogenic polydipsia.
- Serum osmolality is normal:
  - usually spurious, e.g. in severe hyperlipidaemia when the amount of sodium in the aqueous phase of plasma is normal, but its concentration is expressed in terms of the volume of the aqueous and lipid phase.

Management

Salt depletion is corrected with NaCl, either orally (slow sodium tablets) or as intravenous normal saline (0.9%, 150 mmol/l each of Na⁺ and Cl⁻). Water excess in inappropriate ADH secretion and psychogenic polydypsia is treated by water restriction (< 600 ml/24 h).

Serum sodium increased (hypernatraemia)

Aetiology

Too much sodium or too little water.

Investigation

Check urine sodium (normal 10–20 mmol/l) and whether urine osmolality is low (< 300 mosmol/l) or high (> 800 mosmol/l).

If:
- Urine osmolality decreased and urine sodium increased:
  - excess sodium load, either iatrogenic or endocrine (e.g. Conn syndrome, Cushing syndrome)
  - previous renal loss of water and sodium (e.g. osmotic diuresis resulting from glucose).
- Urine osmolality decreased and urine sodium decreased:
  - diabetes insipidus (p. 220).
- Urine osmolality increased and urine sodium decreased:
  - previous and continuing extrarenal loss of sodium and water (e.g. from sweat, gastrointestinal tract).
- Urine osmolality increased and urine sodium increased or normal:
  - previous and continuing extrarenal loss of water but not sodium (e.g. from lungs during febrile illness).

Serum potassium

Around 98% of potassium is intracellular (in contrast to sodium which is predominantly extracellular). Normal potassium intake = 60–200 mmol/day.

Serum potassium decreased (hypokalaemia)

Aetiology

- Gastrointestinal losses: diarrhoea and/or vomiting (colonic tumours, particularly villous adenomas, may secrete large amounts of potassium), laxative abuse.
- Renal loss:
  - diuretic therapy (thiazides, loop diuretics)
  - mineralocorticoid excess. Renin secreted by the juxtaglomerular apparatus in the kidney converts angiotensinogen to angiotensin. Angiotensin stimulates aldosterone secretion from the adrenal cortex which causes urinary sodium retention and potassium loss. Causes include Conn syndrome, Cushing syndrome, corticosteroid therapy, ectopic adrenocorticotropic hormone (ACTH, tumours) and Bartter syndrome (renal potassium loss associated with juxtaglomerular cell hyperplasia and hyperreninaemia)
  - osmotic diuresis (e.g. uncontrolled diabetes)
  - renal tubular acidosis (p. 169).
- Shift to intracellular compartment (e.g. insulin therapy, familial periodic paralysis).
- Poor intake (including eating disorders, which may be associated with laxative or diuretic abuse).
Clinical features
Weakness and lethargy. The electrocardiogram (ECG) shows flat T and prominent U waves.

Management
Treat the underlying cause.
- Give oral potassium as potassium chloride.
- Where oral administration is not possible (e.g. vomiting), potassium is given intravenously: 2 g/l (26 mmol/l) intravenous solution.

Serum potassium increased (hyperkalaemia)

Aetiology
- potassium retention:
  - renal failure (prerenal, renal, postrenal)
  - decreased mineralocorticoids: Addison’s disease, spironolactone (aldosterone antagonist), angiotensin-converting enzyme inhibitors
- increased supply of potassium – potassium is predominantly intracellular and released following cell destruction, e.g. haemolysis, trauma, cytotoxic therapy

Clinical features
Severe hyperkalaemia (> 6–7 mmol/l) may be associated with life-threatening ECG abnormalities.

Metabolic alkalosis

Aetiology
- excess intake of alkali, e.g. milk-alkali syndrome, massive blood transfusion (citrate is metabolised to bicarbonate)
- loss of gastric acid, e.g. pyloric stenosis
- increased renal losses of acid with bicarbonate generation, as in hyperaldosteronism, elevated corticosteroids or severe hypokalaemia

Management
Identify and treat the underlying cause.

Hypercaldcaemia

Aetiology
- primary (parathyroid adenoma or hyperplasia)
- secondary: increased PTH secretion occurs in response to a fall in serum calcium (e.g. in renal failure, malabsorption) by definition the calcium is normal
tertiary hyperparathyroidism: if secondary hyperparathyroidism gets ‘out of control’ autonomous parathyroid hormone secretion develops, causing elevation of both PTH and serum calcium

**Malignancy**
- bone metastases (commonly breast, lung, prostate, kidney, thyroid)
- multiple myeloma, leukaemia, Hodgkin’s disease
- secretion of a PTH-like factor

**Sarcoid**
Increased sensitivity to vitamin D – hypercalcaemia often precipitated by exposure to sunlight.

**Drugs**
- excess vitamin D
- calcium-containing antacids (milk-alkali syndrome)
- rarely, thiazides

**Endocrine (rare)**
Thyrotoxicosis, adrenal insufficiency.

---

**Hypocalcaemia**

**Aetiology**

**Hypoparathyroidism**
- idiopathic
- post-thyroid or parathyroid surgery
- pseudohypoparathyroidism (reduced sensitivity to PTH)

**Inadequate dietary intake of vitamin D or calcium (rarely, vitamin D resistance)**
- malabsorption
- renal disease
- acute pancreatitis

---

**Hypomagnesaemia**
Magnesium is the second most abundant intracellular cation. Normal requirement is 150mg/day. Normal intake is 300–400 mg/day.

**Aetiology**
Occurs in starvation, enteral nutrition with inadequate replacement, prolonged diarrhoea, enteral fistulae and drugs (diuretics, aminoglycosides, amphotericin, carbenicillin). Usually associated with hypocalcaemia.

Reduced calcium and magnesium are often found in the seriously ill where nutrition has been inaccurately estimated.

**Clinical features**
Paraesthesia, cramp, tetany, apathy.

---

**Hyperphosphataemia**

**Aetiology**
- reduced loss:
  - renal failure
  - hypoparathyroidism
- increased load:
  - excessive vitamin D intake

---

**Hypophosphataemia**

**Aetiology**
- increased loss:
  - diuretic therapy
  - hypoparathyroidism
  - renal tubular defects (e.g. Fanconi syndrome – glycosuria, aminoaciduria, phosphaturia, renal tubular acidosis)
- decreased absorption:
  - malabsorption
  - vitamin D deficiency or resistance
  - malnutrition
- intracellular shift:
  - diabetes mellitus
  - ‘refeeding syndrome’ (after starvation or severe illness)

---

**Uric acid**
Levels of uric acid are increased by stress and fasting.

**Serum uric acid increased**

**Causes**
- primary gout
- 25% of relatives with primary gout (p 290)
- diuretics (particularly thiazides)
- small doses of aspirin (up to 2 g/day)
- renal failure
- increased destruction of nucleoproteins, usually in myeloproliferative disorders – particularly at the start of cytotoxic therapy or radiotherapy
- psoriasis (one-third of patients)
Headache

Headache is the most frequently reported neurological symptom, accounting for considerable morbidity in the general population. The clinician’s challenge is to exclude a treatable underlying intra- or extracranial secondary cause (Table 15.1) and to make a definitive diagnosis. The history provides important clues and should ascertain:

- date of onset, frequency and duration of episodes
- precipitating and relieving factors
- type and location of pain
- severity
- associated features.

Primary headache syndromes

Tension headache (chronic daily headache)

Characteristically a continuous severe pressure is felt bilaterally over the vertex, occiput or eyes. It may be ‘band-like’ or non-specific and of variable intensity. Aetiology remains unclear but may be musculoskeletal in origin. It is most common in middle-aged women, but may occur at any age and in either sex, especially in the context of stress or depression.

The headache often occurs on a daily basis and may persist for months or even years. Standard analgesics are reported to be ineffective and continuous analgesic use may exacerbate the situation, especially when the effects of medication wear off (so-called ‘rebound headache’). Aside from nausea, there are no other associated features and neurological examination is normal.

Treatment is difficult: reassurance that there is no sinister underlying cause may help in some cases, as may teaching relaxation techniques and addressing underlying stressors. The patient should be advised to avoid excessive analgesic use, but a small dose of amitriptyline taken at night may help.

Migraine

Migraine is episodic and affects approximately 10% of the population. It usually begins around puberty and continues intermittently to middle age. It is three times more common in women and there is often a family history. It may be associated with menstruation or triggered by contraceptive pill usage, physical exercise, alcohol, various specific foods (especially chocolate, cheese and red wine) or heightened emotions. There is a link with hypertension and prior head injury.

The pathophysiology remains poorly understood. Prodromal sensory phenomena (‘aura’) have been attributed to vasoconstriction within intracerebral vessels, although a wave of depolarisation spreading across the cerebral cortex may account for this early phase. Thereafter, vasodilatation of extracerebral vessels correlates with the onset of headache. A number of vasoactive peptides including calcitonin-gene-related peptide (CGRP) and serotoninergic (5-HT) pathways have been implicated in the pathogenesis.

Clinical presentation

Classical migraine with aura

Characteristically migraine starts with a sense of ill health (lasting up to several hours) followed by a visual aura (e.g. shimmering lights, fortification spectra, scotomata) usually in the field opposite to the side of the succeeding headache and lasting up to 1 h. In severe cases the patient may develop a homonymous hemianopia or even complete blindness. Sensory symptoms (e.g. unilateral numbness/paraesthesia) are less commonly seen, and speech disturbance or motor weakness are very rare. Thereafter, a throbbing unilateral headache is associated with anorexia, nausea, vomiting, photophobia and withdrawal. The
Migraine without aura
Although the classical aura is absent, patients may feel non-specifically unwell prior to the onset of headache.

Hemiplegic and ophthalmoplegic migraine
Rarely focal neurological features may persist for several days. Other structural lesions (e.g. arteriovenous malformation, aneurysm) must be excluded.

Investigation
When the diagnosis is clear, investigation is not required; otherwise brain imaging should be performed.

Management
Acute attack
- Sleeping in a quiet darkened room is effective in many patients.
- Simple analgesics (e.g. aspirin, paracetamol) and an antiemetic agent.
- 5-HT1B/D agonists (e.g. rizatriptan, sumatriptan, zolmitriptan) are effective when taken early and may abort an established attack. They are contraindicated in patients with known/suspected coronary or cerebrovascular disease or uncontrolled hypertension and must be used cautiously in those with vascular risk factors.

Clinical trials with a novel class of agent, CGRP antagonists, are currently underway and may be effective in the third of all migraine sufferers who do not respond well to ‘triptans’.

Prophylaxis
Precipitating causes should be identified and avoided. Oestrogen-containing preparations must be used with caution. Preventative treatment for migraine should be considered for patients who suffer:
- > 1 acute attack per month
- increasing frequency of headaches
- significant disability despite appropriate treatment for acute attacks.

Therapeutic options include:
- β-blockers – usually propranolol
- amitriptyline
- pizotifen
- topiramate
- others, e.g. sodium valproate, verapamil, methysergide (the latter has potentially serious fibrotic side effects and must only be used under expert supervision).
Cluster headache

These are relatively short-lived (30–120 min) episodes of severe pain, typically centred on one eye and affecting men more than women (~3 : 1), with an age of onset between 20 and 60 years. Attacks start without warning and are associated with red eye, eye and nose watering and vomiting. They may occur several times a day, often waking the patient from sleep. Usually cluster headaches are recurrent for several days, weeks or months before the disorder remits and the patient becomes pain-free for months or years. Alcohol is a recognised precipitant.

Sumatriptan (self-administered by subcutaneous injection) is the treatment of choice for cluster headaches – simple analgesics are rarely effective in this condition. High-flow oxygen and corticosteroids have also been reported to be efficacious in some patients. Prophylaxis with verapamil or lithium may be tried (methysergide is reserved for refractory cases and, as with migraine prophylaxis, must be used under expert supervision because of the risk of inducing fibrotic disorders).

Secondary causes of headache

See Table 15.1.

Raised intracranial pressure

Usually secondary to an intracranial tumour, haematoma or abscess, the pain is worse on waking and associated with nausea and vomiting. It improves 1–2 h after rising and is exacerbated by coughing, sneezing, straining and bending down. Visual function may be preserved despite papilloedema, but other neurological symptoms and signs related to the primary lesion are usually evident. The pain often responds to simple analgesics.

Idiopathic (‘benign’) intracranial hypertension (IIH; Pseudotumour Cerebri)

IIH is commonest in young obese women with symptoms and signs of raised intracranial pressure but no mass lesion on brain imaging. Altered cerebrospinal fluid (CSF) dynamics (with impaired absorption) have been suggested to underlie the disorder. The patient may report visual disturbance, including diplopia and obscurations (abrupt onset transient visual loss secondary to changes in posture), and examination reveals bilateral papilloedema. Occasionally, bilateral sixth cranial nerve palsies are present and reflect raised intracranial pressure (‘false-localising’ sign). Pulsatile tinnitus is another recognised feature.

CT/MRI scanning of the brain is normal without hydrocephalus but lumbar puncture confirms raised CSF pressure. Intracranial venous sinus thrombosis, disorders of calcium metabolism, drugs (tetracyclines, isotretinoin, hormonal contraceptives, growth hormone and corticosteroids), systemic lupus erythematosus and hypervitaminosis A may all present with a syndrome similar to IIH, thus secondary causes must always be excluded.

Weight loss may facilitate spontaneous remission. Serial ‘therapeutic’ lumbar punctures can be used to lower CSF pressure but are unpopular with patients. In more chronic cases, medical therapy with acetazolamide, other diuretics or corticosteroids may be tried but surgical intervention (lumboperitoneal shunt or optic nerve sheath decompression) is often required to relieve symptoms and/or protect vision – prolonged raised intracranial pressure predisposes to optic atrophy.

Meningeal irritation

Irritation of the meninges (meningism) occurring in meningitis or following subarachnoid haemorrhage characteristically produces a triad of symptoms:

- severe headache – global or occipital associated with nausea/vomiting
- photophobia
- neck stiffness.

In meningitis the headache evolves over minutes to hours whereas in subarachnoid haemorrhage it is abrupt in onset and may be followed by loss of consciousness.

Post-concussion

Similar to tension headache but usually associated with dizziness (not vertigo) and impaired concentration, post-concussion headache persists for months and there may be a history of inadequate recovery following the head injury.

Giant-cell arteritis

This is an important cause of headache in patients over 50 years of age (see rheumatology, p. 284).

Neuralgias

Neuralgias are intermittent, brief, severe, lancinating pains occurring along the distribution of a nerve.

Trigeminal neuralgia

Trigeminal neuralgia predominantly affects those over 50 years of age. It reflects compression of the sensory
root of the trigeminal nerve (e.g. by a tumour or aberrant vessel) or may complicate multiple sclerosis. The agonising sharp pain is confined to the distribution of the trigeminal nerve on one side, commonly the maxillary or mandibular divisions. It lasts only seconds and is usually triggered from a place on the lips, side of the face or nose, by chewing, eating, speaking, or by a cold breeze. It tends to get worse with age, and eventually a continuous background pain may develop if left untreated. Physical examination is usually normal but may reveal neurological signs in the presence of an underlying mass lesion.

Simple analgesics are generally ineffective. Usually carbamazepine provides good symptom control, but gabapentin, sodium valproate, clonazepam and tricyclic antidepressants may be tried.

Radiofrequency thermocoagulation or chemical (glycerol) ablation of the trigeminal ganglion produce benefits in some patients.

**Glossopharyngeal neuralgia**

A rare disorder precipitated by swallowing, which produces pain in the pharynx or deep inside the ear.

**Postherpetic neuralgia**

Patients have a history of herpes zoster infection (shingles) in the distribution of one of the branches of the trigeminal nerve (usually ophthalmic). Pain, itching and altered sensation develop along the course of the affected nerve and persist after the rash has healed. The pain may be difficult to treat, but sometimes responds to tricyclic antidepressants, carbamazepine or topically applied capsaicin.

**Atypical facial pain**

This describes episodic aching in the jaw and cheek (in a non-anatomical distribution), lasting several hours and usually occurring in young to middle-aged women who often exhibit coexistent features of anxiety or depression. It is often bilateral and may respond to antidepressants.

**Epilepsy**

Epilepsy results from intermittent paroxysmal electrical discharges of cerebral neurons causing stereotypical attacks of altered consciousness, motor or sensory function, behaviour or emotion. A single unprovoked episode (i.e. a seizure) is insufficient to make a diagnosis as the term should be reserved for those with a recurring tendency to seizures. Ideally, all patients with a first unexplained seizure should be rapidly assessed by a neurologist in a specialist clinic.

Up to 1% of the general population suffers from epilepsy. Each year a small number of individuals with this condition (1–2 per 100,000) die prematurely as a consequence of status epilepticus (see below), accidental injury or sudden unexplained death – the latter is assumed to be related to seizure activity with associated cardiorespiratory dysfunction.

**Classification**

**Partial seizures**

These have a single focus of activity, which may be scar tissue related to previous trauma, a cerebrovascular accident or tumour. They are classified as:

- simple partial seizures: with no impairment of consciousness
- complex partial seizures: consciousness is impaired at some stage.

Partial seizures may progress to generalised seizures.

**Generalised seizures**

Generalised seizures are typified by widespread activity affecting both cerebral hemispheres and include:

- childhood absence seizures (petit mal) and atypical absence seizures
- myoclonic epilepsy
- tonic–clonic (grand mal) seizures
- tonic (spasm), clonic (jerking), atonic or akinetic seizures.

**Aetiology**

Most epilepsy is idiopathic. There may be a family history suggesting genetic susceptibility, particularly with petit mal seizures. Seizures may be secondary to cerebral disorders, metabolic dysfunction and drug ingestion (Table 15.2).

**Provocation of seizures**

A variety of factors can provoke seizures in patients not usually prone to epilepsy (e.g. drug overdose, hypoglycaemia). In those with known epilepsy, seizures may be provoked by sleep deprivation, stress, alcohol and, occasionally, stimuli such as television or strobe lighting. In some women seizures may increase in frequency around the time of menstruation.

**Differential diagnosis**

- syncope: e.g. vasovagal faints, postmicturition and cough syncope
- cerebrovascular disease: e.g. transient ischaemic attacks, critical carotid artery stenosis, vertebro-basilar ischaemia
- vestibular disorders
- low cardiac output states
**Clinical features**

**Absence seizures (‘petit mal’)**
This usually presents between 4 and 10 years and is more common in girls. It is characterised by brief (10–15 s) moments of absence without warning (e.g. the child stops talking and stares blankly) followed by immediate recovery. It rarely continues beyond puberty, although 5–10% of children will develop adult seizures.

**Ferbile convulsions**
These are seizures occurring in the context of fever, usually in young children under 5. The majority are ‘one-off’ events although up to 5% go on to develop epilepsy. They are usually generalised and brief but occasionally longer lasting or focal in nature.

**Infantile spasms**
These are brief spasms (typically ‘shock-like’ with flexion of the arms, head and neck and drawing up of the knees) associated with progressive learning difficulties. Aetiology includes perinatal asphyxia, metabolic disorders, encephalitis and cerebral malformations.

**Juvenile myoclonic epilepsy**
This form of primary generalised epilepsy with typical onset in teenagers is characterised by relatively infrequent generalised seizures, daytime absences and myoclonus.

**Epilepsy in adulthood**

**Primary generalised epilepsy (tonic–clonic seizures/grand mal)**
Seizures may be preceded by a prodrome/aura in which the patient reports dizziness, irritability or other non-specific symptoms. This is followed by loss of consciousness and the tonic phase (characterised by generalised muscle spasms), which usually lasts up to 30 s. Cyanosis may occur. The clonic phase, characterised by sharp repetitive muscular jerks in all limbs, follows. Tongue biting, salivation and involuntary micturition may occur. Consciousness remains impaired typically for around 30 min, with drowsiness and confusion lasting several hours.

**Temporal lobe epilepsy**
Patients typically experience an aura which may include a sense of fear or déjà-vu, hallucinations (visual, olfactory or gustatory) or a rising sensation in the epigastrium. Confusion and anxiety may develop and some patients exhibit automatism (organised stereotyped movements, e.g. chewing, lip-smacking).

**Jacksonian (focal) epilepsy**
Epileptic activity originates in one part of the motor cortex. Each seizure begins in one body part and may proceed to involve that side of the body and then the whole body. Temporary paresis of the originally affected limb may persist after the attack (Todd’s paralysis). Sensory epilepsy is a parallel condition originating in the sensory cortex.

---

### Table 15.2 Causes of epilepsy

<table>
<thead>
<tr>
<th>Type</th>
<th>Cause</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Idiopathic</strong></td>
<td>Often unknown, but likely significant inherited component</td>
</tr>
<tr>
<td><strong>Secondary to other disorders</strong></td>
<td>Birth trauma, including intracranial haemorrhage</td>
</tr>
<tr>
<td><strong>Neonatal</strong></td>
<td>Hypoxia</td>
</tr>
<tr>
<td><strong>Childhood</strong></td>
<td>Congenital anomalies</td>
</tr>
<tr>
<td></td>
<td>Tuberous sclerosis</td>
</tr>
<tr>
<td></td>
<td>Metabolic storage disorders</td>
</tr>
<tr>
<td><strong>Adulthood</strong></td>
<td>Head injury</td>
</tr>
<tr>
<td><strong>Elderly</strong></td>
<td>Drug and/or alcohol intoxication or withdrawal</td>
</tr>
<tr>
<td><strong>All/most ages</strong></td>
<td>Degenerative disorders (e.g. Alzheimer’s disease, Huntington’s disease)</td>
</tr>
<tr>
<td></td>
<td>Metabolic disturbance (e.g. hypoglycaemia, hypocalcaemia, hyponatraemia)</td>
</tr>
<tr>
<td></td>
<td>Cerebral infection (e.g. meningitis, encephalitis, abscess)</td>
</tr>
<tr>
<td></td>
<td>Cerebral tumour or arteriovenous malformation</td>
</tr>
<tr>
<td></td>
<td>Inflammation (e.g. vasculitis, SLE, rarely demyelination)</td>
</tr>
</tbody>
</table>

*A wide variety of drugs have been reported to provoke seizures – a list is available at www.epilepsy.com. SLE, systemic lupus erythematosus.*

- metabolic: e.g. hypoglycaemia
- postural hypotension
- narcolepsy
- psychiatric disorders: e.g. conversion hysteria
Investigation

The object is to detect treatable underlying brain disease and identify provoking factors.

A full history and clinical examination should identify other causes of loss of consciousness. Biochemical evidence of excess alcohol, hypoglycaemia, hyponatraemia or hypocalcaemia should be sought.

An EEG should help to confirm the diagnosis, but both false positive (in 1% of the normal population) and false negative results occur. EEG diagnosis can be enhanced by prolonged recording especially after sleep deprivation.

CT or MRI scanning is performed in most adult patients presenting with a seizure to identify structural lesions. Imaging is of particular value in late-onset epilepsy, partial seizures and in patients with generalised epilepsy where the EEG discloses a focal abnormality.

Management

A single fit rarely requires treatment but an underlying cause should be sought. Most neurologists would begin treatment with prophylactic anticonvulsants after a second episode. However, it may be prudent to treat after a first seizure when neuroimaging reveals a structural lesion or when there is no reversible precipitant.

The choice of pharmacological therapy is determined by the type of epilepsy, for example:

- **Partial seizures (with or without secondary generalisation):** carbamazepine, lamotrigine, oxcarbazepine and sodium valproate are the drugs of choice; second-line agents include clobazam, gabapentin, levetiracetam, pregabalin and topiramate.
- **Generalised tonic–clonic:** carbamazepine, lamotrigine and sodium valproate are first-line agents; clobazam, levetiracetam, phenytoin and topiramate are useful second-line options.
- **Absence:** ethosuximide or sodium valproate are the drugs of choice for classical absence seizures; clonazepam and lamotrigine are alternatives.
- **Myoclonic:** sodium valproate is the drug of choice for most cases; clonazepam, levetiracetam and topiramate may be tried as second-line agents.

In addition, age, sex, child-bearing potential, comorbidity and concomitant medication should be taken into account. Seizure control with minimal adverse effects can be achieved using a single anticonvulsant in ~75% of patients. The addition of a second drug produces satisfactory control in a further subgroup.

Refractory epilepsy (inadequate control on multiple agents) may reflect:

- poor compliance
- pseudoseizures or non-epileptic attacks (either alone or in combination with genuine seizures)
- an underlying structural brain lesion
- excess alcohol or illicit drug usage.

Status epilepticus

This is defined as recurring or continuous seizures, in which the patient does not regain consciousness between attacks. It is a medical emergency as hypoxia/anoxia can lead to permanent brain damage or even death. Key principles of management include:

- basic life support/resuscitation
- seizure control
- identification and correction of predisposing cause.

The choice of agent used to terminate seizure activity depends on the stage/duration, but may include:

- Intravenous lorazepam (4 mg) (clonazepam and diazepam are alternatives) – dose may be repeated after 10 min if seizures recur/continue.
- Intravenous phenytoin (15 mg/kg, maximum rate of 50 mg/min), fosphenytoin (prodrug of phenytoin), both of which require ECG monitoring, or phenobarbitone (10 mg/kg, maximum rate of 100 mg/min) should be used when there is established status.
- Intravenous thiopentone (bolus followed by infusion), combined with ventilation/neuromuscular blockade, is required when seizures continue beyond 30–60 min. Midazolam and propofol have also been used in this setting. EEG monitoring is required to confirm termination of seizure activity.

Patients should be nursed in a high dependency/intensive care setting. Regular anticonvulsant therapy should be reinstituted as soon as possible in those with known epilepsy.

Surgical treatment of epilepsy

This should be considered in patients with intractable epilepsy if a focus for seizure onset can be identified using MRI and electrophysiology mapping.

Epilepsy and pregnancy

Uncontrolled seizures in pregnancy present a serious risk to both mother and fetus. Anticonvulsant drugs must be continued especially if there is a history of recent seizure activity. In women with no recent (2–3 years) history of seizures, a trial off therapy before pregnancy should be considered.

Women with epilepsy who wish to become pregnant should receive pre-pregnancy counselling about the risk of congenital abnormality and the individual
pros and cons of continuing treatment. Wherever possible, the lowest dosage of a single agent should be used. Screening for neural tube defects is especially indicated in women taking sodium valproate or carbamazepine, and folic acid supplementation is essential both preconception and throughout the pregnancy.

For mothers taking carbamazepine, phenobarbitone or phenytoin (enzyme inducing agents), vitamin K should be prescribed before delivery and for the newborn.

NB Carbamazepine, phenytoin and phenobarbitone all induce hepatic microsomal enzymes and increase metabolism of oestrogens and progestagens, making oral contraception unreliable.

**Epilepsy and driving**

In the UK all patients with a history of seizures must report their condition to the Driver and Vehicle Licensing Agency (DVLA). Currently, for an isolated seizure, a 6-month ‘off driving period’ is stipulated providing the individual has undergone assessment by an appropriate specialist and no relevant abnormality has been identified on investigation. A 12-month ‘off driving period’ applies if there is deemed to be the potential for further seizures. Patients with a history of epilepsy must be seizure free for 1 year before being allowed to drive. More stringent regulations apply to licences for heavy goods or passenger-carrying vehicles (www.dft.gov.uk/dvla/drivers.aspx). Patients with sleep-related epilepsy may drive if they have an established pattern of seizures that have occurred only in relation to sleep during the previous 3 years.

**Epilepsy and employment**

There are certain statutory employment restrictions for individuals with epilepsy, including in relation to the emergency and armed services, pilots and train drivers.

**Epilepsy and lifestyle**

There are no ‘absolute rules’, but it is sensible to avoid heights/ladders, operating heavy machinery, working underground and activities such as unsupervised swimming until seizure control is established. Fires should be guarded and children should not be left in the bath unattended.

**Prognosis in epilepsy**

The long-term prognosis of epilepsy is good, with most patients attaining a 5-year remission and many stopping treatment in due course. The decision to discontinue anticonvulsant therapy is determined by: type of epilepsy; duration of remission; potential deleterious effects of seizure recurrence (driving and employment) and side effects of treatment.

---

**Stroke**

Stroke is characterised by rapidly developing symptoms and/or signs of loss of central nervous system function. It is distinguishable from a transient ischaemic attack (see below) by virtue of symptoms persisting for more than 24 h. Stroke has an annual incidence of 1–2 per 1000 population, is the third most common cause of death in industrialised countries and is a major cause of morbidity in those who survive.

**Aetiology and pathophysiology**

Approximately 85% of cases are ischaemic (thrombosis or embolism) in origin, 10% are caused by intracerebral haemorrhage and 5% by subarachnoid haemorrhage.

Thrombosis is due to one or more of the following:

- abnormal blood vessel wall
- polycythaemia
- altered blood flow.

Emboli may arise from vascular or cardiac sources, including:

- degenerative vascular disease
- atrial fibrillation
- cardiac valvular disease
- post-myocardial infarction.

Degenerative arterial disease is the most common cause of stroke. Risk factors include family history of premature vascular disease, smoking, hypertension, hyperlipidaemia, diabetes mellitus, excess alcohol ingestion and certain oral contraceptive preparations.

A small number of cases have a non-vascular lesion (tumour, subdural haematoma, migraine, intracranial infection, metabolic disturbance).

In the absence of a collateral blood supply, the brain territory supplied by an occluded artery undergoes infarction. Potentially salvageable surrounding areas of brain which lie within the so-called ischaemic penumbra remain viable for a period of time and may recover function if their blood supply is restored.

Both cytotoxic (accumulation of water in damaged neurones and glial cells) and vasogenic (extracellular fluid accumulation secondary to disruption of the blood–brain barrier) oedema may complicate infarction.
Clinical features

Symptoms and signs are dictated by the vascular territory that is rendered ischaemic. As a general rule, the carotids supply the anterior and middle cerebral arteries (anterior circulation), while the vertebrobasilar system feeds the posterior cerebral arteries which, together with branches supplying the cerebellum and the brainstem, constitute the posterior circulation.

Total anterior circulation infarct
- hemiplegia (corticospinal tract)
- homonymous hemianopia (optic tract/radiation)
- cortical deficits, e.g. dysphasia (dominant hemisphere), visuospatial loss (non-dominant hemisphere)

Partial anterior circulation infarct
- two of the above or cortical deficit alone

Lacunar infarct
- pure motor or sensory stroke or ataxic hemiparesis

Multiple/serial lacunar infarcts
These may produce cumulative neurological deficits including:
- cognitive impairment (multi-infarct dementia)
- gait disturbance/apraxia.

Posterior circulation infarct
- brainstem dysfunction, e.g. vertigo, diplopia, altered conscious level
- homonymous hemianopia

Spinal cord infarct
See below (spinal disorders, p. 192).

Diagnosis and initial investigation

The introduction and promotion of ‘diagnostic aids’ such as ‘FAST’ (Box 15.1) and ‘ROSIER’ (Fig. 15.1) have facilitated earlier assessment and treatment, including thrombolysis in selected cases.

Although the diagnosis of stroke is primarily clinical, CT scanning is required to reliably distinguish cerebral infarction from haemorrhage, and early scanning is therefore recommended in the majority of patients (on CT a low-density area appears within a few hours of a cerebral infarct, whereas a high-density area appears immediately after a bleed; brainstem, cerebellar and small cortical infarcts may not be visible). MRI is more sensitive for detecting ischaemic stroke, but takes longer to perform and requires greater cooperation from the patient. Immediate CT/MRI scanning is especially important if any of the following are present:
- indication for thrombolysis or early anticoagulation treatment
- on anticoagulant therapy or known bleeding diathesis
- reduced level of consciousness or unexplained progressive/fluctuating symptoms
- papilloedema, neck stiffness or fever
- headache at onset of symptoms.

Investigations to establish the aetiology
- full blood count (± ESR), coagulation (± thrombophilia) screen, urea and electrolytes, glucose/HbA1c, fasting lipids
- ECG
- chest X-ray
- echocardiography
- duplex imaging of the extracranial carotid and vertebral arteries

**Box 15.1 The Face, Arm and Speech Test (‘FAST’)**

<table>
<thead>
<tr>
<th>Facial weakness</th>
<th>Ask the person to smile or show their teeth. Look for an unequal smile or grimace – has their mouth or eye drooped or is there obvious facial asymmetry?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm weakness</td>
<td>Lift the patient’s arms together and ask them to hold the position for 5 s after you have let go. Does one arm drift down or fall rapidly?</td>
</tr>
<tr>
<td>Speech problems</td>
<td>Check for difficulties with speech. Can the person speak clearly and understand what you say? Is there any slurring of speech or difficulty finding words/naming common objects?</td>
</tr>
</tbody>
</table>

Time to call emergency services

Less common causes of stroke should be considered, particularly in young patients and those without risk factors (serum protein electrophoresis, autoantibody screen, protein C, S and antithrombin III levels, sickle test, blood cultures, urine for homocystinuria). Angiography may be helpful in detecting cerebral vasculitis.

**Early management**

Wherever possible, patients should be admitted as soon as possible to a specialist stroke unit, as research demonstrates significant improvements in outcome when patients are managed by a multidisciplinary specialist team. Thrombolysis with recombinant...

---

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom onset</td>
<td>Date</td>
<td>Time</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GCS</th>
<th>E=</th>
<th>M=</th>
<th>V=</th>
<th>BP</th>
<th>*BM</th>
</tr>
</thead>
</table>

*If BM <3.5 mmol/L treat urgently and reassess once blood glucose normal

- Has there been loss of consciousness or syncope? Y (-1) N (0)
- Has there been seizure activity? Y (-1) N (0)
- Is there a **NEW ACUTE** onset (or on awakening from sleep)
  - I. Asymmetric facial weakness Y (+1) N (0)
  - II. Asymmetric arm weakness Y (+1) N (0)
  - III. Asymmetric leg weakness Y (+1) N (0)
  - IV. Speech disturbance Y (+1) N (0)
  - V. Visual field defect Y (+1) N (0)

*Total Score________(-2 to +5)

Provisional diagnosis

- Stroke
- Non-stroke (specify) ________________

*Stroke is unlikely but not completely excluded if total scores are ≤0.

---

Figure 15.1 The Recognition of Stroke In the Emergency Room scale ("ROSIER"). BM = blood glucose; BP = blood pressure (mmHg); GCS = Glasgow Coma Scale; E = eye; M = motor; V = verbal component. Reproduced with permission from Elsevier. Nor et al., Lancet Neurology 2005; 4: 727–734.
tissue plasminogen activator (alteplase) should be considered and commenced within 3 h of symptom onset for patients whose CT or MRI scan excludes cerebral haemorrhage. The efficacy of thrombolysis is highly time dependent and the decision to thrombolise should be taken by a specialist stroke physician/neurologist.

For patients with haemorrhagic stroke, any pre-disposing coagulopathy (including warfarin therapy) should be immediately corrected. Neurosurgical intervention is only rarely indicated in acute stroke, e.g. for symptomatic hydrocephalus.

Once admitted to the stroke unit, further assessment/management includes:

- administration of aspirin 300 mg unless contraindicated; this is typically continued for 2 weeks after symptom onset, following which long-term anti-thrombotic therapy is instituted (see below)
- swallowing screen and institution of alternative feeding strategies if required
- malnutrition screen and nutritional support as required
- early mobilisation wherever possible
- specialist physiotherapy, occupational therapy and speech therapy input.

Prevention and treatment of complications

- Antithrombotic therapy: long-term aspirin (or clopidogrel) is indicated in most patients for secondary prevention. Anticoagulants should be considered for those with atrial fibrillation or other cardiac sources of emboli.
- Hypertension: in the longer term, good blood pressure control is crucial to reducing the risk of further cerebrovascular events. Unless there is evidence of hypertensive encephalopathy, hypertensive cardiac or renal failure, aortic dissection or pre-eclampsia/eclampsia, most physicians do not treat high blood pressure in the early stages following stroke for fear of lowering cerebral blood flow and exacerbating ischaemia.
- Chest infection: aspiration is common and treatment with antibiotics and physiotherapy should be started early.
- Deep venous thrombosis and pulmonary embolism: use graduated compression stockings and consider low molecular weight heparin prophylaxis.
- Pressure sores: avoidance requires careful positioning, regular turning and use of appropriate pressure-relieving mattresses.
- Urinary infections/septicaemia: especially in those requiring catheterisation.
- Seizures: (5% patients) may require treatment with anticonvulsants.
- Hyponatraemia: may complicate intravenous fluid use or reflect syndrome of inappropriate antidiuretic hormone secretion.

Venous infarction

Thrombosis of the intracranial venous sinuses produces clinical syndromes which are distinct from those of arterial infarction. Superior sagittal sinus thrombosis may present with headache, papilloedema and features suggestive of raised intracranial pressure, together with seizures and bilateral neurological deficits. It may arise during extreme dehydration, in the puerperium and in those taking oral contraceptive preparations.

Treatment is aimed at the underlying cause, with antibiotics for any predisposing infection; heparinisation should be considered for non-infective cases.

Transient ischaemic attack (TIA)

TIA describes sudden onset of focal neurological dysfunction of presumed vascular origin that, by definition, resolves within 24 h (usually much sooner). It is a predictor of progression to completed stroke. Non-focal features such as syncope, confusion or dizziness are not diagnostic.

Aetiology

The most common cause is thromboembolism from atherosclerotic neck vessels. A cardiac source of emboli (e.g. atrial fibrillation) may be present or, rarely, cerebral vasculitis, hypercoagulable states or arterial dissection.

Non-vascular conditions that may mimic TIA include seizures, migraine, intracranial tumour and vascular malformation, subdural haematoma, multiple sclerosis, vestibular dysfunction, hypoglycaemia and psychogenic disorders.

Clinical features

Symptoms and signs depend on the arterial territory involved:

- Carotid artery TIAs affect the cortex inducing ipsilateral monocular visual loss (amaurosis fugax) or contralateral weakness or sensory disturbance. Involvement of the dominant hemisphere may produce dysphasia.
- Vertebrobasilar TIAs affect the brainstem causing dizziness, ataxia, vertigo, dysarthria, diplopia with
unilateral or bilateral weakness and numbness in the limbs. Bilateral sudden visual loss may occur.

At presentation, neurological signs have often fully resolved. Cholesterol emboli may be seen on fundoscopy in patients with amaurosis fugax. A detailed history, risk factor assessment and a full physical examination should be performed, checking for hypertension, cutaneous stigmata of hyperlipidaemia, atrial fibrillation, cardiac murmurs and carotid bruits.

**Subclavian steal syndrome**

Rarely, stenosis in the proximal subclavian artery is associated with retrograde flow down the vertebral artery when the arm is exercised. There may be an audible bruit in the root of the neck and reduced blood pressure in the affected arm.

**Diagnosis and investigation**

Recent recommendations, such as the UK National Clinical Guideline for Stroke, have emphasised the importance of early clinical assessment in patients suspected of suffering a TIA. As outlined above for stroke, effective early intervention in TIA is dependent on patients seeking medical help as soon as they develop symptoms/signs.

**Assessment of those at highest risk of stroke following a TIA**

Epidemiological studies have shown that the highest risk of progression to stroke is seen in older people (> 60 years) and those with hypertension, diabetes mellitus, longer duration of symptoms, speech problems or motor weakness.

A scoring system such as ‘ABCD²’ may identify patients who need immediate specialist assessment (within 24 h) and those requiring assessment within 1 week (Table 15.3). A score of ≥ 4 is deemed ‘high risk’ (> 4% risk of stroke over the next week) and requires immediate referral to a specialist unit. For patients with a score of < 4, aspirin should be commenced immediately and the patient referred for specialist review as soon as possible.

| Age | 60 years = 1 point |
| Blood pressure elevation | Systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg = 1 point |
| Clinical features | Unilateral weakness = 2 points |
| Speech impairment without weakness = 1 point |
| Duration of TIA | 60 min = 2 points |
| 10–59 min = 1 point |
| Diabetes = 1 point |

NB Scoring systems such as ‘ABCD²’ may fail to identify some ‘high risk’ patients (e.g. those suffering recurrent events (‘crescendo TIA’ = ≥ 2 TIs in a week) or receiving treatment with antiocoagulation) who merit urgent evaluation. In addition, their relevance to patients who present late is unclear.

**Management**

**Acute management**

- Exclude hypoglycaemia: this is an important mimic of stroke/TIA – correct the blood sugar and reassess the patient.
- Confirm no ongoing/residual neurological deficit.
- Check full blood count (+ ESR), electrolytes/renal function, glucose/HbA1c, fasting lipids, ECG.
- Commence aspirin (300 mg/day, unless contraindicated).
- Establish ‘high’ or ‘low risk’ – i.e. do they need specialist review within 24 h or within 1 week?

**Specialist management**

- Confirmation of the diagnosis.
- Assessment/treatment of risk factors (e.g. hypertension, diabetes mellitus, dyslipidaemia, smoking, atrial fibrillation) and institution of secondary prevention measures/advice.
- Early pharmacological therapy.
- Timely referral for brain and carotid imaging.

Brain imaging is recommended when the diagnosis remains unclear, when the vascular territory affected is uncertain and the patient is a potential candidate for carotid endarterectomy, and to exclude intracerebral haemorrhage.

Diffusion-weighted MRI is the imaging modality of choice for patients with suspected TIA. It should be performed within 24 h of onset of symptoms if the patient is deemed at ‘high risk’ (‘ABCD²’ score ≥ 4) of subsequent stroke, and within 1 week in other cases. Patients with anterior circulation events who are deemed potential candidates for carotid

---

**Table 15.3** The ‘ABCD²’ score for assessment of risk of stroke following transient ischaemic attack (TIA)

| Age | 60 years = 1 point |
| Blood pressure elevation | Systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg = 1 point |
| Clinical features | Unilateral weakness = 2 points |
| Speech impairment without weakness = 1 point |
| Duration of TIA | 60 min = 2 points |
| 10–59 min = 1 point |
| Diabetes = 1 point |

Adapted from Johnston et al., Lancet 2007; 369: 283–292. Reproduced with permission from Elsevier.
endarterectomy should be referred for carotid imaging within 1 week.

Medical treatment
Aspirin reduces the risk of stroke, myocardial infarction and vascular death in patients with a history of TIA. Clopidogrel is an alternative in those who are aspirin intolerant. In the absence of risk factors for cardioembolism there are no conclusive data to support the routine use of oral anticoagulants.

Surgical treatment
The decision to perform carotid endarterectomy depends on several factors, including the severity of the stenosis and the extent of comorbidities. In centres with low surgical morbidity/mortality, endarterectomy is of proven benefit in patients with a severe stenosis (70–99% according to the European Carotid Surgery Trial (ECST) criteria) and should be undertaken within 2 weeks of symptom onset.

Extracerebral haemorrhage
Extradural haematoma
This results from traumatic damage to the middle meningeal artery as it passes upwards on the inside of the temporal bone. Momentary loss of consciousness is followed by apparent recovery, but if left untreated progressive neurological dysfunction with deteriorating consciousness and even death ensues. A high index of clinical suspicion is required to facilitate early neurosurgical intervention.

Subdural haematoma
This occurs most frequently in the elderly, especially in those with a coagulopathy. It often follows trauma, which may seem relatively minor at the time. A small venous haemorrhage occurs and the clot slowly enlarges in size, absorbing fluid osmotically from the CSF.

Symptoms may develop over a period of weeks to months. Headache, confusion and progressive loss of conscious level occur with fluctuation of consciousness. Focal neurology and/or signs of raised intracranial pressure may be evident. If undiagnosed, patients with chronic subdural haematoma may present with features of dementia. Following radiological confirmation, evacuation of the haematoma may permit full recovery, irrespective of the patient’s age. Subdural haematomas are not infrequently bilateral.

Subarachnoid haemorrhage
Subarachnoid haemorrhage presents with the abrupt onset of severe generalised headache, loss of consciousness, vomiting or seizures. Meningeal irritation causes neck stiffness and photophobia. Focal neurological signs may point to the site of the lesion or may reflect raised intracranial pressure (false localising signs), coexistent intracerebral haemorrhage or vasospasm (due to the irritant effect of blood). It may result from:

- rupture of an aneurysm of the circle of Willis
- arteriovenous malformation
- trauma
- mycotic aneurysm
- pituitary apoplexy.

NB In the case of an aneurysm, some patients give a history of previous similar but milder episodes, possibly caused by smaller leaks.

Unenhanced CT scanning shows subarachnoid blood in over 90% of cases and reveals haematoma, the site of a leaking aneurysm and associated hydrocephalus. If intracranial blood is not seen, but there is a reasonable clinical index of suspicion, then lumbar puncture should be performed to examine CSF for uniform bloodstaining (i.e. frank blood that fails to clear in subsequent bottles) and xanthochromia (the CSF supernatant becomes straw-coloured due to the presence of haemoglobin breakdown products). Lumbar puncture can be safely performed once imaging has excluded a mass lesion, providing there is no bleeding diathesis.

Management

- resuscitation
- analgesia/bedrest
- Nimodipine (to reduce vasospasm)
- cerebral angiography followed by surgical intervention (e.g. clipping of the aneurysm)

The timing of investigation and surgery in patients with severe subarachnoid haemorrhage and impaired consciousness remains a matter of debate.

Aneurysmal subarachnoid haemorrhage carries a very high mortality (up to 30–40% of patients within the first few days). There is a significant risk of re-bleeding, with the second bleed often more severe than the first. Hydrocephalus occurs in 20% of patients and may require ventricular drainage. Delayed ischaemic brain damage caused by cerebral vasospasm presents with deteriorating conscious level or focal neurological signs.
**Dementia**

Dementia is a major public health problem, with substantial social and financial implications in ageing populations. It is characterised by significant impairment in two or more domains of cognition, one of which must be memory (the others being abstract thought, language, praxis, personality, social behaviour or visuospatial skills). Typically, there is progressive, global impairment of intellectual function in the context of normal consciousness.

*Dementia* must be distinguished from *delerium* (i.e. an acute confusional state in which patients may exhibit lack of clarity of thought (and hence speech), memory impairment (especially with respect to new material/recent events), mood change, altered sleep (with disturbed sleep–wake cycle) and possible hallucinations) and psychiatric disorders (e.g. depression or schizophrenia) which may cause ‘pseudodementia’.

**Causes (Table 15.4)**

Many diseases including infective, inflammatory, metabolic/endocrine and neurodegenerative disorders may predispose to cognitive impairment which may be reversible – hence the need to ascertain the underlying cause wherever possible.

**Clinical assessment**

The history should include information from a knowledgeable relative or friend. A full physical examination and cognitive assessment should be performed.

**Investigation**

This is aimed at establishing the diagnosis and excluding treatable causes. The following should be considered:

- full blood count and ESR
- creatinine and electrolytes, glucose, liver, bone and thyroid function tests, vitamin B₁₂
- chest X-ray (for bronchial carcinoma)
- CT/MRI scan of the head.

In other patients additional investigations may be required, including:

- serological tests for syphilis and HIV (human immunodeficiency virus)
- functional imaging (e.g. with PET) may be useful in cases where diagnostic uncertainty persists
- EEG (useful if Creutzfeld–Jacob disease (CJD) or epileptic amnesia suspected)
- CSF analysis

<table>
<thead>
<tr>
<th>Table 15.4 Causes of dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>Inherited</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Infective</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Inflammatory</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Metabolic/endocrine</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Drug/toxin-induced</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td>Trauma</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Neoplasia</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Degenerative</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

AIDS, acquired immune deficiency syndrome.

- genetic testing (in patients with a relevant family history or appropriate clinical phenotype)
- tissue biopsy (very rarely indicated).

**Alzheimer’s disease**

Alzheimer’s disease (AD) is the most common form of dementia in all age groups, with increasing prevalence with advancing age.
Aetiopathogenesis

AD is a neurodegenerative disorder. The so-called amyloid hypothesis proposes that altered metabolism of the transmembrane amyloid precursor protein (APP; genetic locus 21q21–22) results in the production of amyloid β-peptides (Aβ). Studies of patients with Down syndrome (trisomy 21) also support a pathogenic role for amyloid, where a ‘gene dosage effect’ has been implicated in early onset AD in this setting. Understanding of the pathogenesis of AD has been aided by the study of rare familial (autosomal dominant) cases, arising as a consequence of mutations in three different genes: APP, presenilin-1 and presenilin-2, all of which alter Aβ production. However, even when taken together, mutations in these genes account for < 1% of all AD. Susceptibility to AD is also conferred by genetic variation at other loci, the most important to date being the e4 allele of the lipid transport protein apolipoprotein E (ApoE). Genome-wide association studies have identified other potential susceptibility genes, several of which may influence Aβ metabolism.

Two characteristic pathological features are found in the brain of patients with Alzheimer’s disease:

1. Senile plaques, consisting of extracellular deposits of Aβ.
2. Neurofibrillary tangles, which are dense bundles of abnormal fibres (paired helical filaments) in the cytoplasm of neurones, containing an altered form of the microtubule-associated protein, tau (τ).

NB Neither senile plaques nor neurofibrillary tangles are specific to AD; they can occur in other chronic cerebral conditions and are found in elderly patients without dementia.

‘Toxic’ Aβ oligomers may exert effects on structural proteins of the neuronal cytoskeleton, while altered phosphorylation and aggregation of τ lead to reduced axonal transport, synaptic loss and ultimately neuronal death in specific areas of the cerebral cortex crucial to cognition. Cholinergic neurones appear to be particularly affected.

Box 15.2 Diagnostic criteria for Alzheimer’s disease (AD)

<table>
<thead>
<tr>
<th>Definite AD</th>
<th>Probable AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical features + neuropathological confirmation or Clinical features + identification of a causative gene mutation</td>
<td>Core criterion: Early significant episodic memory impairment, including: Gradual/progressive change in memory function over at least a 6-month period Evidence of significantly impaired episodic memory on formal testing Episodic memory impairment, isolated or associated with other cognitive changes at onset of AD Together with one or more of the following ‘supportive’ features: Medial temporal lobe atrophy on MRI Abnormal CSF biomarker (e.g. total τ or phospho-τ; ↓ Aβ42) Specific pattern on functional neuroimaging with PET Proven autosomal dominant AD familial mutation</td>
</tr>
</tbody>
</table>

Aβ, amyloid β-peptides; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; PET, positron emission tomography; τ, tau protein. Source: Dubois et al., Lancet Neurology 2007; 6: 734–746.

Clinical features

Loss of memory for recent events is the characteristic presenting feature. Patients have great difficulty learning and retaining new information. Although insight may be preserved in the early stages, some patients appear relatively unaware of their limitations. Later more marked memory disturbance results in disorientation with altered behaviour/personality. Ultimately there is global loss of cognitive function with complete dependence and death usually within 5–10 years.

Diagnostic criteria

Recent revisions to clinical diagnostic criteria incorporating new knowledge from neuroimaging findings, CSF biomarkers and genetic screening allow for earlier and more accurate diagnosis in more than three-quarters of all cases (Box 15.2).

Management

The use of simple memory aids, avoidance of sedative drugs/alcohol and maintenance of general health can all contribute to preservation of function and independence in the early stages of the disease.

Cholinesterase inhibitors, e.g. donepezil, rivastigmine and galantamine, and memantine (which regulates glutaminergic signalling) are the mainstays of pharmacological intervention. These agents are symptomatic, their effects are not long-lasting and they do not slow the progression to more advanced forms of the disease.
The development of potential disease-modifying agents is currently a central focus of research in AD, with candidates including immunotherapy (to target Aβ), secretase inhibitors (which prevent cleavage of APP to Aβ) and inhibitors of τ protein aggregation. Adjunctive therapies, including behavioural approaches, and use of antidepressants, antipsychotics and anti-epilepsy drugs may be required. Later in the illness there is increasing dependence and requirement for full-time care.

Multi-infarct dementia

Multi-infarct dementia is often of abrupt onset with a stepwise progression over time and focal neurological features may be evident. Predisposing factors (e.g. smoking, hypertension, hyperlipidaemia, diabetes mellitus) and more widespread vascular disease are often present. Postmortem studies have shown that pathological changes associated with vascular lesions and AD often coexist, in keeping with current beliefs that vascular dementia and AD are part of a continuum.

Fronto-temporal dementia (Pick’s disease)

There is focal cortical atrophy with astrocytosis and intraneuronal inclusion bodies (Pick bodies) in surviving pyramidal cells. Patients present with frontal type dementia, i.e. altered personality, disinhibition (including violence), apathy, and poverty of speech with relatively preserved spatial skills and memory, which distinguish the disease clinically from AD. Pick’s disease is also more common in a younger age group. Treatment is limited to supportive measures and symptomatic control of aberrant behaviours.

Dementia with Lewy Bodies (DLB)

Characterised by widespread distribution of Lewy bodies in the CNS, DLB is increasingly recognised as a relatively common cause of dementia. Clinical features include:

- fluctuating cognition (often with nocturnal confusion)
- visual hallucinations
- Parkinsonism
- worsening of features with neuroleptic and antiparkinsonian drugs.

Treatment with cholinesterase inhibitors may be beneficial.

Parkinson’s disease with dementia (PDD)

In PDD dementia arises several years after onset of the movement disorder. The clinical and neuropsychological phenotype of PDD overlaps with that of DLB. When the movement disorder and dementia present within a year of each other, the patient is deemed to have DLB.

Prion diseases including Creutzfeldt–Jakob disease (CJD)

This rare group of neurodegenerative disorders has attracted considerable media attention following linkage of a variant of CJD to human consumption of prion-contaminated beef (bovine spongiform encephalopathy, BSE).

Classical CJD presents in late middle age with dementia accompanied by cortical visual problems, myoclonus and muscle wasting/fasciculation, which progresses to death within months. The EEG may show a characteristic abnormality and spongiform changes are found in the brain at postmortem. CJD, together with the other spongiform encephalopathies scrapie and BSE, is both inheritable and transmissible, the phenomenon being due to prion proteins (PrP) that are highly resistant to inactivation by heat or chemicals. An isoform of PrP exists in normal cells and mutations in its gene may give rise to inheritable autosomal dominant forms of disease. ‘Infectious’ transmission between humans (e.g. accidental inoculation following corneal grafts or after the use of human pituitary extract-derived growth hormone) or species (e.g. variant CJD and BSE) may occur, although how the abnormal form of PrP leads to disease remains unclear. There appears to be a long latency between exposure to infected material and clinical presentation, meaning that the true extent of the BSE-related CJD ‘outbreak’ remains to be seen.

Variant CJD occurs in younger patients, and its onset may be heralded by the development of psychiatric features, ataxia and sensory disturbance before the appearance of dementia.

Diagnosis remains largely clinical and treatment is supportive.

Huntington’s disease

Progressive dementia and involuntary chorea typically develop in middle age. Inheritance is autosomal dominant, although the disease may be late and variable in its presentation. Death usually occurs 10–15 years after the onset of symptoms. The Huntington’s gene (chromosome 4p16) contains an expanded CAG trinucleotide repeat which tends to increase as the gene passes from parent to offspring, providing an explanation for ‘anticipation’, the phenomenon by which the disease gets progressively more severe through successive generations.
Management

Tetrabenazine may help the chorea by depleting nerve endings of dopamine, but extrapyramidal dysfunction and depression are common side effects. Presymptomatic genetic screening of unaffected family members must be approached with great care because of the implications of a positive test for the patient and family whilst no disease modifying therapy is available.

Alcohol-related dementia

This is distinct from Wernicke–Korsakoff syndrome (due to thiamine deficiency) and likely reflects synaptic and neuronal loss due to direct toxic effects of alcohol.

HIV-associated dementia

Although there has been a decline in the prevalence of frank HIV-associated dementia with the advent of highly active antiretroviral therapy (HAART), the prevalence of HIV-associated neurocognitive disorders is increasing with improved life expectancy.

Normal-pressure hydrocephalus

This condition presents with dementia, pyramidal signs in the limbs causing ataxia and urinary incontinence. Gross ventricular enlargement without cortical atrophy is evident on CT/MRI scanning. Isolated CSF pressure measurements are typically normal, but continuous monitoring may reveal intermittent periods of raised pressure. Some patients respond to ventriculoperitoneal shunting.

Multiple sclerosis

Multiple sclerosis (MS) is a demyelinating disease characterised by episodes of neurological deficit appearing irregularly throughout the CNS both in anatomical site and time. The UK prevalence is estimated at 1 : 1000 with a slight preponderance in women (male : female ratio ~1 : 1.5). First episodes usually occur in young adulthood, with a peak at around 30 years.

Aetiology

The aetiology of MS remains unknown. Currently, the favoured hypothesis is that an environmental trigger (e.g. a viral infection) precipitates the condition in a genetically susceptible individual.

The presence of chronic inflammatory cells in active plaques and linkage of the disease to certain major histocompatibility complex (MHC) genotypes suggests an immune basis for the disorder. MHC linkage, together with the observation that MS is more common in monozygotic than dizygotic twins, suggests a genetic component.

Pathophysiology

Patches of demyelination occur in discrete areas (plaques) in the white matter of the brain and spinal cord (with relative axonal sparing), especially in:

- optic nerves
- brainstem
- cerebellar peduncles
- dorsal and pyramidal (lateral) tracts.

Demyelination leads to a reduction in conduction velocity, with initial distortion and subsequent loss of impulse conduction. Oedema around acute lesions contributes to the neurological deficit. Function typically improves as oedema resolves. Later, scarring (gliosis) gives rise to the characteristic white plaque.

Clinical presentation

Symptoms include visual disturbance, clumsiness, weakness, numbness, tremor, cognitive impairment, bowel or bladder disturbance and sexual dysfunction reflecting the distribution of plaques.

- **Visual disturbance:** optic (retrobulbar) neuritis is a common presenting feature. Symptoms include pain around one eye (exacerbated by movement), blurred vision and loss of colour vision. On examination visual acuity/colour vision are reduced with a relative afferent pupillary defect, there may be a field defect (typically central scotoma) and the optic disc is pink and swollen. Diplopia with internuclear ophthalmoplegia may occur. A single episode of optic neuritis does not necessarily herald the onset of MS and in isolation should not be used to make the diagnosis.

- **Upper motor neurone deficit:** paraparesis, hemiparesis or monoparesis.

- **Sensory deficit:** paraesthesia and proprioceptive loss in a limb or half of the body. Lesions in the posterior columns of the cervical cord may induce tingling sensations shooting down the arms or legs on neck flexion (L’Hermitte phenomenon).

- **Cerebellar signs:** intention tremor, nystagmus, vertigo and dysarthria.

- **Bladder dysfunction:** urgency and frequency, followed by incontinence.

- **Bowel disturbance:** constipation, urgency of defecation.

- **Erectile dysfunction and ejaculatory failure** are common.
- Cognitive impairment: IQ and language skills are preserved until late in the disease. Memory, learning and the ability to deal with abstract concepts may deteriorate in chronic forms.

Symptoms are commonly made worse by exertion and heat (Uhthoff phenomenon).

Clinical features

Clinical features commonly evolve over days or weeks, reach a plateau and gradually resolve (partially or completely) over weeks or months. Recurrences are unpredictable and may affect the same or different parts of the CNS. There are no clearly identified precipitating factors, although intercurrent illness and pregnancy may be implicated in relapses.

Four main patterns of disease are recognised:

- Relapsing–remitting (~80% of cases): initial episodes may resolve completely or nearly so. Subsequent episodes usually result in some residual disability, with patients eventually progressing to the secondary progressive form.
- Secondary progressive: steady progression without remission.
- Primary progressive: no clear-cut relapses or remissions; more common in those presenting in middle age with a spastic paraparesis.
- Progressive-relapsing (rare): variable history. Some patients have years between relapses while others experience a debilitating progressive deterioration from an early stage.

Diagnosis/investigation

Clinically the diagnosis is made on the basis of at least two characteristic episodes of neurological dysfunction, separated in time and space. Diagnosis is confirmed by anatomical evidence of separate lesions in the CNS, demonstrating CNS immunological dysfunction and excluding other diagnoses.

- Visual evoked potentials (VEP): demyelination causes an abnormality (usually delay) in occipital EEG tracings in response to a stimulus presented to the eyes. Abnormalities are present in 95% of patients with MS, but are not specific; sensory and auditory evoked potentials may also show delay.
- Lumbar puncture: reveals a lymphocytosis and raised CSF protein (up to 1 g/l) in the presence of active disease; CSF immunoelectrophoresis shows an increased proportion of immunoglobulin G (IgG) and oligoclonal bands.
- MRI: plaques of demyelination appear as bright lesions and clinically silent lesions are frequently revealed. These features are not specific to MS and false-negative scans may occur.

Differential diagnosis

For relapsing–remitting disease:

- transient ischaemic attack
- systemic lupus erythematosus
- sarcoidosis.

For primary progressive disease:

- other causes of a spastic paraparesis
- motor neurone disease
- spinal/cerebellar degenerative disorders.

Management

Physiotherapy, rehabilitation, medical therapy, surgery and psychological support all have a role. Treatment is aimed at:

- management of an acute relapse
- modifying the course of the disease
- symptom control.

Acute relapse

High dose corticosteroids (e.g. methylprednisolone intravenously) may improve the speed of recovery during acute exacerbations.

Disease-modifying agents

- Interferon beta: two forms are available – interferon beta-1a (identical to its natural counterpart) and interferon beta-1b (harbouring a single amino acid substitution); primarily for use in relapsing–remitting MS, but not all patients respond. The results of clinical trials have shown varying efficacy, but, in general, treatment is associated with an approximately one-third reduction in relapse frequency and a small slowing of the rate of progression. Its role in secondary progressive disease remains unclear.
- Glatiramer: an immunomodulating agent, reduces relapses and MRI abnormalities in patients with relapsing–remitting disease.
- Several other biological agents have also shown significant efficacy in MS. Natalizumab, a monoclonal antibody that inhibits leucocyte migration into the CNS, is an option for the treatment of adults with highly active relapsing–remitting MS that has not responded to other disease-modifying agents. However, its more widespread use is limited due to an increased risk of opportunistic infections and the potentially fatal side effect of progressive multifocal leucoencephalopathy. Other monoclonal antibodies (e.g. Alemtuzumab, which targets CD52 on the surface of mature lymphocytes) are also the subject of ongoing clinical trials, and again show promise in relapsing–remitting disease.
Symptom control in chronic disease

- Weakness: physiotherapy and rehabilitation are important.
- Spasticity/flexor spasms: may respond to stretching exercises, alone or in combination with antispasmodic agents such as benzodiazepines or baclofen. Dantrolene acts directly on skeletal muscle to reduce spasm. Botulinum toxin injections may be tried. Intractable spasticity may require tenotomy or neurectomy.
- Bladder dysfunction: antimuscarinic agents (e.g. oxybutynin, tolterodine) increase bladder capacity by diminishing unstable detrusor contractions and α-adrenoceptor blockers may be of benefit. Self-catheterisation enables some patients to remain free from a permanent indwelling catheter.
- Sexual dysfunction: oral phosphodiesterase type 5 inhibitors (e.g. sildenafil) or intracavernosal injection of papaverine may be of benefit for erectile dysfunction.
- Psychological support: patients may remain euphoric but often there is marked depression.

Prognosis

The average life expectancy from onset of symptoms is 20–30 years. Overall, 80% of patients experience steadily progressive disability, 15% follow a relatively benign course and 5% die within 5 years. There may be a long latent period (15–30 years) after an episode of optic neuritis before further symptoms occur. Patients whose disease onset is sensory tend to have a better prognosis. Poor prognostic factors are older age at onset, early cerebellar involvement and loss of mental acuity.

Motor neurone disease

Motor neurone disease (MND) is an adult-onset neurodegenerative disorder characterised by progressive degeneration of:

- anterior horn cells in the spinal cord
- cells of the lower cranial motor nuclei
- neurones of the motor cortex with secondary degeneration of the pyramidal tracts.

MND causes progressive weakness of limb, bulbar and respiratory muscles, with death typically ensuing in 3–5 years, commonly due to respiratory failure.

It usually presents between the ages of 50 and 70 years, more frequently in men than women (1.5 : 1). The UK incidence is 1–2 per 100,000, with a prevalence of 5 per 100,000 of the population; 90% of MND occurs sporadically. Most familial MND is autosomal dominant with ~ 20% of cases exhibiting mutations in the antioxidant enzyme copper-zinc superoxide dismutase (SOD1) gene. Mutations in two other genes encoding RNA/DNA binding proteins (TARDBP and FUS genes) have also been reported, accounting for a further 10% of inherited cases.

Two main mechanisms are thought to contribute to motor neurone degeneration:

- excitotoxicity – overstimulation of glutamate receptors with consequent cellular calcium overload
- free radical damage.

Classification

- **Amyotrophic lateral sclerosis (ALS; most common):** loss of upper and lower motor neurones (UMN and LMN) producing a mixed picture
- **Progressive muscular atrophy (PMA):** predominantly LMN
- **Primary lateral sclerosis (PLS; rare):** predominantly UMN

MND may be associated with extra-motor features, e.g. fronto-temporal dementia in ALS. Progressive bulbar palsy is considered a variant of ALS, affecting the bulbar region.

Clinical presentation

- LMN weakness, with wasting and fasciculation of the small muscles of the hand followed by wasting of upper and lower limb muscles
- LMN weakness, fasciculation and wasting of the tongue and pharynx producing dysarthria, dysphagia, choking and nasal regurgitation
- UMN spastic weakness starting in the legs and spreading to involve the arms

Fasciculation of some limb musculature is a hallmark of the disease. Lower limb lesions are often UMN type and upper limb lesions LMN type. The limbs may demonstrate marked muscular wasting, but still have exaggerated reflexes. Pseudobulbar palsy may occur. The bladder is not affected.

Diagnosis

Criteria for the diagnosis of ALS have been proposed and include:

- evidence (clinical, electrophysiological or neuropathological) of LMN degeneration
- evidence (clinical) of UMN degeneration
- progressive spread of symptoms or signs within a region or to other regions
- no radiological, electrophysiological or pathological evidence of other disease.
Investigation

There is currently no definitive test for MND. Investigations are geared towards excluding other (potentially treatable) conditions which can mimic the different subtypes of MND:

- **ALS**: multiple-level spinal cord/root compression, paraneoplastic syndromes, thyrotoxicosis, inclusion body myositis
- **PLS**: multiple sclerosis, spinal cord compression, hereditary spastic paraplegia
- **PMA**: multifocal motor neuropathy, Kennedy’s disease, spinal muscular atrophy, porphyria, lead poisoning.

Investigations include:

- Electrophysiology: useful in identifying LMN features in both clinically affected and clinically silent regions; electromyographic features include evidence of active and chronic denervation.
- Imaging: not required in all cases but may be undertaken to exclude other pathology.
- Other tests: these are generally dictated by the clinical presentation, but may include full blood count, ESR, renal, liver, bone and thyroid function, glucose, creatine kinase, serum electrophoresis/urine Bence–Jones protein, acetylcholine receptor antibody, CSF analysis, syphilis serology and genetic testing if familial disease is suspected.

Management

MND is optimally managed by a specialist multidisciplinary team, including:

- neurologist
- nurse specialist
- physiotherapist
- occupational therapist
- speech and language therapist
- dietician
- gastroenterology and respiratory teams for nutritional/feeding and ventilatory support
- psychologist
- social worker and local hospice support are also important.

In the UK, the MND Association provides useful advice and support for patients and their relatives.

Disease-modifying therapy

Riluzole, which reduces presynaptic glutamate release, has been shown in a small number of trials to extend the lifespan of patients with ALS by an average of 3–4 months. Its role in PMA and PLS remains unclear.

Nutritional support

Good nutritional support from an early stage significantly contributes to quality of life and prognosis. Most MND patients eventually develop progressive bulbar problems, and advice regarding posture, airway protection and use of thickened fluids is important. Careful consideration is required regarding placement of a gastrostomy tube.

Respiratory support

Lung function tests should be performed at baseline and regularly thereafter – reduced forced vital capacity (FVC) in the supine versus upright position is an indicator of early respiratory failure. Aspiration pneumonia requires aggressive treatment.

Non-invasive positive pressure ventilation (NIPPV) confers a survival benefit and improves quality of life providing that bulbar dysfunction is not severe.

Other measures

- quinine for cramps
- baclofen and diazepam for spasticity
- carbocisteine (mucolytic), a ‘cough assist’ machine, suction and antimuscarinics for thick secretions
- laxatives for constipation
- tricyclic antidepressants or selective serotonin reuptake inhibitors for low mood/depression; these agents may also help with emotional lability due to pseudobulbar palsy

Prognosis

The median survival is 4 years, with a poorer prognosis in patients with bulbar onset.

---

Parkinson's disease and other extrapyramidal disorders

Parkinson's disease

Parkinson’s disease is a degenerative disorder predominantly affecting the extrapyramidal pathways and is associated with impaired dopaminergic neurotransmission. It is an akinetic-rigid syndrome (Table 15.5), estimated to affect ~1% of the population over the age of 60 years in the UK, with no significant gender bias.

Aetiology

In the majority of patients with Parkinson’s disease the cause remains unknown. Although a small number of causative gene mutations have been demonstrated
(in ~15% of patients), the majority of cases occur sporadically. It has been speculated that an as yet unidentified environmental toxin may selectively damage dopaminergic neurones in the substantia nigra, possibly acting in a similar manner to MPTP (methyl-phenyl-tetrahydropyridine), a synthetic heroin by-product, which was responsible for causing Parkinsonism in a group of illicit drug users in the USA in the 1980s (MPTP is converted by monoamine oxidase type B in glial cells to MPP\(^+\), a free radical and mitochondrial toxin, which is taken up and concentrated in dopaminergic neurones). The dopaminergic neurones projecting from the substantia nigra in the midbrain to the striatum of the basal ganglia (in particular the caudate nucleus and putamen) are the primary site of neuronal loss in Parkinson's disease. An imbalance between dopaminergic and cholinergic signalling in the extrapyramidal pathways ensues (dopaminergic insufficiency or cholinergic excess results in an akinetic-rigid syndrome; dopaminergic excess or cholinergic insufficiency leads to involuntary movements, i.e. dyskinesia).

### Clinical presentation

Parkinson’s disease is characterised by the triad of rigidity, tremor and bradykinesia plus postural abnormalities. The classical picture of Parkinsonism is of immobile flexion at all joints (neck, trunk, shoulders, elbows, wrists and metacarpophalangeal joints) except the interphalangeal, producing a flexed or stooped posture. From the early stages, on walking the arms do not swing fully and later in the disease the gait is stuttering and shuffling and the patient may show festination. He/she is slow and unstable on the turn and may ‘freeze’. The face is expressionless (‘mask-like facies’), eyes unblinking and speech quiet and monotonous.

- difficulty in initiating movement
- poor balance with a tendency to fall because of slow correcting movements (± postural hypotension)
- small handwriting (micrographia)
- seborrhoea
- increased salivation (which, with dysphagia, may give rise to drooling)
- a soft unintelligible voice (dysarthria)
- constipation and urinary frequency, sometimes with incontinence
- oculogyric crises (forced upwards deviation of the eyes); this occurs characteristically in drug-induced and postencephalitic Parkinsonism.

Parkinsonism is usually asymmetrical. The repetitive, rhythmic tremor (frequency: 4–6 Hz) is usually most obvious in the hands (where it is described as ‘pill-rolling’). It is typically improved by voluntary movement and made worse by anxiety. Titubation refers to tremor involving the head. Repeated movements, such as tapping with the fingers, although regular in rate, are reduced in both amplitude and speed. The rigidity may be lead-pipe or, with the tremor superimposed, cogwheel. There may be a positive glabellar tap sign (blinking on repeated tapping of the forehead). With advanced disease, patients may suffer insomnia, depression and dementia.

### Diagnosis

Diagnosis is based on the classical clinical triad. The history may help reveal an underlying cause for Parkinsonism or other causes of an akinetic-rigid syndrome, thus helping to target treatment more effectively. Brain imaging is rarely helpful. An empirical trial of therapy may help confirm the diagnosis in less clear-cut cases.

### Management

The object is to reduce each of the symptoms using a combination of pharmacological agents, physiotherapy, occupational and speech therapy. Coexistent depression should be treated. Postural hypotension may be exacerbated by certain drug treatments.

Two major classes of drugs are used: dopaminergic and anticholinergic agents, which help to address the
imbalance between insufficient dopaminergic and relatively excessive cholinergic tone respectively. As a general rule, treatment is best delayed until symptoms warrant it.

**Dopaminergic agents**

Levodopa (L-DOPA) is a precursor of dopamine which crosses the blood–brain barrier following oral administration. It is given in combination with a peripherally acting DOPA decarboxylase inhibitor (e.g. benserazide (i.e. co-beneldopa) or carbidopa (i.e. co-careldopa)) to prevent its peripheral metabolism, which also helps to reduce side effects. It is effective in 75% of patients with idiopathic Parkinson’s disease and excellent in 20%, particularly in those with bradykinesia.

After several years (typically 2–5) of treatment, the efficacy of L-DOPA therapy may be limited by the development of ‘late’ side effects including:

- Motor fluctuations: e.g. ‘wearing-off’ where the response to a given dose is shorter-lived than previously, and ‘on-off’ phenomenon where the patient may switch from being reasonably well-controlled (‘on’) to an akinetic-rigid state (‘off’), but without any obvious relationship to the timing of drug doses.
- Dyskinesias: related to high dopamine levels (‘peak-dose dyskinesias’), or painful dystonia as dopamine levels fall (‘wearing-off dystonias’).

Helpful pharmacological manipulation includes increasing the dose frequency (but not the total daily dosage) of L-DOPA, using a slow-release preparation, or adding one of the following drugs:

- Selegiline and rasagiline: slow the enzymatic degradation of dopamine by monoamine oxidase type B (MAO-B).
- Entacapone: slows the enzymatic degradation of dopamine by catechol-O-methyl-transferase (COMT).
- Dopamine receptor agonists including ergot derivatives (bromocriptine, cabergoline), ropinirole (a D2-agonist) and pramipexole (a D2- and D3-receptor agonist). These also may be used as mono-therapy in early Parkinson’s disease, potentially delaying the need for L-DOPA.

NB Ergot-derived dopamine receptor agonists have been linked with pulmonary, retroperitoneal and cardiac valvular/pericardial fibrotic disorders when used at the high dosages required for the treatment of Parkinson’s disease. Many neurologists therefore consider these to be second-line agents, and close surveillance (echocardiography, pulmonary function testing, ESR) is required in all those receiving treatment with these agents.

- Apomorphine: a potent D1- and D2-receptor stimulant.

Domperidone (limited central antidopaminergic activity) for nausea, and atypical antipsychotic agents (e.g. olanzapine, quetiapine) or cholinesterase inhibitors (e.g. donepezil, rivastigmine) for hallucinations in those with cognitive impairment, may be used to alleviate the side effects of L-DOPA therapy.

**Anticholinergic agents**

Antimuscarinic drugs (e.g. trihexyphenidyl (benzhex-ol), orphenadrine, procyclidine) can be tried as first-line therapy in mild disease, in patients poorly tolerant of dopaminergic therapy, and in drug-induced Parkinsonism. Anticholinergic side effects limit their use especially in the elderly.

**Amantadine**

This promotes dopamine release and inhibits its re-uptake, but is only mildly beneficial in early Parkinson’s disease. It improves mild bradykinesia, tremor and rigidity. It may be useful for alleviating dyskinesias in more advanced disease.

**Surgical treatment**

Stereotactic thalamotomy is rarely used for intractable tremor in the non-dominant limbs on the contralateral side. Pallidotomy may alleviate drug-induced dyskinesias. Newer approaches include stimulation of these deep brain nuclei and surgical approaches to the subthalamic nucleus.

Cell transplantation, using fetal substantia nigra, is considered primarily an experimental technique.

**Prognosis**

Parkinson’s disease is progressive in most cases, and if left untreated most patients succumb to complications (e.g. pneumonia, pulmonary emboli) within 10 years.

**Other idiopathic akinetic-rigid syndromes**

**Multiple system atrophy**

Extrapyramidal features occur in combination with one or more of the following:

- autonomic failure (Shy–Drager syndrome)
- cerebellar dysfunction
- pyramidal features.

**Supranuclear palsy (Steele–Richardson–Olszewski syndrome)**

A very rare degenerative condition of the upper brainstem similar to Parkinson’s disease. It is characterised by:
• expressionless facies
• axial rigidity
• limb extension rather than flexion
• lead-pipe rigidity and cogwheeling
• fixation of voluntary vertical, followed by lateral and convergence, eye movements
• pseudobulbar palsy
• falls
• later dementia.
Response to anti-Parkinson’s therapy is poor.

Other movement disorders

Tremor
Causes include:
• physiological tremor, including exacerbation by anxiety, alcohol, drugs, thyrotoxicosis
• essential tremor
• postural tremor
• Parkinson’s disease and other akinetic-rigid syndromes (associated with ‘rest tremor’)
• cerebellar disorders (associated with ‘intention tremor’).

Chorea
Irregular random and variable movements which may have a flowing/semipurposeful quality. Any part of the body can be affected. Causes include:
• hereditary (e.g. Huntington’s chorea)
• post-infectious (e.g. Sydenham’s chorea in association with rheumatic fever)
• polycythaemia rubra vera
• thyrotoxicosis
• systemic lupus erythematosus
• pregnancy and oral contraceptive
• phenytoin, neuroleptics, alcohol.

Hemiballismus
Violent jerky movements, typically restricted to one side of the body and secondary to damage to the contralateral subthalamic nucleus.

Athetosis
Slow writhing movements most commonly seen with congenital brain damage in cerebral palsy.

Dystonia
Involuntary sustained muscle contractions resulting in abnormal postures which may be focal (e.g. blepharospasm, spasmodic torticollis, laryngospasm, trismus) or generalised (e.g. primary torsion dystonia).

Myoclonus
Rapid, abrupt, jerky movements of part or all of the body, which may occur in epilepsy or arise from elsewhere in the central nervous system causing myoclonic jerks.

Tics
Rapid, compulsive, repetitive stereotyped movements, also referred to as ‘habit spasms’. In Gilles de la Tourette syndrome, complex tics are associated with involuntary utterances which may be repetitive (‘echolalia’) and obscene (‘coprolalia’).

Disorders of the spinal cord (Table 15.6)

Spinal cord compression

Aetiology
Disorders of vertebrae (extradural; ~45% of cases)
• cervical spondylosis
• collapsed vertebral body (malignancy, osteoporosis)
• prolapsed intervertebral disc
• tuberculosis, abscesses, Paget’s disease, reticuloses, angiomas, cervical and lumbar stenosis

Meningeal disorders (intradural; ~45%)
• neurofibromas
• meningiomas

Disorders of the spinal cord (intramedullary; 5–10%)
• gliomas
• ependymomas

Clinical presentation
Patients present with a spastic paraparesis:
• upper motor neuron weakness in the legs
• loss of sphincter control
• loss of abdominal reflexes if the lesion is in or above the thoracic cord.

The level of the sensory loss (‘sensory level’) may, but does not necessarily, equate to the level of the lesion – it is vital not to unduly restrict imaging of the spine, otherwise a lesion at a higher level may be missed.
Lesions in the high cervical cord cause a spastic tetraparesis. Bladder involvement is an early feature of spinal cord disease, presenting with urgency, frequency and urge incontinence; bowel involvement occurs later; men may report erectile dysfunction. Cord compression is a neurosurgical emergency, particularly if of recent onset and rapid progression.

**Differential diagnosis**

Other causes of spastic paraparesis include:
- multiple sclerosis
- subacute combined degeneration of the cord
- transverse myelitis
- anterior spinal artery thrombosis
- motor neurone disease
- parasagittal cranial meningioma

**Cervical spondylosis**

Over 70% of the adult population in the UK have X-ray changes of osteoarthritic of the joints of the cervical spine, usually osteophytes. These radiological changes are unrelated to the presence or severity of symptoms.

**Clinical features**

Most patients are symptom-free. Clinical features may include:
- neck pain associated with and precipitated by movements of the neck
- cervical nerve root pain, paraesthesiae, numbness and sometimes segmental weakness with muscle wasting
- brisk reflexes in the arms and upper motor neurone damage affecting the legs caused by narrowing of the cervical canal with compression of the spinal cord or occlusion of the spinal cord vessels (spinal stenosis).

**Brown–Séquard syndrome**

Damage to one side of the cord produces a very characteristic pattern of sensory and motor loss with:
- an upper motor neurone weakness on the same side as the lesion (the descending corticospinal tracts have already crossed in the medulla)
- ipsilateral loss of position and vibration sense (the ascending fibres in the dorsal columns do not cross until they reach the medulla)
- contralateral spinothalamic (pain and temperature) sensory loss (as these pathways cross at, or just above, their point of entry into the cord); however, a narrow band of ipsilateral spinothalamic sensory loss may be seen at/close to the level of the lesion, reflecting involvement of fibres which have not yet decussated.

In its most severe form (cord hemisection), this is known as the Brown–Séquard syndrome.

**Syringomyelia**

A rare condition characterised by development of a longitudinal CSF-filled cyst/cavity (syrinx) in the
cervical cord and/or brainstem (syringobulbia) anterior to the central canal which spreads asymmetrically to each side. It may be caused by outflow obstruction of the fourth ventricle from a congenital anomaly such as the Arnold–Chiari malformation. It is usually slowly progressive over 20–30 years.

Damage to the cord occurs as follows:

- at the root level of the lesion in the decussating fibres of the lateral spinothalamic tracts (pain and temperature) and anterior horn cells where the lower motor neuron starts
- distant from the lesion in the upper motor neuron in the pyramidal tracts.

Syringomyelia presents with painless injury to the hands (sensory C6, 7, 8) and weakness and wasting in the small muscles of the hands (T1).

Examination may reveal more extensive asymmetrical dissociated sensory loss in the cervical segments, upper motor neuron signs in the legs and Charcot joints in the upper limbs. Surgical decompression of the foramen magnum and aspiration/drainage of cysts should be considered.

Syringobulbia

In syringobulbia the descending root of the trigeminal nerve (pain and temperature) may be involved with a Horner syndrome from involvement of the cervical sympathetic tract. The motor nuclei of the lower cranial nerves may cause rotatory nystagmus from involvement of vestibular and cerebellar connections.

Subacute combined degeneration of the cord

The neurological consequences of vitamin B₁₂ deficiency include subacute combined degeneration of the cord, signs of peripheral neuropathy, dementia and optic atrophy.

Combined degeneration refers to the combined demyelination of both pyramidal (lateral columns) and posterior (dorsal) columns.

Clinical presentation

Sensory peripheral neuropathy with numbness and paraesthesia in the feet are the usual presenting symptoms. Less commonly, the disease presents as a spastic paraparesis. The signs are:

- posterior column loss (vibration and position senses, with positive Romberg’s sign, p. 49)
- upper motor neurone lesion (weakness, hypertonia and hyperreflexia, with absent abdominal reflexes and upgoing toes)
- peripheral neuropathy (absence of all the jerks, reduced touch sense).

Investigation

- serum B₁₂ and folate levels
- bone marrow aspiration/biopsy
- parietal cell and intrinsic factor antibodies

Management

Vitamin B₁₂ (hydroxocobalamin).

Prognosis

Neurological symptoms and signs usually improve but may remain unchanged or, rarely, continue to progress. Sensory abnormalities resolve more completely than motor.

Spinal root disease (radiculopathy)

Spinal nerve roots may be compressed or damaged as they emerge from the intervertebral foramina on either side of the spinal column. Examples of radiculopathy include:

- Cervical radiculopathy: e.g. due to degenerative cervical intervertebral disc disease, spondylosis or tumour.
- Cauda equina: the spinal cord ends with the conus medullaris (usually at the lower border of the L1 vertebra), below which the lumbar and sacral nerve roots follow a long course in the spinal canal (comprising the cauda equina), before exiting through their respective foramina; compression of the cauda equina is typically associated with lower motor neurone signs and sensory features at several levels, and bladder involvement is common (retention with overflow); if there is also involvement of the lower end of the cord (‘conus lesion’), then mixed upper and lower motor neurone signs may be present; disturbance of the blood supply to the cauda equina may result in transient/intermittent neurological symptoms and signs, which are exacerbated by exercise, and which can be confused with intermittent claudication due to vascular insufficiency – however, recovery from the latter is typically more rapid (1–2 min as opposed to 5–10 min at rest) and there are no sensorimotor features.
- Prolapsed lumbar intervertebral disc.
- Acute central disc prolapse: this is a neurosurgical emergency, typically presenting with severe back pain, bilateral lower limb weakness and urinary retention/bowel dysfunction. Urgent imaging and decompression are required.
Peripheral nerve disorders

Peripheral nerves may be affected:
- in isolation (e.g. by trauma) leading to a mononeuropathy
- as part of a systemic disorder that renders them susceptible to pressure (e.g. diabetes mellitus)
- by compromise of their vasculature, e.g. vasculitis in multifocal neuropathy (mononeuritis multiplex)
- as part of a polyneuropathy (classical peripheral neuropathy), commonly due to inflammatory, metabolic or toxic disorders.

Mononeuropathies

Carpal tunnel syndrome

Due to compression of the median nerve as it passes under the flexor retinaculum and through the carpal tunnel at the wrist; commonly bilateral. Predisposing conditions include:
- pregnancy
- local deformity (e.g. secondary to osteoarthritis, fracture)
- diabetes mellitus
- rheumatoid arthritis
- hypothyroidism
- acromegaly
- amyloidosis.

It is characterised by pain and tingling paraesthesia in the hand or arm, typically worse at night, with wasting of the muscles of the thenar eminence and sensory loss in the distribution of the median nerve (radial three-and-a-half digits).

Tinel’s (tapping over the median nerve) and Phalen’s (forced flexion of the wrist) tests may reproduce tingling paraesthesia.

Diagnosis can be confirmed with electromyography, and secondary causes should be sought. Treatment depends on severity, but may include splinting (especially at night), local injection of corticosteroids and surgical decompression.

Ulnar neuropathy

Typically due to compression of the ulnar nerve at the elbow. It is characterised by pain and/or paraesthesiae radiating along the ulnar border of the forearm, with wasting of the small muscles of the hand but sparing of the thenar eminence; there is also sensory loss in the hand in the distribution of the ulnar nerve.

Electromyography can be used to confirm the diagnosis; treatment may involve splinting and/or surgical decompression/transposition of the ulnar nerve.

Radial neuropathy

Pressure on the radial nerve in the upper arm may lead to wrist drop – most commonly seen with prolonged abnormal posture of the upper arm (e.g. draped over the back of a chair).

Others
- Brachial plexus lesions – including: Erb’s palsy (upper nerve roots) and Klumpke’s palsy (lower nerve roots) typically due to traction injury (e.g. as a result of birth injury or RTA); cervical rib; Pancoast tumour (may be associated with Horner syndrome).
- Meralgia paraesthetica – numbness in the thigh due to compression of the lateral cutaneous nerve of the thigh as it passes under the inguinal ligament.
- Lateral popliteal palsy – the common peroneal nerve is susceptible to pressure damage as it travels around the neck of the fibula, resulting in foot drop (weakness of ankle dorsiflexion and eversion and extensor hallucis longus, with variable sensory disturbance); it is more common in diabetes mellitus.

Multifocal neuropathy/mononeuritis multiplex

An asymmetrical neuropathy affecting two or more peripheral nerves at one time, producing symptoms of numbness, paraesthesiae and sometimes pain in their sensory distribution with associated muscle weakness and wasting.

Causes are shown in Table 15.7.

Peripheral polyneuropathy

Diffuse disease of the peripheral nerves classified according to whether there is sensory or motor involvement or both, and whether the site of disease is the myelin sheath (demyelinating neuropathy) or the nerve fibre (axonal neuropathy). Long-standing disease may result in claw deformities of the foot (pes cavus) and hand and sensory loss may lead to neuropathic ulceration and joint deformity (Charcot arthropathy). Coexistent autonomic symptoms may be present. Numerous causes are recognised (Table 15.8), but four disorders account for most cases:
- diabetes mellitus
- carcinomatous neuropathy
- vitamin B deficiency (including B12)
- drugs or toxins.

In a significant number the aetiology remains unknown.
Diabetic neuropathy (see metabolic disorders, p. 243)

Diabetes mellitus causes a distal, predominantly sensory neuropathy commonly affecting the lower limbs in a stocking distribution. Symptoms of numbness, paraesthesia and sometimes pain in the feet are associated with loss of vibration and position sense and loss of the ankle reflex. It may be associated with Charcot arthropathy.

Carcinomatous neuropathy

Cancer may be associated with either a sensory neuropathy in a 'glove-and-stocking' distribution or motor neuropathy in which there is muscle weakness and wasting, usually of the proximal limb muscles. The neuropathy may be mixed.

Vitamin B Deficiency

Vitamin B1 deficiency, usually seen in patients with alcoholism, presents with a sensory neuropathy characterised by numbness ('walking on cotton wool'), paraesthesia, pain and soreness of the feet. In vitamin B12 deficiency the peripheral neuropathy may be associated with megaloblastic anaemia and subacute combined degeneration of the cord (p. 194).

Disorders of the neuromuscular junction

Myasthenia gravis

A rare disorder (estimated incidence < 1/100,000, but prevalence ~1 : 10,000) in which muscle weakness results from failure of neuromuscular transmission. The number of functioning postsynaptic acetylcholine receptors (AChR) is reduced and a high titre of specific anti-AChR antibodies is found in ~85% of cases. Ten percent of patients have an associated thymoma. Excessive muscular fatigability may also occur in polymyositis and SLE and there is an increased incidence of myasthenia gravis in thyrotoxicosis. The Eaton–Lambert myasthenic syndrome is associated with malignant disease.

Clinical presentation

Painless muscular weakness is produced by repetitive or sustained contraction (fatigability typically worse at the end of the day or after exercise). This is most marked in the face and eyes, producing
a symmetrical ptosis and diplopia. Dysarthria and dysphagia with nasal regurgitation of liquids may occur. Proximal muscles are more often affected than the distal, and the upper limb more than the lower. There is no wasting and tendon reflexes are preserved. Involvement of respiratory muscles may require emergency treatment.

**Diagnosis**
- serum anti-AChR antibody titre
- edrophonium (‘Tensilon’) test: intravenous injection of edrophonium (short-acting anticholinesterase producing a temporary increase in synaptic acetylcholine levels) produces rapid, albeit transient, improvement in clinical features. Cardiac monitoring/resuscitation should be available (risk of bradycardia/asystole)
- EMG
- thyroid function tests
- CT scan of thorax for thymoma

**Treatment**
- Long-acting anticholinesterases orally: neostigmine or pyridostigmine, preferably titrated by increasing the dosage slowly until measured muscular strength is optimised.
- Corticosteroids: an alternate-day regimen (between 10 and 80 mg of prednisolone) should be started in hospital at a low dosage as there is a risk of increasing weakness in the early stages of therapy.
- Immunosuppression with azathioprine may be useful as a steroid-sparing agent.
- Thymectomy at any age increases the chance of remission.
- Plasmapheresis or intravenous immunoglobulin may be valuable in intractable cases, but the effect is short-lasting and best reserved for those preparing for thymectomy.

NB Certain antibiotics (e.g. aminoglycosides) may exacerbate neuromuscular blockade and should be avoided in patients with myasthenia gravis.

**Differential diagnosis**
- other causes of ptosis
- muscular dystrophies involving the face
- familial hypokalaemic paralysis

**Prognosis**
Myasthenia gravis may never progress beyond ophthalmoplegia and periods of remission of up to 3 years occur. The outlook is poor if the respiratory muscles are involved. Thymectomy usually improves the outlook unless a thymoma is present.

**Eaton–Lambert myasthenic syndrome**
A disorder of acetylcholine release in which myasthenia is usually associated with small cell carcinoma of the bronchus. It differs from classical myasthenia gravis in that the eyes are less frequently affected, proximal limb muscle weakness is common and their strength is initially increased by repeated movement. There is no response to edrophonium, but oral 3,4-diaminopyridine may help.

**Disorders of muscles**

**Myotonia**
Myotonia describes the inability of muscles to relax normally after contraction, producing a ‘reluctant release’ of handshake and percussion contraction (‘percussion myotonia’).

**Myotonic dystrophy (dystrophia myotonica)**
This is a rare autosomal dominant (chromosome 9) disorder producing progressively more severe symptoms and signs with succeeding generations, i.e. ‘anticipation’, and due to expansion of a CTG repeat in the 3’ untranslated region of the myotonin protein kinase gene (genetic locus 19q13). Both males and females are affected with usual onset at 15–40 years. UK incidence is estimated at 1 in 20,000.

**Clinical presentation**
- typical facies include frontal balding, ptosis, a smooth expressionless forehead, cataracts and a ‘lateral smile’
- wasting of the facial muscles, sternomastoids, shoulder girdle and quadriceps
- loss of limb reflexes with no fasciculation
- myotonia which increases with cold, fatigue and excitement and may reduce with repeated activity
- testicular or ovarian atrophy with impotence and infertility
- diabetes mellitus
- mental impairment
- cardiac abnormalities (e.g. conduction block)

**Treatment**
Phenytoin or mexiletine may reduce myotonia.
Muscular dystrophies

Pseudohypertrophic (Duchenne; Becker)

An X-linked recessive disorder due to mutations in the gene encoding the muscle cytoskeletal protein dystrophin. Prevalence is 3 in 100,000 and incidence 25 in 100,000 male births.

The severe childhood form (Duchenne muscular dystrophy) presents from an early age with difficulty in walking, climbing stairs and rising from the floor (children use their hands to ‘climb’ up their legs). On examination lordotic posture and waddling gait are seen because of weakness of the muscles of the pelvic girdle and proximal lower limb. The calves are hypertrophied but weak and the creatine kinase level is raised. Diagnosis is confirmed by EMG and muscle biopsy. Subsequent leg muscle contracture may produce talipes equinovarus and muscle weakness may spread to the upper limbs. Affected individuals usually die in their teens and 20s from associated complications including chest infections and cardiomyopathy.

Less severe mutations may present in adolescence or adulthood (Becker muscular dystrophy) and are compatible with a normal life span but may be associated with progressive disability.

Facio-scapulo-humeral (Landouzy–Déjérine)

A rare autosomal dominant trait which affects both sexes equally. The onset is at puberty with progressive wasting in the upper limb–girdle and face, with characteristic ‘winging’ of both scapulae. It may cease spontaneously or progress to the muscles of the trunk and lower limbs.

Limb-girdle (Erb)

A rare autosomal recessive trait which affects both sexes equally. It presents at 20–40 years and progressively involves the muscles of the shoulders and pelvic girdles.

Acquired muscular disorders

Inflammatory myopathies

Polymyositis may occur in isolation or in association with autoimmune connective tissue disorders (see rheumatology, p. 283). Dermatomyositis is characterised by an inflammatory myopathy in association with a characteristic ‘heliotrope’ facial rash and may indicate underlying malignancy in the elderly.

Neurological infections

Bacterial meningitis

Bacterial meningitis is usually caused by infection with one of three organisms: Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae. The annual incidence of bacterial meningitis is 5–10 per 100,000 in developed countries.

Meningococcal meningitis

N. meningitidis (meningococcus) is carried in the nasopharynx and produces epidemics of infection chiefly in children and young adults. These occur in conditions of overcrowding and in closed communities.

Clinical presentation

After an incubation period of 1–3 days, the disease begins abruptly with fever, headache, photophobia, nausea, vomiting and neck stiffness. Mental confusion, seizures and coma may follow. Physical examination reveals signs of infection (fever, tachycardia, hypotension) and there may be a characteristic purpuric/petechial rash. Neurological signs include ‘meningism’ (neck stiffness, positive Kernig’s sign), altered conscious level, features of raised intracranial pressure, cranial nerve palsies and other focal neurology.

Acute complications of meningitis include abscess formation, hydrocephalus, septic shock with cardiorespiratory collapse, disseminated intravascular coagulation and adrenal haemorrhage (Waterhouse–Friderichsen syndrome).

Investigations

CSF analysis typically reveals:

- purulent/turbid fluid
- raised opening pressure
- marked polymorph leucocytosis
- raised protein
- low glucose (< 50% of paired blood glucose level)
- Gram-negative diplococci may be identified on Gram stain, CSF culture or by molecular techniques.

In most UK centres CT head scan is now performed routinely before lumbar puncture to exclude raised intracranial pressure.

Other investigations should include:

- full blood count (neutrophilia)
- coagulation profile (disseminated intravascular coagulation)
- renal function (hyponatraemia, renal failure)
• blood cultures (may be positive even with negative CSF findings).

Treatment must not be delayed while investigations are being performed – bacterial meningitis may be fatal within hours, and early diagnosis and treatment with high dose antibiotics are essential. Urgent blood cultures should be taken and antibiotics started immediately.

**Treatment**

In suspected meningococcal meningitis, general practitioners should give a single dose of intravenous or intramuscular benzylpenicillin while arranging urgent transfer to hospital. Benzylpenicillin (2.4 g, 4-hourly) remains the drug of choice for meningococcal infection. Treatment is continued for 7 days.

Second-line treatment (when the patient is allergic to penicillins) involves cefotaxime (2 g, 6-hourly) or chloramphenicol (20 mg/kg, 6-hourly).

Supportive therapy with analgesics, intravenous fluids, anticonvulsants, inotropes and clotting factors may be needed. Early corticosteroid therapy may be important for reducing morbidity and mortality in uncomplicated bacterial meningitis.

**Prevention**

Chemoprophylaxis

Rifampicin or ciprofloxacin should be considered to eliminate nasopharyngeal carriage and for household or close contacts in consultation with the infectious diseases or communicable disease control team.

NB Meningitis is a notifiable disease in the UK.

**Vaccination**

Vaccines are currently available against *Neisseria meningitidis* serogroups A and C; most cases in the UK are caused by serogroups B and C. Childhood vaccination programmes are combined with targeted vaccination for non-immunised individuals considered to be at particular risk (e.g. students attending university, those with asplenia/splenic dysfunction and travellers to high-risk areas). The choice of vaccine depends on individual circumstances (for further information see the British National Formulary).

**Pneumococcal meningitis**

Infection may be secondary to pneumococcal pneumonia, or may spread from infected sinuses or ears or through skull base fractures. It is more common in children and the elderly and in patients with asplenia.

Benzylpenicillin is the drug of choice in penicillin-sensitive cases, but the emergence of resistant pneumococcal strains means that cefotaxime (or ceftiraxone) is preferred as first-line therapy. Treatment is continued for 10–14 days. Early corticosteroid therapy may confer benefits in pneumococcal meningitis.

Pneumococcal vaccination is advisable in patients with asplenia, chronic cardiac, renal or liver disease (especially if > 65 years), immunosuppression and conditions predisposing to CSF leakage. In addition, long-term phenoxymethylpenicillin (500 mg b.d.) is recommended for patients with asplenia.

**Haemophilus influenzae meningitis**

Usually occurring in the under-5s, the introduction of a vaccination programme has dramatically reduced the number of cases of meningitis due to *H. influenzae*. It often follows an influenzal type of illness, has a longer, insidious onset and presents with fever, nausea and vomiting.

Cefotaxime is the drug of choice and is given for at least 10 days (ceftriaxone and chloramphenicol are alternatives). Adjunctive dexamethasone therapy should be considered.

Chemoprophylaxis with rifampin is advised to prevent secondary infection. Immunisation using *H. influenzae* type b vaccine is routinely recommended for children at the ages of 2, 3 and 4 months.

**Acute bacterial meningitis of unknown cause**

In clinical practice this is a common scenario, especially when no organisms are seen with Gram staining of CSF. There is no time to wait for the results of culture, and antibiotics must be started immediately. In this setting, cefotaxime (or ceftiraxone) is the drug of choice (chloramphenicol is an alternative for those with a history of hypersensitivity to cephalosporins).

**Prognosis**

The mortality from acute bacterial meningitis remains high (~10% overall) and is greatest in pneumococcal disease, which is also more likely to leave patients with long-term sequelae, e.g. hydrocephalus, cranial nerve palsy, epilepsy.

**Tuberculous meningitis (see also tuberculosis, p. 349)**

This may present as acute meningitis but usually as an insidious illness with fever, weight loss and progressive signs of confusion and cerebral irritation (seizures and focal neurological signs) leading to mental deterioration and finally coma. Immunocompromised
individuals and those from certain ethnic groups are at greatest risk. At lumbar puncture the opening pressure is raised, polymorphs and lymphocytes are typically present, with raised protein and very low glucose. Auramine or Ziehl–Neelsen staining may reveal organisms, but prolonged culture is often required. Polymerase chain reaction (PCR) for bacterial nucleic acids offers a faster diagnostic route.

Treatment is with rifampicin, isoniazid (with pyridoxine cover), pyrazinamide and either ethambutol or streptomycin (the fourth agent can often be stopped after 3 months). A prolonged course (12 months or more) is usually required under close supervision. Corticosteroids are used during the early phase of treatment to suppress the host’s inflammatory response and risk of developing cerebral oedema.

**Intracranial abscess**

Brain abscess is rare. It may complicate otitis media or paranasal sinus infections or occur secondary to haematogenous spread from bacterial endocarditis or pulmonary infection. There may be a history of head injury or neurosurgery. The clinical features are typically those of an expanding mass lesion with fever and possible systemic illness. CT/MRI is required in any suspected case and lumbar puncture must not be performed where there is a risk of raised intracranial pressure.

Treatment involves surgical drainage, broad-spectrum antibiotics until an organism/sensitivities are available and high dose corticosteroids once antibiotics have commenced. It is essential to identify and treat the source of primary infection.

The mortality rate is high in cerebral abscess, and of those who survive up to one-third develop epilepsy.

**Parameningeal infections**

Occasionally pus collects in the epidural space, especially in the spine. *Staphylococcus aureus* is the most common organism, usually from skin infections. Vertebral osteomyelitis and accompanying discitis may complicate the picture. Fever and systemic upset are accompanied by severe back pain and paraparesis.

MRI scanning of the spine is the investigation of choice. Treatment is with anti-staphylococcal antimicrobial therapy and surgical drainage if there is neural compression.

**Lyme disease**

The spirochaete *Borrelia burgdorferi*, transmitted by tick bite, may produce neurological manifestations including fever, meningism and arthralgia in the acute phase. In chronic disease, meningitis, encephalitis, cranial nerve palsies, and spinal root and peripheral nerve lesions can occur.

Serological diagnosis is available in specialist laboratories. Treatment is with cefotaxime or ceftriaxone.

**Leprosy**

*Mycobacterium leprae* directly invades peripheral nerves leading to a patchy sensory (poly)neuropathy with associated thickening of peripheral nerves, which become palpable. Skin in affected areas may be depigmented and anaesthetic.

**Bacterial toxins**

**Botulism**

*Clostridium botulinum* causes acute gastrointestinal upset followed by a ‘descending paralysis’ (ptosis, diplopia, difficulty with accommodation, then bulbar and limb involvement); assisted ventilation may be required.

**Diphtheria**

*Corynbacterium diphtheriae* may cause a polyneuropathy.

**Tetanus**

*Clostridium tetani* causes tonic spasms of the jaw (‘lock-jaw’; trismus) and trunk (opisthotonos) and whole body fever. Treatment is supportive with muscle relaxants and ventilation together with penicillin, human antitetanus immunoglobulin and wound cleansing.

**Viral meningitis**

Many viruses have been implicated including:

- enteroviruses (coxsackie A and B, echoviruses, polioviruses)
- herpes simplex viruses HSV-1, HSV-2
- Epstein–Barr virus
- varicella zoster virus
- mumps
- measles
- adenoviruses.

Symptoms of headache and meningism are self-limiting and complications rare. At lumbar puncture the opening pressure may be raised but the CSF is clear with normal or modestly raised protein content and normal glucose. Mononuclear cells (lymphocytes) may be seen but no organisms.

**Viral encephalitis**

Viral infection of the brain parenchyma resulting in a lymphocytic inflammatory reaction with necrosis.
The most common cause is herpes simplex (HSV), but other pathogens include herpes zoster, cytomegalovirus, Epstein–Barr virus, adenovirus and mumps.

**HSV encephalitis**

Most episodes are thought to result from reactivation of latent virus and it is most common in immunocompromised subjects. A brief prodrome of headache, fever and malaise is followed by severe CNS dysfunction, with focal signs, seizures and reduced consciousness/coma.

CT/MRI may show low-density lesions with ring enhancement typically in the temporal lobes, although these can take several days to appear. EEG is abnormal with evidence of diffuse brain dysfunction and CSF findings are similar to those in viral meningitis. Identification of HSV viral DNA in CSF by polymerase chain reaction or detection of viral antigen by immunoassay, rising antibody titres to HSV and/or brain biopsy may all aid diagnosis. Treatment with intravenous aciclovir should be started as soon as the diagnosis is suspected.

**Retroviral infections (p. 343)**

HIV-AIDS may affect neurological function including:

- direct involvement of the nervous system causing a meningoencephalitic-like illness around the time of seroconversion and later a slowly progressive dementia with involvement of the spinal cord and peripheral nerves
- opportunistic infections such as cerebral toxoplasmosis, cryptococcal meningitis, cytomegalovirus, herpes simplex, herpes zoster
- progressive multifocal leukoencephalopathy (PML)
- cerebral lymphoma.

These events are rare in patients treated with HAART.

The human T cell lymphotrophic virus type 1 (HTLV-1), prevalent in certain equatorial areas, including the Caribbean, is neurotropic and causes tropical spastic paraparesis (HTLV-1-associated myelopathy, HAM).

**Protozoal infections**

- malaria – *Plasmodium falciparum* can cause haemorrhagic encephalitis
- toxoplasmosis
- trypanosomiasis – may present with low-grade encephalitis, hypersonolence and seizures (‘sleeping sickness’)

**Metazoal infections**

- hydatid disease – intracranial cysts present as mass lesions or rupture to produce meningitis
- cysticercosis – multiple cyst formation results in raised intracranial pressure, focal neurology and seizures

**Rabies**

Although eradicated from the UK and other countries, rabies remains endemic in certain parts of the world. Following a bite by an infected animal the virus migrates slowly to the CNS where it promotes an inflammatory reaction. Brainstem involvement induces fever, psychiatric disturbance and hydrophobia, whereas spinal cord involvement causes a flaccid paralysis. Prophylactic immunisation is advised when travelling to endemic regions and active and passive immunisation should be commenced after a ‘suspect’ animal bite, together with thorough wound cleansing.

**Poliomyelitis**

Polio remains endemic in the tropics despite its near eradication from the developed world following introduction of immunisation with the oral Sabin vaccine (live attenuated poliovirus).

**Clinical features**

Ninety to ninety-five percent of infected patients have mild upper respiratory or gastrointestinal symptoms that settle completely. The rest have a more severe early infection with fever, sore throat, diarrhoea or constipation and muscle pains. The minor illness usually settles, but 1–2% of patients go on to develop a major illness 5–10 days later with features of acute viral meningitis. A small number of patients with poliovirus meningitis develop flaccid lower motor neurone muscle paralysis with loss of reflexes following anterior horn cell damage. The legs are most commonly affected but paralysis may spread to the arms; involvement of the medulla oblongata and lower pons causes bulbar palsy.

Respiratory failure is a result of paralysis of the respiratory muscles and may be complicated by aspiration pneumonia secondary to dysphagia and an inability to cough caused by bulbar palsy.

There are no sensory neurological changes.

**Diagnosis**

CSF analysis reveals raised protein, increased polymorphs and lymphocytes and normal glucose. The virus can be grown from throat, stool and CSF and paired sera show a rising titre.

**Management**

There is no specific treatment but patients should be isolated and contacts immunised.
Management is supportive:
- artificial ventilation for respiratory failure
- careful nursing to prevent sores
- monitoring of fluid and electrolyte balance
- nutritional support
- physiotherapy and progressive rehabilitation are started after the fever has settled.

Prognosis
Patients with isolated bulbar palsy usually recover completely. In limb paralysis full muscle recovery is rare and paralysis of the respiratory muscles often requires continued artificial ventilation.

Syphilis of the nervous system
Neurosyphilis is now rare and can be avoided by early and correct treatment. There are several distinct clinical entities:
- **Mild (self-limiting) meningitis.**
- **Meningovascular disease:** occurs 3-4 years after primary infection involving fibrosis and thickening of the meninges with nipping and paralysis of cranial nerves, endarteritis causing cerebral ischaemic necrosis or spinal transverse myelitis and paraplegia, spinal meningeal thickening involving posterior spinal roots to produce pain and anterior roots to cause muscle wasting.
- **Tabes dorsalis:** occurs 10-35 years after primary infection. Degeneration of the dorsal columns and nerve roots causes severe paroxysmal stabbing pains that occur in the limbs, chest or abdomen. Paraesthesiae may occur with ataxia and a wide-based gait due to numbness and loss of joint position and vibration sensation. There are absent reflexes, positive Rombergism and a typical facies with Argyll Robertson pupils.
- **Generalised paralysis of the insane:** occurs 10-35 years after primary infection and is characterised by the physical signs of tabes dorsalis, plus evidence of cerebral cortical degeneration, and loss of memory and concentration with associated anxiety and/or depression. Later, insight is lost and the patient may become euphoric with delusions of grandeur and loss of emotional responses. Epilepsy is common.

Investigation
- Serological tests for syphilis may be performed on blood and CSF. CSF analysis may also reveal lymphocytosis, raised protein and oligoclonal bands.

Management
- Penicillin by injection is the drug of choice for active syphilitic infection. Improvement, stabilisation or deterioration may occur in any one case despite adequate penicillin therapy.
- The Jarisch–Herxheimer reaction is an acute hypersensitivity reaction and results from toxins produced by spirochaetes killed on the first contact with penicillin. Death has been reported in some cases, and hence corticosteroids are often given during the first few days of penicillin therapy to mitigate this risk.

Miscellaneous neurological disorders
Cerebral tumours
Intracranial neoplasms can be classified as:
- **Benign** – generally arising from meninges, cranial nerves or other structures and leading to extrinsic compression of the brain. They may be life-threatening due to local mass effect.
- **Malignant** – predominantly arising from the brain parenchyma. They may be primary (~20%, most commonly gliomas) or secondary (~80%, usually from bronchus, breast, kidney, colon, ovary, prostate or thyroid cancer).

Symptoms and signs
Caused by raised intracranial pressure
- headache
- mental confusion, change in personality, apathy, drowsiness
- sixth-nerve palsy results from pressure on the nerve as it crosses the petrous temporal bone (‘false localising sign’)

Epilepsy
Progressive focal neurological signs
These depend upon the site of the tumour:
- **Prefrontal:** progressive dementia with loss of affect and social responsibility, anosmia and positive grasp reflex in the contralateral hand.
- **Precentral:** contralateral hemiplegia (± Jacksonian epilepsy).
- **Parietal:** falling away of the contralateral outstretched arm, astereognosis, tactile inattention, apraxia and spatial disorientation. Low-sited tumours may produce lower quadratic
homonymous hemianopia rather than complete homonymous hemianopia. Dysphasia occurs with lesions in the dominant temporoparietal region.

- **Temporal lobe**: temporal lobe epilepsy, aphasia (if on the dominant side) and an upper quadrantic homonymous hemianopia.
- **Occipital lobe**: homonymous hemianopia with macular sparing.

**Investigation**

- CT or MR scanning will identify the tumour.
- Screening for primary tumours at the sites that most frequently metastasise to the brain should be undertaken if secondaries are suspected.

**Management**

Management depends upon the type of tumour and combines surgery, radiotherapy and chemotherapy. Some benign tumours may be amenable to complete excision. For malignant primary or secondary tumours, cure is generally not possible. Surgery may be indicated to establish a histological diagnosis and to relieve symptoms through debulking of the tumour. Pathological analysis confirms the nature of the lesion, excludes other treatable conditions (e.g. CNS lymphoma, cerebral abscess) and allows grading of the tumour which has prognostic value. Radiotherapy may treat both primary and secondary malignant CNS tumours and is also indicated in some benign lesions (e.g. recurrent pituitary adenoma, meningioma).

Chemotherapy may be used as an adjunct to surgery and/or radiotherapy. The oral alkylating agent temozolomide improves survival in gliomas when given in combination with radiotherapy.

Corticosteroids (e.g. dexamethasone) are used in patients with focal neurological features and/or raised intracranial pressure to reduce cerebral oedema. Anticonvulsants are used to control/reduce associated seizure activity.

**Specific intracranial tumours**

**Acoustic neuroma (Schwannoma)**

Arises from the nerve sheath cells of the acoustic (eighth) nerve in the region of the internal auditory meatus. It is more common in neurofibromatosis. Symptoms include progressive unilateral sensorineural deafness, diminished reaction on caloric testing, tinnitus and vertigo. Pressure on other ipsilateral cranial nerves at the cerebellopontine angle may produce:

- facial nerve palsy
- trigeminal nerve involvement.

Tumour growth produces ipsilateral ataxia (brainstem-cerebellar compression) and bulbar cranial nerve involvement.

**Meningioma**

Generally benign (although sometimes locally invasive or aggressive) tumours that arise from the meninges. In addition to clinical features common to all intracranial tumours, meningiomas in certain locations may manifest specific presenting symptoms/signs:

- olfactory groove: anosmia, papilloedema, frontal lobe dysfunction
- sphenoid wing: optic nerve compression with unilateral visual loss and optic atrophy
- parasagittal: spastic paraparesis
- cavernous sinus/parasellar region: cavernous sinus syndrome and/or hypothalamic-pituitary dysfunction.

Surgical excision or debulking is undertaken wherever possible, with radiotherapy reserved for surgically inaccessible, incompletely resected, or recurrent tumours.

**Pituitary adenomas**

These account for ~10% of all diagnosed intracranial neoplasms. Presentation is typically with one or more of the following:

- endocrine hyperfunction (e.g. hyperprolactinaemia, Cushing syndrome, acromegaly)
- endocrine hypofunction (i.e. varying degrees of hypopituitarism)
- local mass effects (e.g. optic chiasmal compression, cavernous sinus syndrome).

High resolution CT/MR scanning reveals pituitary ‘incidentalomas’ in 10–15% of the population, although most of these are non-functioning lesions that do not require treatment.

See pituitary disorders in Chapter 16.

**Guillain–Barré syndrome (GBS)**

GBS is characterised by ascending paralysis with subacute weakness and reduced tendon reflexes usually without sensory loss. There is an inflammatory demyelinating polyradiculoneuropathy affecting predominantly motor nerves. It has an annual incidence of 1–2 per 100,000 and is the most common cause of neuromuscular paralysis in the Western world.

**Aetiology**

GBS is due to an autoimmune peripheral neuropathy, usually in healthy individuals with no antecedent
history of autoimmune disease. Around 75% of patients give a history of an infectious illness preceding the onset of weakness by 1–2 weeks. Some antecedent infections share structural similarities with peripheral nerve components, e.g. *Campylobacter jejuni* contains \( \beta \)-N-acetylglucosamine residues homologous to the terminal carbohydrate residue of ganglioside GM1 and antibodies to one or more gangliosides are found in up to one-quarter of patients. Antibodies to ganglioside GQ1b are found in patients with the Miller–Fisher syndrome/variant.

**Clinical features**

Paraesthesia in the toes is followed within hours by flaccid paralysis of the lower limbs ascending to involve the arms and sometimes facial muscles, the muscles of the palate and pharynx and the external ocular muscles. Less commonly, the disease affects the upper limbs or the cranial nerves alone, or proximal more than distal muscles. Sensory symptoms are minimal or absent. GBS can be difficult to diagnose in the early stages as it may manifest with vague symptoms of weakness, neck or back pain and paraesthesia.

Paralysis is of lower motor neurone type and maximal disability occurs at 2–4 weeks. The major complications are:
- respiratory failure from weakness of respiratory muscles
- autonomic involvement causing lability of blood pressure and arrhythmias
- venous thrombosis with pulmonary embolism.

Very occasionally, patients present with a relapsing variant of GBS.

The Miller–Fisher variant is characterised by brainstem features of ataxia, ophthalmoplegia and areflexia.

**Differential diagnosis**

- brainstem infarct
- acute spinal cord lesion
- infection (e.g. Lyme disease, poliomyelitis)
- inflammation (e.g. neurosarcoidosis)
- paraneoplastic syndrome
- malignant infiltration of nerve roots
- vasculitis
- porphyria
- metabolic dysfunction (e.g. vitamin B\(_1\) deficiency)
- hysteria

**Investigation**

GBS is predominantly a clinical diagnosis, supported by excluding other diagnoses and demonstrating characteristic findings in tests including:

- Electrophysiology: may show dispersed motor potentials and prolonged distal motor latencies; also helps to subclassify as predominantly demyelinating or axonal.
- Lumbar puncture: characteristically reveals a high CSF protein (> 1 g/l) with no, or very few, white cells – a raised white cell count should prompt consideration of other diagnoses, e.g. human immunodeficiency virus (HIV), Lyme disease, leptomeningeal malignancy.
- Antganglioside antibodies: see above.

**Management**

The most important aspect of treatment is the prevention of complications. Complete recovery occurs over several months in 80–90% of patients. Clinical management involves:

- Careful nursing with physiotherapy usually in a high-dependency/intensive care setting. Attention to preventing pressure sores, chest infection and contractures.
- Anticoagulants, passive movements of the legs and graduated compression stockings help reduce the risk of deep venous thrombosis and pulmonary embolism.
- Careful fluid balance and nutritional support.
- Vital capacity (VC) monitoring regularly with oxygen saturations (not peak flow alone).
- Intubation with ventilation may be necessary.
- Cardiac monitoring; temporary cardiac pacing may be required for persistent bradycardia.

Randomised controlled trials suggest that the recovery of non-ambulant patients treated early (within 2 weeks of symptom onset) is hastened by intravenous immunoglobulin for 5 days or by four to six plasma exchanges. Plasma exchange may also help ambulant patients and those with more long-standing symptoms. Corticosteroids are of no benefit in GBS.

Rehabilitation is an important part of the recovery process.

**Prognosis**

GBS has a high mortality rate (up to 10%) in the acute phase even with supportive care and immunoglobulin therapy. Causes of death include cardiac dysrhythmias, pulmonary embolism and sepsis. Residual disability and chronic fatigue affect a significant proportion of sufferers. Poor prognostic indicators include older age, rapid onset of weakness, requirement for ventilation, evidence of axonal degeneration on EEG and detectable antiganglioside antibodies.
Hereditary disorders

Hepatolenticular degeneration (Wilson's disease)

An autosomal recessive disorder (due to mutation of the \textit{ATP7B} gene) where the primary defect is a failure to excrete copper into bile. Accumulation of hepatic copper inhibits the formation of serum caeruloplasmin. When hepatocytic storage capacity is exceeded, copper is released into the blood and deposited in the:

- liver – producing cirrhosis, hepatosplenomegaly and jaundice
- basal ganglia – producing choreoathetosis
- cerebrum – producing dementia and emotional lability
- eyes – producing Kayser–Fleisher rings (a green–gold ‘fuzz’) around the cornea (detectable on slit lamp examination) and cataract
- renal tubules (rarely) – producing the effects of heavy metal poisoning and renal tubular acidosis
- bones – producing osteoporosis and osteoarthritis
- red cells – producing haemolytic anaemia.

The cerebral type is more common than the hepatic type.

Management

- low dietary copper intake
- d-penicillamine (a chelating agent to increase 24-h urinary copper excretion)

Prognosis with treatment is very good. Siblings should be examined and screened for serum copper and caeruloplasmin levels plus 24-h urinary copper output.

Huntington's chorea

An autosomal dominant disorder, with symptom onset usually between 30 and 45 years. The chorea is distal initially and involves the legs (with ataxia), arms (with clumsiness) and face. Rapid and jerky movements occur together with epilepsy. Chorea may respond to tetrabenazine, which depletes nerve endings of dopamine. Mental changes develop gradually with progression to dementia and death in about 10–15 years.

Hereditary ataxias

These are rare familial disorders, usually transmitted as autosomal dominant traits. Pathological changes of degeneration are present in one or more of the optic nerves, cerebellum, olives and long ascending tracts of the spinal cord. Each family presents its own particular variants.

Friedreich's ataxia

A rare autosomal recessive disorder (due to triplet repeat expansion in the \textit{FXN} gene) characterised by degeneration in the dorsal and lateral (pyramidal) columns of the cord and the spino cerebellar tracts.

Clinical presentation

Cerebellar ataxia is noted at 5–15 years of age, affecting first the lower and then upper limbs. Pes cavus and spinal scoliosis may be present. Pyramidal tract involvement produces upper motor neurone lesions of the legs, and dorsal column involvement, sensory changes and absent ankle jerks. Cardiomyopathy causes arrhythmias and heart failure and there may be optic atrophy. Mild dementia occurs late in the disease and patients usually die from cardiac disease in their 40s.

Cerebellar degeneration

This rare group of hereditary ataxias affects primarily the cerebellum and the cerebellar connections of the brainstem. They present in late middle age and must be distinguished from:

- posterior fossa tumours;
- paraneoplastic syndromes;
- vascular, metabolic, toxic infective or inflammatory disorders.

Hereditary spastic paraplegia

The pyramidal tracts are affected and patients develop progressive spasticity. The onset occurs from childhood to middle age. The disorder, when first seen, must be distinguished from cord compression and multiple sclerosis.

Leber's optic neuropathy (atrophy)

Typically presents in adolescence or young adulthood with subacute unilateral, then bilateral, visual failure. Males are more commonly affected than females, although inheritance is mitochondrial.

Hereditary motor and sensory neuropathy (Charcot–Marie–Tooth disease; peroneal muscular atrophy)

This condition is often confused with the muscle dystrophies. It is rare and genetic counselling is advisable. It is usually transmitted as an autosomal dominant trait, but in some families is recessive or sex-linked (i.e. multiple gene defects have been
implicated). It may be classified into two groups of hereditary motor and sensory neuropathy affecting the peripheral nerves:

- type I with thickened peripheral nerves as a result of repeated demyelination and remyelination (ulnar at elbow, and common peroneal at the neck of the fibula)
- type II as a result of axonal degeneration, without thickening.

Clinical presentation

It presents about the age of 20 years with wasting and weakness of all the distal lower limb muscles and pes cavus. Later, the upper limbs may be affected. The wasting stops at mid-thigh, producing an inverted champagne-bottle appearance, and at the elbows. Fasciculation and sensory loss are sometimes present and reflexes depressed. The disease usually arrests spontaneously and life expectancy is normal. Con- tractions may produce talipes equinovarus.

Narcolepsy

This rare condition usually starts in late puberty. The onset is sudden, with episodes of irresistible and inappropriate sleep typically lasting 10–20 min and from which the patient awakes refreshed. It is associated with cataplexy (attacks of sudden, brief muscle atonia often causing falls but without loss of consciousness, precipitated by strong emotions such as stress or laughter). The aetiology of narcolepsy remains poorly understood although there is an association with human leucocyte antigen (HLA) DR2. Modafinil, a central nervous system stimulant, is the preferred first-line treatment, although the long-term risk of dependency remains unclear. Cataplexy may respond to clomipramine.

Head injury and the Glasgow Coma Scale

Brain injury following head trauma reflects:

- primary damage at impact – including contusion and laceration of the cerebral cortex (both at the site of impact and ‘contre-coup’) and diffuse white matter injury (due to axonal shearing)
- secondary complications – including haematoma, oedema, ischaemia, coning and infection.

The latter are potentially treatable, and early intervention can reduce the extent of residual neurological deficit in those who survive the initial insult.

Clinical presentation

Important clinical features in the history (possibly obtained from a third party) include:

- circumstances of injury
- duration of loss of consciousness and post-traumatic amnesia
- occurrence of a ‘lucid interval’, suggesting development of a secondary complication (haematoma, oedema)
- persistent headache and vomiting (raised intracranial pressure).

Examination

Check carefully for:

- external evidence of trauma
- features suggestive of skull base fracture (e.g. bilateral periorbital haematoma and/or haematoma over the mastoid (‘Battle’s sign’); bleeding from the ear; subconjunctival haemorrhage; CSF leakage).
- Other neurological signs.

Conscious level should be charted using the Glasgow Coma Scale (Table 15.9).

Investigations

Although plain skull radiography may be used to detect fractures, most centres now routinely perform cranial CT in any patient in whom there is concern

<table>
<thead>
<tr>
<th>Table 15.9 Glasgow Coma Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td><strong>Eye-opening</strong></td>
</tr>
<tr>
<td>To speech</td>
</tr>
<tr>
<td>To pain</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td><strong>Best verbal response</strong></td>
</tr>
<tr>
<td>Confused</td>
</tr>
<tr>
<td>Inappropriate words</td>
</tr>
<tr>
<td>Incomprehensible sounds</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td><strong>Best motor response</strong></td>
</tr>
<tr>
<td>Localises to pain</td>
</tr>
<tr>
<td>Withdraws from pain (normal flexion)</td>
</tr>
<tr>
<td>Flexes abnormally to pain (spastic flexion)</td>
</tr>
<tr>
<td>Extends to pain</td>
</tr>
<tr>
<td>None</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
</tr>
</tbody>
</table>
(e.g. transient/persistent impairment of consciousness, focal neurological signs, features to suggest skull base fracture) following head injury.

**Management**

Minor head injuries may be managed locally with wound cleansing/suturing and neurological observation, but patients with more severe injuries should be transferred to a specialist neurosurgical unit once stabilised. Surgical intervention may be required in cases of intracranial haematoma and for depressed skull fractures.

Medical therapy may include:

- intravenous mannitol and/or artificial hyperventilation for raised intracranial pressure
- anticonvulsants
- prophylactic antibiotics for suspected/confirmed skull base fracture(s).

**Prognosis**

Survivors of serious head injury may be left with numerous sequelae including:

- residual neurological deficit/cognitive impairment including persistent vegetative state
- post-traumatic epilepsy
- post-concussion syndrome
- late complications including meningitis in cases of undetected CSF leakage and chronic subdural haematoma.

**Criteria for diagnosis of brainstem death**

In certain circumstances, irreversible brain damage occurs with permanent loss of brainstem function, but with preservation of cardiovascular function. The decision to remove cardiorespiratory support in such cases is dependent on a number of factors, including formal demonstration that the patient meets the criteria for brainstem death (Table 15.10). The assessment must be carried out by two doctors with appropriate expertise, at least one of whom should be a consultant. All ‘preconditions’ must be met before the tests are performed, which should be repeated at an interval, with death being certified at the time of the second set of tests providing the criteria are met.

<table>
<thead>
<tr>
<th>Preconditions</th>
<th>Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure CNS depressant drugs are not contributing to clinical state</td>
<td>Absent oculocephalic (‘doll’s head’) reflex*</td>
</tr>
<tr>
<td>Confirm requirement for ventilatory support due to inadequate spontaneous respiration (effects of neuromuscular blockade must be excluded)</td>
<td>No pupillary response to light</td>
</tr>
<tr>
<td>Exclude hypothermia (core temperature &lt; 35 °C)</td>
<td>Absent corneal reflexes</td>
</tr>
<tr>
<td>Exclude severe metabolic/endocrine disorders</td>
<td>No gag reflex and no response to tracheal suction</td>
</tr>
<tr>
<td>Ensure cause of patient’s condition is known and that it is compatible with irreversible brain damage</td>
<td>No motor response in cranial nerve territory to painful stimulus (e.g. supraorbital and nail bed pressure)</td>
</tr>
<tr>
<td></td>
<td>No spontaneous respiratory effort when patient is disconnected from ventilator†</td>
</tr>
</tbody>
</table>

*When the head is gently, but fully, rotated to either side there is absence of the normal transient eye movement in the opposite direction.

†PaO₂ is maintained throughout by preoxygenation of the patient prior to disconnection of the ventilator, and continued supply of high flow oxygen (6 l/min) via endotracheal tube thereafter, but PaCO₂ is allowed to rise to > 6.65 kPa.

### Table 15.10 Criteria for brainstem death

<table>
<thead>
<tr>
<th>Preconditions</th>
<th>Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure CNS depressant drugs are not contributing to clinical state</td>
<td>Absent oculocephalic (‘doll’s head’) reflex*</td>
</tr>
<tr>
<td>Confirm requirement for ventilatory support due to inadequate spontaneous respiration (effects of neuromuscular blockade must be excluded)</td>
<td>No pupillary response to light</td>
</tr>
<tr>
<td>Exclude hypothermia (core temperature &lt; 35 °C)</td>
<td>Absent corneal reflexes</td>
</tr>
<tr>
<td>Exclude severe metabolic/endocrine disorders</td>
<td>No gag reflex and no response to tracheal suction</td>
</tr>
<tr>
<td>Ensure cause of patient’s condition is known and that it is compatible with irreversible brain damage</td>
<td>No motor response in cranial nerve territory to painful stimulus (e.g. supraorbital and nail bed pressure)</td>
</tr>
<tr>
<td></td>
<td>No spontaneous respiratory effort when patient is disconnected from ventilator†</td>
</tr>
</tbody>
</table>

*When the head is gently, but fully, rotated to either side there is absence of the normal transient eye movement in the opposite direction.

†PaO₂ is maintained throughout by preoxygenation of the patient prior to disconnection of the ventilator, and continued supply of high flow oxygen (6 l/min) via endotracheal tube thereafter, but PaCO₂ is allowed to rise to > 6.65 kPa.
Endocrine disorders

Diabetes mellitus (p. 229) and disorders of the thyroid gland are the most commonly encountered endocrine conditions in clinical practice.

Thyroid

The term ‘goitre’ simply denotes enlargement of the thyroid gland. It may be diffuse or nodular, simple or toxic, benign or malignant, and physiological or pathological. Minor enlargement of the thyroid is common, especially in women. Both hypothyroidism and hyperthyroidism are also common. In contrast, thyroid cancer is relatively rare.

Non-toxic goitre

Aetiology

A variety of factors may predispose to thyroid enlargement:

- **Simple goitre**: iodine deficiency, especially in areas of endemic goitre. Sporadic goitre may reflect relative iodine deficiency for that patient. Iodine requirement is increased at puberty in girls and during pregnancy.
- **Goitrogens**: e.g. iodide in large doses, antithyroid drugs, lithium.
- **Inborn errors of thyroid hormone biosynthesis (dyshormonogenesis)**: the production of thyroid hormones is mediated by iodide uptake and oxidation, organification of thyroglobulin to generate iodothyrosines followed by their coupling to yield thyroxine (T4) and triiodothyronine (T3). Several genetic disorders involving proteins in this biosynthetic pathway have been described. For example, Pendred syndrome, which is characterised by sensorineural deafness and goitre, is caused by defects in pendrin, which transports iodine into the follicular lumen.

Clinical presentation

The patient (or a relative) usually notices a painless swelling of the thyroid. With time it may develop into a large nodular goitre and cause pressure on the trachea, oesophagus or veins, especially if there is significant retrosternal extension.

Differential diagnosis

The differential diagnosis of thyroid enlargement is shown in Table 16.1.

Investigation

- **Thyroid function tests**: serum-free thyroxine (FT4) and thyrotropin (thyroid-stimulating hormone, TSH); if TSH is suppressed, but with normal FT4, check serum-free triiodothyronine (FT3) for possible T3-toxicosis.
- **Thyroid autoantibodies** (e.g. antithyroid peroxidase) for Hashimoto’s disease.
- **CT scan of neck and thorax** if pressure symptoms are present; respiratory flow-volume loops may also help to confirm/refute significant airway obstruction.
- **Ultrasound** can help distinguish solid or cystic masses and whether single or multiple nodules but is not required in all cases.
- **Fine-needle aspiration biopsy (FNAB)** with cytology may be required for solitary or dominant nodules or if there is clinical concern regarding possible malignancy.

NB Thyroid radioisotope scans are not generally performed unless the patient is thyrotoxic (see below).

Treatment

If the patient is euthyroid and there are no concerns regarding possible malignancy, treatment is not required unless the swelling is unsightly or causing pressure symptoms, when surgery (or occasionally radioiodine therapy) may be indicated. If TSH is
raised (subclinical hypothyroidism), thyroxine can be
given to suppress TSH hypersecretion (TSH is trophic
for thyroid growth).

**Thyrotoxicosis (hyperthyroidism)**

Thyrotoxicosis is the clinical disorder resulting from
exposure to raised circulating levels of thyroid hor-
mone (T4 and/or T3). It is most commonly due to
thyroid gland dysfunction (hyperthyroidism), but can
occur when exogenous T4 and/or T3 is taken in excess.
The prevalence of hyperthyroidism in the UK has
been estimated at 1–2%, with a female predominance

**Aetiology**

The causes of thyrotoxicosis are shown in Table 16.2.
Graves’ disease is an autoimmune disorder in which
autoantibodies against the TSH receptor (TRAb)
provide continual (unregulated) stimulation of thy-
roid follicular cells leading to thyroid enlargement
(diffuse smooth goitre) and thyrotoxicosis. Involvement
of the retro-orbital tissues and skin may also
result in Graves’ ophthalmopathy and dermopathy
(pretibial myxoedema). Environmental ‘triggers’
(e.g. stress, pregnancy, drugs) combined with genet-
ic susceptibility (e.g. HLA-DR3, cytotoxic T-lympho-
cyte antigen 4 (CTLA4) variants) are implicated in
many cases.

**Clinical presentation**

The symptoms and signs of thyrotoxicosis are shown
in Fig. 16.1. Several of these are reminiscent of a
‘hyperadrenergic state’. However, other features are
specific for the underlying disorder (see Box 16.1).

**Other presentations**

- hyperactivity, increased linear growth and weight
gain in children
- apathy and depression, atrial fibrillation and car-
diac failure in the elderly

**Table 16.2 Causes of thyrotoxicosis**

<table>
<thead>
<tr>
<th>Type</th>
<th>Frequency</th>
<th>Condition(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Common</td>
<td>Graves’ disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Toxic multinodular goitre</td>
</tr>
<tr>
<td></td>
<td>Less common</td>
<td>Solitary toxic adenoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thyroiditis (e.g. post-partum; subacute)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug-induced (e.g. amiodarone; over-treatment with/inappropriate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>administration of L-T4 and/or L-T3 therapy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Excess iodine intake (e.g. health food supplements such as kelp, or drugs,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>e.g. amiodarone)</td>
</tr>
<tr>
<td></td>
<td>Rare</td>
<td>‘Hashitoxicosis’ (hyperthyroid phase of Hashimoto’s thyroiditis)</td>
</tr>
<tr>
<td>Secondary</td>
<td>Rare</td>
<td>Metastatic follicular thyroid carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Struma ovarii</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TSH-secreting pituitary adenoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resistance to thyroid hormone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trophoblastic tumour secreting hCG (shared/common α sub-unit with TSH)</td>
</tr>
</tbody>
</table>

TSH, thyrotropin (=thyroid-stimulating hormone) hCG, human chorionic gonadotrophin.
thyroid crisis – mainly seen in patients with unrecognised or poorly controlled disease; intercurrent illness, surgery or radioiodine therapy may serve as precipitants; typical features include hyperpyrexia, profuse sweating, restlessness, confusion/psychosis, dysrhythmias and cardiac failure. If untreated coma and death may ensue.

Differential diagnosis
Thyrotoxicosis may be difficult to differentiate from an anxiety state (with hyperadrenergic features), particularly when this is coincidentally associated with a simple goitre.

Investigation
• TSH – fully suppressed (i.e. < 0.1 mU/l. NB Modern TSH assays may report even lower limits of detection, e.g. < 0.03 mU/l).
• FT4 and FT3 – typically both are elevated, although FT4 may fall within the reference range, but with raised FT3 in cases of ‘T3-toxicosis’.
• TSH receptor antibody (TRAb) – many laboratories now routinely offer TRAb measurement, which is both sensitive and specific for Graves’ disease.

### Box 16.1 Specific features of Graves’ disease

<table>
<thead>
<tr>
<th>System/organ</th>
<th>Features</th>
</tr>
</thead>
</table>
| Eyes         | Exophthalmos/proptosis (may be unilateral)  
Ophthalmplegia (especially upward and lateral gaze)  
Chemosis  
Periorbital oedema |
| Skin/nails   | Pretibial myxoedema  
Thyroid acropachy |
| Thyroid      | Bruit (reflecting increased vascularity of gland)  
Pretibial myxoedema |

**Figure 16.1** Schematic representation of the symptoms and signs associated with thyrotoxicosis.
NB Thyroid peroxidase (TPO) titres are not elevated in all patients with Graves’ disease and are not therefore routinely measured.

- A radioiodine or (more commonly) technetium uptake scan can help distinguish Graves’ disease, toxic nodular goitre, toxic adenoma or thyroiditis in cases where there are no specific clinical features of Graves’ disease (Box 16.1) and TRAb is not raised.
- CT/MRI of the orbits may be required to assess the extent of eye disease in Graves’ ophthalmopathy.

**Treatment**

**β-Blockers**
- Preferably non-selective, e.g. propranolol 20–40 mg t.d.s. for rapid relief of symptoms.

**Antithyroid drug (ATD) therapy**
- Carbimazole (CBZ) or propylthiouracil (PTU): result in long-term remission in ~40–50% of cases of Graves’ disease; regimens include (1) ‘titration’, i.e. beginning with a higher dose (e.g. CBZ 40–60 mg/day), then titrating to a lower maintenance level (e.g. CBZ 5–15 mg/day) and continuing for 12–18 months; (2) ‘block and replace’, in which the ATD dose is maintained at a higher level (e.g. CBZ 40 mg/day), with thyroxine added back (once FT4/FT3 levels are controlled), and typically continued for 6–12 months.
- ATDs control, but do not cure, thyrotoxicosis in toxic multinodular goitre/toxic solitary adenoma; ATDs are ineffective in cases of inflammatory/destructive thyroiditis where stored hormone is released – β-blockers are preferred to block peripheral actions of excess hormone.
- It is important to avoid inducing hypothyroidism, especially in patients with co-existent Graves’ ophthalmopathy, which can be exacerbated.
- Side effects of ATDs include skin rashes (often minor and respond to antihistamines or changing agent) and the more serious agranulocytosis and/or thrombocytopenia. All patients on ATDs must therefore be warned of this possibility and given instructions (including in written format) advising them to immediately stop treatment and attend their GP or local hospital for a full blood count if they develop a sore throat, mouth ulceration or fever. If confirmed, the patient should not be restarted on/switched to an alternative ATD, as the risk of recurrence is high. Hepatic dysfunction (PTU) and cholestatic jaundice (CBZ) are also important recognised side effects.
- Traditionally treatment with PTU in a titration regimen has been preferred in pregnancy because of the risk, albeit rare, of fetal malformation (in particular aplasia cutis) with CBZ therapy; however, concerns regarding potential PTU-induced hepatic dysfunction have resulted in many clinicians now favouring a mixed regimen whereby PTU is used during the first trimester, but if ongoing treatment is required thereafter, the woman is switched to CBZ.

**Radioactive iodine therapy (RAI; 131I)**
- May be used as first line therapy (especially for toxic nodular goitre/nodule) or following ATD failure.
- Typically given in doses ranging from 300–800 MBq; using higher doses reduces rates of relapse but increases rates of hypothyroidism.
- ATDs must be discontinued prior to RAI (~1 week before for CBZ, but longer for PTU) to ensure adequate thyroid uptake, but can be restarted 5–7 days later and continued for 2–3 months, at which point residual thyroid status should be assessed.
- Patients with a single toxic adenoma or a toxic multinodular goitre can receive a large dose of RAI with relatively little chance of subsequent hypothyroidism, because the unaffected parts of the thyroid lie dormant following suppression of TSH by excessive thyroid hormone secretion and therefore do not take up the RAI.
- RAI is contraindicated in pregnancy (which should be avoided for 6 months after treatment) and in breast-feeding mothers.
- Most centres avoid RAI in patients with severe Graves’ ophthalmopathy, but permit treatment in mild to moderate cases under steroid cover (e.g. prednisolone 30–40 mg/day).

**Surgery**
- Total or subtotal thyroidectomy may be performed.
- Normally reserved for those with relapsing thyrotoxicosis who decline or who are not suitable for RAI, or if there are significant compressive symptoms.
- Potential complications include haemorrhage, vocal cord paresis, hypoparathyroidism and hypothyroidism.

**Treatment of complications**

**Eyes**
- Control of the underlying thyrotoxicosis is essential in all patients; lid retraction usually resolves with restoration of euthyroidism.
- Simple lubricants and taping the eyelids closed at night may help in milder cases.
- In severe cases of Graves’ ophthalmopathy, and in those failing to improve with correction of the thyroid disturbance, treatment with high dose corticosteroids, other immunosuppressive agents,
orbital decompression or radiotherapy may be required.
- Smoking exacerbates ophthalmopathy.

**Atrial fibrillation**
- Atrial fibrillation responds poorly to digoxin and larger doses are often needed until the patient is rendered euthyroid. Propranolol or other β-blockers may provide better rate control.
- Anticoagulation is also required as the risk of embolisation is relatively high.

**Thyrotoxic crisis/thyroid storm**
This is a rare but potentially life-threatening disorder, which requires urgent treatment targeted at various steps in the thyroid hormone synthesis/action pathway:
- Stop further hormone synthesis: CBZ (20 mg orally or via nasogastric tube 4–6 hourly) or PTU (200 mg orally or via nasogastric tube 4–6 hourly).
- Impair release of stored hormone: sodium iodide (0.5–1 g IV 12 hourly) or saturated solution of potassium iodide (6–8 drops orally every 6 h); the radiographic contrast agents ipodate and iopanoic acid may also be used and have the added benefit of markedly impairing T4 to T3 conversion.
- Block peripheral manifestations of excess thyroid hormones: propranolol (initially 0.5–2 mg IV slowly, followed by 40–80 mg orally 6–8 hourly). Verapamil can be used in those with a history of asthma.
- High dose glucocorticoids: dexamethasone (2 mg orally or IV 6–8 hourly) reduces peripheral conversion of T4 to T3.
- Supportive measures: O2 therapy, intravenous fluids, active cooling, diuretics, chlorpromazine as indicated.

**Hypothyroidism**
Hypothyroidism is the clinical condition resulting from low levels of circulating thyroid hormones. The term ‘myxoedema’ refers to the deposition of mucopolysaccharide beneath the skin, producing a non-pitting swelling of the subcutaneous tissues.

Hypothyroidism is common, with a prevalence of 1–2% in the general population. Females are much more commonly affected (female to male ratio ~10 : 1), reflecting the high proportion of cases due to autoimmune disease (see below).

Congenital hypothyroidism occurs in 1 in 3,000 to 1 in 4,000 live births in the UK.

**Aetiology**
The causes of hypothyroidism are shown in Table 16.3.

**Clinical presentation**
The symptoms and signs of hypothyroidism are shown in Fig. 16.2.

**Other presentations**
- Subclinical hypothyroidism – characterised biochemically by normal FT4 and FT3 levels in the presence of a mildly elevated TSH. The patient may be asymptomatic or manifest mild hypothyroid features or hypercholesterolaemia.
- Pregnancy – untreated maternal hypothyroidism is associated with higher rates of miscarriage, stillbirth and congenital abnormalities. Even mild maternal hypothyroidism may be associated with a reduction in IQ of the offspring. Thyroxine requirements can increase by 50–100% during pregnancy and thyroid function tests should ideally be checked prior to conception and at regular intervals during pregnancy.

<table>
<thead>
<tr>
<th>Table 16.3 Causes of hypothyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td>Primary</td>
</tr>
<tr>
<td>Less common</td>
</tr>
<tr>
<td>Rare</td>
</tr>
<tr>
<td>Secondary</td>
</tr>
</tbody>
</table>

RAI, radioactive iodine therapy; ATD, antithyroid drug therapy.
Myxoedema coma – a rare but life-threatening medical emergency.

Investigation

- Serum FT4 is reduced and this stimulates pituitary secretion of TSH (raised in primary hypothyroidism). FT3 is also low, although routine measurement is not required in most instances.
- Elevated antithyroid peroxidase (TPO) antibodies.
- The serum cholesterol is often raised and creatine kinase (CK) may also be elevated, reflecting hepatic and muscle hypothyroidism respectively.
- Anaemia (microcytic if menorrhagia, macrocytic if co-existent pernicious anaemia, or normocytic).
- ECG shows slow rate and low voltage with flattened or inverted T waves.

NB Check for use of drugs, e.g. lithium, amiodarone. Amiodarone is rich in iodine and also inhibits peripheral conversion of T4 to T3, making thyroid investigations more difficult to interpret. Ideally, before starting treatment with amiodarone, basal FT3, FT4 and TSH levels should be checked to identify any underlying thyroid disease.

- The finding of low FT4 and FT3 levels with an inappropriately low or normal TSH is strongly suggestive of a central (hypothalamic/pituitary) disorder (p. 214).

Figure 16.2 Schematic representation of the symptoms and signs associated with hypothyroidism.
Low TSH with low FT3 and low/low-normal FT4 may also be seen in non-thyroidal illness (so-called sick-euthyroid syndrome).

**Treatment**

- Standard treatment is with levo-thyroxine (L-T4), typically beginning with a dose of 50 mcg/day.
- A full replacement dose (e.g. in an adult patient post-total thyroidectomy) is ~1.6 mcg/kg/day.
- Lower starting doses should be used in the elderly or in those with known or suspected ischaemic heart disease.
- Reassess clinically and check FT4 and TSH at 4- to 6-weekly intervals until stabilised on treatment.
- In primary hypothyroidism, titrate L-T4 to achieve TSH level in the lower half of the reference range (i.e. 0.4–2.0 mU/l); in central hypothyroidism TSH is unreliable and treatment should be titrated to alleviate symptoms and achieve an FT4 level in the normal (typically upper half of the) reference range.

**Myxoedema coma**

- Treatment includes ventilatory and circulatory support, correction of hypothermia and hypoglycaemia, glucocorticoid replacement until normal adrenal reserve is demonstrated, treatment of precipitating event and thyroid hormone replacement (L-T4 or L-T3 – dose and regimen should be decided in conjunction with an endocrinologist).
- In subjects with suspected co-existent hypoadrenalism do not start L-T4 until the diagnosis has been excluded or confirmed and glucocorticoid replacement commenced.
- Occasionally prednisolone 30 mg/day is necessary, but this can usually be tailed off rapidly.
- ATDs are ineffective in the treatment of the thyrotoxic phase; β-blockers control symptoms.

**Thyroiditis**

**Acute thyroiditis**

- Although relatively uncommon, acute thyroiditis may follow an upper respiratory tract or other infection.
- There is fever and malaise, usually with some local swelling and tenderness of the gland and sometimes dysphagia.
- Initially the patient may experience thyrotoxic features as stored hormone is released from the gland, prior to developing hypothyroidism which may be transient or occasionally permanent.
- Classical appearance on radioiodine/technetium scan with very low or absent uptake.
- Treatment with simple analgesia (e.g. NSAID) may suffice.
- Occasionally prednisolone 30 mg/day is necessary, but this can usually be tailed off rapidly.
- ATDs are ineffective in the treatment of the thyrotoxic phase; β-blockers control symptoms.

**Post-partum thyroiditis**

- Typically occurs within the first 6 months post-delivery
- Usually painless
- Thyrotoxic phase must be distinguished from Grave’s disease developing/relapsing in the post-partum period. TRAb antibodies are typically raised in the latter.

**Thyroid cancer (p. 215)**

- Commonest endocrine cancer, although still relatively rare
- Table 16.4 summarises important features of each of the subtypes

---

**Pituitary**

**Pituitary anatomy and physiology**

The hypothalamus and pituitary lie in close proximity to each other and are connected by the pituitary stalk. Both are surrounded by a number of important structures and the pituitary gland sits within a bony seat, the sella turcica (Fig. 16.3). The optic chiasm lies just above the pituitary fossa, and on either side are the cavernous sinuses (venous lakes) through which the intracavernous carotid artery passes. The third, fourth, upper division of the fifth and sixth cranial nerves lie within the lateral and inferior aspects of the cavernous sinuses, rendering them susceptible to compression by tumours with parasellar extension. The sphenoid sinus, which is below the pituitary fossa, is the route through which the pituitary gland is approached during transsphenoidal surgery (Fig. 16.3).

The hypothalamus and pituitary work in concert to regulate a number of different endocrine systems involved in processes as diverse as growth, metabolism and reproduction. Hypothalamic releasing factors (e.g. growth hormone releasing hormone (GHRH), gonadotrophin releasing hormone (GnRH), corticotropin releasing hormone (CRH) and thyrotropin releasing hormone (TRH)) travel down the pituitary stalk to regulate release of growth hormone (GH), the gonadotrophins (luteinising hormone (LH) and follicle stimulating hormone (FSH)), adrenocorticotrophic hormone (ACTH) and thyrotropin (TSH) from anterior pituitary somatotrophs, gonadotrophs, corticotrophs and thyrotophs respectively. In addition, the inhibitory hormones somatostatin and dopamine are also released by the hypothalamus to regulate pituitary hormone synthesis and secretion. For example, somatostatin negatively regulates GH, TSH and to
### Table 16.4 Thyroid malignancy

<table>
<thead>
<tr>
<th>Type</th>
<th>Epidemiology/aetio-pathogenesis</th>
<th>Clinical features/spread/metastases</th>
<th>Treatment/prognosis</th>
</tr>
</thead>
</table>
| Papillary thyroid cancer | • ~70–80% of all cases  
• \(\gg\) ~1 : 3  
• Peak incidence during fourth and fifth decades of life, but also smaller peak in second and third decades  
• External irradiation or exposure to radioactive iodine isotopes (e.g. following the Chernobyl nuclear incident) at an age < 20 years is associated with ↑ risk  
• RET-PTC proto-oncogene rearrangements are found in some papillary tumours, especially after irradiation  
• Overexpression of the ras and PTTG oncogenes may be found and correlate with adverse prognosis | • Slow growing  
• Local spread to cervical lymph nodes is common at presentation, but distant metastases are rare | • Total thyroidectomy for all but the smallest of tumours  
• Modified radical neck dissection for cervical node involvement  
• Ablative radiiodine therapy is also required in most cases  
• Life-long thyroxine therapy to suppress TSH  
• For refractory/relapsing disease kinase inhibitors may be beneficial in some patients, but further trials are awaited  
• Thyroglobulin levels serve as a useful tumour marker following total thyroidectomy  
• Cancer-related deaths occur in < 5% of cases during 10 years’ follow-up |
| Follicular thyroid cancer | • ~10–15% of all cases  
• \(\gg\) ~1 : 2–3  
• Peak incidence during fifth decade of life | • More aggressive than papillary carcinoma  
• Local spread to cervical lymph nodes may occur  
• Haematogenous spread (e.g. to lung and bone) is much more common than with papillary carcinoma | • Treatment as per papillary carcinoma  
• Cancer-related deaths in 5–10% of cases during 10 years’ follow-up |
| Medullary thyroid cancer | • ~5% of all cases  
• \(\gg\) ~1 : 1  
• Peak incidence during fourth and fifth decade of life for sporadic MTC, but much earlier (including in childhood) for hereditary cases | • More aggressive than papillary or follicular carcinoma  
• Locally invasive  
• Distant spread by lymphatics and blood | • Possible phaeochromocytoma (as part of the MEN-2 syndrome) must be excluded before surgical intervention  
• Total thyroidectomy may be curative in the early stages – hence the rationale for genetic screening of relatives |

(Continued)
<table>
<thead>
<tr>
<th>Type</th>
<th>Epidemiology/aetio-pathogenesis</th>
<th>Clinical features/spread/metastases</th>
<th>Treatment/prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaplastic thyroid cancer</td>
<td>• Both sporadic and hereditary MTC are associated with mutations in the RET proto-oncogene</td>
<td>• Aggressive</td>
<td>• Central compartment/lymph node dissection is required in most cases</td>
</tr>
<tr>
<td></td>
<td>• A component of the MEN-2A and MEN-2B syndromes</td>
<td>• Typically presents with painful, rapidly expanding thyroid mass, which infiltrates local tissues and hence does not move on swallowing</td>
<td>• Radioiodine and TSH suppression are not indicated in MTC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Systemic chemotherapy and external beam irradiation are of limited value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• For refractory/relapping disease kinase inhibitors may be beneficial in some patients, but further trials are awaited</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Plasma calcitonin levels serve as a useful tumour marker</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Although surgery, external irradiation and chemotherapy may be tried, few patients survive for more than 6–12 months</td>
</tr>
</tbody>
</table>

MTC, medullary thyroid carcinoma; MEN, multiple endocrine neoplasia.
a lesser extent ACTH release, while pituitary lactotrophs are under tonic inhibitory control by dopamine (Fig. 16.4).

In contrast to the anterior pituitary, hormonal synthesis does not occur within the posterior pituitary, but instead hormones (antidiuretic hormone (ADH = vasopressin) and oxytocin) synthesised by hypothalamic neurones travel down the pituitary stalk in axonal projections that finish in the posterior pituitary where the mature hormones are stored in vesicles for release.

Knowledge of the anatomy and physiology of the hypothalamus and pituitary helps to understand the different presentations of patients with sellar and parasellar lesions. In essence, pituitary disorders typically present with one or more of the following:

- Hormone hypersecretion – e.g. excess production of growth hormone in acromegaly and ACTH in Cushing’s disease.
- Hormone hyposecretion – e.g. partial or complete hypopituitarism as a consequence of damage to/ suppression of the remaining normal pituitary tissue.
- Local mass effects – due to compression/infiltration of adjacent structures, e.g. bi-temporal field defects (due to optic chiasmal compression), third, fourth or sixth cranial nerve palsies (if there is involvement of the cavernous sinuses, especially if this occurs acutely, e.g. pituitary apoplexy) or headache (due to invasion of the bony wall of the sphenoid sinus).

**Pituitary adenomas and hypopituitarism**

The term hypopituitarism denotes an insufficiency of one or more of the anterior or posterior pituitary hormones. With pituitary tumours, the usual sequence in which pituitary hormone function is lost is GH, followed by LH/FSH, followed by ACTH and finally TSH. Interestingly, prolactin insufficiency is rare in this setting and indeed the lactotrophs are remarkably resistant to pressure effects, such that prolactin levels often rise as the tonic inhibitory control of dopamine is lost due to stalk compression. ADH insufficiency is also unusual in this setting. In contrast, inflammatory or infiltrative disorders of the pituitary may be associated with ADH deficiency and different patterns of anterior hypopituitarism.
Aetiology

Destruction/compression of the normal pituitary tissue or reduction in the blood supply (including the hypothalamic–pituitary portal circulation) accounts for the majority of cases of hypopituitarism (Table 16.5). Aside from a small number of genetic cases, the factors underlying pituitary adenoma formation remain poorly understood.

Clinical presentation

This is variable and depends on not only the aetiology but also the extent of endocrine dysfunction and the rapidity of onset. In the majority of cases patients present with features of one or more of hormone hypersecretion, hormone hyposecretion or local mass effects, as outlined above.

Hormone hypersecretion

Prolactinomas are the most commonly encountered functioning pituitary adenoma, and tumours secreting growth hormone, ACTH and TSH are seen less frequently.

Hyperprolactinaemia per se is associated with reduced libido in both sexes and galactorrhoea in females. In addition, however, even in the presence
of a small prolactinoma, which is insufficient to cause compression of the adjacent normal pituitary tissue, hypogonadotrophic hypogonadism is frequently seen as a consequence of the suppressive effect of high prolactin levels on the hypothalamic GnRH pulse generator. Accordingly, oligomenorrhoea/amenorrhoea in females and erectile dysfunction in males are commonly encountered. It is important to note, however, that hyperprolactinaemia is not always caused by a prolactinoma. Physiological stimuli such as stress, use of certain drugs (e.g. antidopaminergic agents), inhibition of dopaminergic tone through pituitary stalk compression (e.g. by a non-functioning pituitary adenoma), renal failure and several other disorders can all lead to elevated serum prolactin levels.

Clinical features of Cushing syndrome due to hypercortisolism and acromegaly due to GH/insulin-like growth factor-1 (IGF-1) excess are shown in Figs. 16.5 and 16.6 respectively.

Table 16.5 Causes of hypopituitarism

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Condition(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>Pituitary/peripituitary tumours (or as a complication of treatment, including surgery and radiotherapy)</td>
</tr>
<tr>
<td>Rare</td>
<td>Vascular (e.g. pituitary apoplexy, Sheehan syndrome)</td>
</tr>
<tr>
<td></td>
<td>Pituitary infiltration (e.g. metastasis, sarcoidosis, histiocytosis)</td>
</tr>
<tr>
<td></td>
<td>Infection (e.g. tuberculosis, pituitary abscess)</td>
</tr>
<tr>
<td></td>
<td>Autoimmune (lymphocytic hypophysitis)</td>
</tr>
<tr>
<td></td>
<td>Traumatic (e.g. post head injury)</td>
</tr>
<tr>
<td></td>
<td>Congenital</td>
</tr>
<tr>
<td></td>
<td>Idiopathic</td>
</tr>
</tbody>
</table>

Figure 16.5 Schematic representation showing the key clinical features associated with Cushing syndrome.
Hormone hyposecretion

In addition to features of hypogonadism, patients may manifest with features of GH deficiency (e.g. tiredness, reduced stamina, impaired cognition), ACTH deficiency (pallor, postural hypotension, reduced axillary/pubic hair, tiredness/lethargy) and TSH deficiency (tiredness/lethargy, cold intolerance, constipation, etc.).

Posterior pituitary dysfunction, and in particular diabetes insipidus (DI) due to ADH deficiency, is very rarely a presenting manifestation of a pituitary adenoma, and is more commonly encountered following pituitary surgery (when it is often transient), but can also be seen with infiltrative disorders (e.g. sarcoidosis). When present, cranial (hypothalamic) DI must be distinguished from nephrogenic DI (in which there is renal resistance to the action of ADH) and also from habitual/compulsive water drinking (dipsogenic DI). Lack of ADH action results in polyuria (greater than 3 litres of urine output per 24 h), which in turn stimulates thirst and leads to polydipsia.

Local mass effect(s)

In addition to compression of the normal pituitary gland, sellar/parasellar lesions may cause compression of the optic chiasm, resulting initially in a superior quadrantic bi-temporal field defect (signifying pressure on the underside of the chiasm), which ultimately progresses to a complete bitemporal hemianopia (Fig. 16.7). In contrast, lesions originating in the suprasellar region (e.g. craniopharyngioma) may initially give rise to inferior quadrantic field defects, reflecting chiasmal compression from above. Third, fourth and sixth cranial nerve palsies are relatively rare even with lateral tumour extension, but may be seen with infiltrative lesions or if there is rapid expansion of a tumour, for example following haemorrhage, as occurs in pituitary apoplexy.

Investigation

Again, for ease of memory, the investigation of pituitary disorders can be considered under the headings
of hormone hypersecretion, hormone hyposecretion and local mass effects.

**Hormone hypersecretion**

**Hyperprolactinaemia**
Wherever possible the confounding effects of medications and other disorders (e.g. renal failure, macroprolactinaema (a condition in which prolactin is bound by immunoglobulin thus rendering it biologically inactive but with preserved immunoreactivity in laboratory assays)) should be excluded; thereafter, genuine hyperprolactinaemia should be confirmed on at least two separate samples.

**Cushing syndrome**
(NB Pituitary-dependent Cushing syndrome = Cushing’s disease)
Investigation of pathological hypercortisolaemia is approached in two stages:

1 **Confirm diagnosis**
Most centres use one or more of the following for screening purposes, with confirmation/further investigation of positive results:

   - 24-h urinary free cortisol excretion (at least three separate collections)
   - loss of diurnal cortisol variation (measured either on serum or on salivary samples)
   - overnight dexamethasone suppression test (1 mg at 23:00 h with serum cortisol measured at 09:00 h the following morning)
   - low dose dexamethasone suppression test (0.5 mg every 6 h for a total of 8 doses with serum cortisol measured at 09:00 h following the final dose).

Normal subjects suppress serum cortisol to <50 nmol/l in both dexamethasone tests.

2 **Define aetiology**
Once the diagnosis has been confirmed tests are undertaken to establish the cause. Measurement of plasma ACTH distinguishes between ACTH-dependent (pituitary adenoma (i.e. Cushing’s disease) and ectopic ACTH secretion (e.g. due to small cell bronchial carcinoma or thymic carcinoid tumour)) and ACTH-independent (adrenal adenoma, adrenal carcinoma, adrenal nodular disease) causes.

NB It is important to exclude exogenous glucocorticoid administration (which is the commonest cause of Cushing syndrome in clinical practice) before embarking on extensive investigations.
If an ACTH-dependent cause is suspected, then imaging (MRI of the pituitary, CT of the thorax and abdomen) and further biochemical tests (e.g. inferior petrosal sinus sampling for ACTH pre- and post-CRH injection, high dose dexamethasone suppression test and peripheral CRH test) may be required to differentiate pituitary disease from an ectopic source of ACTH. ACTH-independent disease is investigated with adrenal CT/MRI in the first instance.

**Acromegaly**

The diagnosis of acromegaly is confirmed by the finding of:
- failure of GH suppression (to < 0.4 µg/l) during an oral glucose tolerance test
- an elevated IGF 1 level.

NB Complications of hormone hypersecretory states (e.g. hypertension, diabetes mellitus, osteoporosis in Cushing syndrome; hypertension, diabetes mellitus, osteoporosis, cardiac hypertrophy, sleep apnoea, colonic neoplasia in acromegaly) should also be screened for.

**Hormone hyposecretion**

Screening for hypopituitarism includes measurement of:
- free T4 and TSH (remember TSH alone is unreliable in hypothalamic/pituitary disease)
- LH, FSH and testosterone or oestradiol
- prolactin (rarely low; typically raised – see above)
- 09:00 h cortisol
- creatinine and electrolytes with paired serum and urine osmolalities if DI is suspected.

In addition, dynamic testing for growth hormone deficiency (e.g. with a glucagon stimulation test or insulin tolerance test (ITT)) may be required. The ITT is also the preferred means of excluding significant ACTH/cortisol deficiency but is contra-indicated in patients with a history of epilepsy, dysrhythmias or suspected/know ischaemic coronary disease. The short Synacthen® test is a reasonable alternative in this setting (p. 224).

NB Hypertension, dyslipidaemia and other features of the metabolic syndrome should also be screened for in patients with hypopituitarism.

**Local mass effect(s)**

- MRI/high resolution CT of the pituitary fossa
- formal visual perimetry (Fig. 16.7)

**Treatment**

**Hormone hypersecretion**

Prolactinomas (both micro- and macro-adenomas) are usually treated with medical therapy with a dopamine agonist (e.g. bromocriptine or cabergoline), which achieves control of hyperprolactinaemia, tumour shrinkage and resolution of symptoms in the majority of patients. Somatostatin analogues (e.g. octreotide, lanreotide) may be used to control symptoms in acromegaly and to promote tumour shrinkage. However, transsphenoidal surgery remains the mainstay of treatment for pituitary adenomas (micro or macro) causing Cushing’s disease, acromegaly and also for non-functional pituitary adenomas, which typically present with local mass effects. In cases where there is incomplete tumour resection, adjunctive radiotherapy may be considered, depending on the extent of residual tumour, threat to neurological structures (e.g. the optic chiasm), degree of pituitary dysfunction and patient preference. For secretory tumours medical therapy may be used, while the beneficial effects of radiotherapy are awaited (e.g. octreotide/lanreotide and/or the growth hormone receptor antagonist pegvisomant for acromegaly). Cortisol hypersecretion can be controlled with metyrapone or ketoconazole (which block adrenal steroid biosynthesis). Bilateral adrenalectomy may be required in patients with severe hypercortisolism refractory to medical therapy; however, if radiotherapy is not given in this setting, then the patient is at risk of developing Nelson syndrome (progressive pituitary enlargement and pigmentation due to rising ACTH levels).

Non-pituitary causes of Cushing syndrome are usually treated surgically (e.g. unilateral or bilateral adrenalectomy (increasingly laparoscopic) for primary adrenal disease). Pre-operative control of hypercortisolism is important to reduce operative risk and post-operative complications, e.g. poor wound healing.

**Correction of hormone hyposecretion**

- GH insufficiency may be corrected with a daily SC injection of growth hormone titrated against IGF 1 levels and symptom control.
- Cyclical oestrogen/progesterone therapy in premenopausal females and testosterone replacement in males corrects hypogonadism, although combination hCG (substituting for LH) and recombinant FSH may be required for infertility.
- ACTH/cortisol deficiency is corrected with hydrocortisone typically given in a b.d./t.d.s. regimen.

NB Fludrocortisone replacement is not required in cases of secondary hypoadrenalism, as aldosterone production is preserved (under renin control).
• Thyroxine replacement is used to correct hypothyroidism.
• Desmopressin is effective in treating cranial DI.

Local mass effect
Although bromocriptine/cabergoline may induce rapid tumour shrinkage in cases of prolactinoma, surgical decompression (transsphenoidal or transcranial) is required in the majority of patients with compression of the optic chiasm in order to avoid permanent loss of vision. This should not be delayed.

Prognosis and treatment
Untreated Cushing syndrome is often fatal, predominantly as a consequence of cardiovascular complications and increased susceptibility to infection. Control of hypercortisolism is therefore mandatory and may require combination therapy to achieve this. Similarly, uncontrolled acromegaly is associated with excess morbidity and mortality secondary to cardiovascular and respiratory disease. In addition there appears to be an increased incidence of colonic polyp/carcinoma in acromegalic subjects. Control of growth hormone hypersecretion restores morbidity/mortality levels to that of the general population.

Hypopituitarism per se is associated with an increased mortality rate of approximately twice that of the general population.

Adrenal
The adrenal glands comprise two major ‘functional units’ – the cortex and the medulla. The cortex consists of three zones: an ‘inner’ zona reticularis (secreting androgens, e.g. dehydroepiandrosterone sulphate (DHEAS)), a ‘middle’ zona fasciculata (secreting glucocorticoids, e.g. cortisol) and an ‘outer’ zona glomerulosa (secreting mineralocorticoids, e.g. aldosterone). Glucocorticoid and androgen secretion is directly under the control of pituitary ACTH, which in turn is regulated by hypothalamic CRH. Aldosterone production is independent of the hypothalamus and pituitary and controlled by the renin-angiotensin system.

Cortisol has many vital metabolic and immunomodulatory effects and is important in the maintenance of normal circulatory function. Aldosterone promotes renal sodium retention and potassium excretion.

Cushing syndrome
See earlier section on pituitary disorders.

Primary hyperaldosteronism
Primary hyperaldosteronism is an important treatable cause of hypertension in the young to middle-aged.

Aetiology
Many cases are caused by benign aldosterone producing adenomas (so-called Conn’s adenomas), but bilateral adrenal hyperplasia/nodular disease is also found in a significant number of patients. Rarely adrenal carcinoma and familial hyperaldosteronism are seen.

Clinical presentation
Most cases come to light during investigation of hypertension or unexplained hypokalaemia. Non-specific symptoms including weakness, lassitude and polyuria (hypokalaemia may be associated with nephrogenic DI) are reported by some patients. Evidence of end organ damage (e.g. hypertensive retinopathy and nephropathy) may be seen in longstanding, inadequately treated cases.

Investigation
Prior to investigation it is important to ensure satisfactory dietary sodium intake, which may otherwise mask the condition. Screening tests are also traditionally performed having withdrawn agents (e.g. β-blockers) that interfere with the renin-angiotensin-aldosterone system, substituting other antihypertensives (e.g. α-blockers) where necessary.

• Creatinine and electrolytes – the classical picture is one of hypokalaemic alkalosis: the accompanying serum sodium level is typically normal to high. However, some patients with primary hyperaldosteronism are normokalaemic at presentation.
• Urinary potassium and sodium – hypokalaemia is associated with an inappropriate kaliuresis. Urinary sodium estimation can be used to ensure adequate dietary sodium intake.
• Plasma renin and aldosterone – the hallmark of primary hyperaldosteronism is excessive autonomous production of aldosterone, occurring in the face of renin suppression.
• Salt loading – it may be necessary to ‘salt-load’ the patient to confirm ongoing inappropriate aldosterone production. However, this should only be undertaken under specialist supervision and not in patients prone to fluid overload (e.g. those with cardiac failure, renal impairment).

Once a diagnosis of primary hyperaldosteronism has been established, CT/MRI of the adrenals may help to distinguish unilateral adenoma from bilateral hyperplasia. However, selective adrenal venous sampling
and/or functional imaging (radionuclide scanning or PET-CT) are typically required to help confirm the site of excess aldosterone production.

**Management**

Spironolactone is the medical treatment of choice by virtue of its ability to block the action of aldosterone at the mineralocorticoid receptor. Treatment is titrated to normalise blood pressure and restore normokalaemia. Eplerenone (an aldosterone antagonist without the anti-androgenic side effect profile of spironolactone) and amiloride are alternatives if spironolactone is poorly tolerated.

Thereafter specific therapy is directed at the underlying cause:
- adrenal adenoma – unilateral adrenalectomy (typically laparoscopic)
- idiopathic hyperaldosteronism/bilateral hyperplasia – long-term medical therapy.

**Primary adrenal insufficiency**

NB Adrenocortical insufficiency may be:
- primary – arising as a consequence of destruction or dysfunction of the adrenal cortex (as described by Thomas Addison)
- secondary – consequent on ACTH insufficiency due to hypothalamic/pituitary dysfunction (see above).

**Aetiology**

Although tuberculosis probably remains the commonest cause of primary adrenal insufficiency worldwide, in the UK the majority of cases are due to immune-mediated destruction of the adrenal glands and may be associated with other autoimmune glandular hypofunction (see autoimmune polyglandular syndromes, p. 227). Rarer causes of primary adrenal failure include infection (e.g. histoplasmosis, AIDS) and infiltration, although it is important to note that despite adrenal metastases being a relatively common finding on imaging, clinically evident adrenal insufficiency is rare in this setting. Adrenal haemorrhage, severe sepsis (e.g. meningococcaemia), congenital adrenal hyperplasia (CAH) and adrenoleukodystrophy (rare X-linked disorder) may also present with primary adrenal failure.

**Clinical presentation**

The clinical picture varies widely from the acutely ill patient in Addisonian crisis (Box 16.2) to the relatively asymptomatic patient with increased pigmentation. When present, symptoms may be non-specific, leading to a delay in diagnosis. Tiredness, weakness, dizziness, anorexia, weight loss and gastrointestinal disturbance are frequently reported. Female patients may present with menstrual disturbance (oligo/amenorrhoea). Salt ‘craving’ is common.

Increased pigmentation in the palmar creases, buccal mucosa and scars may be noted on examination. Postural hypotension is also common and females may exhibit loss of axillary and pubic hair (due to lack of adrenal sex steroids e.g. DHEAS).

**Investigation**

NB In the acutely ill patient in whom you suspect adrenal insufficiency treatment must not be delayed. Venous access should be established (taking blood for creatinine and electrolytes, glucose and cortisol) and intravenous hydrocortisone (100 mg) must be given immediately. A 0.9% saline drip should also be set up and blood glucose checked using both a finger-prick and laboratory sample.

In non-emergency cases consider the following:
- Creatinine, electrolytes and glucose. NB The classic pattern of low sodium, high potassium, high urea and low glucose is not seen in all cases.
- Full blood count – normochromic normocytic anaemia, neutropenia and eosinophilia are all recognised associations.
- Short Synacthen® test – serum cortisol measured pre- and 30 (± 60) min post-250 mcg of Synacthen® IM/IV. Normal subjects exhibit a peak response > 500 nmol/l at 30 min (precise thresholds depend on individual laboratory reference ranges). Occasionally the longer ‘depot’ Synacthen® test is used to distinguish primary and secondary adrenal dysfunction.
- Adrenal autoantibodies.
- Exclusion of other associated conditions (see autoimmune polyglandular syndromes, p. 227).

**Management**

Hypo-adrenal crisis should be treated as above, with the patient then established on regular IM hydrocortisone (e.g. 50–100 mg t.d.s./q.d.s.) until the acute phase has resolved. Underlying precipitants/causes should be sought and treated appropriately.
Routine replacement with hydrocortisone is typically given using a twice or thrice daily regimen (e.g. 10 mg on waking, 5 mg at lunch-time and 5 mg in the late afternoon). Adequacy of replacement is assessed clinically, with some centres also advocating cortisol day profiles. Larger patients and those on enzyme-inducing agents (e.g. phenytoin, carbamazepine, rifampicin) typically require higher doses of corticosteroid replacement therapy. Patients must be advised about the steroid ‘sick day rules’, should carry a card/emergency bracelet and be provided with an emergency pack (containing injectable hydrocortisone).

Fludrocortisone replacement is also required in primary (but not in secondary) adrenal insufficiency. The usual maintenance dose is 50–200 mcg/day.

NB In patients with concomitant hypothyroidism, thyroxine replacement should not be commenced until glucocorticoid replacement has been established, due to the risk of precipitating an Addisonian crisis.

**Congenital adrenal hyperplasia**

Congenital adrenal hyperplasia (CAH) is not a single disease entity but encompasses several autosomal recessive disorders (due to inborn errors in adrenocortical enzyme function) that result in differing degrees of impairment in the synthesis of cortisol and aldosterone. Deficiency of 21-hydroxylase is the most common enzyme defect (approximately 90–95% of all cases) and classical 21-hydroxylase deficiency affects approximately 1/14,000 live births in caucasians.

Reduced cortisol synthesis results in elevated circulating ACTH, thereby further stimulating steroidogenesis. However, precursors that cannot be metabolised by the deficient enzyme are then shunted down adjacent (e.g. androgenic) pathways, with the resulting clinical phenotype reflecting both hormone deficiency (e.g. cortisol and aldosterone) and excess (e.g. androgen) states.

**Clinical presentation**

Both ‘classical’ and ‘non-classical’ variants of CAH are recognised. The former denotes a more severe form, predominantly seen in the neonate/young child, and is characterised by hypoadrenalism with salt wasting (especially in males) or ambiguous genitalia and virilisation (in females). Non-classical CAH is typically ‘milder’ and may only come to light in adulthood (e.g. with hirsutism, menstrual irregularities and/or infertility).

**Investigation**

Depending on the enzyme defect different steroid precursors/androgens accumulate and can be measured in plasma. In practice, most laboratories restrict screening to the following:

- 17-hydroxyprogesterone – this precursor accumulates in 21-hydroxylase deficiency
- testosterone ± DHEAS and androstenedione
- plasma ACTH – elevated (although serum cortisol may be low or normal)
- plasma renin activity/mass – usually elevated in proportion to mineralocorticoid deficiency.

Genetic screening to identify mutations/deletions within the genes encoding the different enzymes involved in adrenal steroidogenesis is increasingly undertaken and has particular application in prenatal diagnosis.

**Management**

Episodes of acute adrenal insufficiency should be managed along conventional lines (see above). Routine replacement in ‘classical’ forms typically requires glucocorticoids (titrated against symptoms/signs, plasma ACTH, 17-hydroxyprogesterone and testosterone levels) and mineralocorticoid replacement (titrated against symptoms/signs, electrolytes, postural blood pressure and plasma renin).

‘Non-classical’ cases presenting with hirsutism may be managed with prednisolone (sometimes given in a ‘reverse circadian rhythm’, i.e. with a higher dose at night time to suppress the nocturnal ACTH drive) together with cosmetic measures.

Psychological support is often an important component of the long-term management. Patients with CAH wishing to fall pregnant require shared care between the endocrine and genetic teams to ensure optimisation of CAH therapy and appropriate counselling regarding risks to the offspring.

**Phaeochromocytoma**

Phaeochromocytoma is a rare but potentially life-threatening disorder. The majority of tumours arise within the adrenal medulla, but a smaller number are derived from sympathetic/parasympathetic ganglia (so-called paragangliomas). Tumours of adrenal origin commonly secrete noradrenaline (norepinephrine) and adrenaline (epinephrine), whereas paragangliomas as a rule do not secrete the latter (as they are unable to convert noradrenaline to adrenaline). In some (especially malignant) tumours significant amounts of dopamine may be released, while others appear to be non-secretory.

Although phaeochromocytomas were originally known as the ‘10% tumour’ (10% extra adrenal, 10% bilateral/multiple, 10% malignant, 10% familial) this is now considered to be outdated. For example, increasing numbers of cases are recognised to be familial, and the prevalence of bilateral tumours is much greater than 10% in certain familial syndromes.
So far, germline mutations in a variety of genes have been found in association with familial phaeochromocytoma, including the RET proto-oncogene (MEN-2A and MEN-2B), the VHL tumour suppressor gene (von Hippel-Lindau syndrome: comprising renal cysts/carcinoma, pancreatic tumours and cysts, retinal and craniospinal (e.g. cerebellar) haemangioblastomas, phaeochromocytomas, endolymphatic sac tumours), NF1 (neurofibromatosis type 1) and mitochondrial succinate dehydrogenase subunits (e.g. SDHB, SDHC and SDHD – familial paraganglioma/phaeochromocytoma syndromes).

Clinical presentation
Increasing numbers of phaeochromocytomas are identified incidentally on cross-sectional imaging undertaken for other purposes. These tumours may be asymptomatic. Other cases come to light during the investigation of poorly controlled hypertension, when closer questioning reveals an array of other manifestations of catecholamine excess including episodic or paroxysmal ‘attacks/spells’ in which the patient develops pallor/sweating, palpitations and headaches. Indeed, this triad of symptoms is considered to be highly suggestive of a diagnosis of phaeochromocytoma. Occasional cases may present with myocardial infarction, cerebrovascular accident, dilated catecholamine cardiomyopathy or pregnancy-associated hypertension.

Investigations
This typically involves two stages:

1. Confirmation of diagnosis
   • Urinary catecholamines and their metabolites – 24 h urine collections for estimation of urinary free catecholamines (adrenaline, noradrenaline and dopamine) are used for screening in many centres. Assays for the catecholamine metabolite vanillylmandelic acid (VMA) are no longer routinely performed because of their relatively low sensitivity. In contrast, measurement of urinary fractionated metanephrines (normetanephrine and metanephrine) are finding increasing use and offer increased sensitivity and specificity when compared with catecholamine measurements.
   • Plasma free metanephrines (normetanephrine and metanephrine) are currently the most sensitive test for detecting phaeochromocytoma.

2. Localisation of tumour
   Various imaging strategies may be employed, including:
   - CT/MRI
   - radioiodine-labelled metaiodobenzylguanidine (123I-MIBG) scintigraphy
   - 18F-DOPA PET(-CT).

Genetic testing is particularly indicated in younger patients, those with paraganglioma syndromes or if there is a family history of phaeochromocytoma or other associated conditions.

Management
Prior to surgical removal, medical treatment must be instituted with the aims of:

- ameliorating symptoms
- normalising blood pressure
- correcting intravascular depletion.

The non-competitive α-adrenoceptor antagonist phenoxybenzamine is the treatment of choice. The competitive antagonist doxazosin may be considered in those intolerant of phenoxybenzamine. Occasionally intravenous phentolamine is also required, e.g. in the setting of a phaeochromocytoma crisis.

Although β-blockade may be required for symptom control and relief of tachycardia/dysrhythmias (especially in those with elevated adrenaline levels), it is important to note that β-blockers must not be commenced in a patient with suspected or proven phaeochromocytoma until adequate α-blockade has been established, since there is a significant risk of precipitating a life-threatening hypertensive crisis due to unopposed α-adrenoceptor activity.

Once the patient is adequately ‘blocked’ surgical excision can be undertaken (either traditional or laparoscopic approach). Therapeutic 131I-MIBG therapy may be used in patients with recurrent/metastatic disease, and preliminary studies suggest a possible role for tyrosine kinase inhibitors in this setting.

Multiple endocrine neoplasia (MEN)
Three main multiple endocrine neoplasia syndromes are recognised: MEN-1, MEN-2A and MEN-2B. Each is characterised by autosomal dominant inheritance. Table 16.6 outlines the key features of each syndrome.
Investigation and management

Although the individual components of the MEN syndromes are generally managed along standard lines, there are some important differences:

- four gland parathyroid hyperplasia is more common than a single adenoma
- pancreatic tumours are often multiple
- phaeochromocytoma must be excluded in patients with suspected/confirmed MEN-2 before they undergo surgery for MTC or hyperparathyroidism.

In general, genetic testing has now effectively replaced biochemical screening in the identification of affected members in the majority of MEN kindreds. Because MTC is aggressive and the only effective cure is thyroidectomy, genetic screening is now increasingly offered to young children in affected kindreds, raising important ethical issues.

Autoimmune polyglandular endocrinopathies

Autoimmune-mediated dysfunction in two or more endocrine glands is recognised in the context of the autoimmune polyglandular endocrine syndromes (APS). Table 16.7 shows the key features of the two major syndromes.

Polycystic ovarian syndrome

Polycystic ovarian syndrome (PCOS) is the commonest cause of hirsutism and menstrual disturbance in females. It has been estimated that this condition affects ~5% of all women of reproductive age. Increasing evidence suggests a complex interplay between genetic susceptibility and environmental factors in the aetiopathogenesis of this disorder. Reduced insulin sensitivity, with consequent hyperinsulinaemia, are key features of the metabolic derangements that are typically seen in PCOS (including impaired glucose tolerance/type 2 diabetes mellitus and other features of the metabolic syndrome).

Clinical presentation

The symptoms of PCOS usually date from menarche and develop gradually. These include features of hyperandrogenism (e.g. hirsutism, acne) and menstrual irregularity (oligomenorrhoea or occasionally amenorrhoea). Weight gain and obesity tend to exacerbate the disorder. Clinical and/or biochemical evidence of hyperandrogenism, together with a history of anovulatory cycles (typified by oligomenorrhoea), are sufficient to make a diagnosis of PCOS. In addition, ultrasound of the ovaries may reveal the typical appearance of multiple peripherally sited follicles (‘string of pearls’) with
increased ovarian stroma. However, the presence of polycystic ovaries on ultrasound does not in itself indicate that the woman has PCOS (approximately 15–20% of all women have polycystic changes on ultrasound, although only one-third of these have PCOS).

Testosterone levels may be increased, but this is not an absolute requirement for diagnosis of the disorder – clinical evidence of hyperandrogenism suffices.

Fasting glucose/oral glucose tolerance test and lipid profiles should be checked for evidence of features of the metabolic syndrome.

Measurement of 17-hydroxyprogesterone (to exclude CAH) and adrenal androgens (e.g. DHEAS to exclude adrenal tumours) can help to distinguish from other causes of hirsutism/hyperandrogenism.

Weight loss often improves many of the features of PCOS. Other therapies are targeted to the principle complaint: for example, treatment of hirsutism with cosmetic measures or anti-androgens; infertility with clomifene. Cardiovascular risk factors should also be addressed.

<table>
<thead>
<tr>
<th>Type</th>
<th>Type 1*</th>
<th>Type 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epidemiology</strong></td>
<td>• Rare, autosomal recessive</td>
<td>• Autosomal dominant, recessive or polygenic</td>
</tr>
<tr>
<td></td>
<td>• Childhood onset</td>
<td>• Young adults</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Females &gt; males</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• DR3, DR4</td>
</tr>
<tr>
<td><strong>HLA associations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Genetic loci</strong></td>
<td>Chromosome 21: mutations in the AIRE gene</td>
<td></td>
</tr>
<tr>
<td><strong>Common endocrinopathies</strong></td>
<td>• Hypoparathyroidism</td>
<td>• Primary adrenal insufficiency</td>
</tr>
<tr>
<td></td>
<td>• Primary adrenal insufficiency</td>
<td>• Primary hypo- (or hyper-) thyroidism</td>
</tr>
<tr>
<td><strong>Less common endocrinopathies</strong></td>
<td>• Primary gonadal failure</td>
<td>• Type 1 diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td>• Primary hypo- (or hyper-) thyroidism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Type 1 diabetes mellitus</td>
<td></td>
</tr>
<tr>
<td><strong>Non-endocrine associations</strong></td>
<td>• Mucocutaneous candidiasis</td>
<td>• Myasthenia gravis</td>
</tr>
<tr>
<td></td>
<td>• Chronic active hepatitis</td>
<td>• Pernicious anaemia</td>
</tr>
<tr>
<td></td>
<td>• Pernicious anaemia</td>
<td>• Vitiligo</td>
</tr>
<tr>
<td></td>
<td>• Vitiligo</td>
<td>• Alopecia</td>
</tr>
<tr>
<td></td>
<td>• Alopecia</td>
<td></td>
</tr>
</tbody>
</table>

* Also known as autoimmune polyendocrinopathy, candidiasis and epidermal dystrophy (APECED); AIRE, autoimmune regulator gene.
Metabolic disorders

**Diabetes mellitus**

Diabetes mellitus (DM) is the term used to describe a group of metabolic disorders characterised by hyperglycaemia and due to:

- deficiency in pancreatic beta (β)-cell insulin production; and/or
- impaired insulin action (typically due to insulin resistance).

**Diagnostic criteria**

The World Health Organization (WHO) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus recommends that DM should be diagnosed in the following circumstances:

- symptoms of diabetes and random venous plasma glucose ≥ 11.1 mmol/l;
- fasting venous plasma glucose (FPG) ≥ 7.0 mmol/l (confirmed on a second occasion in asymptomatic individuals).

The term impaired fasting glycaemia (IFG) has also been introduced for those with fasting venous plasma glucose levels in the range 6.1–6.9 mmol/l. The WHO recommends that patients in the latter category should proceed to an oral glucose tolerance test (OGTT):

- Venous plasma glucose ≥ 11.1 mmol/l (2 h after 75 g of oral anhydrous glucose) confirms a diagnosis of DM; those with 2-h venous plasma glucose levels in the range 7.8–11.0 mmol/l are deemed to have impaired glucose tolerance (IGT).

The American Diabetes Association (ADA) has recently accepted the addition of haemoglobin A1c (HbA1c) ≥ 6.5% as sufficient criteria for a diagnosis of DM (with HbA1c values in the range 5.7–6.4% denoting ‘prediabetes’); however, there is considerable ongoing debate regarding this, and the WHO position is currently awaited.

**Classification**

Diabetes mellitus can be broadly classified into type 1 and type 2, although not all patients are easily assigned to one or other category. In addition, there are other specific types of diabetes (e.g. gestational DM and diabetes due to specific genetic defects), which are best considered independently (Table 17.1).

**Type 1 diabetes mellitus**

This was previously referred to as insulin-dependent diabetes mellitus (IDDM).

- An autoimmune disorder in which the insulin-producing β-cells of the pancreas are destroyed; hence there is absolute insulin deficiency.
- Although type 1 DM develops mostly during childhood and adolescence, it may also present in later life.
- Patients typically experience an acute onset of the disease (weeks rather than months) and often give a history of significant weight loss. They are dependent upon insulin therapy and are prone to ketoacidosis (see below).

**Type 2 diabetes mellitus**

This was previously referred to as non-insulin-dependent diabetes mellitus (NIDDM).

- The predominant form worldwide, accounting for ~90% of patients with DM.
- Tissue insensitivity to insulin action (i.e. insulin resistance), and an inability of the pancreatic β-cells to compensate adequately for this, leads to overproduction of glucose by the liver and under utilisation by other tissues, with an inevitable rise in blood glucose levels.
Traditionally this form of DM was considered predominantly a disease of obese, older adults, although now it is being increasingly diagnosed in adolescents and younger adults (and even in some children) due to the increasing prevalence of obesity in these age groups.

Symptoms are often mild in the early stages, which can lead to a delay in the patient seeking medical attention; hence, diagnosis may occur later in the disease process, with some cases presenting with established complications (e.g. retinopathy, neuropathy or cardiovascular disorders).

- There may be a history of recurrent infections and injuries that are slow to heal.
- Ketosis is uncommon, except in situations of extreme stress, as patients usually have sufficient insulin to prevent lipolysis.
- Although initially controlled with diet and/or oral hypoglycaemic agents, many patients eventually need supplemental insulin.
- Type 2 DM is recognised as part of the so-called metabolic syndrome, where it is associated with central obesity, hypertension, dyslipidaemia (low HDL cholesterol and hypertriglyceridaemia – see later) and premature cardiovascular disease.

Gestational diabetes mellitus (GDM)

Most women who develop DM during pregnancy have normal glucose homeostasis during the first half of gestation, but develop a relative insulin deficiency during the second half, leading to hyperglycaemia. The guidelines published in March 2010 by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommends that all women without a prior diagnosis of DM be considered for a 75 g anhydrous glucose OGTT at 24–28 weeks’ gestation. If two of the following criteria are met, then the woman is deemed to have a diagnosis of GDM:

- Fasting venous plasma glucose ≥5.3 mmol/l
- 1 h venous plasma glucose level ≥10.0 mmol/l
- 2 h venous plasma glucose level ≥8.6 mmol/l.

The UK National Institute for Health and Clinical Excellence (NICE) guidance (2008), however, only advises screening the following ‘at risk’ groups:

- BMI ≥30 kg/m²
- Previous macrosomic baby (weighing ≥4.5 kg)
- Previous GDM
- First-degree relative with DM
- Ethnic origin with a high prevalence of DM (South Asian, black Caribbean and Middle Eastern).

If screen positive (i.e. one positive risk factor), offer 75 g OGTT at 28 weeks. If ≥ two of the following criteria are met, then the woman is deemed to have a diagnosis of GDM:

- Fasting venous plasma glucose ≥5.3 mmol/l
- 1 h venous plasma glucose level ≥10.0 mmol/l
- 2 h venous plasma glucose level ≥8.6 mmol/l.

Other specific types of diabetes mellitus

This category includes a diverse spectrum of conditions, ranging from rarer genetic disorders to primary pancreatic pathology, endocrine diseases and drug-induced DM (Table 17.1).
Epidemiology
According to the WHO, the number of adults with DM worldwide was estimated to be 171 million in 2000 and is expected to rise to 366 million by 2030. The prevalence of DM in the UK is approximately 4% and has more than doubled since 1991.

Aetiology
Genetics
Type 1 DM
The identical twin of a person with type 1 DM has a 30–50% chance of developing the disease, implicating both genetic and environmental factors in its aetiology. A number of genetic susceptibility loci have been identified and include:

- **IDDM1** in the major histocompatibility complex (MHC)/human leucocyte antigen (HLA) region on chromosome 6p21.3.
- **IDDM2** near the insulin gene locus on chromosome 11p15.

Overall, the risk of a sibling or offspring of an individual with type 1 DM developing the same condition is relatively low but increased compared to the background population. The risk is higher if the father has the condition (6–8% versus 2–4% if the mother is affected).

Type 2 DM
Typically, there is a positive family history. In most affected individuals the inherited component is likely to be polygenic, involving interaction between multiple genes involved in both insulin secretion and insulin action. Overall, the risk of a sibling or offspring of a person with type 2 DM developing the condition is high (as much as 33%; identical twins are affected in 60–100% of cases). Lifestyle changes can modify this risk (see below).

MODY
MODY is an autosomal dominant condition. Individual subtypes are associated with mutations in a variety of different genes that encode factors involved in insulin production/release by pancreatic β-cells. For example, MODY type 2 is caused by mutations in the gene coding for glucokinase, a rate-limiting enzyme in the glycolytic pathway, which acts as a pancreatic ‘glucose sensor’, regulating insulin release in response to a rise in blood glucose levels. Mutations in glucokinase are associated with an altered ‘set-point’ for glucose sensing, i.e. insulin release is triggered at higher ambient blood glucose levels compared with the general population. Accordingly, hyperglycaemia tends to be mild and relatively stable over time, and is often detected incidentally or as part of family screening: severe hyperglycaemia and complications are rare. In contrast, in MODY type 3, mutations in a transcription factor, hepatocyte nuclear factor 1α (HNF1α), which regulates β-cell mass/insulin production, result in DM that typically presents in adolescence or young adulthood, with progressive hyperglycaemia over time such that treatment with oral hypoglycaemic agents and/or insulin is usually required. Patients with MODY 3 are particularly sensitive to the blood glucose lowering effects of sulphonylureas (see below), and patients started on insulin therapy prior to the diagnosis being made may be able to transition back to a sulphonylurea with maintenance of excellent glycaemic control; however, many patients ultimately require insulin therapy. Currently, HNF1α mutations account for ~70% of all MODY cases.

Environmental/other factors
Type 1 DM
In genetically susceptible individuals, one or more environmental factors may ‘trigger’ immune-mediated destruction of islet β-cells (‘insulinitis’). A variety of agents have been implicated including viruses (e.g. coxsackie, rubella, mumps, cytomegalovirus), dietary constituents (e.g. bovine serum albumin in cow’s milk, especially if fed to infants) and stress.

Type 2 DM
This is strongly linked to obesity, which predisposes to insulin resistance. Fetal malnutrition in utero may also be associated with an increased risk (so-called fetal programming).

Clinical presentation
The classic triad of diabetic symptoms include:

- polyuria
- increased thirst (polydipsia)
- weight loss.

These features typically manifest in an acute or subacute fashion in those with type 1 DM, but may be of gradual onset in the setting of type 2 DM. Other presenting features include:

- tiredness/fatigue
• blurred vision
• opportunistic infections (e.g. balanitis, thrush, pruritus vulvae).

Individuals with type 1 DM are traditionally thought of as being ‘lean’ as opposed to their type 2 DM counterparts, who are often overweight/obese. However, with the rising ‘obesity epidemic’ the margins have begun to ‘blur’ as more obese type 1 cases are identified. Similarly, not all patients with type 2 DM are necessarily obese.

Occasionally, diabetes may present as part of another disorder (e.g. Cushing syndrome, acromegaly, haemochromatosis) where features of the primary condition dominate the clinical picture, or may be detected incidentally or during screening (e.g. on urinalysis or a fasting/random blood sample).

Once the clinical diagnosis of DM is suspected, it is usually relatively easily confirmed (see diagnostic criteria above). In cases where there is difficulty in distinguishing between type 1 and type 2 DM, measurement of plasma C-peptide (low/absent in type 1 DM; present/elevated in type 2 DM) and screening for islet cell and anti-GAD (glutamic acid decarboxylase) antibodies may be of help.

Management

General principles

The major aim of management is to achieve near normal glucose homeostasis (for which patient education is a key component), initially to provide symptom relief and in the longer term to prevent/minimise complications – surveillance for, and treatment of, the latter is also a priority. Management should be coordinated by a specialist multidisciplinary diabetes team, based in either primary or secondary care, and individuals with DM should be reviewed at least once, and ideally twice, a year by this team. Table 17.2 shows aspects of the patient’s care that should be assessed during each ‘annual review’ process.

<table>
<thead>
<tr>
<th>Table 17.2</th>
<th>Key elements of the diabetic ‘annual review’ process</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Element</strong></td>
<td><strong>Comment(s)</strong></td>
</tr>
<tr>
<td>Diet and eating habits</td>
<td>Promote healthy diet/eating habits with specific advice pertaining to DM</td>
</tr>
<tr>
<td>Weight</td>
<td>Encourage maintenance of optimal weight</td>
</tr>
<tr>
<td>Physical activity</td>
<td>Explain that exercise improves glycaemic control, blood pressure and lipid profile</td>
</tr>
<tr>
<td>Glycaemic control</td>
<td>Assess by reviewing home blood glucose diary/meter in conjunction with HbA1c</td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>Check: frequency; awareness; ability to recognise and treat appropriately</td>
</tr>
<tr>
<td>Complications: retinopathy</td>
<td>Confirm enrolment into retinal photography screening programme; ask about visual change/symptoms</td>
</tr>
<tr>
<td>nephropathy</td>
<td>Check serum creatinine and urine ACR</td>
</tr>
<tr>
<td>neuropathy</td>
<td>Enquire about symptoms and examine for evidence of impaired sensation</td>
</tr>
<tr>
<td>foot problems</td>
<td>As for neuropathy, but also check: peripheral pulses; for callus, ulceration and Charcot arthropathy</td>
</tr>
<tr>
<td>cardiovascular disease</td>
<td>Ask about/examine for features of IHD; stroke/TIA; peripheral vascular disease</td>
</tr>
<tr>
<td>Associated risk factors</td>
<td>Advise avoidance of/cessation from smoking; ensure within targets for blood pressure and lipids (see text)</td>
</tr>
<tr>
<td>Medications</td>
<td>Check: DM treatment regimen, antihypertensive/renal protection therapy, lipid-lowering agents and, where appropriate, antiplatelet therapy</td>
</tr>
<tr>
<td>Injection sites</td>
<td>Look for evidence of lipohypertrophy (or rarely lipoatrophy) and advise rotation of injection sites</td>
</tr>
<tr>
<td>Driving</td>
<td>Ensure awareness of DVLA regulations/advice (e.g. test blood glucose before driving – should be &gt; 5 mmol/l)</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Advise variable impact on blood glucose – mainly risk of late hypoglycaemia and possible requirement for adjustment to insulin regimen</td>
</tr>
<tr>
<td>Sexual function</td>
<td>Ask about erectile dysfunction in men; advise on contraception and preconception glycaemic control in women</td>
</tr>
<tr>
<td>Psychological factors</td>
<td>Check for concerns, e.g. regarding coping with a chronic illness</td>
</tr>
<tr>
<td>Blood tests</td>
<td>Electrolytes, renal function, liver function, glucose, HbA1c, fasting lipid profile, full blood count</td>
</tr>
</tbody>
</table>

ACR, albumin : creatinine ratio; DM, diabetes mellitus; DVLA, Driver Vehicle and Licensing Authority; HbA1c, haemoglobin A1c; IHD, ischaemic heart disease; TIA, transient ischaemic attack.
In addition to the diabetologist/GP with a specialist interest, diabetes specialist nurse/practice nurse and dietician, patients with diabetes may also require input from the following disciplines: chiropody, psychology, orthopaedics, vascular surgery, ophthalmology and urology.

A plethora of clinical trials have confirmed the benefits of achieving/maintaining good glycaemic control in DM, but two landmark studies merit particular mention: the Diabetes Control and Complications Trial (DCCT – type 1 DM) and the United Kingdom Prospective Diabetes Study (UKPDS – type 2 DM) – see Box 17.1.

**Box 17.1 Glycaemic control in diabetes – landmark trials**

The **Diabetes Control and Complications Trial (DCCT)** compared intensive and standard treatment in 1,441 patients with type 1 DM (mean age 27 years) over a 6.5-year period; 726 patients had no retinopathy (primary prevention cohort), whereas 715 had mild retinopathy (secondary prevention cohort). Intensive treatment involved insulin given by a pump, or by three or more daily subcutaneous injections, with dosages adjusted according to blood glucose measured at least four times daily. Standard treatment involved insulin given once or twice daily, with once-daily monitoring of blood or urinary glucose. The study showed that:

- Intensive treatment reduced the risk of developing retinopathy by 76% in the primary prevention group, and of worsening retinopathy by 54% (and of developing proliferative or severe non-proliferative retinopathy by 47%) in the secondary prevention group.
- In the two groups combined, intensive therapy reduced the risk of developing microalbuminuria by 39%, albuminuria by 54% and neuropathy by 60%.
- The major adverse event in the intensively treated group was a two- to threefold increase in severe hypoglycaemic episodes.


The **United Kingdom Prospective Diabetes Study (UKPDS)** was a multicentre trial involving 5,102 patients with newly diagnosed type 2 DM. It ran for 20 years (1977–1997) in 23 UK clinical centres and demonstrated conclusively that the complications of type 2 DM could be reduced by improving glycaemic and/or blood pressure control. UKPDS randomised newly diagnosed patients with type 2 DM into conventional (target FPG < 15 mmol/l) and intensive (FPG < 6 mmol/l) glucose control treatment arms. The study showed that:

- Retinopathy, nephropathy and possibly neuropathy are benefited by lowering blood glucose levels in type 2 DM with intensive therapy, which achieved a median HbA1c of 7.0% compared with conventional therapy with a median HbA1c of 7.9%.
- The overall microvascular complication rate was decreased by 25%, and for every percentage point decrease in HbA1c there was a 35% reduction in the risk of complications; there was no evidence of any glycaemic threshold for any of the microvascular complications above normal glucose levels.
- A 16% reduction (which was not statistically significant, p = 0.052) in the risk of combined fatal or non-fatal myocardial infarction and sudden death was observed.
- For every percentage point decrease in HbA1c, there was a 25% reduction in diabetes-related deaths, a 7% reduction in all-cause mortality, and an 18% reduction in combined fatal and non-fatal myocardial infarction. Again no glycaemic threshold for these macrovascular complications was observed.
- Lowering blood pressure to a mean of 144/82 mmHg significantly reduced strokes, diabetes-related deaths, heart failure, microvascular complications and visual loss.
- A log-linear relationship between the incidence of complications and increasing HbA1c or systolic blood pressure indicated that any improvement in glycaemic or blood pressure control would be advantageous.
- Metformin appeared to confer particular benefits in obese subjects with T2DM, and was associated with less weight gain and fewer hypoglycaemic episodes.


DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c.
Glycaemic control

Monitoring
This is typically assessed using a combination of the patient’s home blood glucose monitoring (HBGM) records and glycosylated haemoglobin $A_{1c}$ (HbA$_{1c}$) measurement. The latter provides an estimate of overall glycaemic control during the past 6–8 weeks, and can be assayed either using a near-patient testing kit or in the clinical biochemistry laboratory. Due to potentially significant variations in analytical methods and quality control, all assays have traditionally been aligned to that used in the DCCT and expressed as a percentage. However, a new standard has recently been introduced by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which expresses HbA$_{1c}$ values in mmol/mol of unglycosylated haemoglobin. Table 17.3 shows DCCT and IFCC equivalents.

The frequency/necessity of HBGM continues to be widely debated. At a minimum, testing should be undertaken during periods of change or intercurrent illness, and in all patients on insulin therapy, with recommendations determined on an individual patient basis. Continuous glucose monitoring systems (CGMS) are available, but are expensive and generally reserved for ‘difficult cases’ and/or highly engaged individuals.

Similarly, ‘ideal’ blood glucose targets are often debated and ‘one size does not fit all’; in general, HBGM levels of 4–8 mmol/l are likely to correlate with a satisfactory HbA$_{1c}$ (< 7.0%; 53 mmol/mol). However, individualised targets should be agreed between the patient and his/her clinician, bearing in mind the large volume of trial data showing that good glycaemic control reduces the risk of microvascular and macrovascular complications, and that in some settings (e.g. pregnancy – see below) tight glycaemic control is particularly important (to reduce the risk of fetal malformations and macrosomia), but that for others (e.g. the frail/elderly living alone) the need to avoid hypoglycaemia may necessitate running the HbA$_{1c}$ at less than optimal levels.

Treatment of hyperglycaemia

Type 1 DM
Patients with type 1 DM require insulin to control their blood glucose levels. Education about the effects of diet, physical activity and illness upon glycaemic control, and hence insulin requirements, is critical.

Insulin preparations
Based on source, insulins are classified as animal (porcine, bovine), human or analogue. The use of animal insulins has fallen in recent years, but there are still a small number of patients who derive particular benefits from these preparations. Based on the duration of action, insulin can be classified as rapid-, short-, intermediate- or long-acting. In addition, various mixed preparations exist, containing different proportions of faster- and slower-acting insulins; for example, Novomix-30 is a pre-mixed insulin analogue which contains 30% soluble insulin aspart (rapid-acting form) and 70% insulin aspart protamine (intermediate-acting form) (Tables 17.4 and 17.5).

Insulin administration
Options include:
- syringe and needle
- ‘pen devices’
- insulin pump/continuous subcutaneous insulin infusion (CSII) therapy.

Insulin regimens
A variety of different insulin regimens exist (Table 17.6).

Patient education
Accredited evidenced-based programmes have now been developed, and the most widely recognised is DAFNE (Dose Adjustment For Normal Eating). DAFNE offers a comprehensive programme designed to deliver the specific knowledge required by patients with type 1 DM to manage their daily insulin requirements based on diet, activity, illness, etc.

Other therapeutic options
A small number of patients may ultimately be considered for whole organ (pancreas – often combined with kidney) or islet cell transplantation, but currently these options are limited and only available in a small number of centres.

Type 2 DM

Patient education
Type 2 DM may be prevented, or at least its onset delayed, by making significant lifestyle changes in

---

Table 17.3 Diabetes Control and Complications Trial (DCCT) and International Federation of Clinical Chemistry (IFCC) equivalent HbA$_{1c}$ values

<table>
<thead>
<tr>
<th>DCCT-aligned HbA$_{1c}$ (%)</th>
<th>IFCC-standardised HbA$_{1c}$ (mmol/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0</td>
<td>20</td>
</tr>
<tr>
<td>5.0</td>
<td>31</td>
</tr>
<tr>
<td>6.0</td>
<td>42</td>
</tr>
<tr>
<td>6.5</td>
<td>48</td>
</tr>
<tr>
<td>7.0</td>
<td>53</td>
</tr>
<tr>
<td>7.5</td>
<td>59</td>
</tr>
<tr>
<td>8.0</td>
<td>64</td>
</tr>
<tr>
<td>8.5</td>
<td>69</td>
</tr>
<tr>
<td>9.0</td>
<td>75</td>
</tr>
<tr>
<td>9.5</td>
<td>80</td>
</tr>
<tr>
<td>10.0</td>
<td>86</td>
</tr>
</tbody>
</table>
those at high risk of the condition. Dietary modification and physical activity are critically important for achieving good glycaemic control. A comparable programme to DAFNE for type 2 DM – DESMOND (Diabetes Education and Self-Management for On-going and Diagnosed) is recommended by NICE. If these measures alone fail to control blood glucose levels, then oral hypoglycaemic agents are typically commenced. Ultimately, many patients require combination therapy with oral hypoglycaemic agents and/or injectable therapies (e.g. incretin mimetics or insulin – see below).

Table 17.7 shows the oral hypoglycaemic agents currently available in the UK.

**Biguanides**
Metformin, the only biguanide licensed in the UK, reduces hepatic glucose production, mainly by inhibiting gluconeogenesis. It also increases peripheral insulin sensitivity, albeit through a poorly understood mechanism. Beneficial effects include promotion of

<table>
<thead>
<tr>
<th>Table 17.4 Classification of insulin preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of insulin (with examples)</strong></td>
</tr>
<tr>
<td>---------------------------------</td>
</tr>
<tr>
<td><strong>Rapid-acting</strong></td>
</tr>
<tr>
<td>Insulin aspart, insulin glulisine, insulin lispro</td>
</tr>
<tr>
<td><strong>Short-acting/neural</strong></td>
</tr>
<tr>
<td>Actrapid®, Humulin S®, Insuman® rapid</td>
</tr>
<tr>
<td>Hypurin® bovine neutral, Hypurin® porcine neutral</td>
</tr>
<tr>
<td><strong>Intermediate/long-acting</strong></td>
</tr>
<tr>
<td>Humulin I®, Insulatard®, Insuman® basal</td>
</tr>
<tr>
<td>Hypurin® bovine isophane, Hypurin® bovine lente, Hypurin® porcine isophane</td>
</tr>
<tr>
<td><strong>Long-acting</strong></td>
</tr>
<tr>
<td>Insulin detemir, insulin glargine</td>
</tr>
<tr>
<td>Hypurin bovine protamine zinc insulin (PZI)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 17.5 Types of mixed/biphasic insulins</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Examples</strong></td>
</tr>
<tr>
<td>Humulin M3®, Insuman® Comb 15, Insuman® Comb 25, Insuman® Comb 50</td>
</tr>
<tr>
<td>Hypurin porcine 30/70 mix</td>
</tr>
<tr>
<td>Humalog® Mix25, Humalog® Mix50, NovoMix® 30</td>
</tr>
</tbody>
</table>
weight loss, reductions in total and low-density lipoprotein (LDL) cholesterol and triglycerides.

Gastrointestinal side effects are common, especially during the early stages of treatment, but usually subside (hence the mantra ‘low (dosage) and slow (dosage increments)’). It should be avoided in patients with renal impairment (serum creatinine > 150 mmol/l or GFR < 30 ml/min) to reduce the risk of lactic acidosis. In addition, its use should be suspended in those undergoing radiological contrast studies or general anaesthesia and not restarted until renal function has returned to baseline.

Vitamin B₁₂ deficiency may develop as a result of decreased absorption – annual full blood count is therefore recommended.

**Table 17.6 Insulin regimens**

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Example</th>
<th>Indication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once-a-day</td>
<td>Insulin detemir, insulin glargine</td>
<td>Type 2 DM together with oral hypoglycaemic agents</td>
</tr>
<tr>
<td>Twice-a-day</td>
<td>Mixed/biphasic insulins</td>
<td>Type 2 (or type 1) DM</td>
</tr>
<tr>
<td>Thrice-a-day</td>
<td>Mixed insulin (morning), rapid acting (evening), long acting (night) or mixed biphasic insulin thrice daily</td>
<td>Used mostly in children to avoid the need to inject while at school; rarely used in adults (e.g. if high total daily insulin requirement)</td>
</tr>
<tr>
<td>Four times a day</td>
<td>Long-acting insulin once (or occasionally twice) daily and rapid-acting insulin with each meal</td>
<td>Preferred regimen in type 1 DM; also used for young type 2 DM failing oral hypoglycaemic agents and once daily insulin</td>
</tr>
</tbody>
</table>

**Sulphonylureas (sulfonylureas)**

Sulphonylureas augment residual pancreatic β-cell function, hence the term ‘insulin secretagogues’ (Table 17.7). They are licensed for monotherapy (mainly used in patients who are intolerant of metformin or in whom there is a specific indication for sulphonylurea therapy, e.g. MODY 3 (see earlier)), or in combination with other oral hypoglycaemic agents or insulin. Sulphonylureas are generally not recommended for use during pregnancy, although some clinicians believe that glibenclamide (US approved name glyburide) can be used safely after the first trimester.

Their major side effects are hypoglycaemia (especially in the elderly) and weight gain.

**Prandial glucose regulators (‘meglitinides’)**

Repaglinide and Nateglinide are rapid-acting insulin secretagogues with a fast onset and short duration of action. They should be taken 15–30 min before each main meal. However, they are relatively expensive and although there are theoretical advantages to their use, in practice they offer few benefits over sulphonylureas.

**Thiazolidinediones (TZDs; ‘glitazones’)**

The TZDs are high affinity ligands for the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ), which is expressed ubiquitously, but at particularly high levels in adipose tissue.

Both pioglitazone and rosiglitazone are known to cause fluid retention and are contraindicated in those with/at risk of heart failure – this tendency is exacerbated when used in conjunction with insulin therapy. In addition, significant concerns have been raised regarding a possible increased risk of adverse ischaemic coronary events/outcomes in patients taking rosiglitazone and, after a series of reviews/updates to the product licence, eventually the marketing authorisation for rosiglitazone was suspended by the European Medicines Agency in September 2010. At the same time, the US Food and Drug Administration (FDA) placed significant restrictions on the use of this drug. Currently therefore, pioglitazone is the only TZD available for use in the UK.

Other adverse effects of TZD therapy include weight gain, increased fracture rate at peripheral sites in women and, rarely, hepatic dysfunction; in addition, specific concerns have been raised regarding an increased risk of bladder cancer in those taking pioglitazone.

**Alpha-glucosidase inhibitors**

These agents inhibit the function of intestinal alpha-glucosidases, thereby delaying the digestion and absorption of complex carbohydrates (e.g. starch, sucrose). Currently, only one agent, acarbose, is licensed for use in the UK. It has a relatively small effect on lowering blood glucose levels and is associated with an unwelcome side effect – flatulence!

**Dipeptidylpeptidase-4 inhibitors (DPP-4 inhibitors; ‘gliptins’)**

Glucagon-like peptide 1 (GLP-1), an incretin that is secreted from the intestinal L-cells in response to nutrients, promotes glucose-dependent insulin secretion from pancreatic β-cells, while simultaneously suppressing glucagon release. In addition, GLP-1 slows gastric emptying and may confer additional ‘protective effects’ on the β-cells, through as yet unclear mechanisms. Endogenous GLP-1 has a very
short half-life in the circulation and is rapidly degraded by the enzyme dipeptidylpeptidase-4 (DPP-4). Accordingly, inhibitors of DPP-4 (e.g. saxagliptin, sitagliptin and vildagliptin) enhance endogenous GLP-1 signalling and are of potential benefit in the treatment of type 2 DM. DPP-4 inhibitors are generally weight neutral. Hypoglycaemia is relatively uncommon.

Glucagon-like peptide 1 (GLP-1) agonists/
analogues (‘incretin mimetics’)

Exenatide and liraglutide are the first agents to become available in this class, and mimic the effects of endogenous GLP-1. Both are given by subcutaneous injection. Unlike the DPP-4 inhibitors, they promote weight loss, which has been postulated to occur via a variety of mechanisms, including delayed gastric emptying, which results in early satiety, and central appetite suppressant effects. Weight loss may be profound with a resultant reduction in insulin resistance to such an extent that other oral hypoglycaemics can be reduced/withdrawn. The risk of hypoglycaemia is generally low, which is advantageous for those occupations where insulin use is prohibited. However,

---

Table 17.7 Oral hypoglycaemic agents and non-insulin-based injection therapy for type 2 diabetes mellitus

<table>
<thead>
<tr>
<th>Class</th>
<th>Comment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanides</td>
<td>Suppress basal hepatic gluconeogenesis (major contributor to fasting hyperglycaemia in type 2 DM); also reduce peripheral insulin resistance, thereby increasing glucose utilisation.</td>
</tr>
<tr>
<td>e.g. metformin</td>
<td>– preferred first-line agent in type 2 DM, especially in overweight/obese subjects – does not cause hypoglycaemia.</td>
</tr>
<tr>
<td>Sulphonylureas</td>
<td>Insulin secretagogues, which act on ATP-sensitive potassium channels in pancreatic β-cells to promote insulin secretion.</td>
</tr>
<tr>
<td>1st generation e.g. chlorpropamide, tolbutamide</td>
<td>– rarely used due to less favourable side effect profile, e.g. long duration of action of chlorpropamide, which predisposes to hypoglycaemia</td>
</tr>
<tr>
<td>2nd and 3rd generation e.g. gliclazide, glimepiride, glipizide</td>
<td>– more potent, but generally better tolerated than first generation agents – predispose to hypoglycaemia, especially in the elderly and those with renal/hepatic impairment.</td>
</tr>
<tr>
<td>Meglitinides</td>
<td>Insulin secretagogues, which bind to ATP-sensitive potassium channels on pancreatic β-cells in a similar manner to sulphonylureas, but at a discrete binding site.</td>
</tr>
<tr>
<td>e.g. nateglinide, repaglinide</td>
<td>– rapid onset and very short duration of action; controls prandial hyperglycaemia – reduced risk of postabsorptive hypoglycaemia.</td>
</tr>
<tr>
<td>Thiazolidinediones (TZDs)</td>
<td>Selective agonists of the nuclear receptor PPARγ, which improve peripheral insulin sensitivity and promote more favourable adipose tissue distribution/function, but at a cost of overall weight gain.</td>
</tr>
<tr>
<td>e.g. pioglitazone</td>
<td>– hypoglycaemia is relatively uncommon with monotherapy, but risk may be increased by concomitant use of certain other oral hypoglycaemic agents (especially sulphonylureas) or insulin.</td>
</tr>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>Impair the enzymatic degradation of complex carbohydrates (e.g. starch and sucrose) in the small intestine, thereby delaying their digestion and absorption.</td>
</tr>
<tr>
<td>e.g. acarbose</td>
<td>– modest effect on lowering blood glucose – not associated with hypoglycaemia when used alone.</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>Inhibit the function of DPP-4, thus impairing the degradation of the endogenous incretin GLP-1, which leads to an increase in GLP-1 levels, thereby promoting insulin release and suppressing glucagon secretion.</td>
</tr>
<tr>
<td>e.g. saxagliptin, sitagliptin, vildagliptin</td>
<td>– hypoglycaemia is relatively uncommon.</td>
</tr>
<tr>
<td>GLP-1 agonists/ analogues</td>
<td>Incretin mimetics, which mimic endogenous GLP-1 action, thereby increasing insulin secretion, suppressing glucagon secretion and slowing gastric emptying.</td>
</tr>
<tr>
<td>e.g. exenatide, liraglutide</td>
<td>– hypoglycaemia is a recognised albeit uncommon side effect.</td>
</tr>
</tbody>
</table>

ATP, adenosine triphosphate; DM, diabetes mellitus; DPP-4, dipeptidylpeptidase-4; GLP-1, glucagon-like peptide 1; PPARγ, peroxisome proliferator-activated receptor γ.
when used in combination with sulphonylureas (see below), there is a significant increase in the risk of hypoglycaemia, and patients should be advised of this. Gastrointestinal side effects, particularly nausea, are common; severe (rarely fatal) pancreatitis has also been reported and patients should be carefully counselled and advised of symptoms to report.

Insulin

The natural history of type 2 DM with insulin resistance is progressive pancreatic β-cell failure; so while good glycaemic control may initially be achievable through lifestyle measures alone, eventually most patients progress to require oral hypoglycaemic agents followed by incretin mimetics or insulin. Unfortunately, the use of insulin in type 2 DM is often complicated by weight gain. The different types of insulin regimen used in type 2 DM are shown in Table 17.6.

Diabetic emergencies

There are two common types of diabetic coma:

- hypoglycaemic (the most common)
- hyperglycaemic (diabetic ketoacidosis (DKA) or hyperosmolar non-ketosis (HONK)).

Hypoglycaemia (‘hypo’)

Hypoglycaemia in the context of DM occurs in patients who are treated with insulin and, less commonly, in those receiving certain oral hypoglycaemic agents (Table 17.7). It reflects an imbalance between insulin and carbohydrate, the most frequent precipitants being inappropriate medication use, excess physical activity, decreased food intake, excess alcohol ingestion or a combination of factors.

Hypoglycaemia is usually associated with the development of so-called warning symptoms – hypoglycaemic awareness involves:

- ‘Autonomic’ symptoms – a physiological response that is associated with the release of counter-regulatory hormones (adrenaline (epinephrine) and noradrenaline (norepinephrine)). Clinical signs include tremor, sweating, anxiety, palpitations and shivering.
- ‘Neuroglycopenic’ symptoms – manifest if hypoglycaemia is prolonged and more profound; as glucose is the only fuel source readily utilised by the brain, cognitive function is affected with symptoms of tiredness, dizziness, drowsiness, difficulty in speaking, inability to concentrate, confusion and aggression; as a general rule, neuroglycopenic symptoms develop when blood glucose is < 2.6 mmol/l; if left untreated coma and death may ensue.

Although the blood glucose level at which people begin to experience hypoglycaemic symptoms varies, the consensus for defining hypoglycaemia in the context of DM is a blood glucose value of < 4 mmol/l. ‘Four is the Floor’ has proved to be a successful awareness campaign.

Management

The Joint British Diabetes Societies Inpatient Care Group (JBDS IP Group) has published recommendations for the treatment of hypoglycaemia, with the aim of standardising treatment within the National Health Service (NHS):

- If the patient is conscious, advise 15–20 g of rapidly acting carbohydrate (e.g. 50 ml Lucozade™, 3 dextrose tablets) to correct the hypoglycaemia, always followed with longer acting/complex carbohydrate to maintain glucose in the normal range (this may be the next meal if imminent; if not, offer toast or a sandwich).
- If the patient is semiconscious, then apply commercially available glucose gel to the buccal mucosa; this may allow sufficient improvement in conscious level to continue treatment as per a conscious individual.
- If the patient is unconscious, administer 50 ml of 20% dextrose intravenously (50% dextrose may cause significant phlebitis) via a large vein, followed by a generous flush; if intravenous access is not available, then 1 mg of glucagon can be given intramuscularly while awaiting further medical help.

Ascertaining the cause of recurrent hypoglycaemia is often neglected by the individual, or clinician. It should be sought and remedial action taken. Sometimes early morning headaches or a restless night may be the only indication of nocturnal hypoglycaemia.

NB Recurrent and severe hypoglycaemia may cause a downregulation of the autonomic respose to hypoglycaemia, resulting in reduced warning, so-called hypoglycaemic (‘hypo’) unawareness. Development of the latter has significant social/lifestyle implications, particularly with respect to driving.

Hyperglycaemia

Diabetic ketoacidosis (DKA)

DKA most commonly occurs in the context of type 1 DM, but is also occasionally seen in type 2 DM under conditions of extreme stress. Glucose cannot be utilised as an energy substrate in the absence of insulin, and the body ‘perceives’ itself to be lacking in glucose, hence hepatic gluconeogenesis and glycosgenolysis are
enhanced, exacerating the hyperglycaemia. An alternative energy substrate is sought, and lipolysis occurs with the mobilisation and increased production of fatty acids and amino acids; ketones are produced as a toxic metabolite of this process within the liver, resulting in the development of metabolic acidosis.

DKA is defined as a triad of:
- hyperglycaemia (plasma glucose > 11 mmol/l)
- acidosis (venous pH < 7.3)
- ketosis (either ketonaemia (> 3 mmol/l) and/or ketonuria (> 2 + )).

The incidence, using all three criteria, is estimated at 4-8 episodes per 1000 diabetic individuals. It is a potentially life-threatening catabolic state, but fortunately mortality rates are now low in the developed world (< 1%). Life-threatening complications include cerebral oedema (remains the commonest cause of mortality in the young), hypokalaemia and the development of adult respiratory distress syndrome.

The two major precipitating factors for DKA are inadequate insulin therapy, either deliberate or accidental, and intercurrent infection. All patients with type 1 DM should be educated regarding the nature, cause and prevention of DKA, often referred to as the ‘sick day rules’.

Symptoms of DKA include thirst, dry mouth, polyuria, nausea, vomiting, weakness, myalgia, headache and abdominal pain. Drowsiness may progress to confusion and coma. It is rare for DKA to develop without a prodromal phase, and symptoms of hyperglycaemia have often been present for at least 24 h, but missed or ignored. Clinical signs include dehydration, tachycardia, hypotension, hyperventilation (Kussmaul breathing) and the characteristic smell of ketones. Hypovolaemic shock can ensue in more severe cases.

Management

The primary aim of treatment is to suppress ketogenesis, rather than normalise hyperglycaemia. The JBDS IP Group has released guidance on the management of DKA (March 2010). As with hypoglycaemia, the aims are to standardise care within the NHS, while at the same time incorporating recent advances in technology and recognising the changing presentation of DKA.

The major technological advance relates to near patient (i.e. bedside) routine testing of blood ketones (3-betahydroxybutyrate), and using the fall in ketonaemia as a guide to the response to treatment.

Recognition that ‘euglycaemic acidosis’ is now a more common presentation (with improved education, individuals often manage to partially treat their acidosis, often leading to lower blood glucose levels at presentation) is also emphasised in the guidance.

The management of DKA revolves around:
- fluid replacement
- insulin replacement
- metabolic treatment targets
- additional measures.

Fluid replacement

It is universally acknowledged that the most important therapeutic intervention in DKA is the immediate administration of fluids. Crystalloid is the fluid of choice (0.9% sodium chloride) even in the hypotensive individual. Fluids are required to:
- **Restore circulatory volume**: the required rate of fluid infusion will vary depending on the age of the patient (children and young adults appear to be at increased risk of cerebral oedema from overexuberant fluid resuscitation, while otherwise previously fit adults generally tolerate rapid initial fluid replacement, e.g. first 1 l of 0.9% sodium chloride over 1 h, with the second and third litres over 2 h each, increasing to 4-hourly bags for the fourth and fifth litres, and then 6-hourly, with reassessment of cardiovascular status on a regular basis). Care must also be exercised in the elderly, during pregnancy and in patients with pre-existing renal or cardiac failure or other serious comorbidities.
- **Enable clearance of ketones**: with lower glucose levels at presentation, administration of intravenous insulin can lead to hypoglycaemia well before ketogenesis is fully suppressed; as it is imperative to continue the insulin infusion until the latter has been achieved, the administration of 10% glucose, often concurrently with 0.9% sodium chloride, is often required (most units would start intravenous glucose when blood glucose levels fall below 14 mmol/l).
- **Correct electrolyte imbalance**: potassium is the predominant intracellular cation and is actively transported into cells through a glucose/insulin-dependent channel; at presentation hyperkalaemia is common in DKA, as potassium cannot enter the cells in the absence of insulin; however, total body potassium is low and following the administration of intravenous insulin serum potassium levels plummet and regular monitoring is therefore mandatory.

NB Hypo- and hyperkalaemia are important causes of mortality in DKA.

The JBDS IP Group also provides simple guidance for the addition of potassium to intravenous fluids during the first 24 h of treatment:
- serum potassium > 5.5 mmol/l – none
- serum potassium 3.5–5.5 mmol/l – add 40 mmol/l
- serum potassium < 3.5 mmol/l – senior review as additional potassium is required and the patient may require transfer to a higher care setting to allow this to be given safely.
NB Caution must be exercised in patients with suspected renal failure, especially in those with poor/no urine output despite initial fluid resuscitation.

**Insulin replacement**

The most significant change in the new guidance is the replacement of the traditional insulin sliding scale (variable rate intravenous insulin infusion (variable rate IVII)) with a fixed rate intravenous insulin infusion (fixed rate IVII). The predominant rationale for this change is the increasing prevalence of obesity, an insulin resistant state. Hence, the fixed rate is calculated per kilogram of body weight – initially 0.1 unit/kg/h. The previous recommendation for a ‘priming bolus’ has also been dropped, given that evidence has proven no benefit, providing the insulin infusion is started promptly, and in reality it was often omitted.

Continuation of a subcutaneous long-acting analogue insulin alongside the insulin infusion is now recommended (it facilitates a smoother transition back to the individual’s normal subcutaneous regimen, without rebound hyperglycaemia).

**Metabolic treatment targets**

- Reduction of blood ketone concentration by ≥ 0.5 mmol/l/h: generally measured hourly for the first 6 h; if ketonaemia is not responding adequately, reassess patient and increase fixed rate IVII by 1 unit/h, until adequate rate of resolution achieved.
- If blood ketone measurement is not available, aim to increase the venous bicarbonate by ≥ 3 mmol/l/h: again if there is an inadequate response to treatment, increase fixed rate IVII as above.

NB However, after 6 h, venous bicarbonate may become unreliable, particularly in the presence of hyperchloraemia as a consequence of the 0.9% sodium chloride infused.
- Alternatively, aim for a reduction in capillary blood glucose (CBG) of ≥ 3 mmol/l/h: again this is an alternative to ketone analysis; however, falling CBG is not an accurate indicator of the resolution of acidosis (especially in ‘euglycaemic acidosis’), which should be confirmed on venous gas analysis.

NB If ketones and glucose are not falling as expected, check that the insulin infusion pump is working and connected and that the expected amount of insulin has been infused.
- Maintenance of serum potassium between 4.0 and 5.0 mmol/l: serum potassium should be measured at least 2 hourly for the first 6 h, and at regular intervals thereafter.

**Additional measures**

- Screen for infection: mid-stream urine sample, chest radiograph, blood cultures.
- ECG: screen for silent myocardial ischaemia, but also to assess the impact of hypo-/hyperkalaemia on the myocardium.
- Urethral catheterisation: accurate fluid assessment is critical to effective management; placement of a urinary catheter is not mandatory, but if accurate urine volume assessment is not possible without a catheter, then one is required.
- A nasogastric tube should be placed if the conscious level is depressed, as acidosis predisposes to gastric stasis and the individual is therefore at high risk of aspiration.
- Adequate fluid and insulin therapy should produce prompt resolution of acidosis, and intravenous bicarbonate is therefore not routinely required and indeed may worsen the metabolic situation – acidosis promotes a right shift in the oxygen dissociation curve which may be an adaptive response; rapid correction of acidosis with bicarbonate leads to a rise in arterial PaCO₂ and a paradoxical fall in cerebrospinal fluid pH, exacerbating central nervous system depression.
- Whilst it is recognised that whole body deficit of phosphate is high, routine phosphate supplementation has no proven benefit. However, in the case of respiratory and muscular weakness it may be considered.

Resolution of DKA is defined as a blood ketone level of < 0.3 mmol/l and venous pH > 7.3. If the individual is tolerating normal dietary intake they should be converted back to an appropriate subcutaneous insulin regimen. Trace/mild ketonuria may persist for a short time post-resolution of the acidosis.

The diabetes specialist team should be involved in the care of all DKA episodes, in particular the diabetes specialist nurse who will be required to check education/understanding of possible DKA precipitants and the required actions to deal with these, as well as to facilitate follow-up post-discharge.

**Hyperosmolar non-ketotic coma (HONK)**

This typically occurs in the elderly, often previously undiagnosed, patient with type 2 DM. The onset may be drawn out, with polyuria precipitating dehydration over several days or even weeks. Precipitating factors include myocardial infarction, stroke and intercurrent infection. Unlike DKA, there is sufficient residual
endogenous insulin to prevent ketogenesis, and hence no acidosis. Hyperosmolality is the predominant biochemical feature, in association with marked hyperglycaemia (blood glucose can exceed 100 mmol/l in extreme cases).

These patients are profoundly dehydrated and are at high risk of thrombosis (both arterial and venous), which is a significant contributor to the high mortality of this condition (30–50%). Low molecular weight heparin is therefore recommended unless there is a contraindication to its use (e.g. haemorrhagic stroke). Patients require rehydration to replace the massive fluid deficit, but this must be undertaken in a controlled manner (often with the aid of central venous pressure monitoring) especially where there is significant co-morbidity (e.g. cardiac disease). In addition, overzealous rehydration may cause rapid osmotic shifts, precipitating cerebral oedema. Paradoxically these patients are often very insulin sensitive and may need only small amounts of insulin to lower their blood glucose satisfactorily – aim for a fall of 3 mmol/l/h.

As with DKA, close monitoring of cardiovascular, renal and metabolic status, with regular checking of electrolytes, glucose, and osmolality is mandatory. Unlike DKA, insulin therapy is not always subsequently required once the acute episode has subsided, and survivors may manage on diet and oral hypoglycaemic agents.

**Long-term diabetic complications**

Long-term complications occur in all forms of DM and are broadly classified as microvascular or macrovascular in origin (Table 17.8).

**Macrovascular complications**

Diabetes is a major risk factor for the development of atherosclerotic vascular disease.

### Table 17.8 Long-term complications of diabetes mellitus

<table>
<thead>
<tr>
<th>Microvascular complications</th>
<th>Macrovascular complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinopathy</td>
<td>Coronary heart disease</td>
</tr>
<tr>
<td>Neuropathy – peripheral</td>
<td>Peripheral vascular disease</td>
</tr>
<tr>
<td>and autonomic</td>
<td>disease</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>Cerebrovascular disease</td>
</tr>
<tr>
<td></td>
<td>(stroke, transient</td>
</tr>
<tr>
<td></td>
<td>ischaemic attack)</td>
</tr>
</tbody>
</table>

**Attention to other cardiovascular risk factors in the patient with diabetes mellitus**

**Hypertension**

With time, blood pressure targets in the context of diabetes have progressively fallen as data have emerged to show that in most cases ‘the lower the better’. Combination therapy is often required to achieve a blood pressure of $\leq 130/80\text{ mmHg}$, or even lower in those with concomitant renal involvement. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are usually the preferred first-line agents, especially when there is evidence of microalbuminuria (see below). Calcium antagonists, $\alpha$-adrenoceptor blockers and diuretics are useful adjuncts.

**Dyslipidaemia**

Several large-scale trials have shown that statins reduce both non-fatal and fatal cardiovascular events in patients with DM, when used in both primary and secondary prevention settings. Targets continue to be refined, but in general a total cholesterol level $< 4\text{ mmol/l}$ with low density lipoprotein cholesterol (LDL-C) $< 2\text{ mmol/l}$ are considered desirable.

**Microvascular complications**

**Retinopathy**

- The most common cause of visual loss in adults of working age in the UK.
- Proliferative retinopathy is more common in type 1 DM, and maculopathy in type 2 DM.
- Good glycaemic control is the key factor in preventing the development of, or deterioration in, retinopathy.
- Other risk factors include hypertension, smoking and pregnancy.

Various classification schemes for diabetic retinopathy have been proposed based largely on ophthalmological findings or functional severity: Table 17.9 provides an example of a traditional classification scheme; however, others argue for a simplification to just ‘non-proliferative’ and ‘proliferative’ subgroups, but again with maculopathy considered as a separate entity.

**Management**

Modification of all treatable risk factors and annual screening (visual acuities and retinal photography) are the mainstay of prevention and early intervention. If background retinopathy is present, glycaemic control should be reviewed, microalbuminuria, hypertension and dyslipidaemia sought and actively treated, and
the patient kept under close surveillance. The presence of preproliferative retinopathy requires prompt referral for formal ophthalmological review. Laser photocoagulation, in which laser therapy is applied to peripheral areas of the retina (thereby reducing total oxygen requirements across the retina, and ameliorating ischaemia in other areas that are critical for vision), may be indicated. Again, maintenance of good glycaemic, blood pressure and lipid control is of paramount importance. For proliferative retinopathy, laser photocoagulation can reduce visual loss; here laser therapy is used to induce regression of new blood vessels (thus reducing the risk of haemorrhage), in addition to reducing oxygen requirements throughout the retina, thereby retarding further new vessel proliferation. Laser therapy can also improve maculopathy. Vitrectomy (surgical removal of the vitreous) may be used as a salvage procedure in those with vitreous haemorrhage. It aims to improve vision by removing any blood from in or behind the vitreous, reattaches detached areas of retina, and is combined with pan-retinal laser photocoagulation to reduce the stimulus for further neovascularisation.

The potential role of antivascular endothelial growth factor treatments in the management of diabetic retinopathy is an area of current research interest, with early trials showing promising results. However, treatment programmes are likely to be costly and time-consuming.

Cataracts are more common and occur at an earlier age in patients with DM, and should therefore be actively sought and treated.

### Table 17.9 Classification of diabetic eye disease

<table>
<thead>
<tr>
<th>Type</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>Microaneurysms&lt;br&gt;Haemorrhages (dot and blot/flame-shaped)&lt;br&gt;Hard exudates (lipid deposits)&lt;br&gt;Occasional (&lt;5) soft exudates ('cotton wool' spots)</td>
</tr>
<tr>
<td>Preproliferative</td>
<td>As above&lt;br&gt;Soft exudates&lt;br&gt;Intraretinal microvascular abnormalities (IRMAs)&lt;br&gt;Venous beading, venous reduplication</td>
</tr>
<tr>
<td>Proliferative</td>
<td>New vessel formation at the disc/within one disc diameter (NVD)&lt;br&gt;New vessels elsewhere (NVE)&lt;br&gt;Rubeosis iridis</td>
</tr>
<tr>
<td>Maculopathy</td>
<td>Focal or diffuse oedema at the macula&lt;br&gt;Haemorrhages, exudates or other changes at the macula</td>
</tr>
<tr>
<td>Advanced eye disease</td>
<td>Preretinal or vitreous haemorrhage&lt;br&gt;Retinal detachment</td>
</tr>
<tr>
<td>Cataract</td>
<td><em>Multiple cotton wool spots signify retinal ischaemia.</em></td>
</tr>
</tbody>
</table>

Microalbuminuria and diabetic nephropathy

- Data from the UK Renal Registry show that diabetic nephropathy is the most common single cause of end-stage renal failure amongst adults starting renal replacement therapy.
- Nephropathy, i.e. the development of macroalbuminuria and a progressive decline in renal function (with falling glomerular filtration rate (GFR) and rising serum creatinine), ultimately affects approximately 20–30% of patients with DM, although this percentage is falling as earlier and more aggressive management of DM and its complications is pursued.
- Microalbuminuria heralds the onset of diabetic renal disease and, if left unchecked, progresses to intermittent and then persistent proteinuria. Progression is associated with either localised (Kimmelstiel–Wilson nodules) or diffuse fibrotic thickening of afferent and efferent arterioles. Proteinuria, hypertension and oedema become clinically apparent. Serum creatinine only rises after significant renal damage has occurred.
- Incipient nephropathy is synonymous with microalbuminuria. Normal urinary albumin excretion is <20 mg/l. Microalbuminuria is present when the urine albumin concentration is in the range 20–200 mg/l (30–300 mg/24 h), and macroalbuminuria when levels exceed this. Nephrotic syndrome is associated with urinary protein loss of >3 g/24 h.
- Screening for microalbuminuria is most commonly undertaken through estimation of the urine albumin : creatinine ratio (ACR) on a spot urine sample: values >2.5 mg/mmol in men and >3.5 mg/mmol in women signify the presence of microalbuminuria if confirmed on at least one further independent sample during the next few months. In practice, 24-hour urine collections are now rarely performed.
- The presence of microalbuminuria is also indicative of progressive generalised vascular disease, and attention must be paid to the management of other cardiovascular risk factors (e.g. hypertension, dyslipidaemia, smoking history).
- Other causes of renal impairment may coexist (e.g. hypertension, renal artery stenosis) and should be sought if there are specific clinical pointers or atypical features (e.g. development of renal disease in the absence of retinopathy).
NB Intravenous contrast studies can precipitate acute renal failure in those with pre-existing renal impairment – adequate hydration and temporary withdrawal of agents such as metformin and ACE inhibitors/ARBs help reduce the risk in susceptible individuals – if in doubt, discuss with radiology and/or nephrology.

Management

The attainment of good glycaemic and, in particular, good blood pressure control is essential for the prevention and treatment of microalbuminuria. There is a large amount of data showing that ACE inhibitors are particularly effective in this setting, with ARBs a reasonable alternative in patients intolerant of the former. Both classes of agent appear to reduce proteinuria at levels above and beyond their antihypertensive effects.

Good blood pressure control remains the mainstay of treatment in those with established nephropathy, and again ACE inhibitors/ARBs are the preferred option(s), although additional antihypertensive therapy is often required, and diuretics may be helpful in treating fluid overload. Antihyperglycaemic agents that are long-acting and/or renally excreted (including insulin) should be reviewed on a regular basis and dosages adjusted or alternatives substituted where necessary.

NB Metformin should be avoided in those with established renal impairment (serum creatinine > 150 mmol/l or GFR < 30 ml/min) because of the risk of inducing lactic acidosis.

Early referral to a renal specialist service is generally recommended to ensure appropriate management of complications (e.g. secondary hyperparathyroidism, anaemia) and for consideration of prepara- tion for renal replacement therapy (dialysis and/or transplantation).

Continued aggressive management of cardiovascular risk factors is mandatory, as this is the major cause of morbidity and mortality in this group of patients.

Neuropathy

• More common in patients with a long history of DM (males > females), especially in those with poor glycaemic control.
• Multifactorial, reflecting a combination of metabolic and vascular factors.

Distal symmetrical polyneuropathy (‘sensory peripheral neuropathy’)

This is the most common form of diabetic neuropathy (characterised by loss of both myelinated and unmyelinated nerve fibres) and typically affects the longest fibres first – hence the so-called ‘glove and stocking’ distribution. Symptoms include dyseaesthesia (numbness and tingling), often worse at night, progressing to chronic pain (stabbing/burning/shooting) with time. Examination reveals absent ankle jerks, diminished vibration sense in the lower limbs, and an inability to feel the standard 10-g monofilament. Reduced pain and temperature sensation follow, with muscular wasting and weakness late features. Affected individuals are at high risk of developing diabetic foot complications (neuropathic/neuroischaemic ulcers, Charcot arthropathy).

Optimal diabetic control is central to the prevention of distal symmetrical polyneuropathy. Tricyclic antidepressants (e.g. amitriptyline), duloxetine (a serotonin and noradrenaline reuptake inhibitor) and various anticonvulsants (e.g. carbamazepine, gabapentin and pregabalin) may help with symptom relief. Topical capsaicin may also be tried.

Acute (painful) sensory neuropathy

This is predominantly seen in male patients and is associated with poor glycaemic control or rapid improvement in glycaemic control (e.g. following commencement of insulin therapy).

Acute mononeuropathies

These motor neuropathies are thought to result from ischaemia and occlusion of vasa nervorum. Various cranial nerves (e.g. third, fourth and sixth), the ulnar nerves and the lateral common peroneal nerves are most commonly affected, and more than one nerve can be involved at any given time (i.e. mononeuritis multiplex). It is often transient and spontaneous recovery of function usually occurs over a period of months, but can be variable.

Diabetic amyotrophy (proximal motor neuropathy)

This is a rare disorder, which usually occurs in middle-aged men who develop painful, asymmetric weakness and wasting of the quadriceps muscles, and is often associated with marked anorexia and weight loss. Insulin, even in those with apparently satisfactory glycaemic control, remains the mainstay of treatment.

Autonomic neuropathy

Autonomic neuropathy may manifest in a number of different ways, including:
• cardiovascular: postural hypotension, tachycardia, painless ischaemia
• gastrointestinal: constipation, diarrhoea (especially nocturnal), gastroparesis
• genitourinary: erectile dysfunction/impotence, atonic bladder
• others: hypoglycaemia unawareness, gustatory sweating, oedema.

Other complications
The diabetic foot
Foot problems are very common and give rise to significant morbidity and mortality. The most commonly encountered problems are:

• **Neuropathic ulceration** – typically painless and occurring at pressure points (e.g. under the first and fifth metatarsal heads); lack of pain sensation and build-up of callus are predisposing factors; may be complicated by abscess formation/osteomyelitis. Ulcers should be swabbed and plain radiographs performed; if there is any suggestion of more deep-seated infection/osteomyelitis, consider MRI scan of the foot and isotope bone scintigraphy. Depending on the absence or presence of infection and the extent of tissue involvement, treatment may involve removal of callus and debridement, oral or intravenous antimicrobials and surgical drainage/debridement/amputation. Specialist non-weight-bearing footwear is also often required to facilitate healing.

• **Neuroischaemic ulceration** – here the situation is exacerbated by concomitant vascular insufficiency; patients may also complain of intermittent claudication and/or rest pain; ulcers also occur over the heel and dorsum of the foot/toes, and pre-gangrenous or frankly gangrenous changes may be present. Investigation and management is similar to that for neuropathic ulceration, but in addition the extent of vascular disease requires formal assessment, often with a combination of doppler ultrasound studies and arteriography to determine the feasibility of attempted revascularisation.

• **Neuropathic joints (Charcot arthropathy)** – a less common but well-recognised complication, often affecting the tarsometatarsal joints (i.e. mid-foot) and/or the ankle; impaired sensation with abnormal mechanical stresses/load-bearing may contribute to its development/progression. Left unchecked, joint instability and trophic bone changes lead to major and severe deformities of the foot. MRI scanning can help to differentiate from infection and, in combination with isotope bone scintigraphy, may reveal new bone formation. If recognised at an early stage, intravenous bisphosphonates may help in preventing bone resorption; however, the mainstay of treatment is to prevent deformity and destruction of the foot by strict avoidance of weight bearing, e.g. through the use of a total contact cast. Surgical reconstruction of affected joints may be indicated in refractory cases.

Diabetes-related skin conditions
Skin changes in diabetes may reflect:

• an immediate consequence of hyperglycaemia, e.g. opportunistic infection including candidiasis (particularly genital, e.g. balanitis) and *S. aureus* folliculitis
• long-term changes resultant from chronic hyperglycaemia
• a consequence of treatment.

Necrobiosis lipoidica diabeticorum (pretibial diabetic dermopathy) is pathognomonic of DM. It is characterised by atrophy of subcutaneous collagen, usually over the shins. Lesions typically start as small, brownish, erythematous shiny patches and may evolve to develop a central yellow area with atrophy that can ulcerate. Unfortunately, no treatment has been shown to be of benefit – the most important management is to protect the lesions from trauma. Granuloma annulare typically manifests as a cluster of small papules that form a ring on the back of the hands or feet. Although spontaneous resolution usually occurs, cryotherapy or intralesional corticosteroid therapy may hasten the process. Skin changes associated with insulin resistance include acanthosis nigricans (pigmented velvety thickening of the skin, typically seen in the axillae and nape of the neck, and considered a marker of severe insulin resistance) and scleroderma diabeticorum (thickening of the skin on the upper back and neck).

Lipoatrophy is painless localised necrosis of subcutaneous fat tissue at the site of insulin injection therapy; it is now uncommon following the introduction of recombinant/analogue human insulins. In contrast, lipohypertrophy (localised accumulation of fat tissue at the site of multiple injections) is very common, as hypertrophied sites are relatively painless to inject into! However, the insulin absorption from these sites is erratic, leading to unpredictable glycaemic excursions.

Diabetes and pregnancy
Pregestational DM
Commissioned in 2002, and reporting in 2007, the UK Confidential Enquiry into Maternal and Child Health (CEMACH) quantified the risks of diabetic pregnancy: perinatal mortality was 3–5 times higher and congenital malformation rate 4–10 times higher than in the general population; ‘suboptimal care’
was highlighted as a major factor in those cases with poor outcomes.

**Prepregnancy counselling**

The importance of optimal diabetic control before conception should be strongly emphasised. Women should be given realistic information regarding the effects of diabetes on pregnancy (miscarriage, congenital malformation, stillbirth and neonatal death) and advised that these risks can be reduced (but not eliminated) with good preconceptual and antenatal glycaemic control. Counselling should also discuss the potential effects of pregnancy on the progression of diabetic complications.

**Antenatal care**

Daily oral folic acid supplements (5 mg) should be taken from 3 months prior to conception, and for at least the first 12 weeks of gestation, to reduce the risk of neural tube defects. Tight glycaemic control must be maintained throughout pregnancy. To facilitate this, women should undergo an early antenatal assessment (as soon as pregnancy is confirmed) and antenatal care should be provided by a multidisciplinary team (as described above).

**Glycaemic control**

Targets for self-monitoring of blood glucose (HBGM) should be agreed with the individual woman. Where possible, aim to keep fasting blood glucose levels between 3.5 and 5.9 mmol/l. HBGM should be performed 1h after each meal, with the aim, where safe, of keeping levels below 7.8 mmol/l. HBGM should also be performed before retiring to bed each night.

NB HbA1c is less reliable in the second and third trimester to gauge the adequacy of control.

Women should have regular contact with the diabetes centre, ideally on a weekly basis (and no less than fortnightly), for regular reassessment. They must be advised of the increased risk of hypoglycaemia in pregnancy, and that hypoglycaemia unawareness is also more common – this is particularly important with respect to driving.

It is also important to warn of the increased risk of ketogenesis and the particular hazards to the fetus/pregnancy of ketosis. Clear guidance should be offered regarding testing for ketosis and the ‘sick day rules’ (see below) reiterated. Ketone testing strips (either for ketonuria or ketonaemia) should be prescribed.

**Medication**

All oral hypoglycaemics with the exception of metformin, should be discontinued prior to conception or as soon as pregnancy is confirmed. Metformin can be offered as a first-line agent where glycaemic control has not been achieved through lifestyle measures alone.

NB Although the use of metformin is supported by NICE, it is not currently licensed in pregnancy and women should therefore be appropriately counselled.

If glycaemic control is not achieved rapidly, i.e. within 10–14 days, insulin therapy should be commenced. An MDI (‘basal-bolus’) regimen is preferred for all women requiring insulin therapy. Although NICE does not currently recommend the routine use of basal analogue insulin preparations in pregnancy, most units will continue their use if started preconceptually, and indeed many diabetologists would also initiate treatment with them when required, because of their favourable hypoglycaemic profile.

Drugs affecting the renin-angiotensin system (e.g. ACE inhibitors, ARBs) should be stopped as soon as possible as they are potentially fetotoxic. Alternative antihypertensive agents (e.g. methyldopa, labetalol) can be substituted where necessary.

Where an ACE inhibitor/ARB has been used prior to pregnancy for the purpose of renoprotection, close surveillance for nephropathy must be observed. Statins should be discontinued, and the risk:benefit ratios of all other medications must be carefully discussed.

**Retinal assessment**

Women should be advised of the importance of retinal assessment in the preconception period, and during and after pregnancy.

**Renal assessment**

Renal assessment is important both in the preconception period and during pregnancy. Diabetic nephropathy is a progressive disease that can significantly adversely affect the outcome of the pregnancy; in addition, pregnancy can accelerate the progression of nephropathy. Early involvement of the renal team is therefore advisable in any patient in whom there is concern regarding renal status.

NB eGFR is not validated for use in pregnancy and should not therefore be used as an indicator of renal function.

**Fetal growth and well-being**

Women should have all aspects of routine fetal monitoring and well-being offered. In addition a four-chamber view of the fetal heart and outflow tracts should be offered at 18–20 weeks’ gestation. Assessment of fetal growth and amniotic fluid volume by ultrasonography every 2–4 weeks is recommended between 28 and 38 weeks’ gestation. Routine monitoring of fetal well-being (e.g. cardiotocography) prior
to 38 weeks is not generally recommended; however, in women at risk of intrauterine growth retardation (IUGR; i.e. those with macrovascular disease/nephropathy) an individualised approach should be tailored to assess fetal growth and well-being.

Women with DM in pregnancy should be advised of the possibility of fetal macrosomia and its associated risks (e.g. birth trauma, and an increased requirement for induction of labour and/or caesarean section).

Intrapartum care

Delivery should be completed by 39 weeks’ gestation; every woman should have an individualised care plan for her glycaemic control during the intrapartum and immediate postpartum period, and this should be clearly documented in her notes. During labour, blood glucose must be monitored hourly, aiming to keep levels between 4 and 7 mmol/l; if this cannot be achieved using the patient’s standard diabetes treatment, then a variable rate intravenous insulin infusion (i.e. sliding scale) should be initiated.

Neonatal care

Blood glucose testing is carried out routinely in all offspring of mothers with DM, and babies should remain in hospital for 24 h post-delivery to ensure maintenance of adequate glucose levels.

Preterm labour

In the case of threatened or actual preterm labour, women with DM receiving corticosteroids antenatally require admission for blood glucose monitoring. If glycaemic control is not maintained between 4 and 7 mmol/l on the patient’s regular treatment regimen, then a variable rate intravenous insulin infusion should be initiated and continued for 24 h after the last dose of steroids.

Gestational diabetes mellitus

Gestational diabetes mellitus (GDM) is diabetes that develops or is first recognised in pregnancy. In the UK, the prevalence varies from 1 in 220 to 1 in 330 depending on the ethnicity of the region. Both IADPSG and NICE have recently issued guidance on the definition of, and screening for, GDM (see classification, above).

Management is along similar lines as for pregestational DM, with a particular emphasis on diet and HBGM; target glycaemic levels and fetal surveillance strategies are the same. Glucose tolerance often returns to normal after delivery. NICE recommends that a fasting venous plasma glucose level be checked at 5–6 weeks postnatally, repeated on an annual basis thereafter, as it is well recognised that a substantial proportion of women affected with GDM go on to develop type 2 DM in later life, with estimates varying from 20–50% depending on the population under study.

Other important information for patients with diabetes

Diabetes and intercurrent illness

‘Sick day rules’

During times of illness, particularly when oral intake is poor, many insulin-dependent/treated patients with DM become concerned regarding the risk of developing hypoglycaemia; however, in reality hepatic glycogenolysis provides sufficient glucose to prevent the development of hypoglycaemia during most intercurrent illnesses, even when calorie intake is markedly reduced. In fact, the main risk with intercurrent illness is of developing hyperglycaemia, precipitated by relative insulin resistance, which may lead to DKA/HONK, particularly if insulin doses are inappropriately omitted or reduced. It is important therefore that patients are educated to:

- never stop insulin during intercurrent illness
- perform HBGM frequently
- check for ketones regularly
- maintain a high fluid intake wherever possible.

Most patients require frequent small doses of rapid-acting insulin to avoid developing hyperglycaemia and, in the case of type 1 DM, ketoacidosis. If in doubt, they should be advised to seek early medical advice. This information should be provided in written format, as well as verbally, and reinforced at each annual review.

Diabetes and surgery

Most hospitals have protocols for the management of individuals with DM undergoing procedures that require a period of fasting, e.g. colonoscopy through to major abdominal surgery. Ideally patients should be given written as well as verbal instructions on medication adjustments at their preprocedural/preoperative assessment. To facilitate optimal glycaemic control, those with DM should be scheduled as early on the operative/procedure list as is practical, and a variable rate intravenous insulin infusion instituted to maintain euglycaemia as the stress of surgery (cortisol, glucagon, growth hormone and catecholamine surges) predispose to hyperglycaemia. The variable rate intravenous insulin infusion is usually combined with an infusion of 5% dextrose containing 20 mmol/l potassium chloride, but tailored to the individual’s medical/electrolyte status. Once the
Dyslipidaemia

The major importance of dyslipidaemia lies in its close relationship with cardiovascular disease. At a simplistic level, LDL cholesterol is potentially ‘deleterious’, as small dense LDL particles are capable of penetrating the endothelial barrier and are taken up by macrophages before undergoing oxidation to give rise to ‘foam cells’. The latter contribute to atheromatous plaque formation and instability, e.g. in coronary blood vessels. In contrast, HDL particles predominantly work to remove excess cholesterol from cells for transport back to the liver in a process known as reverse cholesterol transport. Hence, LDL cholesterol is sometimes referred to as ‘bad cholesterol’ and HDL as ‘good cholesterol’. Hypertriglyceridaemia is also considered an independent risk factor for vascular disease, and predisposes to pancreatitis.

Classification

A practical classification is shown in Table 17.10.

Primary dyslipidaemias

Familial hypercholesterolaemia

Familial hypercholesterolaemia (autosomal dominant) is caused by mutations in the LDL receptor gene, which results in reduced LDL cholesterol clearance and consequent hypercholesterolaemia (severe in the homozygous form, less marked in heterozygotes) leading to premature atherosclerosis. Affected individuals are often asymptomatic but manifest clinical signs including corneal arcus, xanthelasma and tendon xanthomata. Left untreated, premature cardiovascular death is common. Heterozygotes respond to pharmacological management of their hypercholesterolaemia and modification of other cardiovascular risk factors. Homozygotes often fare badly and may require liver transplantation. Family screening is strongly recommended.

Familial defective apolipoprotein B-100

This is caused by a single amino-acid substitution in apolipoprotein B, resulting in defective binding of LDL to its receptor. It is clinically indistinguishable from familial hypercholesterolaemia and treated in the same way.

Polygenic hypercholesterolaemia

Often considered a diagnosis of exclusion in which there is isolated LDL cholesterol elevation without peripheral stigmata, but premature ischaemic heart disease within a family. Variants in Apo E4 alleles have been implicated in some instances. Statins are the preferred treatment option.

Familial hypertriglyceridaemia

This may be caused by either increased hepatic VLDL production or a failure of triglycerides to be cleared from chylomicrons by lipoprotein lipase. Inheritance is autosomal dominant. Marked hypertriglyceridaemia is associated with eruptive xanthomata, lipaemia retinæalis and acute pancreatitis. Management involves avoiding/treating potential exacerbating conditions such as obesity, hypothyroidism and diabetes mellitus.
together with pharmacotherapy aimed at reducing the hypertriglyceridaemia (e.g. fibrates and nicotinic acid).

**Familial combined hyperlipidaemia**
This condition is inherited as an autosomal dominant trait and affects ~1% of the general population but up to 15% of patients suffering myocardial infarction who present before 60 years of age. It is characterised by an overproduction of hepatic-derived Apo B100 (genetic basis unknown). Cholesterol and triglycerides are classically both increased (with increases in LDL and/or VLDL cholesterol; HDL cholesterol is typically low), but one or other may be normal. Clinical signs include corneal arcus and xanthelasmata, but not tendon xanthomata. The risk of atherosclerosis is increased. Treatment often requires combination statin (targeting LDL cholesterol) and fibrate (triglyceride lowering) therapy, with the attendant increased risks of rhabdomyolysis and hepatic upset.

**Familial dysbetalipoproteinaemia**
This is a rare (autosomal recessive) disorder characterised by elevations in triglyceride and total cholesterol levels. The disease develops in individuals who are homozygous for apolipoprotein E2 (Apo E2) variants. There is a reduced ability to convert VLDL and IDL to LDL particles in the blood and decreased clearance of chylomicron remnants. Affected individuals are at increased risk of atherosclerotic cardiovascular disease and peripheral vascular disease. Linear xanthomata of the palmar creases are considered pathognomonic. The condition responds well to avoidance/treatment of other disorders that predispose to hypertriglyceridaemia, and to medications that reduce blood triglyceride concentrations (e.g. fibrates, nicotinic acid).

**Secondary dyslipidaemias**
Secondary dyslipidaemias are very common, and treatment of the underlying cause, with the exception of gout and chronic renal failure, generally improves the dyslipidaemia. Common secondary causes include endocrine disorders (e.g. hypothyroidism, Cushing syndrome, acromegaly), renal failure/nephrotic syndrome, drugs (e.g. oral oestrogen, thiazide diuretic or retinoid therapy), alcohol excess, obstructive liver disease, diabetes mellitus and obesity.

**Associations between lipids and vascular disease**
Epidemiological studies such as the Multiple Risk Factor Intervention Trial (MRFIT) and Prospective

---

**Table 17.10 Classification of dyslipidaemia**

<table>
<thead>
<tr>
<th>Lipoprotein class</th>
<th>Fredrickson type</th>
<th>Primary causes</th>
<th>Secondary causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypercholesterolaemia</td>
<td>↑ LDL</td>
<td>IIA</td>
<td>Familial hypercholesterolaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Polygenic hypercholesterolaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertriglyceridaemia</td>
<td>↑ CM</td>
<td>I</td>
<td>Lipoprotein lipase deficiency</td>
</tr>
<tr>
<td></td>
<td>↑ VLDL</td>
<td>IV</td>
<td>Apo CII deficiency</td>
</tr>
<tr>
<td></td>
<td>↑ CM and VLDL</td>
<td>V</td>
<td>Familial combined hyperlipidaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Familial hypertriglyceridaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lipoprotein lipase deficiency</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Apo CII deficiency</td>
</tr>
<tr>
<td>Mixed dyslipidaemia</td>
<td>↑ Remnants</td>
<td>III</td>
<td>Familial dysbetalipoproteinaemia</td>
</tr>
<tr>
<td></td>
<td>↑ VLDL and LDL</td>
<td>IIb</td>
<td>Familial combined hyperlipidaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CM, chylomicron; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein.
Cardiovascular Munster study (PROCAM) have examined the potential links between dyslipidaemia and ischaemic heart disease. In general, most have shown a strong curvilinear association between plasma total cholesterol or LDL cholesterol and ischaemic heart disease (IHD), whereas there is an inverse relationship with HDL cholesterol. For example, a 10% increase in total/LDL cholesterol increases the IHD risk by 20%. (As 60–70% of plasma cholesterol is present in LDL, total cholesterol is often used as a surrogate measure of LDL cholesterol.) Raised levels of lipoprotein A also predict the risk of ischaemic heart disease. In contrast, studies have given variable results with regard to the association of hypertriglyceridaemia and IHD, although on balance it appears that raised plasma triglyceride levels are a risk factor.

Clinical presentation

Dyslipidaemia is typically identified in the context of cardiovascular disorders or other related metabolic conditions (e.g. diabetes mellitus). Occasionally the clinical stigmata of dyslipidaemia trigger screening (xanthelasma, corneal arcus and tendon xanthomata are associated with hypercholesterolaemia, and eruptive or tuberous xanthomata and lipoaemia retinalis with hypertriglyceridaemia). Screening should also be offered to asymptomatic individuals with a positive family history. Patients with more marked hypertriglyceridaemia (> 10 mmol/l) are prone to pancreatitis.

Investigation

Total cholesterol

Fasting samples are not strictly necessary, although should be requested when patients record non-fasting cholesterol levels that would require treatment, and in those suspected of having dyslipidaemia.

NB A mild or moderate elevation in LDL cholesterol with an associated reduction in HDL cholesterol can result in a normal total cholesterol level, which can therefore be misleading with respect to cardiovascular risk.

LDL cholesterol

A fasting sample is required for an accurate result. However, the assay is difficult and expensive to run and the majority of laboratories actually calculate/estimate the LDL level, from the Friedewald equation (LDL cholesterol = (Total cholesterol) – (HDL cholesterol) – (triglycerides/2.2)) (all values in mmol/l).

NB The Friedewald equation should not be used when chylomicrons are present, when plasma triglycerides exceed 4.5 mmol/l or in patients with known dysbetalipoproteinaemia.

HDL cholesterol

Measurement is not standardised and there are generally only small differences between normal and abnormal levels. However, the ratio of total serum cholesterol:HDL-cholesterol is commonly used in coronary risk prediction charts.

Triglycerides

Plasma triglycerides rise dramatically after a meal so a fasting sample, preferably overnight, is required.

Other investigations

- Fasting blood glucose: to exclude dyslipidaemia secondary to DM.
- Renal function: to exclude chronic kidney disease.
- Liver function tests (transaminases): to exclude intrinsic liver disease, and as a baseline for monitoring while on statin therapy.
- Creatine kinase: some advocate measuring at baseline prior to statin therapy, while others suggest checking only in those complaining of muscle symptoms while on treatment.
- Thyroid function tests: to exclude hypothyroidism.
- Genetic testing/screening: as clinically indicated (see above).

Management

The primary purpose of treating dyslipidaemia is to prevent or reduce the risk and complications of cardiovascular disease. There is a large volume of powerful clinical trial data to show that lipid-lowering therapy reduces the risk of cardiovascular morbidity and mortality in at-risk individuals – both in the context of primary and secondary prevention. The decision to initiate treatment in those without a prior history of vascular disease is often based on an assessment of overall risk of coronary heart disease. For example, this can be calculated from cholesterol levels, age, sex and blood pressure using risk tables, such as those provided by the Joint British Societies (available at http://www.bhsoc.org/Cardiovascular_Risk_Charts_and_Calculators.stm).

Current Joint British Societies’ guidelines recommend that in those with:

- established IHD
- diabetes mellitus and
- in asymptomatic individuals at high cardiovascular risk (i.e. 10-year IHD risk > 20%)

lipid targets should be:

- total cholesterol < 4.0 mmol/l and LDL-cholesterol < 2.0 mmol/l

or
• a 25% reduction in total cholesterol and a 30% reduction in LDL-cholesterol, whichever achieves the lowest absolute values.

However, NICE considers that the case for the cost-effectiveness (including adverse events) of higher intensity statin therapy (either alone or in combination with other agents) to reduce CVD events by treating to target levels of total cholesterol of either 5 mmol/l or 4 mmol/l (or comparable LDL-cholesterol levels) has yet to be proven.

Non-drug therapy

Diet
Dietary modification may lower cholesterol and triglyceride levels, but typically only by 5–10% (remember, < 15% of cholesterol is dietary in origin). Longer chain saturated fatty acids raise and mono- and polyunsaturated fatty acids lower LDL cholesterol.

In general, individuals should aim for:
• total fat intake ≤ 30% of total energy intake
• saturated fats ≤ 10% of total energy intake
• dietary cholesterol < 300 mg/day
• replacement of saturated fats with mono- or polyunsaturated fats
• five portions of fruit and vegetables per day
• two portions of fish per week, including one portion of oily fish.

Other lifestyle measures
• weight reduction
• regular physical exercise
• smoking cessation
• avoidance of excess alcohol ingestion
• good blood pressure and glycaemic control

Drug therapy

Statins
Statins are competitive inhibitors of HMG CoA reductase. They are potent in lowering LDL cholesterol, but less effective than fibrates in reducing triglycerides or raising HDL cholesterol levels. They reduce cardiovascular disease events irrespective of the starting cholesterol concentration, although patients with a total serum-cholesterol concentration of ≥ 5 mmol/l are likely to derive most benefit. In diabetes mellitus it is generally advised that all patients > 40 years of age be considered for statin therapy, which may also be indicated in younger subjects with complications (however, statins should be avoided in females desiring pregnancy owing to risk of fetal anomalies).

Myositis (which can lead to rhabdomyolysis) is a rare, but potentially serious, adverse effect of statin therapy – patients should be warned to promptly report unexplained muscle pain, tenderness or weakness. Liver function should be monitored during treatment.

NICE currently recommends simvastatin as first-line therapy, but allows for the use of other statins with similar acquisition costs. Other options include atorvastatin, fluvastatin, pravastatin and rosuvastatin.

Simvastatin is initiated at a dose of 40 mg/day (usually taken at night-time) unless potential drug interactions or adverse effects are a concern, when a lower dose of simvastatin or pravastatin should be offered. Dose reduction or temporary cessation of treatment may need to be considered in cases where there is a ‘temporary’ drug interaction or intercurrent illness that predisposes to statin toxicity.

Fibrates
Fibrates (which are high affinity ligands for the nuclear receptor peroxisome proliferator-activated receptor α (PPARα)) act mainly by decreasing serum triglycerides; they also tend to raise HDL cholesterol levels, but have variable effects on LDL cholesterol. They are generally considered first-line therapy only in those who have marked hypertriglyceridaemia (> 10 mmol/l) or in those who cannot tolerate a statin.

The fibrates may also cause a myositis-like syndrome (particularly in those with chronic renal impairment), and this risk is significantly increased when used in conjunction with statins. Dual therapy should therefore only be initiated under expert supervision.

Bile acid sequestrants
These agents bind bile acids in the small intestine, preventing their reabsorption, which in turn promotes hepatic conversion of cholesterol into bile acids; the resultant increase in hepatic LDL receptor expression/activity increases LDL cholesterol clearance from plasma. Colestyramine, colestipol and colesevelam are all effective in reducing hypercholesterolaemia, but may worsen hypertriglyceridaemia and cause malabsorption of fat-soluble vitamins.

Nicotinic acid group (acipimox and nicotinic acid)
Agents in this category reduce the synthesis of both cholesterol and triglycerides; they also increase HDL cholesterol. However, their use is limited by side effects, particularly vasodilatation leading to flushing. Nicotinic acid is licensed for use with a statin or in those intolerant of statins.

Ezetimibe
Ezetimibe inhibits the intestinal absorption of cholesterol. It is licensed as an adjunct to dietary manipulation in patients with primary hypercholesterolaemia in combination with a statin (or alone if a statin is inappropriate or not tolerated), and in patients with homozygous familial hypercholesterolaemia in
combination with a statin. Side effects include gastrointestinal upset, and there is an increased risk of myositis/rhabdomyolysis when used in conjunction with a statin.

**Omega-3 fatty acid compounds (commonly known as fish oils)**
These may be used as an adjunct to reduce serum triglycerides; however, there is little evidence that they reduce cardiovascular risk.

### Obesity
Traditionally, body mass index (BMI = weight in kilogrammes divided by height in metres squared) has been used to categorise body weight: < 18.5 = underweight; 18.5–24.9 = normal; > 25 = overweight; > 30 = obese; > 40 = severe/morbid obesity. However, BMI takes no account of body composition, overestimating obesity in muscular individuals and failing to discriminate between central (visceral) and peripheral (gluteal, limb) adipose tissue accumulation. The former (i.e. central obesity) is particularly associated with metabolic dysfunction (and the metabolic syndrome) and increased cardiovascular risk. In addition, obesity predisposes to sleep apnoea, joint failure (especially hips and knees) and cancer.

The prevalence of overweight/obesity has been estimated to be as high as 50% or more in Western societies, and childhood/adolescent obesity is an increasing problem. Sadly, the developing world is also catching up as the ‘obesity epidemic’ becomes truly global.

**Aetiology**
In most instances, obesity is the result of complex interactions between genetic, environmental and behavioural factors. Although a sedentary lifestyle and excess caloric intake are major predisposing factors, there is increasing evidence to suggest that not only extreme forms of obesity but also more common variants are linked to genetic predisposition, i.e. put simply, some individuals are genetically more prone to weight gain than others. Table 17.11 lists some of the recognised factors that contribute to being overweight/obese.

**Clinical features**
Age at onset, previous success/failure in attempts to lose weight, family history, diet/alcohol consumption and physical activity should all be enquired about when assessing patients who are overweight/obese. Specific features of conditions that predispose to obesity (e.g. hypothyroidism, Cushing syndrome) should also be sought and a careful drug

<table>
<thead>
<tr>
<th>Type</th>
<th>Example(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diet</td>
<td>Simple over-eating (especially energy dense foods)</td>
</tr>
<tr>
<td>Exercise</td>
<td>Sedentary work/lifestyle</td>
</tr>
<tr>
<td></td>
<td>Enforced inactivity (e.g. following surgery/injury)</td>
</tr>
<tr>
<td></td>
<td>Ageing</td>
</tr>
<tr>
<td>Social/behavioural</td>
<td>Habitual eating</td>
</tr>
<tr>
<td></td>
<td>Binge-eating</td>
</tr>
<tr>
<td>Genetic variation</td>
<td>FTO gene polymorphisms</td>
</tr>
<tr>
<td></td>
<td>• Common variants</td>
</tr>
<tr>
<td></td>
<td>• Rare conditions</td>
</tr>
<tr>
<td>Drugs</td>
<td>Leptin and leptin receptor gene defects; melanocortin 4-receptor gene defects; Prader–Willi syndrome; Laurence–Moon–Biedl syndrome</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td>Others</td>
<td>Glucocorticoids, oral contraceptive preparations, sulphonylureas, insulin, TCAs, SSRIs, olanzapine, clozapine, lithium, sodium valproate</td>
</tr>
<tr>
<td></td>
<td>Cushing syndrome</td>
</tr>
<tr>
<td></td>
<td>Hypothalamic disorders</td>
</tr>
<tr>
<td></td>
<td>Low birth weight (‘fetal programming’)</td>
</tr>
<tr>
<td></td>
<td>Cardiac/renal/hepatic failure – with fluid retention</td>
</tr>
</tbody>
</table>

FTO, fat mass and obesity associated gene; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.
history taken. Clinical examination is important in determining the pattern of obesity (e.g. global versus central) and identifying specific markers of insulin resistance (e.g. acanthosis nigricans) or other disorders.

**Investigation**

If there is suspicion of an underlying predisposing condition (e.g. hypothyroidism, Cushing syndrome, monogenic form of obesity), then investigations should be tailored accordingly. In all other cases, investigations are directed towards assessment of cardiovascular risk and other comorbidities.

**Management**

Wherever possible, underlying predisposing disorders should be treated and offending drugs withdrawn/substituted. Care of the obese patient is best provided by a multidisciplinary team, which usually includes a physician trained in obesity medicine, a nurse specialist, obesity dietitian and a psychologist. The treatment strategy typically involves five elements:

- **Dietary modification**: a variety of regimes exist, which in general involve three phases: (1) a screening phase, (2) an intensive weight loss phase and (3) a weight maintenance phase. Specialist advice should be sought if considering the use of more calorie restricted regimes, to minimise the risk of adverse effects.
- **Exercise programme**: in particular, aerobic exercise.
- **Behavioural modification**: a core feature of any weight reduction programme; may involve goal setting, meal planning, self-monitoring and group work.
- **Medical therapy**: considered if dietary/behavioural modification/exercise in combination are ineffective. Currently, the gastric/pancreatic lipase inhibitor orlistat is the only agent licensed for use in the UK: it facilitates mild to moderate weight loss when used in combination with lifestyle measures, but may be associated with malabsorption of fat soluble vitamins. Although initially introduced to improve glycaemic control in type 2 DM, GLP-1 agonists/analogues (e.g. exenatide and liraglutide – see diabetes mellitus) have shown great potential to promote weight loss, and studies to assess their efficacy in this regard outside the context of DM are in progress.
- **Bariatric surgery**: two main forms exist – gastric banding or stapling and malabsorptive (i.e. bypassing the small bowel) – which are sometimes combined; both types are effective in promoting weight loss, but long-term outcomes/adverse effects are still unknown.

**Prognosis**

- Data from prospectively followed cohorts, such as the Framingham study, indicate that morbidity and mortality are substantially increased in obese individuals.
- Common complications of obesity include hypertension, diabetes mellitus, ischaemic heart disease, osteoarthritis/joint failure, herniae, gallstones and varicose veins. In women there is an increased incidence of hirsutism/ menstrual disturbance and breast and endometrial carcinoma. Obese subjects also present an increased surgical risk.

**Under(mal)nutrition**

Undernutrition is a major problem of the developing world. *Marasmus* refers to severe protein-energy malnutrition. Children are grossly underweight with muscle wasting and markedly diminished fat. There is no oedema. In *kwashiorkor* there is protein deficiency, but with adequate calorie intake. There is oedema from hypoproteinaemia, and lipids accumulate in the liver, causing hepatomegaly.

In industrialised countries, undernutrition may be seen during any acute illness, but particularly those involving the gastrointestinal tract. Protein loss may also be substantial following burns (due to cutaneous loss), and can arise postoperatively (reflecting reduced intake and increased catabolism).

**Vitamin deficiencies**

Vitamins are organic substances, each with specific biochemical functions. They are mostly found in food and typically only required in small amounts.

**Fat-soluble vitamins**

- **Vitamin A** (retinol): found in liver, fish and dairy products; it is also produced in the intestine by cleavage of β-carotene (found in carrots and other vegetables); it is required for night vision (11-cis-retinaldehyde combines with rhodopsin in retinal rods) and is important for epithelial keratinisation; deficiency is rarely seen in industrialised countries, but it is associated with night blindness, xerophthalmia (a relatively common cause of blindness in the developing world) and increased susceptibility to infections. Overdosage reduces keratinisation of skin and sebum production (causing rough, dry skin and hair, but explaining the efficacy of agents such as isotretinoin in the treatment of conditions such as
acne) and liver enlargement. Vitamin A and its derivatives should be avoided in pregnancy (teratogenic).

- **Vitamin D** (see metabolic bone disorders).
- **Vitamin E** (a-tocopherol and related compounds) is found in vegetable oils. It is anti-oxidant and present in all cell membranes. Severe deficiency, especially in childhood, may predispose to haemolytic anaemia, and muscular and neurological disorders.

- **Vitamin K** is found in green vegetables. It is a cofactor for the synthesis of several clotting factors (II, VII, IX and X), and deficiency causes a prolonged prothrombin time and bleeding tendency. Oral coumarin anticoagulants (e.g. warfarin) act by interfering with vitamin K metabolism in hepatocytes.

### Water-soluble vitamins

- **Vitamin B₁ (thiamine):** found in many foods, including wheat, cereals and meat. Deficiency rapidly occurs if dietary intake is low as body stores are small. It is a cofactor in many metabolic pathways. Deficiency causes:
  - Wernicke–Korsakoff syndrome: typically occurs in chronic alcoholics; there is ataxia, nystagmus and ophthalmoplegia, and confusion; the inability to retain new memories is accompanied by confabulation (Korsakoff’s psychosis); ischaemia and capillary haemorrhages occur in the mammillary bodies and around the aqueduct in the midbrain; red cell transketolase levels are reduced; the disorder usually responds to parenteral thiamine (50–100 mg), although the memory defect often persists.
  - *Beriberi*: now rare outside Asia; in addition to Wernicke’s encephalopathy, there is cardiomyopathy and peripheral neuropathy.

- **Vitamin B₂ (riboflavin):** found in most foods (rich sources are dairy products, liver and cereals); it is a cofactor for cellular oxidation; deficiency causes angular stomatitis, atrophic glossitis and seborrhoeic dermatitis, and usually occurs in the context of other B vitamin deficiencies.

- **Nicotinamide:** found in many foods, including liver, meat, fish and cereals; it can also be synthesised from the amino acid tryptophan; it forms part of the coenzymes nicotinamide adenine dinucleotide (NAD) and nicotinamide dinucleotide phosphate (NADP); deficiency causes pellagra with dermatitis, diarrhoea and dementia.

- **Vitamin B₆ (pyridoxine):** found in many foods, including liver, meat, fish and cereals. Dietary deficiency is rare, but a number of drugs, including isoniazid, penicillamine and hydralazine, antagonise its effects. Isoniazid peripheral neuropathy is preventable by cotreatment with pyridoxine.

- **Vitamin B₁₂ and folic acid** (see haematology, p. 324).
- **Vitamin C** (ascorbic acid): main sources are fresh fruits and vegetables; it is an antioxidant; one of its many roles is the reduction of proline to hydroxy-proline, which is necessary for collagen formation, and impaired collagen production is the principal defect in scurvy, which is characterised by swollen, spongy gums, spontaneous bleeding/bruising, peril follicular haemorrhages, subperiosteal haemorrhages, anaemia and hair follicle keratosis with ‘corkscrew hairs’.

### Enteral feeding

#### Indications

Patients who are unable/unwilling to eat sufficient food but who have a functioning gut may be subjected to enteral feeding. Potential indications include:

- unconsciousness
- dysphagia: neurological; oesophageal obstruction; following head and neck surgery
- loss of nutrients from fistulas or stomas
- any major illness, e.g. postoperatively, following radiotherapy or chemotherapy, with moderate/severe burns.

#### Administration

A fine-bore nasogastric (NG) tube is usually well tolerated. If there is oesophageal obstruction or prolonged feeding is necessary, a tube can be inserted directly into the stomach via the abdominal wall (percutaneous endoscopic gastrostomy – PEG).

#### Requirements

Average adult daily requirements include:

- 2000–3000 kcal
- 10–15 g nitrogen (60–90 g protein)
- vitamins (see above) and trace elements.

A number of commercial preparations are available. Most contain milk or soya proteins. Protein hydrolysates or free amino acids are only necessary if the ability to break down protein is limited by pancreatic or bowel disease.

#### Complications

- vomiting/aspiration
- diarrhoea
- electrolyte and metabolic disturbances.
Parenteral nutrition

Parenteral nutrition is indicated when feeding via the gut is not possible because of:

- a reduction in functioning gut mass, either because of parenchymal disease or loss of small intestine
- ileus (usually postoperatively)
- loss of intestinal contents via fistulas.

It may supplement oral or enteral feeding, or be the only source of nutrition (total parenteral nutrition).

Administration

The tendency for peripheral veins to thrombose makes administration through a tunnelled central venous catheter necessary. Patients requiring long-term parenteral nutrition can be taught to administer infusions overnight at home.

Requirements

Protein is provided as essential and non-essential L-amino acids. Energy is given as 150–250 kcal/g nitrogen. Glucose is the usual source of carbohydrate. Insulin may be necessary, particularly if more than 180 g of glucose is given daily. Some 30–40% of required energy is provided as fat. Fat emulsions provide essential fatty acids and have a high energy : volume ratio. The mixture of amino acids, glucose and fat together with trace elements and vitamins is prepared under sterile conditions by pharmacy, e.g. in a 3-l bag.

Complications

- catheter-related infection, blockage or venous thrombosis
- air embolism
- metabolic disorders, e.g. hyperglycaemia, electrolyte imbalance, trace element or vitamin deficiencies
- fluid overload if renal insufficiency or cardiac impairment.

Porphyria

The porphyrias are a group of inherited or acquired metabolic disorders due to enzymatic defects in the haem biosynthetic pathway (Fig. 17.1). In most familial cases, inheritance occurs in an autosomal dominant fashion, but autosomal recessive and X-linked forms are also recognised. Porphyria cutanea tarda shows heritability in only a small number of cases.

Classification

The porphyrias may be classified as (1) hepatic or erythropoietic (according to the principal site of the enzyme defect and excess precursor production) or (2) acute or non-acute (Table 17.12).

Clinical presentation

Acute porphyrias

These disorders show autosomal dominant inheritance. The biosynthesis of haem (Fig. 17.1) involves eight stages and enzymes and is subject to negative feedback control by haem itself. Reduction in intermediary enzyme activity renders patients susceptible to an increased demand for haem, with reduced negative feedback such that excess toxic precursors (e.g. porphobilinogen and δ-aminolevulinic acid (d-ALA)) accumulate. Attacks may be triggered by a variety of agents including:

- drugs: e.g. sex steroids, enzyme inducers and many other commonly prescribed medications – hence, it is vital to check with either the British National Formulary (BNF) or another reliable source (see below) before prescribing treatment in a patient with known or suspected acute porphyria
- alcohol, prolonged fasting
- stress, including intercurrent infection
- electrolyte disturbances
- hormonal changes: e.g. during the menstrual cycle.

The clinical manifestations vary according to subtype, but in general the acute porphyrias

Anorexia nervosa

This is a relatively common disorder of young women who fast, vomit and/or purge to maintain a markedly low weight. Bulimia nervosa is habitual vomiting or purging, with eating binges between. Anorexia nervosa is associated with extreme thinness, anovular amenorrhoea and fine hairs on the arms and legs (lanugo). Such patients have a markedly altered body image. There is often evidence of hypothalamic-pituitary dysfunction with low levels of luteinising hormone (LH), follicle-stimulating hormone (FSH) and oestradiol, related in part to low circulating levels of the adipose tissue-derived hormone leptin. More global hypothalamic-pituitary dysfunction may also be evident (e.g. thyroid function tests may show the pattern of ‘non-thyroidal illness’, while the hypothalamic-pituitary-adrenal axis is ‘activated’). Treatment requires expert psychiatric advice and often periods of hospitalisation with the aim of readjusting abnormal psychopathology and increasing weight/correcting nutritional deficiencies.
predominantly exhibit neurovisceral symptoms, including:

- abdominal pain, vomiting, constipation (which may therefore mimic obstruction)
- sensorimotor neuropathy, seizures, confusion/coma, bulbar paralysis, quadraplegia, respiratory muscle weakness
- psychiatric disorders, including acute psychosis, depression
- sinus tachycardia, hypertension, postural hypotension and rarely left ventricular failure
- hyponatraemia (due to syndrome of inappropriate antidiuretic hormone) in acute intermittent porphyria.

Figure 17.1 Schematic representation of the different steps in the haem biosynthetic pathway, showing the various enzyme defects in porphyria. AIP, acute intermittent porphyria; ALA, aminolevulinic acid.
Acute intermittent porphyria (AIP)
Presentation is typically between 15 and 35 years of age, with abdominal pain and vomiting the most common features. The skin is ‘never’ affected. There may be a positive family history.

Variegate porphyria (VP)
Clinical features overlap those of AIP, but cutaneous manifestations are also seen (the skin, photosensitised by porphyrins, is fragile, particularly on the back of the hands).

Hereditary coproporphyria (HCP)
Features are similar to variegate porphyria. HCP is extremely rare.

Non-acute porphyrias
The non-acute porphyrias are typically associated with photosensitivity due to activation by ultraviolet light of porphyrins deposited in the skin.

**Table 17.12 Classification of porphyria**

<table>
<thead>
<tr>
<th>Type</th>
<th>Enzyme defect</th>
<th>Inheritance</th>
<th>Key clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute porphyrias</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute intermittent porphyria (AIP) (hepatic)</td>
<td>Porphobilinogen deaminase</td>
<td>AD</td>
<td>Neurovisceral symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Skin not affected</td>
</tr>
<tr>
<td>Hereditary coproporphyria (hepatic)</td>
<td>Coproporphyrinogen oxidase</td>
<td>AD</td>
<td>Neurovisceral symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cutaneous features present</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Extremely rare</td>
</tr>
<tr>
<td>Variegate porphyria (hepatic)</td>
<td>Protoporphyrinogen oxidase</td>
<td>AD</td>
<td>Neurovisceral symptoms</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cutaneous features present</td>
</tr>
<tr>
<td><strong>Non-acute porphyrias</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Porphyria cutanea tarda (hepatic)</td>
<td>Uroporphyrinogen decarboxylase</td>
<td>AD</td>
<td>Chronic blistering skin lesions in sun-exposed areas</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Most common porphyria</td>
</tr>
<tr>
<td>Erythropoietic protoporphyria (erythropoietic)</td>
<td>Ferrochelatase</td>
<td>AD</td>
<td>Painful cutaneous photosensitivity, which</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>may initially present in childhood</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatic involvement may occur in long-standing disease</td>
</tr>
<tr>
<td>Congenital erythropoietic porphyria (erythropoietic)</td>
<td>Uroporphyrinogen (co)synthase</td>
<td>AR</td>
<td>Cutaneous features (may present in early childhood)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dystrophic nails; red staining of teeth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ocular and skeletal manifestations can also occur</td>
</tr>
<tr>
<td>X-linked sideroblastic anaemia (erythropoietic)</td>
<td>ALA-synth(et)ase</td>
<td>X</td>
<td>Pallor, fatigue, hepatosplenomegaly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Microcytic (hypochromic) anaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ringed sideroblasts in bone marrow</td>
</tr>
</tbody>
</table>

AD, autosomal dominant; AR, autosomal recessive; X, X-linked.

Acute intermittent porphyria (AIP)
Presentation is typically between 15 and 35 years of age, with abdominal pain and vomiting the most common features. The skin is ‘never’ affected. There may be a positive family history.

Variegate porphyria (VP)
Clinical features overlap those of AIP, but cutaneous manifestations are also seen (the skin, photosensitised by porphyrins, is fragile, particularly on the back of the hands).

Hereditary coproporphyria (HCP)
Features are similar to variegate porphyria. HCP is extremely rare.

Non-acute porphyrias
The non-acute porphyrias are typically associated with photosensitivity due to activation by ultraviolet light of porphyrins deposited in the skin.

Porphyria cutanea tarda (PCT)
PCT is predominantly an acquired disorder and is sometimes seen in the context of liver disease (particularly alcoholic), although in this setting there may be a genetic predisposition. Patients are not usually susceptible to drug-induced attacks, although they can present following an alcoholic ‘binge’. Manifestations are predominantly cutaneous with porphyrin-induced photosensitivity leading to bullae on sun-exposed areas (which heal by scarring) and hyperpigmentation. Other features can include hepatomegaly and an association with haemochromatosis.

Congenital erythropoietic porphyria (CEP)
CEP is characterised by marked skin manifestations which may develop at a very young age. Other features include nail dystrophy, red staining of dentition and in some cases ocular and skin manifestations. CEP is extremely rare.
Erythropoietic protoporphyria (EPP)
This typically presents in childhood with cutaneous photosensitivity of varying severity. Unlike the other porphyrias, the rash is usually non-blistering. Hepatic dysfunction is a recognised association, especially in long-standing disease.

Investigation
The diagnosis of acute porphyria is readily established in patients who present during an acute episode by finding a substantial elevation of urinary porphyrins in a spot urine sample. Porphobilinogen (PBG) accumulation (Fig. 17.1) yields a red/brown colour due to production of porphobilin (a brownish auto-oxidation product of PBG) and porphyrins (which are reddish). PBG in fresh urine can be detected by the development of a distinct pink/red colour on mixing with Ehrlich’s reagent, which is not absorbed out by chloroform or other organic solvents.

AIP, VP and HCP all cause increases in PBG and can be differentiated from each other on the basis of profiling of blood, urinary and faecal porphyrins, together with assessment of enzymatic activity. For example, the identification of increased urinary excretion of both PBG and d-ALA in the context of reduced PBG deaminase activity is diagnostic of AIP.

NB Biochemical testing must be carried out during an acute attack as profiling may be normal between episodes. Samples should be protected from light and sent urgently to the laboratory.

Abnormal liver function tests may be found during an acute episode

Genetic screening for mutations in specific enzymes is possible and permits easier family screening.

Management
Acute porphyrias
Wherever possible, triggers should be avoided and intercurrent infections and electrolyte disturbances promptly treated/corrected. During acute episodes, supportive measures remain the mainstay of treatment, including:

- fluids (with attention to electrolytes)
- antimicrobial therapy if infection suspected (avoid ‘unsafe’ drugs)
- analgesia/antiemetics (avoid ‘unsafe’ drugs)
- ventilatory support if respiratory muscle involvement (can be monitored by using bedside spirometry)
- high carbohydrate intake (glucose polymer drinks or intravenous infusion of 10% dextrose) provides nourishment and rehydration and suppresses ALA synth(et)ase activity
- An infusion of haem arginate (3 mg/kg/day for 4 days) as haem replacement may help to restore ‘negative feedback’ and curtail severe/refractory attacks.

Once the acute attack has subsided patients should be (re)educated about future avoidance of drug precipitants and alcohol and advised to wear a medical bracelet.

Relatives should be offered screening.

NB A list of drugs that are considered ‘unsafe for use’ in acute porphyrias is provided in the British National Formulary (BNF), while an up-to-date list of treatments that are considered ‘safe’ is available at www.wmic.wales.nhs.uk/porphyria_info.php.

Non-acute porphyrias
Measures include:

- Avoidance of sunlight in cutaneous porphyrias.
- PCT may respond to iron reduction (e.g. through venesection) or low-dose hydroxychloroquine; avoidance of alcohol is also important.
- Beta-carotene may improve sunlight tolerance in EPP.

Metabolic bone disease
Physiology
Hormonal control of bone homeostasis involves three important hormones – parathyroid hormone (parathormone, PTH), calcitonin and vitamin D.

- PTH secretion is predominantly controlled by the concentration of ionised calcium in extracellular fluid. PTH increases osteoclastic cell number and activity and thereby increases bone resorption, but at low and intermittent levels PTH increases bone formation. PTH decreases renal tubular phosphate reabsorption and increases renal tubular calcium reabsorption. It indirectly increases intestinal calcium absorption through increased formation of active (1,25-dihydroxy) vitamin D.
- Calcitonin is secreted by C cells of the thyroid. Its principal action is to inhibit osteoclastic bone resorption.
- Vitamin D is predominantly synthesised from 7-dehydrocholesterol in the skin in response to exposure to ultraviolet light. Dietary intake is only important when ultraviolet irradiation does not occur. The major circulating/storage form is 25-hydroxycholecalciferol (25(OH)D₃ = 25-hydroxyvitamin D₃), which is converted to either 1,25-dihydroxycholecalciferol (1,25(OH)₂D₃) or 24,25-dihydroxycholecalciferol in the kidney.
1,25-dihydroxycholecalciferol is the most potent vitamin D metabolite. It decreases renal 1(α)-hydroxylase activity and increases 24(α)-hydroxylase activity, whereas PTH increases 1(α)-hydroxylase activity and decreases 24(α)-hydroxylase activity. The vitamin D receptor is a member of the steroid nuclear receptor superfamily.

**Osteoporosis**

- Osteoporosis is a condition characterised by loss of bone mass and alteration in the microarchitecture, leading to increased bone fragility and fracture risk. The most common fracture sites are the spine, femoral neck and radius.
- In clinical practice osteoporosis is considered to be present if bone mineral density (BMD) as determined by dual-energy X-ray absorptiometry (D(Ex)A – see below) is > 2.5 standard deviations (SD) below peak bone mass, or if susceptibility fractures have occurred (e.g. low impact hip or wrist fractures, non-traumatic vertebral fractures).

**Aetiology**

Broadly speaking, osteoporosis can be considered as primary (e.g. postmenopausal and age-related) or secondary (when occurring in the context of a predisposing condition) (Box 17.2).

**Clinical features**

Osteoporosis is often asymptomatic, only manifesting when the patient suffers a fracture:

- Vertebral fractures (wedge or crush) are most common in the mid-thoracic spine and at the thoraco-lumbar junction (T12 and L1). They may be asymptomatic, or cause sudden onset severe back pain. Spinal cord compression is rare, and other causes such as metastases should be sought. Multiple fractures cause loss of height and spinal deformity (e.g. kyphosis).
- Hip fractures invariably follow a fall.
- Colles’ fracture usually follows a fall onto the outstretched hand.

Immobility and chronic pain (e.g. due to secondary osteoarthritis) may ensue in some cases.

**Investigations**

**Biochemistry**

The standard bone profile (serum calcium, phosphate and alkaline phosphatase) is normal.

NB Alkaline phosphatase may be elevated following a fracture.

Other markers of bone turnover (e.g. procollagen type 1 N-terminal peptide (P1NP) for bone formation; N-terminal telopeptide (NTX) or C-terminal telopeptide (CTX) of collagen crosslinks for bone resorption) are available, but their use is still largely restricted to research studies or specialist clinical services.

**Radiology**

Lateral X-rays of thoracic and lumbar spine may reveal wedging or concave deformities (codfishing) of the vertebral bodies.

**Bone densitometry**

Quantitative computed tomography (QCT), single- and dual-photon absorptiometry (SPA/DPA), D(Ex)A and radiation absorptiometry (RA) assess bone

---

**Box 17.2 Recognised risk factors for osteoporosis**

- History of fracture as adult
- History of fracture in first-degree relative
- Caucasian race
- Advanced age
- Female sex
- Poor health, frailty
- Reduced physical activity, immobility
- Low body weight
- Current cigarette smoking
- Chronic excess alcohol intake
- Drugs, e.g. corticosteroids, heparin, ciclosporin, certain anticonvulsants
- Endocrine disorders, e.g. thyrotoxicosis, hypogonadism, hyperparathyroidism, Cushing syndrome, growth hormone deficiency
- Gastrointestinal disorders, e.g. malabsorption states, chronic liver disease
- Chronic illness, e.g. renal failure, rheumatoid arthritis
- Others, e.g. haematological disorders (multiple myeloma, haemoglobinopathies), neoplastic disorders
density by measuring the absorption of γ- or X-rays at clinically relevant sites such as the radius, hip or spine. D(E)XA is the preferred method, providing a rapid method of assessment which is associated with low-radiation exposure. Bone density can be reported as either T-scores (SD compared to young normal individuals, i.e. compared to peak bone mass) or Z-scores (SD above or below the mean age-matched BMD at that site). Z-scores are generally preferred in younger patients.

According to the WHO classification of BMD (based on T-scores), values above –1 SD are normal, values between –1 and –2.5 SD signify osteopenia and scores below –2.5 SD indicate osteoporosis.

Screening for secondary causes
This should be considered in all patients, and especially when there are atypical features, e.g. low-impact fracture at young age (Box 17.2).

Prevention and treatment
As always, prevention is better than cure and efforts should be directed towards prevention in those with identifiable risk factors (e.g. early menopause, long-term corticosteroid therapy, excess alcohol ingestion and smoking).

The UK National Osteoporosis Guideline Group working in collaboration with the WHO has produced a risk calculator called FRAX® which integrates clinical risk factors, with or without femoral neck BMD, to calculate the 10-year probability of hip fracture or a major osteoporotic fracture (clinical spine, hip, forearm or proximal humerus). Postmenopausal women with a previous fragility fracture should be considered for treatment without further need for risk assessment. For other groups FRAX is a useful tool in helping to determine who should receive intervention.

Current NICE recommendations for the treatment of osteoporosis can be found at www.nice.org.uk and typically involve one or more of the following strategies/agents:

**Exercise**
Physical activity (especially weight-bearing) helps to maximise BMD during childhood, adolescence and early adulthood, maintain bone mass through mid-life, diminish bone loss with ageing, and improve stability and strength to minimise falls and fractures in the elderly.

**Calcium**
A daily calcium intake of 0.5–1 g is recommended.

**Vitamin D**
Various studies have shown that small doses of vitamin D (400–800 IU/day) can reduce bone loss and prevent fractures in women with postmenopausal osteoporosis.

**Hormone replacement therapy (HRT)**
HRT slows bone loss and reduces the occurrence of fractures when started at the menopause. However, the results of several studies have shown HRT to be associated with an increase in the risk of breast cancer, cardiovascular disease and thromboembolic disorders. Accordingly, HRT is no longer routinely recommended for prophylaxis or treatment of osteoporosis in the postmenopausal setting.

NB In contrast, hypogonadism in premenopausal females and in males should be corrected wherever possible.

**Selective oestrogen receptor modulators (SERMs)**
Raloxifene exhibits variable effects depending on the tissue, e.g. oestrogen-like effect in bone, but anti-oestrogen effects in breast and uterus.

**Bisphosphonates**
Bisphosphonates, which are synthetic analogues of inorganic pyrophosphate, are a mainstay of prophylaxis and treatment of osteoporosis in many settings, and are potent inhibitors of bone resorption. Commonly used preparations range from those given once weekly, to monthly or even annually. Oral preparations can cause oesophageal irritation and should be taken before breakfast on an empty stomach with the patient upright. In addition, concern has arisen recently that prolonged use may be linked to atypical fractures of the femur. Osteonecrosis of the jaw is a rare but potentially serious complication most commonly seen in those with pre-existing dental disease receiving intravenous therapy.

**Strontium ranelate**
This acts by increasing bone formation and decreasing bone resorption. However, treatment renders subsequent D(E)XA difficult to interpret.

**Teriparatide (recombinant parathyroid hormone)**
This is very effective but currently very expensive and reserved for severe/refractory osteoporosis.

**Denosumab**
Recently introduced monoclonal antibody targeting RANK ligand (inhibits osteoclast formation/function).
Treatment of underlying cause
Wherever possible predisposing factors/conditions should be actively addressed.

Osteomalacia
In osteomalacia (‘soft bones’) there is inadequate mineralisation of bone, resulting in weakness, with propensity to fracture and subsequent deformity. If this occurs during childhood before fusion of the epiphyseal growth plates, then it is referred to as rickets.

Causes
The most common cause is vitamin D deficiency. Other causes are shown in Table 17.13.

Clinical features
Adult osteomalacia
Patients may be asymptomatic or can present with:

- generalised muscle aches and pain – worse with activity
- bone pain and tenderness
- pathological fractures
- proximal myopathy
- features of underlying disease (e.g. malabsorption)
- very rarely hypocalcaemia may be evident.

Childhood rickets
- deformities in the legs (bow-legs, knock-knees)
- deformities in the chest (prominent costochondral junctions = ‘ricketic rosary’)

Investigation

Biochemistry
- Serum calcium is usually low/low normal (maintained by secondary hyperparathyroidism).
- Serum phosphate is low (except in the presence of renal failure).
- Serum alkaline phosphatase is raised.
- Serum vitamin D levels: 25-hydroxycholecalciferol is low in vitamin D deficiency, but otherwise often normal. In contrast, 1,25-dihydroxycholecalciferol may be low (vitamin D deficiency, renal failure, vitamin D-dependent rickets type I), elevated (vitamin D-dependent rickets type II) or inappropriately normal.
- Plasma PTH is commonly raised (secondary hyperparathyroidism).

X-ray
- Generalised osteopenia with cortical thinning may be associated with multiple fractures, particularly in the ribs.
- Pseudofractures (‘Looser’s zones’) are translucent bands perpendicular to the surface of the bone, extending from the surface inwards (best seen in the pubic ramus, femoral or humeral neck, and outer borders of the scapula).
- In rickets, in addition to bone deformities there are widened and irregular metaphyses (‘cupping, splaying and fraying’).

Table 17.13 Causes of osteomalacia

<table>
<thead>
<tr>
<th>Type</th>
<th>Mechanism</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D deficiency/</td>
<td>Reduced substrate</td>
<td>Limited sunlight exposure</td>
</tr>
<tr>
<td>altered metabolism</td>
<td></td>
<td>Inadequate dietary intake</td>
</tr>
<tr>
<td></td>
<td>Enhanced clearance</td>
<td>Small bowel malabsorption</td>
</tr>
<tr>
<td></td>
<td>Reduced hydroxylation</td>
<td>Liver disease (e.g. PBC)</td>
</tr>
<tr>
<td>Hypophosphataemia</td>
<td>Impaired action</td>
<td>Vitamin D-dependent rickets type I (AR)</td>
</tr>
<tr>
<td></td>
<td>Reduced intake</td>
<td>Renal disease (1α-hydroxylation)</td>
</tr>
<tr>
<td></td>
<td>Increased loss</td>
<td>Vitamin D-dependent rickets type II (AR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Impaired 25α-hydroxylation (very rare)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>X-linked hypophosphataemia (vitamin D-resistant rickets, XLD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fanconi syndrome and/or RTA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oncogenic osteomalacia</td>
</tr>
</tbody>
</table>

AR, autosomal recessive; PBC, primary biliary cirrhosis; RTA, renal tubular acidosis; XLD, X-linked dominant.

1 25-hydroxycholecalciferol 1α-hydroxylase deficiency.
2 Defective vitamin D receptor signalling.
Bone scan
There is a generalised diffuse increase in uptake, although routine scanning is not required. Occasionally, Looser's zones show multiple areas of increased uptake (c.f. in osteoporosis bone scanning is normal, whereas in Paget's disease there is typically strong focal uptake).

Investigation of underlying disease (malabsorption, uraemia) may be required.

Treatment
Vitamin D
The dosage and formulation depend on the underlying aetiology. Serum calcium must always be monitored, especially in those receiving larger (pharmacological) doses and activated forms.

NB Ergocalciferol = calciferol = vitamin D$_2$; Cholecalciferol = vitamin D$_3$; alfacalcidol = 1α-hydroxycholecalciferol; calcitriol = 1,25-dihydroxycholecalciferol – both alfacalcidol and calcitriol are considered ‘activated’ forms of vitamin D.

- Deficiency states: in mild deficiency 400–800 units/day (of simple ergocalciferol or colecalciferol) is sufficient in most patients; rarely, in severe osteomalacia pharmacological doses may be required.
- Malabsorption/chronic liver disease: pharmacological doses (e.g. 40–50,000 units/day of ergocalciferol) may be required; water-soluble hydroxylated metabolites are absorbed by the small intestine, e.g. 1α-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol.
- Vitamin D-resistant states: in familial vitamin D-resistant (hypophosphataemic) rickets treatment is with oral phosphate supplements and calcitriol. Type II vitamin D-dependent rickets (end-organ resistance) responds poorly to treatment, although huge doses of calcitriol with calcium supplements are sometimes effective.
- In uraemia there is failure of 1α-hydroxylation: treatment is with 1α-hydroxycholecalciferol or 1,25-dihydroxycholecalciferol (i.e. activated forms).
- Calcium supplements are not usually required unless there is severe osteomalacia or poor dietary intake.
- Clinical and biochemical improvement takes weeks to months.

Paget's disease (osteitis deformans)
This is a localised disorder of bone remodelling, in which excessive bone resorption is followed by excessive bone formation, leading to hypertrophic osteosclerotic bone formation with deformity and fragility. It is a disease chiefly of the elderly, and shows geographical variation, being more common in North America and Europe, but rare in Asia. Only 5–10% of those with radiological evidence of bone involvement manifest clinical features.

Aetiology
Familial clustering and the finding of viral inclusions in osteoclastic nuclei has been taken to suggest that the disease may be triggered by viral infection in genetically predisposed individuals.

Clinical features
- Many patients are asymptomatic.
- Pain is the most common symptom, sometimes with a rise in temperature over the site of the lesion.
- Bone deformity is most obvious when there is enlargement of the skull with frontal bossing or bowing of the legs.

Complications
- Fractures: up to 15% of patients suffer pathological fractures in abnormal bone.
- Deafness is common in patients with skull involvement; it may result from involvement of the ossicles or compression of the cochlea or internal auditory canal.
- Occlusion of other foramina of the skull leading to compression of other cranial nerves occurs less often; platybasia or flattening of the base of the skull may, rarely, lead to brainstem compression or obstructive hydrocephalus.
- Spinal involvement may cause cord compression, particularly in the cervical and thoracic regions.
- Less than 1% of patients develop osteogenic sarcoma in Pagetic bone (the pelvis and femur are the most common sites); it may be heralded by increasing pain.
- High-output cardiac failure is a rare complication of extensive disease.

Investigations
Biochemistry
- Bone profile: increased osteoblastic activity is reflected in increased levels of serum alkaline phosphatase; serum calcium levels are usually normal.
- Markers of increased bone activity.

Radiology
- Expansion and disorganisation of bone with both lytic and sclerotic lesions are characteristic; there is cortical thickening and coarsening of trabeculae; the pelvis and lumbar spine are most frequently affected, followed by the sacrum, thoracic spine, skull, lower limbs and upper limbs.
Bowing deformity occurs in weight-bearing long bones, and osteoarthritis is common in adjacent joints.
Bone scintigraphy shows increased uptake at affected sites and helps to define the full extent of the disease.

**Treatment**
- Pain may be controlled with analgesics and NSAIDs.
- Physiotherapy maintains mobility.
A number of specific treatments are now available. These agents are effective in relieving symptoms.
- **Bisphosphonates**: the mainstay of treatment in symptomatic patients; their role in asymptomatic patients remains controversial, but should be considered if complications due to hypervascularity or disease progression are likely (e.g. fractures, nerve entrapment).
- **Calcitonin**: can be given subcutaneously in those who are intolerant to bisphosphonates.

Serum alkaline phosphatase and 24-h urinary hydroxyproline measurement can be used to monitor response to treatment. Urinary hydroxyproline levels reflect bone resorption and give a more rapid indication of response and an earlier warning of relapse.

**Hypercalcaemia**

True hypercalcaemia is defined as an elevation in free ionised serum calcium. However, ionised calcium is not always measured/available, and for practical purposes total calcium is therefore used in most clinical settings. Calcium is bound to albumin and ‘correction’ should be performed when albumin levels are abnormal. For every 1 g/l that the serum albumin level is lower than 40 g/l, add 0.02 mmol/l to the serum calcium (or subtract if serum calcium is raised above 40 g/l). Most laboratories routinely provide a corrected calcium value.

NB Acidotic states increase ionised calcium by decreasing binding of calcium ions to albumin, whereas alkalosis has the reverse effect.

**Aetiology**

Primary hyperparathyroidism (see below) and malignancy are the commonest causes of hypercalcaemia. A variety of mechanisms may underlie malignant hypercalcaemia, including: tumour secretion of parathyroid hormone-related peptide/protein (PTHrP); osteolytic metastases with local release of osteoclast-activating cytokines; systemic production of cytokines that promote bone resorption; local production/activation of vitamin D. Other causes of hypercalcaemia are listed in Table 17.14.

**Clinical features**

The clinical features depend predominantly on the rapidity of onset and, to a lesser extent, on the magnitude of the rise in serum calcium levels. Slow-onset, mild hypercalcaemia (< 3.0 mmol/l) is usually asymptomatic. Severe hypercalcaemia, usually caused by malignant disease, with an onset over only a few weeks or months, may produce significant symptoms. Remember the old adage – *‘bones, stones, moans and groans’!*

- musculoskeletal (*‘bones’*) – muscle weakness, bone pain, arthritis
- renal (*‘stones’*) – polyuria (nephrogenic diabetes insipidus), nephrolithiasis, nephrocalcinosis, acute or chronic renal impairment
- neuropsychiatric (*‘moans’*) – anxiety, depression, cognitive dysfunction and hypotonicity; lethargy, confusion stupor and coma may occur in severe cases
- gastrointestinal (*‘groans’*) – anorexia, nausea/vomiting, constipation, dyspepsia/peptic ulceration, pancreatitis

Cardiovascular complications include bradycardia, shortened QT interval and cardiomyopathy.

**Investigation**

After excluding iatrogenic causes, paired measurement of serum parathyroid hormone and serum calcium is the first key step in elucidating the underlying cause:

- If PTH is elevated or inappropriately normal in the presence of raised serum calcium, then the diagnosis is usually one of primary hyperparathyroidism. Tertiary hyperparathyroidism is normally easily distinguishable based on the clinical context, as is hyperparathyroidism due to lithium therapy. However, familial hypocalciuric hypercalcaemia (FHH) must be excluded before considering treatment for presumed primary hyperparathyroidism (see section on primary hyperparathyroidism for further investigation to distinguish these two entities).
- If PTH is low/suppressed, then PTH-independent causes should be considered. Further investigations will be determined by the clinical context, but may include:
  - full blood count, ESR, electrolytes, renal/liver function, serum electrophoresis/urinary Bence–Jones protein, serum angiotensin converting enzyme (ACE)
chest radiograph/cross-sectional imaging; isotope bone scintigraphy, skeletal survey; endocrine testing (thyroid function, Synacthen®, plasma/urinary metanephrines); PTHrP measurement (but not routinely available).

NB As vitamin D metabolism is intricately linked with PTH and calcium metabolism, many endocrinologists recommend routinely assessing vitamin D status in all patients with hypercalcaemia. Typically, vitamin D excess is associated with a suppressed PTH level, but less commonly recognised is that vitamin D deficiency can be associated with a mild elevation in PTH and serum calcium.

In addition, consideration should be given to screening for secondary complications of long-standing hypercalcaemia, e.g. nephrolithiasis/nephrocalcinosis.

Management

Mild hypercalcaemia (< 3.0 mmol/l)

This rarely requires urgent treatment. Advice should be given to avoid factors that can aggravate hypercalcaemia (predominantly dehydration and medications). Further investigation should be undertaken to determine the cause, and then treatment targeted as appropriate.

Moderate hypercalcaemia (3.0–3.5 mmol/l)

Although chronic hypercalcaemia of this magnitude may not outwardly appear to be associated with significant symptomatology in all cases, these patients are at significant risk of developing more severe hypercalcaemia, e.g. during intercurrent illness, and treatment is therefore required – however, the extent and aggressiveness of the intervention should be determined based on symptoms, comorbidities, magnitude of hypercalcaemia and underlying cause (see below for management options).

Severe hypercalcaemia (> 3.5 mmol/l)

This requires urgent treatment regardless of whether the patient is symptomatic or not as there is a significant risk of cardiac dysrhythmias.

Principles of treatment

- Rehydrate with intravenous 0.9% sodium chloride – typically 3–6 l over the first 24 h, aiming to achieve a high urine output (100–150 ml/h).
- NB Caution should be exercised in those with renal and/or cardiac impairment.
- NB Furosemide is no longer routinely recommended – the risk of exacerbating intravascular depletion largely outweighs any potential benefit of enhancing renal calcium excretion – however, it may still be useful in those at risk of fluid overload.
- Following adequate rehydration, intravenous bisphosphonate (e.g. disodium pamidronate – typically 30–60 mg in a single infusion or in divided doses up to a maximum of 90 mg) inhibits osteoclast-mediated bone resorption; the hypocalcaemic effect develops over 24–72 h and typically lasts for several weeks, at which point further courses can be considered if the underlying cause is not amenable to correction.
- Corticosteroids (e.g. prednisolone 40–60 mg/day) can be used to suppress hypercalcaemia associated with haematological malignancy (myeloma, lymphoma), sarcoidosis and vitamin D toxicity.
- Calcitoning (initially 5–10 units/kg/day in divided doses) can be used to rapidly reduce serum calcium levels in severe life-threatening hypercalcaemia;

<table>
<thead>
<tr>
<th>Type</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parathyroid-dependent</td>
<td>Primary hyperparathyroidism – adenoma or hyperplasia of parathyroid</td>
</tr>
<tr>
<td></td>
<td>Tertiary hyperparathyroidism</td>
</tr>
<tr>
<td></td>
<td>Familial hypocalciuric hypercalcaemia</td>
</tr>
<tr>
<td>Parathyroid-independent</td>
<td>Malignancy</td>
</tr>
<tr>
<td></td>
<td>Vitamin D-related: e.g. excess ingestion; granulomatous disorders, William syndrome</td>
</tr>
<tr>
<td></td>
<td>Endocrine disorders: e.g., thyrotoxicosis; adrenal failure; phaeochromocytoma</td>
</tr>
<tr>
<td></td>
<td>Iatrogenic: e.g. thiazide diuretics; total parenteral nutrition</td>
</tr>
<tr>
<td></td>
<td>Milk-alkali syndrome (excess ingestion of calcium and absorbable alkali)</td>
</tr>
<tr>
<td></td>
<td>Prolonged immobilisation</td>
</tr>
<tr>
<td></td>
<td>Vitamin A intoxication</td>
</tr>
<tr>
<td></td>
<td>Jansen’s metaphyseal chondrodysplasia</td>
</tr>
</tbody>
</table>

Table 17.14 Causes of hypercalcaemia
however, its effects are short-lived and concomitant bisphosphonate therapy is also required. Adverse effects, including nausea/vomiting, abdominal pain, diarrhoea and flushing are common and limit its utility.

• Dialysis is reserved for severe hypercalcaemia or those with renal impairment/fluid balance problems.

Hyperparathyroidism

Parathyroid hormone (PTH) is secreted from the four parathyroid glands in response to a fall in serum calcium. PTH exerts its effects by:

• Increasing calcium absorption from the gut through activation of vitamin D; PTH upregulates renal 1α-hydroxylase, which converts inactive 25-hydroxyvitamin D₃ to active 1,25-dihydroxyvitamin D₃.

• Mobilising calcium from bone (through indirect activation of osteoclasts; osteoclasts do not express PTH receptors, so this effect is mediated via osteoblast action).

• Reducing renal calcium clearance (PTH stimulates calcium and magnesium reabsorption from the distal tubule; at the same time, it also increases renal phosphate clearance and this may indirectly facilitate mobilisation of calcium from bone).

The term hyperparathyroidism simply denotes overproduction of PTH. It may be primary or secondary/tertiary in origin.

Primary hyperparathyroidism

Primary hyperparathyroidism shows a female preponderance (female: male ratio = 2–3:1) and is more common in the > 45 years age group. In most cases this results from the development of a single autonomous parathyroid adenoma (90%); other causes include multiple adenomas (4%), hyperplasia of all four parathyroid glands (6%) and, rarely, parathyroid carcinoma (<1%).

In those with four-gland hyperplasia, consideration must be given to the possibility of multiple endocrine neoplasia (MEN), especially MEN 1.

Another rare cause of ‘apparent’ primary hyperparathyroidism is familial hypocalciuric hypercalcaemia (FHH), an autosomal dominant condition associated with loss-of-function mutations in the calcium-sensing receptor – it is important to distinguish this disorder from true primary hyperparathyroidism as parathyroidectomy is not indicated in FHH.

Secondary/tertiary hyperparathyroidism

Secondary hyperparathyroidism is a physiological response to hypocalcaemia caused by another disorder, e.g. chronic renal failure or hypovitaminosis D. Serum calcium may be normal (compensated), frankly low, or even occasionally raised (see below). Histologically, there is four-gland hyperplasia.

Tertiary hyperparathyroidism refers to the situation in which chronic secondary hyperparathyroidism ultimately progresses to autonomous adenoma/hyperplasia, with hypercalcaemia and elevated PTH levels.

High serum phosphate levels, due to renal failure, may be seen in both secondary and tertiary hyperparathyroidism (this is in contrast to primary hyperparathyroidism where phosphate levels are typically low).

Clinical presentation

Primary hyperparathyroidism is commonly associated with mild hypercalcaemia that develops slowly over many months or even years. Patients are often asymptomatic, and the hypercalcaemia is discovered incidentally during investigation for other reasons. Moderate to severe hypercalcaemia may result in a variety of symptoms (see hypercalcaemia, p. 262). Chronic hypercalciuria predisposes to renal calculi, nephrocalcinosis and, eventually, renal failure. Classical skeletal changes of hyperparathyroidism (see below) are now rarely seen in the Western world; however, routine D(E)XA scanning frequently reveals previously unsuspected osteopaenia/osteoporosis. In addition, in patients presenting with fragility fractures, there is a relatively high prevalence of previously undiagnosed primary hyperparathyroidism.

Investigation

Biochemistry

Primary hyperparathyroidism

Classically:

• ↑ serum calcium
• ↓ or low normal serum phosphate
• serum alkaline phosphatase may be normal or raised (reflecting increased bone turnover)
• ↑ or inappropriately normal PTH.

NB Most laboratories measure PTH using a two-site immunoassay, with antibodies directed against both ends of the PTH molecule, which therefore only detects intact full length PTH and not the smaller fragment PTHrP.

• Twenty-four-hour urinary calcium excretion is high normal/raised (as opposed to low normal/low
in FHH; measurement of a spot calcium:creatinine excretion ratio is another helpful way of distinguishing primary hyperparathyroidism and FHH).

**Secondary hyperparathyroidism**

Traditionally, secondary hyperparathyroidism in the context of renal impairment is characterised by:

- ↓ or low normal serum calcium
- ↑ serum phosphate
- ↑ PTH
- ↑ serum urea and creatinine/↓ eGFR.

Occasionally mildly elevated serum calcium, with raised PTH and alkaline phosphatase, may be seen in the context of vitamin D deficiency, with resolution of the biochemical abnormalities following replenishment of vitamin D stores (therefore arguing against autonomous adenoma/hyperplasia formation). However, this condition is difficult to distinguish clinically from true primary hyperparathyroidism with coincident vitamin D deficiency, and vitamin D supplementation in the latter setting can result in rapid development of moderate/severe hypercalcaemia – hence, referral to an endocrinologist is recommended for further assessment and trial of vitamin D therapy under close supervision.

**Radiology**

**Screening for complications**

The radiological hallmark of hyperparathyroidism is subperiosteal bone resorption, most easily seen in the distal phalanges of the hands; a similar process in the skull gives rise to the so-called ‘pepper-pot’ skull appearance. Other specific changes include loss of the lamina dura of the teeth (25%) and osteitis fibrosa cystica with bone cysts (rare).

D(E)XA scanning typically reveals reduced BMD, which is more pronounced in the forearm (cortical bone) than in the spine (trabecular bone) and hip (mixed cortical and trabecular bone).

Abdominal ultrasound or plain radiographs may help identify/exclude nephrolithiasis/nephrocalcinosis.

**Tumour localisation for operative planning**

Although preoperative localisation may be deemed unnecessary for an experienced parathyroid surgeon undertaking a conventional neck exploration in a previously untreated patient with primary hyperparathyroidism, recently there has been a resurgence of interest in preoperative imaging. This has been driven in large part by the move towards minimally invasive parathyroidectomy, in which only unilateral neck exploration is performed. In addition, preoperative localising strategies may be helpful in cases requiring surgical re-exploration.

NB In MEN, four-gland hyperplasia is common, and full neck exploration is therefore required in virtually all cases, thus rendering preoperative imaging of limited value.

- $^{99}$Technetium-sestamibi scanning: early phase images typically show both thyroid and parathyroid tissue, although asymmetric foci of increased radiotracer uptake may be seen in the presence of abnormal parathyroid tissue. Delayed images (≥ 2h after radiotracer administration) are acquired to look for foci of retained radiotracer, characteristic of hyperfunctioning parathyroid tissue (the use of SPECT can increase sensitivity). If doubt remains as to whether an abnormality resides within parathyroid or thyroid tissue, then thyroid scintigraphy (using a radioisotope not taken up by the parathyroids), with subsequent overlay and subtraction of the superimposed images may help.
- Neck ultrasound: non-invasive, but requires a skilled operator; most adenomas are greater than 1 cm in size and homogeneously hypoechoic; hyperplastic glands are generally smaller and more difficult to detect.
- CT/MRI and/or selective venous sampling: generally reserved for cases who have previously undergone parathyroid surgery which has failed to control hyperparathyroidism; interpretation may be confounded by altered anatomy following surgery.

**Management**

Hypercalcaemia should be managed as outlined above.

**Surgery**

The definitive treatment for primary hyperparathyroidism is resection of the affected parathyroid gland(s). Most single/ipsilateral double adenomas can now be resected as a minimally invasive day case procedure; however, patients with suspected bilateral disease should be considered for conventional full neck exploration.

The US National Institutes of Health (NIH), recognising (1) the changing presentation of primary hyperparathyroidism (with increasing numbers of younger patients being detected), (2) the potential for long-term adverse sequelae in untreated cases (especially renal, bone and cardiovascular (hypertension) complications), and (3) improved surgical techniques, has issued revised guidance as to which patients with ‘apparently asymptomatic disease’ should be referred for surgery (those with symptoms should be automatically referred):
• all patients who are < 50 years of age
• when the serum corrected calcium level is > 0.25 mmol/l above the upper limit of the reference range
• when the 24-h urine calcium excretion is persistently > 10 mmol/l
• in the presence of impaired renal function (30% reduction in creatinine clearance, age-matched)
• in the presence of nephrolithiasis
• in the presence of osteoporosis
• in hyperparathyroidism complicated by osteitis fibrosa cystica
• in patients with demonstrable proximal weakness, hyperreflexia or ataxia.

The more complex issue of surgical intervention and its effects on psychiatric function/performance is not fully addressed by the NIH guidance, but some studies have shown benefits in cognition and well-being in asymptomatic patients postoperatively.

Surgical complications include haematoma and wound infection (as with any surgical procedure) and hypocalcaemia, producing hypocalcaemic tetany in severe cases (including the so-called 'hungry bones syndrome', which is more common in those with significant hypercalcaemia and multigland involvement; a raised level of alkaline phosphatase preoperatively may provide an important clue as to the risk of this complication).

Routine prescription of activated vitamin D and calcium supplements followed by early postoperative review (at approximately day 14) facilitates early discharge following surgery.

**Medical management**
Calcimimetics (e.g. cinacalcet), which lower PTH and hence serum calcium levels through activation of the calcium-sensing receptor, may provide an alternative treatment strategy for selected cases, including in patients:
• with recurrent/relapsing disease
• deemed unsuitable for surgery
• with refractory secondary/tertiary hyperparathyroidism, especially if total parathyroidectomy is contraindicated
• with parathyroid carcinoma failing primary surgery.

**Hypocalcaemia**
Symptomatic hypocalcaemia is rare but potentially life-threatening.

NB During alkalosis there is a reduction in free ionised calcium, and hypocalcaemic symptoms may be present despite normal total serum calcium levels; the presence of other anions, particularly citrate following large-scale blood transfusion, can promote a similar picture.

**Aetiology**
The majority of cases of hypocalcaemia are related to abnormalities in PTH secretion/action and vitamin D deficiency/resistance (Table 17.15).

**Clinical features**
These are highly dependent upon the rapidity and severity of onset of the hypocalcaemia: rapid significant falls are classically associated with tetany, i.e. neuromuscular irritability. Symptoms range from mild to severe, from perioral paraesthesia through to laryngeal spasm and seizure activity. Trousseau’s sign denotes carpopedal spasm induced by inflation of a sphygmomanometer cuff above systolic blood pressure (for 3 min) in a patient with hypocalcaemia. Chvostek’s sign signifies contraction of the facial muscles in response to tapping over the facial nerve in the preauricular region. It may be seen in up to 10% of the normocalcaemic population.

Papilloedema, lethargy, malaise and rarely psychosis are features of chronic hypocalcaemia. Dental abnormalities (e.g. enamel hypoplasia) may be evident if hypocalcaemia occurs during childhood/youth, as may other features of chronic/congenital hypoparathyroidism (e.g. candidiasis with the type 1 polyglandular syndrome (see endocrine disorders, p. 227), basal ganglia calcification with extrapyramidal features and cataracts).

Cardiac arrhythmias and conduction abnormalities may be seen, including prolongation of the QT interval.

**Investigations**
As with hypercalcaemia, paired measurement of PTH and calcium is invaluable in defining the cause of hypocalcaemia in the majority of individuals. Vitamin D measurement is also often useful (but check which form of vitamin D is routinely measured by your laboratory – see osteomalacia, p. 260)

Other investigations will be determined by the clinical presentation but may include full blood count, electrolytes, renal/liver/bone function tests, serum magnesium, arterial blood gas (to check acid–base status and ionised calcium level) and vitamin D metabolites. A modified Ellsworth–Howard test can be
used to demonstrate failure to increase urinary cAMP excretion in response to infused PTH in pseudohypoparathyroidism.

Management
Severe symptomatic hypocalcaemia
This requires urgent treatment:

- 10–20 ml of 10% calcium gluconate intravenously: this should be followed by a maintenance infusion (e.g. a further 40 ml infused over 24 h, with close monitoring of serum calcium).

NB Calcium-containing solutions must be infused slowly (e.g. 10 ml of calcium gluconate given over a 10-min period); otherwise there is a risk of precipitating dysrhythmias. Cardiac monitoring is advised.

- Commence oral calcium and vitamin D replacement without delay.
- Wherever possible, attention should be paid to identifying/treating the underlying cause.

NB Undetected/untreated concomitant hypomagnesaemia is likely to render the patient refractory to correction of hypocalcaemia.

Chronic hypocalcaemia
Currently, long-term therapy for hypoparathyroidism involves the use of vitamin D analogues (alfacalcidol or calcitriol) ± calcium supplements to raise the serum calcium towards normal levels – in the majority of subjects with a normal dietary calcium intake additional exogenous calcium is not required and overtreatment predisposes to nephrocalcinosis and nephrolithiasis. Again, the underlying cause should be addressed where possible. Recombinant human PTH may offer an alternative in the future, but further efficacy and safety studies are required.

Hypoparathyroidism
Decreased PTH leads to:

- increased renal loss of calcium and retention of phosphate
- reduced bone resorption
- reduced calcium absorption.

Aetiology
Table 17.15 outlines the common causes of hypoparathyroidism mediating hypocalcaemia.

NB Pseudohypoparathyroidism (very rare) is caused by a failure of end-organ response in bone and kidney to endogenous PTH, which is thus present in excess amounts. Unlike patients with true idiopathic hypoparathyroidism, there is no increase in urinary cAMP excretion when PTH is injected.

Table 17.15 Causes of hypocalcaemia

<table>
<thead>
<tr>
<th>Type</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low PTH hypoparathyroidism</td>
<td>Idiopathic parathyroid gland failure&lt;br&gt;Post-surgery or neck irradiation&lt;br&gt;Type 1 autoimmune polyglandular syndrome&lt;br&gt;Infiltration (haemochromatosis, Wilson’s disease, granulomatous disorders, neoplasia)&lt;br&gt;Congenital (e.g. DiGeorge syndrome)</td>
</tr>
<tr>
<td>impaired PTH secretion</td>
<td>Hypomagnesaemia&lt;br&gt;Treatment with cinacalcet (calcimimetic)&lt;br&gt;Activating mutations of the calcium-sensing receptor</td>
</tr>
<tr>
<td>High PTH resistance to PTH action</td>
<td>Drugs: e.g. bisphosphonates, calcitonin&lt;br&gt;Renal failure&lt;br&gt;Pseudohypoparathyroidism</td>
</tr>
<tr>
<td>Vitamin D deficiency/resistance</td>
<td>See Table 17.13</td>
</tr>
<tr>
<td>Other causes</td>
<td>Drugs: e.g. chelators (citrate)&lt;br&gt;Osteoblastic metastases&lt;br&gt;Acute pancreatitis&lt;br&gt;Alkalosis&lt;br&gt;Severe hyperphosphataemia: e.g. acute renal failure, rhabdomyolysis, tumour lysis</td>
</tr>
</tbody>
</table>
Clinical presentation

This depends upon its speed of onset and its degree.

- Acute hypocalcaemia – see above.
- Ectodermal changes: teeth, nails, skin and hair; there is an excessive incidence of cutaneous moniliasis in primary hypoparathyroidism.
- Ocular changes: cataract and, occasionally, papilloedema.
- Calcification in the basal ganglia and, less commonly, other soft tissues.
- The hereditary syndrome of pseudohypoparathyroidism is caused by tissue resistance to PTH and usually presents in childhood. The patients have a moon face, short stature, reduced IQ, calcification of the basal ganglia and often short fourth or fifth metacarpals. The biochemistry is similar to idiopathic hypoparathyroidism.
- Pseudopseudohypoparathyroidism refers to patients who have the somatic manifestations of pseudohypoparathyroidism but normal biochemistry.

Investigation

- Typically, there is a low serum calcium and a high serum phosphate level with normal alkaline phosphatase.
- Investigation for other features depends on the clinical presentation.

Management

As per hypocalcaemia.
Rheumatology

Rheumatological disorders are common, ranging from simple musculoskeletal problems to complex or rare diseases requiring specialist secondary care and multidisciplinary input.

Osteoarthritis (OA)

This common degenerative disorder, characterised by inadequate repair of cartilage and periarticular bone in response to damage or injury, ultimately leads to joint failure. Radiological evidence of OA can be detected in a quarter of the population by their mid-40s, and in virtually everyone by their mid-60s. Both sexes are affected, although severe disease and hand involvement are seen more frequently in women. The most common joints to be affected are the interphalangeal joints, the 1st carpometacarpal joint, cervical and lumbar spine, knees and hips.

Genetic factors play a role in the pathogenesis of OA but remain poorly understood. Obesity increases the prevalence of OA in the weight-bearing joints of the lower limb. Other predisposing factors include trauma, meniscectomy, joint inflammation, neuropathic joints, acromegaly, haemochromatosis, haemoglobinopathies, alkaptonuria and Gaucher's disease.

OA is characterised by progressive disruption and loss of hyaline cartilage, with sclerosis, cysts and osteophyte formation in underlying subchondral bone and narrowing of the joint space. Secondary changes are seen in the adjacent synovium.

Clinical presentation

OA may be asymptomatic (especially in the spine). Clinical features vary depending on the joint(s) involved, but symptoms include the following:

- joint pain, worse with movement and towards the end of the day
- stiffness
- swelling, e.g. of the distal and proximal interphalangeal joints with Heberden’s and Bouchard’s nodes respectively.

On examination there is tenderness, bony swelling (osteophyte formation), painful restriction of movement, crepitus and, if long-standing, muscle wasting. Joints may be red, warm and tender and associated with an effusion (synovial inflammation).

Functional impairment, immobility, deformity and occasionally nerve (e.g. carpal tunnel syndrome) or nerve root (cervical or lumbar spine) entrapment may all complicate OA.

Investigation

Diagnosis depends on clinical assessment and radiological findings. Plain radiographs typically reveal:

- loss of joint space (cartilage loss)
- osteophytes
- sclerosis of subchondral bone
- ± bone cyst formation.

Management

- Analgesia – initially paracetamol and NSAIDs.
- Weight loss in obese subjects.
- Physiotherapy and graded exercise help to maintain muscle bulk and strength.
- Walking aids and orthotics may offer effective symptomatic relief.
- Intra-articular corticosteroids where there is worsening pain and evidence of synovial inflammation (warmth, effusion).
- Joint replacement especially in those with reduced mobility and rest or nocturnal pain.
- Domestic and mobility aids.
Prognosis
Usually the condition slowly progresses over time, although in some patients symptoms will abate.

Rheumatoid arthritis (RA)
The commonest cause of polyarticular joint inflammation, RA is characterised by a distinct pattern of joint involvement often accompanied by extra-articular disease manifestations. It occurs throughout the world, with an estimated prevalence of 1%. Women are more frequently affected than men (3:1), with a peak age of onset between 40 and 60 years, although RA may present as early as young adulthood.

RA is associated with certain HLA haplotypes, including HLA-DR4. HLA-DR4 positivity is associated with erosive seropositive disease. Environmental factors that have been implicated in the development of RA include cigarette smoking, diet, hormonal changes and infections, although epidemiological studies have failed to establish a causal link with any specific organism.

Synovial inflammation is the hallmark of RA. In the early stages there is disruption of the synovial microvasculature, followed by synovial thickening and heavy infiltration with lymphocytes, macrophages and plasma cells. The latter may secrete rheumatoid factors (RF; see below). Inflamed hypertrophied synovium (pannus) encroaches on the adjacent cartilaginous surface, resulting in thinning of the cartilage and erosion of the underlying bone. An array of cytokines (interleukin-1 (IL-1), IL-2, IL-4, IL-6 and tumour necrosis factor-α (TNF-α)) have been implicated in the pathogenesis of RA.

Clinical presentation
RA is a multisystem disorder in which extra-articular manifestations are key to long-term outcomes. Extra-articular disease is more likely in RF seropositive patients. Figure 18.1 summarises the diverse array of clinical features associated with RA.

Musculoskeletal system
The small joints of the hands and feet are the most commonly affected, usually symmetrically, but large synovial joints (hips, knees, elbows) are often involved. Gradual onset with progressive pain, early-morning stiffness and swelling of joints is usual, although acute onset associated with fever and general malaise is recognised.

Hands
- symmetrical polyarthropathy involving proximal joints
- tenderness and diminished movement of involved joints:
  - sparing of the terminal interphalangeal joints
  - the wrists are commonly involved
- deformity due to joint subluxation and tendon misalignment
  - swan-neck
  - boutonnière
  - z-deformity of the thumb
  - metacarpophalangeal subluxation
  - ulnar deviation at the metacarpophalangeal joints
- swelling:
  - fusiform soft-tissue swelling of the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints
  - soft tissue involvement causes swelling, tenosynovitis and tendon rupture
- wasting:
  - combination of disuse atrophy, vasculitis and peripheral neuropathy
  - reduced function

Other joints
- Elbows, shoulders and knees commonly involved.
- Ankles, costovertebral, temporomandibular and the cricoarytenoid joints may be affected.
- Cervical spine: the axial skeleton is generally spared, except for the cervical spine—laxity of the atlantoaxial joint ligaments with erosion of the odontoid peg may result in acute or chronic cord compression. Subluxation is life-threatening and should be particularly considered if general anaesthesia is required.

Skin and subcutaneous tissues
- palmar erythema
- rheumatoid nodules – typically on the ulnar border of the forearms and only in patients who are rheumatoid factor positive
- scars of previous surgery (e.g. metacarpophalangeal joint replacement, excision of the ulnar styloid process, extensor tendon repair, carpal tunnel release)
- pyoderma gangrenosum
- vasculitis including lower limb ulceration
- thin, fragile skin in those on long-term corticosteroid therapy with other features of iatrogenic Cushing syndrome

Ocular
- episcleritis/scleritis
- keratoconjunctivitis sicca in approximately 15% of patients with RA
**Pulmonary**
- Pleurisy ± effusion(s)
- Rheumatoid nodule(s)
- Fibrosis
- Caplan syndrome

**Musculoskeletal**
- Joint swelling/tenderness/deformity
  - hands: MCP and PIP joints
  - wrists
  - feet
  - ± other joints
- Muscle wasting
- Secondary osteoporosis

**Neurological**
- Entrapment neuropathies
- Peripheral neuropathy
- Mononeuritis multiplex
- Spinal cord compression (cervical spine compression)

**Cardiovascular**
- Pericarditis
- Myocarditis
- Cardiac nodule(s) ± conduction defect
- Atheromatous disease
- Vasculitis
- Raynaud’s phenomenon

**Renal**
- Amyloidosis

**Haematological**
- Anaemia (multifactorial)
- Lymphadenopathy
- Leucocytosis or leucopenia
- Thrombocytosis or thrombocytopenia
- Splenomegaly

**General**
- Weight loss
- Constitutional upset (malaise, fever)

**Ophthalmic**
- Episcleritis
- Scleritis
- Keratoconjunctivitis sicca
- Scleromalacia perforans

**Scleromalacia perforans**
- Iatrogenic – lens opacities and retinal degeneration with chloroquine treatment and cataracts from corticosteroid therapy

**Cardiovascular**
- Pulmonary
  - Pleurisy ± effusion(s)
  - Rheumatoid nodule(s)
  - Fibrosis
  - Caplan syndrome

**Musculoskeletal**
- Joint swelling/tenderness/deformity
  - hands: MCP and PIP joints
  - wrists
  - feet
  - ± other joints
- Muscle wasting
- Secondary osteoporosis

**Neurological**
- Entrapment neuropathies
- Peripheral neuropathy
- Mononeuritis multiplex
- Spinal cord compression (cervical spine compression)

**Cardiovascular**
- Pericarditis
- Myocarditis
- Cardiac nodule(s) ± conduction defect
- Atheromatous disease
- Vasculitis
- Raynaud’s phenomenon

**Renal**
- Amyloidosis

**Haematological**
- Anaemia (multifactorial)
- Lymphadenopathy
- Leucocytosis or leucopenia
- Thrombocytosis or thrombocytopenia
- Splenomegaly

**General**
- Weight loss
- Constitutional upset (malaise, fever)

**Ophthalmic**
- Episcleritis
- Scleritis
- Keratoconjunctivitis sicca
- Scleromalacia perforans

**Pulmonary**
- Pleurisy ± effusion(s)
- Rheumatoid nodule(s)
- Fibrosis
- Caplan syndrome – the presence of multiple round well-defined nodules (typically 0.5–2 cm, but in some cases as large as 5 cm in diameter) in the lungs of miners (coal, silicosis, asbestos) with RA; they may calcify, cavitate or coalesce and be mistaken for tuberculosis.

**Neurological**
- Entrapment neuropathies
- Peripheral neuropathy
- Mononeuritis multiplex
- Spinal cord compression (cervical spine compression)

**Cardiovascular**
- Pericarditis
- Myocarditis
- Cardiac nodule(s) ± conduction defect
- Atheromatous disease
- Vasculitis
- Raynaud’s phenomenon

**Renal**
- Amyloidosis

**Haematological**
- Anaemia (multifactorial)
- Lymphadenopathy
- Leucocytosis or leucopenia
- Thrombocytosis or thrombocytopenia
- Splenomegaly

**General**
- Weight loss
- Constitutional upset (malaise, fever)

**Ophthalmic**
- Episcleritis
- Scleritis
- Keratoconjunctivitis sicca
- Scleromalacia perforans

**Cardiovascular**
- Pericarditis (with or without effusion)
- Myocarditis
- cardiac nodules

Vascular manifestations include:
- arteritic lesions:
  - nail fold infarcts
  - “splinter” necrosis in the digital pulps
  - necrotising arteritis affecting larger vessels causing digital gangrene, bowel infarction or stroke
vascularitis
- Raynaud’s phenomenon.

Neurological
- entrapment neuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy)
- peripheral neuropathy – predominantly sensory, secondary to arteritis or complicating drug therapy
- mononeuritis multiplex – usually digital, ulnar and lateral popliteal nerves
- spinal cord compression – secondary to cervical spine joint involvement

Haematological (Table 18.1)
- Normochromic normocytic anaemia is common and its severity relates to that of the underlying disease.
- Iron deficiency secondary to drug therapy.
- The height of the ESR reflects the activity of the disease.
- CRP is raised.
- Leucocytosis may signify active disease, intercurrent infection or corticosteroid therapy.

Reticuloendothelial system
- Generalised lymphadenopathy is present in up to 10% of cases.
- The spleen is enlarged in about 5% of patients and 1% develop leucopenia.
- Felty syndrome: the triad of RA, splenomegaly with neutropenia and thrombocytopenia, and lymphadenopathy may also be present.

Renal
- Amyloidosis is now less common in RA, reflecting improved disease control.
- Proteinuria or overt nephrotic syndrome may complicate treatment with penicillamine and gold.

Iatrogenic
Clinical evidence of side effects of therapy may be observed (see below).

The American College of Rheumatology has proposed criteria (1987) for the diagnosis of RA based on these clinical features (Box 18.1).

Box 18.1 American College of Rheumatology (ACR) revised criteria for the diagnosis of RA

To establish a diagnosis of RA, ≥ four of the following criteria are required:
- morning stiffness of > 1 h duration most mornings for > 6 weeks
- arthritis involving at least three areas (soft tissue swelling or fluid) for > 6 weeks
- arthritis of hand joints for > 6 weeks
- symmetrical arthritis for > 6 weeks
- rheumatoid nodules
- positive rheumatoid factor
- radiological changes of RA (wrists, hands)

NB These criteria were originally intended for research categorisation; however, in practice it would be unwise to defer treatment until a patient meets all of the ACR criteria for RA as early intervention is paramount for preserving long-term structure/function.

Investigation
Currently there are no laboratory or radiological tests that reliably confirm or rule out RA in all patients and clinical impression remains crucial to diagnosis. A high index of suspicion and early onward referral for expert opinion are recommended as uncontrolled inflammation translates into joint damage and subsequent disability.

Serology
Rheumatoid factor (RF)
High titres of IgM RF correlate with more severe arthritis and with extra-articular disease. RF is not specific to RA, being found in low titres in ~5% of the general population (and does not predict disease in clinically normal individuals), in Sjögren syndrome and in other connective tissue disorders. Some patients with RA remain seronegative.

| Table 18.1 Causes of anaemia in RA |
|-------------------------------|------------------------------|
| Type                          | Cause                        |
| Normochromic normocytic       | Anaemia of chronic disease   |
| Hypochromic microcytic         | Iron deficiency secondary to aspirin and other NSAIDs (e.g. ibuprofen) |
| Macrocytic                    | Folate deficiency secondary to methotrexate or sulphasalazine; vitamin B₁₂ deficiency (due to associated pernicious anaemia) |
| Haemolytic                    | Drug-induced (e.g. sulphasalazine, dapsone) |
| Bone marrow suppression       | Drug-induced (e.g. sulphasalazine, gold, cytotoxics) |
| Hypersplenism                 | Felty syndrome               |
Recently, alternative serological tests appear to offer comparable sensitivity but improved specificity to RF for diagnosing RA, e.g. anti-citrullinated protein antibodies (ACPAs), including anti-CCP (cyclic citrullinated peptide).

Radiology
The joints may be radiologically normal in the earliest disease stages. The characteristic sequence of abnormalities is:
- soft-tissue swelling and periarticular osteoporosis
- narrowing of joint space and periarticular erosions
- subluxation and osteoarthritis (in long-standing disease); and finally
- fibrosis or bony ankylosis.

Management
Assessment of disease activity depends on both clinical and laboratory findings. The objectives of therapy are:
- symptom relief – in particular control of pain and stiffness
- suppression of active disease and arrest of disease progression
- restoration of joint function.

This requires a multidisciplinary team (MDT) approach involving rheumatologists, physiotherapists, occupational therapists, orthopaedic surgeons, specialist nurses and social services. Patient education should involve information about the disease chronicity and tendency to cycle between exacerbations and remissions. Patients should have a named contact (usually a specialist nurse) who can ensure rapid access to the team in the event of a disease flare. The UK National Institute for Health and Clinical Excellence (NICE) issued guidelines in 2009 emphasising the importance of the MDT in ensuring high quality care for patients with RA (Box 18.2).

During the active phase, treatment involves both local measures (physiotherapy, use of splints, intra-articular corticosteroids) and systemic drug therapy.

Drug therapy
- Simple analgesics: help some patients with mild disease
- NSAIDs: useful symptom relief but do not alter the underlying disease process. Should not be used in isolation and long-term use is limited by side effects.
- Cyclo-oxygenase-2 inhibitors: an alternative to NSAIDs, contraindicated in patients at risk of vascular disease.

Disease-Modifying AntiRheumatic Drugs (DMARDs)
A heterogenous group of drugs for use under expert supervision. Treatment should be commenced once the diagnosis has been established, and not delayed until complications develop. Combination therapy is usually favoured:
- Methotrexate: first-line DMARD provided there are no contraindications to its use. Given weekly with folic acid supplementation on a different day; adverse effects include gastrointestinal disturbance, bone marrow suppression, hepatotoxicity, pneumonitis, renal damage.
- Sulphasalazine: adverse effects include gastrointestinal upset, skin rashes, bone marrow suppression, hepatotoxicity.
- Hydroxychloroquine (chloroquine): adverse effects include ocular toxicity, particularly with chloroquine, gastrointestinal upset, skin reactions, seizures, myopathy and psychiatric disturbance.
- Azathioprine: adverse effects include gastrointestinal upset and bone marrow suppression.
- Leflunomide: adverse effects include gastrointestinal upset, raised blood pressure, bone marrow suppression, hepatotoxicity.
- Gold (intramuscular sodium aurothiomalate or oral auranofin): adverse effects include oral ulceration/stomatitis, irreversible skin pigmentation in sun-exposed areas, gastrointestinal upset, hepatotoxicity, blood dyscrasias (may be sudden and fatal), nephrotic syndrome.
- Penicillamine: adverse effects include gastrointestinal upset, transient loss of taste, skin disorders, bone marrow suppression, cholestatic jaundice.
- Ciclosporin and cyclophosphamide may be effective in severe disease refractory to other agents.

Tumour necrosis factor-α inhibitors (anti-TNFα therapies)
These are generally reserved for use in patients who fail conventional DMARD therapy. Three drugs are currently available: infliximab and adalimumab are monoclonal anti-TNFα antibodies, and etanercept is a soluble TNF receptor. All are given by injection and methotrexate should be continued if possible. Adverse side effects include hypersensitivity reactions/anaphylaxis, gastrointestinal upset, increased susceptibility to infections including tuberculosis and hepatitis B reactivation, bone marrow suppression and cardiac failure.

Rituximab
Rituximab is reserved for the treatment of severe active RA in patients whose condition has not responded adequately to DMARDs and at least one TNFα inhibitor. It works by depleting circulating
Box 18.2 Summary of National Institute for Health and Clinical Excellence (NICE) 2009 guidance for the management of rheumatoid arthritis in adults

- Referral, diagnosis and investigations – consider early serological and radiological screening and referral for expert review in all suspected cases
- Communication and education – offer verbal and written information to patients with RA; encourage involvement in self-management programmes
- MDT – ensure ongoing regular access to the individual members of the MDT (e.g. physiotherapist, occupational therapist, podiatrist); patients should have easy access to a named point-of-contact (e.g. nurse specialist)
- Management of symptoms: analgesics and NSAIDS – offer simple analgesics if pain control is inadequate; NSAIDs and COX-2 inhibitors should be used at the lowest effective dose for the shortest time possible (choice of agent should be decided on an individual basis), with coprescription of a PPI to provide gastric protection; if symptom control is inadequate, review DMARDs/biologics’ regimens
- Management of symptoms: DMARDs:
  - For newly diagnosed active disease – offer a combination of DMARDs; ideally include methotrexate + at least one other agent + short-term corticosteroids
  - For recent onset disease (< 2 years) – once sustained and satisfactory disease control established, cautiously try to reduce dosages of DMARDs
  - For established disease (> 2 years) – if disease is stable, cautiously reduce dosages of DMARDs or ‘biologics’, but return promptly to disease-controlling regimens at the first sign of a flare-up; when introducing new drugs to improve disease control, consider decreasing or discontinuing pre-existing agents
- Management of symptoms: corticosteroids:
  - For recent onset or established disease – offer short-term courses for flare-ups
  - For established disease – continue long-term therapy only after careful discussion with the patient regarding adverse effects, and after offering all other treatment options
- Monitoring RA – regularly monitor CRP and key components of disease activity (e.g. using a composite score such as DAS28 that includes assessment of 28 joints) to help guide treatment decisions; arrange regular clinic/specialist nurse follow-up; check for comorbidities (e.g. hypertension, ischaemic heart disease, osteoporosis, depression); assess for complications (e.g. ocular involvement, disease of the cervical spine)
- Timing and referral for surgery – offer early referral for specialist surgical opinion when there is persistent pain, worsening joint deformity/function or persistent synovitis despite medical therapy; urgent surgical review is also indicated when there is imminent/actual tendon rupture, nerve entrapment, stress fracture or evidence of cervical myelopathy
- Diet and complementary therapies – for patients wishing to experiment with their diet explain that currently there is no strong evidence that their arthritis will benefit; advice to follow a ‘Mediterranean diet’ is reasonable; advise that there is little or no evidence for complementary therapies offering long-term efficacy in RA, and therefore if tried these should not replace conventional treatment even if they yield short-term symptomatic benefit

COX-2, cyclo-oxygenase 2; CRP, C-reactive protein; DMARDs, disease modifying antirheumatic drugs; MDT, multidisciplinary team; NSAIDs, non-steroidal anti-inflammatory drugs; PPI, proton-pump inhibitors; RA, rheumatoid arthritis.

B-cells and is used in conjunction with methotrexate. It predisposes to infection.

Corticosteroids
Glucocorticoids are effective for symptomatic relief and suppressing disease activity, although concerns over side effects limit their use. Commonly administered parenterally or as intra-articular injections, they should be reserved for use in acute disease flares or while waiting for DMARDs to take effect. Oral or pulsed intravenous therapy is effective for systemic manifestations of RA.

Surgical management
Synovectomy, realignment and repair of tendons, joint prostheses and arthrodesis may be required for severe pain or deformity.

Prognosis
Although DMARDs and TNFα inhibitors may induce remission, for most patients RA is a progressive disorder, with up to 10% of cases suffering severe disability. Cardiovascular disease, infection and secondary amyloidosis are major causes of
morbidity and mortality. Young age at onset, severe disease/disability at presentation, extra-articular manifestations and high RF titres all predict a worse prognosis.

Seronegative spondyloarthropathies

A group of rheumatological disorders sharing common features:
- sacroileitis
- peripheral arthritis (typically large joints, especially of the lower limbs)
- mucocutaneous inflammation
- familial aggregation
- absence of rheumatoid factor (hence ‘seronegative’).

Psoriatic arthritis

Psoriatic arthritis affects between 0.01 and 0.1% of the population, with a mean age of onset between 30 and 50 years and equal sex distribution. It is associated with HLA-DR4 (peripheral joint involvement) and HLA-B27 (spinal disease) haplotypes, and is more prevalent in HIV-positive subjects. A similar pathological process (increased vascularity with an inflammatory cell infiltrate) occurs in the joints as in the skin.

Clinical presentation

Approximately 10% of patients with psoriasis develop arthritis. There is no correlation between the presence or severity of psoriatic skin changes and joint involvement. Several different (not mutually exclusive) patterns are recognised:
- Asymmetric oligoarthritis (~30–50% of cases) typically affecting a few large or small joints. Diffuse swelling of the digits (dactylitis), in which one or two digits take on a ‘sausage-like’ appearance, is a distinctive feature.
- Symmetrical polyarthritis (~20–40%).
- Sacroileitis and spondylitis (~5–30%) which may be associated with Achilles tendonitis and plantar fasciitis.
- Distal interphalangeal joint involvement (~5–15%).
- Arthritis mutilans (up to 15%) causes gross joint destruction in which resorption of terminal digits and juxta-articular bone results in ‘telescoping’ of the digits.

Nail pitting and onycholysis may be the only evidence of underlying psoriasis, but a careful search for skin changes (including the scalp, hairline and behind the ears) should be performed. Pustular psoriasis of the palms and soles may be confused with the rash of Reiter syndrome (keratoderma blennorrhagica).

Investigation

There is no single diagnostic test for psoriatic arthritis and a high index of clinical suspicion is required. The following may be useful:
- normochromic, normocytic anaemia and raised inflammatory markers
- negative RF
- HLA-B27 positivity (~20% of all cases, and 50% of cases with spondylitis)
- radiological evidence of sacroileitis, distal interphalangeal joint involvement or digital juxta-articular bone resorption.

Management

- Supportive measures – physiotherapy, aids.
- Simple analgesics.
- NSAIDs.
- DMARDs – especially for the symmetrical RA-like pattern, with methotrexate being the preferred option. Hydroxychloroquine should be avoided as it may cause psoriatic flares.
- Tumour necrosis factor-α inhibitors (anti-TNFα therapies) – current NICE guidance recommends considering etanercept, adalimumab and infliximab in those patients with ≥ three tender and swollen joints failing treatment with ≥ two DMARDs.

Prognosis

This is dependent on the pattern of disease. The symmetrical polyarthritis form follows a similar course to RA, sacroileitis/spondylitis resembles ankylosing spondylitis and oligoarticular disease tends to run a more benign course. Arthritis mutilans is associated with considerable disability.

Ankylosing spondylitis

Ankylosing spondylitis (AS) affects between 0.1% and 1% of white populations. It is strongly associated with HLA-B27 and affects males more commonly than females (~4:1), with a peak age of onset in adolescence/young adulthood. There may be a history of inflammatory bowel disease, psoriasis or reactive arthritis.

Enthesitis (inflammation of ligament or muscle tendon attachments to bone) is the cardinal pathological finding. Inflammation of the sacroiliac, facet and intervertebral joints is followed by ossification of spinal ligaments and intervertebral discs. Bony outgrowths from the vertebral margins extend vertically and coalesce. Eventually spinal fusion occurs.
Clinical presentation

Spinal symptoms

- pain (worse at night and in the morning, improving with exercise)
- stiffness (particularly after inactivity)
- reduced movement (especially the lumbosacral and cervical spine)

Advanced AS may result in a characteristic posture with cervical hyperextension, exaggerated thoracic kyphosis, loss of lumbar lordosis and compensatory knee flexion.

Systemic symptoms

- large joint involvement (lower limbs)
- plantar fasciitis
- achilles tendinitis
- anterior uveitis
- apical pulmonary fibrosis ± respiratory failure (fixed ribcage with kyphoscoliosis)
- aortitis with aortic incompetence
- amyloidosis

Investigation

Diagnosis rests on the history and examination findings combined with the following.

Blood tests

- rheumatoid factor negative
- ESR elevated (~80% of cases) and CRP
- HLA-B27 positivity (in 95% compared with 5–10% of the general population and 50% of asymptomatic relatives)

Radiography: plain X-ray findings

- sacroiliitis
- squaring of vertebrae
- syndesmophytes (bridging spurs of bone at the corners of adjacent vertebral bodies)
- facet joint involvement
- ossification (‘bamboo spine’)

Management

- Physiotherapy.
- NSAIDs.
- Sulphasalazine may be effective for peripheral joint involvement.
- Tumour necrosis factor-α inhibitors (anti-TNFα therapies): current NICE guidance recommends considering etanercept or adalimumab in patients with severe AS with evidence of sustained active spinal disease and where treatment with two or more NSAIDs for 4 weeks has failed to control symptoms.
- Corticosteroids are occasionally required.

Prognosis

With expert care most individuals will maintain complete or almost complete activity. In patients with more severe AS, moderate to severe bony ankylosis of the spine produces fixation of mobility and rounded kyphosis of the cervical and thoracic spine which may impair ventilation. In severe cases extreme rigidity of the spine may occur within 3–5 years. The disease may remit at any stage but recurrent episodes can occur. Poor prognostic indicators include onset in adolescence, high CRP and extraspinal joint involvement.

Reactive arthritis (Reiter syndrome)

The term reactive arthritis is used to denote joint inflammation arising in relationship to an infectious episode, which has usually resolved. The infective organism is not found within the joint itself as the inflammatory process probably results from an immune response to one or more bacterial antigens, following which activated T-lymphocytes and macrophages migrate to the synovium. Reactive arthritis is seen most commonly in young adults of either sex following infection with one of the following organisms:

- Chlamydia trachomatis
- Salmonella species
- Shigella species
- Campylobacter jejuni
- Yersinia enterocolitica

There is an increased incidence in populations where HLA-B27 is prevalent (HLA-B27 is involved in the presentation of bacterial antigens to CD8+ T cells).

Clinical presentation

An episode of diarrhoea or urethritis may precede the onset of arthritis by up to a month. In up to half of all cases no prior infective episode can be identified. Clinical features include:

- Arthritis: acute or subacute, usually oligoarticular and asymmetrical affecting large joints of the legs (especially the knees). There may be associated fever and weight loss.
- Sacroilitis: in up to 30% of cases.
- Plantar fasciitis and Achilles tendinitis.
- Conjunctivitis: common in the acute phase.
Anterior uveitis is a feature of chronic recurrent disease, particularly when associated with sacroiliitis. Urethritis and circinate balanitis may persist in some patients. Pustular hyperkeratotic lesions of the soles of the feet and palms of the hands (keratoderma blennorrhagica) occurs in ~15% of patients. Distal interphalangeal joint swelling or dactylitis may be seen in chronic disease.

Investigation

There is no single diagnostic test for reactive arthritis and a high index of clinical suspicion is required. The following may be useful:

- Raised inflammatory markers.
- Negative screen for IgM RF.
- Joint aspiration: fluid is turbid, but contains no organisms or crystals.
- HLA-B27 positive.
- Radiological changes: joint erosions and sacroiliitis may be seen.
- All patients should be screened for Chlamydia trachomatis infection, which can be clinically silent.

Management

Acute phase

- simple analgesics
- NSAIDs
- joint aspiration and intra-articular injection of corticosteroids

Chronic peripheral joint disease

- DMARDs (e.g. sulphasalazine, methotrexate) may be required.
- Treat underlying sexually transmitted infection (this does not influence the course of joint disease).

Prognosis

Most patients recover within weeks or months. A small number may suffer recurrence at a later date. For 15–30% it becomes a chronic disorder requiring ongoing treatment. Persistence and recurrence are more likely in HLA-B27 positive individuals.

Enteric arthropathy

Around 20% of patients with inflammatory bowel disease (Crohn’s disease, ulcerative colitis) develop an arthropathy, in the form of a peripheral mono- or oligoarticular arthritis or sacroiliitis. Treatment is with simple analgesics, NSAIDs, intra-articular or oral corticosteroids and, where necessary, DMARDs.

Autoimmune rheumatic disorders (connective tissue diseases)

Systemic lupus erythematosus (SLE)

SLE is nine times more common in women than men and usually presents at age 20–40 years (90% of cases). It is exacerbated by exposure to ultraviolet radiation, infections, certain drugs, stress and pregnancy. In North America and Northern Europe the prevalence per 100,000 is estimated at 30–50 for white women, 100 for Asian women and 100–200 for African-Caribbean women. Cause unknown, it seems likely that environmental triggers act together with a genetic predisposition to cause the disease. HLA-B8, DR2 and DR3 are associated with SLE, and other non-HLA loci have been implicated.

The development of antinuclear antibodies (ANA positivity) is the key serological finding in patients with SLE, commonly with lymphocytic infiltration and deposition of immunoglobulins and immune complexes in affected tissues/organs, although whether antibodies drive the disease is uncertain. Vasculitis leads to ischaemic damage.

Clinical presentation

Early manifestations are:

- fever
- arthralgia
- general ill health and fatigue
- weight loss
- skin rash.

SLE can mimic rheumatoid arthritis or bacterial endocarditis and may cause nephrotic syndrome. Major organ involvement may be present at the outset or can evolve over time. One or more of the following systems are typically involved (Fig. 18.2).

Musculoskeletal system (in 90% of cases)

- Myalgia.
- Migratory polyarthralgia with early morning stiffness is common.
- Jaccoud’s arthropathy: non-deforming arthropathy caused by tendonitis rather than synovitis affecting the fingers, wrists, elbows, shoulders, knees and ankles.
- Avascular necrosis may follow prolonged corticosteroid therapy.
### Skin and Mucous Membranes
- Malar ("butterfly") rash
- Discoid lupus
- Non-scarring alopecia
- Photosensitivity, erythema
- Oral/mucosal ulceration
- Raynaud’s phenomenon

### Pulmonary
- Pleurisy ± effusion (serositis)
- Fibrosis/"shrinking lung syndrome"
- Pulmonary emboli (aPL positive)
- Pneumonitis

### Musculoskeletal
- Arthralgia (polyarticular)
- Jaccoud’s (non-deforming) arthropathy
- Avascular necrosis (e.g. hip)
- Myalgia (rarely myopathy)

### Neuropsychiatric
- Headaches
- Seizures
- Cranial/peripheral neuropathies
- Stroke
- Movement disorder
- Depression/psychosis

### Cardiac
- Pericarditis (serositis)
- Endocarditis (non-infective, thrombotic)

### Renal
- Glomerulonephritis
- Hypertension

### Haematological
- Anaemia (normochromic, normocytic)
- Leucopenia (esp. lymphopenia)
- Thrombocytopenia
- (Hepato)splenomegaly
- Lymphadenopathy
- Antiphospholipid syndrome

### Pulmonary
- Pleurisy ± effusion (serositis)
- Fibrosis/"shrinking lung syndrome"
- Pulmonary emboli (aPL positive)
- Pneumonitis

### Cardiac
- Pericarditis (serositis)
- Endocarditis (non-infective, thrombotic)

### Renal
- Glomerulonephritis
- Hypertension

### Haematological
- Anaemia (normochromic, normocytic)
- Leucopenia (esp. lymphopenia)
- Thrombocytopenia
- (Hepato)splenomegaly
- Lymphadenopathy
- Antiphospholipid syndrome

**Skin and Mucous Membranes (in 80% of cases)**

Lupus may be confined to the skin as discoid or subacute cutaneous lupus; typically a raised, scarring rash on the face, scalp or limbs. Other features include:

- Raynaud’s phenomenon in between a quarter and half of all cases
- Non-specific erythema
- Photosensitivity
- Alopecia
- Malar ‘butterfly’ rash – bridging the nose and cheeks in 30%
- Oral and mucosal ulceration (30%)
- Nail fold infarcts (10%)
- Livedo reticularis
- Panniculitis
- Bullous eruptions

**Kidneys (in ~100% of cases)**

SLE is associated with a range of glomerulonephritides. Almost all patients with SLE have histological abnormalities on renal biopsy and 50% develop overt renal involvement. When present, it is associated with a worse prognosis. Clinical presentation includes:

- Hypertension
- Haematuria
- Proteinuria
- Nephrotic syndrome
- Acute kidney injury
- End-stage renal disease.

**Neuropsychiatric Manifestations (in 50–60% of cases)**

Neurological involvement in lupus usually arises in the context of active systemic disease. Manifestations include:

- Headache
- Peripheral neuropathy
- Cranial nerve abnormalities
- Mononeuritis multiplex
- Tremor
- Strokes
- Seizures

---

**Figure 18.2** Schematic representation of the major systems affected by systemic lupus erythematosus.
psychoses/depression
limb weakness/numbness.

Central nervous system (CNS) abnormalities are associated with a poorer prognosis.

Lungs (in 40–50% of cases)
Commonly:
- pleurisy, occasionally with effusion
- patchy consolidation and areas of collapse
- diffuse reticulonodular shadowing on chest X-ray.

Rarely:
- ‘shrinking lung syndrome’
- lupus pneumonitis, which may be haemorrhagic, is rare but often fatal
- pulmonary emboli in patients who are antiphospholipid antibody positive.

Cardiovascular system (in 40% of cases)
- mild pericarditis: may be the first presenting feature of SLE
- non-infective thrombotic endocarditis (Libman–Sacks)
- hypertension is usually associated with renal involvement

Haematology
- raised ESR in active disease
- normochromic normocytic anaemia
- mild lymphopenia
- mild thrombocytopenia
- occasionally severe thrombocytopenia, leucopenia and haemolytic anaemia
- antiphospholipid syndrome (~20%)
- reactive lymphadenopathy (30–40%)
- splenomegaly (10%)

The American College of Rheumatology has proposed criteria for the diagnosis of SLE based on a combination of clinical and laboratory features (Box 18.3).

Investigation
- Routine blood tests:
  - normal or low white blood cell count (WBC), particularly lymphopenia
  - elevated ESR
  - normal or mildly elevated CRP
  - renal and liver function may be abnormal.
- Urinalysis:
  - proteinuria, haematuria (± casts).
- Antibodies to nuclear antigens (ANA): ANA positivity is found in virtually all patients with active disease. Antibodies to double-stranded DNA (dsDNA) are specific for lupus or lupus overlap disorders. Antibodies to extractable nuclear antigens (ENA) are common (e.g. anti-Sm).
- Serum complement levels; low C3 and C4, especially in lupus nephritis.
- Antiphospholipid antibodies: anticardiolipin antibodies and lupus anticoagulant occur in up to one-third of cases and are a marker for thrombosis.
- Further investigations depending on presentation include: e.g.
  - renal or skin biopsy
  - pulmonary function tests/CT chest
  - CT/MRI of the head.

Disease activity can be assessed by monitoring titres of dsDNA, complement levels and ESR. The development of intercurrent infection may produce rises in both WCC and CRP.

Management

Patient education and support are vital – SLE is a chronic relapsing condition with potentially life-threatening complications.
General measures:

- Avoidance of UV light.
- Warm socks and gloves for Raynaud’s phenomenon.
- Antibiotics for intercurrent infection.
- NSAIDs may be sufficient to relieve joint symptoms.
- Sunscreen preparations and topical steroids.
- Antimalarials (e.g. hydroxychloroquine) when skin and joint disease predominate and can be used to maintain remission. They may cause lens opacities, which resolve on stopping treatment, and rarely irreversible retinal degeneration.
- Immunomodulation: systemic corticosteroids (oral or pulsed intravenous) when NSAIDs and antimalarials are insufficient to control symptoms. Steroid-sparing agents (e.g. azathioprine, methotrexate) can be used once the disease is under control. Cyclophosphamide and mycophenolate mofetil are reserved for cases of organ- or life-threatening disease. A number of different ‘biologics’ are currently being developed/tested for use in SLE.
- Formal neurocognitive and psychiatric assessment is helpful in those with CNS involvement.
- Patients with the antiphospholipid syndrome (see below) require antithrombotic therapy.

Prognosis

The natural history of SLE is of episodic relapses and remissions lasting months to years. Five-year survival is > 90%, although patients with renal involvement have a higher mortality rate. Death usually results from active generalised disease, sepsis or cardiovascular complications.

Antiphospholipid syndrome

Although first described in SLE, most patients with the antiphospholipid syndrome (APS) do not meet the diagnostic criteria for SLE.

APS is an autoimmune disorder characterised by:

- venous thrombosis (deep vein thrombosis, DVT) and pulmonary embolism (PE) and/or arterial thromboses (TIA, stroke); and/or
- obstetric morbidity (recurrent spontaneous miscarriage, usually in the second or third trimester); and/or
- thrombocytopenia, and abnormalities of the CNS, skin (livedo reticularis) and heart valves.

Antiphospholipid antibodies (aPL, e.g. anticardiolipin, ‘lupus anticoagulant’) bind to plasma proteins or charged phospholipids in cell membranes. These antibodies bind phospholipids used in coagulation tests, paradoxically causing an anticoagulant effect in vitro with prolongation of the activated partial thromboplastin time (APTT), hence the term lupus anticoagulant.

Management involves anticoagulation and antiplatelet therapy (see Box 18.4).

Scleroderma (systemic sclerosis)

Scleroderma (SS) is rare (estimated incidence of 1–2 per million in the UK), with females more commonly affected than males (~3:4:1). It is an autoimmune disorder characterised by the excessive deposition of collagen and other matrix proteins in various organs, including the skin. Inflammation is followed by progressive fibrosis with narrowing of blood vessels. There is vasomotor instability (usually Raynaud’s phenomenon) and blood vessels also show proliferative intimal thickening leading to ischaemia. The cause of scleroderma remains unclear and no reproducible environmental trigger or genetic predisposition has been identified, although associations with certain HLA-DR subtypes have been noted. Pathologically various immunological changes have been reported, including infiltration of skin and other affected organs by activated CD4+ and CD8+ T cells, increased

Box 18.4 Clinical trials/recommendations in antiphospholipid syndrome

In a retrospective study of 147 patients with APS and a history of thrombosis, treatment with high-intensity warfarin (INR > 3), with or without low-dose aspirin, was more effective in preventing thrombosis than treatment with low-intensity warfarin (INR < 3), with or without low-dose aspirin, or treatment with aspirin alone. Khamashta et al., New England Journal of Medicine 1995; 322: 993–997.

Recently, however, several authors have proposed a more targeted/personalised approach for patients with aPL or different manifestations of APS. For example, it has been argued that those with asymptomatic aPL should only be treated with aspirin if they have persistently positive aPL, obstetric APS or coexistent SLE. For those with APS, lower risk patients (i.e. first venous thrombosis) should be treated with warfarin to an INR 2.0–3.0. Those at higher risk (i.e. arterial thrombosis or recurrent events) should be treated with warfarin to an INR > 3.0. During pregnancy in APS, low molecular weight heparin (LMWH) and aspirin should be used under the care of a specialist team. Additional vascular and thrombotic risk factors should be actively reduced in all groups. Tuthill and Khamashta, Journal of Autoimmunity 2009; 33: 92–98.

aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; INR, international normalised ratio.
production of cytokines (including interleukin (IL)-1, IL-2, IL-6, TNF and transforming growth factor (TGF)-β), increased expression of adhesion molecules (e.g. selectins, integrins) and polyclonal B-cell activation (with associated hypergammaglobulinaemia).

Clinical presentation (Fig. 18.3)

- Limited cutaneous systemic sclerosis (LCSS). formerly known as CREST syndrome (calcinosis, Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia). Usually seen in females aged 30–50 years with a long history of Raynaud’s phenomenon, LCSS is characterised by limited skin involvement (typically face, hands and feet) and late appearance of visceral complications often limited to pulmonary hypertension.

- Diffuse cutaneous systemic sclerosis (DCSS): a more extensive form of the disease often with abrupt onset. Skin involvement is both truncal and acral; visceral involvement may include the heart, lungs, kidneys, gastrointestinal tract.

- Systemic sclerosis without scleroderma: a small number of patients have visceral disease without cutaneous involvement.

- Morphoea: changes are limited to the skin and may be localised or generalised.

Investigation

- elevated ESR and CRP
- blood pressure/renal biochemistry/urinalysis: early detection of renal involvement in DCSS

Figure 18.3 Schematic representation of the major systems affected by scleroderma (systemic sclerosis).
antinuclear antibodies:
- anti-centromere antibodies in LCSS
- anti-DNA topoisomerase-1 (anti-Scl-70) antibodies in DCSS associated with pulmonary fibrosis and peripheral vasculopathy
- anti-RNA polymerase I/II/III may also occur in DCSS where they are associated with renal involvement

radiography:
- hand X-ray: soft tissue calcification (calcinosis), loss of terminal phalangeal tufts
- chest X-ray/lung function testing
- doppler echocardiography
- gastrointestinal endoscopy ± contrast studies/oesophageal manometry/malabsorption screen

Management
No treatment has been proven to alter the course of the disease. Symptomatic treatment includes:
- Calcium-channel antagonists, vasodilators, cold avoidance/use of thermal gloves and abstinence from smoking reduce the symptoms of Raynaud’s phenomenon.
- Antacid therapy/PPIs and sleeping upright help alleviate the symptoms of oesophageal reflux; antibiotics may assist in bacterial overgrowth.
- Physiotherapy relieves joint stiffness and helps maintain muscle strength/function.
- Prostaglandins, phosphodiesterase type 5 inhibitors and endothelin antagonists may help reduce progression of pulmonary hypertension and digital ulceration.
- Angiotensin converting enzyme inhibitors (ACE-I) reduce the risk of renal failure/crisis; renal replacement therapy is, however, still required in a subgroup of patients.
- Penicillamine may be of value; trials of other immunomodulators and alkylating agents are ongoing.
- NSAIDs, corticosteroids and other immunosuppressants are sometimes tried for pleurisy, pericarditis and lung fibrosis.

Prognosis
The extent of skin involvement, and cardiac, pulmonary and renal disease dictate the outcome in DCSS; LCSS has a more favourable outcome.

Sjögren syndrome
Sjögren syndrome is a chronic autoimmune disorder characterised by keratoconjunctivitis sicca (KCS) and xerostomia (dryness of the eyes and mouth ± other mucosal surfaces), due to inflammation and fibrosis of the lacrimal and salivary glands (which are infiltrated by CD4+ T-lymphocytes). The aetiology remains unclear but is likely to reflect a combination of genetic (HLA-DR3 and HLA-DQ2) and environmental factors including Epstein–Barr virus, cytomegalovirus and hepatitis C.

It may occur in isolation (primary) or in association with a connective tissue disease or rheumatoid arthritis (secondary). The condition is most commonly seen in middle-aged women (male:female ~1:10).

Clinical presentation
- dry, gritty eyes which may lead to corneal ulceration (keratoconjunctivitis sicca)
- dry mouth (xerostomia), with dysphagia for dry foods, and predisposition to oral candidiasis and accelerated dental caries
- salivary gland enlargement

Less commonly other exocrine glands may be affected leading to sinusitis and dyspareunia.

Extraglandular features may include:
- non-erosive arthritis/arthralgia (up to 60–70% of cases)
- Raynaud’s phenomenon
- cutaneous leukocytoclastic vasculitis
- purpura (mixed cryoglobulinaemia)
- interstitial lung disease
- interstitial nephritis
- distal renal tubular acidosis
- peripheral neuropathy/mononeuritis multiplex.

Sjögren syndrome is also associated with an increased risk of B-cell lymphoma. Babies born to mothers with Sjögren syndrome who are Ro antibody positive are at risk of congenital heart block.

Investigation
- Schirmer’s test: a small strip of filter paper is hooked over the lower eyelid; wetting of < 5 mm in 5 min is considered abnormal.
- Slit lamp examination with Rose Bengal staining confirms dryness and corneal damage.
  - Assessment of saliva flow rates and salivary gland scintigraphy.
- ESR is raised, but CRP is often normal.
- Rheumatoid factor is typically detected (~90% of cases) and ANA frequently present (~70%).
- Anti-Ro (anti-SSA) and anti-La (anti-SSB) antibodies are found in approximately 50% of cases.
Biopsy of minor salivary glands shows a focal T cell infiltrate. Other investigations are dictated by the clinical presentation.

Management

Treatment is predominantly symptomatic with artificial tears and saliva and meticulous oral hygiene. Diuretics and anticholinergic agents are best avoided. Corticosteroids and other immunosuppressive agents may be required for extraglandular complications.

Prognosis

There is no cure. Awareness of the possible development of lymphoma is important for long-term surveillance.

Inflammatory myopathies

Polymyositis and dermatomyositis

These are rare autoimmune disorders with an incidence of ~1 per million per year; peak onset is in middle age with a male:female ratio of ~1:2. Several forms include:

- polymyositis (primary idiopathic)
- dermatomyositis (primary idiopathic)
- polymyositis or dermatomyositis with malignancy (~10% of cases, e.g. bronchus, breast, stomach, ovary, lymphoma)
- polymyositis or dermatomyositis with another connective tissue disease
- juvenile dermatomyositis
- inclusion body myositis
- other rare forms of idiopathic myositis (e.g. eosinophilic, focal)

In polymyositis and inclusion body myositis muscle damage is driven predominantly via CD8⁺ T cells, whereas in dermatomyositis it is antibody/complement mediated.

Clinical presentation

The onset may be acute or chronic. In dermatomyositis, skin and muscle changes occur in any order, or together. General ill health and fever are common.

Muscle involvement

- Proximal muscle weakness and associated stiffness are common; mild pain and muscle tenderness may occur. Patients report difficulty climbing stairs and with tasks of daily living.
- Involvement of other striated and smooth muscle groups may result in cardiac and/or respiratory failure, oropharyngeal dysfunction and dysphagia.
- Skin involvement in dermatomyositis
  - classically, a purple heliotrope photosensitive rash occurs around the eyes; the remainder of the face, neck, shoulders and extensor surfaces of the fingers and forearms may be involved
  - raised scaly nodules over the small joints of the hands (Gottron’s papules)
  - nail fold infarcts
  - generalised telangiectasia and/or angio-oedematous changes, especially of the face, chest and arms

Other systems

- lungs – interstitial disease with fibrosis (~20% of cases)
- joints – arthralgia and/or RA-like changes in the fingers

Investigation

- Serum creatine kinase (CK) levels: usually markedly raised and a marker of response to treatment; alanine transaminase levels are also elevated.
- Electromyography (EMG) – confirms myopathy and excludes denervation.
- Muscle biopsy for definitive diagnosis.
- MRI – to identify a suitable site for biopsy if the myositis is patchy.
- Autoantibody profile: one-third of all patients with polymyositis or dermatomyositis do not have any detectable auto-antibodies.
- Positive ANA and anti-ENA antibodies are common but do not reliably distinguish from other connective tissue diseases.
- Anti-U1 RNP (uridine-rich ribonucleoprotein) and anti-PM-Scl antibodies are associated with syndromes that include myositis, lung disease and scleroderma-like changes.
- Antibodies to Jo-1 identify a subgroup of patients with anti-synthetase syndrome (fever, myositis, interstitial lung disease, Raynaud’s phenomenon and symmetrical non-erosive arthritis).

The extent of investigation for underlying malignancy is determined by clinical suspicion and the patient’s age.

Management

- Corticosteroids (initially at high dosages).
- Steroid-sparing agents, e.g. azathioprine, methotrexate or ciclosporin, are substituted as the corticosteroid dose is lowered.
- Intravenous immunoglobulin may help, especially if the initial response to treatment is poor and/or there is evidence of respiratory compromise.
• Occasionally more aggressive immunosuppressive therapy is required for pulmonary involvement.
• Physiotherapy is important in restoring muscle strength/function.

Prognosis

This is variable but generally worse in older patients. The disease may remit spontaneously, particularly in younger subjects, but relapse/progression is a feature in at least half of all cases. Underlying malignancy determines the outcome if polymyositis or dermatomyositis is associated with malignant disease.

Mixed connective tissue disease (MCTD)

This is a rare overlap disorder in which patients present with features that resemble elements of SLE, scleroderma and poly-/dermatomyositis. Affected individuals exhibit high titres of autoantibodies to a uridine-rich ribonucleoprotein (U1-RNP).

MCTD often merges with other auto-immune syndromes such as:

• dermatomyositis or scleroderma, in which skin manifestations are a dominant feature
• polymyositis, in which muscle weakness is marked
• SLE.

Investigations and treatment are generally along the lines of the individual component disorders.

Vasculitides

These are a heterogeneous group of disorders characterised by vascular inflammation. Several classifications have been proposed, but currently the most useful are those based on (1) vessel size and (2) serological markers, in particular antineutrophil cytoplasmic antibodies (ANCA) (Fig. 18.4). They may occur as idiopathic or secondary phenomena. The cause remains unknown, although flare-up of disease is often associated with intercurrent infection. Various organs can be affected including skin, lungs, kidneys, joints, eyes and the nervous system.

Clinical features

• malaise, fever, rashes, uveitis, arthritis
• dyspnoea, cough, haemoptysis (pulmonary haemorrhage)
• haematuria, renal failure (glomerulonephritis)
• psychiatric disturbance
• epilepsy, stroke, peripheral neuropathy

Large-vessel vasculitis

Giant-cell arteritis (GCA; temporal arteritis, cranial arteritis) and polymyalgia rheumatica (PMR)

Giant-cell arteritis (GCA) is the most common of all the vasculitides and in view of the risk to eyesight, it is a medical emergency. The aetiology of GCA and PMR remains unclear. Both share common epidemiological, clinical and serological features, although GCA is a granulomatous large vessel vasculitis, whereas PMR is an inflammatory disorder classically manifesting with shoulder and pelvic girdle muscular pain and stiffness in the absence of weakness. The cellular infiltrate (macrophages, T cells, giant cells) in the synovium in PMR is similar to that found in the vascular lesions of GCA, where thickening of the arterial intima may be associated with luminal thrombosis. Associations with HLA-DR4 and HLA-DRB1 suggest a genetic predisposition. Both conditions are more common in women over the age of 50.

Clinical presentation

Giant-cell arteritis (GCA)

Although occasionally headaches and scalp pain are absent, symptoms usually include the following:

• mild or severe unilateral, temporal headaches, often of abrupt onset
• burning sensation and tenderness over the scalp
• claudication of the jaw (± tongue) muscles, producing pain on chewing in 33–50% of cases
• blurring of vision, diplopia or amaurosis fugax: initially transient, ultimately progressing to complete visual loss if not recognised and treated. Occurring in up to 20% of patients they reflect involvement of the arteries supplying the retina and/or optic nerve
• systemic manifestations: fatigue, fever and weight loss
• features of large vessel involvement: limb claudication
• symptoms of PMR.

Examination

• ipsilateral temporal artery tender, thickened and irregular with reduced or absent pulsation
• scalp tenderness
• visual field defect
• relative afferent pupillary defect
• anterior ischaemic optic neuritis (pale swollen optic disc with haemorrhages). Occasionally central retinal artery occlusion
Polymyalgia rheumatica (PMR)

Features:
- relatively abrupt onset of pain and stiffness in the shoulder and/or pelvic girdles
- symptoms are typically worse after periods of inactivity
- few physical signs.

Restricted movement, weakness and tenderness are not features of PMR and should prompt consideration of other diagnoses, e.g. frozen shoulder, osteoarthritis or inflammatory myositis.

Investigation

There is no specific serological test for either GCA or PMR. ESR and CRP are typically markedly raised (e.g. ESR > 90 mm/h), although GCA may be diagnosed in the presence of normal inflammatory markers. A mild normocytic anaemia is often present.

- Temporal artery biopsy: classical pathological appearances of arterial wall thickening with mononuclear cell infiltration or granulomatous inflammation with giant cells throughout the vessel wall causing luminal occlusion confirms the diagnosis of GCA. The biopsy often remains positive for 2–6 weeks even after treatment is started, so institution of corticosteroid therapy must not be delayed.
Normal biopsy appearances do not exclude the condition, as skip lesions may occur. Patients with negative biopsies should be managed as having GCA if the clinical and biochemical picture are consistent with the diagnosis, especially if there is a rapid response to corticosteroid therapy.

- **Duplex ultrasonography:** may detect a characteristic ‘hypoechoic halo’, vessel occlusions and stenosis.
- **MRI and PET imaging:** show promise for diagnosis and monitoring of response to treatment in GCA, especially in the context of large vessel involvement.
- **Muscle enzymes, radiology, electromyography, muscle biopsy:** normal in PMR; may be undertaken to exclude other diagnoses.
- The American College of Rheumatology (1990 classification criteria) has proposed that a patient should be deemed to have GCA if he/she exhibits at least three of the following: age at disease onset \( \geq 50 \) years; new headache; temporal artery abnormality; ESR \( > 50 \) mm/h; abnormal artery biopsy.

### Management

GCA and PMR are very sensitive to corticosteroid therapy.

- **GCA:** high dose prednisolone (40–80 mg/day).
  - Treatment should be started without delay, and intravenous methylprednisolone may be used in the early stages if there is visual involvement.
  - Treatment should continue for at least 12–24 months.
  - Monitor response by clinical review and serial monitoring of ESR/CRP.
  - Low dose aspirin may reduce the rate of visual loss and cerebrovascular accidents in GCA.
- **PMR:** prednisolone 10–20 mg/day is usually sufficient.

### Prognosis

The prognosis in GCA is determined by the extent of visual involvement. Most patients with PMR can discontinue steroid therapy within 2 years, although some require long-term low dose maintenance therapy.

### Takayasu’s arteritis ('pulseless disease')

This is a rare disorder affecting the aorta and its major branches and sometimes the pulmonary arteries. Its aetiology remains unknown, but the pathology is similar to GCA with focal granulomatous arteritis. It is most common in young females of Asian and South American origin.

### Clinical presentation

- **systemic features:** fever, arthralgia, myalgia, anaemia
- **symptoms of arterial insufficiency/ischaemia:** typically upper limbs but may also result in TIA/stroke
- **bruits:** aortic, carotid and subclavian
- **hypertension:** in the majority of cases

### Investigation

- ESR and CRP are typically elevated, with anaemia and leucocytosis.
- Aortic arch angiography: reveals diffuse narrowing of the aorta and main arteries.
- MR angiography: increasingly used to monitor disease activity and lesion progression.
- Although PET imaging is also effective in demonstrating the extent of arterial involvement, its utility for serial monitoring is limited by radiation exposure.

### Management

- Treatment is with high-dose corticosteroids (e.g. prednisolone 60–80 mg/day), with gradual dose reduction guided by inflammatory markers.
- Additional immunosuppression (e.g. azathioprine, methotrexate or cyclophosphamide) may be required in some cases.
- Hypertension is managed conventionally.
- Surgical intervention may be required for critical carotid or renal artery stenosis, or significant aortic regurgitation.

### Prognosis

The prognosis is generally good, although relapse is common.

### Medium-sized vessel vasculitis

#### Polyarteritis nodosa (PAN)

Polyarteritis nodosa is characterised by necrotising inflammation of medium-sized arteries, leading to the formation of small aneurysms. It is an immune-complex-mediated vasculitis of unknown aetiology, although some cases are associated with hepatitis B virus (HBV) infection. It has an estimated annual incidence of between 1 and 10 cases per 10 million population.

### Clinical presentation

Clinical features of PAN are shown in Fig. 18.5.
Investigation
- marked inflammatory response, raised ESR and CRP with anaemia and leucocytosis
- renal and liver function tests
- HBV status
- urinalysis – proteinuria and microscopic haematuria
- renal/visceral angiography: reveals vessel narrowing, pruning of the peripheral vasculature and aneurysms
- biopsy of involved tissue (e.g. muscle, nerve, skin, kidney): vasculitic changes with segmental fibrinoid necrosis of the walls of medium-sized arteries and arterioles and cellular infiltration

Management
- Systemic disease is treated with a combination of corticosteroid and cytotoxic chemotherapy. PAN confined to the skin may be treated with corticosteroids alone.
- HBV infection should be treated appropriately and complications (hypertension, bowel infarction or perforation) managed along conventional lines.
- Renal impairment, proteinuria > 1 g per 24 h and visceral involvement are adverse prognostic markers.

Kawasaki disease
This condition typically affects children, causing fever, mucocutaneous features (e.g. conjunctival infection, fissuring of the lips, erythema and desquamation of the hands) and lymphadenopathy. Various organs may be affected, including the coronary vasculature. Treatment is with aspirin and intravenous immunoglobulin therapy.

Small-vessel vasculitis
ANCA positive: these constitute Wegener’s granulomatosis and microscopic polyangiitis.
- cytoplasmic staining (classical or cANCA; usually PR3-ANCA directed against proteinase 3) in Wegener’s granulomatosis
- perinuclear staining (perinuclear or pANCA; usually MPO-ANCA (directed against myeloperoxidase) in microscopic polyangiitis, also in a subset of patients with Churg–Strauss syndrome

ANCA negative: these include hypersensitivity vasculitis, Henoch–Schönlein purpura, cryoglobulinaemia.
Wegener’s granulomatosis

Wegener’s granulomatosis (granulomatosis with polyangiitis) is characterised by necrotising granulomatous vasculitis with few or no immune deposits. Localised inflammation, usually in the upper or lower respiratory tract, is followed by the development of a systemic vasculitis and glomerulonephritis. It affects both sexes equally, can occur at any age (commonly in middle age) and has an estimated annual incidence of between 10 and 20 per million population.

Clinical presentation

The key clinical features are shown in Fig. 18.6. Typically Wegener’s involves the upper and lower airways and the kidneys, although rarely other organ systems including the gastrointestinal tract, heart, central nervous system and pituitary gland are involved.

Investigation

- ESR and CRP: typically raised in proportion to disease activity
- renal function: requires close monitoring
- urinalysis: for proteinuria, microscopic haematuria and casts
- cANCA (usually PR3-ANCA): positive in the majority of cases
- plain chest X-ray, CT chest and CT/MRI of the nasal sinuses: elucidate respiratory tract involvement
- biopsy of affected tissue (nasal, lung or renal): shows necrotising vasculitis with granuloma formation

Management

Corticosteroids and cyclophosphamide: first-line therapy.

*Rituximab*: (an anti-CD20 monoclonal antibody, which depletes B-cells) may be as effective as cyclophosphamide in inducing remission. Corticosteroid and cyclophosphamide-sparing therapy (e.g. azathioprine, methotrexate) may be used for maintenance therapy.

Prognosis

The 5-year survival rate is > 80%, although up to 50% of patients will suffer one or more relapses during this time. Superadded infection and renal and respiratory failure are major causes of long-term morbidity.
**Microscopic polyangiitis**

**Clinical presentation**

Necrotising vasculitis predominantly affects the kidneys, causing rapidly progressive glomerulonephritis. Approximately 50% of patients have associated lung involvement presenting as haemoptysis, pleurisy or asthma. Frank pulmonary haemorrhage is rare but potentially fatal. Other features include arthralgia, vasculitic or purpuric rashes, hypertension, mononeuritis multiplex and peripheral neuropathy.

**Investigation and management**

As for Wegener’s granulomatosis. Microscopic polyangiitis is characterised by elevated titres of pANCA (usually MPO-ANCA) and absence of granulomas on biopsy.

**Hypersensitivity (leucocytoclastic) vasculitis**

This is characterised by inflammation of small vessels, resulting in palpable purpuric skin lesions which coalesce to form plaques or ecchymoses, especially on the lower limbs. There may be joint, renal or gastrointestinal involvement. Usually idiopathic, it is associated with autoimmune/connective tissue diseases (RA, SLE, Sjögren syndrome), infections (hepatitis B/C, HIV), drugs (penicillin, sulphonamides, thiazides) and lympho- and myeloproliferative disorders.

**Henoch–Schönlein purpura (HSP)**

This is a systemic vasculitis characterised by deposition of immunoglobulin A (IgA)-containing immune complexes, usually following an upper respiratory tract infection. It typically occurs between the ages of 3 and 15 years, more commonly affects males and is rare in adults, in whom the prognosis is worse. A palpable purpuric rash develops over the buttocks and legs, with arthritis, abdominal pain with bloody diarrhoea and glomerulonephritis which is indistinguishable from IgA nephropathy. A leucocytoclastic necrotising vasculitis with IgA deposition is demonstrable at the dermo-epidermal junction in skin biopsies, and there is mesangial IgA deposition in the kidneys. Episodes are usually self-limiting (days or weeks) but relapses may occur, especially in the elderly and those with nephritis. Evidence of progressive renal involvement is an indication for high dose corticosteroid/immunosuppressive therapy.

**Churg–Strauss syndrome**

This systemic vasculitis affects various organs:
- lungs: infiltrates and haemorrhage
- GI tract: pain, diarrhoea, bleeding, perforation
- peripheral nerves: mononeuritis multiplex
- heart: myocardial infarction
- brain: stroke
- skin: purpura
- kidneys: mild focal segmental necrotising glomerulonephritis.

Affected individuals often have pre-existing asthma and allergic rhinitis. There is an eosinophilia in peripheral blood and eosinophils predominate in the inflammatory infiltrates, which may be granulomatous. pANCA (MPO-ANCA) positivity is seen in most patients.

Treatment is with corticosteroids ± cyclophosphamide.

**Cryoglobulinaemic vasculitis**

An immune complex-mediated vasculitis typically arising in the setting of mixed cryoglobulinaemia (MC) types II and III. Between two-thirds and three-quarters of cases are associated with underlying hepatitis C virus (HCV) infection. Females are affected more commonly than males; the estimated incidence is 10 per million.

**Clinical presentation**

- purpura
- arthralgia
- glomerulonephritis
- abdominal pain
- mononeuritis multiplex
- chronic renal failure, hypertension and leg ulcers: in long-standing disease
- liver failure and B-cell lymphoma are rare associations

**Investigation**

- Correct sample collection and transport to the laboratory (at 37°C) is essential if cryoglobulinaemia is suspected.
- Very low complement (C4) levels and a positive rheumatoid factor are seen. HCV serology should be checked and HCV RNA may be detected in the cryoprecipitate.
- Skin and/or renal biopsy should be performed to determine the extent of renal involvement.

**Management**

- *Treat hepatitis C* if present (p. 146).
- *Immunosuppressive therapy*—corticosteroids, azathioprine, mycophenolate mofetil or cyclophosphamide are used in those with idiopathic MC and progressive renal or hepatic disease.
**Rituximab** is effective in both HCV-associated and idiopathic MC. **Plasmapheresis** may be used as adjunctive therapy.

**Prognosis**

The long-term outcome is largely dictated by the extent of renal disease.

**Behçet’s disease**

Behçet’s disease is a condition of unknown aetiology characterised by disordered regulation of the inflammatory response with vasculitis of veins and arteries of all sizes, hypercoagulability and neutrophil dysfunction. It occurs with greater prevalence in the Middle East and Central Asia but is not restricted to these areas. Globally, males are more commonly affected than females, with a peak age of onset in the 20s. An association with HLA-B51 has been reported in some populations.

**Clinical presentation**

The diagnosis remains predominantly clinical (see Box 18.5). Common manifestations include:

- **mucocutaneous**
  - oral aphthous ulcers
  - ano-genital ulcers
  - erythema nodosum
  - acneiform lesions
  - vasculitic lesions
  - a papule or pustule may form at sites of minor trauma (pathergy)

- **eyes**
  - relapsing anterior and posterior uveitis
  - retinal vasculitis

- **joints** (50–60% of cases)
  - arthralgia or non-deforming mono- or polyarthritis

- **neuro (-psychiatric)** (10–20% of cases)
  - transient ischaemic attacks
  - cerebrovascular accidents
  - seizures
  - dementia/psychosis reflecting involvement of cerebral vessels

- **cardiovascular/respiratory**
  - dyspnoea, haemoptysis (pulmonary vasculitis), pulmonary embolism
  - myocardial ischaemia/infarction
  - thrombophlebitis, deep vein thrombosis

- **gastrointestinal**
  - abdominal pain, constipation, bloody diarrhoea (intestinal vasculitis with mesenteric ischaemia).

**Differential diagnosis**

- herpes simplex: recurrent oro-genital ulceration
- sarcoidosis: erythema nodosum, uveitis, pulmonary involvement
- inflammatory bowel disease: oral/perianal ulceration, gastrointestinal involvement
- seronegative arthritis: arthritis, uveitis

**Investigation**

- ESR/CRP are raised in active disease
- biopsy of affected tissues: vasculitic changes with neutrophil infiltration of small- and medium-sized vessels
- MRI brain: high-signal white matter changes
- lumbar puncture: raised protein level with lymphocytes and neutrophils

**Management**

- corticosteroids: topical therapy may be tried for local ulceration, but systemic high dose therapy is often required
- cytotoxics: methotrexate, cyclophosphamide, chlorambucil
- thalidomide, colchicine, interferon-α have all been tried with variable response
- azathioprine and ciclosporin: especially for eye involvement
- anti-tumour necrosis factor-α (anti-TNFα) therapy may be useful
- anticoagulation to treat thrombosis

---

**Box 18.5 International Study Group for Behçet’s Disease diagnostic criteria**

To establish a diagnosis of Behçet’s disease the following criteria are required:

- oral ulceration – occurring on ≥ three occasions during a 12-month period together with ≥ two of the following ‘hallmark’ features:
  - genital ulceration (majority of cases)
  - skin lesions (> two-thirds of cases)
  - eye lesions (half to three-quarters of cases)
  - pathergy

**NB** In addition, alternative diagnoses (see text) should be excluded.

---

**Crystal arthropathies**

**Gout**

Gout is a disorder of uric acid metabolism. Hyperuricaemia leads to deposition of monosodium urate (MSU) crystals in soft tissues, especially
cartilage/synovium, skin and renal tubules. Joint involvement results in an inflammatory arthropathy. Gout is common, affecting up to 1% of the UK population. Its prevalence varies according to social and geographical factors, being more common in affluent societies. It is usually found in men (uric acid levels are higher in men than women), although postmenopausal women may be affected (when uric acid levels rise).

Hyperuricaemia results from overproduction, inefficient renal excretion or a combination of the two. Overproduction may be caused by:

- obesity
- excess alcohol ingestion
- consumption of purine-rich foods (e.g. red meat)
- increased cell turnover states: haematological disorders (myeloid leukaemia, myelofibrosis, polycythaemia rubra vera, multiple myeloma, Hodgkin’s disease), antimetabolite chemotherapy and psoriasis are associated with enhanced purine production due to increased rates of DNA breakdown
- genetic factors: may contribute to a predisposition to gout; rarely, an X-linked disorder of the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase (HPRT) results in hyperuricaemia and gout in childhood/adolescence (Lesch–Nyhan syndrome).

Impaired excretion may be the result of:

- alcohol
- diuretics (thiazide and loop)
- low dose aspirin
- dehydration
- renal failure.

Trauma, surgery, infection, alcohol/dietary excess or starvation may trigger an acute attack.

MSU crystals shed into the joint cavity from microtophi on the joint lining provoke an intense inflammatory reaction, with activation of synovial macrophages and recruitment of neutrophils.

### Clinical presentation

#### Acute gout

In the first attack, the first metatarsophalangeal joint is affected in 75% of cases, the ankle or tarsus in 35%, the knee in 20%, with polyarticular involvement in 10% of cases. The onset is usually sudden and reaches maximum intensity by 8–12h. The affected joint is red, hot, swollen and exquisitely tender and there may be fever with systemic upset. Initially monoarticular in most patients, attacks tend to be recurrent and become polyarticular, also involving the upper limbs and eventually leading to deformity.

#### Tophaceous gout

Uric acid deposition in the skin produces *tophi* (well-demarcated crystal aggregates that can rupture, releasing a chalky substance), commonly on the pinna of the ear, the fingers and toes and over pressure sites. They are a feature of chronic disease and may be confused with rheumatoid nodules and nodular OA.

#### Nephrolithiasis and urate nephropathy

Uric acid-containing stones account for 5–10% of all cases of renal/ureteric calculi. Deposition of urate crystals in the renal interstitium or collecting ducts can lead to progressive renal impairment.

### Investigation

- Joint aspiration: definitive test, excludes septic arthritis. The aspirated fluid is turbid, containing MSU crystals which are needle-shaped and exhibit negative birefringence under polarised light microscopy. Crystals can also be identified in material aspirated from bursae or tophi.
- Serum uric acid levels: but NB 10% of patients with acute gout have normal serum uric acid levels, while approximately 5% of the population have raised serum uric acid levels without any clinical manifestations of gout.
- Routine blood tests: leucocytosis is common and the ESR and CRP are often markedly raised. Renal function and evidence of co-morbidities (hypertension, dyslipidaemia, glucose intolerance/type 2 diabetes mellitus) should be investigated.
- Radiology:
  - asymmetrical soft-tissue swelling may be the only visible abnormality in acute gout
  - irregular punched-out bony erosions near the articular margins (seen in chronic disease)
  - calcified tophi
  - osteoarthritic changes may develop in chronic disease
  - uric acid renal/ureteric stones are radiolucent.

### Management

#### Acute episodes

- **NSAIDs.** the treatment of choice in those with no contraindications.
- **Corticosteroids.** in patients for whom NSAIDs are contraindicated. Intra-articular injection is effective; alternatively, oral prednisolone (up to 40 mg/day, with or without dose tapering, for a total of 7–10 days).
- **Colchicine.** effective, but often poorly tolerated, causing diarrhoea and/or abdominal pain. It should be used in low doses and is useful in patients at risk of heart failure as it does not promote fluid retention.
Long-term control of gout and hyperuricaemia

Potential precipitating factors should be sought and addressed, e.g. promotion of weight loss, reduction in/abstinence from alcohol consumption, dietary modification, withdrawal of offending drugs.

Medical therapy should be considered for:
- recurrent acute attacks
- chronic tophaceous gout
- renal involvement
- patients with haematological malignancy/high cell turnover states/inherited defects in purine metabolism.

Treatment options include:
- **Allopurinol**: xanthine oxidase inhibitor which blocks conversion of hypoxanthine to xanthine, and xanthine to uric acid. It is useful in patients with urate stones/renal impairment where uricosuric drugs cannot be used. Allopurinol (300 mg/day) should be started 1–2 weeks after an acute attack has settled as the initiation of treatment may precipitate an acute attack. An NSAID or colchicine should be used as a prophylactic and continued for 3–4 weeks after the hyperuricaemia has resolved. In tumour lysis syndrome it should be commenced in advance of cytotoxic chemotherapy. Allopurinol is generally well tolerated but may cause rashes and rarely a hypersensitivity syndrome.

NB: it is important to be aware of several potentially serious adverse interactions between allopurinol and other drugs that may be coprescribed, including azathioprine (which is metabolised by xanthine oxidase, thus predisposing to bone marrow toxicity), ciclosporin (risk of nephrotoxicity), ACE-I and diuretics (increased risk of hypersensitivity reaction).

- **Febuxostat**: recently introduced non-competitive xanthine oxidase inhibitor.
- **Uricosuric agents**: sulphinpyrazone and probenecid both block renal tubular reabsorption of uric acid; benzbromarone is an alternative for use in patients with mild renal impairment.
- **Rasburicase**: a recombinant urate oxidase, which catalyses the conversion of uric acid to allantoin. It is licensed for the prophylaxis and treatment of acute hyperuricaemia, before and during initiation of chemotherapy in patients at risk of tumour lysis syndrome.

Pseudogout (calcium pyrophosphate deposition disease; chondrocalcinosis)

Calcium pyrophosphate dihydrate (CPPD) crystals form in articular cartilage and are shed into the joint cavity to provoke an inflammatory response similar to that seen in gout. Calcification of the joint cartilage (chondrocalcinosis) commonly occurs. Pseudogout is mainly seen in elderly subjects, with a slight female preponderance, and is often associated with osteoarthritis. In younger patients predisposing factors include:
- previous joint trauma/surgery/intra-articular bleeding
- primary hyperparathyroidism
- hereditary haemochromatosis
- hypophosphatasia
- wilton’s disease.

Clinical presentation

Chondrocalcinosis may be asymptomatic and is frequently seen on plain radiographs of the knees. Presentation can mimic OA, RA or neuropathic joints. Acute attacks present as pain and effusion in a large joint (knees, wrists, shoulders). It may thus mimic gout, although the big toe is seldom affected and symptoms are usually less acute, less severe and more prolonged. Systemic upset and fever may occur.

Investigation

- Joint aspiration: for confirmation of diagnosis and exclusion of gout and septic arthritis. Aspirated fluid is turbid and CPPD crystals are found which are rhomboid or oblong with blunt ends and exhibit positive birefringence under polarised light microscopy.
- Routine blood tests: leucocytosis is common and the ESR and CRP are markedly raised.
- Radiology: chondrocalcinosis is typically evident in affected joints ± changes of osteoarthritis.
- Screening for predisposing causes: e.g. serum calcium and parathyroid hormone, serum ferritin/ transferrin saturation, serum caeruloplasmin.

Management

Acute episodes

In addition to joint aspiration, treatment options include:
- NSAIDs
- corticosteroids: in patients in whom NSAIDs are contraindicated. Intra-articular injection is appropriate in most cases, but a short course of oral prednisolone is an alternative.

Prognosis

Acute gout is self-limiting even without treatment. Recurrences are common and may occur even in the face of successful biochemical control of hyperuricaemia.
Long-term control
Underlying metabolic disorders should be treated. There is no specific therapy for pseudogout, although low-dose colchicine may be tried.

Prognosis
Most acute episodes resolve within days, although low-grade inflammation may persist.

Miscellaneous rheumatological disorders
Carpal tunnel syndrome
Entrapment of the median nerve as it passes under the flexor retinaculum causes carpal tunnel syndrome. Although it may occur spontaneously, recognised associations include pregnancy, RA, previous wrist trauma/fracture, hypothyroidism, acromegaly and amyloidosis. Bilateral disease is relatively common, especially in the presence of an underlying systemic disorder, although symptoms are usually worse on one side than the other.

Clinical presentation
- Sensory disturbance (pain and paraesthesia) affecting the radial three-and-a-half digits, worse at night. Some patients report symptoms in the whole hand and extending up the forearm.
- Impaired function with clumsiness may be a feature.
- Symptoms may be relieved by hanging the arm out of bed at night or shaking the hand.

Physical examination can be normal, especially if symptoms are intermittent. When present, sensory disturbance is evident over the thumb, index and middle fingers, while the ring finger shows a loss of sensation on its radial border with preservation on the ulnar aspect; sensation in the little finger is also normal. In long-standing cases, there may be wasting and weakness of the muscles of the thenar eminence. Two additional clinical tests that are often employed to reproduce the patient’s symptoms are:
  - Tinel’s test: percussion over the median nerve as it passes under the flexor retinaculum.
  - Phalen’s test: in which the wrist is maintained in a fixed flexion position.

Investigation
- Nerve conduction studies: confirm compression of the median nerve at the wrist.
- Perform investigation of underlying causes as indicated clinically.

Management
Treatment is dictated by the severity of the condition but may involve:
- splinting of the wrists at night
- injection of corticosteroids
- surgical decompression of the flexor retinaculum.

Prognosis
Complete resolution of symptoms is usually achievable except in the most long-standing cases when permanent nerve damage has occurred.

Septic arthritis
Septic arthritis is a rheumatological/orthopaedic emergency. Although it may occur in patients of any age or gender, it is more common in the very young, the elderly, those with pre-existing abnormal/damaged joint(s), immunocompromised individuals and intravenous drug users.

Bacteria reach the joint through one of three routes:
- direct inoculation, e.g. following a penetrating injury, joint injection or surgery
- haematogenous spread during an episode of bacteraemia
- spread from neighbouring soft tissue (cellulitis) or bone (osteomyelitis) infection.

The most commonly implicated organisms include *Staphylococcus aureus*, β-haemolytic streptococci, Gram-negative bacilli (e.g. *Escherichia coli*, *Pseudomonas*) and *Neisseria gonorrhoea*.

Clinical presentation
The sudden development of a painful/swollen joint in the context of pre-existing infection or in a patient with otherwise quiescent chronic joint disease should be assumed to be septic arthritis until proven otherwise.

Usually a single joint is affected (most commonly the knee), but several sites may be involved. Septic joints are very painful and are often held immobile to minimise discomfort. Systemic upset with pyrexia ± rigors is common, but occasionally the patient may appear otherwise well.

Gonococcal infection may present with polyarthralgia and a migratory arthritis, associated with a purpuric rash – clinically apparent genital infection is not always present.

Investigation
- Joint aspiration: joint fluid is turbid and microscopy excludes crystal arthropathy; a Gram stain may confirm the presence of bacteria, although the
results of formal culture are required to confirm a bacterial origin and identify the organism.
- Routine blood tests: leucocytosis is common and the ESR and CRP are raised.
- Blood cultures: may confirm bacteraemia and identify an organism.
- Radiology: narrowing of the joint space signifies destruction of cartilage.

Management
Following joint aspiration, empiric intravenous antibiotic therapy should be commenced, pending definitive identification of an organism. The initial choice of antibiotics must cover the most likely organisms, *Staphylococcus aureus* and β-haemolytic streptococci. The intravenous route should be continued for 7–14 days depending on local microbiological and rheumatological/orthopaedic advice. Oral antibiotics are normally required for a further 3–4 weeks.

Repeated joint aspiration ± surgical drainage/lavage may be indicated.

Prognosis
Early recognition and treatment are critical to preventing joint damage and destruction. Osteomyelitis and septicemia may complicate cases in which the diagnosis is delayed.

Shoulder pain

Frozen shoulder
This is a relatively common and potentially disabling condition affecting 1–2% of the middle-aged and elderly population. For reasons that are unclear, the joint capsule becomes adherent to the overlying rotator cuff muscles.

It is typically unilateral and characterised by progressive pain and reduced mobility. Untreated, improvement with time is generally the rule but may take up to 2 years. Intra-articular injection of corticosteroid may help ease the pain and should be combined with regular exercises to restore movement.

Rotator cuff tendonitis
Repetitive or unaccustomed movements of the shoulder may result in inflammation of one or more of the rotator cuff muscle tendons (e.g. supraspinatus). Pain during abduction, flexion or rotation of the shoulder is often accompanied by point tenderness. Plain radiology may show tendon calcification, but an ultrasound or MRI scan will demonstrate oedema or tears within the tendon. Treatment options include NSAIDs, physiotherapy, local injection of corticosteroids and surgery.

Rotator cuff degeneration
This is commonly seen in the elderly patients who have restricted shoulder movements in all directions which limit activities of daily living. Local injection of corticosteroids may be tried, but the underlying pathological process tends to be progressive.

Back pain

Mechanical back pain
Typically this comes on suddenly and the precipitating episode is readily identified (e.g. lifting a heavy object). It may also arise more gradually particularly in relation to repetitively adopting a fixed posture. On examination there is localised tenderness and restricted movement but neurological examination is normal.

Investigation should be considered if symptoms persist. Advice regarding posture and lifting techniques, avoidance of bending, adjustments to work/leisure activities, etc. is usually all that is required. Simple analgesics and heat therapy may help during the acute phase; some patients advocate manipulation or acupuncture by an experienced practitioner.

Vertebral disc prolapse
Bulging of the gelatinous central nucleus pulposus through the annulus fibrosus of the intervertebral disc most commonly occurs in a posterolateral direction, and may lead to impingement of the nerve roots as they emerge from the spinal cord. Less commonly, direct posterior protrusion threatens the cord itself (e.g. lumbar disc protrusion can result in spinal stenosis and the cauda equina syndrome).

Sudden cervical or lumbar disc protrusion is associated with pain in the neck or lower back, which is referred down the upper or lower limbs (e.g. sciatica). There is often associated sensory disturbance.

MRI scanning of the spine is preferred for demonstrating disc protrusion and nerve root/spinal cord impingement.

In addition to simple measures (advice regarding posture, lifting techniques, avoidance of bending, adjustments to work/leisure activities, etc.), local/epidural injection of corticosteroids/local anaesthetic may be helpful. Surgical decompression should be considered in those with persistent symptoms or if there is cord impingement.

Vertebral crush fracture
This is most commonly seen in middle-aged to elderly females in the context of osteoporosis of the thoracic spine. Sudden vertebral collapse results in abrupt
onset of severe pain. Long-term involvement at several levels may result in kyphosis.

Plain radiographs confirm the extent of vertebral involvement. Further investigation is geared towards excluding other underlying conditions (e.g. malignant infiltration), screening for osteoporosis and identifying potentially reversible causes of the latter. Achieving adequate pain control can be challenging and may require opioid analgesia. Osteoporosis is treated along conventional lines. If there are neurological symptoms/signs, then MRI scanning should be undertaken urgently.

Systemic Still's disease
Juvenile-onset (juvenile idiopathic arthritis)

This is a childhood disease which usually presents with:

- constitutional upset
- fever
- skin rashes
- joint pain in 75% of cases at onset which may be monoarticular (30%)
- persistent joint swelling (knee, ankle, wrist and small joints of the hands and feet)
- eye changes: chronic iridocyclitis (10%), corneal band opacity and cataracts
- lymphadenopathy, splenomegaly and pericarditis
- one-third of patients present with a history of insidious polyarthritis similar to adult RA, but rheumatoid factor is usually not detected
- growth retardation may result from the primary condition and/or its treatment (e.g. corticosteroid therapy).

The aetiology remains unclear, with both genetic and environmental factors (e.g. viral infections) implicated. Physiotherapy, NSAIDs and intra-articular corticosteroid injections are used in treatment. Other immunosuppressive agents (e.g. methotrexate) and the TNFα inhibitor etanercept may also be required in refractory cases with more extensive joint involvement.

Adult-onset

An acute systemic inflammatory disorder of unknown aetiology, onset is typically between 16 and 35 years of age, with both sexes affected approximately equally. It is characterised by:

- high spiking fever
- evanescent rash
- arthralgia/arthritis
- sore throat
- generalised myalgia
- weight loss
- lymphadenopathy
- splenomegaly
- pleurisy
- pericarditis
- neutrophil leucocytosis
- renal/hepatic abnormalities.

In the absence of a specific disease marker, the diagnosis is based on clinical features: the presence of five or more criteria, including at least two major, has a diagnostic sensitivity of > 95% and specificity of > 90%:

- major: spiking fever (≥ 39 °C for ≥ 1 week), arthralgia (≥ 2 weeks), typical rash, leucocytosis (> 10 × 10⁹/l, with > 80% neutrophilia)
- minor: sore throat, lymphadenopathy and/or splenomegaly, liver dysfunction, negative anti-nuclear antibody and rheumatoid factor screens
- exclude: infections, malignancies and other rheumatological disorders.

Marked elevation of serum ferritin is a key finding in most patients and correlates with disease activity. The ESR and CRP are also normally significantly elevated. Aspirin and other NSAIDs may help as first-line therapy, but long-term treatment with corticosteroids is required in at least half of all patients. DMARDs and TNFα inhibitors may be required.

Acute rheumatic fever

This acute febrile systemic disorder affects mainly the heart and joints following a streptococcal infection (group A, β-haemolytic) and usually occurs between the ages of 5 and 15 years. The diagnosis is made when there is evidence of previous streptococcal infection plus one major and two minor or two major (Jones) criteria.

In the section below, double asterisks denote major criteria, single asterisks minor criteria.

Clinical presentation

Symptoms

The disease usually presents with:

- flitting polyarthritis*: common in adults
- carditis*: common in children
- arthralgia*: exquisitely tender joints and history of streptococcal infection of the throat or skin 10–20 days previously
- chorea*: Sydenham’s chorea; usually in children.

Signs

The dominant features are:

- fever*
- flitting arthropathy of large joints (small joints may be affected in the elderly)
• erythema nodosum and erythema marginatum: more common in children
• symmetrical subcutaneous nodules: over bony prominences and extensor surfaces in children correlating with severe carditis
• myocardiitis: tachycardia, cardiomegaly, heart failure
• endocarditis: any valve may be involved and cause transient murmurs. A transient mitral diastolic murmur (Carey Coombs) is the most common. Mitral systolic and aortic murmurs also occur
• pericarditis: friction rub or small effusion

Investigation
• raised or rising antistreptolysin (ASO) or DNAase titre: evidence of preceding group A streptococcal infection
• throat swab: haemolytic streptococci may be isolated
• leucocytosis and hypochromic normocytic anaemia
• ESR and CRP elevated
• ECG: may show first-degree heart block or other rhythm disorder
• chest X-ray: progressive cardiac enlargement

Management
• Anti-inflammatory therapy: aspirin or other NSAIDs can be tried.
• Corticosteroids may be required, especially if there is evidence of cardiac involvement.
• Antistreptococcal therapy: intravenous benzylpenicillin during the acute phase and oral phenoxy-methylpenicillin continued in those with cardiac involvement for at least 5 years and preferably until 20 years of age to prevent recurrence. Erythromycin may be used for patients sensitive to penicillin.
• Neuroleptics: may help with chorea.

Postinfectious arthralgia
Low-grade (poly)arthritis frequently follows some infections, e.g. glandular fever, Rubella, Mycoplasma pneumoniae and viral hepatitis, and may persist for months or years. The association with erythema chronicum migrans is seen in Lyme disease following tick-borne infection with the spirochaete Borrelia burgdorferi.

Fibromyalgia
The lack of evidence of underlying musculoskeletal pathology means that fibromyalgia is often considered in the same category as other so-called ‘functional (non-organic) syndromes’. It also often coexists with depression and other psychiatric disorders, and this means that a diagnosis of fibromyalgia often attracts a degree of stigma. Some have proposed that it be considered first and foremost as a disorder of bodily perception, in which pain is perceived centrally even in the absence of a peripheral cause – added to which, affected individuals often exhibit features of somatisation, i.e. the expression of psychological distress in physical terms. Factors which are recognised to exacerbate fibromyalgia include sleep deprivation and depression.

Classically, patients present with widespread pain and disability, together with marked generalised tiredness/fatigue. Review of the past medical history may reveal other unexplained physical symptoms (e.g. headache, dizziness, breathlessness, chest pain, gynaecological symptoms).

The lack of a specific diagnostic test means that fibromyalgia is often a diagnosis of exclusion, based on clinical features. However, it is reasonable to arrange a simple panel of tests to exclude other causes including: full blood count, ESR, CRP, renal and liver biochemistry, CK, thyroid function tests, antinuclear antibodies, myeloma screen (in those >50 years of age) and a plain chest X-ray (especially in smokers). It is desirable to avoid over-investigation, which can reinforce the patient’s belief that there is an underlying physical cause.

Once the clinician is satisfied that there is no underlying physical disorder, it is important to openly discuss the diagnosis with the patient – while some argue that the label ‘fibromyalgia’ is unhelpful and may lead to stigmatisation, others find it helpful in that it allows a ‘diagnosis’ to be made and a management strategy planned – understanding the individual patient’s needs is a key part of effective management. Options include:

• Cognitive behavioural therapy ± antidepressants.
• Low-dose tricyclic antidepressants (e.g. amitriptyline) to improve sleep quality and help with pain management.
• Programmes to improve physical fitness.
• Avoidance of factors that precipitate exacerbations.
• Involvement of the liaison psychiatry and pain management teams.
• In addition, it is important to consider the issues of the ‘sick role’ and ‘secondary gain’ as tackling these may help to improve outlook more than any of the other interventions.
Skin disorders are common and a frequent mode of presentation to general practitioners. They are often associated with not only physical but also significant psychological effects due to their general visibility. In some instances they may be indicative of underlying systemic disease.

Psoriasis

Psoriasis is a relatively common disorder affecting 1–2% of the population. Classically it presents with red, raised, scaly patches or plaques, which reflect increased keratinocyte proliferation within the epidermis, associated with an inflammatory cell infiltrate (including polymorph microabscesses). There is also increased vascularity within the upper dermis.

The aetiology of psoriasis remains relatively poorly understood. Although there is clearly a genetic component, with younger patients in particular often reporting a positive family history, patterns of inheritance vary and further studies are ongoing to try to understand which genetic factors are at play. In addition, it remains unclear why some areas of skin are affected, but others remain normal in the face of an underlying genetic predisposition. Triggers that can be associated with the development or flare-up of psoriasis in susceptible individuals include infections and trauma, and possibly stress, although the latter is contested by some dermatologists.

Clinical presentation

Several different patterns of psoriasis are recognised, some of which are common, while others are only rarely seen. The key clinical features of each subtype are shown in Table 19.1 and Plates 19.1–19.4.

Psoriatic arthropathy

Arthropathy occurs in 5–10% of patients with psoriasis and may take one of several forms:

- predominant distal interphalangeal joint involvement
- symmetric polyarthritis (seronegative rheumatoid-like changes)
- asymmetric oligo/pauciarticular arthritis
- spondylitis (+ sacro-ileitis) with stiffness in the back/neck; HLA B27 positive
- arthritis mutilans, a severe deforming destructive arthritis.

Nail changes are common in patients with psoriatic arthropathy, but not all cases are associated with skin disease.

Treatment

Topical agents

- Emollients help to control scaling.
- Salicylic acid reduces hyperkeratotic, scaling lesions; often used in combination with coal tar, dithranol or topical corticosteroids.
- (Coal) tar is effective but unpleasant to use; typically reserved for scalp involvement; sometimes used in combination with ultraviolet (UV) radiation therapy (see below).
- Dithranol is effective for chronic plaque psoriasis; applied directly to lesions (may be covered with a dressing) and left for up to an hour (occasionally longer, but only under supervision); dithranol is irritant (start with 0.1% and gradually increase as required/tolerated) and stains skin, hair and bedding/clothes brown; avoid use on the face or in flexures; may be combined with tar and UV radiation.
<table>
<thead>
<tr>
<th>Type</th>
<th>Clinical features</th>
<th>Specific treatment(s)</th>
</tr>
</thead>
</table>
| Classical plaque psoriasis   | • Single or multiple red plaques, ranging from a few millimetres to several centimetres in diameter  
• Scaly surface – gentle scraping yields a silvery appearance; more vigorous rubbing may result in focal haemorrhage (Auspitz sign)  
• Plaques most commonly develop on extensor surfaces – elbows, knees – but may affect any part of the body – typically in a symmetrical manner  
• Most plaques are chronic and stable, although some will evolve/coalesce slowly over time, while others may disappear. New lesions may develop at sites of trauma (Köbner phenomenon)  
|                              | • First choice options include vitamin D analogues, dithranol, topical corticosteroids (± tar or salicylic acid)  
• UV radiation therapy may be helpful  
• For more severe cases consider PUVA, cytotoxics, retinoids or biological agents |
| Scalp psoriasis              | • Commonly coexists with classical plaque psoriasis, but may occur in isolation  
• Varies from one or two isolated plaques to a thick scaly sheet covering the whole scalp  
|                              | • Tar shampoos/gels may be effective (± salicylic acid)  
• Topical corticosteroids (± salicylic acid) can also be used |
| Nail psoriasis               | • Pitting – typically large/irregular  
• Onycholysis – separation of the nail plate from the nail bed; often begins as a small area of red/brown discolouration, but may spread to involve the whole nail  
|                              | • Often difficult to treat with topical agents; however, use of systemic agents is seldom justified |
| Guttate psoriasis            | • Typically presents suddenly with a ‘shower’ of small round plaques, often on the trunk  
• May develop after an infective episode (especially streptococcal sore throat)  
• More likely to be itchy than other forms of psoriasis  
• Lesions may regress rapidly even without treatment  
|                              | • First choice therapy is UV radiation (± tar, emollients)  
• Topical vitamin D analogues and corticosteroid therapy (often in combination) may be effective |
| Flexural psoriasis           | • May accompany plaque, scalp or nail psoriasis or occur in isolation  
• Affects groin, axillae, natal cleft, submammary folds  
• Maceration of the skin can result in marked redness and loss of the typical scaly appearance  
• Often itchy  
|                              | • Difficult to treat: tar-based therapies and topical corticosteroids may help, but long-term use can lead to skin atrophy/striae  
• Low-strength dithranol or vitamin D analogues can be tried but often cause local stinging/irritation |
| Brittle psoriasis            | • Thinner scales  
• May develop in a patient with previously stable plaque psoriasis  
• Rapid generalisation/coalescence of lesions leads to erythroderma or acute pustular psoriasis (see below)  
• Episodes may be triggered by use of potent topical or systemic corticosteroid therapy  
|                              | • Requires careful management under expert supervision  
• Emollients may be tried, but PUVA or systemic therapy (e.g. methotrexate or retinoids) is often required |
<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
<th>Treatment/Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythrodermic psoriasis</td>
<td>Occurs when plaques merge to involve most or all of the skin</td>
<td>Requires urgent dermatological review; may become life-threatening if treatment is delayed</td>
</tr>
<tr>
<td></td>
<td>May develop rapidly and occasionally arises <em>de novo</em></td>
<td>Methotrexate or ciclosporin are effective</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Biological agents are finding increasing use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>As for erythrodermic psoriasis</td>
</tr>
<tr>
<td>Acute pustular psoriasis</td>
<td>Characterised by widespread erythema with sterile pustules, which may coalesce</td>
<td>As for erythrodermic psoriasis</td>
</tr>
<tr>
<td></td>
<td>Associated with systemic upset, including fever</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Secondary bacterial infections may be life-threatening if not treated promptly</td>
<td></td>
</tr>
<tr>
<td>Chronic palmo-plantar pustulosis</td>
<td>Erythematous patches with multiple pustules, which dry to form circumscribed brown areas that eventually peel off</td>
<td>Difficult to treat; topical measures are usually ineffective</td>
</tr>
<tr>
<td></td>
<td>May affect only a small area of one hand or foot or involve the entire surface of both palms and soles</td>
<td>PUVA or oral retinoid therapy may be tried, but relapses are common</td>
</tr>
</tbody>
</table>
• **Topical corticosteroids** may suppress (although not eradicate) lesions (e.g. scalp, flexures), but should be used with care (risk of precipitating brittle or erythrodermic psoriasis) (Table 19.1).
• **Vitamin D analogues** (e.g. calcipotriol, tacalcitol) and **activated vitamin D** (e.g. calcitriol) are useful in mild to moderate psoriasis; serum calcium levels must be monitored in those using larger doses.
• **Tazarotene** is a retinoid; irritant, especially if applied to normal skin.

**Phototherapy**

• **UVB radiation** is effective in the treatment of chronic stable psoriasis and guttate psoriasis, especially when topical agents have proved ineffective; must be used with care due to risk of sunburn; typically given as short courses, e.g. 2–3 times per week until clearance is achieved; combination with coal tar, dithranol or vitamin D analogues increases efficacy.
• **Photochemotherapy** (psoralens and ultraviolet A phototherapy (PUVA)). Psoralens (given either by mouth or topically) enhance the effect of UV radiation; treatment is typically given twice weekly, and protective glasses are required to avoid ocular damage. Higher cumulative doses exaggerate skin ageing and are associated with an increased risk of keratoses and neoplastic lesions (especially squamous carcinoma).

**Systemic therapy**

• **Methotrexate**. Once weekly dosing, together with folic acid; effective in severe psoriasis refractive to topical therapy; patients should be advised of potential adverse effects including myelosuppression (sore throat, mouth ulceration, abdominal pain, dark urine), respiratory effects (shortness of breath), inhibition of spermatogenesis and teratogenicity (effective contraceptive measures must be in place before treatment is commenced).
• **Retinoids** (e.g. acitretin) are reserved for severe, resistant psoriasis. Side effects include dryness and cracking of skin and lips, epistaxis, transient hair loss, myalgia, hepatotoxicity, hyperlipidaemia and teratogenicity (effective contraceptive measures must be in place before treatment is commenced).
• **Ciclosporin** (cyclosporin) is effective even in very severe psoriasis; nephrotoxic and requires close monitoring of renal function, especially in the early stages of treatment; avoid concomitant UVB/PUVA therapy.
• **Biological agents**. Anti-TNFα therapies (e.g. etanercept, adalimumab, infliximab) may be used in very severe plaque psoriasis that has failed to respond to systemic treatments and to photo(chemo)therapy, or in cases where standard treatments are not tolerated/contraindicated. Ustekinumab (a monoclonal antibody that targets interleukins 12 and 23) has also shown benefit.
• **Systemic corticosteroids**. Only rarely indicated and must be given under expert supervision.

Table 19.1 shows preferred treatment options for each subtype of psoriasis. Psoriatic arthropathy often responds to simple anti-inflammatory agents. In more severe cases, methotrexate or biological agents can be tried.

**Eczema/dermatitis**

Although the term ‘dermatitis’ is sometimes used specifically to describe skin inflammation caused by an exogenous agent, it is in fact synonymous with the term ‘eczema’ (Greek, meaning ‘boiling over’). Eczema is common, affecting approximately 10% of the population at some stage during life.

**Clinical presentation**

In acute eczema the skin is erythematos and oedematous, with papules/vesicles and weeping (i.e. ‘boiling over’). In chronic eczema, oedema is absent and the epidermis becomes thickened/hyperplastic, with exaggeration of the skin markings (so-called lichenification) (Plate 19.6). Itching may be the dominant symptom. Secondary infection is common: bacterial (commonly staphylococcal) or viral (herpes simplex). Healed lesions do not scar, but may pigment.

Secondary spread to involve other areas is a well-recognised phenomenon of acute eczema and may even involve areas that have not been directly exposed to a particular allergen in cases of contact dermatitis. Rarely, the whole of the body may be affected by a generalised exfoliative dermatitis.

Several different patterns of eczema are recognised; the key clinical features of each subtype are shown in Table 19.2 and Plates 19.5–19.7.

**Treatment**

Wherever possible, the local irritant or sensitizer should be removed. Many commercial soaps contain such irritants and washing with water ± soap substitutes is advised. If the lesion is weeping, local soaks, e.g. potassium permanganate (antiseptic and astrin- gent) may aid healing; if dry, emollients should be applied liberally and regularly to the affected areas – bath/shower oils may further help. Continued emollient use is required even when the acute episode has subsided. Sedative antihistamines by mouth may relieve pruritus and allow sleep. Bandages (including those containing zinc and ichthammol) may be applied over topical corticosteroids (see below) or
### Table 19.2 Causes, clinical features and specific treatments for different types of eczema (dermatitis)

<table>
<thead>
<tr>
<th>Type</th>
<th>Subtype</th>
<th>Epidemiology/aetiopathogenesis</th>
<th>Clinical features/investigation</th>
<th>Specific treatment(s)</th>
</tr>
</thead>
</table>
| Exogenous eczema  | Primary irritant dermatitis (Plate 19.5) | • Direct exposure of the skin to water and soaps/detergents or other solvents (e.g. petroleum products), removes the protective lipid layer and provokes an inflammatory response from keratinocytes  
• Delayed (type IV) hypersensitivity reaction to an external antigen  
• Examples include:  
  - nickel (in jewellery and metal clips/studs in clothing)  
  - perfumes, hair dyes  
  - latex, rubber chemicals, epoxy resin  
  - chromate (used in industrial processes)  
  - plants (e.g. hogweed)  
  - medicaments (e.g. antibiotics, antihistamines, topical corticosteroids, vehicle/preservatives)  
  - fungal, viral, parasitic infections |
|                   | Allergic contact dermatitis           | • Most commonly affects the hands, which are often repeatedly immersed in the irritant  
• Characterised by dryness and painful fissures |
|                   |                                      | • A detailed history should be taken including occupation (past and present), hobbies, use of perfumes/skin creams and medications  
• Distribution/pattern may suggest a specific allergen (e.g. at sites of earrings, metal clips on underwear, on scalp)  
• Patch testing may be required with a battery of standard allergens and/or specific suspected allergens (e.g. occupational) |
|                   |                                      | • Remove from contact with irritant or protect skin (e.g. use of gloves)  
• Liberal use of emollients |
|                   |                                      | • Avoidance of the offending allergen is crucial to successful prevention/treatment  
• Emollients and topical corticosteroids may be used to settle a patch of eczema |
| Endogenous eczema  | Atopic eczema (Plate 19.6)            | • Typically presents in infancy or early childhood; may resolve in later childhood/adulthood  
• Genetic predisposition coupled with environmental trigger(s)  
• Altered immune function with antigen responses diverted down the Th2 pathway, leading to enhanced IgE production |
|                   |                                      | • Positive family history in many cases  
• Associated features include tendency to asthma and rhinitis/conjunctivitis  
• Eczema may be generalised in early stages but usually settles into a pattern involving flexural surfaces (e.g. wrists, antecubital and popliteal fossae, dorsal surfaces of feet) |
|                   |                                      | • Provision of information/explanatory leaflets  
• Reduce exposure to soap and water  
• Liberal use of emollients (soap substitutes, bath oils, emollient creams)  

(Continued)
<table>
<thead>
<tr>
<th>Type</th>
<th>Subtype</th>
<th>Epidemiology/aetiopathogenesis</th>
<th>Clinical features/investigation</th>
<th>Specific treatment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>• Associated with disordered epidermal barrier function with reduced filaggrin expression in some patients</td>
<td>• Skin is dry and itchy • Repeated scratching leads to skin thickening (= lichenification) • Clinical course is often characterised by episodic exacerbations • May be complicated by secondary bacterial (foliculitis, impetigo) or viral (herpes simplex) infections, which can be life-threatening • Serum IgE levels are often raised</td>
<td>• Topical corticosteroids: aim to use the lowest strength preparation that is sufficient to control the condition; combination preparations including an antibacterial may be useful in those prone to secondary bacterial infection • Systemic antibacterial and/or antiviral therapy when obvious secondary infection is present • Topical tacrolimus or pimecrolimus may help in more refractory cases, while oral ciclosporin can be used for severe eczema. Short courses of systemic corticosteroids may also be helpful in poorly controlled eczema, but prolonged/repeated courses should be avoided • Wet wraps and antihistamines help with itchiness • Topical antifungal therapy ± topical hydrocortisone cream • Ketoconazole-containing shampoo for scalp involvement • Treatment of secondary bacterial infection • Very occasionally systemic corticosteroids are required for widespread involvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Colonisation with exotoxin-producing staphylococci may also contribute to pathogenesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seborrhoeic dermatitis</td>
<td>(Plate 19.7)</td>
<td>• Affects 1–2% of the population; more common in fairer-skinned individuals • Onset in young adulthood or middle age • Postulated to be a response to an antigen of the yeast <em>Malassezia</em> • More common and severe in the presence of HIV/AIDS</td>
<td>• Three patterns of involvement: - scalp, face (nasolabial folds, forehead, eyebrows) - sternum, upper back - flexures (axillae, groin, submammary areas) • Chronic condition requiring long-term treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Clinical Features</td>
<td>Treatment Options</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous (varicose) eczema</td>
<td><em>Typically seen in the context of chronic venous hypertension</em></td>
<td><em>Affects lower legs/gaiter area; initially may be unilateral, but often spreads to involve other leg, upper limbs and even the trunk</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Exacerbated by dry/warm environments and excessive bathing</em></td>
<td><em>Topical corticosteroids</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Compression therapy (check ankle-brachial pressure index first to exclude vascular insufficiency)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discoid eczema</td>
<td><em>In the absence of atopy, and with negative patch testing/mycology, a diagnosis of pompholyx (idiopathic vesicular eczema of the palms and soles) should be considered</em></td>
<td><em>Exclude ringworm</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Well-demarcated patches of eczema on the limbs and trunk</em></td>
<td><em>Topical corticosteroids control the condition</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Tends to wax and wane</em></td>
<td><em>Topical corticosteroids</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Typically symmetrical</em></td>
<td><em>Altretinoin reserved for severe/refractory hyperkeratotic hand eczema</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Bullae formation may occur in pompholyx</em></td>
<td><em>Treatment of secondary bacterial infection</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hand and foot eczema</td>
<td><em>In the absence of atopy, and with negative patch testing/mycology, a diagnosis of pompholyx (idiopathic vesicular eczema of the palms and soles) should be considered</em></td>
<td><em>Potassium permanganate soaks may also help in pompholyx</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Typically symmetrical</em></td>
<td><em>Minimise triggers</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Emollients</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Mild topical corticosteroids occasionally required</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asteatotic eczema</td>
<td><em>Really a consequence of normal ageing, with reduced lipid content in the stratum corneum resulting in reduced water retention</em></td>
<td><em>Itchy</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus; IgE, immunoglobulin subtype E; Th2, T-helper 2 cell.
emollients to treat eczema of the limbs. Systemic antibiotics are required for secondary bacterial infections and antiviral therapy for cases complicated by herpes simplex infection. Antifungal therapy may be useful in cases of seborrhoeic dermatitis where the yeast Malassezia is implicated.

Topical corticosteroids remain the mainstay of treatment for most patients with eczema. The potency of the corticosteroid should be appropriate for the site and severity of the condition, e.g. weaker preparations are preferred for the face and on flexures, while more potent preparations may be required on the limbs/trunk, especially if there is associated lichenification.

In more severe/refractory cases immunomodulatory agents can be tried, including topical tacrolimus or pimecrolimus and oral ciclosporin. The oral retinoid altretinoin is also licensed for the treatment of severe chronic hand eczema refractory to potent topical corticosteroids (cautions and adverse effects are similar to those of other retinoid preparations; pregnancy must be excluded and effective contraception practised).

Table 19.2 shows preferred treatment options for each subtype of eczema.

Investigation

In the majority of patients investigation is not required, but disorders associated with hyperandrogenism should be considered in female subjects with later onset disease or in the presence of virilising features (e.g. Cushing syndrome, androgen-secreting tumours).

Treatment

Options include:
- over-the-counter preparations – effective in milder cases and work mainly as astringents/keratolytics, drying the skin and unblocking hair follicles
- topical benzoyl peroxide – astringent, keratolytic and delivers oxygen locally, reducing bacterial proliferation without inducing resistance; may cause local skin irritation
- topical antibiotics – e.g. tetracyclines, erythromycin, clindamycin; effective in the early stages of treatment, but resistance often develops
- topical retinoids – e.g. isotretinoin, adapalene; reduce sebum production and attenuate inflammation
- oral antibiotics – e.g. tetracyclines, erythromycin; both antibacterial and anti-inflammatory
- oral isotretinoin (Roaccutane®) – shrinks sebaceous glands, dramatically reducing sebum production; side effects are common, including facial erythema, dry skin and lips, nose bleeds, myalgia, hyperlipidaemia and abnormal liver function tests. It is teratogenic: pregnancy must be excluded and reliable contraception established before commencing treatment.

Patients should be warned that most treatments take several months of continued use before benefits become apparent.

It is important to tackle underlying disorders when present (e.g. promoting weight loss in overweight/obese females with polycystic ovarian syndrome; treating Cushing syndrome).

The role of UV light therapy in treating active acne and healing scar tissue is currently under investigation.

Acne vulgaris

Acne vulgaris is a disease chiefly of puberty (but onset can occur up to 40 years of age, and even at later ages if there is an underlying endocrine disorder, e.g. Cushing syndrome) in which androgens (typically in normal amounts) promote increased sebaceous gland activity, leading to greasy skin. Hyperkeratosis results in plugging of hair follicles, and subsequent secondary infection with the obligate anaerobe Propionibacterium acnes leads to release of chemicals into the surrounding dermis, which provoke an intense inflammatory response.

Clinical presentation

Several different lesions may be seen:
- Comedones – closed (‘whitehead’) or open (‘blackhead’)
- Papules and pustules – spots or pustules on a red base; may recur repeatedly in the same locations
- Nodules and cysts – seen in more severe cases, as inflammation extends deeper; if these are numerous they are referred to as ‘acne conglobata’; very rarely nodulocystic acne is associated with fever, malaise and systemic upset (‘acne fulminans’)
- Scars – these may be pitting and disfiguring, and in extreme cases associated with keloid formation.

Rosacea

This is a disorder, more common in women, beginning usually after 30 years of age, with erythema, papules, pustules and telangiectasia over the cheeks, nose, chin and forehead. It may be mistaken for acne, but there are no comedones. Flushing is common, especially in warm environments or in response to alcohol. In men, sebaceous hyperplasia on the nose leads to the condition ‘rhinophyma’.
Oral tetracyclines are preferred for treatment but as with acne take several months to produce maximum benefits. Topical metronidazole may also be added. Oral isotretinoin can be effective in more resistant/severe cases. Plastic surgery may be required for rhinophyma. Precipitating factors should be avoided (e.g. hot drinks, warm environments, alcohol, sunlight, topical corticosteroids).

**Hidradenitis suppurativa**

A rare disorder characterised by relapsing suppurative infection in the axillae and groins – sites at which apocrine glands open into pilosebaceous follicles. It is more commonly seen in females, and flare-ups may correlate with changes in hormonal levels, e.g. in the menstrual cycle. Obesity exacerbates, but does not cause, the condition. Recurrent painful abscesses and sinus tracks develop, which discharge unpleasant material. Although oral antibiotics and oral isotretinoin can be tried, success is usually limited and surgical intervention is often required to lay open the sinus tracks and excise chronically infected areas.

**Bacterial, viral, fungal and parasitic skin infections**

A number of different organisms are capable of causing primary cutaneous infections/infestations. The more commonly encountered pathogens and their associated clinical sequelae are shown in Tables 19.3–19.6 and Plate 19.8.

**Cutaneous drug reactions**

Cutaneous drug reactions are relatively common and may arise through one of several different mechanisms:

- intolerance
- hypersensitivity (types I, II, III and IV)
- interactions with other drugs
- interactions with other environmental or host factors (e.g. sunlight exposure)
- pharmacokinetic disturbances

Table 19.7 show the different types of eruption that may be encountered. Drugs that are particularly prone to causing cutaneous reactions include antibiotics (e.g. sulphonamides, penicillins – although not all patients who state they are ‘penicillin allergic’ are truly allergic!), NSAIDs and hypnotics/tranquilisers.

Key features of the major types of drug reaction are described below.

**Clinical features/causative agents**

**Exanthematous eruptions**

- variable speed of onset – typically starts within the first few days of treatment, but may develop more quickly (e.g. within hours of exposure) or appearance may be delayed (e.g. several weeks, making the link more difficult to establish)
- usually widespread, symmetrical, erythematous maculopapular rash, often resembling a viral exanthem (Plate 19.9)
- itchy
- examples: penicillins, sulphonamides, NSAIDs

**Urticaria and anaphylaxis**

- secondary either to direct effect on mast cells or type I or type III hypersensitivity reaction
- eruption usually occurs 3–7 days after therapy is started
- rarely, rapid onset anaphylactic reactions (with fever, wheezing, arthralgia and hypotension) occur and are potentially fatal if not rapidly recognised and treated
- examples: penicillins, cephalosporins, aspirin, opioids, certain vaccines

**Eczema**

- type IV hypersensitivity reaction
- typically in response to a topical agent
- examples: lanolin, preservatives, topical antibiotics (especially aminoglycosides), topical antihistamines, topical local anaesthetics (although not lignocaine), topical corticosteroids

**Exfoliative dermatitis (erythroderma)**

- widespread reddening/inflammation of the skin ± scaling
- in more severe cases may be associated with loss of temperature regulation, dehydration, superadded infection, hyperdynamic circulation (± cardiac failure in the elderly)
- examples: phenytoin, sulphonylureas, sulphonamides, allopurinol, gold, barbiturates

**Fixed drug eruptions**

- typically manifests as a circular/oval patch of erythema with central purple discolouration ± bullous change
- single or multiple sites
- often initially misdiagnosed as ringworm infection
<table>
<thead>
<tr>
<th>Bacterium</th>
<th>Condition</th>
<th>Epidemiology/pathogenesis</th>
<th>Clinical features/investigation</th>
<th>Specific treatment(s)</th>
</tr>
</thead>
</table>
| *Streptococcus pyogenes*  | Cellulitis        | • Bacteria enter via minor abrasions, fissures or pre-existing ulcers  
   • More common in the presence of tinea pedis or peripheral oedema | • Affected area is red, hot and swollen  
   • Systemic upset is common  
   • Blood cultures should be taken in all patients with pyrexia/systemic features  
   • Positive antistreptolysin O (ASO) titre | • Oral or intravenous penicillin remains the treatment of choice for streptococcal infection depending on severity  
   • Elevate lower limbs  
   • Treat predisposing factors  
   • Surgical debridement if extensive tissue necrosis  
   • Consider prophylactic oral penicillin for prevention of recurrent episodes |
|                           | ‘Erysipelas’ is the term used to describe a well-demarcated superficial rash without oedema |                                                                                                                                                                                                                           |                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                  |
| Necrotising fasciitis     |                   | • Exotoxin-mediated tissue destruction  
   • Exuberant host inflammatory response may also be contributory | • Pain, which may initially appear disproportionate  
   • Rapid progression to extensive tissue necrosis  
   • Marked systemic upset  
   • Blood cultures may identify the underlying organism and direct more specific therapy | • Broad-spectrum intravenous antibiotics to cover all potential pathogens  
   • Early and aggressive tissue debridement |
| *Staphylococcus aureus*   | Folliculitis       | • Superficial infection of hair follicle(s) | • Small pustule(s) centred on follicle  
   • Painful abscess | • Topical or systemic antibiotic depending on extent  
   • Often resolve spontaneously  
   • Systemic antibiotic (e.g. flucloxacillin or erythromycin) ± drainage occasionally required  
   • Systemic antibiotic (e.g. flucloxacillin or erythromycin) ± drainage |
|                          | Furuncule (boil)  | • Deep infection of hair follicle | • Painful abscess |                                                                                      |
|                          | Carbuncle         | • Deep infection of a group of adjacent hair follicles | • Common on back/neck  
   • Erythema and suppuration with discharge from several follicles |                                                                                      |
|                          | Impetigo          | • Non-bullous impetigo is caused by *S. aureus*, streptococci or both organisms together  
   • Bullous impetigo is caused by *S. aureus*  
   • May complicate atopic eczema | • Non-bullous form is characterised by small pustules which rupture with crust ing exudates  
   • In the bullous form large superficial blisters form, which rupture with exudation and crusting | • Topical antibiotic (e.g. mupirocin) for localised infection  
   • Systemic antibiotic (e.g. flucloxacillin, erythromycin) for more extensive infection |

*Table 19.3 Bacterial infections involving the skin*
<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
<th>Investigations/Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scalded skin syndrome</td>
<td>- Caused by epidermolytic exotoxins produced by certain <em>S. aureus</em> phage types</td>
<td>- Extensive peeling of superficial epidermis, leaving a 'scalded skin' appearance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Intravenous flucloxacillin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Supportive measures (e.g. correction of fluid and electrolyte imbalances)</td>
</tr>
<tr>
<td>Scrofuloderma</td>
<td>- Spread to involve the skin overlying a tuberculous focus, e.g. lymph node</td>
<td>- Multiple fistulae</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Scar tissue</td>
</tr>
<tr>
<td>Lupus vulgaris</td>
<td>- Slow but progressive spread</td>
<td>- Reddish-brown nodular plaque</td>
</tr>
<tr>
<td></td>
<td>- Typically affecting head and neck with eventual destruction of cartilaginous structures if left unchecked</td>
<td>- Destruction of cartilage of nose and ears</td>
</tr>
<tr>
<td>Atypical mycobacteria</td>
<td>- E.g. <em>Mycobacterium marinum</em> in 'swimming pool' or 'fish tank' granuloma; direct inoculation into the skin</td>
<td>- Solitary granulomatous nodule at site of inoculation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Secondary spread along line of lymphatics</td>
</tr>
<tr>
<td>Leprosy</td>
<td>- Acquired through close physical contact or nasal spray</td>
<td>- Tuberculoid: one or two skin lesions only</td>
</tr>
<tr>
<td></td>
<td>- Clinical pattern of disease is determined by the host's immune response to the organism: tuberculoid (good), borderline (intermediate), lepromatous (poor response)</td>
<td>- Borderline: scattered skin lesions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Lepromatous: extensive skin lesions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Tuberculoid: rifampicin and dapsone for 6 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Lepromatous: rifampicin, dapsone and clofazimine for at least 24 months</td>
</tr>
<tr>
<td>Virus</td>
<td>Condition</td>
<td>Epidemiology/pathogenesis</td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Human papillomavirus (HPV) family</td>
<td>Common warts</td>
<td>• Common in childhood and early adulthood</td>
</tr>
<tr>
<td>A poxvirus</td>
<td>Molluscum contagiosum</td>
<td>• Common in childhood</td>
</tr>
<tr>
<td>A parapoxvirus</td>
<td>Orf</td>
<td>• Transmitted from sheep to man</td>
</tr>
<tr>
<td>Herpes simplex types 1 and 2 (HSV)</td>
<td>Primary herpes simplex&lt;br&gt;• Type 1 HSV classically causes cold sores&lt;br&gt;• Genital herpes may result from sexual transmission of type 2 HSV or orogenital transmission of type 1 HSV</td>
<td>• Primary infection occurs by direct contact, e.g. with a cold sore&lt;br&gt;• Following primary infection, the virus settles in sensory ganglia, where it lies dormant until it is reactivated</td>
</tr>
<tr>
<td>Recurrent herpes simplex</td>
<td></td>
<td>• Triggers for reactivation include intercurrent illness, strong sunlight, stress</td>
</tr>
<tr>
<td>Eczema herpeticum</td>
<td></td>
<td>• Widespread herpes simplex infection complicating atopic eczema</td>
</tr>
<tr>
<td>(Herpes) Varicella zoster</td>
<td>Chickenpox</td>
<td>Shingles (herpes zoster)</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>• Airborne droplet transmission; 2- to 3-week incubation period</td>
<td>• Prodromal symptoms including fever precede the appearance of the characteristic papulo pustules</td>
<td>• Resolves spontaneously</td>
</tr>
<tr>
<td>• Common in childhood, but may affect all ages</td>
<td>• Lesions appear in crops, which crust; removal of the crusts may result in long-term scarring</td>
<td>• Systemic aciclovir for immunocompromised patients, pregnant mothers, chickenpox pneumonia</td>
</tr>
<tr>
<td>• Following primary infection, the virus settles in sensory ganglia, where it lies dormant until it is reactivated</td>
<td>• Varies from mild illness with relatively few lesions in young children to a more debilitating condition with widespread rash in adults or immune-compromised patients</td>
<td>• Avoid contact with immunocompromised individuals</td>
</tr>
</tbody>
</table>

| | Common in childhood, but may affect all ages | Lesions appear in crops, which crust; removal of the crusts may result in long-term scarring |
| | Prodromal symptoms including fever precede the appearance of the characteristic papulo pustules | Varies from mild illness with relatively few lesions in young children to a more debilitating condition with widespread rash in adults or immune-compromised patients |
| | Airborne droplet transmission; 2- to 3-week incubation period | Systemic aciclovir for immunocompromised patients, pregnant mothers, chickenpox pneumonia |
| | Common in childhood, but may affect all ages | Avoid contact with immunocompromised individuals |
| | Following primary infection, the virus settles in sensory ganglia, where it lies dormant until it is reactivated | Ophthalmic zoster may be associated with conjunctivitis, keratitis and iridocyclitis |

*Famciclovir and valaciclovir are alternatives to aciclovir for the treatment of herpes zoster, acute genital herpes and recurrent genital herpes where oral therapy will suffice.*
<table>
<thead>
<tr>
<th>Fungus</th>
<th>Condition</th>
<th>Epidemiology/pathogenesis</th>
<th>Clinical features/investigation</th>
<th>Specific treatment(s)</th>
</tr>
</thead>
</table>
| *Candida albicans* (yeast) | Candidiasis        | - Normal commensal of the gastrointestinal tract  
  - Pathogenicity is related to the development of conditions favourable to its multiplication, e.g. warm moist skin, poorly controlled diabetes mellitus, pregnancy, use of broad-spectrum antibiotics, corticosteroid therapy, immunocompromise (e.g. lymphoma, AIDS) | - Buccal mucosal candidiasis: white curd-like plaques and mucosal erythema  
  - Balanitis: white patches on the foreskin and glans with erythema  
  - Vulvovaginitis: creamy vaginal discharge; pruritus  
  - Intertrigo  
  - Angular cheilitis  
  - Chronic paronychia  
  - Diagnosis can be confirmed on swabs/skin scrapings taken from affected areas  
  - Screen for diabetes mellitus and/or other underlying conditions | - Wherever possible, underlying predisposing factors should be corrected/treated  
  - Nystatin (oral suspension), amphotericin (lozenges) or miconazole (gel) for oral candidiasis  
  - Topical imidazole-containing preparations usually suffice for the treatment of balanitis, vulvitis, intertrigo, angular cheilitis and chronic paronychia  
  - Combination anti-*Candida* therapy and corticosteroids (e.g. hydrocortisone) may confer additional benefits in intertrigo and angular cheilitis  
  - Systemic antifungal therapy can be used in recurrent/refractory disease  
  - Do not forget to treat the partner if appropriate!  
  - Options include: selenium sulphide shampoo (used as a lotion); topical imidazole creams and ketoconazole shampoo; topical terbinafine  
  - Recurrence is common and retreatment often necessary; pigmentary changes resolve over months |
| *Malassezia* (yeast)  | Pityriasis versicolor (Plate 19.8) | - Commonly affects younger adults, especially in warmer climates  
  - Corticosteroid therapy and immunocompromise may be associated with more extensive disease  
  - Fungal hyphae interfere with melanin production/deposition | - Light brown macules  
  - Fine scaly surface  
  - Common sites: trunk, upper arms  
  - Patches of hypopigmentation in those with pigmented skin  
  - Diagnosis is confirmed through skin scrapings | - Systemic antifungal therapy can be used in recurrent/refractory disease  
  - Do not forget to treat the partner if appropriate!  
  - Options include: selenium sulphide shampoo (used as a lotion); topical imidazole creams and ketoconazole shampoo; topical terbinafine  
  - Recurrence is common and retreatment often necessary; pigmentary changes resolve over months |
### Dermatophytes

*(Microsporum, Trichophyton, Epidermophyton)*

<table>
<thead>
<tr>
<th>Tinea ('ringworm')</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Non-yeast fungi which live and multiply in the outermost layer of the epidermis (i.e. in dead keratin)</td>
</tr>
<tr>
<td>- Infection typically occurs through direct contact with infected material</td>
</tr>
</tbody>
</table>

| Tinea pedis ('athlete’s foot'): scaling/peeling skin, typically between the toes and on the soles of the feet; itchy |

| Tinea cruris: scaly, reddened margins, usually on the medial aspects of the thighs |

| Tinea corporis: erythematous, scaling, with central clearing |

| Tinea manuum (palmar or dorsal surface, usually of one hand) |

| Tinea unguium: toenail involvement is common in adults and often associated with tinea pedis |

| Tinea capitis: scaly patch of scalp with broken hairs ± papules/pustules |

| Diagnosis is confirmed by sending skin scrapings, nail clippings and hairs for mycological assessment |

| Topical antifungal agents including imidazoles and terbinafine may be tried when small areas of skin are involved |

| For larger areas, and in cases of scalp ringworm, oral therapy is preferred, e.g. griseofulvin (preferred in children), itraconazole, terbinafine |

| Prolonged courses of treatment (weeks/months) are often required |

<p>| Wherever possible, underlying predisposing factors should be corrected, e.g. foot hygiene |</p>
<table>
<thead>
<tr>
<th>Parasite</th>
<th>Condition</th>
<th>Epidemiology/pathogenesis</th>
<th>Clinical features/investigation</th>
<th>Specific treatment(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Sarcoptes scabiei</em></td>
<td>Scabies</td>
<td>• Transmitted by close/prolonged physical contact</td>
<td>• Pruritus, especially nocturnal</td>
<td>• Treatment consists of a cream or lotion applied to the whole body except the scalp and central part of the face</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Affects all ages</td>
<td>• Burrows: especially on hands and feet, but may be widespread</td>
<td>• Options include 5% permethrin, 0.5% malathion, benzyl benzoate (rarely used now)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Female mite burrows in the epidermis, laying eggs behind her</td>
<td>• Rash: eruption of tiny inflammatory papules, commonly seen around the umbilicus, in the axillae and on the thighs (represents allergic response)</td>
<td>• Topical application of crotamiton and use of sedative antihistamines at night may help with itching</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Several weeks after initial infection, the development of host hypersensitivity (type IV) to the mite and/or its products heralds the onset of pruritus</td>
<td>• Secondary changes including excoriations, eczema and secondary bacterial infection may also be present</td>
<td>• All members of the family and close contacts should also be treated</td>
</tr>
<tr>
<td></td>
<td>Crusted ('Norwegian') scabies</td>
<td>• Large-scale infestation, with crusting</td>
<td>• Skin scrapings from a burrow allows identification of the mite and eggs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Secondary to altered host response (e.g. lack of itching/scratching with failure to destroy burrows/dislodge mites; immunocompromise)</td>
<td>• Multiple crusting lesions (burrows may be difficult to see due to the crusting)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Thickened nails</td>
<td></td>
</tr>
<tr>
<td><em>Pediculus</em></td>
<td>Pediculosis ('lice')</td>
<td>• The head louse (<em>Pediculus capitis</em>) is a wingless insect that lives on the scalp and feeds on blood. It is transmitted by head-to-head contact. Females lay eggs which are ‘cemented’ to hair shafts.</td>
<td>• Itching is the main symptom</td>
<td>• Application of shampoo and conditioner and then combing with fine-toothed comb is an effective means of removing lice. The process should be repeated every 4–5 days for 2–3 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Lice may be visible in heavier infestations</td>
<td>• Topical malathion and other pediculicides may be used, but resistance is common; repeat application after 7 days is required</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• The whole body should be treated with an aqueous preparation of permethrin or malathion, repeated after 7 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Sexual contacts should be traced and treated</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 19.6 Parasitic infections involving the skin**
usually affects the same area(s) of skin each time the patient is exposed to the offending drug.

postinflammatory pigmentation.

examples: phenolphthalein-containing laxatives, tetracyclines, sulphonamides, dapsone.

Vasculitis (p. 284)

typically a cutaneous small vessel vasculitis (leuko-cytoclastic vasculitis).

numerous palpable, purpuric lesions (often on the lower limbs); occasionally developing into haemorrhagic vesicles/bullae.

may be associated with systemic involvement (e.g. renal).

examples: thiazide diuretics, cimetidine, sulphonamides.

Erythema multiforme (Plate 19.10)

target lesions.

examples: sulphonamides, cotrimoxazole, rifampicin, barbiturates.

Erythema nodosum

tender, red, raised lesions (Plate 19.11).

typically on the shins, but may also affect upper limbs.

examples: sulphonamides, salicylates.

Pigmentary changes

various drugs can be associated with different pigmentary skin changes.

examples: blue-black (chloroquine, amiodarone (in sun-exposed areas)); brown (oestrogens = chloasma).

Bullous/blistering reactions

may be seen in the context of a fixed drug eruption or with drug-induced pemphigus, pemphigoid or porphyria cutanea tarda.

Photosensitivity

direct phototoxic effect or exacerbation of a pre-existing condition.

in phototoxic reactions, the dose of the drug and the degree of ultraviolet radiation exposure determine the extent of the reaction; characterised by erythema, swelling/eczematous changes.

examples: tetracyclines, sulphonamides, phenothiazines, thiazide diuretics.

Acneiform eruptions

papules/pustules.

examples: corticosteroids, androgenic drugs, lithium.

Lupus-erythematous-like syndrome

rare.

examples: hydralazine, isoniazid, minocycline.

Lichen planus-like eruptions

rare.

may be indistinguishable from idiopathic lichen planus, although eczematous/scaly changes are more common.

examples: antimalarials, sulphonylureas, gold, thiazide diuretics (in sun-exposed areas).

Purpura

may be a feature of any severe drug reaction and typically results from capillary damage and/or thrombocytopenia.

Management

Wherever possible discontinue suspected offending drug.

Minimise other potential provoking factors, e.g. UV radiation exposure.

Oral antihistamines for urticaria.

Mild topical steroids may help itching.

Adrenaline (epinephrine) may be life-saving in acute hypersensitivity reactions including shock and angioedema (p. 115), and systemic steroids may be required in severe but less acute cases.
Skin manifestations of systemic disease

Skin involvement in systemic disease is not uncommon and can be the presenting feature, e.g. erythema nodosum in sarcoidosis (p. 120). In some instances, several different underlying disorders can give rise to the same skin condition (Table 19.8), while other cutaneous manifestations are more specific. Some disorders (e.g. diabetes mellitus) are associated with a wide array of cutaneous features.

Infections
- haemolytic streptococcal infection—erythema nodosum (Table 19.8, Plate 19.11), erythema multiforme (Table 19.8, Plate 19.10), erythema marginatum
- acquired immune deficiency syndrome (AIDS) – oral/oesophageal candidiasis, ‘hairy leukoplaikia’ (Epstein–Barr virus), seborrhoeic dermatitis, perianal warts, recurrent/severe herpes simplex, Kaposi’s sarcoma, lipodystrophy (in those on highly active antiretroviral therapy)
- Lyme disease (due to infection with the spirochaete Borrelia burgdorferi; transmitted by Ixodid tick bite) – erythema chronicum migrans
- diabetes mellitus
  - neuropathic and neuroischaemic ulcers
  - xanthomata – signifying hyperlipidaemia
  - lipohypertrophy (rarely lipoatrophy)
  - necrobiosis lipoidica – typically occurs on the shins; initially erythematous, but becomes yellowish brown and atrophic with visible vessels beneath the skin; occasionally ulcerates (Plate 19.12)
  - diabetic dermopathy – small brown scar-like lesions, often on the shins
  - acanthosis nigricans – indicating the presence of severe insulin resistance (Plate 19.13)
  - cheiroarthropathy – thickening of the skin of the hands
  - mucosal candidiasis (e.g. balanitis, vulvovaginitis)
  - granuloma annulare.

Endocrine disorders
- hyperthyroidism – pallor, malar flush (which together may lead to the classical ‘strawberries and cream’ appearance), thinning of scalp hair, loss of outer part of eyebrows, thickened/dry skin (myxoedema)
- Cushing syndrome – thinning of skin, spontaneous/easy bruising, acne, hirsutism, violaceous striae
- Addison’s disease – hyperpigmentation (especially palmar creases, buccal mucosa, scars); may be associated with vitiligo

Hyperlipidaemia

Both primary and secondary hyperlipidaemia may be associated with lipid deposits in the skin (xanthomata), which are yellow/orange in colour and may occur as:
- xanthelasma(ta) – eyelids
- tendon xanthomata – extensor tendons of the hands, Achilles tendons
- palmar xanthomata – creases of the palms
- tuberous xanthomata – over bony prominences
- eruptive xanthomata – crops of papules (indicative of hypertriglyceridaemia).

Rheumatological disorders
- gout – tophaceous deposits
- rheumatoid arthritis – palmar erythema, rheumatoid nodules, vasculitic lesions, pyoderma gangrenosum
- systemic lupus erythematosus – facial erythema (‘butterfly rash’), photosensitivity, alopecia, Raynaud’s phenomenon
- discoid lupus erythematosus – principally affects light-exposed areas, with scaling and erythematous plaques; healed areas show scarring and hypopigmentation
- dermatomyositis – purple heliotrope discoulouration, classically around the eyes, but may involve other areas, especially sun-exposed; periorbital oedema; vasculitic lesions in the childhood variant
- systemic sclerosis – tight, shiny appearance of the skin over the face, with beaked nose and restriction of mouth-opening; facial telangiectasia; sclerodactyly, digital infarcts, calcinosis, Raynaud’s phenomenon
- Reiter syndrome – keratoderma blennorrhagicum, buccal mucosal ulceration, circinate balanitis

Sarcoidosis

Skin manifestations include:
- erythema nodosum (Table 19.8, Plate 19.11)
- lupus pernio – purplish discolouration of the skin of the nose and ears
- papules, nodules, plaques, sarcoid granulomas.
<table>
<thead>
<tr>
<th>Cutaneous manifestation</th>
<th>Associated systemic disease(s)</th>
<th>Clinical features/treatment</th>
</tr>
</thead>
</table>
| **Erythema nodosum** (Plate 19.11) | • Sarcoïdosis  
• Streptococcal infection  
• Tuberculosis  
• Inflammatory bowel disease  
• Systemic fungal infections  
• Herpes simplex infection  
• Mycoplasma infection  
• Less commonly: connective tissue disorders; malignancy | • Tender, red, raised areas, typically on the shins but occasionally on the forearms  
• With time the lesions pass through the colour changes of a bruise before resolving  
• Simple analgesia usually suffices in the acute phase  
• Target lesions, typically over extensor surfaces of arms and legs, but may spread to involve other areas of the body; dusky purplish centre which may blister  
• Self-limiting in most cases  
• Occasionally associated with major systemic upset (Stevens–Johnson syndrome), with lesions in the mouth, conjunctiva and anogenital regions; treatment is supportive (the role of systemic corticosteroids remains controversial)  
• Necrotic ulceration with characteristic bluish/purplish undermined edge  
• Single or multiple lesions, usually on the lower limb  
• Painful  
• Treatment of the underlying condition, with judicious use of systemic corticosteroids; azathioprine and ciclosporin may also be effective |
Malignancy

Skin manifestations of malignancy include:

- cutaneous deposits, e.g. breast, bronchus, renal, ovarian (including 'Sister Joseph’s nodule', an umbilical metastatic nodule)
- generalised pruritus (associated with a wide array of systemic malignancies, especially lymphoma)
- acanthosis nigricans (Plate 19.13) (gastrointestinal adenocarcinoma)
- dermatomyositis (bronchus, breast, stomach, ovary)
- thrombophlebitis migrans (pancreatic carcinoma)
- flushing (carcinoid syndrome)
- necrolytic migratory erythema (glucagonoma)
- pyoderma gangrenosum (Table 19.8, Plate 19.14) (myeloma)
- acquired ichthyosis (lymphoma).

Miscellaneous disorders

- liver disease – pruritus, palmar erythema, spider naevi, xanthelasma(ta)
- inflammatory bowel disease – erythema nodosum, pyoderma gangrenosum (Table 19.8, Plate 19.14), buccal mucosal and perianal ulceration
- amyloidosis – yellow waxy periorbital and perianal plaques
- scurvy (due to vitamin C deficiency) – perifollicular purpura, easy bruising, bleeding gums, poor wound healing
- pellagra (due to nicotinic acid deficiency) – triad of dermatitis (in sun-exposed areas, e.g. ‘Casal’s necklace’), diarrhoea and dementia
- neurofibromatosis – café-au-lait spots, axillary freckling, neurofibromas
- porphyria – photosensitive rash/blistering in certain types of porphyria (see p. 254)
- Ehlers-Danlos syndrome – skin hyperextensibility and fragility
- tuberous sclerosis complex (Epiloia) – hamartomas, angiofibromas, shagreen patch, periungual fibromas, hypopigmented (ash leaf) macules
- Peutz-Jeghers syndrome – pigmented macules (lentigines) in the mouth, on the lips, hands and feet
- hereditary haemorrhagic telangiectasia – facial telangiectasia
- pseudoxanthoma elasticum – ‘plucked chicken’ skin appearance

Bullous disorders

Blisters and bullae can be caused by a wide variety of disorders including physical injury (e.g. friction, extremes of temperature, chemicals, insect bites), infection (e.g. impetigo, varicella zoster), drugs (e.g. sulphonamides, barbiturates), systemic disease (e.g. porphyria) and primary skin conditions. The latter may be congenital (e.g. epidermolysis bullosa) or acquired (e.g. pemphigus, pemphigoid, dermatitis herpetiformis).

Epidermolysis bullosa

A rare disorder, which presents in the newborn with fragile skin that blisters on minimal contact; may be fatal.

Pemphigus

In pemphigus, splits occur within the epidermis above the basal layer, with degeneration of epidermal cells (acantholysis). Pemphigus vulgaris is the most commonly encountered variant.

Clinical presentation

Pemphigus is a relatively rare disorder of middle age, some of the characteristics of which are explained by the very superficial site of the lesions: clinically, it presents with widespread erosions and relatively few bullae (because they rupture so easily, leaving flaccid blisters), which are located over the limbs and trunk (Plate 19.15). Most patients have lesions in the mouth and these may be the only visible lesions in the early stages. The surrounding skin is normal. The superficial skin layer at the edge of a blister can be moved over the deeper layers (Nikolsky’s sign) and tends to disintegrate. Lesions appear at sites of pressure and trauma and are painful. Secondary bacterial infection may complicate the primary condition.

Investigation

- skin biopsy – for histopathology (to confirm superficial nature of the blister/bulla) and direct immunofluorescence on perilesional tissue (which shows staining around epidermal cells with antibodies directed against immunoglobulin G (IgG) and C3)
- serum for detection of anti-epithelial antibody

Management

Aggressive management is required including:

- High dose systemic corticosteroids (e.g. prednisolone initially 60–120 mg/day), with gradual dose tapering as blistering settles. Steroid-sparing agents (e.g. azathioprine, cyclophosphamide, methotrexate) are often substituted after the acute phase has subsided.
Secondary bacterial infection is common and should be treated promptly.
Significant fluid and protein loss may occur from weeping skin, and supportive treatment (including enteral/parenteral feeding in cases of severe oral involvement) may be required.

Pemphigoid
In contrast to pemphigus, blisters are subepidermal.

Clinical presentation
Bullous pemphigoid affects those > 60 years of age. Clinically, it often presents with prodromal itch ± areas of erythema, which may predate the appearance of bullae by several weeks. Numerous tense, subepidermal bullae then form, ranging in size from a few millimetres to several centimetres (Plate 19.16). They are less likely to rupture than in pemphigus, but this can be provoked by trauma. Nikolsky’s sign is negative. Scarring is rare and only a small number of cases develop mucosal ulceration.

Cicatricial pemphigoid is a distinct variant in which scarring occurs and can be pronounced.

Investigation
- Skin biopsy – for histopathology (to confirm subepidermal blister/bulla). Immunofluorescence shows linear IgG and C3 at the basement membrane.
- Circulating IgG against antigen in the basement membrane is detectable in the serum of approximately two-thirds of patients with bullous pemphigoid.

Management
- Moderate dose systemic corticosteroids (e.g. prednisolone initially 40–60 mg/day) are required, with dose tapering as blistering settles, which usually occurs quite rapidly in bullous pemphigoid.
- Long-term low dose maintenance therapy is often required; azathioprine may be substituted after the acute phase has subsided.

Dermatitis herpetiformis
A rare disorder associated with subepidermal blisters. It is classically seen in the context of coeliac disease.

Clinical presentation
Dermatitis herpetiformis is characterised by itchy erythematous papules and vesicles, which are common on the elbows and other extensor surfaces. Blisters/bullae may be burst by scratching, with marked excoriation.

Investigation
- skin biopsy – for histopathology (to confirm subepidermal blister/bulla and ‘microabscesses’ at the edge of vesicles) and direct immunofluorescence (which shows granular deposits of IgA in dermal papillae)

Management
- gluten-free diet
- dapsone

Benign and malignant skin tumours
Skin tumours are common. Most are benign, but it is important to identify malignant or potentially malignant lesions. They may arise within the epidermis or the dermis. Clinical features and treatments for the more commonly encountered/important skin tumours are shown in Table 19.9 and Plates 19.17–19.21.

Miscellaneous skin conditions
Skin pigmentation
Abnormalities of skin pigmentation are seen in a variety of settings and may be localised to small areas or more generalised. Table 19.10 lists some of the more common causes of hypo- and hyperpigmentation.

Urticaria
Urticaria describes a group of disorders that are characterised by weals, which typically appear and then disappear spontaneously in a matter of hours. Mast cell degranulation leads to vasodilatation with consequent dermal oedema. Often itching is the first symptom, followed shortly afterwards by the development of pink weals over a variable-sized area, e.g. localised in response to a nettle sting or more generalised as part of an allergic reaction (e.g. food or drug allergies). When part of a more systemic anaphylactic reaction, urticaria may be accompanied by angioedema, with swelling/oedema of the subcutaneous tissues, especially around the eyes, mouth and upper airway. A chronic relapsing form, in which attacks last for weeks, months or even years, is believed to be of autoimmune origin.

If possible, triggers should be identified and avoided. Aspirin is best avoided. Most types of
### Table 19.9 Skin tumours

<table>
<thead>
<tr>
<th>Tumour</th>
<th>Epidemiology/clinical features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benign</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seborrhoeic keratoses (basal cell papillomas; seborrhoeic warts)</td>
<td>• Common, especially in the elderly</td>
<td>• If required, treatment options range from cryotherapy for smaller lesions to curettage and surgical excision for larger ones</td>
</tr>
<tr>
<td></td>
<td>• Solitary or multiple</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Typically occurring on the head, neck, trunk, hands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Raised, flat-topped lesions, ranging in colour from light brown to deeply pigmented</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• May be associated with pruritus</td>
<td></td>
</tr>
<tr>
<td>Keratoacanthoma</td>
<td>• Typically seen in elderly people</td>
<td>• Surgical excision and histological examination should be considered for (1) all lesions that cannot be reliably differentiated clinically from a squamous cell carcinoma and (2) persistent lesions</td>
</tr>
<tr>
<td></td>
<td>• Round with raised edges and characteristic central keratin plug ± reddened/inflamed base</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Develops over a relatively short time period (2–3 months) and ultimately regresses spontaneously</td>
<td></td>
</tr>
<tr>
<td>Dermatofibroma</td>
<td>• Commonly seen as single or multiple lesions on the lower limbs, especially in females</td>
<td>Usually none required; surgical excision can be considered but may leave scarring</td>
</tr>
<tr>
<td></td>
<td>• May arise at sites of minor trauma or insect bites</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Slightly raised, skin-coloured or pigmented</td>
<td></td>
</tr>
<tr>
<td>Pyogenic granuloma (benign proliferation of blood vessels/ fibroblasts)</td>
<td>• Polypoidal lesion, which may bleed profusely following minor trauma</td>
<td>• Curettage or surgical excision with histological examination</td>
</tr>
<tr>
<td><strong>Dysplastic/malignant</strong></td>
<td>• Areas of dysplastic squamous epithelium, which typically develop in UV radiation exposed areas (e.g. scalp, face, hands, lower legs)</td>
<td>• Topical application of 5-fluorouracil, imiquimod or a non-steroidal anti-inflammatory cream is generally effective</td>
</tr>
<tr>
<td>Actinic (solar) keratoses (Plate 19.17)</td>
<td>• Dry, rough, scaly lesions, with erythematous background</td>
<td>• Cryotherapy (if lesions limited in size and number)</td>
</tr>
<tr>
<td></td>
<td>• May undergo spontaneous involution</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Commonest skin cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• UV radiation exposure is an important trigger, and lesions are most commonly seen in sun-exposed areas, e.g. on the face</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Often begins as a nodule, which develops a central depression as the lesion extends outwards, leaving a 'rolled' edge appearance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Contact bleeding from overlying telangiectasia and central ulceration may be seen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Locally invasive, but rarely metastasise</td>
<td></td>
</tr>
<tr>
<td>Basal cell carcinoma (BCC; 'rodent ulcer') (Plate 19.18)</td>
<td></td>
<td>• For superficial tumours, curettage, topical imiquimod, cryotherapy or photodynamic therapy may suffice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Surgical excision and/or radiotherapy are required for deeper lesions</td>
</tr>
</tbody>
</table>
| **Squamous cell carcinoma in situ** (Bowen’s disease) | • Confined to the epidermis, and typically arises in regions subjected to long-term UV radiation exposure (e.g. lower legs), but may also occur in non-exposed areas  
• Often presents as a single red, scaly patch, which may be mistaken for psoriasis | • Curettage, cryotherapy, photo(dynamic) therapy or surgical excision may be required |
| **Squamous cell carcinoma (SCC)** (Plate 19.19) | • Aetiological factors include UV radiation exposure, smoking in perioral tumours, human papilloma virus infection in genital lesions and immunosuppression (e.g. in transplant recipients)  
• Locally invasive, with greater propensity to metastasise than BCCs  
• Varied appearance: ulcer, keratotic nodule, rapidly expanding polypoidal mass | • Surgical excision and/or radiotherapy |
| **Lentigo maligna (‘Hutchinson’s malignant freckle’) (Plate 19.20)** | • Patch of malignant melanocytes that have not yet become invasive  
• Typically develops in UV radiation-damaged skin  
• Flat, brown with variable pigmentation | • Biopsy to confirm diagnosis followed by surgical excision  
• Occasionally surveillance (e.g. in a very elderly patient) may be reasonable  
• Cryotherapy and topical therapies are associated with higher rates of local recurrence |
| **Malignant melanoma (Plate 19.21)** | • Worldwide incidence has risen in recent years, especially in younger age groups  
• UV radiation damage to skin (e.g. repeated sunburn) significantly increases risk  
• May arise de novo or in a long-standing mole  
• Metastasise to loco-regional and then distant lymph nodes  
• Different patterns are recognised:  
  - *lentigo maligna melanoma*: malignant nodule developing within a patch of lentigo maligna  
  - *superficial spreading melanoma*: irregularly pigmented patch with irregular margins; may itch or bleed  
  - *nodular melanoma*: more rapidly growing; occasionally lacks pigment (‘amelanotic melanoma’)  
  - *acral melanoma*: pigmented patch on the sole or palm or subungal (must be distinguished from a haematoma!) | • Prognosis is related to the ‘Breslow thickness’ (i.e. depth of tumour at first surgical excision): in essence the thinner the melanoma the better the prognosis (< 1 mm, 95% 5-year survival; > 3.5 mm, < 45% 5-year survival)  
• Surgical excision remains the mainstay of treatment  
• Standard chemotherapy regimens show limited efficacy; radiotherapy may be used for local/distant spread, but generally does not improve prognosis  
• Immunotherapy and agents targeting specific cellular components (e.g. mutated BRAF protein) are under development |
| **Kaposi’s sarcoma** | • Multicentric malignant vascular tumour, originally limited to those of Mediterranean and Jewish descent, but now recognised as an AIDS-defining condition  
• Purple to brown/black plaques/nodules | • In the context of AIDS, lesions often resolve in response to HAART |

**HAART**, highly active antiretroviral therapy.
urticaria respond to antihistamines (both H1 and H2 antagonists may be helpful). Angioedema/anaphylaxis are medical emergencies (p. 115).

Lichen planus

Lichen planus is uncommon, usually presenting in middle age with an irritating rash affecting the flexures of the wrist and forearms, lower back, mouth and genitalia. The rash consists of discrete, purple, shiny, polygonal papules with fine white lines (‘Wickham’s striae’), often occurring in scratch marks and other sites of injury (Köbner phenomenon). The papules may be widespread or confined to one or two sites. Lesions may arise on the buccal mucosa with a white, lacy network, or in the nails without other lesions on the skin. The disorder usually resolves within 6 months but can recur. The cause is unknown, but several drugs can produce an identical eruption, e.g. gold, antimalarials and antituberculous drugs. The epidermis is infiltrated with T cells.

Topical corticosteroids are usually sufficient to suppress symptoms until resolution has occurred. Systemic corticosteroids or ciclosporin may be required for extensive/severe disease.

Pityriasis rosea

A self-limiting disorder, of unknown aetiology, commonest in children and young adults. Following a mild prodromal illness one or more ‘herald patches’ (red, oval, scaly) appear either on the trunk or arm. Several days later, multiple pink/red oval patches erupt over the trunk, upper arms and thighs, with the long axis of the oval appearing to follow individual dermatomes/spinal roots. It resolves spontaneously over 6–8 weeks.

Table 19.10 Causes of hypo- and hyperpigmentation

<table>
<thead>
<tr>
<th>Hypopigmentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitiligo</td>
</tr>
<tr>
<td>Pityriasis versicolor</td>
</tr>
<tr>
<td>Postinflammatory disorders</td>
</tr>
<tr>
<td>Drug/chemical-induced try</td>
</tr>
<tr>
<td>Lichen sclerosus</td>
</tr>
<tr>
<td>Congenital: albinism, phenylketonuria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hyperpigmentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addison’s disease</td>
</tr>
<tr>
<td>Renal or liver failure</td>
</tr>
<tr>
<td>Haemochromatosis</td>
</tr>
<tr>
<td>Postinflammatory disorders</td>
</tr>
<tr>
<td>Drug/chemical-induced try</td>
</tr>
<tr>
<td>Chloasma</td>
</tr>
<tr>
<td>Acanthosis nigricans</td>
</tr>
<tr>
<td>Congenital: neurofibromatosis, Peutz–Jeghers syndrome</td>
</tr>
</tbody>
</table>

Disorders of the hair and nails

Hair abnormalities

These generally fall into one or more of three categories:

- Changes in colour or texture (e.g. brittleness, coarseness).
- Thinning or loss of hair – may be congenital or, more commonly, acquired, e.g. *telogen effluvium* (in which large numbers of hairs suddenly stop growing and enter the ‘telogen’ phase simultaneously; often triggered by stress/intercurrent illness), *androgenetic alopecia*, *alopecia areata* (autoimmune disorder, with patchy loss of scalp hair (close inspection at the edge of the patch reveals ‘exclamation mark hairs’); tends to run a relapsing/remitting course; occasionally involves the whole scalp (alopecia totalis) or whole body (alopecia universalis)) and *trichotillomania* (compulsive plucking of the hair). It may also be seen in the context of skin conditions (e.g. psoriasis, seborrhoic dermatitis, tinea capitis) and systemic disorders (e.g. hypothyroidism, hypopituitarism) and following drug therapy (e.g. cytotoxic agents).
- Excessive hair growth and development of hair in abnormal sites – *hirsutism* describes male-pattern hair growth in a female and is most commonly ‘idiopathic’ or associated with the polycystic ovarian syndrome (p. 227), but occasionally can be a sign of a virilising tumour; *hypertrichosis* is excessive hair growth in a non-sexual distribution and may occur in both sexes (e.g. in response to drugs such as minoxidil and ciclosporin).

Nail abnormalities

Nail disorders may occur in isolation or may be a sign of more generalised skin disease (e.g. psoriasis, fungal infections) or of an underlying systemic disorder (e.g. koilonychia in iron deficiency anaemia). They include:

- Beau’s lines (horizontal lines following major illness)
- brittleness
- clubbing
- koilonychia (‘spoon-shaped’)
- onychogryphosis (gross thickening)
- onycholysis (lifting of the nail plate off the nail bed, e.g. in psoriasis, Graves’ disease)
- paronychia
- pitting (e.g. in psoriasis)
- Pterygium (e.g. in lichen planus).
Diagnosis of haematological disorders is made or confirmed on the basis of laboratory findings.

Peripheral blood film features (Fig. 20.1)

- reticulocytes (active marrow) – haemolysis or chronic blood loss
- anisocytes (variation in red cell size) or poikilocytes (variation in red cell shape) – iron deficiency
- target cells ('Mexican hat' cells) – thalassaemia
- rouleau formation (clumping together of red cells) – raised ESR (check for myeloma)
- burr cells (echinocytes with irregular 'crinkled' red cell membrane) – renal failure, carcinoma
- hypersegmented polymorphs – vitamin B₁₂ or folic acid deficiency
- Howell–Jolly bodies (remnants of nuclear material) – splenectomy (or non-functioning spleen)
- blast cells (immature cells) – acute leukaemia
- eosinophilia – parasitic infection, allergy, occasionally systemic vasculitis or Hodgkin’s disease

Reticulocytes

Normal range is 10–100 × 10⁹/l. Reticulocytes are premature red cells in which traces of nucleoprotein remain as fine, reticular strands. They are larger than mature red cells and, if increased, may cause macrocytosis. An increase (reticulocytosis) suggests marrow hyperactivity because of:

- loss or destruction of red cells, e.g. bleeding
- a response to treatment of anaemia, e.g. of pernicious anaemia with vitamin B₁₂
- haemolysis.

Normocytic anaemia

Mean corpuscular volume (MCV) is in the normal range. Usually anaemia is secondary to chronic disease. It is usually insidious, not progressive and fairly mild (> 9 g/dl) except in chronic kidney disease. It may become slightly hypochromic and/or microcytic. The white cell count and platelets are normal. The serum transferrin is normal or low but, unlike iron deficiency, the serum ferritin is normal or high (with increased iron stores in the bone marrow). A marrow examination may show malignant disease (leukaemia, myeloma, metastasis) or myelofibrosis.

Anaemia of chronic diseases occurs in:

- chronic kidney disease (p. 159) – check serum creatinine and estimated glomerular filtration rate (eGFR, p. 160)
- chronic liver disease – check liver function tests, γ-glutamyl transferase, prothrombin time
- auto-immune disease (e.g. rheumatoid arthritis, systemic lupus erythematosus (SLE)) – check ESR, C-reactive protein and autoantibodies: rheumatoid factor, anti-nuclear antibodies and if positive specific tests for antibodies against nuclear antigens (p. 279), anti-neutrophil cytoplasm antibodies (ANCA; present in systemic vasculitis)
• chronic infection – abscesses, tuberculosis, bacterial endocarditis
• cancer.

NB The anaemia of chronic kidney disease can be effectively reversed by treatment with recombinant human erythropoietin (p. 162). Erythropoietin can also reverse anaemia associated with cancer, although concerns have been raised that erythropoietin may contribute to tumour progression.

**Microcytic anaemia**

MCV is low, e.g. < 80 fl. The serum iron is either low (iron deficiency) or normal (haemoglobinopathies, usually thalassaemia minor, p. 329). The mean corpuscular haemoglobin (MCH) is usually low (hypochromic), i.e. < 25 pg.

Iron deficiency is caused by poor intake, poor absorption, poor iron use by the marrow or increased blood loss (menstrually or from the gut). Check with serum iron (very low) and transferrin, which tends to be high. If in doubt check the serum ferritin (low) and demonstrate low iron stores in the marrow.

**Macrocytic anaemia**

MCV is raised, often > 100 fl.

• vitamin B_{12} deficiency (usually pernicious anaemia) – check serum B_{12}
• folic acid deficiency – check red cell folate
• hypothyroidism – check thyroid function tests
• liver disease (usually excess alcohol) – check liver function, including γ-glutamyl transferase

Pernicious anaemia is now usually diagnosed by finding low serum vitamin B_{12} with parietal cell and intrinsic factor antibodies, rather than with the
Schilling test (B12 absorption before and after intrinsic factor). Check the haemoglobin, and reticulocyte response to therapy. If in doubt, marrow examination may provide a definitive diagnosis (megaloblastic).

### Anaemia secondary to chronic disease

Anaemia about 10 g/dl, usually normocytic, is associated with chronic infection, malignant disease, chronic kidney disease and chronic inflammation. The serum iron is characteristically reduced, and so is the transferrin (iron-binding capacity), unlike the findings in iron-deficiency anaemia. The marrow iron stores are increased, but the iron is not incorporated fully into red cell precursors.

### Pancytopenia

This is a rare combination of anaemia, leucopenia and thrombocytopenia. It is caused by either:

- reduced production of cells, caused by:
  - bone marrow infiltration (leukaemia, myeloma, carcinoma, myelofibrosis)
  - bone marrow aplasia: idiopathic or drug-induced (e.g. NSAIDs, chloramphenicol, chemotherapy for malignancy); severe vitamin B12 or folate deficiency
- increased destruction of cells, caused by hyper-splenism; or autoimmune disease (e.g. SLE).

Bone marrow examination is the most important investigation in distinguishing these causes.

### Marrow suppression

Secondary bone marrow failure may affect one or all of the formed elements of the blood – red cells, white cells or platelets. It may be idiopathic or secondary to infiltration, drugs, (gold, penicillamine, chloramphenicol, carbimazole), radiation, leukaemias, infections or other disorders such as uraemia, hypothyroidism and chronic disease.

### Erythrocyte sedimentation rate (ESR)

ESR measures the rate of sedimentation (in millimetres per hour) of red cells in a column of anticoagulated blood. Rapid sedimentation (increased ESR) suggests increased levels of immunoglobulins or acute phase proteins, which cause the red cells to stick together. A raised ESR is therefore a non-specific indicator of inflammation or infection. The ESR is usually very high in myeloma.

A very high ESR (> 100 mm/h) suggests:

- multiple myeloma
- SLE or vasculitis
- temporal arteritis
- polymyalgia rheumatica
- rarely, carcinoma or chronic infection, including tuberculosis.

### Anaemia

There are three major types of anaemia, classified by cause: deficiency, haemolysis and marrow disorders. The symptoms are tiredness, physical fatigue and dyspnoea, with angina, heart failure and confusion in older people.

Anaemia can be caused by a deficiency in:

- iron
- vitamin B12
- folic acid.

### Iron-deficiency anaemia

#### Diagnosis

The cause of the iron deficiency must be identified and corrected. In premenopausal women, excess menstrual loss is often the cause, although this should not be accepted uncritically because other important causes may be present as well. Slow gastrointestinal loss is a common cause, with peptic ulceration, gastric carcinoma and carcinoma of the descending colon most common. Carcinoma of the ascending colon or caecum frequently produces no symptoms and its presence must be considered in all cases of iron-deficiency anaemia. In the elderly, dietary deficiencies remain an important cause, and remember that hypothyroidism can present as iron-deficient anaemia.

#### Examination

This includes assessment of pallor (very imprecise), glossitis, angular stomatitis, koilonychia and rectal examination. Investigate the gastrointestinal tract if no other cause is identified. Early colonoscopy, especially in the asymptomatic patient, can detect carcinoma of the large bowel at a curable stage.

#### Laboratory investigation (Table 20.1)

The peripheral blood count shows hypochromia (MCH < 27 pg) and microcytosis (MCV < 80 fl),
possibly with poikilocytosis (variation in shape) and anisocytosis (variation in size). The serum iron is low and the transferrin raised, with a low saturation. The serum iron is also low in anaemia secondary to chronic disease, but normal in haemoglobinopathies and, usually, thalassaemia minor (p. 329). Serum ferritin reflects the state of the iron stores and is therefore low. There is a reduction in stainable iron in the marrow.

The bone marrow shows adequate iron in macrophages but reduced amounts in developing erythroblasts. Thalassaemia (p. 329) also causes hypochromic, microcytic anaemia.

Management

In the absence of active bleeding, ferrous sulphate 200 mg b.d. before food is usually all that is required. The reticulocyte count rises first and then the haemoglobin (at about 1 g/week), but iron should be continued for another 3 months to replenish the stores.

NB "Hypochromic anaemia", unresponsive to oral iron therapy, occurs in:

- incorrect diagnosis or mixed deficiency
- continued bleeding (reticulocytosis persists), e.g. microscopic from tumour of the bowel
- patients who do not take their tablets
- rheumatoid arthritis (p. 270)
- malabsorption (p. 136)
- thalassaemia (p. 329)
- myelodysplastic syndrome (p. 330) – refractory anaemia (if ringed sideroblasts present in marrow, sideroblastic anaemia - p. 330).

Hazards of blood transfusion

- Transfusion reaction – minimise risk by cross-matching patient’s serum with donor blood. If clinical manifestations of a transfusion reaction occur (fever, backache, hypotension and haemoglobinuria), stop the transfusion immediately and initiate supportive treatment to alleviate shock.
- Transmission of infection – blood is screened for hepatitis B and C and human immunodeficiency virus (HIV).
- Circulatory overload – give furosemide with transfusion in patients at risk of heart failure.
- Coagulation defects and electrolyte abnormalities – particularly hyperkalaemia (red cell breakdown releases potassium) where large volumes are transfused.

Vitamin B₁₂ deficiency (usually pernicious anaemia)

Vitamin B₁₂ is present in liver, and small amounts also in milk and dairy products, and requires intrinsic factor for absorption. The most common cause of vitamin B₁₂ deficiency in the UK is lack of intrinsic factor as a result of parietal cell and intrinsic factor antibodies. It is associated with other organ-specific autoimmune disorders. Achlorhydria is invariably present. Rare causes of B₁₂ deficiency include gastrectomy, intestinal blind loops (in which bacteria multiply using up B₁₂), a vegan diet, Crohn’s disease involving the absorbing surface in the terminal ileum, other causes of malabsorption and *Diphyllobothrium*
Finnish tapeworm that consumes B₁₂. Stores of B₁₂ last 3–4 years.

**Clinical features**

Pernicious anaemia occurs in the middle-aged and elderly and is more common in women. Exhaustion and lethargy are the most common presenting complaints, although pallor may be noticed incidentally, or the blood picture noticed in the laboratory.

In chronic, severe B₁₂ deficiency, which is uncommon, the skin has a pale lemon tint, the hair is snow white and the sclera may be slightly jaundiced as a result of mild haemolysis. The tongue may be tender, smooth and red because of atrophy of the mucosa. Peripheral neuropathy may be the presenting feature with pain, soreness or numbness of the feet on walking. Later, features of subacute combined degeneration of the cord may develop. Cardiac failure is common if the anaemia is marked. The spleen is sometimes palpable. There is an increased incidence of gastric carcinoma.

**Diagnosis**

The haemoglobin may be very low, i.e. 3–4 g or less. The blood film shows macrocytes usually with anisocytosis and poikilocytosis, and the MCV is usually > 100 fl. The total white blood cell (WBC) count may fall because of reduced numbers of both lymphocytes and neutrophils (Table 20.2). Some neutrophils may show hypersegmentation of the nuclei (> 5 lobes). There may also be a moderate fall in the platelet count. Reticulocytes are generally not increased until treatment is started.

The marrow is hypercellular, with giant metamyelocytes and megaloblasts present – evidence that anaemia is in part caused by suppression of cell release. Megaloblasts (Fig. 20.2) are found only rarely in the peripheral blood. They are characterised by a large and inactive nucleus (maturation arrest) in a relatively hypermature, and even haemoglobinised, cytoplasm. They are not present in normal marrow and their presence denotes vitamin B₁₂ or folate deficiency, which may be secondary to antifolate or phenytoin.

**Table 20.2 White cells. Normal white cell count: 4–10 × 10⁹/l**

| Neutrophils | – normal range: 2.0–7.5 × 10⁹/l (40–75% of total white cells) |
| Causes of neutrophilia (raised neutrophil count) | |
| • Acute bacterial infections |
| • Inflammation, e.g. arteritis |
| • Acute tissue necrosis, e.g. myocardial infarction, large pressure sores, burns |
| • Acute haemorrhages |
| • Leukaemias |

| Causes of neutropenia (low neutrophil count) | |
| • Viral infections, e.g. glandular fever, measles, acquired immunodeficiency syndrome (AIDS) |
| • Drug reactions, e.g. carbimazole, chemotherapy |
| • Blood diseases, e.g. leukaemias, pernicious anaemia, aplastic anaemia |

| Lymphocytes | – normal adult range: 1.5–4.0 × 10⁹/l (20–45% of total) |
| There are two main subpopulations of T lymphocytes, which bear different surface markers, or cluster of differentiation (CD) antigens. CD8 cells are ‘cytotoxic’ – their main function is to recognise and kill cells expressing foreign (usually viral) proteins. CD4 cells are ‘helper’ cells – they help B lymphocytes to differentiate into plasma cells and produce antibodies. The normal ratio of CD4: CD8 cells is 2:1. |

| Causes of lymphocytosis (raised lymphocyte count) | |
| • Acute viral infections, e.g. glandular fever, chickenpox, rubella, mumps |
| • Lymphatic leukaemia |
| • Vasculitis and drug hypersensitivity |

| Causes of lymphopenia (low lymphocyte count) | |
| • AIDS – a severely depressed CD4 count predicts the onset of opportunistic infections |
| • Ionising radiation (treatment for malignancy or accidental) |
| • Chemotherapy for malignancy |
| • Steroid therapy or Cushing syndrome |

| Eosinophils | – normal range: 0.04–0.4 × 10⁹/l |
| Causes of eosinophilia (raised eosinophil count) | |
| • Allergies, e.g. bronchial asthma, urticaria, hay fever, drug reaction |
| • Parasitic infestation of gut or other tissues (muscles, subcutaneous tissues, liver, urinary tract) |
| • Systemic vasculitis (see polyarteritis nodosa, p. 286; Churg–Strauss syndrome, p. 289); Hodgkin’s disease, p. 332 |
therapy. If sufficiently severe, vitamin B₁₂ and folate deficiencies produce depression of all the marrow elements, including neutrophils and platelets. There is usually some haemolysis with a raised unconjugated serum bilirubin. The haptoglobins are reduced. Urobilinogen is present in the urine as a result of reduced red cell survival and ineffective erythropoiesis. Antibodies to parietal cells are present in > 90% of patients and to intrinsic factor in approximately 55%. Not all individuals who have parietal cell antibodies have pernicious anaemia.

Patients with pernicious anaemia treated with vitamin B₁₂ usually have normal peripheral blood and a normal marrow within 24 h. The serum folates and B₁₂ are normal. Parietal cell and intrinsic factor antibodies are still present.

**Treatment**

Vitamin B₁₂ as hydroxocobalamin 1 mg is given five times at 2-day intervals and then every 3 months for life. The response of the marrow to therapy is very rapid with an early reticulocyte response maximal on the fourth to sixth day. The haemoglobin follows this and rises about 1 g/dl every 1–2 weeks. The WBC and platelets are normal in about 7 days. The rapid production of cells with therapy may reveal an associated deficiency of, and demand for, iron, potassium or folic acid and supplements should be given where necessary.

Neurological features of B₁₂ deficiency usually improve to some degree; sensory abnormalities more completely than motor, and peripheral neuropathy more than myelopathy. However, neurological features may remain static and occasionally even deteriorate.

NB If folic acid alone is given to patients with pernicious anaemia the neurological features may become worse.

Blood transfusion contains enough B₁₂ to correct the marrow and to make interpretation of serum B₁₂ levels difficult. It may precipitate heart failure and death – some authorities believe that transfusion must never be given to patients with pernicious anaemia. A poor response to B₁₂ therapy suggests that the diagnosis is wrong.

**Folic acid deficiency**

Folic acid is found in green vegetables and liver.

- **Dietary deficiency.** In the UK this is most commonly seen in chronic alcoholics, the poor and the elderly who eat no green vegetables. In the tropics it is often seen in association with multiple deficiencies and with gut infection and infestation.
- **Malabsorption** (p. 136).
- **Increased requirement.** Pregnancy and infancy. Haemolysis results in increased red cell formation, which requires folate more than B₁₂.
- **Folate metabolism.** Phenytoin therapy interferes with folate metabolism.
Haemolytic anaemia (Table 20.3)

Haemolytic anaemias are rare in the UK. Haemolysis is characterised by jaundice with a raised unconjugated serum bilirubin, increased urobilinogen in urine and stools, increased haptoglobins and reticulocytosis. The degree of reticulocytosis is an indirect measure of the rate of haemolysis. There is no bile pigment in the urine (the jaundice is acholuric). The rate of disappearance of chromium-tagged red cells gives a more accurate measure of the rate of haemolysis. Splenomegaly and pigment stones may occur. The blood film may show polychromasia, spherocytes, and crenated and fragmented red cells. There may be features of:

- rapid red cell destruction – increased plasma haemoglobin, methaemalbuminaemia, decreased haptoglobins, haemoglobinuria and haemosiderinuria;
- excess red cell formation – reticulocytosis, erythroid hyperplasia and increased folate requirements.

Hereditary haemolytic anaemias

These are caused by defects in the red cell membrane or specific red cell enzyme deficiencies.

Hereditary spherocytosis

An autosomal dominant disorder that causes increased osmotic fragility and produces spherocytes in the peripheral blood. Patients present with an intermittent jaundice, which may be confused with Gilbert syndrome or with recurrent hepatitis. Gallstones, leg ulcers, splenomegaly and haemolytic or aplastic crises during intercurrent infections may occur.

Splenectomy relieves the symptoms but does not cure the underlying defect.

Hereditary elliptocytosis

This is also inherited as an autosomal dominant trait and produces elliptical red blood cells, variable degrees of haemolysis and, rarely, splenomegaly.

<table>
<thead>
<tr>
<th>Table 20.3 Classification of haemolytic anaemias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intrinsic red cell disorders</strong> (abnormal RBCs)</td>
</tr>
<tr>
<td>(all Coombs-negative)</td>
</tr>
<tr>
<td><strong>Membrane disorder</strong></td>
</tr>
<tr>
<td>Hereditary spherocytosis*;</td>
</tr>
<tr>
<td>hereditary elliptocytosis</td>
</tr>
<tr>
<td><strong>Enzyme deficiency</strong></td>
</tr>
<tr>
<td>G6PD*; pyruvate kinase</td>
</tr>
<tr>
<td><strong>Haemoglobinopathy</strong></td>
</tr>
<tr>
<td>Sickle-cell anaemia;</td>
</tr>
<tr>
<td>thalassaemia</td>
</tr>
<tr>
<td><strong>Non-immune</strong> (Coombs-negative)</td>
</tr>
<tr>
<td>Mechanical haemolytic anaemias: disseminated intravascular coagulation,</td>
</tr>
<tr>
<td>microangiopathic haemolytic anaemia (thrombotic thrombocytopenic</td>
</tr>
<tr>
<td>purpura), haemolytic-uraemic syndrome, postcardiotomy – prosthetic</td>
</tr>
<tr>
<td>heart valves (red-cell fragmentation), march haemoglobinuria,</td>
</tr>
<tr>
<td>hypersplenism and burns</td>
</tr>
<tr>
<td>Infections: malaria, Clostridium perfringens, viral infections</td>
</tr>
<tr>
<td>Paroxysmal nocturnal haemoglobinuria (p. 328)</td>
</tr>
<tr>
<td>Drugs: e.g. oxidative damage, dapsone, salazopyrine</td>
</tr>
<tr>
<td>Secondary to renal or liver disease</td>
</tr>
</tbody>
</table>

CLL, chronic lymphoid leukaemia; G6PD, glucose-6-phosphate dehydrogenase; RBC, red blood cell; SLE, systemic lupus erythematosus.
*Most frequent.
Glucose-6-phosphate dehydrogenase deficiency

This is a disease found in Africa, the Mediterranean, the Middle and Far East. Inheritance is sex-linked on the X chromosome (affected males always show clinical manifestations but females will have variable degrees of haemolysis). Because of the phenomenon of random inactivation of the X chromosome, females will have two populations of red blood cells (RBCs), one normal and one glucose-6-phosphate dehydrogenase (G6PD) deficient: the susceptibility to haemolysis will be greater, the greater the size of the deficient population. In the UK, acute haemolytic episodes are usually drug-induced (sulphonamides, primaquine) or occur during acute infections. Other features are neonatal jaundice and favism.

The diagnosis is confirmed by reduced or absent enzyme activity in the red cells.

Paroxysmal nocturnal haemoglobinuria

This is an acquired clonal disorder of haematopoesis in which cells have deficient production of the phospholipid glycosylphosphatidylinositol that anchors certain proteins to the cell surface. These include CD59, which protects cells from complement-mediated lysis. This accounts for the increased sensitivity of red cells to complement, which forms the basis of Ham’s acid lysis test.

The clinical features occur usually in the over-30s, who develop paroxysmal haemolysis (with anaemia, macrocytosis, reticulocytosis, haemoglobinuria and haemosiderinuria) and life-threatening venous thromboses. Patients may develop aplastic anaemia. Spontaneous remission occurs in about 15% of cases. Long-term anticoagulation should be considered.

Haemoglobinopathies

Clinical features

Normal adult haemoglobin is made up of two polypeptide chains, the alpha- and beta-chains, which are folded such that each chain can hold an oxygen-binding haem molecule. The haemoglobinopathies are a diverse group of autosomal recessive disorders of haemoglobin synthesis which include sickle-cell anaemia (abnormal beta-chain synthesis) and the thalassaemias (deficient or absent alpha- or beta-chain synthesis). Together they form the most common group of single-gene disorders worldwide.

Genetic basis of haemoglobinopathies

Genes encoding five different beta-globin chains (beta, delta, gamma-A, gamma-C, epsilon) and three different alpha-globin chains are expressed in a precisely regulated manner during different stages of development. During fetal life the two beta-globin variants called gamma-globin combine with two alpha-globin chains to give rise to fetal haemoglobin (HbF). During adult life the beta-globin variants combine with alpha-globin chains to form adult haemoglobin (HbA). HbA2 is <3% of haemoglobin in adults and possesses two alpha- and two delta-chains.

The five beta-globin chain genes are clustered on chromosome 11, whereas the alpha-globin chain genes occur together on chromosome 16. Numerous different mutations in the alpha- and beta-globin genes have been described, which give rise to alpha- or beta-thalassaemia respectively. Sickle-cell anaemia is caused by a point mutation, which involves substitution of T for A in the second nucleotide of the sixth codon, changing the sixth amino acid from glutamine to valine in beta-globin.

NB HbA is 95% of haemoglobin in adults and possesses two alpha- and two beta-chains (alpha_2beta_2). HbF is <0.5% of haemoglobin in adults and possesses two alpha- and two gamma-chains (alpha_2gamma_2). Sickle-cell haemoglobin (HbS) possesses two alpha- and two abnormal beta-chains. Haemoglobin A2 (HbA2) is <3% of haemoglobin in adults and possesses two alpha- and two delta-chains (alpha_2delta_2).

Sickle-cell disease

Sickle-cell disease is found in Africa, the Middle East, the Mediterranean and India and is transmitted as an autosomal dominant trait. Sickle-cell trait occurs in heterozygotes (HbA-HbS) whose haemoglobin contains characteristically 60% HbA and 40% HbS. Patients with the trait are usually symptom-free except when the oxygen tension is very low, e.g. through altitude and anoxic anaesthesia. The prevalence of the gene is probably because the HbS protects against the serious and occasionally lethal effects of falciparum malaria.

Sickle-cell disease occurs in homozygotes (HbS-HbS). The abnormal haemoglobin renders the RBCs susceptible to very small reductions in oxygen tension. This leads to the sickling phenomenon and to abnormal sequestration with thrombosis in small arterioles. The subsequent infarction may affect any part of the body.

Clinical features

In sickle cell disease anaemia occurs within the first months of life as levels of HbF fall. Acute haemolytic crises begin after 6 months, causing bone infarcts, which are common, and children may present with pain and swelling in the fingers and toes (dactylitis). Infarcts may cause abdominal pain, haematuria or cerebrovascular accidents. Splenic infarction is common and by the age of 1 year children can be functionally asplenic. Repeated renal infarction causes
tubular damage and failure to concentrate urine, compounding sickle-cell crises.

**Prognosis**

Sickle cell disease carries a high infant and child mortality from thrombosis to a vital organ or infection, with pneumococcus the most common as a result of hypoplasmenism. Children who survive beyond 4–5 years continue to have chronic ill health with anaemia, haemolytic and thrombotic crises, leg ulcers and infections (which may precipitate crises), and rarely survive beyond 50 years. Folate supplements are required throughout life. Pneumococcal vaccine should be given and penicillin prescribed to reduce mortality from pneumococcus. Hydroxyurea can help by increasing HbF production. Bone marrow transplantation is curative but limited by availability of well matched donors.

**Thalassaemia**

Thalassaemia is found in the Middle and Far East and the Mediterranean and is caused by deficient alpha-or beta-chain synthesis. The deficiency is genetically determined and results in α- or β-thalassaemia. In the latter, gamma-chains continue to be produced in excess into adult life and excess HbF is present.

**β-Thalassaemia minor** (heterozygote)

This usually presents as a symptom-free, mild, microcytic, hypochromic anaemia which may be confused with iron deficiency. It is diagnosed by finding a raised HbA2 level generally (4–7%). HbF levels may also be slightly raised (1–3%).

**β-Thalassaemia major** (homozygote)

Patients are relatively normal at birth (little beta-chain anyway) but develop severe anaemia later with failure to thrive and are prone to infection. The anaemia is hypochromic and the film contains target cells ('Mexican hat' cells) and stippling. Erythroid hyperplasia occurs in the marrow and chain precipitation appears as inclusion bodies on supravital staining. Infants who survive develop hepatosplenomegaly, bouting of the skull, brittle and overgrown long bones, gallstones and leg ulcers.

Treatment consists of transfusion to maintain the haemoglobin at 10 g/dl, but this, combined with increased iron absorption, results in iron overload. Desferrioxamine is given to reduce haemosiderosis with folic acid replacement, and splenectomy may be indicated if hypersplenism supervenes. Bone marrow transplantation has been used successfully.

**Marrow disorders**

**Myeloproliferative disorders**

Polycythaemia vera (PV), essential thrombocytopaenia (ET) and primary myelofibrosis (PMF) are related myeloproliferative disorders in which there is clonal expansion of haematopoietic progenitors. A somatic point mutation in the JAK2 (Janus kinase 2) non-receptor tyrosine kinase (JAK2V617F) was identified in most patients with PV and in about half of patients with ET and PMF. JAK2V617F has constitutive tyrosine kinase activity and is able to activate JAK-STAT signalling and transform hematopoietic cells. Median survival in both essential thrombocythaemia and polycythaemia vera exceeds 15 years and the 10-year risk of developing either myelofibrosis or acute myeloid leukemia is relatively low. Prognosis is worse in primary myelofibrosis.

Polycythaemia vera presents in late middle age (50–60 years), most commonly as a chance haematological finding. If symptomatic, it presents usually with vascular occlusion, arterial or venous or, much less often, with gout, pruritus or a finding of splenomegaly. Diagnosis is established by the presence of:

- a raised haemoglobin or red cell mass (RCM > 25% above mean normal predicted value) and the presence of JAK2V617F or a similar mutation (major criteria);
- evidence of bone marrow trilineage myeloproliferation or subnormal erythropoietin levels or endogenous erythroid colony growth (minor criteria).

A diagnosis of polycythaemia vera can also be made if there is a raised haemoglobin and two minor criteria.

Secondary causes to be excluded include hypoxaemia and renal disease (ultrasound for polycystic disease and hypernephroma). Cerebellar haemangio-blastoma and hepatoma are associated but very rare. Treatment is with repeated venesection, low-dose aspirin to reduce the incidence of intravascular coagulation and hydroxyurea in high risk patients who are elderly or have a history of thrombosis.

NB In polycythaemia vera, all cellular elements are raised (RBCs, WBCs and platelets). In secondary polycythaemia (e.g. caused by increased erythropoietin production in hypoxia or renal disease) only the red cell count is raised.

Essential thrombocythaemia, if not found incidentally, presents with small vessel vascular occlusion. Diagnosis depends on finding all four major criteria:

1. a platelet count > 450 x 10^9 l^-1 and
2. megakaryocyte proliferation with no or little granulocyte or erythroid proliferation and
3. presence of JAK2V617F or other clonal marker or no evidence of reactive thrombocytosis and
not meeting criteria for other myeloid neoplasms. Treatment is with low dose aspirin and hydroxyurea in high risk patients who are elderly or have a history of thrombosis.

Primary myelofibrosis typically presents with the finding of huge and increasing splenomegaly, and evidence of bone marrow failure: anaemia, infection, bleeding. Diagnosis depends on finding all three major criteria:

1 proliferation of atypical megakaryocytes with either reticulin and/or collagen fibrosis, or megakaryocyte changes accompanied by increased marrow cellularity, granulocytic proliferation and often decreased erythropoiesis;
2 presence of JAK2V617F or other clonal marker or no evidence of reactive marrow fibrosis and
3 not meeting criteria for other myeloid neoplasms.

In addition, two of the minor criteria should be met: leucoerythroblastosis, raised LDH, anaemia and splenomegaly.

Hydroxyurea, thalidomide and the thalidomide analogue lenalidomide have been used in therapy. Allogeneic hematopoietic stem cell transplantation is potentially curative.

Myelodysplastic syndromes

Myelodysplastic syndromes are a heterogeneous group of disorders that are characterised by clonal and ineffective hematopoiesis in the setting of a dysplastic bone marrow, peripheral blood cytopenias and progressive bone marrow failure. Transformation to acute myeloid leukaemia occurs in approximately 30% of cases. Survival following diagnosis varies from a few months to > 10 years.

It is usually discovered on a routine peripheral blood film, usually as macrocytosis (with normal B12, folates, liver and thyroid function tests, and γ-glutamyl transferase). Less commonly, patients may present with a refractory anaemia, pancytopenia, neutropenia or thrombocytopenia (Table 20.4).

Classification is continuously under review, but there are five major subgroups which tend to have decreasingly satisfactory prognoses:

1 refractory anaemia
2 refractory anaemia with ringed sideroblasts
3 refractory anaemia with excess blasts
4 refractory anaemia with excess blasts in transformation
5 chronic myelomonocytic leukemia.

NB Sideroblasts are nucleated red cells that contain perinuclear rings of iron-containing granules. Although hereditary forms of sideroblastic anaemia exist, sideroblasts are most frequently seen in myelodysplastic syndromes.

<table>
<thead>
<tr>
<th>Table 20.4 Causes of platelet disorders. (Normal range 150–400 × 10⁹/l.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thrombocytosis</strong> (increased platelets)</td>
</tr>
<tr>
<td>• After haemorrhage, surgery or trauma</td>
</tr>
<tr>
<td>• Splenectomy or splenic atrophy</td>
</tr>
<tr>
<td>• Inflammation (as part of an inflammatory response)</td>
</tr>
<tr>
<td>• Malignancy</td>
</tr>
<tr>
<td>• Myeloproliferative disorders, e.g. megakaryocytic leukaemia (rare)</td>
</tr>
<tr>
<td><strong>Thrombocytopenia</strong> (decreased platelets)</td>
</tr>
<tr>
<td>• Adverse drug reactions (e.g. NSAIDs, phenothiazines, gold, thiazides)</td>
</tr>
<tr>
<td>• Autoimmune thrombocytopenic purpura, in which circulating antiplatelet antibodies lead to premature platelet destruction</td>
</tr>
<tr>
<td>• Marrow aplasia</td>
</tr>
</tbody>
</table>

NB If also anaemic, exclude disseminated intravascular coagulation (p. 331) and prosthetic valve dysfunction.

Treatment

Haematinics (iron, folate, B12) are ineffective. Blood transfusion is necessary and has to be repeated regularly. Chemotherapy, lenalidomide and allogenic bone marrow transplantation have all been used in therapy.

Complications

Anaemia (requiring the transfusion of about 1 unit blood/week), infection, haemorrhage and blast transformation.

Marrow failure

Marrow aplasia

Primary aplastic anaemia gives a pancytopenia with reduction in all the formed elements. It is rare. Patients present with:

• anaemia; and/or
• spontaneous bleeding because of lack of platelets; and/or
• infection caused by lack of polymorphonuclear leucocytes.

A peripheral blood film reveals a pancytopenia, although one cell line may be affected more than the others. A bone marrow aspiration is performed. If it is difficult to aspirate (possible myelofibrosis or malignancy), a trephine biopsy may be necessary to obtain a diagnostic specimen of marrow. The drugs that most
commonly cause marrow suppression include cytotoxic drugs, gold, indometacin and chloramphenicol. Some marrow suppression is associated with uraemia, rheumatoid arthritis and hypothyroidism.

**Bleeding disorders**

**Haemophiliaas**

Haemophilia A (classical haemophilia) or haemophilia B (Christmas disease) results from defects in the clotting factor VIII (on chromosome Xq28) or factor IX (on chromosome Xq27), respectively. They are sex-linked recessive clotting disorders of men, carried by women, in which patients suffer mainly from spontaneous bleeding into joints and soft tissues and excessive bleeding in response to trauma or surgery. All carriers who wish to have children should receive genetic counselling. The diseases can be detected in utero.

**Treatment**

Treatment is by replacement of the deficient clotting factor. As soon as possible after bleeding has started, purified factor VIII or IX is given as required. Purified factor VIII is also used to raise factor VIII levels in von Willebrand’s disease (see below). Fresh frozen plasma contains both factors but is best reserved for when the single factors are not available. Aspirin-containing preparations should be avoided because they impair platelet function and may cause gastric erosion. Desmopressin can be used to increase factor VIII levels in mild to moderate haemophilia.

**Von Willebrand’s disease**

This is a autosomal dominant disease of both sexes which causes abnormal bleeding, particularly from mucous membranes. There is a prolonged bleeding time, low factor VIII clotting activity and poor platelet adhesion. (Von Willebrand factor is a cofactor for this adhesion.)

**Skin haemorrhage**

- Purpura refers to small areas of cutaneous bleeding. The purplish red spots do not fade on pressure. Ecchymosis refers to larger lesions (bruises). Purpura is rare, but bruising is very common.
- The most common causes of skin haemorrhage are senile purpura, therapy with corticosteroids or anticoagulants and, less commonly, thrombocytopenia caused by leukaemia and marrow aplasia.

**Thrombocytopenia**

This may result from decreased production (marrow aplasia, leukaemia or infiltration) or increased destruction (idiopathic thrombocytopenic purpura, hypersplenism and consumption coagulopathy).

**Idiopathic thrombocytopenic purpura**

Idiopathic thrombocytopenic purpura (ITP) is rare and not to be confused with thrombotic thrombocytopenic purpura (TTP), which is very rare. ITP occurs chiefly in children following a respiratory or gastrointestinal viral infection. Patients present with purpura and a low platelet count. If the platelet count is very low, major bleeding may occur from the nose or gut or into the brain. The bleeding time is prolonged but coagulation times are normal. Spontaneous recovery is the rule. Steroids or intravenous immunoglobulin may be of benefit in the more severe cases, occasionally with lasting remission. Splenectomy should be avoided if possible, especially in children, in view of the risk of pneumococcal septicaemia in asplenic patients, but may be curative when medical management is unsuccessful.

**Thrombotic thrombocytopenic purpura**

Thrombotic thrombocytopenic purpura (TTP) is a rare disease that usually occurs in young adults and is characterised by microangiopathic haemolytic anaemia and thrombocytopenia, and microvascular thrombosis that causes variable tissue ischaemia and infarction. It typically occurs in patients with an acquired deficiency of the plasma metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, also known as von-Willebrand factor cleaving protease), which responds to plasma exchange in approximately 80% of cases. Prognosis is worse when it is associated with malignancy, drugs or transplantation. Familial TTP due to an inherited deficiency of ADAMTS13 can be treated with plasma infusions.

**Henoch–Schönlein purpura**

(See p. 289.)

**Osler’s disease (Osler–Weber–Rendu)**

This is a hereditary haemorrhagic telangiectasia (autosomal dominant) which may present as intermittent bleeding, usually gastrointestinal. There are small capillary angiectases throughout the gastrointestinal tract, including the buccal mucosa and tongue.
Disseminated intravascular coagulation (DIC)

This occurs in many severe insults including sepsis, trauma, malignancy, organ failure, obstetric practice (amniotic fluid embolism, placental abruption, pre-eclampsia), transplantation and mismatched blood transfusion. There is systemic activation of coagulation pathways that leads to formation of fibrin clots, which may cause organ failure, together with consumption of platelets and coagulation factors, which may result in bleeding. Diagnosis is based on finding a low platelet count and evidence of intravascular coagulation – prolonged clotting times with low fibrinogen and increased fibrin degradation products.

Treatment is of the underlying disease, usually septicaemia. Transfusions of platelet, plasma or factor concentrates may be used to prevent or stop bleeding. Heparin may be of value in cases where thrombosis predominates. Human activated protein C should be considered in patients with sepsis and severe DIC, but should not be given if there is a high risk of bleeding.

Leukaemia

This refers to malignant proliferation of blood-forming cells and is broadly classified according to:

- whether the disease, if untreated, is likely to follow an acute or more prolonged chronic course and
- whether lymphocytic or myeloid (marrow-related) cell lines are primarily involved.

Acute lymphatic leukaemia

This, the most common form of childhood leukaemia, accounts for 75–80% of all childhood leukaemias. Infiltration of bone marrow with lymphoblastic cells causes anaemia, bruising (thrombocytopenia) and infections (neutropenia). Lymphoblasts are usually present in the peripheral blood and always in the marrow. Lymphadenopathy, splenomegaly and hepatomegaly occur. Most children with acute lymphatic leukaemia can now be ‘cured’.

Chronic lymphatic leukaemia

This occurs in the elderly with a generalised lymphadenopathy and a raised white cell count with lymphocytosis. It usually follows a benign course and treatment is only indicated if symptoms develop.

Acute myeloid leukaemia

This occurs at all ages but less commonly in childhood. Myeloblasts infiltrate the marrow and are found in the blood. Anaemia, bleeding or infections are common. Involvement of other organs is unusual.

Chronic myeloid leukaemia

This usually presents in middle age, often insidiously with anaemia, weight loss and fever. White cell count is markedly raised with myeloid precursors in the marrow and peripheral blood. The spleen, and in later stages the liver, are markedly enlarged. In over 90% of patients leukocytes contain the Philadelphia chromosome, a translocation of the breakpoint cluster region (bcr) gene on the long arm of chromosome 22 to a position adjacent to the c-abl gene on chromosome 9. This results in formation of a bcr-abl fusion gene, and the subsequent expression of the BCR-ABL fusion protein is involved in the malignant transformation of myeloid cells.

Lymphoma

These are solid tumours of the lymphoreticular system that are divided histologically into two main types: Hodgkin’s disease, characterised by the presence of multinucleated giant cells (Reed–Sternberg cells); and non-Hodgkin’s lymphoma (Fig. 20.3).

Clinical features

Patients may present with painless lymphadenopathy. Symptoms, if present, include lethargy, anorexia, weight loss, fever, night sweats and pruritus. Hepatomegaly and splenomegaly may occur.

Lymphomas are staged according to the extent of disease:

- Stage I: involvement of a single lymph node region.
- Stage II: two regions involved on the same side of the diaphragm.
- Stage III: disease on both sides of the diaphragm, but limited to nodes, spleen or a single extralymphatic organ or site.
- Stage IV: diffuse involvement of one or more extralymphatic sites, with or without lymph node involvement.

In Hodgkin’s disease the suffix A (e.g. stage IIA) denotes the absence of symptoms, whereas the suffix B denotes the presence of > 10% loss of body weight, fever or night sweats.
The diagnosis is usually made on lymph node biopsy. Staging requires careful examination for superficial nodes and computed tomographic (CT) scanning. Treatment is with chemotherapy, radiotherapy or a combination of the two depending on clinical, radiological and histological staging.

Myeloma

There is malignant proliferation of a specific clone of plasma cells resulting in the production of a monoclonal immunoglobulin known as a paraprotein.
Clinical features

Eighty percent of cases occur after the age of 50. Non-specific symptoms include malaise, lethargy and weight loss. Bone destruction from the expanding plasma cell clone causes pain, fractures and hypercalcaemia. Normochromic anaemia, thrombocytopenia and leukopenia (infections are common) occur as the normal bone marrow is replaced. Renal failure may result from hypercalcaemia or the presence of light chains, which may be nephrotoxic or become precipitated in tubules.

The International Myeloma Working Group has produced a classification system for monoclonal gammopathies, multiple myeloma and related disorders:

**Monoclonal gammopathy of undetermined significance (MGUS)**
- monoclonal protein (M-protein) $< 30$ g/l and bone marrow clonal cells $< 10\%$ with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis.

**Asymptomatic myeloma**
- M-protein $\geq 30$ g/l and/or bone marrow clonal cells $\geq 10\%$ but no related organ or tissue impairment (ROTI) (end-organ damage, see below).

**Symptomatic myeloma**
- M-protein $\geq 30$ g/l and/or bone marrow clonal cells $\geq 10\%$ and evidence of ROTI, which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process.

**Non-secretory myeloma**
- absence of an M-protein in the serum and urine with bone marrow plasmacytosis and ROTI.

The classification defines solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomatas (± recurrent) as distinct entities.

Investigation

There is usually anaemia with a markedly raised ESR. The monoclonal antibody is detected as a discrete M band on plasma protein electrophoresis. Free immunoglobulin light chains may be detectable in the urine (Bence Jones proteins are urinary light chains that precipitate on heating to $56^\circ C$ and redissolve on boiling). There may be hypercalcaemia and renal failure. Osteolytic lesions are seen on X-ray. Alkaline phosphatase is usually normal (lesions are destructive without osteoclastic activity).

In *Waldenström’s macroglobulinaemia* a monoclonal IgM paraprotein is produced. Radiological involvement of bone is rare, but anaemia and a bleeding tendency occur. Plasmapheresis is indicated if symptoms related to hyperviscosity are present.

Management of haematological malignancies

Management of haematological malignancies is under continuous review, and many patients are entered into multicentre trials. Patients should be treated in units with specialist experience of the drug regimens and supportive treatment, including transfusions and antibiotics.

Cytotoxics (to destroy rapidly dividing cells) are used alone or in combination with radiotherapy. In some cases induction of remission by intensive chemotherapy is followed by bone marrow transplantation. The following drugs are commonly used.

Alkylating agents

Alkylating agents transfer alkyl groups to DNA, interfering with its replication. They reduce fertility in males (consider sperm storage) and may be associated with premature menopause in females. They are teratogenic, but there does not appear to be an increase in fetal abnormalities in patients who are fertile after treatment. Bone marrow depression is common and prolonged use is associated with an increased incidence of acute non-lymphocytic leukaemia.

- **Cyclophosphamide** and the related drug ifosfamide for chronic lymphocytic leukaemia and lymphoma. Mesna is given if high intravenous doses are given to prevent haemorrhagic cystitis, which is caused by the urinary metabolite acrolein.
- **Chlorambucil** for chronic lymphatic leukaemia, lymphoma and Waldenström’s macroglobulinaemia.
- **Melphalan** for myeloma.
- **Busulphan** for chronic myeloid leukaemia.
- **Lomustine (CCNU)** is a nitrosourea used for Hodgkin’s disease.
- **Carmustine** is related to lomustine and used for multiple myeloma and non-Hodgkin’s lymphoma.

Antimetabolites

Antimetabolites are usually competitive analogues of normal metabolites. They cause gastrointestinal upsets and bone marrow depression.

- **Mercaptopurine, cladribine, clofarbine, nelarabine** are purine analogues used in acute leukaemias.
- **Cladribine** is a purine analogue used for hairy cell leukaemia.
Cytarabine, fludarabine and fluorouracil are pyrimidine analogues. Cytarabine is used in the induction of remission in acute myeloblastic leukaemia. Fludarabine is used in B-cell chronic lymphocytic leukaemia.

Tioguanine (thioguanine) is a guanine analogue that it used for acute leukaemias and chronic myeloid leukaemia.

Methotrexate inhibits dihydrofolate reductase, preventing synthesis of tetrahydrofolic acid that is needed as a coenzyme for synthesis of nucleic acids. It is used for childhood acute lymphoblastic leukaemia and non-Hodgkin’s lymphoma. Folinic acid can help to prevent myelosuppression and mucositis. It is excreted by the kidneys.

**Vinca alkaloids**

The vinca alkaloids arrest the cell cycle in mitosis. They cause peripheral and autonomic neuropathy and alopecia. Vincristine, vinblastine and vindesine are used for lymphomas and acute leukaemias.

**Cytotoxic antibiotics**

Cytotoxic antibiotics interfere with DNA or RNA synthesis through various mechanisms. Doxorubicin is used to treat lymphomas and acute leukaemias. Bleomycin is used to treat lymphomas. Mucositis and skin pigmentation occur. Dose-related pulmonary fibrosis limits prolonged use.

---

**Amyloidosis**

Amyloidosis is characterised by the tissue deposition of fibrillar proteins that stain with Congo red. Excess κ and λ light chains, associated with abnormal plasma cell proliferation, can form AL-type amyloid. In reactive (secondary or AA-type) amyloidosis, amyloid A protein is deposited, usually after many years of an inflammatory response induced by chronic infection or rheumatic disease. Amyloid A is a 76-amino-acid polypeptide fragment of an acute-phase protein termed serum amyloid A.

Although any organ can be involved, proteinuria is the most common presenting feature. Other sites commonly involved are the gastrointestinal tract, heart and liver.

Treatment is aimed at reducing production of amyloid precursor proteins through immunosuppression or chemotherapy. Chemotherapy followed by autologous stem cell transplantation has been used in AL amyloidosis.

In long-term dialysis, the patient’s β₂-microglobulin is deposited as amyloid in musculoskeletal tissue and the carpal tunnel. In Alzheimer’s disease and Down syndrome amyloid plaques are found in the cerebral cortex.
Infectious diseases

Within the community, virus infections of the upper respiratory and gastrointestinal tract are the most common, followed by common virus infections usually of children such as chickenpox, and the venereal diseases. Infections seen more frequently in hospitals usually relate easily to a single organ system and are dealt with in the relevant chapters.

Less frequent, but in diagnostic and management terms more difficult, are the imported diseases, sepsicaemia, pyrexia of unknown origin and infections of the immunosuppressed. The common infections, likely organisms and antibiotics of choice are shown in Table 21.1.

Imported diseases

The common diseases of travellers (Table 21.2) returning to temperate climates are malaria, acute gastroenteritis including typhoid, infectious hepatitis and worm infestation. Diarrhoea in returning travellers requires investigation for worms and parasites (especially *Giardia* and amoeba), but usually no organism is found and the symptoms settle spontaneously or with simple therapy. Other diseases common in the tropics but rarely seen in returning travellers include tuberculosis, schistosomiasis, hydatid disease, poliomyelitis, tetanus, cholera, leprosy and trypanosomiasis.

Malaria

Malaria is a disease of the subtropics and where the anopheline mosquito is found. Transmission is via the mosquito, which carries infected blood from infected to uninfected humans. The mosquito lives chiefly between latitude 15° north and south and not more than 1,500 m (5,000 ft) above sea level.

Clinical features

The patient presents with fever and rigors usually within 4 weeks of returning from or travelling through a malarial zone. Occasionally symptoms may not develop for 12 months or more. The patient has usually failed to take antimalarials regularly, not slept under mosquito nets or failed to continue prophylaxis for 6 weeks after returning. The fever may fit the pattern of tertian (a 3-day pattern with fever peaking every other day (*Plasmodium vivax* and *P. ovale*)), quartan (a 4-day pattern with fever peaking every third day) or subtetian (a non-specific febrile pattern (*P. falciparum*)). Diagnosis depends upon clinical awareness and then seeing the parasite in a blood film. In the UK, *P. falciparum* and *P. vivax* are most frequently seen in travellers from Africa and Asia. Malignant tertian malaria refers to *P. falciparum* which, very occasionally, produces high levels of parasitaemia (only *P. falciparum* gives red blood cell parasitaemia of > 1–2%), serious complications of cerebral malaria or acute haemolysis and renal failure (blackwater fever).

Prophylaxis

Prophylaxis is by a combination of mosquito control, sleeping under mosquito nets and specific prevention with proguanil (Paludrine) 200 mg/day, with chloroquine 300 mg twice weekly. For regions known to have chloroquine-resistant malaria, mefloquine, doxycycline and atovaquone-proguanil are used. Prophylaxis should be continued for 6 weeks after returning home.

NB Before advising travellers, check whether they are entering a malarial zone, and seek advice from the nearest centre for tropical diseases about the current recommended prophylaxis because drug resistance, particularly of *P. falciparum* malaria, is continually changing.
<table>
<thead>
<tr>
<th>Infection</th>
<th>Likely organism</th>
<th>Antibacterial of choice</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ear, nose and throat</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sore throat</td>
<td>Viral (most commonly)</td>
<td>Nil</td>
</tr>
<tr>
<td></td>
<td>Haemolytic streptococcus</td>
<td>Pencillin V or erythromycin q.d.s. if allergic to penicillin. Avoid amoxicillin if glandular fever possible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Amoxicillin or doxycycline or erythromycin</td>
</tr>
<tr>
<td>Sinusitis</td>
<td><em>Streptococcus pneumoniae</em></td>
<td>Amoxicillin or doxycycline or erythromycin</td>
</tr>
<tr>
<td></td>
<td><em>(pneumococcus)</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Haemophilus influenzae</em></td>
<td></td>
</tr>
<tr>
<td>Otitis media</td>
<td>Viral</td>
<td>Nil</td>
</tr>
<tr>
<td></td>
<td>As above plus haemolytic streptococcus</td>
<td></td>
</tr>
<tr>
<td>Acute epiglottitis</td>
<td><em>Haemophilus influenzae</em></td>
<td>Maintain airway plus cefotaxime or chloramphenicol (intravenous)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urinary tract</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute cystitis</td>
<td><em>Escherichia coli</em></td>
<td>Trimethoprim, or amoxicillin, or quinolone or cephalosporin</td>
</tr>
<tr>
<td>Acute pyelonephritis</td>
<td><em>Escherichia coli</em></td>
<td>Quinolone or cephalosporin</td>
</tr>
<tr>
<td>Prostatitis</td>
<td><em>Escherichia coli</em></td>
<td>Trimethoprim or quinolone</td>
</tr>
<tr>
<td><strong>Bone and soft tissue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulitis</td>
<td>Haemolytic streptococcus</td>
<td>Flucloxacillin and penicillin (or erythromycin if penicillin allergy)</td>
</tr>
<tr>
<td></td>
<td><em>Staphylococcus aureus</em></td>
<td>Flucloxacillin (or erythromycin if penicillin allergy)</td>
</tr>
<tr>
<td>Drip sites</td>
<td><em>Staphylococcus aureus</em></td>
<td>Penicillin (by injection initially if severe; or erythromycin if penicillin allergy)</td>
</tr>
<tr>
<td>Erysipelas</td>
<td>Haemolytic streptococcus</td>
<td>Penicillin (by injection initially if severe; or erythromycin if penicillin allergy)</td>
</tr>
<tr>
<td>Osteomyelitis</td>
<td><em>Staphylococcus aureus</em></td>
<td>Penicillin (by injection initially if severe; or erythromycin if penicillin allergy)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flucloxacillin (clindamycin if penicillin allergic) or vancomycin if meticillin-resistant staphylococcus. Vancomycin + fusidic acid if prosthesis or severe infection</td>
</tr>
<tr>
<td><strong>Gastrointestinal infections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute gastroenteritis</td>
<td>Viral</td>
<td>Nil</td>
</tr>
<tr>
<td>Shigellosis</td>
<td><em>Campylobacter</em></td>
<td>Erythromycin or ciprofloxacin</td>
</tr>
<tr>
<td>Amoebic</td>
<td><em>Shigella species</em></td>
<td>Ciprofloxacin or trimethoprim</td>
</tr>
<tr>
<td>Typhoid</td>
<td><em>Entamoeba histolytica</em></td>
<td>Metronidazole</td>
</tr>
<tr>
<td>Salmonella food poisoning</td>
<td><em>Salmonella species (&gt;1,000)</em></td>
<td>Ciprofloxacin or cefotaxime or chloramphenicol</td>
</tr>
<tr>
<td>Pseudomembranous colitis</td>
<td><em>Clostridium difficile</em></td>
<td>Nil (usually) unless invasive when ciprofloxacin or cefotaxime are used</td>
</tr>
<tr>
<td>Acute cholangitis</td>
<td><em>Escherichia coli</em></td>
<td>Metronidazole or vancomycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ciprofloxacin or gentamicin or cefotaxime (one-third of biliary coliforms are resistant to ampicillin/amoxicillin)</td>
</tr>
<tr>
<td><strong>Chest infections – in-hospital practice</strong></td>
<td>Gram-stain of sputum may identify the organism</td>
<td></td>
</tr>
<tr>
<td>Acute bronchitis</td>
<td>Viral</td>
<td>Nil</td>
</tr>
<tr>
<td>Acute on chronic bronchitis</td>
<td>Bacterial (<em>H. influenzae</em>)</td>
<td>Amoxicillin or tetracycline or erythromycin</td>
</tr>
<tr>
<td></td>
<td>(<em>Streptococcus pneumoniae</em>)</td>
<td></td>
</tr>
</tbody>
</table>

*Continued*
### Treatment

See Table 21.3.

### Acute attacks

Patients with malaria should be given oral quinine (or Malarone or Riamet). Intravenous quinine is potentially dangerous because it may produce cardiac asystole but is used in those who are vomiting or too ill to take oral therapy. Exchange transfusion may be required in very ill patients with high parasitaemia – consider if levels above 10%. Some require full intensive care, including treatment of cerebral oedema, renal and liver failure and shock. Hypoglycaemia from a combination of liver failure and quinine-induced insulin secretion is easily overlooked; pulmonary oedema from fluid overload is common in those treated for shock.

After treatment of the acute attack, falciparum malaria is cleared with Fansidar or doxycycline, and vivax malaria with primaquine (check the glucose-6-phosphate dehydrogenase status first).

### Typhoid

#### Clinical features

Symptoms begin with malaise, headache, dry cough and vague abdominal pain, up to 21 days after returning from a typhoid area. Travellers to any area with poor sanitation are at risk and typhoid occasionally occurs in non-travellers. In the first week, fever is marked, with dry cough and constipation typical features. In the second week, the fever persists, the abdomen distends, diarrhoea may or may not occur and rose spots develop as crops of pale pink macules on the sides of the

---

**Table 21.1 (Continued)**

<table>
<thead>
<tr>
<th>Infection</th>
<th>Likely organism</th>
<th>Antibacterial of choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia (community acquired)</td>
<td><em>S. pneumoniae</em>, <em>Mycoplasma pneumoniae</em>, <em>Legionella pneumoniae</em> (rarely <em>H. influenzae</em>, psittacosis)</td>
<td>Amoxicillin or erythromycin if penicillin allergic or atypical pathogen suspected. Add flucloxacillin or vancomycin if staphylococci suspected (e.g. complicating influenza)</td>
</tr>
<tr>
<td>In very unwell</td>
<td>Consider <em>Coliforms</em>, <em>Klebsiella</em>, <em>Staphylococci</em> during influenza epidemics</td>
<td>Erythromycin plus cephalosporin (cefotaxime, cefuroxime)</td>
</tr>
<tr>
<td><strong>Meningitis (adult) – most are viral (90%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes simplex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td><em>Streptococcus pneumoniae</em></td>
<td>Cefotaxime. Substitute penicillin if sensitive</td>
</tr>
<tr>
<td>Meningococcal</td>
<td><em>Neisseria meningitidis</em></td>
<td>Penicillin or cefotaxime</td>
</tr>
<tr>
<td>Haemophilus (more common in children)</td>
<td><em>Haemophilus influenzae</em></td>
<td>Cefotaxime (chloramphenicol is an alternative)</td>
</tr>
<tr>
<td>Listeriosis</td>
<td><em>Listeria monocytogenes</em></td>
<td>Amoxicillin + gentamicin</td>
</tr>
</tbody>
</table>

* Recurrent infection or ‘odd’ organisms, e.g. *Klebsiella, Pseudomonas*, suggest an underlying abnormality such as stone or tumour and further investigation is required. It is rarely possible to clear infection if there is an indwelling catheter (only treat if systemically ill). It is best to remove it if possible and, if not, try instilling an antiseptic, e.g. chlorhexidine 0.2%. Antibiotic use encourages the development of resistant organisms.

† Persistent bacteriuria is difficult to eradicate but patients can be kept relatively symptom-free with daily low dose prophylaxis with trimethoprim or cefalexin or nitrofurantoin.

‡ Treatment of osteomyelitis may be started by injection for 5–7 days depending upon response and may need to continue for 6 weeks or at least 12 weeks if chronic.

§ Patients with mild gastroenteritis without systemic illness or suspected systemic infection and who are excreting *Shigella* or *Salmonella* (including *S. typhi*) do not require antibiotics. The major problem is usually dehydration. Children in particular need fluid and electrolyte replacement.
abdomen. Delirium and death may occur in untreated cases.

NB Symptoms of dry cough, constipation and fever should be sufficient to alert the clinician, particularly in returning holiday-makers.

Investigation
Leukopenia and neutropenia may or may not be present. Blood culture is mandatory if typhoid is suspected and culture of urine and stool should also be performed.

Treatment
*Salmonella typhi* responds to ciprofloxacin. Cefotaxime is also effective.

NB
- It is unnecessary to give antibiotics to patients who are clinically well but from whom *S. typhi* is grown from the stools. If these patients are given antibiotics, they are more likely to become chronic excretors of antibiotic-resistant *S. typhi*.
- Typhoid must be reported to the public health authorities.
- Excretors of *S. typhi* are not allowed to work in the food industry.

### Dysentery

**Bacillary dysentery (shigellosis)**

Bacillary dysentery is caused by the genus *Shigella*. *S. sonnei* is the most common and occurs in outbreaks in close communities. It produces the most serious clinical form of the disease, including sepsicaemia. It is transmitted by faecal contamination of food and water and 2–4 days after ingestion produces acute diarrhoea, sometimes accompanied by abdominal colic, vomiting and tenesmus. If severe, there is rectal blood, mucus and pus. Asymptomatic carriage can occur.

The disease is prevented by good sanitation, clean water supplies and good personal hygiene. Infected patients should be isolated and rehydrated. Ciprofloxacin (or amoxicillin or trimethoprim if sensitive) are required if the patient is unwell, but antibiotics are not indicated for mild cases. The public health service must be informed and patients and close contacts should not handle food until the stool cultures are negative.

*Shigella* dysentery can be confused with *Salmonella* food poisoning, and amoebic and ulcerative colitis (p. 130).

**Amoebic dysentery**

This is an infection of the colon by the protozoon *Entamoeba histolytica*. In the acute dysenteric form, the illness begins suddenly with fever, abdominal pain, nausea, vomiting and diarrhoea containing mucus and blood. More commonly, amoebic colitis presents less acutely with intermittent diarrhoea with or without abdominal pain, mucus and blood.

The major complications are hepatic abscesses and pericolic amoebomas which can be confused with colonic carcinoma. The diagnosis is made by finding trophozoites or cysts in fresh faeces, rectal mucus or rectal biopsy and supported by a positive complement fixation test.

Metronidazole is the treatment of choice for all invasive forms of amoebiasis, but abscesses may have to be drained if they do not resolve on drug therapy. Diloxanide is used to eradicate chronic amoebic cysts.

Cyst excretors should not handle food, and contacts should be screened. Acute amoebiasis can be confused with bacillary dysentery, *Salmonella* food poisoning and ulcerative colitis, and chronic infection with *Giardia lamblia*, tropical sprue, ulcerative colitis and diverticular disease (p. 139).

### Giardiasis

*Giardia lamblia* is a flagellate protozoon which infects the small intestinal wall but not the blood. Viable cysts are ingested with contaminated food and may be excreted asymptptomatically, or produce diarrhoea and...
steatorrhoea. The diagnosis is confirmed by the presence of trophozoites or cysts in stools or duodenal aspirates. Tinidazole and metronidazole are the drugs of choice.

Pyrexia of unknown origin

There are many definitions of pyrexia of unknown origin. In practice, the difficulty arises when the cause is unidentified after the clear clinical possibilities have been excluded and a basic set of tests performed. It is usually a hospital problem. A broad-spectrum antibiotic has commonly been given. The causes are listed in Table 21.4.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Important side effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloroquine</td>
<td>GI upset, headache, retinal damage and cataracts, rarely myelotoxicity, psychosis.</td>
<td>Resistance is widespread, but confined to <em>Plasmodium falciparum</em>. Not active against dormant hepatic forms (hypnozoites) of <em>Plasmodium vivax</em> and <em>Plasmodium ovale</em></td>
</tr>
<tr>
<td>Fansidar (pyrimethamine and sulphasoxazole)</td>
<td>Skin rash, myelotoxicity</td>
<td>For eradication of <em>Plasmodium falciparum</em> infection</td>
</tr>
<tr>
<td>Maloprim (pyrimethamine and dapsone)</td>
<td>Skin rash, myelotoxicity</td>
<td>Prophylaxis only</td>
</tr>
<tr>
<td>Malarone (proguanil and atovaquone)</td>
<td>GI upset, mouth ulcers, insomnia, blood disorders, skin rash, hyponatraemia</td>
<td>Prophylaxis and treatment of uncomplicated <em>Plasmodium falciparum</em></td>
</tr>
<tr>
<td>Mefloquine</td>
<td>Contraindicated in first trimester, breast-feeding, neurological disease, epilepsy (including family history), liver disease, concurrent β-blocker therapy. Causes neuropsychiatric effects and GI upset. Avoid pregnancy for 3 months after stopping treatment. Treatment duration should not exceed 1 year</td>
<td>Prophylaxis and treatment of chloroquine-resistant <em>Plasmodium falciparum</em> malaria</td>
</tr>
<tr>
<td>Primaquine</td>
<td>GI upset, haemolysis, particularly in G6PD deficiency</td>
<td>Eradication of dormant hepatic forms (hypnozoites) of <em>Plasmodium vivax</em> and <em>Plasmodium ovale</em></td>
</tr>
<tr>
<td>Proguanil</td>
<td>GI upset, rarely mouth ulcers, Reduce dose in renal failure</td>
<td>Prophylaxis only</td>
</tr>
<tr>
<td>Quinine</td>
<td>Tinnitus, hypoglycaemia, headaches, flushing, GI upset, rash, myelotoxicity</td>
<td>Agent of choice for treatment of chloroquine-resistant or severe <em>Plasmodium falciparum</em> malaria</td>
</tr>
<tr>
<td>Riamet (artemether and lumefantrine)</td>
<td>GI upset, skin rash, arthralgia, myalgia, arrhythmias (QT prolongation)</td>
<td>Treatment of uncomplicated <em>Plasmodium falciparum</em></td>
</tr>
</tbody>
</table>

GI, gastrointestinal; G6PD, glucose-6-phosphate dehydrogenase.
* Doxycycline is an alternative in patients with epilepsy.

Special points in the history

- exposure to infection (meals away from home, febrile illness in household contacts, unpasteurised milk or cheese, undercooked eggs and poultry).
- drug history, e.g. antibiotics, methyldopa, hydralazine, phenytoin, including non-prescribed preparations.
- travel (malaria, amoebiasis) and sexual history.
- pets, including dogs, cats and birds.
Special points in examination

NB Repeat regularly, e.g. on alternate days, if the fever persists.

- **cardiovascular**: murmurs, especially if changing, suggest infective endocarditis; tender temporal arteries; Dressler syndrome
- **respiratory**: crackles (crepitations or rales) for early pneumonia (e.g. Legionnaires' disease); sinuses; consider recurrent pulmonary thromboembolic disease
- **abdomen**: palpable liver, gall bladder or spleen (with or without tenderness)
- **musculoskeletal**: muscle stiffness and tenderness of inflammatory diseases, e.g. polymyalgia rheumatica
- **skin rashes**: (drugs, rose spots of typhoid): splinter haemorrhages; Osler’s nodes
- **lymph nodes**: (all groups)
- **check all orifices**: mouth (teeth for apical abscesses), ears, perineum (anus and genitourinary tract)

**Table 21.4 Causes of pyrexia of unknown origin (mnemonic – IMAGINE)**

<table>
<thead>
<tr>
<th>Infections</th>
<th>Bacterial: Bacillary endocarditis and septicaemia (including culture-negative) Collections of pus Subphrenic Intrahepatic Perirenal Pleura Bone (osteomyelitis) Viral/rickettsial (including hepatitis B) Protozoal Malaria, amoeba, spirochaetes Specific Tuberculosis* (all sites), typhoid, Brucella, Lyme disease (Borreliaburgdorferi)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignancy</td>
<td>Kidney and liver (primary and secondary) Pancreas Micrometastases, lymphoma (Hodgkin’s and non-Hodgkin’s), leukaemia</td>
</tr>
<tr>
<td>Autoimmune diseases</td>
<td>Systemic lupus erythematosus, polyarteritis nodosa, systemic vasculitis Chronic active hepatitis Rheumatoid disease, Still’s disease (including adult Still’s disease, p. 295)</td>
</tr>
<tr>
<td>Granulomas</td>
<td>Sarcoid Crohn’s disease</td>
</tr>
<tr>
<td>Iatrogenic</td>
<td>Drug fever Factitious fever</td>
</tr>
<tr>
<td>Nurses and doctors and all paramedics, etc.</td>
<td>Consult exhaustive lists in big books, but remember that the cause is more often a rare manifestation of a common disease than a common manifestation of a rare disease</td>
</tr>
</tbody>
</table>

* Denotes a more likely cause of pyrexia of unknown origin; all are treatable and potentially curable.

**Basic screening tests already performed (check)**

Most will need to be repeated until a diagnosis has been achieved.

- **Haemoglobin**: if anaemia is present and considerable, it is usually relevant. If iron-deficient and there is no overt blood loss, exclude gut malignancy.
- **White blood cell (WBC) count**: neutrophilia is associated with pyogenic infection and neoplasia, and neutropenia with viral infection. Lymphocytosis may suggest tuberculosis. Leukaemia and infectious mononucleosis are usually associated with abnormal peripheral counts and cell types (remember direct tests for infectious mononucleosis). Eosinophilia may suggest parasites or polyarteritis nodosa.
- **Erythrocyte sedimentation rate**: if over 100 mm/h, check for myeloma and consider polymyalgia rheumatica or underlying malignancy.
- **Mid-stream urine**: haematuria, possibly microscopic, occurs with bacterial endocarditis, renal carcinoma, polyarteritis nodosa and leptospirosis. WBCs in infection. Early morning urine for acid-fast bacillus (AFB). NB Glycosuria suggests infection somewhere.
- **Chest X-ray**: carcinoma (primary or secondary) in lungs, and bone metastases. Miliary shadowing in miliary tuberculosis and sarcoid. Hilar nodes in tuberculosis, lymphoma, sarcoid and carcinoma.
- **Sputum**: for microorganisms, including AFB.
- **Liver function tests (LFTs)** for secondary or primary malignancy, abscess, biliary disease, hepatitis (p. 144).
- **Infectious mononucleosis** screening test, e.g. Monospot.
- **Blood culture** (∗3).

**Further tests commonly required as determined by clinical leads**

- viral, brucella, mycoplasma and coxiella antibody titres
- auto-antibody screen
- ultrasound or computed tomographic (CT) scan of abdomen for liver abscesses, and for secondaries,
for renal tumours and abscesses, and for splenic enlargement, and of the pelvis for pelvic lesions

- echocardiography for vegetations
- CT scanning of chest for lymphadenopathy and infection

**Invasive procedures as indicated**

- temporal artery biopsy
- liver needle biopsy (tuberculosis, granulomas, neoplasm)
- muscle biopsy

Go back again and again to take a new history, to re-examine the relevant areas and to repeat selected investigations, especially those that might have been performed too early, i.e. before they could have become abnormal.

**Other imported pathogens: nematodes, schistosomes**

The worms listed in Table 21.5 are found worldwide and not uncommonly in travellers who live rough or enter areas of poor sanitation.

**Septicaemia**

Common organisms are *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae* and *Enterococcus* species. Common sources include intravenous catheters, genitourinary and respiratory tract, and intra-abdominal foci. Coagulase-negative staphylococci isolated from blood cultures may be contaminants and not clinically significant, but they are a common cause of hospital-acquired bacteraemia related to intravenous catheters.

**Management**

General measures include good nursing care and fluid and electrolyte balance, and in severe cases intensive therapy, including treatment of shock and renal failure.

The key management points are:

1. Drain pus.
2. Antibiotics (see Table 21.6 for guidelines for appropriate choice).
5. If the patient is shocked:
   1. Treat hypovolaemia with plasma substitutes (e.g. dextran, gelatin).
6. Intensive care monitoring of:
   - (a) renal function and fluid balance
   - (b) right atrial pressure.
7. Consider use of inotropics sympathimetics (dobutamine, dopamine or dopexamine) or vasoconstrictor sympathimetics (norepinephrine).
8. Treat disseminated intravascular coagulation (DIC) by replacing deficient blood factors as required. The presence of DIC indicates a poor prognosis and the best means of treatment remains uncertain. Both extrinsic and intrinsic coagulation systems are activated, leading to consumption of coagulation factors and in turn to the widespread bleeding of DIC.

NB Corticosteroids are not of proven value in septicaemic shock unless there is associated adrenal damage (consider performing a short Synacthen test).

**Antibiotics**

The choice of antibiotic depends upon the likely organism and local policies and knowledge of antibiotic sensitivities (Table 21.6).

---

**Table 21.5 Common worms**

<table>
<thead>
<tr>
<th>Worm</th>
<th>Major clinical features</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Threadworm</td>
<td>Anal itch</td>
<td>Piperazine, Thiabendazole</td>
</tr>
<tr>
<td><em>(Enterobius vermicularis)</em></td>
<td>Worm on stool</td>
<td>(treat all household members to prevent reinfection)</td>
</tr>
<tr>
<td>Roundworm</td>
<td>Worm on stool</td>
<td>Piperazine</td>
</tr>
<tr>
<td><em>(Ascaris lumbricoides)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hookworm</td>
<td>Nil. If severe infection, iron-deficient anaemia; malnutrition in children Eggs or worms in stools</td>
<td>Bephenium (Alcopar), Pyrantel, Tetrachloroethylene</td>
</tr>
<tr>
<td><em>(Necator americanus: Ancylostoma duodenale)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schistosoma</td>
<td>Fever and eosinophilia</td>
<td>Praziquantel (for both)</td>
</tr>
<tr>
<td><em>S. mansoni</em> (spur on side)</td>
<td>Initially diarrhoea</td>
<td></td>
</tr>
<tr>
<td><em>S. haematobium</em> (spur on tail)</td>
<td>Haematuria</td>
<td></td>
</tr>
</tbody>
</table>
Influenza

Influenza viruses are enveloped single strand RNA viruses that require an RNA-dependent RNA polymerase of viral origin for replication. Their importance lies in their ability to cause epidemics (they occur more frequently than expected in a community or region) and pandemics (spread through populations). The virus escapes host immunity by mutation of surface antigens, and in particular haemaglutinin (HA), which is an important target for host antibodies. Vaccine development relies on worldwide surveillance to detect this process, which is known as antigenic drift.

Influenza viruses primarily cause upper respiratory tract infection, typically with fever, headache, malaise and myalgia. Secondary bacterial pneumonia, particularly due to *Staphylococcus aureus*, is common in the elderly. Oseltamivir and zanamivir reduce viral replication by inhibiting viral neuraminidase. They are licensed for use within the first 48 h of the onset of symptoms.

<table>
<thead>
<tr>
<th>Table 21.6 Antibiotics for septicaemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Community-acquired septicaemia</strong></td>
</tr>
<tr>
<td>Broad spectrum anti-pseudomonal penicillin (e.g. piperacillin, ticarcillin)</td>
</tr>
<tr>
<td>Add</td>
</tr>
<tr>
<td>• aminoglycoside if pseudomonas suspected</td>
</tr>
<tr>
<td>• vancomycin if meticillin-resistant <em>Staphylococcus aureus</em> suspected</td>
</tr>
<tr>
<td>• metronidazole if anaerobes suspected</td>
</tr>
<tr>
<td><strong>Hospital-acquired septicaemia</strong></td>
</tr>
<tr>
<td>Broad spectrum anti-pseudomonal beta-lactam antibiotic (e.g. piperacillin, ticarcillin, ceftazidime, or meropenen)</td>
</tr>
<tr>
<td>Add</td>
</tr>
<tr>
<td>• aminoglycoside if pseudomonas suspected</td>
</tr>
<tr>
<td>• vancomycin if meticillin-resistant <em>Staphylococcus aureus</em> suspected</td>
</tr>
<tr>
<td>• metronidazole if anaerobes suspected</td>
</tr>
<tr>
<td><strong>Septicaemia related to vascular catheter</strong></td>
</tr>
<tr>
<td>Vancomycin</td>
</tr>
<tr>
<td>Add</td>
</tr>
<tr>
<td>• aminoglycoside and broad spectrum antipseudomonal beta-lactam if Gram-negative sepsis suspected</td>
</tr>
<tr>
<td>If possible remove or replace vascular catheter.</td>
</tr>
</tbody>
</table>

*Beta-lactam antibiotics share a common structural feature, the beta-lactam ring, and include penicillins, cephalosporins, carbapenems, monobactams and beta-lactamase inhibitors.*

**Human immunodeficiency virus infection**

HIV-1 and HIV-2 are members of the Lentivirus family of retroviruses. The virus preferentially infects CD4+ helper T lymphocytes, leading to a decline in CD4 cell counts with impaired cell-mediated immunity. Eventually, the immune system becomes clinically compromised and the patient develops the infectious, neurological and neoplastic complications characteristic of acquired immunodeficiency syndrome (AIDS). HIV-2 shares 45% sequence homology with HIV-1, and is found mainly in West Africa. It is less pathogenic in vitro and transmission rates appear to be lower.

Viral transmission is through sexual contact (homo- and heterosexual) or blood-borne (intravenous drug abuse or transfusion of blood or blood products). Blood for transfusion must be routinely screened. Approximately 20% of children born to HIV-positive mothers are infected, some through breast-feeding.

**Clinical features**

Half of cases develop a febrile illness with malaise, headache, pharyngitis, lymphadenopathy and maculopapular rash 2–4 weeks after infection. Antibody tests for HIV become positive 2–6 weeks after this illness. Patients then remain free from serious illness for a number of years. They may then develop symptoms of malaise, fever, weight loss with features of mild immunodeficiency (e.g. oral *Candida*, cutaneous herpes zoster or herpes simplex) or immune dysfunction (immune thrombocytopenia, drug allergies). There may be generalised lymphadenopathy.

Once HIV infection has been confirmed by serological and/or virological evidence of HIV infection, HIV infection can be classified according to immunological and clinical criteria (Tables 21.7–21.9). Clinical stages are related to prognosis and survival, and can be used to guide treatment. The World Health Organization (WHO) has defined four clinical stages of HIV infection (Tables 21.7–21.9).

**Opportunistic infections**

These remain the most frequent complications of HIV infection.

**Candidiasis**

Oral *Candida albicans* infection is common, presenting with typical white plaques or mucosal erythema or candidiasis. Topical treatments (nystatin or amphotericin lozenges) may be effective, but oesophageal or genital candidiasis are indications for systemic therapy with fluconazole.
Pneumocystis jiroveci pneumonia

Exposure is common in the general population, but clinical disease only occurs in severe immunodeficiency. Up to 85% of AIDS patients develop Pneumocystis jiroveci pneumonia (PCP), 60% at presentation.

Cough and progressive dyspnoea are accompanied by fever, cyanosis, tachycardia, tachypnoea and confusion. Auscultation of the chest may be normal. Chest X-ray is normal early in the disease, but widespread, diffuse interstitial shadowing develops. Twenty percent of cases have atypical features of lobar consolidation, upper zone shadowing or hilar lymphadenopathy. Pneumothorax is a recognised complication. Patients are usually hypoxic.

Diagnosis depends on identification of the organism by microscopy in sputum, bronchoalveolar lavage or transbronchial biopsy, although treatment is often commenced on clinical grounds.

Treatment is high-dose co-trimoxazole (100 mg/kg/day sulfamethoxazole and 20 mg/kg/day trimethoprim) in divided doses orally or intravenously for 21 days. Adverse reactions are common and intravenous pentamidine 4 mg/kg/day is an alternative.

High-dose oxygen and mechanical ventilation may be required in severe disease. Steroids improve survival in patients with hypoxia ($\text{PaO}_2 < 9.3 \text{ kPa}$).

Prophylaxis is continued with co-trimoxazole 960 mg/day three times per week or monthly inhaled pentamidine.

Mycobacterial infections

*Mycobacterium tuberculosis* infection is the most frequent life-threatening opportunistic infection and the leading cause of death in people with HIV. It may occur as a result of reactivation or primary infection at any stage of HIV infection. Pulmonary presentation may be with typical apical cavitation and fibrosis or more generalised lung infiltrates. Extrapulmonary tuberculosis (lymph nodes, bone, bone marrow, genitourinary tract, liver, spleen, skin, peritoneum, central nervous system) occurs in 50% of patients. Antiretroviral therapy is the most important measure in reducing the incidence of TB. Standard treatment regimens (e.g. isoniazid with pyridoxine, rifampicin, pyrazinamide and ethambutol) are usually used (p. 349).
<table>
<thead>
<tr>
<th>Clinical stage 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic</td>
</tr>
<tr>
<td>Persistent generalised lymphadenopathy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical stage 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate unexplained weight loss</td>
</tr>
<tr>
<td>(&lt; 10% of presumed or measured body weight)</td>
</tr>
<tr>
<td>Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media and pharyngitis)</td>
</tr>
<tr>
<td>Herpes zoster</td>
</tr>
<tr>
<td>Angular cheilitis</td>
</tr>
<tr>
<td>Recurrent oral ulceration</td>
</tr>
<tr>
<td>Papular pruritic eruptions</td>
</tr>
<tr>
<td>Seborrhoeic dermatitis</td>
</tr>
<tr>
<td>Fungal nail infections</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical stage 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unexplained severe weight loss (&gt; 10% of presumed or measured body weight)</td>
</tr>
<tr>
<td>Unexplained chronic diarrhoea for longer than 1 month</td>
</tr>
<tr>
<td>Unexplained persistent fever (above 37.6 °C intermittent or constant for longer than 1 month)</td>
</tr>
<tr>
<td>Persistent oral candidiasis</td>
</tr>
<tr>
<td>Oral hairy leukoplaikia</td>
</tr>
<tr>
<td>Pulmonary tuberculosis (current)</td>
</tr>
<tr>
<td>Severe bacterial infections (such as pneumonia, empyema, pyomyositis, bone or joint infection, meningitis or bacteraemia)</td>
</tr>
<tr>
<td>Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis</td>
</tr>
<tr>
<td>Unexplained anaemia (&lt; 8 g/dl), neutropenia (&lt; 0.5 x 10^9 per litre) or chronic thrombocytopenia (&lt; 50 x 10^9 per litre)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical stage 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV wasting syndrome</td>
</tr>
<tr>
<td>Pneumocystis pneumonia</td>
</tr>
<tr>
<td>Recurrent severe bacterial pneumonia</td>
</tr>
<tr>
<td>Chronic herpes simplex infection (orolabial, genital or anorectal of more than 1 month’s duration or visceral at any site)</td>
</tr>
<tr>
<td>Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)</td>
</tr>
<tr>
<td>Extrapulmonary tuberculosis</td>
</tr>
<tr>
<td>Kaposi’s sarcoma</td>
</tr>
<tr>
<td>Cytomegalovirus infection (retinitis or infection of other organs)</td>
</tr>
<tr>
<td>Central nervous system toxoplasmosis</td>
</tr>
<tr>
<td>HIV encephalopathy</td>
</tr>
<tr>
<td>Extrapulmonary cryptococcosis including meningitis</td>
</tr>
<tr>
<td>Disseminated non-tuberculous mycobacterial infection</td>
</tr>
<tr>
<td>Progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>Chronic cryptosporidiosis (with diarrhoea)</td>
</tr>
<tr>
<td>Chronic isosporiasis</td>
</tr>
<tr>
<td>Disseminated mycosis (coccidiomycosis or histoplasmosis)</td>
</tr>
<tr>
<td>Recurrent non-typhoidal Salmonella bacteraemia</td>
</tr>
<tr>
<td>Lymphoma (cerebral or B-cell non-Hodgkin’s) or other solid HIV-associated tumours</td>
</tr>
<tr>
<td>Invasive cervical carcinoma</td>
</tr>
<tr>
<td>Atypical disseminated leishmaniasis</td>
</tr>
<tr>
<td>Symptomatic HIV-associated nephropathy or symptomatic HIV-associated cardiomyopathy</td>
</tr>
</tbody>
</table>

Assessment of body weight in pregnant women needs to consider the expected weight gain of pregnancy.

1 Unexplained refers to where the condition is not explained by other causes.

2 Some additional specific conditions can also be included in regional classifications (such as reactivation of American trypanosomiasis (meningoencephalitis and/or myocarditis)) in the WHO Region of the Americas and disseminated penicillosis in Asia.)
Co-trimoxazole is usually given as prophylaxis against other infections. Multi-drug-resistant TB is a major threat to individuals with HIV and public health, particularly in countries with a high prevalence of HIV.

**Cytomegalovirus**

Cytomegalovirus (CMV) retinitis occurs in 10% of AIDS patients, usually presenting as unilateral visual loss. Asymptomatic lesions may be detected as fluffy white areas of necrosis and haemorrhage on fundoscopy. Untreated progression to bilateral blindness occurs. Initial treatment is with intravenous ganciclovir. Maintenance therapy with oral or intravenous ganciclovir is continued, although ultimately progression occurs. CMV encephalitis presents with cognitive loss, and motor and behavioural abnormalities. It can be difficult to distinguish from other causes of AIDS dementia complex (direct effect of HIV infection, herpes simplex encephalitis, *Toxoplasma gondii*), although diagnosis can be established by brain biopsy. Response to ganciclovir is limited.

**Cryptococcal infection**

*Cryptococcus neoformans* is a capsulate yeast widely present in bird droppings. Infection occurs by inhalation. Meningitis is the most common manifestation in AIDS, although pneumonia and skin sepsis also occur.

Presentation of cryptococcal meningitis is usually non-specific, with prolonged fever, headache, malaise, nausea and vomiting. Diagnosis is confirmed by identification of capsulate yeasts or cryptococcal antigen in cerebrospinal fluid. Treatment is with intravenous amphotericin followed by oral fluconazole, aciclovir.

**Toxoplasma**

Primary infection with the protozoon *Toxoplasma gondii* is usually acquired during childhood by eating infected cat faeces or undercooked meat. An infectious mononucleosis-type illness is followed by persistence of *Toxoplasma* cysts in the central nervous system and elsewhere. Vertical transmission from mother to child also occurs and causes fetal abnormalities, including central nervous system abnormalities.

Reactivation of *T. gondii* in AIDS usually manifests with neurological features, including fever, confusion, fits and focal neurological deficit. Choroidoretinitis may precede encephalitis. Patients are seropositive for *T. gondii* and cranial CT reveals multiple hypodense lesions. Treatment is with pyrimethamine and folinic acid (to reduce haematological toxicity of pyrimethamine) and sulfadiazine or clindamycin.

**Diarrhoea**

Abdominal pain, diarrhoea and weight loss are common, and usually indicate infection, although no specific pathogen is identified in 25–50% of cases. Bacterial pathogens such as *Salmonella*, *Shigella*, *Campylobacter jejuni*, *Giardia lamblia* and *Entamoeba histolytica* should be excluded by stool microscopy and culture. *Cryptosporidium parvum* usually causes a self-limiting illness in normal individuals, but causes severe, prolonged diarrhoea in AIDS patients who may also develop cholangitis and cholecystitis. It may respond to paromycin.

**Herpes simplex**

Recurrent oral, genital or perianal ulceration is common and usually responds to systemic (oral or intravenous) aciclovir. Herpes simplex encephalitis typically presents with headache, fever, confusion and temporal lobe abnormalities. Culture of cerebrospinal fluid is usually negative for herpes simplex. Diagnosis can be established by brain biopsy, but treatment with intravenous aciclovir is usually started on clinical grounds.

**Herpes zoster**

Cutaneous dissemination of typical herpes zoster (p. 309) can occur. Treatment is with intravenous aciclovir.

**Progressive multifocal leukoencephalopathy**

Progressive multifocal leukoencephalopathy (PML) is caused by reactivation of the polyomavirus JC which is a common asymptomatic infection in childhood. Two percent of AIDS patients develop PML with development of multiple, progressive, neurological defects. CT scan shows multiple non-enhancing lesions. Brain biopsy may be required to exclude other treatable lesions. There is no specific treatment for PML.

**Malignancy**

Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cervical carcinoma are all AIDS-defining illnesses.

*Kaposi’s sarcoma* occurs almost exclusively in homosexual males, suggesting that an additional sexually transmitted agent is important. Palpable, violaceous cutaneous nodules occur most commonly on the head and neck. Lesions also occur in other organs, including lungs and gastrointestinal tract. Radiotherapy can cause regression of local disease.

*Non-Hodgkin’s lymphoma* often presents with widespread extranodal disease. Differentiation of central nervous system lymphoma from *Toxoplasma gondii* infection can be difficult and require brain biopsy.

*Cervical carcinoma*, abnormal cervical cytology and human papillomavirus infection are all more common in HIV-infected women, who should have cervical smears at least annually.
Primary treatment of HIV

The development of therapies for AIDS requires an understanding of how the HIV-1 virus integrates into the human genome, and how viral replication and viral gene expression are regulated (Figs. 21.1 and 21.2).

The proviral genome of HIV-1 is 9–10 kb long and has three main structural genes:

- The \textit{gag} (group-specific antigen) gene encodes the core protein antigens of the virion (intact virus particle). These are formed as the cleaved products of a larger precursor protein.
- The \textit{pol} (polymerase) gene encodes the viral reverse transcriptase, and also the IN protein required for integration of viral DNA into the host genome.
- The \textit{env} gene encodes the two envelope glycoproteins, which are cleaved from a larger precursor.

When the HIV virion binds to a CD4 molecule on the cell surface, a conformational change occurs in the envelope glycoprotein, and the virus enters the cell via fusion of lipid bilayers at the cell surface. The uncoated core of the virion then uses its viral reverse transcriptase to transcribe one of the two identical strands of positive-sense RNA into DNA. This DNA is duplicated by a host cell DNA polymerase, and migrates to the nucleus where it is integrated at a random site into the genome. Transcription of the integrated viral DNA is regulated by both host factors (such as the DNA-binding protein NFkB), and viral regulatory proteins such as the tat and rev proteins. Virally encoded proteins are processed and assembled in the cytoplasm, and then bud from the cell surface as new infectious virions.

Ideally patients should start antiretroviral treatment before they become unwell or develop opportunistic infection. The WHO recommendations for initiating therapy are shown in Table 21.10.

Anti-retroviral therapy (ART)

Several sites in the viral life cycle have been targeted, and effective treatment requires combination therapy (see Trials Box 21.1).
Nucleoside reverse transcriptase inhibitors (NRTIs)

Zidovudine (AZT) was the first anti-HIV drug to be introduced. It is a nucleoside analogue which binds preferentially to viral reverse transcriptase compared to human DNA polymerase. Other NRTIs include didanosine (ddI), dideoxycytosine (ddC; zalcitabine), abacavir, lamivudine, stavudine, tenofovir and emtricitabine.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Efavirenz and nevirapine are NNRTIs. Most share a conformation that allows them to interact with a hydrophobic site on reverse transcriptase. They are highly selective for HIV1 and do not inhibit HIV2.

Protease inhibitors

Ritonavir, indinavir, amprenavir, lopinavir, atavanavir, nelfinavir, tipranavir and saquinavir prevent viral maturation. Gastrointestinal side effects are common (nausea, diarrhoea, abdominal pain, vomiting). Protease inhibitors are associated with lipodystrophy, hyperlipidaemia, insulin resistance and hyperglycaemia.

Combination antiretroviral therapy for HIV infection has revolutionised the treatment of HIV. Most first-line therapies for adults use a combination of two NRTIs plus one NNRTI, preserving protease inhibitors for second-line treatments. In most patients a rise in CD4 cell counts and immune recovery follow initiation of therapy.

Infectious mononucleosis (glandular fever)

Infectious mononucleosis is a common disease of the young, usually transmitted by saliva, with an excellent prognosis. It is caused by the Epstein–Barr virus (a herpesvirus). Seroprevalence is > 90% in adults.


<table>
<thead>
<tr>
<th>Target population</th>
<th>Clinical condition</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic individuals (including pregnant women)</td>
<td>WHO clinical stage 1</td>
<td>Start ART if CD4 ≤ 350</td>
</tr>
<tr>
<td>Symptomatic individuals (including pregnant women)</td>
<td>WHO clinical stage 2</td>
<td>Start ART if CD4 ≤ 350</td>
</tr>
<tr>
<td></td>
<td>WHO clinical stage 3 or 4</td>
<td>Start ART irrespective of CD4 cell count</td>
</tr>
<tr>
<td>TB and hepatitis B coinfections</td>
<td>Active TB disease</td>
<td>Start ART irrespective of CD4 cell count</td>
</tr>
<tr>
<td></td>
<td>HBV infection requiring treatment (chronic active hepatitis)</td>
<td>Start ART irrespective of CD4 cell count</td>
</tr>
</tbody>
</table>

* The current standard definition of chronic active hepatitis in industrialised countries is mainly based on histological parameters obtained by liver biopsy, a procedure not usually available in the large majority of resource-limited settings. A global definition of chronic active hepatitis for resource-limited settings based on clinical and more simple laboratory parameters is under discussion.

TRIALS BOX 21.1 Anti-retroviral therapy (ART)

The 2NN Study was a multi-centre, open label, randomised controlled trial of the NNRTIs nevirapine and efavirenz, in which 1,216 antiretroviral-therapy-naive patients were assigned nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine, for 48 weeks. Antiretroviral therapy with nevirapine or efavirenz showed similar efficacy, and the authors concluded that triple-drug regimens with either NNRTI are valid for first-line treatment. There were differences in safety profiles, and combination of nevirapine and efavirenz did not improve efficacy but caused more adverse events. (Lancet. 2004; 363: 1253–1263.)
Clinical presentation
Malaise, fever, sore throat, muscle and joint aches. Examination reveals a tonsillar exudate and palatal petechiae with generalised lymphadenopathy and splenomegaly. A macular–papular rash is common and more frequent if ampicillin is given for the sore throat. Mesenteric adenitis with appendicitis may occur.

Investigation
There is a leucocytosis with an absolute and relative (> 50% of total white cells) increase in mononuclear cells. Patients with infectious mononucleosis produce IgM antibodies that bind to and agglutinate red cells from other species, giving rise to a positive Paul Bunnell or monospot test.

Thrombocytopenia and abnormal liver function tests are common but rarely severe.

Complications
Tonsillar enlargement may be severe and prevent swallowing of saliva and even threaten airway obstruction. Rare complications include splenic rupture, autoimmune haemolytic anaemia, encephalitis, transverse myelitis, Bell’s palsy and Guillain–Barré syndrome. Lethargy may last for several months.

Differential diagnosis
The disease may be confused with:
- acute tonsillitis
- infections that produce a similar rash, e.g. measles, rubella
- infections that produce similar malaise and lymphadenopathy, e.g. toxoplasmosis, brucellosis, tuberculosis
- lymphomas and leukaemias
- AIDS
- drug hypersensitivity
- acute appendicitis.

NB Diphtheria should not be forgotten.

Treatment
Usually rest, aspirin gargles and anaesthetic lozenges for the sore throat are sufficient. If the tonsillar enlargement is great and swallowing is difficult or the airway threatened (anginose glandular fever – usually with severe general symptoms), a short course of steroids (prednisolone 40 mg/day for 5–10 days) rapidly reduces the symptoms.

Tuberculosis
Tuberculosis most commonly causes pulmonary disease (p. 122) but can affect any site, including the central nervous system (p. 198). In the UK it is a statutory requirement to notify all cases of tuberculosis, and this initiates contact tracing if appropriate. National Institute for Health and Clinical Excellence (NICE) guidelines (http://www.nice.org.uk/nicemedia/pdf/CG033niceguideline.pdf) recommend a 6-month short course regimen (Table 21.11), with four drugs in the initial phase, should be used for all forms of tuberculosis, except meningitis, in children and adults.

Drug-resistant tuberculosis is increasing and it is vital to confirm bacteriological diagnosis and drug susceptibility whenever possible. Treatment of drug-resistant tuberculosis, and in particular multi-drug-resistance, requires specialist expertise and close collaboration with Mycobacterium reference laboratories.

Chronic fatigue syndrome
A report of the joint working group of the Royal Colleges of Physicians, Psychiatrists and General Practitioners used this term to describe the syndrome characterised by a minimum of 6 months of severe physical and mental fatigue and fatigability, made worse by minor exertion. The term myalgic encephalomyelitis (ME)

<table>
<thead>
<tr>
<th>Table 21.11 Treatment of tuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Respiratory and non-respiratory</strong></td>
</tr>
<tr>
<td>Initial phase</td>
</tr>
<tr>
<td>I, R, P, E</td>
</tr>
<tr>
<td>I, R, P, E</td>
</tr>
<tr>
<td>Meningitis/central nervous system</td>
</tr>
</tbody>
</table>

Liver function tests (LFTs) should be checked before starting therapy. Transient asymptomatic increases in serum transaminases are very common after starting treatment. Discontinuation is not indicated unless there are symptoms of hepatitis (anorexia, vomiting, hepatomegaly) or jaundice. Steroids are used in life-threatening or widespread tuberculosis in an attempt to reduce acute inflammation and allow time for drugs to work. They are usually indicated for pericarditis, extensive pulmonary disease, moderate or severe meningitis, ureteric tuberculosis and pleural effusion.
was first used in 1955 to describe an unexplained illness in the staff of the Royal Free Hospital. Although ME has been linked to chronic fatigue syndrome, it describes a specific pathological process which is not found in these patients.

Apart from profound fatigue, there are no other features or physical signs that distinguish chronic fatigue syndrome. Associated psychiatric disorders, particularly anxiety and depression, are common. There is no convincing evidence that common viral infections are a risk factor for chronic fatigue syndrome, with the exception of the fatigue that follows less than 10% of Epstein–Barr virus infections.

**Investigation**

Criteria for the diagnosis of chronic fatigue syndrome have been described (see Trials Box 21.2). No laboratory tests can confirm the diagnosis. The following should be performed to exclude other causes of fatigue:

- full blood count, erythrocyte sedimentation rate
- creatinine and electrolytes, liver function test, C-reactive protein, glucose
- thyroid and adrenal function
- creatine kinase
- urinalysis for protein and sugar.

**Management**

A gradual planned increase in exercise is the main objective. Cognitive behaviour therapy helps achieve this in some patients. Antidepressants should be given if there is evidence of an associated depressive disorder. NICE guidelines highlight the importance of shared decision-making between the patient and healthcare professional (http://www.nice.org.uk/nicemedia/pdf/CG53FullGuidance.pdf).
Poisoning is one of the commonest medical emergencies and accounts for approximately 5–10% of all acute medical admissions in the UK. Table 22.1 lists the most frequently encountered causes, but is not exhaustive, and the clinician must keep an open mind when poisoning is suspected as patients may take/be exposed to a diverse array of toxic substances (with considerable variation from country to country). Accidental poisoning is common in children and drugs are best kept in child-proof containers out of their reach.

Deliberate self-administration of drugs/substances with a view to causing harm or even death presents a major challenge not only in terms of dealing with the physical consequences of exposure to one or more toxins, but also with respect to addressing underlying psychosocial issues. Clinicians involved in the management of these complex cases need to adopt a holistic approach – ensuring that the patient comes to no/minimal physical harm is only the first step in management, and additional psychological/ongoing support to minimise the risk of further similar episodes is almost always required.

Not all episodes of poisoning are immediately self-evident, and it is important to keep an open mind when assessing patients for whom the immediate cause of their presentation is unclear. Clues that should alert you to a possible case of poisoning include: current/past history of depression/psychiatric illness; previous history of overdose/self-harm; history of excess alcohol consumption; social isolation/difficulties; needle marks; empty packets of drugs brought in by relatives/paramedics; admission from a workplace/ environment where potential toxins are present.

Clinical presentation

Many patients who take drug overdoses are still conscious when seen and will often state which tablets they have taken and/or bring the bottle(s)/packet(s) with them. If unconscious, then other causes of coma must also be considered even if an overdose is suspected, e.g. is the patient known to have diabetes (exclude hypoglycaemia) or be steroid-dependent (check for steroid card or alert bracelet)? Is there any evidence of a head injury? Relatives or friends may know whether the patient is currently under active medical treatment. Patients often take more than one drug and very often alcohol in addition.

As always, a good history and careful physical examination are central both to establishing the extent to which the patient has suffered adverse effects in cases of known poisoning and to providing clues as to possible aetiological factors in suspected cases/where the agent is unknown. Figure 22.1 correlates clinical findings with specific poisons, although it is important to note that in the early stages clinical signs may be limited, while mixed overdoses can be associated with overlapping features.

Typical features of commonly encountered drug overdoses involving prescription/over-the-counter (OTC) medications are shown in Table 22.2, and those resulting from use of ‘recreational’ drugs and/or alcohol/ethanol in Table 22.3.

Management

General measures

All patients with suspected poisoning should be admitted to hospital for further assessment/monitoring. Symptomatic treatment and supportive measures will suffice in most cases, but specific antidotes may be required. Begin with an assessment of:

- Airway
- Breathing
- Circulation
Cardiorespiratory dysfunction

Ventilatory support and optimisation of cardiac function/blood pressure should be provided where necessary in accordance with standard management guidelines/protocols for patients with cardiorespiratory depression. Patients with a reduced conscious level must be monitored in a high-dependency/intensive care setting.

Nausea/vomiting

Vomiting is a common side effect of poisoning and usually responds to anti-emetics.

Agitation

Simple reassurance and support and nursing in a quiet environment will suffice in most cases. Always exclude other possible treatable causes (e.g. hypoxia, hypotension, hypoglycaemia) before considering the use of sedatives. Where required, short-acting agents (e.g. diazepam) are preferred with appropriate monitoring.

Seizures

Single short-lived convulsions do not require treatment – but check that there is no other reversible cause (e.g. hypoglycaemia, electrolyte disturbance). Persistent or recurrent seizures should be treated with lorazepam or diazepam and the patient transferred to a high-dependency/intensive care setting.

Temperature dysregulation

Hypothermia may develop in any patient with a reduced conscious level, especially if cold-exposed. Active warming measures can be used to raise the temperature in a controlled manner, with cardiac monitoring for arrhythmias.

Hyperthermia may occur in patients taking CNS stimulants. Removal of excess clothing, use of a fan and sponging with tepid water may help. In cases of severe hyperthermia check with the National Poisons Information Service (see below) for advice on specific measures.

Psychiatric assessment

Once the physical consequences of poisoning have been prevented/treated, formal psychiatric evaluation is required in all cases of suspected self-harm. For patients deemed to be at high risk of further self-harm/suicidal intent, consider special (one-to-one) nursing while medical management is completed and psychiatric review awaited.

Specific measures

UK National poisons information service and TOXBASE

Specialist information and advice on the management of suspected/confirmed cases of poisoning is available 24 h a day from the UK National Poisons Information Service (NPIS). If in doubt, seek early help. TOXBASE is the primary clinical toxicology database of NPIS and is available online to registered users at www.toxbase.org. It provides a wealth of information about diagnosis, investigation and treatment of patients who have been exposed to drugs, household products and industrial/agricultural chemicals.

Preventing absorption and enhancing elimination of ingested toxins

Gastric lavage

This is rarely required and is of limited value if performed more than 1 h after ingestion. Its use should be reserved for substances that cannot be effectively removed by other means (e.g. iron, lithium), and only if a life-threatening amount has been ingested within the previous hour. It must only be undertaken if the airway is adequately protected/secured, and should not be used if a corrosive substance has been swallowed. It is advisable to check with NPIS/TOXBASE if considering gastric lavage.

Activated charcoal

Given by mouth, activated charcoal (50 g in an adolescent/adult; children 1 g/kg) can bind many drugs/poisons in the gastrointestinal tract, thereby reducing their absorption. It should be given as soon as possible and confers benefits up to 1 h after

---

Table 22.1  Common causes of poisoning in the UK

<table>
<thead>
<tr>
<th>Class/agent</th>
<th>Example(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>Paracetamol (acetaminophen), aspirin and other NSAIDs (e.g. ibuprofen)</td>
</tr>
<tr>
<td>Analgesics</td>
<td>Tricyclic antidepressants, selective serotonin reuptake inhibitors</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Amfetamines, cocaine, opioids</td>
</tr>
<tr>
<td>Carbon monoxide</td>
<td>Glue, lighter fuel</td>
</tr>
<tr>
<td>Drugs of misuse</td>
<td></td>
</tr>
<tr>
<td>Solvents</td>
<td></td>
</tr>
</tbody>
</table>

---

Hyperthermia may occur in patients taking CNS stimulants. Removal of excess clothing, use of a fan and sponging with tepid water may help. In cases of severe hyperthermia check with the National Poisons Information Service (see below) for advice on specific measures.

Psychiatric assessment

Once the physical consequences of poisoning have been prevented/treated, formal psychiatric evaluation is required in all cases of suspected self-harm. For patients deemed to be at high risk of further self-harm/suicidal intent, consider special (one-to-one) nursing while medical management is completed and psychiatric review awaited.

Specific measures

UK National poisons information service and TOXBASE

Specialist information and advice on the management of suspected/confirmed cases of poisoning is available 24 h a day from the UK National Poisons Information Service (NPIS). If in doubt, seek early help. TOXBASE is the primary clinical toxicology database of NPIS and is available online to registered users at www.toxbase.org. It provides a wealth of information about diagnosis, investigation and treatment of patients who have been exposed to drugs, household products and industrial/agricultural chemicals.

Preventing absorption and enhancing elimination of ingested toxins

Gastric lavage

This is rarely required and is of limited value if performed more than 1 h after ingestion. Its use should be reserved for substances that cannot be effectively removed by other means (e.g. iron, lithium), and only if a life-threatening amount has been ingested within the previous hour. It must only be undertaken if the airway is adequately protected/secured, and should not be used if a corrosive substance has been swallowed. It is advisable to check with NPIS/TOXBASE if considering gastric lavage.

Activated charcoal

Given by mouth, activated charcoal (50 g in an adolescent/adult; children 1 g/kg) can bind many drugs/poisons in the gastrointestinal tract, thereby reducing their absorption. It should be given as soon as possible and confers benefits up to 1 h after
Seizures
- Anticonvulsants
- Theophylline
- Tricyclic antidepressants

Jaundice
- Organic solvents
- Paracetamol

Respiratory:
- Bronchospasm/pulmonary oedema
  - Volatile agents (e.g., chlorine gas)
  - Beta-blockers (in susceptible patients)
- Hyperventilation
  - Salicylates

Vomiting
- Aspirin/non-steroidals
- Iron
- Opioids
- Paracetamol

Abdominal pain
- Iron
- Paracetamol

Rhabdomyolysis
- Amphetamines

Hyperthermia
- Amphetamines (e.g., Ecstasy)
- Cocaine
- 5-HT drugs (serotonin syndrome)

Pupil size
- Constricted:
  - Opioids
- Dilated:
  - Amphetamines, cocaine, other stimulants
  - Benzodiazepines
  - Tricyclic antidepressants

Cardiovascular:
- Bradycardia:
  - Beta-blockers
  - Calcium channel antagonists
  - Digoxin
  - Opioids
- Tachycardia/arrhythmias:
  - Cocaine, other stimulants
  - Digoxin
  - Tricyclic antidepressants
- Hypertension:
  - Alpha agonists
  - Cocaine

Hypoglycaemia
- Insulin
- Sulphonylureas

Pruritus
- Opioids

Vomiting
- Aspirin/non-steroidals
- Iron
- Opioids
- Paracetamol

Haemodialysis is generally reserved for patients who have ingested significant amounts of a toxin with a low volume of distribution/weak protein binding, e.g., salicylates, lithium, methanol, ethylene glycol.

Specific toxins
Specific antidotes are available for a small number of toxins and can be life-saving (e.g., N-acetylcysteine in paracetamol overdose) (Fig. 22.2). In addition, complications associated with certain poisons benefit from targeted therapies (e.g., use of sodium bicarbonate to treat arrhythmias caused by tricyclic antidepressant overdose), while in other cases avoidance of ingestion, and occasionally longer if dealing with modified release preparations. Repeated doses may be required for certain toxins whose elimination is aided even after they have been absorbed (e.g., carbamazepine, quinine, theophylline).

Certain substances (acids, alkalis, metals/metallic salts (e.g., mercury, iron, lithium), methanol, ethylene glycol) are not bound by activated charcoal – if in doubt, check with NPIS/TOXBASE.

Alkaline diuresis and dialysis
Alkalisation of the urine (pH 7.5–8.5) may aid elimination of salicylates. It should be undertaken in a high-dependency/intensive care setting.

Figure 22.1 Clinical clues to poisoning with specific drugs/agents.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Clinical features</th>
<th>Specific investigations</th>
<th>Specific management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>• Hyperventilation, tinnitus/deafness, sweating, vasodilatation, abdominal pain</td>
<td>• Plasma salicylate level (repeated measurements may be needed as absorption can be slow); generally the clinical severity of poisoning is low at concentrations &lt; 500 mg/l (3.6 mmol/l) unless there is evidence of metabolic acidosis (note: correlation is less reliable in the young or elderly); severe salicylate poisoning occurs with levels &gt; 700 mg/l (5.1 mmol/l)</td>
<td>• Activated charcoal if presenting within 1 h of ingestion of ≥ 125 mg/kg body weight</td>
</tr>
<tr>
<td></td>
<td>• Complex acid–base disturbances (e.g., respiratory alkalosis with metabolic acidosis)</td>
<td></td>
<td>• Consider alkaline diuresis with sodium bicarbonate if clinical condition dictates or plasma salicylate level &gt; 500 mg/l</td>
</tr>
<tr>
<td></td>
<td>• Seizures/coma in severe cases</td>
<td></td>
<td>• Haemodialysis is the treatment of choice for severe salicylate poisoning</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>• Drowsiness</td>
<td>• CE, ABGs (including pH)</td>
<td>• Activated charcoal if presenting within 1 h of ingestion providing patient is alert and airway protected</td>
</tr>
<tr>
<td></td>
<td>• Ataxia, dysarthria, confusion</td>
<td>• Measurement of plasma drug levels is of little clinical use</td>
<td>• The benzodiazepine antagonist flumazenil should not be routinely used, and must be avoided in those with a history of seizures or if there is concomitant ingestion of tricyclic antidepressants (lowers seizure and arrhythmia thresholds)</td>
</tr>
<tr>
<td></td>
<td>• Mild hypotension and respiratory depression</td>
<td>• Consider oxygen saturation monitoring if concerns regarding respiratory depression</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Increased toxicity when combined with other drugs/alcohol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>• Bradycardia, hypotension</td>
<td>• Measurement of plasma drug levels is of little clinical use</td>
<td>• Cardiac monitoring</td>
</tr>
<tr>
<td></td>
<td>• Bronchospasm or heart failure in susceptible individuals</td>
<td></td>
<td>• Atropine to correct bradycardia/hypotension</td>
</tr>
<tr>
<td></td>
<td>• Seizures and coma may occur with some agents, e.g., propranolol</td>
<td></td>
<td>• Glucagon infusion may be beneficial in refractory/severe cases</td>
</tr>
<tr>
<td></td>
<td>• Hypotension</td>
<td></td>
<td>• Isoprenaline or transvenous pacing may be used to increase heart rate</td>
</tr>
<tr>
<td></td>
<td>• Confusion, coma and metabolic acidosis in more severe cases</td>
<td></td>
<td>• NPIS should be consulted over choice of inotrope in cases of refractory hypotension</td>
</tr>
<tr>
<td></td>
<td>• Bradycardia/arrhythmias with diltiazem and verapamil</td>
<td></td>
<td>• Calcium chloride or calcium gluconate may be tried in severe poisoning</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>• Nausea, vomiting, dizziness, agitation</td>
<td>• Measurement of plasma drug levels is of little clinical use</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Symptoms</td>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>Gastrointestinal upset (nausea, vomiting, diarrhoea) • Altered colour vision • Arrhythmias</td>
<td>Plasma digoxin level does not indicate toxicity reliably, but values &gt; 1.5 mcg/l are associated with rising likelihood of toxicity • CE (check particularly for hypokalaemia) • Cardiac monitoring • Correct hypokalaemia • Consider use of digoxin-specific antibody fragments (Digibind®) in severe poisoning</td>
<td></td>
</tr>
<tr>
<td>Iron salts</td>
<td>Gastrointestinal upset (abdominal pain, nausea, vomiting, diarrhoea, haematemesis and rectal bleeding) • Hypotension • Metabolic acidosis, hepatic failure and coma in more severe cases</td>
<td>Measurement of serum iron level as an emergency • Advice regarding gastric lavage should be sought from NPIS if presenting within 1 h of ingestion • Desferrioxamine (do not delay treatment while awaiting serum iron level)</td>
<td></td>
</tr>
<tr>
<td>Lithium</td>
<td>Apathy and restlessness are early features • Nausea, vomiting, diarrhea • Ataxia, weakness, dysarthria, muscle twitching, tremor • Seizures, coma, renal failure in severe cases</td>
<td>Measurement of serum lithium levels provides an indication of severity of overdose (although in acute overdose higher serum concentrations may be present without features of toxicity) • Advice regarding gastric lavage should be sought from NPIS if presenting within 1 h of ingestion • Consider haemodialysis in more severe cases</td>
<td></td>
</tr>
<tr>
<td>Non-steroidal anti-inflammatory drugs (NSAIDs)</td>
<td>Gastrointestinal upset (abdominal pain, vomiting, diarrhoea); occasionally tinnitus and headache • Seizures (particularly with mefamalic acid) • Renal failure, acidosis, coma in more severe cases</td>
<td>Measurement of plasma drug levels is of little clinical use • FBC, CE, LFTs, ±ABGs (including pH) • Activated charcoal if presenting within 1 h of ingestion of ≥ 100 mg/kg body weight of ibuprofen or ≥ 10 tablets of other NSAIDs • Proton-pump inhibitors may ameliorate gastric irritation</td>
<td></td>
</tr>
<tr>
<td>Opioids</td>
<td>Small or pin-point pupils • Depressed respiration • Reduced conscious level • Needle marks • Marked hypoventilation, hypotension, non-cardiogenic pulmonary oedema, hypothermia and coma occur in more severe cases and may lead to death</td>
<td>Plasma paracetamol level – consider possible overdose with combination analgesics (e.g. co-codamol) • High-dependency monitoring of respiratory status and respiratory support • Naloxone (opioid antagonist) is effective in reversing respiratory depression and coma, but has a short half-life and repeated doses/infusion are often required, especially when long-acting opioids (e.g. methadone) have been ingested</td>
<td></td>
</tr>
<tr>
<td>Paracetamol (acetaminophen)</td>
<td>Initial asymptomatic latent phase of variable duration • Followed by nausea/vomiting, jaundice, hepatic tenderness • Hepatic failure</td>
<td>Plasma paracetamol level (interpret with respect to timing of overdose – see Fig. 22.2); in staggered overdoses levels are not reliable and treatment should be instituted without delay • In those presenting late check CE, LFTs, INR, ABGs • Activated charcoal if presenting within 1 h of ingestion of ≥ 150 mg/kg body weight (≥ 75 mg/kg if considered high risk – see Fig. 22.2) or &gt; 12 g in total (whichever is the smaller) • N-acetylcysteine infusion (most effective if given within 8 h of ingestion); decision to treat is based on single plasma paracetamol level taken at not &lt; 4 h after ingestion (see Fig. 22.2)</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table 22.2 (Continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Clinical features</th>
<th>Specific investigations</th>
<th>Specific management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective serotonin reuptake inhibitors</td>
<td>• Nausea, vomiting, diarrhoea, agitation, tremor</td>
<td>• Routine measurement of plasma drug levels is not indicated</td>
<td>• Contact NPIS if presenting &gt; 8 hours post-ingestion (or staggered overdose) and commence N-acetylcysteine immediately (do not wait for blood level)</td>
</tr>
<tr>
<td></td>
<td>• Drowsiness, tachycardia</td>
<td>• No specific investigations in less severe cases</td>
<td>• Liver transplantation should be considered in those who present with liver failure</td>
</tr>
<tr>
<td></td>
<td>• Seizures</td>
<td>• In more severe cases investigations are directed by presentation</td>
<td>• Activated charcoal if presenting within 1 h of ingestion</td>
</tr>
<tr>
<td></td>
<td>• Rarely ‘serotonin syndrome’ – marked neuropsychiatric effects, neuromuscular hyperactivity, autonomic instability, hyperthermia, rhabdomyolysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td>• Anticholinergic effects: dry mouth/skin, blurred vision/dilated pupils, tachycardia, urinary retention</td>
<td>• Routine measurement of plasma drug levels is not indicated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Seizures, depressed respiration, reduced consciousness, coma, arrhythmias, hypotension</td>
<td>• CE (+ calcium and magnesium if ECG abnormalities); ABGs (including pH)</td>
<td>• Activated charcoal if presenting within 1 h of ingestion</td>
</tr>
<tr>
<td></td>
<td>• Metabolic acidosis</td>
<td>• ECG: prolongation of QRS interval (&gt; 140 ms), SVT, VT/VF</td>
<td>• Cardiac monitoring</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Correct electrolyte abnormalities, hypoxia and acidosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Avoid anti-arrhythmic drugs (pro-arrhythmogenic in this setting)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Sodium bicarbonate (50 ml of 8.4% – repeated as necessary) for those with QRS prolongation, arrhythmias or hypotension; consider transvenous pacing wire if recurrent arrhythmias</td>
</tr>
</tbody>
</table>

ABGs, arterial blood gases; CE, creatinine and electrolytes; ECG, electrocardiogram; FBC, full blood count; INR, international normalised ratio; LFTs, liver function tests; NPIS, National Poisons Information Service; PT, prothrombin time; SVT, supraventricular tachycardia; VT/VF, ventricular tachycardia/fibrillation.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Clinical features</th>
<th>Specific investigations</th>
<th>Specific management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol/ethanol</td>
<td>Impaired coordination/reactions, Dysarthria, ataxia, diplopia, tachycardia, sweating</td>
<td>Breath/blood alcohol level, CE, glucose, ABGs</td>
<td>Monitor respiratory status/protect airway, Correct hypovolaemia and hypoglycaemia, Benzodiazepines if recurrent/ prolonged seizures, Haemodialysis in cases of severe poisoning</td>
</tr>
<tr>
<td>Amphetamines</td>
<td>Wakefulness, excessive activity, agitation, paranoia, hallucinations</td>
<td>CE, LFTs, CK, glucose, FBC, ECG</td>
<td>Close monitoring of temperature and blood pressure, Active cooling if pyrexial, Benzodiazepines for excessive agitation or seizures, Contact NPIS for advice on management of hypertension</td>
</tr>
<tr>
<td>Ecstasy (MDMA)</td>
<td>Nausea, trismus (jaw-clenching), dilated pupils, blurred vision, sweating, hyper-reflexia</td>
<td>ECG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypertension, Exhaustion, seizures, coma, hyperthermia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>As per other amphetamines</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dehydration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>May also cause severe reactions even at previously tolerated doses: delirium, coma, seizures, arrhythmias, hyperthermia, rhabdomyolysis, renal/hepatic failure, ARDS, DIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hyponatraemia (excess water ingestion ± increased ADH secretion)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rarely may cause ‘serotonin syndrome’</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low doses: conjunctival injection, drowsiness, tachycardia, slurred speech and ataxia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High doses: anxiety confusion, paranoid psychosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Although cannabinoid metabolites can be detected in urine, levels do not correlate well with toxicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cocaine can be detected in urine, ECG</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Activated charcoal if presenting within 1 h of oral ingestion, Cardiac monitoring, Close monitoring of temperature and blood pressure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cocaine/crack cocaine</td>
<td>Euphoria, agitation, aggression, hallucinations, Dilated pupils, sweating, pyrexia, nausea, vomiting, Tachycardia, hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Clinical features</td>
<td>Specific investigations</td>
<td>Specific management</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>• Seizures</td>
<td>• Active cooling if pyrexial</td>
<td>• Arrhythmias: correct electrolyte disturbances; consider verapamil for SVT; avoid beta-blockers (unopposed alpha-agonist activity) and other anti-arrhythmic drugs</td>
</tr>
<tr>
<td></td>
<td>• Arrhythmias, hypertensive crisis, myocardial infarct and cerebrovascular accident (vasospasm), hyperpyrexia</td>
<td></td>
<td>• Cerebrovascular/myocardial ischaemia/infarction – seek expert help to confirm secondary to vasospasm (avoid thrombolysis); control blood pressure; symptom control</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Benzdiazepines for seizures</td>
</tr>
</tbody>
</table>

ABGs, arterial blood gases; ADH, antidiuretic hormone; ARDS, adult respiratory distress syndrome; CE, creatinine and electrolytes; CK, creatine kinase; DIC, disseminated intravascular coagulation; ECG, electrocardiogram; FBC, full blood count; LFTs, liver function tests; MDMA, 3,4-methylenedioxymethamphetamine; NPIS, National Poisons Information Service.
Patients whose plasma-paracetamol concentrations are above the **normal treatment line** should be treated with acetylcysteine by intravenous infusion (or, if acetylcysteine cannot be used, with methionine by mouth, provided the overdose has been taken *within 10–12 hours* and the patient is not vomiting).

Patients at high-risk of liver damage include those:
- taking liver enzyme-inducing drugs (e.g. carbamazepine, phenobarbital, phenytoin, primidone, rifampicin, rifabutin, efavirenz, nevirapine, alcohol, St John’s wort)
- who are malnourished (e.g. in anorexia or bulimia, cystic fibrosis, hepatitis C, in alcoholism, or those who are HIV-positive)
- who have not eaten for a few days.

These patients should be treated if their plasma-paracetamol concentration is above the **high-risk treatment line**. The prognostic accuracy after 15 hours is uncertain but a plasma-paracetamol concentration above the relevant treatment line should be regarded as carrying a serious risk of liver damage.

**Figure 22.2** Algorithm for management of paracetamol overdose. Reproduced with permission from University of Wales College of Medicine Therapeutics and Toxicology Centre.
Certain classes of drug is recommended to avoid exacerbating the situation (e.g. anti-arrhythmics in tricyclic antidepressant overdose). Tables 22.2 and 22.3 outline specific investigations and management measures for poisoning associated with prescription/over-the-counter medications (Table 22.2) and alcohol/‘recreational’ drugs (Table 22.3). For more detailed information on a broader range of toxins consult NPIS/TOXBASE.

**Carbon monoxide poisoning**

Carbon monoxide (CO) is a colourless, odourless, non-irritant gas; poisoning is usually due to inhalation of smoke, car exhaust or fumes from incomplete burning of gas fires/cookers, as occurs with blocked flues or when combustion occurs in a confined space. CO reduces the oxygen-carrying capacity of blood by binding to haemoglobin to form carboxyhaemoglobin (COHb) and dramatically reduces tissue oxygen delivery.

Clinical features vary from headache, nausea and vomiting with low level exposure, through drowsiness, hyperventilation and ataxia, to seizures, coma and death after exposure to high concentrations. Cerebral oedema is common and focal neurological signs may be present. If the patient survives the acute episode, neurological sequelae including tremor, memory impairment, personality change and visual loss may ensue, while other patients develop marked Parkinsonian features.

A high index of clinical suspicion is required; demonstration of an elevated COHb concentration in blood confirms the diagnosis but does not accurately predict prognosis, as treatment (\(O_2\) therapy) prior to hospital admission can result in lower measured levels. Arterial blood gases should be checked and ECG monitoring performed.

Removal from the source of exposure is a critical first step in the management of suspected CO poisoning. In addition to basic life-support measures, high flow oxygen (e.g. 15 l/min via a tightly fitting face mask) should be delivered without delay and the patient transferred urgently to hospital for further assessment. Continued/prolonged oxygen therapy is often required until COHb levels fall to < 5% (normal values range from 3–5% in non-smokers, up to 10% in smokers).

NB Standard pulse oximetry is unreliable in CO poisoning as COHb is mistaken for oxyhaemoglobin. A specific pulse CO-oximeter may be used instead.

The role of hyperbaric oxygen in the treatment of CO poisoning remains controversial and all cases being considered for this should be discussed with NPIS. Cerebral oedema is treated along conventional lines.
Figures in italics give the exact conversion factor, those in Roman give a rough approximation. Shaded areas indicate normal ranges (absolute values may vary with sex / age).
Index

Note: page numbers in italics refer to figures, those in bold refer to tables and boxes

ABCD score for stroke risk assessment 181
abdomen 28–38
abnormal masses 29, 30
auscultation 30
CT imaging 32
examination 28–30
observation 28
organs 28–9, 30
palpation 28
percussion 28
right subcostal region mass 31
suprapubic mass 31
see also diarrhoea; jaundice
abdominal wall veins, blood flow 28, 31
acanthosis nigricans 244, 314, 316, Plate 19.13
acceptability, assessment tools 66
accommodation, visual 42–3, 50
acipimox 250
acitretin 300
acne vulgaris 304
acneiform eruptions, drug-induced 313
acoustic neuroma 203
acromegaly 217
clinical features 219, 220
investigations 222
actinic keratoses 318, Plate 19.17
activated charcoal, in poisoning 352–3
acute alcoholic hepatitis 145
acute coronary syndromes 88
acute lymphatic leukaemia (ALL) 332
acute myeloid leukaemia (AML) 330, 332
acute obstruction, limbs 108
acute tubular necrosis (ATN) 157
Addisonian crisis 224
Addison’s disease, skin manifestations 314
adenosine, atrial tachycardia 86
adrenal disorders, skin manifestations 314
agonism, poisoning 352
agnosia 53
akinetic rigid syndromes 190, 191–2
alanine aminotransferase 36
alcohol consumption
dementia 186
gastro-oesophageal reflux 129
hyperuricaemia 291
mortality 147
poisoning 352, 357
alcoholic hepatitis 147–8
alcoholism, Wernicke–Korsakoff syndrome 186, 253
aldosterone antagonists, heart failure 91
alkaline diuresis, poisoning 353
alkaline phosphatase, jaundice 35–6
alkylating agents 335
allopurinol
gout 292
urinary tract stones 154
alopecia areata 320
Alport syndrome 159
alteplase 180
myocardial infarction 80–1
Alzheimer’s disease 183–5
aetiopathogenesis 184
amyloid plaques 335
clinical features 184
diagnostic criteria 184
management 184–5
amantadine 191
5-aminosalicylic acid (5-ASA) 131
amiodarone
atrial fibrillation 85
atrial flutter 85
atrial tachycardia 86
ventricular tachycardia 87
amoebic dysentery 339
amfetamine poisoning 357
amyloidosis 316, 335
amyotrophic lateral sclerosis (ALS) 188
anaemia
aplastic 330
chronic kidney disease 162–3
haematological reference values 324
haemolytic 327–30
assessment (Continued)
standard setting 67
summative 66
tools 66
asthæsia 56
asthma 111–13
occidental 124
physical findings 21
athetosis 56, 192
atmospheric pollution, lung cancer 119
atrial fibrillation 83, 84–5
atrial septal defect complication 102
management 85
mitral stenosis 100
thyrotoxicosis complications 212
Wolff–Parkinson–White syndrome 86–7
atrial flutter 83, 85–6
atrial myxoma 101
atrial septal defect 15, 101, 102
atrial tachycardia 86
atrioventricular fibrillation 18
autoimmune disease
anaemia 321
face examination 8
hepatitis 147, 149
polyglanulard endocrinopathies 227–8
rheumatic disorders 277–83
autonomic neuropathy 243–4
axillae, general examination 9
azathioprine
Crohn’s disease 133
sarcoidosis 122
β-blockers 74
heart failure 91
hypertension 95–6
myocardial infarction 81, 84
pheochromocytoma 226
poisoning 354
thyrotoxicosis 211
B-cell lymphoma, Sjögren syndrome 282
bacillary dysentery 339
back pain 294–5
bacterial infections
acne vulgaris 304
neurological 198–200
septic arthritis 293–4
skin 305, 306–7, Plate 19.8
see also named organisms
bacterial overgrowth 138
bacterial toxins 200
bacteruria 153
bagassosis 125
ballismus 56, 192
bariatric surgery 252
barium enema, Crohn’s disease 132–3
barium swallow X-ray 33, 34
Barrett’s oesophagus 130
Barter syndrome 168
basal cell carcinoma 318, Plate 19.18
Beau’s lines 320
Becker muscular dystrophy 198
behavioural modification, obesity 252
Behçet’s disease 290
bentiromide test 138
benzodiazepine poisoning 354
benzoyl peroxide 304
beriberi 253
bicarbonate deficit 169
bicornes 235–6, 237
bile acid sequestrants 250
bile duct obstruction 36
bile salts
deficiency 137
excretion 139
biliary cirrhosis 148
bilateral jaundice 35, 36
biomarkers, myocardial infarction 75, 77, 80
bird fancier’s lung 125
bisphosphonates 259, 262, 263
bladder
emptying 153
spinal cord disorders 193
blast cells 321
bleeding disorders 331–2
bleomycin 335
blistering 316–17
drug-induced 313
blood gases 22–5
arterial gas patterns 23-4
hypoxaemia 24
blood pressure 10
endocrine disease 58
thyroid status assessment 61
see also hypertension
blood transfusions 326
hazards 324
hepatitis C 146
malaria 338
thalassaemias 329
blueprinting, assessment tools 66
body mass index (BMI) 251
bone
lung cancer 119
metabolic disease 257–62
see also fractures
bone densitometry 258–9
bone marrow disorders 329–30
marrow aplasia/failure 330
suppression 323
bone mineral density 259
borderline group methods 67–8, 71
botulism 200
Bowen’s disease 319
brachial plexus lesions 195
brainstem death, criteria 207
breasts 8, 9
endocrine/metabolic disease 59
bronchial adenoma 120
bronchial obstruction, lung abscess 117
bronchiectasis 117
bronchodilators
asthma 113
COPD 111
bronzed diabetes 151–2
Brown–Séquard syndrome 193
Budd–Chiari syndrome 151
budesonide, Crohn’s disease 133
bulbar palsy 53
bullous disorders 316–17
drug-induced 313
bundle branch block, ECG 79–80
burr cells 321
busulphan 335
caecal carcinoma 136
calcimimetics 266
calcitonin
hypercalcaemia 263–4
metabolic bone disease 257
Paget’s disease 262
calcitriol 300
calcium
hypocalcaemia 267
inadequate intake 170
osteoporosis prevention 259
see also hypercalcaemia; hypocalcaemia
calcium-channel blockers
hypertension 94, 95, 161
poisoning 354
calcium gluconate 267
calcium pyrophosphate deposition disease 292–3
Calgary–Cambridge Guide 2
Campylobacter jejuni diarrhoea 34, 346
Candida albicans
mucosal 314
opportunistic infection in HIV 343
oral/oesophageal infection 314
skin infections 310
cannabis poisoning 357
captopril, urinary tract stones 154
carbon monoxide
poisoning 352, 360
transfer factor 25
carboxyhaemoglobin 360
carcinoid 120
pulmonary stenosis 101
carcinoid syndrome 120
carcinomatous neuropathy 196
cardiac arrhythmias 83, 84–8
sudden death with ventricular arrhythmias 92
cardiac axis 18
cardiac murmurs 13, 15
cardiac rehabilitation programmes 82, 84
cardiac resynchronisation, heart failure 92
cardiomyopathy 107–8
dilated 91, 107
hypertrophic 91, 107
restrictive 107
cardiopulmonary arrest 88, 89, 90
cardiopulmonary resuscitation
face examination 7
hand examination 10
history 11
leg examination 9
poisoning 352
cardiovascular disease 73–109
sudden death with ventricular arrhythmias 92
cardiomyopathy 91, 107–8
cardiorespiratory arrest 88, 89, 90
chronic kidney disease 161–2
congenital heart disease 15, 101–5
constrictive pericarditis 105–6
driving 88
heart failure 13, 88–9, 91–2
ischaemic heart disease 73–5
peripheral arterial disease 108–9
rheumatoid arthritis clinical presentation 271–2
syphilitic aortitis 104, 107
systemic lupus erythematosus 278, 279
valvular heart disease 15, 97–101
see also hypertension; myocardial infarction (MI)
cardiovascular system 10–16, 17, 18
thyroid status assessment 61
carmustine 335
carotid endarterectomy 180
carpal tunnel syndrome 54, 58, 195, 293
cataract, diabetes 242
cauda equina 194
central scotoma 49
cerebellar degeneration 205
cerebellar gait 55
cerebellar incoordination 54
cerebral cortical lesions 54
cerebral tumours 202–3
cervical carcinoma, HIV infection 346
cervical radiculopathy 194
Charcot arthropathy 195, 244
Charcot–Marie–Tooth disease 205–6
cheiroarthropathy 314
chest X-rays 22, 23, 24, 25
children
epilepsy 175
juvenile-onset Still’s disease 295
Kawasaki disease 287
Lesch–Nyhan syndrome 291
leukaemia 332
malnutrition 252
reflux nephropathy 154
rickets 260
urinary tract infection 153, 155
Chlamydia psittaci (psittacosis) 116
chlorambucil 335
chloroquine 340
cholécystite 142–3
cholophíasis 143
cholera 35
cholestasis, drug-induced 152
cholesterol
hypercholesterolaemia 247, 248
levels in diabetes 241
total 249
see also dyslipidaemia
cholestyramine 148
chondrocalcinosis 292–3
chorea 56, 186, 192, 205
chronic fatigue syndrome 349–50
chronic interstitial nephritis 154
chronic lymphatic leukaemia (CLL) 332
chronic myeloid leukaemia (CML) 333
chronic obstructive pulmonary disease (COPD)  110–11
physical findings  21
Churg–Strauss syndrome  289
cicatricial pemphigoid  317
ciclosporin  300, 304
cigarette smoking  see smoking
cinaclacet  266
circulatory overload  324
cirrhosis  148–9
biliary  148
classification  148
end-stage  146
hepatitis C  146
idiopathic haemochromatosis  152
portal hypertension  150–1
rare conditions  151–2
Wilson’s disease  152
cladribine  335
clinical competence assessment  71–2
clonidine  96
clonus  48
clopidogrel  74, 180, 182
Clostridium botulinum (botulism)  200
Clostridium difficile
diarrhoea  34
toxins  131
Clostridium tetani (tetanus)  200
clothing factors  331
cirubbing  19, 20–22
Graves’ disease  314
hand examination  7
inflammatory bowel disease  134
lung cancer  119
nail disorders  320
cogulation defects  324
coal tar  297
cocarctation of the aorta  14, 15, 93, 104
cocaine/crack cocaine poisoning  357–8
cocardecic disease  137
cognitive behavioural therapy, chronic fatigue
syndrome  350
cognitive function, tests  39–40
colchicine  291
colectomy  131, 132
colitis
ischaemic  140
see also Crohn’s disease; pseudomembranous colitis;
ulcerative colitis
colon, angiodyplasia  136
colon carcinoma
bleeding  136
ulcerative colitis differential diagnosis  131
colonoscopy  134
colorectal carcinoma  134
coma
diabetic  238–41
myxoedema  213, 214
combined lower and upper motor neuron lesions  55
comedones  304
communication  1
relationship building  4
skills assessment  6
skills categories  2
computed tomography (CT)
abdominal  32, 36
chest  22, 26
haematuria  156
renal  153, 154
concentration testing  39
concussion, headache  172, 173
congenital adrenal hyperplasia  225
congenital aortic stenosis  97
congenital erythropoietic porphyria  256
congenital heart disease  15, 101–5
congenital hypothyroidism  211
congenital pulmonary stenosis  101
congestive cardiomyopathy  107
conjunctivae, abdomen examination  28
connective tissue, lung cancer  119
connective tissue diseases  277–83
conscious level assessment  206
constructive pericarditis  105–6
consultations, effective  1
continuous ambulatory peritoneal dialysis (CAPD), chronic
kidney disease  163
continuous positive airway pressure (CPAP), obstructive
sleep apnoea  125
coordination
abnormalities  54–5
arm  46
leg  48
coproporphyria, hereditary  256, 257
coronary angiography  75
coronary arteries, anatomy  76
coronary arteriography, angiography  74
coronary artery bypass graft  75
coronary artery disease  73, 75
coronary revascularisation  75
Corrigan’s sign  98
corticosteroids
asthma  113
Crohn’s disease  133
eczema  304
gout  291
hypercalcaemia  263
inhaled in COPD  111
intravenous in ulcerative colitis  131
pemphigoid  317
pemphigus  316
psoriasis  300
rheumatoid arthritis  274
sarcoidosis  121
tonsillar enlargement in infectious mononucleosis  349
Wegener’s granulomatosis  288
 Corynebacterium diphteriae  200
cost-effectiveness, assessment tools  66
cough
lung cancer  119
occupational lung disease  125
cranial arteries  284–6
cranial nerves  41–4
creatinine kinase  77, 80
Creutzfeldt–Jakob disease (CJD)  185
criterion-referencing  67
Crohn’s disease  132–4
aetiology  132
diabetic nephropathy 241, 242–3
diabetic neuropathy 196, 241, 243–4
diabetic retinopathy 241–2
diarrhoea infectious 34, 346
investigations 34–5
diabetes modification in obesity 252
urinary tract stones 154
diabetic fibre 139
diffuse cutaneous systemic sclerosis (DCSS) 281, 282
digoxin atrial fibrillation 85
heart failure 92
poisoning 355
dilated cardiomyopathy 91, 107
dipeptidylpeptidase-4 (DPP-4) inhibitors 236–7
diphtheria 200
direct current cardioversion atrial fibrillation 85
atrial flutter 85, 86
atrial tachycardia 86
ventricular tachycardia 87
direct observations of procedural skills (DOPS) 68, 70, 72
disaccharidase deficiency, malabsorption 138
disc prolapse, acute central 194
discoid lupus erythematosus 314
disopyramide, atrial tachycardia 86
disseminated intravascular coagulation (DIC) 332
septicaemia 342
dissociated anaesthesia 54
distal symmetrical polyneuropathy 243
dithranol 297
diuretics ascites 151
heart failure 91
thiazide hypertension 94, 95, 96, 161
urinary tract stones 154
diuretic disease 136, 139
ischaemic colitis differential diagnosis 140
dizziness 52–3
dorsal column ataxia 55
dorsal column loss 54–5
without spinothalamic loss 54
Down syndrome 101
amyloid plaques 335
doxorubicin 335
doxycycline 338
driving cardiovascular disease 88
diabetes 247
epilepsy 177
drop-foot gait 55
drug hepatotoxicity 152
drug jaundice 152
drug reactions, cutaneous 305, 313
drug toxicity, hypercalcaemia 170
drugs of misuse, poisoning 352, 357–8, 360
dual energy X-ray absorptiometry (DEXA) 258–9
hyperparathyroidism 264, 265
Dubin–Johnson syndrome 37
Duchenne muscular dystrophy 198
duodenal ulceration 128–9
Dupuytren’s contracture 7, 58
dysarthria 40, 53
dysbetalipoproteinaemia 248
dyscalculia 53
dysdiadochokinesia 46
dysentery 34, 35, 339
dysgraphia 53
dyslexia 53
dyslipidaemia 247–51
classification 247–8
clinical presentation 249
diabetes 241
dietary modification 250
drug therapies 250
investigation 249
lifestyle changes 250
management 249–51
primary 247–8
secondary 248
dysphagia 31, 33
barium swallow X-ray 33, 34
gastric ulcer 129
dysphasia 53
expressive 40, 53
receptive 41, 53
dysphonia lung cancer 119
occupational lung disease 125
dystonia 56, 192
dyspnoea lung cancer 119
occupational lung disease 125
dystonia 56, 192
educational impact, assessment tools 66
efavirenz 348
Ehlers–Danlos syndrome, skin manifestations 316
Eisenmenger syndrome 104
atrial septal defect complication 102
patent ductus arteriosus complication 103
elbows 46
elderly people
subdural haematoma 182
vertebral crush fracture 294
electrocardiogram (ECG) 15, 17, 18
angina pectoris 74
bundle branch block 79–80
fascicular block 80
heart failure 91
hyperkalaemia 79
hypertension 94
hypocalcaemia 79
hypokalaemia 79
metabolic disease 79
mitral stenosis 99
myocardial infarction 77, 78
pulmonary embolism 78
sinoatrial disease 80
electrolytes abnormalities with blood transfusion 324
renal disease 167–70
emollients
eczema 300, 304
psoriasis 297
employment, epilepsy 177
encephalitis
CMV 346
viral 200–1
encephalopathy, hepatocellular failure 149
endocarditis, patent ductus arteriosus complication 103
endocrine disease 57–61, 208–28
adrenal disorders 223–8
autoimmune polyglandular 227–8
gut tumours 134
history 57, 58
hypercalcaemia 170
lung cancer 119
pancreatic tumours 134–5
pituitary disorders 214, 217–23
polycystic ovarian syndrome 227–8
skin manifestations 314
see also thyroid disorders
endocrine system
face examination 8
leg examination 9
endocrine tumours
gut 134
pancreas 134–5
dentoscopic retrograde cholangiopancreatography (ERCP) 37
sphincterotomy 138, 141, 143
endothelins, hypertension 92
Entamoeba histolytica (amoebic dysentery) 339, 346
enteral nutrition 253
Crohn’s disease 133
enteric arthropathy 277
enteric fever, diarrhoea 34
Enterococcus septicaemia 342
enthesitis 275
environmental toxins, Parkinson’s disease 190
eosinophilia 321
eosinophils 325
epidermolysis bullosa 316
epilepsy 174–7
aetiology 174, 175
cerebral tumours 202–3
clinical features 175
differential diagnosis 174–5
brainstem 177
employment 177
focal 175
investigations 176
Jacksonian 175
lifestyle 177
management 176
neurosyphilis 202
pregnancy 176–7
primary generalised 175
prognosis 177
refractory 176
sensory 176
surgical treatment 176
temporal lobe 175
Epstein–Barr virus (EBV)
hairy leukoplasia 314
infectious mononucleosis 348
erythema marginatum 314
erythema migrans
chronicum 314
necrotic 316
erythema multiforme 313, 314, 315, Plate 19.10
erythema nodosum 313, 314, Plate 19.11
erythrocyte sedimentation rate (ESR) 323
erthroderma, drug-induced 305
erthropoietic porphyria 257
congenital 256
erythropoietin, chronic kidney disease 163, 322
Escherichia coli
hemolytic uremic syndrome 157
septicaemia 342
essential thrombocytosis 329
essential tremor 55
ethambutol, tuberculosis treatment 124
exanthemeatus eruptions, drug-induced 305, 313
exercise
obesity 252
osteoporosis prevention 259
exfoliative dermatitis, drug-induced 305, 313
expressive dysphasia 40
extracerebral haemorrhage 182
extradural haematoma 182
extrinsic allergic alveolitis 124
eyes
abdomin examination 28
Argyll Robertson pupil 50, 202
diabetes 241–2
endocrine disease 59
examination 41–3
metabolic disease 59
movement disorders 51
pituitary adenoma 220, 221
pupillary reflexes 49–50
retinal assessment in pregnancy 245
rheumatoid arthritis clinical presentation 270–1
Roth spots 105
thyroid status assessment 61
thyrotoxicosis complications 211–12
visual agnosia 53
visual field defects 49
ezetimibe 250–1

face
cranial nerves 43
dentocrine disease 59
expression 43
general examination 7–8
metabolic disease 59
Index

face (Continued)
mouth 43
sensation 43
Face, Arm and Speech Test (FAST) 177
facial pain, atypical 174
facial palsy 51–2
faecal fat excretion 139
Fallot’s tetralogy 101, 103–4
familial defective apolipoprotein B-100 247, 248
familial hypercalciuric hypercalcaemia (FHH) 264, 265
Fanconi syndrome 170
Fansidar 338, 340
farmer’s lung 125
fascicular block, ECG 80
fascioscapulohumeral muscular dystrophy 198
febrile convulsions 175
febuxostat 292
ferritin 324
fentanyl 55
fetal programming 231
fibrates 250
fibromyalgia 296
fibrosing alveolitis 127
finger–nose test 46
fingers 46
hand examination 7
Osler’s nodes 105
see also nails
fish oils 251
fixed drug eruptions 305, 313
flecainide 85
fluid levels, renal disease 167–9
fluid replacement, diabetic ketoacidosis 239–40
focal glomerulosclerosis 166
folic acid deficiency 138, 322, 323, 326
food poisoning, diarrhoea 34
foot
diabetic 59–60, 244
ischaemic 108
neuroischaemic ulceration 244
forced expiratory volume in 1 s (FEV1) 25, 27
forced vital capacity (FVC) 25, 27
fractures
osteoporosis 258
Paget’s disease 261
vertebral crush 294–5
Friedreich’s ataxia 205
Friedewald equation 249
fronto-temporal dementia 185
frozen shoulder 294
fungal infections
cryptococcal 346
nail disorders 320
skin 305, 310–11, Plate 19.8
see also Candida albicans
gait 49
abnormal 55
gall bladder 142–3
gallstones 142–3
GALS screen for musculoskeletal system 62, 64
gastric carcinoma 128–9
bleeding 135
gastric lavage, poisoning 352

gastric ulceration 128–9
bleeding 135
gastro-oesophageal reflux disease (GORD) 129–30
gastrointestinal system 128–43
diverticular disease 136, 139
duodenal ulceration 128–9
endocrine tumours
gut 134
pancreas 134–5
face examination 7
gall bladder 142–3
gastric ulceration 128–9
gastro-oesophageal reflux 129–30
gastrointestinal haemorrhage 135–6
haemorrhage 135–6
hiatus hernia 129–30
inflammatory bowel disease 130–4
irritable bowel syndrome 140
ischaemic colitis 140
key features of history in disease 29
malabsorption 136–9
pancreas 141–2
general examination 7–9
respiratory system 19
generalised paralysis of the insane 202
genitalia, external in endocrine/metabolic disease 59
gestational diabetes 230, 246
gestational hypertension 97
giant-cell arteritis (GCA) 284–6
clinical presentation 284–5
headache 172, 173
management 286
prognosis 286
Giardia lamblia (giardiasis) 339
diarrhoea 346
malabsorption 138
giddiness 52–3
Gilbert syndrome 37
glandular fever 348–9
hepatitis A differential diagnosis 145
Glasgow Coma Scale 206
glitazones 236
globin chain genes 328, 329
glomerulonephritis 163–4
membranoproliferative 165
post-streptococcal 167
renal lesions 166
glomerulus 164
glossopharyngeal neuralgia 174
glucagon-like peptide 1 (GLP-1) agonists/analogues 237–8
glucagonoma 135
glucose-6-phosphate dehydrogenase
deficiency 328
glucose regulators, prandial 236
a-glucosidase inhibitors 236, 237
y-glutamyl transferase 36
gluten-sensitive enteropathy 137
glycaemic control
diabetes 233–8
diabetic nephropathy 243
diabetic retinopathy 242
pregnancy 245
glyceryl trinitrate 74
goitre, non-toxic 208–9
Goodpasture disease 166–7
gout 64, 290–2
  acute 291
  clinical presentation 291
  investigations 291
  long-term control 292
  management 291–2
  prognosis 292
  tophaceous 291, 314
graduated compression stockings 126
grand mal 175
granuloma annulare 244, 314
Graves’ disease 61, 209, 210, 211
  skin manifestations 314
  thyrotoxicosis complications 211–12
Guillain–Barré syndrome 203–4
H2 receptor antagonists 129, 130
haem biosynthetic pathway 254, 255
haematemesis, portal hypertension 150
haematological system/disorders 321–35
  amyloidosis 316, 335
  bleeding disorders 331–2
  bone marrow disorders 329–30
  bone marrow suppression 323
  erythrocyte sedimentation rate 323
  hyperuricaemia 291
  malignancy 332–5
  peripheral blood film 321, 322
  red cells 321, 322
  rheumatoid arthritis clinical presentation 271, 272
  systemic lupus erythematosus 278, 279
  white cells 325
see also anaemia
haematuria 156–7
haemochromatosis 156–7
  cirrhosis 149
  idiopathic 151–2
haemodialysis
  acute kidney injury 159
  adequacy assessment 163
  amyloid deposition 335
  chronic kidney disease 163
  hypercalcaemia 264
  poisoning 353
  haemofiltration, acute kidney injury 159
haemoglobin
  chronic kidney disease 163
  transfer factor 25
haemoglobinopathies 328–9
haemoglobinuria, paroxysmal nocturnal 328
haemolytic anaemias 327–30
  classification 327
  hereditary 327–8
haemolytic jaundice 36, 152
haemolytic uraemic syndrome (HUS) 157–8
haemophilia 331
  Haemophilus influenzae meningitis 198, 199
  Haemophilus pneumonieae
    asthma 113
    COPD 111
    cystic fibrosis 118
haemoptysis 20
haemorrhoids 136
hair
  disorders 320
  thyroid status assessment 61
hairy leukoplakia 314
hands
  abdomen examination 28
  endocrine disorders 31
  examination 10
  general examination 7
  grip 46
  metabolic disorders 57–8
  movement 65
  musculoskeletal system examination 63–5
  respiratory system examination 19
  thyroid status assessment 61
see also fingers; nails
head injury 206–7
headache 171–3
  cluster 172–3
  post-concussion 172, 173
  primary syndromes 171–3
  secondary causes 172, 173
  tension 171, 172
hearing 44, 52
heart 12–13
see also cardiac entries
heart block 83, 87–8
  myocardial infarction complications 82
  heart failure 13, 88–9, 91–2
  aetiology 89, 91
  investigations 91
  malabsorption 138
  New York Heart Association classification 88
  Paget’s disease 261
  patent ductus arteriosus complication 103
  pathophysiology 88–9
  radionuclide studies 91
  treatment 91–2
heart sounds 13, 14
 Helicobacter pylori 128–9
  treatment 136
HELP syndrome 97
hemiatrophy 49
hemifacial spasm 192
hemiplegia 55
Henoch–Schönlein purpura 289
heparin 126
hepatic abscess 339
hepatic failure, fulminant 145, 149
hepatic veins, obstruction 151
hepatitis
  acute 144–7, 152
  drug-induced 153
  alcoholic 147–8
  autoimmune 147
  cirrhosis 149
  chronic 146, 148
  viral 144–7, 149
  acute liver failure 149
hepatitis A 144–5
hepatitis B 145–6
  antigens 146
  polyarteritis nodosa 286, 287
  virion 145
hepatitis C 146
hepatitis D virus 146
hepatitis E 146–7
hepatitis G 146–7
hepatocellular carcinoma 146
hepatocellular failure 149–50
hepatolenticular degeneration see Wilson’s disease
hepatomegaly 30, 33
hepatorenal syndrome 157
hepatosplenomegaly 30, 33
hereditary angioedema 115
hereditary ataxias 205
hereditary coproporphyria 256, 257
hereditary elliptocytosis 327
hereditary haemorrhagic telangiectasia 316, 332
hereditary motor and sensory neuropathy 205–6
hereditary spastic paraplegia 205
hereditary spherocytosis 327
herpes simplex virus (HSV) 346
  encephalitis 201
  opportunistic infection in HIV 346
  skin infections 308
herpes zoster 309, 346
  postherpetic neuralgia 174
hiatus hernia 129–30
  bleeding 135
hidradenitis suppurativa 305
high density lipoprotein (HDL) cholesterol 249
hirsutism 320
HIV-associated dementia 186
HIV infection 201, 343–4, 345, 346–8
  clinical features 343
  diagnostic criteria for advanced disease 344
  malignancy 346
  opportunistic infections 117, 343–4, 346
  skin manifestations 314
  therapy 347–8
  transmission 343
  treatment 347–8
  virion structure 347
  WHO clinical staging 345
  WHO immunological classification 343, 344
HIV virion 347
Hodgkin’s lymphoma 333, 334
homonymous hemianopia 49
hormone replacement therapy, osteoporosis prevention 259
Horner syndrome 50–1
Howell–Jolly bodies 321, 322
human papilloma virus (HPV), skin infections 308
human T cell lymphotropic virus (HTLV) 201
Huntington’s disease 185–6
  chorea 205
Hutchinson’s freckle 319, Plate 19.20
hydatid disease 201
hydralazine, heart failure 91
hydrocephalus, normal-pressure 186
hydrogen breath test 139
hydroxycobalamin 326
hydroxyproline, urinary level monitoring 262
hyperaldosteronism, primary 94, 223–4
hyperbilirubinaemia, congenital non-haemolytic 37
hypercalcaemia 170, 262–4
  aetiology 262, 263
  clinical features 262
  investigations 262–3
  management 263–4
  renal failure 157
  vitamin D 263
hypercholesterolaemia 247, 248
hyperglycaemia
  diabetc coma 238–41
  treatment 234–8
hyperkalaemia 169
  ECG 79
hyperkeratosis, acne vulgaris 304
hyperlipidaemia
  familial combined 248
  skin manifestations 314
hypernatraemia 168
hyperosmolar non-ketotic diabetic coma (HONK) 240–1
  risk with intercurrent illness 246
hyperparathyroidism 128, 264–6
  clinical presentation 264
  complications 265
  hypercalcaemia 170
  investigations 264–5
  management 265–6
  preoperative imaging 265
  primary 264
  secondary 264, 265
  surgery 265–6
  tertiary 264
hyperphosphataemia 170
hyperpigmentation 317, 320
hyperprolactinaemia 163, 218–19, 221
hypersensitivity reactions, drug-induced 152
hypersensitivity vasculitis 289
hypertension 14, 16, 92–7
  accelerated 96
  aetiology 92–3
  black patients 94, 95
  chronic kidney disease 159, 161
  diabetes 96, 241
  diagnosis 93
  endothelins 92
  examination 93–4
  genetic factors 92
  gestational 97
  investigation 94
  left ventricular hypertrophy 93
  nitric oxide 93
  obstructive sleep apnoea 125
  pathophysiology 93
  pregnancy 97
  prostacyclins 93
  renal disease 96
  renovascular 96–7
  severe 96
  stroke 180
  symptoms 93
treatment 94–6

See also portal hypertension; pulmonary hypertension

Hyperthermia, poisoning 352

Hyperthyroidism 61, 209–12

Skin manifestations 314

Hypertriglyceridaemia, familial 247, 248

Hypertrophic cardiomyopathy 91, 107

hyperuricaemia 290–2

Long-term control 292

Hyperventilation syndrome 127

Hypocalcaemia 170, 266–7

Chronic kidney disease 161

ECG 79

Hypoglycaemia

Diabetic coma 238

Driving 247

Hypoglycaemic drugs, pregnancy 245

Hypogonadotropic hypogonadism 219

Hypokalaemia 168–9

ECG 79

Hypomagnesaemia 170

Hypocalcemia 170, 266–7

Hypertrophy 127

Hypocalcaemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7

Hypocalcemia 170, 266–7
Jarisch–Herxheimer reaction 202
jaundice 35–7
abdominal radiology 32, 36
alkaline phosphatase 35–6
bilirubin 35, 36
drug 152
haematology 35
haemolytic 36, 152
hepatitis A 144, 145
liver function tests 35
obstructive 36
hepatitis A differential diagnosis 145
serology 36
transaminases 36
urinalysis 36
joints
examination 62, 63–4
position sense 47, 49
jugular veins 13
jugular venous pressure 11–12
jugular venous pulse waveform 13
juvenile myoclonic epilepsy 175
Kaposi’s sarcoma 314, 319
HIV infection 346
Kawasaki disease 287
Kayser–Fleischer rings 205
keratoacanthoma 318
keratoconjunctivitis sicca 282
keratoderma blennorrhagica 275
Kernig’s sign 198
kidney(s) 29, 30
imaging 153–4
palpable 30–1
see also renal entries
kidney disease, chronic 159–63
anaemia 162–3, 321, 322
bone disease 161
cardiocirculatory disease 161–2
causes 159
clinical features 159
complications 161–3
investigations 159–61
management 161
pathophysiology 161
renal replacement therapy 163
sexual dysfunction 163
kidney injury, acute 157–9
investigation 158
management 158–9
postrenal 156
prerenal 157
renal 157–8
Klebsiella pneumoniae 342
koilonychia 320
Korsakoff’s psychosis 253
Kussmaul’s sign 106
kwashiorkor 252
kyphosis 295
labetalol 97
Landouzy–Déjerine syndrome 198
large-vessel vasculitis 284–6
clinical presentation 284–5
investigations 285–6
management 286
prognosis 286
lateral cutaneous nerve of the thigh 54
lateral popliteal lesion 54
lateral popliteal palsy 195
lateral rectus palsy 51
Leber’s optic neuropathy (atrophy) 205
left ventricular failure 13
left ventricular hypertrophy 93
legionnaire’s disease 116
legs
acute obstruction 108
coordination 48
endocrine disease 59
general examination 9
metabolic disease 59
motor system 48
see also foot
leptospirosis 200
Lesch–Nyhan syndrome 291
leukaemia 330, 332
levodopa (L-DOPA) 191
lichen planus 320
lichen planus-like eruptions, drug-induced 313
lichenification, eczema 300, 304
limb-girdle muscular dystrophy 198
limbs 44–9
acute obstruction 108
diabetic foot 59–60, 244
endocrine disease 59–60
abnormal 55
lower motor neuron lesions 53
metabolic disease 59–60
motor loss 53
proximal myopathy 53
sensory loss 53–4
upper motor neuron lesions 53
see also arms; legs
limited cutaneous systemic sclerosis (LCSS) 281, 282
lipids, vascular disease association 248–9
lipoatrophy 244, 314
lipodystrophy 314
lipohypertrophy 314
lithium poisoning 335
liver 28–9, 30
needle biopsy 36
liver disease 144–52
acute liver failure 149–50
Budd–Chiari syndrome 151
cancer with hepatitis C 146
chronic 148–9
compensated 149
drug hepatotoxicity 152
fulminant hepatic failure 145, 149
hepatocellular failure 149–50
macrocystic anaemia 322
portal hypertension 150–1
primary sclerosing cholangitis 134, 148–9
renal failure 157
schistosomiasis 149
skin manifestations 316
see also cirrhosis; hepatitis; jaundice
liver failure
acute 149–50
anaemia 321
liver function tests, jaundice 35
liver transplantation, hepatitis C 146
lomustine 335
Looser’s zone 261
low density lipoprotein (LDL) 247
low density lipoprotein (LDL) cholesterol 247, 249
Lown–Ganong–Levine syndrome 86, 87
lung(s)
consolidation 21
fibrosis 21
rheumatoid arthritis clinical presentation 271
surface markings 22
systemic lupus erythematosus 278, 279
lung abscess 117
lung cancer 119–20
staging 120
lung transplantation, cystic fibrosis 119
lupus anticoagulant 280
lupus erythematosus-like syndrome, drug-induced 313
lupus pernio 314
Lyme disease 200, 314
lymphadenopathy 9
abdomen examination 28
lymphocytes 325
lymphoma 333, 334
B-cell in Sjögren syndrome 282
macular sparing 50
magnesium sulphate, eclampsia 97
Magnetic resonance cholangiopancreatography 138
malabsorption 136–9
investigation 139
pancreatic 142
post surgical 138
maladie de Roger 103
malnutrition 252
screen 180
maloprim 340
malt worker’s lung 125
marasmus 252
Marfan syndrome 101, 102
maturity-onset diabetes of the young (MODY) 230, 231
mechanical ventilation
adult respiratory distress syndrome 127
asthma 113
respiratory failure 114
median nerve lesion 54
medical interview 1–6
breaking bad news 5
building a relationship 4
closing the session 4, 4
contingency plans 4
exploration 3–4
information gathering 3
initiating the session 2, 3
organising the consultation 4
OSCE Station score sheet 5
planning 3–4
special circumstances 4–5, 6
structure 1–4
medium-sized vessel vasculitis 286–7
mefloquine 340
megablasts 325, 326
meglitinides 236, 237
melaena 135
membranoproliferative glomerulonephritis 165
membranous nephropathy 164–5
meningal irritation 172, 173
meningioma 203
meningitis
bacterial 198–200
cryptococcal 346
intracranial abscess 199–200
meningococcal 198–200
parameningeal infections 200
pneumococcal 198, 199
tuberculous 199–200
viral 200
meningococcal meningitis 198–200
meralgia paraesthetica 195
mercaptopurine 335
mesalazine, Crohn’s disease 133
metabolic acidosis 160
metabolic alkalosis 169
metabolic disease 57–61
bone 257–62
physiology 257–8
ECG 79
examination 57
history 57
metabolic disorders 229–68
anorexia nervosa 254
dyslipidaemia 247–51
diabetes 241
enteral nutrition 253
history 57, 58
hypercalcaemia 170, 262–4
renal failure 157
hyperparathyroidism 128, 264–6
hypercalcaemia 169
hypocalcaemia 170, 266–7
chronic kidney disease 161
ECG 79
hypoparathyroidism 170, 267–8
metabolic disorders (Continued)
malnutrition 180, 252
obesity 251–2
osteomalacia 260–1
osteoporosis 258–60
Paget’s disease 261–2
parenteral nutrition 254
porphyria 254–7
undernutrition 252
vitamin deficiencies 252–3
see also diabetes
metazoal infections 201
metformin 235–6, 237
methicillin-resistant Staphylococcus aureus (MRSA) 116
methotrexate
haematological malignancies 335
sarcoïdosis 122
methyldopa, hypertension 96
metoclopramide
gastro-oesophageal reflux 130
hiatus hernia 130
metronidazole 339
microalbuminuria, diabetes 242–3
microscopic polyangiitis 289
systemic vasculitis 166
micturition, double 153
migraine 171–2
Miller–Fisher syndrome 204
Miller’s triangle 67
mini-clinical examination (mini-CEX) assessment 68, 69, 72
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) 230, 231
mitral incompetence 15
mitral regurgitation 100
mitral stenosis 15, 99–100
mitral valve prolapse 100, 104
mixed connective tissue disease 284
monoclonal gammopathies of undetermined significance (MGUS) 334
mononeuritis multiplex 195, 196
mononeuropathies 195
acute 243
monosodium urate (MSU) crystal deposition 290–1
mood 40
endocrine disorders 57
morphoïa 281
motor neuron lesions, combined lower and upper 55
motor neuron disease 188–9
classification 188
clinical presentation 188
diagnosis 188
investigation 189
management 189
prognosis 189
motor neuropathy, proximal 243
motor pathways 44
mouth 43
movement disorders 189–92
moxonidine, hypertension 96
mucosa-associated lymphoid tissue (MALT) lymphoma 128
mucous membranes, systemic lupus erythematosus 278
multi-infarct dementia 185
multifocal neuropathy/mononeuritis multiplex 195, 196
multiple endocrine neoplasia (MEN) 226–7
hyperparathyroidism 264, 265
syndromes 226, 227
type 1 128
multiple sclerosis 186–8
acute relapse 187
epidemiology 186
clinical features 187
clinical presentation 186–7
diagnosis 187
differential diagnosis 187
disease-modifying agents 187
management 187–8
pathophysiology 186
prognosis 188
symptom control in chronic disease 188
muscle disorders 197–8
acquired 198
muscle power testing 45, 48
muscular atrophy, peroneal 205–6
muscular dystrophy 198
musculoskeletal system 62–5
examination 62–5
history 62, 63
rheumatoid arthritis 270, 271
systemic lupus erythematosus 277, 278
mushroom picker’s lung 125
myalgic encephalitis 349–50
myasthenia gravis 196–7
mycobacterial infections, opportunistic infections in HIV 344, 346
Mycobacterium, skin infections 307
Mycobacterium tuberculosis (tuberculosis) 122, 349
opportunistic infections in HIV 344, 346
Mycoplasma pneumoniae 116
myelodysplastic syndromes 330
myelofibrosis, primary 329–30
myeloma 332–4
myeloproliferative disorders 329–30
opportunistic infections 117
myocardial infarction (MI) 75–7, 78–80, 80–2, 84
aetiology 76
anterior 77
assessment after 82
biomarkers 75, 77, 80
complications 82
diagnostic criteria 75
examination 76–7
inferior 77
investigations 77, 80
management 80–2
reperfusion therapies 80–1
symptoms 76
myocardial rupture 82
myoclonus 192
myopathy
Index

objective structured clinical examinations (OSCEs) 71–2
obstructive sleep apnoea 125
occupational lung disease 124–5
ocular movements, external 43
oesophageal ulcer 135
oesophagitis, bleeding 135
omega-3 fatty acids 251
opening snap 13
opioids, poisoning 355
orientation testing 39
orlistat 343
oseltamivir 343
Osler’s nodes 105
Osler–Weber–Rendu disease 332
ostitis deformans 261–2
osteomalacia 260–1
adult 260
investigations 260–1
osteopenia 261–2
osteoporosis 258–60
aetiology 258
clinical features 258
investigations 258–9
recombinant 259
screening 259
osteomalacia differential diagnosis 261
osteopenia 261–2
osteomalacia 260–1
osteoporosis 258–60
osteotomy 261
evaluation of 261
osteopenia 261–2
osteomalacia 260–1
osteoporosis 258–60
P wave 16, 17
pacemakers, biventricular 92
Paget’s disease 141–2
endocrine tumours 134–5
malabsorption 139
pancreatic carcinoma 141
pancreatic enzyme deficiency 137–8
pancreatitis
acute 141–2
chronic 142
nutrition 142
pantoprazole 323
papillary muscle dysfunction 82
papules, acne vulgaris 304
paracentesis 31
ascites 151
paracetamol overdose 149, 150, 355
management algorithm 359
N-acetylcysteine 353
parameningeal infections 200
paraplegia 55
Paroxysmal nocturnal haemoglobinuria 328
paralytic ileus 324
parathyroid hormone (PTH) 161
effects 264
hypercalcaemia 262, 263
hypocalcaemia 266, 267
metabolic bone disease 257
parathyroid hormone-related peptide/protein (PTHrP) 262, 263
paratyphoid 35
parenteral nutrition 254
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Paromastigotes 338
paroxysmal atrial tachycardia 91
paroxysmal nocturnal haemoglobinuria 328
Paroxysmal supraventricular tachycardia 91
paroxysmal ventricular tachycardia 91
Parietal cell 320
Parietal cell antibodies 320
parotid gland 130
parotid gland disorder 130
parotid duct 130
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Paroxysmal supraventricular tachycardia 91
paroxysmal ventricular tachycardia 91
Parietal cell 320
Parietal cell antibodies 320
parotid gland 130
parotid gland disorder 130
parotid duct 130
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Pars plana vitrectomy 306, 307
Parkinson’s disease 189–91
aetiology 189–90
clinical presentation 190
with dementia 185
diagnosis 190
dopaminergic agents 191
festinant gait 55
management 190–1
prognosis 191
surgical treatment 191
Pars plana vitrectomy 306, 307
physical examination 3
Pick’s disease 185
pigmentary change, drug-induced 313
pimecrolimus 304
pituitary, anatomy/physiology 214, 217
pituitary adenoma 203, 217–23
pituitary disorders 214, 217–23
hormone hypersecretion 218–19, 220, 221–2
hormone hyposecretion 220, 222–3
investigations 220–2
local mass effects 220, 222, 223
prognosis 223
treatment 222–3
pityriasis rosea 320
plantar reflex 48
Plasmodium 336
pleural effusion, physical findings 21
pneumoconiosis 124
Pneumocystis carinii pneumonia (PCP) 344
pneumonia 115–17
adult respiratory distress syndrome 127
aspiration 116
bacterial 115–16
clinical presentation 115
community-acquired 115
investigations 115
lung abscess 117
management 115–16
opportunitis infections 117
viral 116
pneumothorax 21, 117–18
poisoning 351–3, 354–8, 359, 360
activated charcoal 352–3
agitation 352
alcohol 352, 357
alkaline diuresis 353
amphetamines 357
antidepressants 352, 356, 360
aspirin 354
β-blockers 354
benzodiazepines 354
calcium channel blockers 354
cannabis 357
carbon monoxide 360
causes 352
clinical clues 353
clinical presentation 351–3, 354–8, 359, 360
cocaine 357–8
digoxin 355
drugs of misuse 357–8, 360
Ecstasy 357
examination 351
gastric lavage 352
haemodialysis 353
history 351
iron salts 355
lithium 355
management 351–2
nausea 352
NSAIDs 355
opioids 355
psychiatric assessment 352
seizures 352
temperature dysregulation 352
toxin absorption prevention/elimination enhancement 352–3
vomiting 352
see also paracetamol overdose
poliomyelitis 201–2
polyarteritis nodosa 286–7
polycystic kidney disease 14, 94, 159
polycystic ovary syndrome (PCOS) 227–8
polycythaemia vera 329
polymyalgia rheumatica 284–6
clinical presentation 285
management 286
polymyositis 198, 283–4
mixed connective tissue disease 284
porphobilinogen 255, 257
porphyria 254–7
acute 254–6, 257
acute intermittent 256, 257
classification 254, 256
clinical presentation 254–7
congenital erythropoietic 256
cutanea tarda 254, 256
enzyme defects 254, 255
erthyropoietic 257
investigations 257
management 257
non-acute 256–7
skin manifestations 316
variegate 256, 257
portal hypertension 150–1
portal vein occlusion 31
positive end-expiratory pressure (PEEP), ARDS 127
post-concussion headache 172, 173
post-streptococcal glomerulonephritis 167
postherpetic neuralgia 174
postinfectious arthralgia 296
potassium
serum levels 168–9
see also hyperkalaemia; hypokalaemia
Poxvirus 308
PR interval 16, 17
prandial glucose regulators 236
pravastatin 250
pre-eclampsia 97
pre-excitation syndromes 86–7
precordium, auscultation 12–13
pregnancy
ACE inhibitors 245
diabetes 244–6
epilepsy 176–7
fetal growth/well-being in diabetes 245–6
glycaemic control 245
hypertension 97
hypoglycaemic drugs 245
hypothyroidism 212
insulin therapy 245
ketosis testing 245
renal assessment in diabetes 245
retinal assessment in diabetes 245
pressure sores, stroke 180
preterm labour, diabetes 246
primaquine 338, 340
primary lateral sclerosis 188
primary myelofibrosis (PMF) 329–30
primary sclerosing cholangitis 148–9
inflammatory bowel disease 134
prion diseases 185
pro-pafenone, atrial flutter 85
proctocolectomy 132
progressive multifocal leukoencephalopathy 346
progressive muscular atrophy 188
proguanil 340
prolactin 163
prolactinoma 218–19
Propionibacterium acnes (acne) 304
proprioception 47, 49
proprioceptive incoordination 54–5
prostacyclins, hypertension 93
protease inhibitors 348
protein catabolic rate 163
proteinuria 155, 156
proton-pump inhibitors
gastric ulcer 129
 gastro-oesophageal reflux 130
 gastrointestinal haemorrhage 136
 hiatus hernia 130
 variceal bleeding 135
 protozoal infections 201
pruritus 316
pseudobulbar palsy 53
pseudodementia 183
pseudoxanthoma elasticum 316
pseudogout 292–3
pseudohypoparathyroidism 267, 268
pseudomembranous colitis 34
Pseudomonas aeruginosa, cystic fibrosis 118, 119
pseudotumour cerebri 173
psoriasis 64, 297, 298–9, 300
aetiology 297
clinical presentation 297, 298–9
nail disorders 320
subtypes 297, 298–9, Plates 19.1–19.4
 treatment 297, 298–9, 300
psoriatic arthritis 275, 279
psychiatric assessment, poisoning 352
ptoosis 41
pulmonary embolism 125–7
aetiology 125
clinical features/presentation 125–6
ECG 78
investigations 126
prophylaxis 126
stroke 180
 treatment 126–7
pulmonary function tests 25, 27
pulmonary hypertension
 Eisenmenger syndrome 104
 mitral stenosis 99
 pulmonary incompetence 15
pulmonary oedema, adult respiratory distress syndrome 127
pulmonary sarcoid 120, 122
pulmonary stenosis 15, 101
pulmonary sarcoidosis 120
pupal paradoxus 106
pupil constriction 50
pupillary reflexes 42–3, 49–50
purpura 331
 drug-induced 313
pustules, acne vulgaris 304
pyelonephritis
 acute 153
 chronic 154
 pyoderma gangrenosum 315, 316, Plate 19.14
 pyogenic granuloma 318
pyrrolizidine, tuberculosis treatment 124
pyrexia of unknown origin 340–2
 causes 341
examination 341
 history 340, 342
invasive procedures 342
screening tests 341
pyridoxine deficiency 253
Q wave 15, 17
rabies 201
radial nerve lesion 54
radial neuropathy 195
radiculopathy 194
radioactive iodine therapy 211
raloxifene 259
rasburicase 292
Raynaud’s phenomenon 109, 280
re-entrant tachycardia, Wolf-Parkinson-White syndrome 86
receptive dysphasia 41
Recognition of Stroke in the Emergency Room (ROSIER) scale 177, 178
rectal bleeding 34–5
red cells
 morphology 322
 rouleau formation 321
reflexes 45
 arm 46
 leg 48
reflex nephropathy 155
Reiter syndrome 276–7
psoriatic arthritis differential diagnosis 275
skin manifestations 314
reliability, assessment tools 66
renal artery stenosis 14, 93, 96
renal biopsy
chronic kidney disease 161
haematuria 156
renal calculi 154, 291
inflammatory bowel disease 134
renal disease 37–8, 153–70
acute kidney injury 157–9
antiglomerular basement membrane disease 166–7

atherosclerotic 96, 97
calculi 154, 291
inflammatory bowel disease 134
chronic interstitial nephritis 154
diabetic nephropathy 241, 242–3
electrolytes 167–70
fluid levels 167–9
focal glomerulosclerosis 166
glomerulonephritis 163–4
membrano proliferative 165
post-streptococcal 167
renal lesions 166
haematuria 156–7
hypercalcaemia 170
hyperkalaemia 168
hyperphosphataemia 170
hypertension 96
hypocalcaemia 161, 170
hypokalaemia 168–9
hyponatraemia 167–8
Ig A nephropathy 164
infective endocarditis 105
investigations 37–8
membranous nephropathy 164–5
metabolic acidosis 169
metabolic alkalosis 169
minimal-change nephropathy 165
nephrotic syndrome 155–6, 165
proteinuria 155, 156
reflux nephropathy 155
renal lesions 166
renal tubular acidosis 169
rheumatoid arthritis clinical presentation 271, 272
systemic lupus erythematosus 167, 278
systemic vasculitis 166
uric acid increase 170
urinary tract infection 153–4
urinary tract stones 154
see also kidney disease, chronic; kidney entries
renal failure
ACE inhibitors 157
chronic 14, 94, 161
hypercalcaemia 157
liver disease 157
renal replacement therapy
acute kidney injury 159
chronic kidney disease 163
see also haemodialysis
renal transplantation 31
chronic kidney disease 163
renal tubular acidosis 169
renal ultrasound 153, 154
chronic kidney disease 160–1
haematuria 156
Rendu–Osler–Weber syndrome 136
renin–angiotensin–aldosterone system, hypertension 92
renovascular hypertension 96–7
revascularisation 97
respiratory disease 110–27
adult respiratory distress syndrome 127
anaphylaxis 115
asthma 21, 111–13
occupational 124
bronchial adenoma 120
bronchiectasis 117
COPD 20, 110–11
cystic fibrosis 118–19
fibrosing alveolitis 127
hyperventilation syndrome 127
lung abscess 117
lung cancer 119–20
obstructive sleep apnoea 125
occupational 124–5
pneumonia 115–17
pneumothorax 21, 117–18
pulmonary embolism 125–7
ECG 78
sarcoidosis 120–2
tuberculosis 122–4
respiratory failure 113–14
acute on chronic 114–15
cystic fibrosis 119
type 1 24–5
type 2 25
respiratory syncytial virus 116
respiratory system 19–25, 26–7
auscultation 20
blood gases 22–5
chest radiography 22, 23, 24, 25, 26
examination 19–20
history 19, 20
investigations 22–5, 26–7
palpation 19, 22
percussion 19
thyroid status assessment 61
resting tremor 56
restrictive cardiomyopathy 107–8
resuscitation, cardiorespiratory arrest 88, 89
reticulocytes 321
reticuloendothelial system, rheumatoid arthritis 272
retinitis, CMV 346
retinoids
acne vulgaris 304
psoriasis 300
rosacea 305
retinopathy, diabetic 241–2
retroviral infections 201
rheumatic fever
acute 295–6
mitral stenosis 99
pulmonary stenosis 101
rheumatic valve disease
aortic stenosis 98–9
infective endocarditis 104
rheumatoid arthritis 63, 270–5
anaemia 321
clinical presentation 270–2
diagnostic criteria 272
disease-modifying drugs 273
iatrogenic 272
investigations 272–3
management 273–4
NICE guidance 274
rheumatoid arthritis (Continued)
prognosis 274–5
skin manifestations 314
surgery 274
rheumatoid factor (RF) 272–3
rheumatological system 269–96
ankylosing spondylitis 275–6
antiphospholipid syndrome 280
autoimmune disorders 277–83
back pain 294–5
carpal tunnel syndrome 54, 58, 195, 293
connective tissue diseases 277–83
crystal arthropathies 290–3
dermatomyositis 198, 283–4
dentric arthropathy 277
face examination 8
fibromyalgia 296
inflammatory myopathies 198, 283–4
leg examination 9
mixed connective tissue disease 284
osteoarthritis 63, 260–70
polymyositis 198, 283–4
postinfectious arthralgia 296
Reiter syndrome 275, 276–7
scleroderma 280–2
septic arthritis 293–4
seronegative spondylarthropathies 275–7
shoulder pain 294
Sjögren syndrome 282–3
skin manifestations of disease 314
Still’s disease 285
systemic lupus erythematosus 167, 277–80
vасculitides 284–90
rhinophyma 304
Riamet 340
ribavirin 146
riboflavin deficiency 253
rickets, childhood 260
rifampicin, tuberculosis treatment 124
right ventricular failure 13
Rinne test 52
ritonavir 348
rituximab 273–4, 288
rolling gait 55
Romberg’s test 49
rosacea 304–5
rotator cuff degeneration/tendinitis 294
Roth spots 105
rubella, maternal 101
salicylic acid 297
Salmonella diarrhoea 346
Salmonella typhi (typhoid) 339
sarcoidea 120–2
clinical presentation 121
hypercalcaemia 170
investigations 121
management 121–2
non-pulmonary sarcoi 120–1
prognosis 122
pulmonary 120, 122
skin manifestations 314, 315, Plate 19.11
Sarcoptes scabei (scabies) 312
scars, acne vulgaris 304
Schilling test 323
schistosomiasis 149, 342
scleroderma (systemic sclerosis) 280–2, 281
clinical presentation 281
investigations 281–2
management 282
mixed connective tissue disease 284
prognosis 282
skin manifestations 314
scleroderma diabetorum 244
scurvy, skin manifestations 316
seborrhoeic dermatitis 302, 304, 314
seborrhoeic keratoses 318
seizures
absence 175, 176
eclampsia 97
generalised 174
myoclonic 176
partial 174, 176
poisoning 352
provocation 174
stroke 180
tonic–clonic 175, 176
selective oestrogen receptor modulators (SERMs) 259
selective serotonin reuptake inhibitors (SSRIs), poisoning 356
sensation testing
arms 46–8
legs 48–9
sensory ataxia 55
sensory dermatomes 46, 47
sensory neuropathy, acute 243
sensory pathways 45
septic arthritis 293–4
septicaemia 342, 343
seronegative spondylarthropathies 275–7
sexual dysfunction
chronic kidney disease 163
hyperprolactinaemia 218–19
Shigella diarrhoea 346
Shigella dysentery 339
shock, myocardial infarction complications 82
shoulder 46
pain 294
sick day rules, diabetes 239, 245, 246
sick sinus syndrome, ECG 80
sickle-cell disease 328–9
sideroblasts 330
silicosis 124
simvastatin 250
sinoatrial disease, ECG 80
sinus bradycardia 82
sinus tachycardia 83, 84
myocardial infarction complications 82
Sjögren syndrome 282–3
investigations 282–3
management 283
prognosis 283
skin 297–320
acne vulgaris 304
bullous disorders 316–17
dermatomyositis 283
diabetes-related conditions 244
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>syphilitic carditis</td>
<td>104, 107</td>
</tr>
<tr>
<td>syringobulbia</td>
<td>194</td>
</tr>
<tr>
<td>syringomyelia</td>
<td>193–4</td>
</tr>
<tr>
<td>systemic lupus erythematosus (SLE)</td>
<td>167, 277–80</td>
</tr>
<tr>
<td>anaemia</td>
<td>321</td>
</tr>
<tr>
<td>antinuclear antibodies</td>
<td>277, 279</td>
</tr>
<tr>
<td>clinical presentation</td>
<td>277–9</td>
</tr>
<tr>
<td>diagnostic criteria</td>
<td>279</td>
</tr>
<tr>
<td>investigations</td>
<td>279</td>
</tr>
<tr>
<td>management</td>
<td>279–80</td>
</tr>
<tr>
<td>mixed connective tissue disease</td>
<td>284</td>
</tr>
<tr>
<td>prognosis</td>
<td>280</td>
</tr>
<tr>
<td>systemic sclerosis</td>
<td></td>
</tr>
<tr>
<td>without scleroderma</td>
<td>281</td>
</tr>
<tr>
<td>see also scleroderma (systemic sclerosis)</td>
<td></td>
</tr>
<tr>
<td>systemic vasculitis</td>
<td>166</td>
</tr>
<tr>
<td>systolic clicks</td>
<td>13</td>
</tr>
<tr>
<td>T wave</td>
<td>16, 17</td>
</tr>
<tr>
<td>tabes dorsalis</td>
<td>202</td>
</tr>
<tr>
<td>tacrolimus</td>
<td>304</td>
</tr>
<tr>
<td>tactile agnosia</td>
<td>41, 53</td>
</tr>
<tr>
<td>Takayasu’s arteritis</td>
<td>286</td>
</tr>
<tr>
<td>taste sensation</td>
<td>51–2</td>
</tr>
<tr>
<td>tazarotene</td>
<td>300</td>
</tr>
<tr>
<td>telogen effluvium</td>
<td>320</td>
</tr>
<tr>
<td>temperature dysregulation, poisoning</td>
<td>352</td>
</tr>
<tr>
<td>temperature sensation</td>
<td>48, 49</td>
</tr>
<tr>
<td>temporal arteritis</td>
<td>284–6</td>
</tr>
<tr>
<td>temporal hemianopia</td>
<td>49</td>
</tr>
<tr>
<td>tension headache</td>
<td>171, 172</td>
</tr>
<tr>
<td>teriparatide</td>
<td>259</td>
</tr>
<tr>
<td>tetanus</td>
<td>200</td>
</tr>
<tr>
<td>thalassaemias</td>
<td>328, 329</td>
</tr>
<tr>
<td>theophylline, COPD</td>
<td>111</td>
</tr>
<tr>
<td>thiamine deficiency</td>
<td>186</td>
</tr>
<tr>
<td>thiazolidinediones</td>
<td>236, 237</td>
</tr>
<tr>
<td>third nerve palsy</td>
<td>51</td>
</tr>
<tr>
<td>thrills</td>
<td>12</td>
</tr>
<tr>
<td>thrombocytopenia</td>
<td>332</td>
</tr>
<tr>
<td>thrombolysis</td>
<td></td>
</tr>
<tr>
<td>myocardial infarction</td>
<td>80–1</td>
</tr>
<tr>
<td>stroke</td>
<td>179–80</td>
</tr>
<tr>
<td>thrombophlebitis migrants</td>
<td>316</td>
</tr>
<tr>
<td>thrombosis</td>
<td></td>
</tr>
<tr>
<td>hyperosmolar non-ketotic diabetic coma</td>
<td>241</td>
</tr>
<tr>
<td>intracranial venous sinuses</td>
<td>180</td>
</tr>
<tr>
<td>nephrotic syndrome</td>
<td>156</td>
</tr>
<tr>
<td>stroke</td>
<td>177</td>
</tr>
<tr>
<td>thrombotic thrombocytopenic purpura (TTP)</td>
<td>158, 332</td>
</tr>
<tr>
<td>thyroid crisis</td>
<td>210, 212</td>
</tr>
<tr>
<td>thyroid disorders</td>
<td>208–14</td>
</tr>
<tr>
<td>cancer</td>
<td>214, 215–16</td>
</tr>
<tr>
<td>goitre</td>
<td>208–9</td>
</tr>
<tr>
<td>thyroiditis</td>
<td>214</td>
</tr>
<tr>
<td>thyrotoxicosis</td>
<td>209–12</td>
</tr>
<tr>
<td>see also hyperthyroidism; hypothyroidism</td>
<td></td>
</tr>
<tr>
<td>thyroid enlargement, differential diagnosis</td>
<td>208, 209</td>
</tr>
<tr>
<td>thyroid gland examination</td>
<td>60</td>
</tr>
<tr>
<td>thyroid hormone</td>
<td></td>
</tr>
<tr>
<td>inborn errors of biosynthesis</td>
<td>208</td>
</tr>
<tr>
<td>thyrotoxicosis</td>
<td>209</td>
</tr>
<tr>
<td>thyroid malignancy</td>
<td>214, 215–16</td>
</tr>
<tr>
<td>thyroid status assessment</td>
<td>60–1</td>
</tr>
<tr>
<td>thyroid-stimulating hormone receptor anti-</td>
<td></td>
</tr>
<tr>
<td>body (TRAb)</td>
<td>209, 210, 211</td>
</tr>
<tr>
<td>thyroid storm</td>
<td>212</td>
</tr>
<tr>
<td>thyroiditis</td>
<td>214</td>
</tr>
<tr>
<td>thyrotoxicosis</td>
<td>209–12</td>
</tr>
<tr>
<td>aetiology</td>
<td>209</td>
</tr>
<tr>
<td>antithyroid drug therapy</td>
<td>211</td>
</tr>
<tr>
<td>clinical presentation</td>
<td>209</td>
</tr>
<tr>
<td>complications</td>
<td>211–12</td>
</tr>
<tr>
<td>differential diagnosis</td>
<td>210</td>
</tr>
<tr>
<td>investigations</td>
<td>210–11</td>
</tr>
<tr>
<td>radioactive iodine therapy</td>
<td>211</td>
</tr>
<tr>
<td>skin manifestations</td>
<td>314</td>
</tr>
<tr>
<td>surgery</td>
<td>211</td>
</tr>
<tr>
<td>treatment</td>
<td>211</td>
</tr>
<tr>
<td>tics</td>
<td>192</td>
</tr>
<tr>
<td>tioguanine</td>
<td>335</td>
</tr>
<tr>
<td>tissue plasminogen activator (t-PA), recombinant</td>
<td>179–80</td>
</tr>
<tr>
<td>Todd’s paralysis</td>
<td>176</td>
</tr>
<tr>
<td>torsade de pointes</td>
<td>87</td>
</tr>
<tr>
<td>torsion spasm</td>
<td>56</td>
</tr>
<tr>
<td>touch sensation</td>
<td>47, 49</td>
</tr>
<tr>
<td>TOXBASE</td>
<td>352</td>
</tr>
<tr>
<td>toxicology</td>
<td></td>
</tr>
<tr>
<td>see poisoning</td>
<td></td>
</tr>
<tr>
<td>Toxoplasma gondii (toxoplasmosis)</td>
<td>201, 346</td>
</tr>
<tr>
<td>transaminases, jaundice</td>
<td>36</td>
</tr>
<tr>
<td>transfer factor</td>
<td>25</td>
</tr>
<tr>
<td>transferrin</td>
<td>324</td>
</tr>
<tr>
<td>transfusion reaction</td>
<td>324</td>
</tr>
<tr>
<td>transient ischaemic attacks (TIAs)</td>
<td>180–2</td>
</tr>
<tr>
<td>aetiology</td>
<td>180</td>
</tr>
<tr>
<td>clinical features</td>
<td>180–1</td>
</tr>
<tr>
<td>diagnosis</td>
<td>181</td>
</tr>
<tr>
<td>investigations</td>
<td>181</td>
</tr>
<tr>
<td>management</td>
<td>181–2</td>
</tr>
<tr>
<td>stroke risk</td>
<td>181</td>
</tr>
<tr>
<td>surgical treatment</td>
<td>182</td>
</tr>
<tr>
<td>travellers, imported diseases</td>
<td>336, 338–42</td>
</tr>
<tr>
<td>tremor</td>
<td>55–6, 192</td>
</tr>
<tr>
<td>exaggerated physiological</td>
<td>55</td>
</tr>
<tr>
<td>hand examination</td>
<td>7</td>
</tr>
<tr>
<td>physiological</td>
<td>55</td>
</tr>
<tr>
<td>see also Parkinson’s disease</td>
<td></td>
</tr>
<tr>
<td>trichotillomania</td>
<td>320</td>
</tr>
<tr>
<td>tricuspid incompetence</td>
<td>15</td>
</tr>
<tr>
<td>tricuspid regurgitation</td>
<td>100, 102</td>
</tr>
<tr>
<td>tricyclic antidepressant poisoning</td>
<td>356</td>
</tr>
<tr>
<td>trigeminal neuralgia</td>
<td>173–4</td>
</tr>
<tr>
<td>triglycerides, plasma levels</td>
<td>249</td>
</tr>
<tr>
<td>triolein breath test</td>
<td>139</td>
</tr>
<tr>
<td>tropical spastic paraparesis</td>
<td>201</td>
</tr>
<tr>
<td>tropical sprue</td>
<td>136</td>
</tr>
<tr>
<td>tropomin</td>
<td>75, 77</td>
</tr>
<tr>
<td>truncal ataxia</td>
<td>49</td>
</tr>
<tr>
<td>trypanosomiasis</td>
<td>201</td>
</tr>
<tr>
<td>tuberculosis</td>
<td>122–4, 349</td>
</tr>
<tr>
<td>clinical features</td>
<td>122, 123</td>
</tr>
<tr>
<td>diagnosis</td>
<td>123</td>
</tr>
<tr>
<td>drug therapy</td>
<td>124</td>
</tr>
<tr>
<td>immune-based tests</td>
<td>124</td>
</tr>
<tr>
<td>management</td>
<td>123–4</td>
</tr>
<tr>
<td>meningitis</td>
<td>199–200</td>
</tr>
<tr>
<td>multi-drug-resistant</td>
<td>346, 349</td>
</tr>
<tr>
<td>opportunistic infections in HIV</td>
<td>344, 346</td>
</tr>
</tbody>
</table>
Plate 19.1 Psoriatic plaque on the elbow.

Plate 19.2 Scalp psoriasis.

Plate 19.3 Psoriatic onycholysis.

Plate 19.4 Guttate psoriasis.

Plate 19.5 Hand dermatitis in a machine-tool operator.

Plate 19.6 Flexural involvement in atopic eczema.

Figures from Lecture Notes: Dermatology, 9th edition. © RAC Graham-Brown and DA Burns. Published 2007 by Blackwell Publishing Ltd.
Plate 19.7 Seborrhoeic dermatitis.

Plate 19.8 Pityriasis versicolor.

Plate 19.9 A typical exanthematic eruption due to an antibiotic.

Plate 19.10 Target lesions of erythema multiforme.

Plate 19.11 Erythema nodosum.

Plate 19.12 Necrobiosis lipoidica with a small ulcerated area.
Plate 19.13 Acanthosis nigricans.

Plate 19.14 Pyoderma gangrenosum.

Plate 19.15 Pemphigus vulgaris: flaccid blisters and erosions.

Plate 19.16 Bullous pemphigoid: numerous tense blisters.

Plate 19.17 Multiple solar keratoses.

Plate 19.18 (a) Basal cell carcinoma: note the telangiectatic vessels.
Plate 19.18  (Continued)  (b) Basal cell carcinoma: such destruction gives rise to the term 'rodent ulcer'.

Plate 19.19  (a) A polypoid squamous cell carcinoma.  (b) Squamous cell carcinoma on the lip.

Plate 19.20  Lentigo maligna.

Plate 19.21  (a) Superficial spreading melanoma.  (b) Large nodular melanoma.